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The research in this thesis focuses on the use of a range of physical
science techniques to perform quantitative measurements within the
living human body in a non-invasive manner, for the purpose of
understanding disease processes, diagnosing abnormality or monitoring
therapeutic responses. The research publications cover work which has
been undertaken over the last thirty years in the Universities of
Edinburgh, London and Leeds. The research has not concentrated on
one aspect of the physical sciences but has taken advantage of scientific
and technological developments, encompassing neutron, X and y
ionising radiation, laser and THz non-ionising radiation, magnetism,
radio-waves and a range of mathematical and computing techniques.
Clinical applications have encompassed a wide range of diseases and
conditions and include osteoporosis and other metabolic bone diseases,
cardiac disease, vascular disease, rheumatoid arthritis and cancer.
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Background
The publications which I have submitted for consideration for the award of DSc
cover work which has been undertaken over the last thirty years during which I
have worked in the Universities of Edinburgh, London and Leeds in association
with NHS Teaching Hospitals. My research has focused on the use of physical
sciences to perform quantitative measurements within the living human body in a
non-invasive manner, for the purpose of understanding disease processes,
diagnosing abnormality or monitoring therapeutic responses.
This underlying scientific theme has remained constant throughout my research
career but it has been mediated by two other factors which I believe to be
important in the area of applied medical science research. Both are associated with
the transition of the development of an original idea to its eventual widespread
availability in the health sector. I had always envisaged that any new medical
technique should go through a natural, and logical, progression from basic
scientific research to its eventual provision and availability in the health sector.
Given that part of my personal motivation was to develop new techniques which
would have an impact on healthcare, it was natural that I should take an increasing
interest in the subsequent stages of this process after my initial contribution. The
two factors to which I refer were therefore the clinical validation of new techniques
and their commercial development.
At the start of my research career I had thought that my expertise and
responsibility would, and indeed should, be concentrated in the early stages of this
process, ie in the development of new techniques, and that appropriate processes
and funding mechanisms were in place to investigate clinical effectiveness and
efficacy. I subsequently recognised that this was naive, a fact which I attribute to
youthful inexperience, and I became aware that if I did not extend my research
involvement further then appropriate validation would not take place. In addition
this recognition of the importance of the need to evaluate new techniques stemmed
from personal experience, as I recognized that the acceptance of new scientific
techniques by health sectors was not necessarily evidence based. I became aware
that the route from the assessment of the feasibility of the use of a new scientific
technique in clinical practice, to finally a rigorous analysis of the efficacy and
effectiveness of an investigative technique in routine clinical use, generally did not
occur. This compromised the rapid implementation of new techniques into health
provision.
In a number of cases the eventual outcome of my research has been associated
with a medical device which has had commercial potential. From the start of my
career I considered this to be part of the 'research pipeline', a concept which I have
always had, long before 'knowledge transfer' became a significant part of
University life. This was driven by the recognition that if any of the developments
with which I was associated were to become widely available in the medical and
health sector, they would need to be commercially produced and supported. This
extension of my research into the commercial sphere exposed me to an additional
critical environment which encompassed economic and financial issues as well as
perceived user acceptance.
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In my chosen field there has always been a close and synergistic link between the
science and the technology. Often, particularly early in my career, there was a
need to identify innovative scientific solutions to overcome problems which, we can
now see with hindsight, could have been easily solved with later technology or as
the technology matured. Obvious examples include computer power, firmware and
software packages, non-magnetic materials, image storage devices, data
communication protocols and micro-fabrication techniques. As I consider and
review my early research I am conscious that I am doing so from the perspective of
current technology and that initially I had a tendency to be somewhat dismissive of
some of my early innovative work which had to overcome technological
deficiencies. I have made every effort not to fall into this trap but include such work
and the associated publications.
Because of the ongoing nature of developments in science and technology my
research has not concentrated on one aspect of the physical sciences but has
encompassed many, utilising neutron, X and y ionising radiation, laser and THz
non-ionising radiation, magnetism, radio-waves and a range of mathematical
techniques. Likewise the clinical applications have also varied and include
osteoporosis and other metabolic bone diseases, cardiac disease, vascular
disease, rheumatoid arthritis and cancer. This variety is neither dilettantism nor
simple opportunism on my part. Throughout my career I have recognised when it is
time for a physical scientist such as myself to reduce my involvement in a subject
area and pass the baton on to clinicians or the commercial sector. In such cases I
have often retained a significant involvement but have transferred the main focus
of my research attention to another area. Also my desire to pursue research at a
high level has resulted in my willingness to transfer my attention to more promising
scientific methods, when the opportunity arises, and to choose the clinical
applications which are most important or which provide a challenging exemplar for
the new techniques.
In addition to some of the scientific reasons for the evolution of my research, I
would also like to highlight the two other factors which have had an impact. The
first was the impact of career changes which have imposed both constraints and
opportunities. These are generally associated with the equipment and facilities
available and, probably more importantly, scientific and clinical colleagues with
whom it is essential to undertake collaborative research. This collaborative
approach to research is essential for high quality research into the non-invasive
use of physical science in medicine. Throughout my career I have formed research
teams and sometimes the presence or absence of a key team member has
influenced the direction of the research. In my acknowledgements I highlight my
key collaborators. The second factor was the external influence of funding priorities
and opportunities. My research area requires significant equipment and recurrent
expenditure on facilities and, as a consequence, is highly dependent on external
funding. Generally the evolution of my research into a new area anticipated a
change in funding priorities of which I was then able to take advantage (magnetic
resonance imaging in the 1980s, evidence based medicine in the 1990s). Other
research areas were affected by a relative lack of funding opportunities (neutron
activation analysis after the 1970s, physical science aspects of bone measurement
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in the 1980s, and magnetic resonance imaging in the 1990s). Far from criticising
these changes in funding priorities, I would support the necessary change of
emphasis into areas which offer, or potentially offer, better outcomes. In addition
the funding priorities also reflect the correct emphasis away from 'near market'
research.
In this review of my research it will be apparent that though the non-invasive use of
physical science in medicine has remained constant, the primary focus of my
research has changed with time. In addition, as with other things in life, though I
became involved in new areas, association with pre-existing areas continued; as a
consequence there is considerable overlap in time between different research
areas. For ease of understanding I have tried to indicate the time-line of my
research in the table below.
Number of papers in each research area during approximate five year periods
79-84 85-89 90-94 95-99 00-05
Bone Measurement 27 10 10 4
Magnetic Resonance 3 37 17 1 5
Body Composition Measurement 1 10 19 1
Image Analysis (generally MRI) 4 3
Evidence Based Imaging 5 6
Terahertz Imaging and Sensing 11
The table above includes the total number of my refereed publications in the
different research areas. In my DSc submission I have not included all my research
publications but have been selective and included those which contain the major
research outputs. A small number of publications are referred to in the text in
{these} brackets. These include patents, which relate to the research described but
would not be appropriate as part of my DSc submission, and large systematic
reviews, which are in the form of substantial monographs. For reasons of space
hard copies have not been included, but electronic copies have been included on a
accompanying CD.
The publications I am submitting for my DSc are listed chronologically under broad
category headings, rather than in a continuous chronological list. I have only
included a small number of published conference papers; these have all been
refereed and the specific conferences are a recognised route for publication, often
in a rapidly evolving field of research. A small number of publications arose
following my PhD studies at the University of Edinburgh; these are indicated in the




At the start of my research career in Edinburgh in the early 1970s, one of the small
number of physics techniques which had the potential to enable quantitative
measurements to be made in-vivo was neutron activation analysis (NAA), and a
number of research groups were investigating its development and application. My
initial research focused on the development of techniques which could be used in
practice on patients, in a clinical environment. Many other researchers were using
neutron sources such as research reactors and cyclotrons, which may have been
appropriate for the development of a research tool, but were clearly impractical for
clinical use. I developed precise techniques for measuring bone calcium and other
elements in the forearm and spine and applied them to the investigation of
osteoporosis and bone disease associated with renal dialysis [1, 2, 3]. My scientific
research had to overcome problems of relatively low neutron yield from the small
Cf252 sources, minimise the effect of the variation in sensitivity with depth in tissue,
design and construct detection systems for the relatively high y radiation emitted
and develop a computer technique for spectral analysis using matrix inversion. I
also undertook the preliminary clinical evaluation, designing and managing the
small trial in renal dialysis patients.
Whilst developing this technique I became aware of the limitations of studying a
part of the body where there was insufficient accurate knowledge of the location of
the area of measurement. Hitherto the research I had undertaken relied on
accurate repositioning and sequential measurements or assumptions of internal
localisation in the human body. Also the variation between people of different sizes
was clearly a limitation in a fixed geometry and was particularly important in
performing absolute measurements and determining the percentage difference
from normal. This led me to become involved with two different approaches to
resolve this underlying problem, both of which I pursued by attracting external
funding to support additional research support staff.
The first was to extend NAA measurements to the whole human body [4, 11, 22]
using a clinical cyclotron which had just been installed in the hospital. The spectral
analysis programme I had developed was extended to measure a wider range of
body elements including Ca, Na, CI, P and N. Absolute measurements on patients
were obtained by normalising the measurement using an equation based on the
patient's stature; this enabled the results to be expressed as a percentage of
normal. The seasonal variation in total body calcium was also measured [15]. The
whole body technique was applied to a range of clinical conditions, particularly
osteoporosis [12] and osteoarthritis [13, 20], rheumatoid arthritis [7, 17, 18],
ankylosing spondylitis [16] and other osteopenic disorders [14, 19]
The second, and more far reaching, approach was to recognize the opportunities
that medical imaging offered to localise accurately the site in the body where
quantitative measurements were being performed. It was this which led me into
the area of medical imaging. I was less interested in developing new imaging
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techniques per se but rather I recognised the powerful combination of performing
quantitative measurements and identifying where the information was coming from.
Whilst performing NAA measurements to measure bone calcium I had previously
implemented a simple method to measure bone mineral of the wrist by measuring
the absorption of y radiation from a radionuclide source as it traversed the wrist. I
had used it to measure demineralization in patients with Turner's syndrome [6] and
had compared the changes measured using the two techniques [36]. It was natural
to extend this work into two dimensions to obtain quantitative measurement of
bone mineral in the spine. Two radionuclide energies were used, to correct for the
body thickness; the technique was known as dual photon absorptiometry (DPA)
and it was able to obtain both quantitative measurements and relatively low
resolution images to obtain accurate and reproducible localization [8, 10]. This
method was also developed further to measure bone mineral in the whole hand
[21].
Whilst developing DPA I became aware of a potentially significant problem
associated with the interference of one energy with the other which I termed the
'crossover correction' [5]. A consequence of an error in the crossover correction
could, I hypothesised, be responsible for the variation in the decrease in bone
mineral with age which was apparent at different international locations [9].
The focus of my research on bone and the increasing national interest on
osteoporosis led me to consider methods of monitoring or measuring fracture
healing using radionuclides. As a consequence I developed and evaluated a
nuclear medicine technique to predict fracture healing in a relatively large clinical
study [23].
After moving from Edinburgh I maintained my research interest in bone
measurement, both in London where I offered some scientific advice and support
to clinicians, but more so later in Leeds where I provided leadership to the Bone
and Body Composition Research Group. The technology had advanced and
commercially available dual energy X-ray based systems (DPX) were available to
measure bone mineral. My research therefore followed the natural path of
investigating the variation of bone mineral with age in large populations, measured
using DPX [24, 28] and applying the technique to the study of a variety of bone
diseases [27, 30, 32, 33],
In Leeds I also become interested in newer techniques to measure bone mineral.
These included the use of ultrasound for measuring bone parameters and its
relationship with measurements using photon absorptiometry [25]. To support this
work it was necessary to resolve the difficult problem of simulating bone for
ultrasound and so a phantom material for ultrasound was developed [29] and
patented {34}. Availability of new technology enabled me to extend the technique
of single photon absorptiometry, using a radiation sensitive CCD camera, to the
challenging application of the measurement of neonatal bone mineral [26, 31],
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Statistics
Whilst in the early phase of my research career my mathematical background and
computing experience, coupled with my involvement in the clinical evaluation of the
physical science techniques as well as their scientific development, caused me to
become increasing involved in the statistical and data analysis aspect of research.
Initially this led me to consider statistical issues associated with the comparison of
techniques and the level of correlation which was possible due to inherent
precision values [36].
Consideration of a possible clinical study of bone loss after surgery highlighted a
potentially more important problem for research. This was the question of survival
after surgery and whether there was a link to smoking status. An almost unique
patient data set, recorded over several decades, had been maintained by a
surgeon. This, coupled with the recently available computer power (even though
the data were still entered on punch cards), enabled me to undertake a rigorous
statistical analysis and demonstrate the relationship between survival after gastric
surgery and smoking status [37, 38, 39].
Collaborative research with colleagues also led to a number of publications of a
statistical nature [40, 41, 42] whilst I was in Edinburgh and London.
Magnetic Resonance
At the beginning of the 1980s, whilst still in Edinburgh, I recognized the limitations
of neutron activation analysis in the clinical environment and also I felt that there
was limited further physical science research to be done in the area of photon
absorptiometry. I had become aware of exciting developments in in-vivo nuclear
magnetic resonance and I therefore made a conscious decision to change the
physical science techniques I would use for quantitative measurements in-vivo.
Clearly a major difficulty was access to the very expensive equipment which was
still in the early stages of development. I became involved with a proposal to seek
funding to install the first pre-production prototype clinical MRI system in Scotland.
As an MRC senior research fellow I was responsible for the scientific research of
the programme. I therefore became actively involved in research to develop new
techniques of magnetic resonance imaging (MRI) using the low field magnetic
resonance system, and also to explore potential areas of clinical applications.
I published papers on some of the practical aspects of MRI [43, 46, 51, 59] and
collaborated with radiologists on exploring its use for qualitative imaging of the
brain, having extended the system to obtain sagittal images. However my main
research interests were firstly the quantitative measurement of the magnetic
resonance relaxation rate Ti, particularly in the brain and heart and secondly the
quantitative measurement of velocity and flow.
In MRI the Ti value is related to the ratio of free to bound water and, as a
consequence, MRI offered a method to measure water content of tissue. With
colleagues I studied changes in brain water in chronic alcoholic patients [44, 48,
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62, 68] and, more importantly, related T-i measurements to direct measurements of
brain water content in patients with brain tumours [53, 56].
Though elsewhere the use of MRI was generally being investigated in the brain
and CNS, we started investigating its use in the heart [45]. During this time my
research group produced the first quantitative T-i measurements in the human
heart [49] which required the sychronisation of the MRI acquisition with the
movement of the subject's heart. Qualitative cardiac images had recently been
acquired elsewhere but there was much greater complexity involved in obtaining
gated quantitative T-i. The technique was used to investigate acute myocardial
infarction [47, 55, 60, 61] and monitor changes with time; there was a clear
increase in Ti in recent infarcts.
At the time there was some debate about the ability of Ti and T2 to be tissue
specific and I contributed to this debate, based on our experience of quantitative
measurements [50]. There was also a clinical interest in measuring the breast
using MRI but the MRI system was insufficiently sensitive because of its vertical
magnetic field and large body coil. Other MRI systems had horizontal magnetic
fields which easily enabled specialist orthogonal vertical field surface coils to be
developed. I developed an new surface coil for breast imaging for vertical field
magnets [54] which was the subject of two patents {86, 87}.
The influence of movement on the phase of the NMR signal was known and,
utilising this relationship, my research group was one of the first to develop a
quantitative technique to measure fluid velocity in-vivo. We used two separate
gradient pulse sequences which were subtracted to eliminate spatial phase
variations and so produced an image which was directly related to velocity. We
were already using gradient echoes for imaging so were able to develop MRI to
produce velocity maps [52], In addition to measuring blood velocity we explored its
uses at low velocity levels, demonstrating the ability to measure the pulsatility of
CSF [57] and its value for identifying communicating syringomyelia [58].
Having contributed significantly to the development of MRI science and technology
at a low field strength I was approached to move to Guy's Hospital in London in
1986 to take on a senior academic position and continue research using one of the
first high field MRI systems which had the field strength to offer the potential of in-
vivo spectroscopic measurements.
Whilst in London I continued and developed my earlier interest in cardiac imaging
and flow measurement, using the increased sensitivity and resolution of a much
higher field strength magnet. I extended my cardiac research to the investigation of
cardio-vascular abnormalities in infants [65, 66, 67] which concentrated on the
accurate special localisation of the defect. I extended my research into MR flow
measurements to the development of MR angiography [64, 70] and extending the
quantification of it to the measurement of time-average flow [72, 73] and its
evaluation against Doppler ultrasound.
The high field strength magnet offered the opportunity to measure, and potentially
quantify, phosphorus metabolism. Previous research in the field had used surface
coils to localise measurements, predominantly in muscle. My research, along with
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a small number of other centres internationally, focused on image localised
spectroscopic techniques [63] focusing on the effectiveness and characterisation of
the localisation in-vivo [71, 75]. The technique was applied to breast tumours [69,
74, 77, 78] using customised breast coils.
Though this was the early days of MR spectroscopy, I made the decision not to
continue in that area as I felt there were inherent scientific problems in utilising
phosphorous MR spectroscopy for clinical usage. This also corresponded to a
time, in the late 80s, where it was becoming increasingly difficult, if not impossible,
for researchers in an academic environment to make the necessary scientific and
technological changes to commercially produced MR systems to pursue research
in certain areas. In addition this coincided with my view that image analysis would
have an increasing role in the future and that a number of developments in imaging
techniques, including MR, would require an image analysis approach
This awareness coincided with my decision to move to Leeds in 1989 to take up
the chair in Medical Physics at the University of Leeds where, once I had raised
funding to purchase MRI systems, I continued with applied MR research. I
continued research in the area of angiography [76, 79] but also extended this to the
development and implementation of perfusion measurements, particularly in
infants, including neonates [80, 82], The difficult task of attempting to measure
perfusion in cardiac tissue was pursued by my research group, the first stage being
the development of quantitative Ti in different phases of the cardiac cycle in a
single breath-hold [84], Another potential method for estimating perfusion is the
quantification of pharmacokinetic parameters and my research group developed a
practical clinical technique [85] which is being used for cardiac and rheumatologic
applications.
The use of MRI for quantitative radiation dose measurements had been around for
many years. I felt that the technique could have practical use, with the increasing
availability and usage of conformal radiotherapy, but I was concerned about the
relatively poor quality of the evidence which I saw in published papers. On that
basis my research group undertook to review the evidence and evaluate the
performance of the latest generation of polymer gels used for dosimetry [81, 83].
During the period of my research in MRI, the technology had evolved from MRI
systems in the laboratory which I could modify as required, through more restricted
commercial systems which I could configure differently, to finally relatively closed
commercial systems which could not be modified without extensive negotiation and
delay. The opportunity for significant physics research in MRI was therefore
severely restricted for someone like myself, working in the university and health
sectors. I had recognised this growing restriction in the late 1980s at the same time
as I recognised that many research problems may best be resolved by image
analysis methods rather than by developments in MRI techniques. For this reason
my research in image analysis, which only started to flourish in the early 1990s
after my move to Leeds, has often focused on MRI; this work is described in the
later section about image analysis.
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Body Composition Measurement
In the 1980s there was interest in the measurement of body composition in vivo,
particularly body fat and muscle mass, initially to monitor parentral nutrition and the
after effects of surgery; of particular interest was the measurement of nitrogen as a
better indicator of muscle mass. After moving from London to Leeds in 1989 I was
able to utilise my experience in both neutron activation analysis and dual photon
absorptiometry to provide leadership to a newly formed Bone and Body
Composition Research Group.
I had previously been aware of the potential advantages of prompt neutron
activation analysis to measure body nitrogen and initiated a research project whilst
in Edinburgh [88] but recognised problems with that method associated with
sensitivity. My move to Leeds in 1989 offered the unique opportunity to explore the
use of the high and controllable output of neutron generators for body composition
measurement. We developed a much improved pulsed neutron technique to
measure body carbon, hydrogen and oxygen [89, 90] and considered whether it
could be used to measure glycogen [91], This work was extended to consider the
measurement of total body water, fat and protein from the measurement of the
ratio of the major, elements [93].
We also undertook research into a recently published whole body electromagnetic
method for body composition measurement which we thought may overcome some
of the problems of bio-impedance methods [95], However we found major scientific
flaws in the technique [96], which to my knowledge is now no longer in use.
The commercially available techniques such as dual energy X-ray absorptiometry
and bio-impedance analysis and laboratory techniques such as total body
potassium offered an array of measurements of total body fat, fat-free mass, water,
and lean-tissue mass. Research was undertaken to understand the relationship
between the different methodologies [92, 94] with a particular focus on patients on
renal dialysis [97, 98, 99, 100, 101, 102, 103, 105],
Image Analysis
My move to Leeds in 1989 coincided with my emerging view that the development
of medical image analysis was of growing importance in the next stage in
extracting quantitative information from MRI and other imaging techniques; indeed
I had set up a medical image analysis group at Guy's Hospital just prior to my
departure.
As outlined earlier I had become concerned that there should be a natural
progression from basic scientific research, through applied research to a rigorous
analysis of the efficacy and effectiveness of an investigative technique in routine
clinical use. These three fundamental stages in research underpinned the creation
of a multidisciplinary Centre of Medical Imaging Research (CoMIR), which I set up
in Leeds in 1992 and of which I was Director until 1998, to undertake research in
all these three areas. My own personal research which I pursued from the early
1990s in medical imaging was in magnetic resonance imaging (described above),
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image analysis (described in this section) and evidence based imaging which
developed beyond expectations and is described in the next section.
The possibility of using the spatial distribution of mineralisation in low resolution hip
images obtained using DXA to improve the prediction of fracture risk was studied
[106] and the image analysis methods developed demonstrated the benefit of such
an approach. Unfortunately, however, it was beyond the scope of my research
group to test the technique further by implementing it in a sufficiently large
prospective clinical study.
New developments in MR offered the opportunity of superimposing darker grids
onto tissue, so-called 'tagging'; these offered greater opportunity to quantify the
movement of cardiac muscle during the cardiac cycle. Research was undertaken to
perform the necessary simulation before the technique could be used for accurate
quantification of heart movement [107, 109]. The increased usage of 3D data sets
from MR and the need to combine them led to research to develop a
mathematically robust method for 3D registration [110].
Familiarity with techniques for the extraction of quantitative information, such as
texture from medical images, led to research into how, in effect, a reversal of the
process could be used to create better psychophysical tests to access an
individual's ability to view medical images [111]. The outcome of the evaluation of
this method has just been accepted for publication.
Evidence Based Imaging
Over a decade before my first publication in evidence based imaging I had become
concerned about issues associated with the assessment of health technologies
[112], and I had become familiar with the debate around evidence based medicine.
With the creation of CoMIR soon after my move to Leeds I ensured that there was
a focus in the area of evidence based imaging, both in terms of primary research
and also secondary research, ie the scientific evaluation of existing published
material.
My emphasis on evidence based imaging was planned to coincide with changes in
funding policy which offered the opportunity to focus staff and resources
appropriately. Initial research highlighted, somewhat unexpectedly, the relatively
poor quality of evidence in medical imaging research and the presence of bias in
many studies [113]. It was clear that a simple focus on randomised controlled trials,
as used in the Cochrane Collaboration, could not be applied to the evaluation of
medical imaging research, and that we would need to undertake research into
methodological issues.
For example it was necessary to develop a decision analytic model for the role of
ultrasound in primary coronary stenting before a full review could be undertaken. In
addition research had to be undertaken into the identification of studies for
systematic reviews in medical imaging [114] and also how to undertake a review in
a rapidly evolving field [116].
Extensive systematic reviews were undertaken in four areas of medical imaging:
endoscopic ultrasound in gastro-oesophageal cancer [115] {118}; spiral and
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electron beam computed tomography {119}; intravascular ultrasound-guided
interventions in coronary artery disease {120}; and magnetic resonance
angiography of carotid artery stenosis and peripheral vascular disease [117] {121}.
These systematic reviews {118, 119, 120, 121} are large published monographs,
each running to over 100 pages long, and their length precludes the inclusion of
hard copies; instead copies have been included on a CD to be found on the back
cover.
In 1998 I was President of the British Institute of Radiology and chose the subject
of 'Evidence Based Imaging' for my Presidential Lecture giving me the opportunity
to stimulate a wider debate in this area. However although I felt I had made
significant progress in evidence based imaging I came to the conclusion that it was
strategically appropriate to begin to withdraw from the field in the late 1990s for a
number of reasons. Firstly it was difficult to continue our secondary research in
medical imaging because the funding policy was to concentrate support in centres
which specialised in systematic reviews, rather than specialist research centres
such as CoMIR which also undertook systematic reviews; thus it was very difficult
to recruit and retain the necessary expertise. Secondly we were unable to obtain
and maintain the appropriate clinical support for good quality primary research.
Terahertz Imaging and Sensing
Throughout my career I had recognised the value of imaging for the localisation of
quantitative measurements but I also recognised there were limitations about what
could be measured utilising certain physical science techniques. In the late 1990s
this led me to consider other parts of the electromagnetic spectrum where,
perhaps, any signal variation could potentially be influenced more by cellular or
molecular changes. As a consequence I developed an interest in the use of
terahertz radiation [122] which could potentially act both as an imaging technique
[123] and also a sensor in a localised region. I recognised that instead of using
large volume images of a human subject to localise an abnormality and perform a
relatively crude quantitative measurement, it may be possible to develop
techniques that could be delivered using minimal invasive surgery techniques.
Though these may only provide imaging information over a relatively small volume,
they could produce much more valuable information about tissue at a highly
localised point.
My research has been involved in understanding some of the science behind
terahertz radiation and the subject is still in its early days of development.
Research was undertaken to model the propagation of terahertz radiation through
tissue [127, 129] and also catalogue the optical properties of tissue at terahertz
frequencies [125, 132], In developing an imaging technique we were surprised to
identify gaps in data used to define safety criteria which could influence issues of
safety in the terahertz region [126, 130]. As terahertz systems were developed to
image tissue, we undertook research to determine how to evaluate image quality
using test objects [124] and also the effect of frequency on image quality [131].
Multispectral clustering techniques were used for the extraction of quantitative
information from the imaging data to classify histopathology [128].
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Summary
The value and importance of the physical sciences for measurement of health and
disease in-vivo has been demonstrated by my research. I recognise that I have
been fortunate that my research has coincided with significant technological
developments, opening up avenues of research that would have been
unimaginable to my predecessors.
Working over a span of three decades I have contributed to fundamental and
applied knowledge, changing my approach and methodology as opportunities
present themselves, whilst retaining my focus on quantitative, non-invasive
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Abstract. Techniques were developed to measure small changes of calcium in the
forearm and spine in vivo by neutron activation analysis using two sources of 252Cf
in a hospital environment. Using purpose-built part-body counters and bilateral
irradiation with 7-5 cm premoderation between the sources and the bone, peripheral
bone was measured with a total source strength eventually as low as 50 mCi. Two
methods of spectral analysis were used and compared. Patient studies of the forearm
were successfully undertaken, with a precision of 2-6% which included patient
movement, and an annual bone dose of less than 10 rem and skin dose of 35 rem from
six measurements.
Two 100 mCi sources were used for measurements of the lumbar spine. Care was
taken to minimise the problems of non-uniformity of activation which are present
using unilateral irradiation. Emphasis was placed on measuring the bodies of the
vertebrae with adequate sensitivity and uniformity, and the spinous processes and
arches with low sensitivity. A whole body counter was used for the bilateral detection
of the induced activity. The precision of the method was 3-0% with an annual peak
bone dose of 2-1 rem and skin dose of 18 rem from three measurements.
1. Introduction
Since the first measurements in vivo on human volunteers by neutron
activation analysis (Anderson, Osborn, Tomlinson, Newton, Rundo, Salmon
and Smith 1964) the field has expanded to include both whole-body and part-
body measurements of a range of body elements. The element that is of most
clinical interest is calcium, and apparatus for measuring part-body calcium
changes can be constructed relatively cheaply for use in a hospital environment.
Most part-body calcium measurements on patients have been performed on
peripheral bone, and although large neutron sources have been used (Comar,
Riviere, Raynaud and Kellershohn 1968), most studies have been performed
with compact radionuclide neutron sources using the 48Ca (n, y) 49Ca reaction.
Measurements of the hand have been carried out using a single 25 Ci Am-Be
source (Catto, Mcintosh and MacLeod 1973), a single 75 mCi 252Cf source
(Guey, Leitienne, Zech and Traegar 1978) and a combination of two 100 mCi
252Cf and four 10 Ci Pu-Be sources (Maziere and Comar 1976). No activation
measurements have been performed on the forearm, the site which is used for
bone mineral determination by photon absorptiometry (Cameron and Sorenson
1967). In order to make a direct comparison with absorptiometry and because
0031-9155/79/020319+11 $01.00 © 1979 The "Institute of Physics
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the. long bones of the forearm could be easily immobilised during any measure¬
ments, the forearm was chosen as the site for our investigations of peripheral
bone loss.
Although a method of utilising twelve 5 Ci Pu-Be sources has been used for
calcium measurements of the trunk (McNeill, Thomas, Sturtridge and Harrison
1973), part-body measurements of the spine alone have only been performed
using a cyclotron (Al-Hiti, Thomas, Al-Tikrity, Ettinger, Fremlin and Dabek
1976). We have developed apparatus which could be used in a hospital to
measure the calcium changes in the lumbar spine using 252Cf sources.
2. Neutron sources
Two 252Cf sources were obtained for activation analysis'. They had previously
been housed for three years at the Scottish Universities Research and Reactor
Centre where some physical evaluation had taken place (Boddy, Robertson
and Glaros 1974) and a pneumatic delivery system developed (Glaros 1975),
before being moved to Edinburgh. Although the ideal source strength for
patient measurements has been stated as 200 mCi (Boddy et al. 1974) or between
500 mCi and 1500 mCi (Evans, Le Blanc and Johnson 1976), the total combined
source strength that was available for patient measurements over a 2\ year
period was eventually as low as 50 mCi. At this point the sources were replaced
by two 104 mCi sources, mainly for the purpose of spine measurements.
An activation chamber was constructed inside a room by building an
L-shaped baffle of concrete blocks and wax. An access 0-75 m wide allowed
entry into the 2-5mxT4m irradiation chamber where the sources were
stored 3 m below ground.
3. Forearm measurements
3.1. Activation
Two designs of apparatus were used for activation measurements of the
forearm, both using a bilateral irradiation geometry. The sources and limb
were surrounded by a hydrogenous material, which acted as a neutron 'reflector',
to increase the thermal flux through the bone.
The premoderator thickness was chosen not to give the maximum thermal
flux, which occurs at a depth of approximately 1-5 cm, but to give the minimum
absorbed radiation dose for a given induced activity. Combining data from the
variations in dose and thermal flux with thickness of premoderator and
activation measurements of a cadaver limb, it was possible to calculate the
dose per fixed count for a range of premoderator thicknesses (fig. 1). The shape
of the cur ve is a function of the activity of the source when patient measure¬
ments are made of radionuclides with short half-lives.
The first forearm irradiation geometry (A), 19-75 cm source separation,
6 cm.Perspex premoderator and wax blocks above and below the limb has been
previously described (Smith and MacPherson 1977, Smith, Tothill, Simpson,
MacPherson, Merrick, Strong and Boddy 1978). This was improved upon and
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the (second irradiation geometry (B) consisted of the two sources inside
cylindrical wax reflectors each side of a water bath into which the patient's
arm was fixed at an angle of 45° (fig. 2). The dimensions of the tank were
6-
Relative dose/unit activation
Dose for 2% statistical cv
Curve 2
Curve 1
2 4 6 8 10
Premoderator thickness (cm)
Fig. 1. Curve 1 shows the relative dose per unit activation for radionuclides with a long
half-life. For induced radionuclides with a half-life comparable with the irradiation
time, long irradiation times are not rewarding. Curve 2 shows the dose in rem
required to obtain a statistical coefficient of variation of 2% when activating








Fig. 2. Forearm irradiation geometry (B) incorporating a water bath to act as combined
premoderator and reflector. The dotted lines indicate the position of the second
wax reflector.
322 M. A. Smith and P. Tothill
50 em x 45 cm x 17 cm so that the water acted as a premoderator, giving a
* total of about 7-5 cm premoderation between source and bone, as well as a
reflector. With the water bath the sensitivity of activation over a 25 cm
length was found to be improved by a factor of 1-8 compared with the first
irradiation geometry. Part of this improvement, about 30%, was due to the
smaller source separation, but the major increase in sensitivity was due to the
elimination of air gaps around the forearm. The latter also reduced the
variation in calcium counts from patient to patient due to overlying soft tissue,
increasing the possibility of absolute measurements.
During the 10 min activation period the patient gripped a Perspex rod and
the forearm was restrained in a mould constructed from butyrate sheet. The
variation in thermal fluence across the central 5 cm was ±4-2% and the full
width at half maximum (fwhm) of the variation along the arm was 16-2 cm,
measured using 1 cm diameter 0-0025 cm thick gold foils.
Dose measurements were performed in a phantom using gas flow ionisation
chambers and a GM counter (Law, Lawson and Porter 1974). During a 10 min
irradiation with a total source strength of 65 mCi the subject received a
neutron dose of 0-68 rad and a gamma ray dose of 0-59 rad to the skin surface
and a neutron dose of 0-20 rad and a gamma ray dose of 0-26 rad to the bone.
Combining the variation of BBE with energy and the calculated neutron
spectrum, a mean quality factor (QP) of 7-8 was obtained for the neutrons after
6 cm premoderation. The dose equivalent to the skin surface was therefore
5-8 rem and 1-8 rem to the bone. The gonad dose was less than 14 mrem taking
the value QP = 10. Por patient studies the irradiation time was kept constant
so the maximum annual dose to the patient from six measurements was less
than 10 rem to the bone or 4-5 rem averaged over the forearm.
3.2. Detection
A part-body counter (fig. 3) was built for the detection of induced activity in
peripheral bones and the thyroid. Two 15 cm x 10 cm JSTal detectors were
encased in 5-0 cm thick lead and could be used in a bilateral geometry with or
without a large central shield which could surround a limb such as the forearm.
When used with the central shield there was a thickness of at least 7-5 cm of
lead in all directions around the crystal except in the direction of the limb
entrances of the central shield. All three sections could be moved around a
large steel table 0-84 m above the floor. The background in the calcium region,
2-9 MeV to 3-3 MeV, with a 9 cm separation between the detectors in the
central shield was 0-09 cps and with a 12 cm separation without the central
shield was 0-13 cps. The variation in sensitivity at 2-75 MeV in the central
5 cm between the detectors for these separations was ±6% and ±5-8%
respectively. The fwhm for the variation in detection sensitivity along the
arm was 21-8 cm.
At the end of the irradiation period the patient was transferred to the
part-body counter with a delay of 1 min. The forearm was counted for 1000 s
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in the central shield of the counter with a detector separation of 9 cm, the
forearm being constrained in the same way as for activation. The combination
of activation and detection had a rwHM of 12-7 cm centred 13-5 cm from the
centre of the fist (fig. 4).
Steel table
Fig. 3. Part-body counter. One detector had been removed from the central shield to show
the position of the forearm support.
0 cm 10
Fig. 4. Combined activation and detection profiles to show region of measurement of
the forearm. The curves illustrate the improved sensitivity of calcium measurement
using the water bath.
4. Data analysis and precision
The spectrum obtained from a forearm after a 10 min irradiation, 1 min delay
and 1000 s count is shown in fig. 5. It was not possible to wait for the calcium
to decay in order to calculate the contributions from 38C1 and 24Na to the calcium
peak, because during this time there would be a significant decrease in the
24Na peak due to redistribution in blood and soft tissue.
Two methods were used to calculate the 49Ca contributions to the spectrum.
In the first the patient spectrum and standard spectra of 24Na and 49Ca were
integrated over the regions of the two photopeaks. Solutions of the two
£5cm
f
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' simultaneous equations gave the sodium and calcium contributions in the
two regions.
The second method used a computer to fit the standard spectra of 38C1, 24Na
and 49Ca to the patient spectrum. Matrix algebra was used to fit simultaneously
the three standard spectra using a least-squares technique. The intrinsic
MeV
Fig. 5. Standard spectra fitted to a smoothed patient spectrum over the relevant 200
channels of the total spectrum.
precision of the two methods was compared by taking a single patient spectrum
and randomly shifting each point in a Gaussian distribution within the limits
of counting statistics. The coefficient of variation (cv) of the two methods
based on manipulated spectra from a single patient spectrum was 2-4% and
2-1% respectively.
Precision measurements on a cadaver limb showed that with the low source
activity, small changes in a patient could best be detected by performing sets
of three repeated measurements, at the beginning and end of a time period
(e.g. six months) rather than six individual measurements performed throughout
that time period. In addition, this irradiation programme enabled accurate
repeatability figures to be obtained, which could include the effect of patient
movement. Prom the many sets of repeated patient measurements the error
due to movement (cvm), which was independent of the number of counts
measured, was calculated. This could then be combined with the statistical
cv to give the overall precision (total cv) for each patient. Table 1 shows
values for both irradiation geometries and both data processing techniques.
The precision figures quoted were, based on the , mean calcium counts for both
methods and the least significant change was calculated from the standard
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Table 1. Reproducibility of the two forearm irradiation apparatuses and
methods of spectral analysis based on sets of repeated patient measurements
Least No. of sets
cvm Precision significant of patient
(%) (%) change (%) measurements
Perspex pre- Simultaneous 2-66 3-45 5-63 75
moderators and equations
wax. reflectors Spectral 2-20 3-14 513
stripping
Water bath Simultaneous 2-04 2-65 4-33 68
equations
Spectral 1-93 2-57 4-20
stripping
5. Spine measurement
It is recognised that 252Cf is not the ideal source for measurements of the
spine because of its relatively low mean neutron energy. However, extensive
experiments were performed to determine the optimum irradiation geometry
to measure changes in calcium in the lumbar spine using 252Cf.
Changes in the bodies of the vertebrae are of most clinical interest, so good
uniformity of activation and detection was sought in the region 5 cm to 9 cm
below the skin surface, which is the approximate position of the region of
interest (Brinkley and Masters 1967). In addition, effort was made to measure
the region 0 cm to 5 cm deep with as low a sensitivity as possible so that
calcium counts from the spinous processes and arches of the vertebrae
contributed as little as possible to the total calcium counts detected. Thus
changes in the bodies of the vertebrae, where the calcium losses are most
important, would be most likely to be detected.
5.1. Activation
The variation in thermal neutron flux with depth was investigated in
fourteen different irradiation geometries. Reflector position, thickness of pre-
moderator and source to skin distance were varied and the effect of a thermal
neutron absorber was investigated. The efficiency of activation, - using both
phantoms and a cadaver, and the dose were then measured in the geometries
with reasonable thermal neutron flux profiles.
The flux profiles of the two irradiation geometries chosen as most suitable
are shown in fig. 6. Geometry 1, to be used for the majority of patients, gave
the best thermal fluence uniformity. The sources were situated 6 cm from the
skin surface and no premoderator or reflector was used. Geometry 2 would
only be used for patients of very small stature, where the bodies of the vertebrae
were likely to be in the region 3 cm to 6 cm below the skin surface, and so
would be measured fairly uniformly and with higher sensitivity. For this
geometry the sources were situated 6 cm from the skin surface and surrounded
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5.2. Detection
Counting was performed bilaterally with the patient supine in a shadow
shield whole body counter incorporating four 15 cm x 10 cm Nal detectors, two
above and two below, separated by 41 cm. In this position, a background of
0-25 cps was obtained in the 49Ca region. The variation in sensitivity in the
approximate region of the vertebrae, 5 cm to 9 cm above the bed, was ± 8-0%.
The variation along the spine 7 cm above the bed was 43-2 cm (fwhm) which
was compatible with the activation profile 7 cm below the skin surface of
36-0 cm (fwhm).
A pilot study was carried out using the spine irradiation apparatus (geometry
1), sets of three measurements being performed on ten volunteers. The results
showed that using two 100 mCi sources, the lumbar spine could be measured
with a precision of around 3-0%. The dose, measured using nuclear emulsion
films from a 200 s irradiation, would be 6 rem to the skin, 0-7 rem to the bone
(0-4 rem averaged over the whole spine) and 0-2 rem to the female gonads.
The mean calcium count from this dose would be approximately 2000 counts.
The 1000 s counting time was split into three periods of 200 s, 200 s and
600 s, the first two of these being used to determine the feasibility of phosphorus
measurements, via the 31P (n, a.) 28A1 reaction (threshold 2-0 MeV, 1j = 2-3 min).
The number of counts from 28A1 varied enormously, the statistical error being
greater than 10% in five out of nine volunteers. Thus, as would be expected,
the neutron energy of 252Cf is too low for phosphorus activation.
6. Discussion
Apparatus has been developed to use the technique of neutron activation
analysis to monitor calcium changes for use in a hospital. Sequential measure¬
ments of the forearm have been performed now for two years on over 90
patients and the technique has been proved to be a useful research tool.
Significant changes both in individual patients and in groups of patients with
respect to treatment have been detected and new forms of treatment evaluated
(Winney, Tothill, Robson, Abbot, Lidgard, Cameron, Smith, MacPherson and
Strong 1977).
The use of a water bath acting as premoderator and reflector, and the matrix
method of spectral analysis have been shown to give the best precision. The
advantage of this latter technique is, however, marginal when used with the
water bath, and so the simultaneous equations method could be used with
almost equal success for clinical measurements.
The characteristics of the forearm irradiation and detection apparatus
compare favourably with other methods of monitoring sequential changes of
calcium at peripheral sites. The precision value of 2-6% for a single measure¬
ment is better than those achieved by Catto et al. (1973) and Maziere and Comar
(1976) who quote values of 5% and 3% respectively. The bone dose is also less,
due both to the lower mean neutron energy and the relatively large amount of
premoderator used. The precision of activation analysis of the forearm also
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compares well with that achieved by bone mineral absorptiometry (Cameron
and Sorenson 1967).
Tests performed on the spine apparatus suggested that, despite the low
neutron energy, 252Cf is suitable for measurements of the lumbar spine. The
characteristics of the method compare well with the technique using more
suitable higher energy neutrons from a cyclotron (Al-Hiti et al. 1976). This could
be due to the reduction of lordosis in the patient obtained using a tilting
chair-and- also better uniformity of detection obtained by the use of bilateral
geometry.
Californium-252 is a particularly suitable source for neutron activation
analysis in a clinical environment. It is the cheapest of all the radionuclide
sources, although its relatively short half-life must be taken into account
when planning long term clinical studies. The minimum initial total source
activity required for a three-year study would be 100 mCi for the forearm and
200 mCi for the spine.
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Mackie, Mr. W. R. Harvey and Mr. W. R. McBeath for technical assistance.
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Resume
Mise au point des appareillages destines a mesurer les modifications du calcium dans l'avant-bras
et dans la colonne vertebrale par une analyse par activation neutronique, en employant le
californium 252
On a mis au point des techniques pour mesurer in vivo les petites modifications du calcium dans
l'avant-bras et la colonne vertebrale, ce par une analyse par activation neutronique en utilisant
deux sources de 252Cf ambiance hospitaliere. En employant des compteurs specifiquement destines
au prelevement de mesures sur certaines parties du corps, ainsi qu'une irradiation bilaterale avec
une premoderation de 7,5 cm entre les sources et 1'os, on a mesure l'os peripherique avec une
puissance globale de source dont la valeur a pu baisser jusqu'a 50 mCi. Deux methodes d'analyse
spectrale ont ete employees et comparees. Sur six mesures, on a reussi a faire des etudes de l'avant-
bras de patients, avec une precision de 2,6% compte tenu du mouvement du patient, et une dose
annuelle de 10 rem a l'os, la dose au niveau de la peau etant de 35 rem.
Deux sources de 100 mCi ont ete employees pour les mesure de la eolonne lombaire. On a pris
soin de minimiser les problemes d'absence d'uniformite de l'activation auxquels on se heurte
lorsque l'on utilise l'irradiation unilaterale. L'accent a ete mis sur la mesure des corps de vertebres.
avec une sensibilite et une uniformite adequates, ainsi que les arches et proees epineux avee basse
sensibilite. XJn compteur du corps entier a ete employe pour la detection bilaterale de l'activite
induite. La precision de la methode s'est averee etre de 3% avec une dose osseuse annuelle de
pointe de 2,1 rem et une dose de 18 rem au niveau de la peau, ce sur trois mesures prelevees.
zxtsammeneassung
Entwicklung einer Apparatur zur Messung der Anderungen der Kalzramwerte im Vorderarm und
im JK-iickgart mit Hilfe von analytischen Methoden auf der Basis von Neutronenaktivation unter
Einsatz von Californium-252
Es wurden Methoden zur Messung geringfiigiger Anderungen der Kalziummengen im Vorderarm
und im Ruckgrat entwicklet. Sie wnirden am labenden Organismus, d.h. in vivo, durchgefuhrt und
beruhen auf Neutronenaktivierung als analytische Methodik, bei der zwei 252Cf-Quellen im ELranken-
haus verwendet wurden. Unter Einsatz speziell gebauter Zahler zur Messung der Radioaktivitat
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ill bestimmten Kdrperzonen und einer zweiseitigen Strahleneinwirkung bei einem, 7,5 cm langen
Strahlenbremsvorsatz zwischen den. Qnellen und dem zu messenden Knochen wurden die Peri-
pberiezonen von Knochen bei einer Gesamtstarke der Quelle, die zum Scbluss nur nock 50 mCi
betrug, gemessen. Angewandt wurden zwei verscbiedene Methoden der Spektralanalyse und die
so erhaltenen Werte wurden mit einander verglichen. Die Messung des Kalziummetabohsmus im
Vorderarm von Patienten wurde somit erfolgreich durchgefuhrt, indem eine Genauigkeit von 2,6 %
erreicht wurde, sofern man die Bewegung das Patienten noch mitberiicksichtigt. Die jahrliche
Dosis fiir die Knochen lag unter 10 rem und diejenige fiir die Haut bei 35 rem. Diese Werte
versteben sich fur secbs Messungen.
Zwei Strablenquellen mit je 100 mCi wurden zur Messung des Kalziumwechsels im Ruekgrat
in der Lendengegend eingesetzt. Hierbei wurde vorsichtig arauf geachtet, diejenigen Schwierig-
keiten so gering wie moglich au balten, welche sich aus der Ungleischformigkeit der Aktivierung
bei Verwendung einer einseitig wirkenden Bestrablung ergeben. Das Scbwergewicbt wurde darauf
gelegt, die Wirbelsaulenteile mit ausreichender Empfindlichkeit und Gleicbformigkeit sowie die
Veranderungen der Wirbelsaule und der Wolbungen mit niedriger Empfindliehkeit zu messen.
Zur Messung der induzierten Radioaktivitat bei zweiseitiger Strahleneinwirkung wurde ein Zahl-
instrument gewahlt, das den ganzen Korper erfasst. Die Genauigkeit der Methode betrug 3,0%
bei einer jahrlichen Spitzendosis fur die Knochen von 2,1 rem und einer Dosis fur die Haut von
18 rem. Diese Werte gelten fur drei Messungen.
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i. Introduction
Osteoporosis is the most common disease of bone, affecting in particular the elderly
female population. The lumbar spine is of particular interest in the study of this disease
for two reasons. Firstly, lumbar vertebral crush fracture is a common manifestation of
osteoporosis, suggesting that the spine appears to be particularly vulnerable. Secondly,
the normal turnover rate of bone at such trabecular sites is 8% per annum compared
with 3% per annum in the cortical bone of the metacarpals or the radius (ICRP 23
1975). Any change or response to treatment may thus be made more apparent by
measuring the lumbar spine than by using conventional techniques of metacarpal index
or photon absorptiometry of the radius.
Methods for measuring changes in calcium content of the lumbar spine by in vivo
neutron activation analysis have been described using 252Cf (Smith and Tothill 1979),
and elsewhere using a cyclotron (A1 Hiti etal 1976). No report of changes in spinal
calcium content in response to treatment for osteoporosis has yet been published.
This study set out to evaluate the technique of part-body neutron activation analysis
of the spine as a method for monitoring calcium changes in elderly osteoporosis
patients.
2. Methods and patients
The apparatus used consisted of a modified dental chair that could tilt back to minimise
patient movement. Two 252Cf sources, each initially 2.96 GBq (80 mCi), were
positioned behind the patient 6 cm from the skin surface and 20 cm apart, centred on
the iliac crest. No premoderator or hydrogenous reflector was used. The patient was
irradiated for 3.5 min. The induced activity was measured in a whole-body counter
containing four 15 cm x 10 cm Nal detectors for 1000 s (Smith and Tothill 1979). As
there was no collimation of the neutron flux, parts of the thoracic spine, sacrum and
pelvis were also activated, in addition to the lumbar spine.
Twenty-three women presenting with fractured neck of femur were studied. Their
mean age was 69.5 years (range 43-80 years) and all were post-menopausal. Twenty of
these patients had normal blood biochemistry and were randomly allocated to one of
four treatment groups: (a) placebo, (b) ethinyloestradiol (oestrogen) and calcium
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supplement (Ca), (c) la-hydroxycholecalciferol (laOHD3) and Ca, (d) lctOHD3,
oestrogen and Ca (Eastell et al 1980). Three patients with possible osteomalacia, as
indicated by blood biochemistry, were given laOHD3 and Ca.
The patients were measured at intervals of four months for one year. In addition to
the measurement of spinal calcium, the mineral content of the non-dominant forearm
was measured using photon absorptiometry at a site 5 cm proximal to the tip of the
styloid process of the radius. Patients were assessed radiographically at their first and
last visit to detect the occurrence of vertebral crush fractures during the period of the
study. It was recognised that an increase in the thickness of soft tissue over the spine
would decrease the efficiency of activation, so patients who showed a consistent weight
increase of more than 5 kg during the year were omitted from the study.
3. Results
An average of 997 counts was measured in the 49Ca photopeak in these patients. After
correcting for decay of the 252Cf, the annual rate of change in spinal calcium content was
calculated by fitting a regression line to the four measurements. The combined residual
sum of squares from the regression lines gave an overall estimate of reproducibility
(coefficient of variation) of 5% for all the patient data.
Three patients showed a consistent weight increase (probably as a result of the
oestrogen therapy), one suffered a crush fracture during the study and one was found to
suffer from rheumatiod arthritis. The results of the remaining fifteen osteoporotic











Figure 1. Annual changes in spinal calcium content in patients (9) with fractured neck of femur. 0 represents
changes over six months in patients who did not complete the study.
1952) suggested that the results were not of the same population (p = 0.6). The
treatment that was expected to be of most benefit, laOHD3, Ca and oestrogen
(Marshall and Nordin 1977, Nordin et al 1980) was significantly better than placebo
(P<0.05). There were no other significant diffrerences between the groups. The
predictable response to vitamin D therapy in the three osteomalacic patients was
demonstrated by an increase in spinal calcium in all three patients, the increases being
significant (P<0.05) in two of the three.
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Similar analysis of the photon absorptiometry measurements of the forearm gave a
figure for the reproducibility of 4.4%. Analysis of the data suggested that all the results
from the osteoporotic patients came from the same population (p = 0.45) and no
significant differences were seen between groups. No significant correlation was found
between changes in the forearm and spine (r = 0.21).
4. Discussion
The results of this study demonstrate that naa of the spine using 252Cf, perhaps the
most convenient and inexpensive neutron source, can be sucessfully used to monitor
calcium changes due to osteoporosis and its treatment in the elderly female population.
The reproducibility figure of 5% is worse than the figure of 3% which had been
achieved in a previous small pilot study (Smith and Tothill 1979) on a group of patients
not suffering from osteoporosis. This can be accounted for by the lower calcium levels
in the osteoporotic patients and hence a larger error due to counting statistics, plus their
difficulty in sitting still during the activation period, due to pain in their recently
fractured hip. The assesment of reproducibility in the osteoporotic group assumes a
linear change with time; such an assumption may lead to an over-pessimistic figure for
reproducibiltiy.
The expected 'best' treatment regime, Ca, laOHD3 and oestrogen was shown to be
significantly better (P < 0.05) than placebo by spine naa. This result was not demon¬
strated by forearm absorptiometry, even though the latter had better reproducibility.
The lack of correlation between changes in bone mineral in different parts of the
skeleton confirms other findings (Aloia etal 1975, Cohn etal 1975, 1976, Dabek et al
1977, Harrison et al 1974).
The patients in the study were selected from a group of 180 patients presenting with
fractured neck of femur over a seven month period. It had been hoped that about half
of these would be suitable for the study, hence the four treatment groups, but the high
morbidity and morality rates associated with this fracture reduced the available number
considerably. The low admittance rate into the study was not due to difficulties
associated with the naa measurement technique.
Nonetheless there is one drawback of the technique. This is that an increase in body
tissue in the region of the spine will affect the sensitivity of the activation. As some
patients steadily increase their weight as a result of receiving oestrogen, these patients
must be eliminated from any analysis of the results or, preferably, experiments must be
performed to correct for variations in activation and detection efficiency.
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Abstract. The effect of different concentrations of dialysate calcium and treatment with I0C-OHD3 on bone calcium
content in haemodialysis patients was investigated over a 2,/>-year period. Part-body neutron activation analysis of the
forearm with 252Cf was used to measure both an initial absolute calcium content and changes in the bone calcium. A
highly significant inverse correlation (r = —0.84, p< 0.001) was found between the initial calcium content and the
duration of previous dialysis utilising a dialysate calcium concentration of 1.75 mmol/1. No significant difference was
found between the changes in bone calcium in patients who continued using a dialysate calcium of 1.75 mmol/1 and those
whose dialysate calcium was reduced to 1.375 mmol/1. There was a significant increase of 16.7% (p<0.01) in bone
calcium over the 2 'A-year period in the patients receiving I0C-OHD3. The results of the study suggest that bone calcium
loss is not necessarily influenced by dialysate calcium concentration but that 1CC-OHD3 has a beneficial long-term effect
on bone calcium content.
Introduction
Renal osteodystrophy in haemodialysis patients is a
complex mixture of osteomalacia, secondary hyperpara¬
thyroidism and osteoporosis. While it is now recognised
that disturbance of vitamin D metabolism has a central
role in the pathogenesis of renal osteodystrophy, the con¬
centration of calcium in the dialysis fluid has also been
thought to be of importance in haemodialysis patients [1],
However, while using a dialysate calcium concentration of
1.5 mmol/1 or higher may prevent hypocalcaemia and im¬
prove calcium balance [2-5] there is still controversy regard¬
ing the effect of dialysate calcium concentrations on bone
disease [6,7], By contrast, short-term treatment of renal
osteodystrophy with synthetic active metabolites of vit¬
amin D has produced promising improvement in renal
bone disease [8] except when this is aluminium-induced [9],
The end result of all forms of renal osteodystrophy is
loss of bone mineral and calcium which may result in bone
pain and fractures. Since bone mineral content may change
slowly as renal bone disease progresses, assessment of its
response to treatment requires a means of detecting small
changes in bone mineral or bone calcium content. Skeletal
radiography is a qualitative technique which detects only
severe changes while bone histology requires expertise for
quantification of changes and since it is traumatic for the
patient, is not ideal for frequent analyses. Neutron activa-
r-
tion analysis (NAA) is a non-invasive and precise tech¬
nique which measures calcium content and would be of
value in quantitating small changes in the calcium content
of bone. Its usefulness has been confirmed by a number of
studies where use of this technique has detected changes in
calcium content paralleling biochemical, radiological and
histological changes [10].
This study assesses the effect of dialysate calcium and
treatment with la-Jbydroxycholecalciferol (la-OHDs) on
the calcium content of bone in haemodialysis patients over
a 254-year period using NAA to measure changes in cal¬
cium content of the forearm.
✓
Patients and Methods
21 patients, aged 22-56 years (mean 40 years) had been established
on haemodialysis from 2 to 11 years (mean 4.5 years). These were the
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Table I. Initial sex distribution, mean age (range), duration of dialysis.(range) and blood biochemistry (±1 SD) prior to the start of the study
Number in group Age, years Duration Plasma Plasma Plasma
. of dialysis " calcium alkaline parathyroid
? <? months mmol/1 phosphatase hormone
U/l pg/1
Group 1 1 4 42 (27-56) 45 (24-84) 2.65 ±0.11 130 ± 60 1.03 ±0.90
Group 2 2 5 42 (22-52) 65 (33-134) 2.49 ±0.31 134 ±64 1.29 ±0.72
Group 3 3 4 36 (25-56) 53 (37-75) 2.53 ±0.19 156 ±113 1.19 ±1.30
entire population of patients on home dialysis who had not been
treated previously with vitamin D. Patients were dialysed for 5-8 h
twice or thrice weekly using either Gambro 1M2, 1M2 coil or Cordis
Dow 1.3M2 hollow fibre. Prior to this study, dialysis on all patients
was conducted with a dialysate calcium concentration of 1.75 mmol/1
and magnesium concentration of 0.75 mmol/1; their diet contained
70 g of protein, 800 mg (20 mmol) of calcium and 1,100 mg (35.5
mmol) ofphosphorus daily. In addition, patients received aluminium
hydroxide if necessary to maintain the pre-dialysis plasma phosphate
in the range 1.6-2.0 mmol/1.
The patients were randomly allocated into one of three treatment
groups. Group 1 continued their treatment unchanged with a dialysate
calcium concentration of 1.75 mmol/1. 2 patients failed to attend for
the study leaving only 5 in the group. Group 2 contained 7 patients
who were treated with a low dialysate calcium concentration of 1.375
mmol/1. Group 3 also contained 7 patients who were treated with a
low dialysate calcium concentration of 1.375 mmol/1 but in addition
were given I1X-OHD3 in an initial dose of 2 p.g daily, adjusted later if
necessary to avoid hypercalcaemia. The initial characteristics of each
group are shown in table I. There were no significant differences be¬
tween the groups at the start of the study.
The calcium content of the non-fistula forearm was measured by
NAA at time zero before the treatment alteration, then at 8, 16 and
30 months after the start of the trial. 2 patients in Group 1 did not
complete the study: 1 died of cardiac failure after 17 months and 1 had
a fistula inserted in the arm being measured after 18 months. In Group
2, 2 patients also did not complete the study, 1 after 9 months due to
hypocalcaemia and 1 after 17months when I0C-OHD3 treatment com¬
menced. In Group 3, 1 patient died just before the final measurement
whilst receiving treatment of oesophageal carcinoma. Throughout
the period ofthis study, skeletal"radiographs ofthe ankle, hand, pelvis,
chest, lumbar spine and skull were taken to monitor extraosseous
calcification.
The measurement ofcalcium content of boue using NAA involves
irradiating the region of interest with neutrons which react with the
isotope 48Ca in bone to form unstable 49Ca. This induced radio¬
activity, which has a half-life of 8.8 min, can then be measured with
a gamma-ray detector to provide a relative estimate of the calcium
content of the bone, expressed as measured 49Ca counts. In our ap¬
paratus [11,12] the forearm is irradiated with two neutron sources of
2o2Cf and the activity measured with two 15 x 10 cm sodium iodide
detectors placed one on either side of the forearm. A triple irradiation
procedure was adopted at each visit giving a precision of 1.8%, the
same apparatus and procedure being used on each occasion. The
NAA results over the 2 % years of the study were expressed as a
percentage of the initial value.
At the time of the last attendance at 30 months, irradiation ap¬
paratus using a water bath had been developed so an additional
measurement was performed which enabled a more absolute calcium
determination to be made using a normalisation procedure to correct
for variations due to the patient's size [13]. This value, combined with
the changes over the 2%-year period, enabled an initial absolute
forearm calcium content to be established in the 14 patients who
completed the study. A group of 18 patients awaiting treatment with
lithium carbonate were used to define a normal range, so the initial
forearm calcium in the renal patients could be expressed as a percent¬
age of normal.
Analysis of data was made using non-parametric statistics unless
otherwise stated and p> 0.05 was taken to be not significant.
Results
For the dialysis patients as a group the initial calcium
content in the forearm prior to the start of the study was
significantly lower than normal (mean 87%, p<0.05,
t test). A highly significant inverse correlation was found
(r = -0.84, p< 0.001) between the initial bone calcium
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Fig. 1. Relationship between initial calcium content of the fore¬
arm, expressed as a percentage of normal, and duration of previous
haemodialysis.




























Fig. 2. Percentage changes in
forearm calcium in individual
patients in the three groups over
a period of 214 years expressed









DIALYSATE CALCIUM : 1.75 mmol/1
Table n. Mean percentage change ( + 1 SD) in the non-fistula forearm calcium as measured by NAA in the three groups




























n = Number of patients.
The percentage changes in calcium content of the non-
fistula forearm in individual patients in the 3 groups over
the period of study are shown in figure 2. The mean changes
in NAA calcium in each .group expressed as a percentage
change over the different time periods are given in table II.
In the patients in Group 3 treated with IK-OHD3, there
was a consistent increase in calcium content which was
significantly greater than that in Group 1 (p<0.01) and
Group 2 (p < 0.02) over the initial period of 8 months [14],
Group 2 (p < 0.01) over the 16- to 30-month period and in
both groups (p<0.01) over the complete time period of
2 Zi years. The change in calcium content in Groups 1 and 2
was variable but any differences between these two groups
were not significant.
There was no increase in soft tissue or vascular calcifica¬
tion over the period of the study on skeletal radiographs.
Discussion
The reduced forearm calcium content in these patients
at the onset of the study, as well as the clear relationship
between the initial forearm calcium and the duration of
haemodialysis treatment, indicates that prolonged use of a
'high' dialysate calcium concentration of 1.75 mmol/1 did
not prevent bone calcium loss in these patients. In addition
we have also failed to detect any significant difference be¬
tween changes in calcium content in patients treated with
either a high or a low dialysate calcium concentration.
These findings contrast with those in earlier studies which
indicated that use of a dialysate calcium of 1.5 mmol/1 or
higher might prevent the loss -of bone mineral [1, 3, 4], but
confirm similar more recent observations [6,7]. Thus, while
the use of a dialysate calcium of 1.5 mmol/1 or higher may
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improve calcium balance and prevent hypocalcaemia [2,5],
the role of dialysate calcium in the pathogenesis of renal
bone disease requires further study.
The significant increase in forearm calcium content in
patients treated with la-OHD3 compared to the untreated
groups demonstrates the beneficial long-term effect of
I0C-OHD3 on bone calcium in haemodialysis patients. The
rate of increase in bone calcium in patients treated with
la-OHD3 in this study was equivalent to 7.1 % per annum
over the whole period of observation. This compares with
estimated increases of 3% per annum using whole body
NAA over periods of 10-18 months [5] and 8.7% in 3
months using NAA measurements of the hand [15]. The
increases in hand calcium by NAA in the short-term de¬
monstrated by Catto et al. [15], however, did not continue
in the long term [16; Catto pers. commun.]. While the
reason for these differences in results of NAA using these
two part-body sites is not clear, they may reflect regional
differences in the skeletal response to I0C-OHD3.
The increase in bone calcium in this study in response
to I0C-OHD3 occurred despite the use of a dialysate calcium
concentration of 1.375 mmol/1 at which calcium loss into
the dialysate fluid might be expected. The 'low' dialysate
calcium was chosen in this study in the light of previous
experience when the use of a dialysate calcium of 1.75
mmol/1 restricted the dosage of I0C-OHD3 due to hyper-
calcaemia [17]. Since calcium absorption improves with
la-OHD3 it may be unnecessary, indeed undesirable, to
use a 'high' dialysate calcium during treatment with
I0C-OHD3, particularly in view of the uncertainty about the
influence of dialysate calcium on bone disease.
This study indicates that part-body in vivo NAA is a
useful means of monitoring renal osteodystrophy. The
hand is commonly chosen for NAA measurements on renal
patients [18-20] but since NAA measurements of the hand
have failed to demonstrate a long-term beneficial effect of
1 a-OHDs on bone calcium, itis suggested that the forearm,
which in any event contains more calcium, is more reliable
and should be regarded as a more suitable site for moni¬
toring renal bone disease using part body NAA.
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Abstract. An irradiation system has been designed, using a neutron beam from a cyclotron,
which optimises the uniformity of activation of calcium. Induced activity is measured in
a scanning, shadow-shield whole-body counter. Calibration has been effected and repro¬
ducibility assessed with three different types of phantom. Corrections were derived for
variations in body height, depth and fat thickness. The coefficient of variation for repeated
measurements of an anthropomorphic phantom was 1.8% for an absorbed dose equivalent
of 13 mSv (1.3 rem). Measurements of total body calcium in 40 normal adults were used
to derive normalisation factors which predict the normal calcium in a subject of given size
and age. The coefficient of variation of normalised calcium was 6.2% in men and 6.6%
in women, with the demonstration of an annual loss of 1.5% after the menopause. The
narrow range should make single measurements useful for diagnostic purposes..
1. Introduction
Total body neutron activation analysis is now established as one of the most important
methods of determining the elemental composition of the human body. It can be
used to determine both the absolute amount and changes with time of certain body
elements, in particular calcium, sodium, chlorine, phosphorus and nitrogen (Cohn
1981).
In the technique, the subjects are exposed to a beam of partially moderated fast
neutrons which induces amongst others the reactions 48Ca(n, y)49Ca, 23Na(n, y)24Na,
37Cl(n, y)38Cl, 31P(n, a)28Al and 14N(n, 2n)13N. The radioactive isotopes produced
then decay, emitting y-rays which can be readily detected in a whole-body counter.
If the reproducibility of the method were good then small changes in the body
elements with time might be detected relatively easily. Absolute quantification of the
elements is more difficult, because of the natural variation in body dimensions and
the difficulty of obtaining a suitable variable phantom of known composition for
calibration. To overcome these problems several different approaches have been
made. Nelp et al (1972) made repeated measurements on five cadavers of different
sizes and then ashed the skeletons to determine the calcium content. Cohn and
Dombrowski (1971) and Cohn etal (1972) used only one size of phantom for activation
and depended on the invariant response of a 54-detector whole-body counter (Cohn
et al 1969). Three sizes of phantom were used by Williams et al (1978); their patients
0031-9155/82/050697 + 11 $1.50 © 1982 The Institute of Physics 697
698 N S JKennedy et al
were then graded into three groups according to body habitus. Two different sizes
of phantom were used by Spinks et al (1977) and the effects of varying thickness or
adding wax around these phantoms were studied by Spinks (1979). The effect of
varying the thickness of the trunk and thighs was also studied by McNeill et al (1974).
Oxby and Brooks (1979) have tackled the problem of varying body dimensions by
designing a complex phantom of variable shape and content.
This paper describes the technique used in Edinburgh to measure total body
calcium (TBCa) with a high degree of precision and also our methods of overcoming
the problems mentioned above. The technique of evaluating whether a subject
contains a normal amount of calcium is in two parts. Firstly, corrections to eliminate
the effects of variations in activation and detection efficiency due to varying body
dimensions are made. This enables the absolute amount of calcium in the subject in
grams to be evaluated and requires a variety of phantom measurements. Secondly,
the normal predicted total body calcium is calculated using a formula derived from
the results of a group of healthy normal volunteers aged 40-70 years. These results
were used to obtain a range of normal values of the body elements of interest.
Total body calcium measurements of normal volunteers have also been made by
Nelp et al (1972), Cohn et al (1976), Aloia et al (1978), and Chesnut et al (1981).
Where appropriate, the results of these studies and the data presented in this paper
will be compared and discussed.
2. Method
2.1. Neutron activation
The neutron source used for patient activation was a cyclotron producing neutrons
of mean energy 6.5 MeV by the reaction of 15 MeV deuterons on a beryllium target
(Williams et al 1979). During irradiation the subject was positioned in a moderator
kiosk made from 3 cm thick polyethylene sheets mounted on a turntable. The thickness
of the premoderator was chosen, after preliminary measurements, in order to minimise
the variation in the thermal neutron flux through the patient. This was measured
using a 235U fission chamber with and without a cadmium shield; in a phantom 24 cm
Figure 1. The thermal neutron flux profile through a water tank of depth 30 cm; A, with unilateral irradiation;
B, with bilateral irradiation. Using the first and last 3 cm (shaded areas) as premoderator, the profile
through a subject 24 cm deep may be observed.
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Figure 2. The irradiation enclosure. The rear wall is brought forward until the subject's trunk is in contact
with both the front and rear walls. The depth of the perspex window was chosen so that the effect on the
thermal neutron profile was equal to that of the 3 cm thick polyethylene walls.
deep this variation was ±7% (figure 1) and in a limb phantom 12.5 cm in diameter
the variation was ±13%. The back wall of the kiosk was movable and was adjusted
so that the subject's trunk was in contact with both the front and back walls (figure
2). This contact kept the subject in the correct position and gave extra support. The
fixed neutron dose was given to the patient in two successive irradiations each lasting
about 22 s, with the kiosk rotating through 180° in 18 s after the first irradiation and
before the second. These times were checked with a stopwatch and a decay correction
applied if necessary. The target to subject distance was 5.4 m.
Using a Geiger-Miiller tube sheathed in 3 mm of 6LiF, the photon absorbed dose
was measured as 0.4 mGy. The total dose, measured at the position of the pelvis
using a tissue-equivalent ionisation chamber, was 1.68 mGy, and was nearly constant
with depth through the patient. Using a neutron quality factor of 10 therefore, the
total dose equivalent received by the patient was 13.2 mSv. This dose was controlled
by the neutron monitor chamber of the beam and the irradiation calibrated by
activating simultaneously a container of Na2C03 in a polyethylene jacket mounted
on the side of the moderator kiosk. Possible long term variations in the neutron beam
distribution were monitored by weekly measurements of the Bush phantom.
2.2. Measurement of induced activity
After irradiation, the patient was transferred to a shadow-shield whole-body counter
containing four 15 cm diameter x 10 cm thick sodium iodide detectors, two above and
two below the bed, arranged in line across the patient. The separation of the upper
and lower counters was 40 cm. Four 200 cm scans at constant speed, each lasting five
minutes, were then performed. The scan direction was simply reversed at the end of
each scan. The time from the end of the irradiation to the start of the first scan was
measured and was usually about 6 min.
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The patient spectrum, covering the energy range 0-4 MeV, was recorded on a
multichannel analyser. A twenty minute background count, measured using an inactive
phantom, was then subtracted from the patient spectrum and the difference was
punched out on paper tape for computer analysis.
2.3. Spectral analysis
The data were analysed by fitting five standard spectra, those of calcium, sodium,
chlorine, phosphorus and potassium to the smoothed subject spectrum in the energy
range 1.0-3.4 MeV, using a least squares technique (Smith et al 1976, Smith and
Tothill 1979). The standard spectra were obtained by separately filling a phantom of
human dimensions with appropriate solutions, activating the phantom and then record¬
ing the spectra on the whole-body counter. When the best possible fit to the subject's
spectrum had been obtained, the amount of each standard required to make up the
spectrum was listed. These amounts were then divided by the count from a twenty
minute scan of the Na2C03 standard. The values for each element were then corrected
for radioactive decay.
In addition to the major elements of interest, some nuclides are activated which
interfere with the measurement of the elements under analysis. The main interfering
reaction in the measurement of calcium is the 37Cl(n, p)37S reaction, since the 37S
produced has a 5.06 min half-life and a gamma-ray energy of 3.1 MeV. The correction
applied to the calcium content, obtained by activating chlorine in a water-filled
phantom was 3.1% of the chlorine count corrected back to the reference time. By
similar methods, the reaction 39K(n, 2n)38Km was found to contribute 0.9% of the
total counts in the chlorine region (2.00 to 2.32 MeV) and the 24Mg (n, p) 24Na reaction
contributed 0.8% of the total counts measured in the sodium region (2.57 to 2.92 MeV)
when the composition of reference man (IRCP 1975), was assumed. The interferences
from the last two reactions were regarded as negligible.
3. Results
3.1. Reproducibility
The reproducibilities of the measurements of calcium, sodium, chlorine and phos¬
phorus were investigated by repeatedly measuring a phantom which consisted of
hollow polyethylene sections containing known amounts of the elements of interest
(Bush 1946). The water-filled weight of the phantom was 68.5 kg and its height
172 cm. Three separate filling mixtures were used (see table 1) and these mixtures
were irradiated 3, 3 and 7 times respectively. In the final mixture, the total amounts
Table 1. Contents of phantoms (in g).
Phantom composition Reference man
Element 1 2 3 (IRCP 23)
Calcium 600 802 1009 1000
Sodium 60 70 84 100
Chlorine 50 61 70 95
Phosphorus 455 455 455 780
Potassium 120 120 130 140
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5 of the various elements were similar to those in reference man (IRCP 1975) with the
exception of phosphorus where more recent results imply that the quoted content is
too high. There was no significant dependence of the counts obtained per gram of
element on the ratio of the various elements in the phantom. The reproducibilities
(coefficients of variation (cv)) of the measurements of the various elements, obtained
from the 13 irradiations of the phantom, using the same dose as given to the patient,
were ±1.7% for calcium, ±2.2% for sodium, ±4.3% for chlorine and ±4.3% for
phosphorus. The values of the cv for calcium, sodium and chlorine reflect almost
entirely the counting statistics for these elements. For a small female with only 500 g
of calcium the cv for calcium would increase to about 3.0%. The reproducibility of
the measurement of calcium was also investigated by repeatedly measuring a phantom
consisting of a human skeleton with approximately 700 g calcium encapsulated in
tissue-equivalent rubber. The reproducibility in this case, determined from 10
measurements, was 1.8% for calcium and 2.1% for sodium.
3.2. Measurement corrections
In this section the corrections required to allow for the influence of body habitus on
the combined activation and counting efficiency are determined. These corrections
are essential for accurately calculating the absolute amount of calcium in the subject.
3.2.1. Effect of height. The thermal neutron fluence at a depth of 5 cm, over an area
185 cm high and 60 cm wide at the subject irradiation position, was uniform to within
±8% with the maximum incident neutron flux around 85 cm above the chamber floor.
The effect of varying height was tested by altering the height of the water filled
phantom over the range 150 cm to 193 cm by inserting wax spacers between the
various sections. The phantom was measured twice at each of five different positions.
The range 150 cm to 172 cm was investigated by removing the pelvis section. The
results obtained were fitted by the power law:
% loss of counts = 0.5 (subject height - 1.5)2 x 100 height >1.5 m.
3.2.2. Effect of body build and body fat. The effect of variations in thickness of the
subject, measured along the beam direction, was investigated using sections of the
solution-filled phantoms of different sizes, but similar heights. Two repeated measure¬
ments were made at each of five different thicknesses i.e. 11, 14, 16, 18 and 24 cm.
The decrease in measurement efficiency was 1.8% per cm increase in thickness of
the chest section and 1.4% per cm increase in diameter of the limb section.
3.2.3. Effect of wall separation. Ideally the front and back premoderator sections of
the activation chamber are positioned just to touch the subject's trunk at the front
and back. The separation of the walls is dependent, therefore, on the subject's depth
measured along the beam direction (figure 2). Due to patient apprehension in some
cases this is not possible and the walls are positioned further back than normal. The
effect of this extra separation was investigated by repeatedly measuring both the
solution-filled and the skeletal phantoms, increasing the wall separation each time up
to an air gap of 10 cm. Two repeated measurements were made at each of three
different positions. The decrease in activation efficiency was 1.0% per cm increase
in the air gap.
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3.2.4. Absolute calibration of calcium. Using the results from sections 3.2.1 to 3.2.3,
the mass of calcium in the subject in grams was calculated from the equation:
TBCa = measured calcium x height correction x depth correction
xfat correction x wall correction
where
height correction — 0.5 (subject height — 1.50)2+1 height > 1.5 m
= 1 heights 1.5 m
depth correction = 1.6 (Subject depth —tst —0.2) +1
„ ,/tst+ lst\ „
fat correction = 3.6 ^ J +1
wall correction =1.0 (wall separation —subject depth) +1.
All measurements are in metres and tst = mean torso skinfold thickness of subject,
i.e. the mean of the subscapula and iliac crest measurements; lst = mean limb skinfold
thickness of subject, i.e. the mean of the biceps and triceps measurement; 1.6 = mean
fractional loss per m increase in depth; 3.6 = mean fractional loss per m increase in
fat; 0.2 = reference depth, i.e. the depth of the trunk section of the solution filled
phantom. The depth correction makes the assumption that the depths of the various
limbs scale in proportion to the depth of the trunk.
The number of counts obtained per gram of element was checked by repeatedly
activating three phantoms of different sizes similar to the Bush phantom but with the
calcium and phosphorus contained in solid rods which simulated the human skeleton
(Battye et al 1971). The results obtained for sodium and chlorine agreed within
experimental error. However the calcium was on average 3.1% low and the phos¬
phorus result 11.2% low compared with elements dispersed in solution. This effect
might well be explained by the difference in the combined efficiency of activating and
detecting the calcium and phosphorus when they are uniformly distributed in the
phantom compared with when they are contained in a simulated skeleton. This effect
has also been noted by Spinks et al (1977). The necessary change was therefore made
to the conversion factor for calcium to give counts per gram of the element. The
difference between the results of calcium and phosphorus was due to the fact that the
latter undergoes a fast neutron reaction.
4. Normalisation procedures
To establish the range of normal values for total body calcium, 40 normal volunteers
were measured:-twenty males (six aged 40-49, eight aged 50-59 and six aged 60-69)
and twenty females (two aged 40-49, ten aged 50-59 and eight aged 60-69). All the
subjects were active and in good health. None had any history of disease that might
be expected to influence calcium metabolism, and all had normal blood and urine
biochemistry. There was a large variation in the total body calcium results for both
groups (table 2). The females ranged from 596 to 1036 g with a mean of 821 ± 15.2%
(cv), while the males ranged from 886 to 1428 g with a mean of 1143 + 11.7%. Since
the total body composition of the various elements is clearly related to the subject's
build, a mean value based on sex alone is inadequate. Therefore the dependence of
the measured TBCa on height, span, weight, lean body mass (calculated from the
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Table 2. Data for normal controls.
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Means and percent coefficients of vari¬
ation
Male (cv) Female (cv).
Number 20 20
Height (m) 1.770 (4.7) 1.622 (4.2)
Span (m) 1.843 (4.7) 1.655 (4.4)
Weight (kg) 81.8 (13.8) 63.7 (17.2)
Calcium (g) 1143 (11.7)' 821 (15.1)
skinfold thickness measurement), age and number of years post-menopause was
investigated by multiple linear regression analysis.
For males, this gave a formula for predicted total body calcium in grams (TBCap),
TBCap = 347 (height)2 07 (r = 0.84, P < 0.001).
Total body calcium was also found to be strongly dependent on span
TBCap = 384 (span)1'80 (r = 0.74, P < 0.001).
Height and span are measured in metres. Perhaps because the spread in age was
small no significant dependence of total body calcium on age was observed. Weight
and lean body mass also proved to be unimportant. The biological variation in normal
TBCa due to size could be reduced by expressing the subjects result in terms of the
ratio TBCa/TBCap. When height was used in the formula the cv in the male controls
was reduced to 6.2%.
For the female controls, multiple regression gave
TBCap = 399 (span)1'69 exp(—0.015 Y) (r = 0.90, P< 0.001)
where span was measured in metres and Y is the subject's years post-menopause.
This gave a highly significant correlation with an annual loss of calcium after the
0 5 10 15 20 25
Years post-menopause
Figure 3. Total body calcium of normal women, normalised using the span (j), plotted against years
post-menopause. The line representing a loss of 1.5% per annum is plotted with confidence and tolerance
limits, a is a constant = 399; •, normal women; , confidence limits, P = 0.05; , tolerance limits,
P = 0.10.
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menopause of 1.5% (figure 3). An equally good correlation was obtained if a linear
relationship between calcium and years post-menopause was assumed. Total body
calcium, for the female controls, was also found to be strongly dependent on height
TBCap = 443 (height)1'57 exp(0.016 Y) (r = 0.87, P < 0.001).
Since total body calcium was more strongly correlated with span than with height
and as height may be significantly reduced in patients with osteoporosis, it was decided
to use span rather than height as a variable for normalisation for women. The
coefficient of variation of total body calcium in normal women TBCa/TBCap, after
normalisation improved to 6.6%.
The possibility was investigated that the correction factors, applied to the raw
data, described in section 3.2.4 could be replaced with an extra normalisation factor,
namely weight. Regression analysis performed on the uncorrected data for the male
controls gave a low correlation with height, r = 0.40, compared to the corrected data,
r — 0.84. The introduction of weight as a normalisation factor improved the correlation
considerably
TBCap = CM (height)2'15 (weight)-0'34 (r = 0.80)
where the superscript indicates that this equation refers to the raw data, uncorrected
for the height, build and body fat corrections derived in section 3.2.4.
A similar effect was obtained, using the uncorrected female data, after the introduc¬
tion of a normalisation factor for weight
TBCap = CF (span)1'66 (weight)-0'18 exp(—0.016 Y) (r = 0.89)
where CM and CF are constants.
This contrasts with the case of the corrected data, both male and female, where
weight proved to be unimportant. Therefore to a large extent the correction factors
described in section 3.2.4 and the introduction of weight as a normalisation factor
fulfil a similar function. The cv of the TBCa1/TBCp ratio was 7.0% for both men
and women. When the ratio is used, the units of TBCaJ can be left as 49Ca counts.
However, using the results from the calculations of TBCap, the values CM = 1447 and
CF= 870 will give TBCap in grams of calcium.
/
5. Discussion
The technique of total body neutron activation analysis presented in this paper with
its precision of 1.8% on phantoms is suitable for detecting small changes in total body
calcium. The process of correcting for varying body dimensions is most important for
the accurate determination of the absolute amount of calcium in the body. When the
corrections described in section 3.2.4 were applied to the raw data for our normal
male volunteers they increased the estimated body calcium by 16% on average. The
importance of such corrections has also been emphasised by Spinks (1979). Using a
similar irradiation system, he found correction factors for total thickness and wax
layer thickness which were close to ours. McNeill et al (1974) also studied the effect
of body thickness on the efficiency of activation and measurements of calcium in the
trunk. They found a reduction of calcium counts of 5% cm-1. Their figure was
somewhat higher than ours, probably because their Pu-Be sources were a fixed distance
apart and fairly close to the subject's skin. Correction for body stature is important
not only for absolute calcium determinations, but also for studying changes over a
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period if the subject is likely to alter in weight. Some treatments which lead to
osteodystrophy, or which are designed to avoid the condition, are liable in themselves
to change the amount of fat in the body.
The establishment of a normal range of total body calcium for men and women
is vital if full use is to be made of the absolute values. Total body calcium measurements
of normal volunteers have been made by Nelp et al (1972), Cohn et al (1976), Aloia
et al (1978) and Chesnut et al (1981). Partial body (trunk) measurements have been
made by Harrison et al (1975) and by McNeill and Harrison (1977). The most
comprehensive of these studies is that of Cohn et al (1976). They derived equations
for predicting normal values based on measurements on 79 normal individuals, 48 in
the age range covered by this study. Their whole body counter corrects for variations
in response due to different body dimensions, but no attempt was made to separate
variations in activation efficiency from the biological variations of actual calcium
content in the normal population studied.
The equations developed by Cohn et al (1976), which incorporate height, age and
total body potassium levels, therefore included a consideration of measurement errors,
as well as statistical variations. The coefficient of variation of normalised total body
calcium was 7.8% for men and 7.1% for women. As a result of the different approach
to normalisation and because Cohn et al (1976) assumed a uniform age of menopause
at 55, our values of total body calcium are not directly comparable with theirs. As
in this study, Cohn et al (1976) found total body calcium in males to be dependent
approximately on height squared. These results are in slight disagreement with the
total body calcium study of Nelp et al (1972) and the partial body studies (trunk) of
Harrison et al (1975) who found a near cubic relationship between calcium and height.
The percentage of calcium lost by normal women after the menopause of 1.5%
per year from this study is slightly higher than that of 1.1% determined by Cohn et
al (1976). They also calculated a rate of calcium loss of 0.4% per annum between
the ages of 35 and 55. This is probably the combination of a lower (if existent)
pre-menopausal bone loss and a higher post-menopausal loss from those normal
women who were post-menopausal before the age of 55.
Although multiple regression analysis on our male data gave a mean loss of calcium
with age of 0.1% per year, this result was not significantly non-zero. Cohn et al
(1976) reported a mean annual loss of calcium for the average man of 0.70% after
50 years of age. However it is interesting to note that their result, whch was obtained
by omitting their data for men over 80, leads to such a low predicted value of calcium
for older men that the majority of their own male subjects aged 67 and over have
tbCa/tbCap values substantially greaterthan one.
In section 4 it was shown that the introduction of weight as a normalisation factor
applied to the raw data, rather than using the correction factors described in section
3.2.4, implied that total body calcium was dependent partly on (weight)-0'34 for males
and (weight)-018 for females. These values are in broad agreement with the exponent
determined by Cohn et al (1976) of —0.25 (see appendix Cohn etal 1976, substituting
Kp for K). We obtained no significant dependence on weight after multiple regression
analysis was performed on the final data because of the correction factors used in
section 3.2.4. For the determination of a narrow normal range of calcium values the
use of weight as an extra normalisation factor would appear to be almost as good,
and would be simpler than determining and applying the various correction factors
for height, body fat and thickness. The success of weight as a normalisation factor
presumably depends on its close correlation with body thickness. However the body
./
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correction factors described in section 3.2.4 are important for the accurate determina¬
tion of the absolute amount of calcium in grams in individuals whose size or shape
differs, even by only a few centimetres, from the phantom used for calibration. The
values of the correction factors are only applicable to the experimental arrangement
used in this study. However if other research groups were able to calculate accurately
the absolute amount of calcium in grams in their patients then the equations for
TBCap derived from our normal controls could be used to calculate the TBCa/TBCap
ratio.
We -believe that the best approach -is the one we have adopted, of first trying to
establish an accurate measure of whole body calcium, making correction for all the
variables likely to affect activation and detection efficiency, and then deriving normali¬
sation factors which take into account variations of calcium with size, age and sex.
The narrow ranges for normal subjects that we have observed, with coefficients of
variation of 6.2% for men and 6.6% for women, may allow the technique of total
body neutron activation analysis of calcium to be a useful diagnostic procedure.
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Resume
Analyse par activation neutronique du calcium de corps entier: calibration et normalisation.
Nous avons realise un systeme d'irradiation, utilisant un faisceau de neutrons emis par un cyclotron, qui
optimise Tumformite de l'activation du calcium. L'activite induite est mesuree par un compteur corps
entier a balayage 'shadow shield'. Nous avons calibre Ies mesures et teste leur reproductible a partir de
trois types differents de fantomes. Nous en avons deduit des corrections pour les variations de la taille du
corps, de la profondeur et de l'epaisseur de la graisse. Le coefficient de variation pour les mesures repetees
sur un fantome anthropomorphe est de 1,8% pour une dose absorbee equivalente a 13 mSv (1,3 rem).
Nous avons utilise les mesures du calcium global du corps chez 40 adultes normaux pour deduire les
facteurs de normalisation qui predisent le taux normal du calcium chez un sujet d'age et de taille donnes.
Le coefficient de variation du calcium normalise est de 6,2% chez 1'homme et de 6,6% chez la femme
avec une perte annuelle de 1,5% apres la menopause. Cette faible dispersion des valeurs rendrait utile
une seule mesure a des fins diagnostiques.
Zusammenfassung
Ganzkdrper-Nentronenaktivierungsanalyse von Kalzium: Kalibrierung und .Normierung.
Mit Hilfe eines Neutronenstrahls aus einem Zyklotron wurde ein Bestrahlungssystem konstruiert zur
Optimierung der Gleichformigkeit der Kalziumaktivierung, Die induzier.te Aktivitat wurde in einem
Ganzkorperzahler mit Schattenschutzgemessen. Eine Kalibrierung wurde durchgefiihrt. Die Reproduzier-
barkeit wurde mit drei verschiedenen Phantomtypen bestimmt. Korrekturen fur Anderungen der Korper-
hohe, -tiefe und -dicke wurden abgeleitet. Der Variationskoeffizient fur Wiederholungs-Messungen an
einem anthropomorphen Phantom betrug 1.8% fiir eine Aquivalentdosis von 13 mSv (1.3 rem). Messungen
des Ganzkorper-Kalziums bei 40 gesunden Erwachsenen wurden benutzt um Normierungsfaktoren
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abzuleiten, die den normalen Kalziumgehalt eines Menschen bei vorgegebener GroJ3e und Alter vorher-
sagen konnen. Der Variationskoeffizient von normiertem Kalzium var 6.2% bei Mannern und 6.6% bei
-Frauen, mit einem jahrlichen Verlust von 1.5% nach der Menopause. Der eingeschrankte Bereich konnte
einzelne Messungen fur diagnostische Zwecke brauchbar machen.
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1. Introduction
The measurement of the bone mineral content (bmc) by single photon absorptiometry
has long been an established technique for the forearm. However, in the study of
bone disease, the part-body site of most clinical interest is the lumbar spine. Recently,
efforts have been made to measure the bmc using dual photon absorptiometry (dpa),
the second photon energy being used essentially to correct for varying amounts of
soft tissue within the trunk. The energy combinations that have been used are 241Am
and 137Cs with energies at 60 keV and 660 keV and 153Gd with energies at 44 keV
and 100 keV, the latter being generally considered the most suitable energy combina¬
tion for measurements of the spine.
Although reasonable figures of 2-3% for the precision (or reproducibility) have
been obtained by the various methods, there is a degree of disagreement about the
absolute measurements of bmc. This is particularly the case with cross-sectional data
on normal volunteers, i.e. single bmc measurements on subjects of different ages.
Two groups (Madsen 1977, Riggs et al 1981) have reported no increase in the rate
of loss of bmc from the spine at the time of the menopause. The expected increase
in the rate of loss after the menopause, as shown using total body neutron activation
analysis (Cohn et al 1976, Smith et al 1980) and forearm absorptiometry (Mazess
and Cameron 1974) has, however, been shown in the spine by two other groups
(Krplner and Pors Nielsen 1980, Smith et al 1981) in cross-sectional studies and also
in a longitudinal study (Krplner and Pors Nielsen 1981), where the bone loss was
determined from repeated measurements on individual subjects over a period of time.
It is not known whether this discrepancy between the various methods is due to
differences in methodology or in the populations studied. Before accepting the latter
the possibility of the former must be thoroughly investigated.
All but two of the methods of dpa (Roos 1974, Condon et al 1979) which have
been used for patient or normal volunteer studies have used 153Gd as the radionuclide
source. Obviously there are several factors that influence the accuracy of the technique.
This note considers one aspect of the methodology of dpa which is specifically
important when using 153Gd and which will affect the absolute determination of bmc.
This is the contribution to the 44 keV energy window from the 100 keV energy caused
by Compton events within the crystal and scatter within the patients. This will be
referred to as the 'crossover correction' (xo) and is expressed as a percentage of the
100 keV photopeak.
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2. Gadolinium-153
The radionuclide source 153Gd has a half-life of 242 days with gamma-ray energies
(plus approximate abundance) of 103 keV (23%), 97 keV (31%) and 70 keV (2.6%)
and Eu K x-rays with energies 41 keV (86%) and 47 keV (23%). The peaks at
103 keV and 97 keV and at 41 keV and 47 keV cannot be resolved by Nal detectors
and so are considered as 100 keV and 44 keV peaks respectively. The ratio of the
44 keV peak to the 100 keV peak is approximately 2:1 though this falls to about
1.4:1 from an encapsulated sealed source measured by a Ge(Li) detector, due mainly
to the stainless steel window specified as 0.2-0.25 mm for our source, and to 1.1:1
from the same source measured by a 10 cm diameter, 5 cm thick Nal detector,
additional attenuation arising in the crystal housing. The measurements described in
this paper were performed using a 12 mm diameter sealed 153Gd source (ref no X.92/1,
Amersham 1978) of approximate activity 4 GBq, spectra of which are shown in
figure 1.
Figure 1. 153Gd spectra measured by a Nal detector and by a GeLi detector.
3. Bone mineral calculation
The basic equations for calculating the bmc from two photon energies are quoted
elsewhere (Roos and Skoldborn 1974) but can be simplified to
. /T , f-ST, too, ,T ,
bmc a ln(iioo) ln(i44)
/"•ST, 44
where I is the count rate of 100 keV or 44 keV radiation, fj-sr is the attenuation
coefficients through soft tissue at 100 keV or 44 keV, and /44 is (measured count rate
in 44 keV region) — (xo/100) x/100 with xo the crossover correction (per cent).
The two criteria for accurate measurements of bmc by the technique of dpa using
the above equation are that (i) the bmc must be independent of the thickness of soft
tissue and (ii) the measured bmc must be proportional to the actual bmc. The xo
will affect both the estimate of /44 and /tSt,44 in the above equation. The mean supine
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anterior to posterior thickness (with range) at the lumbar region in 180 normal subjects
and patients was found to be 22 cm (15-29 cm) in men and 19.8 cm (15-29 cm) in
women. Criterion (i) must be verified over an appropriate range of soft tissue
thicknesses. For criterion (ii) to be fulfilled the basic assumption that both 44 keV
and 100 keV radiation have exponential attenuation in bone and soft tissue must be
true. In particular the attenuation of the corrected 44 keV radiation through bone
mineral or a similar material such as aluminium must be exponential.
4. Crossover correction
Experiments to investigate the xo were performed using a 13 mm diameter source
collimator and a 20 mm square detector collimator with a separation between the two
of 0.4 m. This collimation, which we have used for spine bmc measurements (Smith
et al 1981), is slightly larger than that used by Wilson and Madsen (1977) and smaller
than that used by Peppier and Mazess (1981). Some experiments were also performed
using 6 mm diameter source and detector collimators, the size used by Riggs et al
(1981) and smaller than that used by Krplner and Pors Nielsen (1980). The Nal
detector used was 10 cm diameter, 5 cm thick, with an energy resolution of 20-25%
over the energy range used.
The standard method adopted in the past to calculate the xo has been to use
copper to filter out the 44 keV peak at the source collimator. This method was used
with a 3.3 mm Cu filter and energy windows from 27-61 keV and 83-121 keV. Using
the larger collimation the xo was found to vary with the thickness of soft tissue
equivalent material (stem) (figure 2) but the two criteria mentioned previously were
STEM thickness (cm)
Figure 2. Variation in the xo with different thicknesses of stem measured using: 9—9 the standard
Cu filter technique, 13 mm source and 20 mm detector collimators; 9•■ ■ 9 Cu filter, 6 mm source and
detector collimators; ■—■ simulated spectrum with U and Hg, 13 mm and 20 mm collimators; ■ ■ ■ • ■
simulated spectrum, 6 mm collimators; using Cu filter multiplied by ratio of portions between the
peaks, 13 mm and 20 mm collimators.
not fulfilled (figure 3) due to an apparent underestimation of the xo. The possible
reasons were investigated.





of 44 keV through AI
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Figure 3. Attenuation of 44 keV radiation using 13 mm source and 20 mm detector collimators through
Al within 20 cm STEM; x, uncorrected; #, corrected using XO from the standard Cu filter technique; ■,
corrected using new XO values. The theoretical attenuation was calculated assuming narrow beam attenu¬
ation (McMaster et al 1969).
The error due to background may be negligible when measuring the bmc but
becomes significant when calculating the xo values. More important than the room
background were the Compton scatter contributions from 152Eu contamination in the
153Gd source. Lead 4 mm thick was used to filter out the 153Gd to assess the
contribution from the higher energy peaks of 152Eu to the 44 keV and 100 keV
channels. The variation in background, including 152Eu, with thickness of stem was
Energy (keV)
Figure 4. Spectra of 153Gd through 10 mm Al and 20 cm stem with and without 3.3 mm Cu filter.
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measured and used to correct subsequent data. No corrections were ever required
for counting losses.
The 153Gd spectrum with stem and aluminium in place to simulate the transmission
through the lumbar spine was compared with the spectrum of the same arrangement
with the Cu filter, both spectra having the same number of counts in the 100 keV
channel (figure 4). It can be seen that the filtered 153Gd spectrum appears to underesti¬
mate the contribution to the 44 keV channel. It seemed likely that the low abundance
70keV peak in the 153Gd spectrum contributes appreciably to the lower energy
channel, but is severely attenuated by the copper used to eliminate the 44 keV
radiation.
The possibility was investigated by using monoenergetic x-rays to simulate the
upper portion of the 153Gd spectrum. Between 4 and 70 GBq of 99Tcm, absorbed
onto ion exchange resin, was used to produce the characteristic 70 keV and 100 keV












Figure 5. Vertical section through the circular source collimation used for measurements with the charac¬
teristic x-rays from mercury and uranium.
separately with the 99Tcm in the position of the 153Gd source so that the geometry
remained the same. The counts in the 44 keV region were expressed as a percentage
of the counts in the respective photopeaks. The proportion of the 70 keV peak
compared with the 100 keV peak from the 153Gd source in air was 4.6% as measured
by a Ge(Li) detector. This value combined with the relative attenuations of the 70 keV
and 100 keV Hg and U peaks through stem enabled the xo contribution from the
70 keV 153Gd peak to be expressed as a percentage of the 100 keV peak. The resulfs
are shown in table 1 and the total xo value plotted in figure 2.
It was found empirically that if the xo derived from the use of the copper filter
was multiplied by the ratio of the portions of the two spectra in figure 4 between the
peaks (60-85 keV) the two criteria required in the calculation of bone mineral were
fulfilled. The values of the xo calculated in this way for the 13 mm source and 20 mm
detector collimation are shown in figure 2 for various thicknesses of stem.
It can be seen that both the new methods of calculating the xo give the same
result (figure 2). When these xo values were used for measurements on 10 mm A1
in depths of water ranging from 8 cm to 27 cm no variation in the apparent mineral
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Table 1. XO values for 44 keV region using Hg and U to simulate the upper part of the 153Gd spectrum
with 13 mm source and 20 mm detector collimators.
Thickness of STEM (cm)
0 5 10 15 20 25
Using U. Percentage of 100 keV photopeak 2.0 1.9 2.3 2.5 3.1 3.4
Using Hg. Percentage of 70 keV photopeak 13.2 13.5 16.6 20.6 25.0 27.2
Combined U and Hg to simulate 1S3Gd. 2.5 2.5 3.1 3.5 4.3 4.7
Percentage of 100 keV photopeak
content was found. In addition the attenuation of the corrected counts in the 44 keV
channel through A1 in 20 cm scattering medium was exponential (figure 3).
5. Discussion
The importance of the correct calculation of the xo value for absolute measurements
of spine bmc should not be underestimated. Although the actual percentage value
may seem low, a xo value of only 3% would reduce the counts in the 44 keV region
by 19% in a subject of average thickness (22 cm) and average bone density, and by
25% in a subject of thickness 27 cm (approximate normal mean + 2sD) and high bone
density (approximate normal mean + 2sD). In a subject 22 cm thick the use of a xo
value of 2.8%, obtained using the standard Cu filter technique, rather than the true
value of 4.4%, will produce an error of 15% in the bmc measurement of a normal
subject.
The xo values quoted vary considerably. Mazess et al (1974) quote 1.9%, Wilson
and Madsen (1977) 3.0%, Wahner and Dunn (1980) 6.0% and Riggs et al (1981)
4-6% depending on the source. The commercial apparatus used by Krplner and Pors
Nielsen (1980) has a xo of 'about 1%' (personal communication). Only Peppier and
Mazess (1980) mention that xo varies with depth, 1.8% at 14 cm and 3.4% at 25 cm;
Wilson and Madsen (1976) specifically state that it does not. Although, as we have
shown, the xo will depend on the size of the beam, the variation in xo values quoted
by different authors cannot be attributed to variations in collimator size and should
not depend on the source. It has been suggested that 'beam hardening' could account
for any deviation from an exponential by the 44 keV radiation (Krplner and Pors
Nielsen 1980). We would suggest that an underestimation of the xo value could be
the true cause. Similarly the non-linear relationship between measured bmc and
actual bmc which sometimes has to be corrected for (Krplner and Pors Nielsen 1980)
is due to the same effect. /
The underestimation of the xo is due to the significant contribution from the small
70 keV 153Gd peak which may be completely filtered out by Cu. This photopeak will
produce an iodine escape peak at 40 keV. Thus, for example, in a 20 cm thick patient
70% of the total xo is due to the 100 keV peak and 30% due to the 70 keV peak.
The xo has been shown to vary with the thickness of the patient though when
small collimation is used this variation is small. If, as is often the case, larger collimators
need to be used to achieve acceptable count rates then a xo value appropriate for
the patient's thickness must be used. The previous standard method of using Cu to
filter the lower energy channel has been shown to be inadequate. It is suggested that
Crossover correction in dual photon absorptiometry 1521
the true xo should be calculated by simulating the 100 keV and 70 keV peaks of the
153Gd spectrum over a range of stem from 12 cm to 28 cm.
Acknowledgments
The authors would like to thank Mr M Connell and Dr C McGeorge for advice and
assistance, Miss J Edwards and Mr J Wilson for technical assistance, Mrs D McKinna
for secretarial services, Miss D Lytton of the Department of Medical Illustrations,
and the Scottish Home and Health Department for funding the purchase of the 153Gd.
References
Amersham Radiation Sources Catalogue 1978 p 441
Cohn S H, Vaswani A, Zanzi I and Ellis K J 1976 Am. J. Physiol. 230 143
Condon B, Tothill P and Smith M A 1979 Calcif. Tissue Int. 27 s 29
Krplner B and Pors Nielsen S 1980 Scand. J. Clin. Lab. Invest. 40 653
1981 Calcif. Tissue Int. 33 s 171
Madsen M 1977 Invest. Radiol. 12 185
Mazess R B and Cameron J R 1974 in Proc. Int. Conf. Bone Mineral Meas. NIH75-683228
Mazess R B, Wilson C R, Hanson J, Kan W, Madsen M, Pelc N and Witt R 1974 in Proc. Symp. on Bone
Mineral Determination, Aktiebolaget Atomenergi, Stockholm-Studsvik 2 40
McMaster W H, Kerr Del Grande N, Mallet J H and Hubbell J H 1969 University of California Radiation
Laboratory Report UCRL-50174 SecII 53
Peppier W W and Mazess R B 1981 Calcif. Tissue Int. 33 353
Riggs B L, Wahner H W, Dunn W L, Mazess R B, Offord K P and Melton L S 1981 /. Clin. Invest. 67 328
Roos B 1974 PhD Thesis University of Gothenburg
Roos B O and Skoldborn H 1974 Acta Radiol. Ther. Phys. Biol. 13 266
Smith M A, Kennedy N S J, Eastell R, Simpson J D, Strong J A and Tothill P 1980 Nucl. Med. Commun.
1 166
Smith M A, Sutton D, Hannan J, Tothill P and Wilson J 1981 in Proc. Symp. on Osteoporosis, Jerusalem
in press
Wahner H W and Dunn W L 1980 Nucl. Med. Commun. 1 211
Wilson C R and Madsen M 1977 Invest. Radiol. 12 180
 
Journal of Medical Genetics, 1982, 19, 100-103
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summary The hypothesis that the demineralisation associated with gonadal dysgenesis is analogous
to post-menopausal osteoporosis was investigated. Bone mineral content of the distal forearm was
measured in 11 adult patients with Turner's syndrome aged 18 to 57 years. As a group these patients
were significantly demineralised (p<0-001) when compared with normal subjects. A bimodr
distribution of bone mineral was demonstrated, the eight patients below the normal range having a
bone mineral content 73% of normal. This may be the usual bone mineral content for a large
proportion of Turner's patients. No steady reduction in mineralisation with age was demonstrated.
The number of osteoporotic type fractures was obtained from the records of 36 adult patients with
Turner's syndrome. From the cumulative total years at risk (770 patient years) from the age of 15
years, it was found that the number of fractures of the distal radius corresponded to the normal
premenopausal rather than post-menopausal fracture incidence. The absence of any reduction in bone
mineral content with age and no clear evidence of an increase in frequency of fractures both suggest
that the demineralisation associated with Turner's syndrome is not analogous to post-menopausal
osteoporosis. The regular use of long term oestrogen therapy as a treatment for 'osteoporosis' in
these patients is therefore not justified.
Qualitative assessment of skeletal radiographs from
patients with Turner's syndrome has demonstrated
that in this condition osteoporosis occurs with a
frequency of between 60 and 80 %.1-4 In affected
children bone histology has shown increased bone
resorption with normal bone formation,5 while
radiographs of the second metacarpals show reduced
total diameters and increased medullary diameters.2 6
The degree of demineralisation owing to osteo¬
porosis can be assessed quantitatively using the
technique of photon absorptiometry. The linear
density of bone is obtained from the degree of
attenuation of radiation from a monoenergetic
radionuclide source.7 This technique has been used
to demonstrate demineralisation of the radius and
os calcis in children and young adults.5 8
Oestrogen inhibits bone resorption in osteo¬
porosis9 and has been advocated for the treatment of
post-menopausal osteoporosis.10 The rationale
behind this treatment is the prevention of the normal
loss of bone mineral of about 1 % per annum,11
thus reducing the likelihood of debilitating fractures
in later life. There are, however, disadvantages since
Received for publication 11 May 1981.
there is evidence that when it is terminated the
mineral content falls to the level at which it would
have been had no treatment been given.12 Thus, to
achieve a long term benefit, oestrogen therapy may
have to be continuous. Other disadvantages include
associated side effects such as increased incidences
of abnormal uterine bleeding and endometrial
carcinoma.13-16
The treatment of osteoporosis in patients wit
Turner's syndrome might depend on whethe.
osteoporosis associated with gonadal dysgenesis is
analogous to post-menopausal osteoporosis in
normal women. If it is, there should be a steady
decrease in bone mineral after the age of about 15
years combined with a raised incidence of fractures.
In these circumstances long term oestrogen therapy
would be indicated.
The present study was undertaken to investigate
the bone mineral content (BMC) in adult patients
with Turner's syndrome, and to assess the severity
and age relationship of any deficit in bone mineralisa¬
tion. The incidence of osteoporotic fractures has
also been examined and compared with the incidence
in the general population.
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Patients and methods
The bone mineral content was studied in 11 adult
patients with Turner's syndrome over a wide age
range (18 to 57 years). These were available patients
with Turner's syndrome in the south-east of Scot¬
land who were over the age of 18 years and who had
been registered with the MRC Cytogenetics Unit.
They had all given informed consent to the investiga¬
tion. Their mean height was 140-8 cm. Other details
of the patients are given in table 1. For comparison
we studied a group of 16 healthy premenopausal
women of presumed normal karyotype aged 18 to
44 years. Within the group of 16 there was a sub¬
group of 11 short women with a mean height of
154-0 cm whose BMC measurements were used to
establish the normal range. The remaining five were
significantly taller with a mean height of 169-1 cm,
and their BMC measurements were used to deter¬
mine the effect of a height difference of 15 cm.
The BMC of the non-dominant forearm was
measured by photon absorptiometry using a
commercial 'Novo Osteodensitometer' which had a
reproducibility of 1 -4%.17 The source and detector
scan the forearm in a rectilinear motion from the
distal end. The BMC is measured for each traverse,
but is only stored once the gap between the radius
and ulna exceeds 6 mm. A further five scans, 4 mm
apart, are performed and the total BMC of the
radius and ulna are recorded. The width of the
radius and the ulna on the third and sixth traverse
were measured from a chart recorder output and
their sum total (W) used as a normalisation factor.
The medical records of the 11 patients with
Turner's syndrome and of 25 others with the same
diagnosis were examined. Their mean age was
36-4+8-4 years (±SD). The number of fractures
since the age of 15 years of the type associated with
osteoporosis, that is, of the distal radius and of the
neck of the femur, was noted and compared with
igures for a normal Scottish population.18 The
cumulative total years at risk in the group of 36
table 1 Details ofpatients with Turner's syndrome on
whom the BMC of the distal forearm was measured
Patient Age Karyotype Oestrogen therapy
ES 18 45 ,X/46,Xi(Xq) 1978-
JC 26 45,X/46,XY Never
CM 26 45,X Never
MV 27 45,X 1972-1973
IC 35 45,X 1965-1977
SG 36 45,X/46,XY 1964-1965
HB 39 46,Xi(Xq) 1974-
MS 42 45,X 1956-1967
FS 47 45,X 1956-1961
ML 45 45,X Irregularly until 1977
HS 57 45,X Never
patients with Turner's syndrome was 770 patient
years.
Results
The results of BMC measurements are displayed in
fig 1. For three patients with Turner's syndrome
they were within the normal range and for eight
they were significantly low (five patients p<0-05,
three patients p<0-01). The mean for the group of
patients with Turner's syndrome was 2-31+0-44
(arbitrary units +SD) which is significantly lower
(p<0-01) than for the group of normal subjects,
whose mean was 2-85+0-27. The results of the
group of taller normals (mean BMC =2-94)
demonstrated that a height difference of 15 cm did
not significantly affect the normalised BMC values.
It can be seen in fig 1 that the eight patients with
values outside the normal range are perhaps a sub¬
group in themselves with a mean value of2 • 07 ±0 • 15
which is 73 % of normal. Indeed, the three patients
(CM, SG, MS) in the normal range were found to be
biochemically hypothyroid, a condition which may
be expected to increase bone mineral. One of these
three patients (SG aged 36) was still menstru¬
ating spontaneously.
The values of BMC are plotted against age in
o?
fig 1 BMC values in patients with Turner's syndrome
compared with the normal range. Note the narrow
spread in BMC values ofpatients below the normal
range.
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table 2 Comparison of all quantitative studies of BMC
in Turner's patients. Note the close agreement in the
results of the three studies.








fig 2 BMC values in patients with Turner's syndrome
plotted against age. The normal rate of loss in post¬
menopausal women is shown.
fig 2. No significant correlation was found whether
or not patients CM, SG, and MS were included in
the analysis. It is apparent from fig 2 that there is no
reduction in mineralisation with age as has been
found in normal post-menopausal women. The
dotted line in fig 2 corresponds to a loss of 1 % per
annum, the value obtained by BMC in post¬
menopausal women,11 starting at the age of 15 years
and with the BMC equal to the value for the sub¬
group of eight patients with reduced mineralisation.
There were only two osteoporotic type fractures
in the group of 36 Turner patients. One patient had
fractured the neck of the femur aged 32 years, and
the other the distal radius aged 35 years. The
incidence of fractures of the distal radius in the
normal population is 0 • 55 % per annum and 0-15%
per annum for post-menopausal and premenopausal
women, respectively.18 Applying these values to the
accumulated Turner patient years at risk, the
expected number of fractures of the distal radius
would be four at the post-menopausal fracture rate
and one at the premenopausal rate. Similar analysis
of neck of femur fractures could not be performed
because the number of fractures based on the normal
incidences was less than one for both pre- and post¬
menopausal periods. The patient with a fracture of
the lower end of the radius (MS) had a normal BMC.
Discussion
The results are in good agreement with those
obtained in another two studies of bone mineral
content in Turner's syndrome.5 8 In both these
studies the mean BMC was significantly reduced
and in both the values fell into two clear groups,
those in the normal range and those which were
distinctly low. All three studies therefore suggest a
bimodal distribution with the mean for the lower
No Age No Mean BMC of
BMC of range significantly demineralised patients
site patients M demineralised ( % of normal)
Radius 8 9-19 6 71% Brown et al5
Os calcis 6 17-28 3 72 % Risch et als
Distal 11 18-57 8 73 % Present study
forearm
values being in close agreement in the three studies
(table 2). This suggests that this may be the usual
bone mineral content for the larger proportion of
Turner patients. The proportion of patients with low
values (73%) also agrees with the prevalence of
'osteoporosis' found radiologically.1-4 The BMC
values of the patients bore little or no relationship,
to whether oestrogen therapy had been administered
previously (table 1). This was not surprising as it is
known that any gain in bone mineral because of
oestrogen therapy disappears once treatment is
stopped,12 and only two of the patients in this
present study are currently receiving oestrogen
(ES and HB). The values for both these patients are
at the upper end of the range for the sub-group with
low BMC values.
The failure to demonstrate a reduction in bone
mineral content with age (fig 2) in this study is
substantiated by measurements of metacarpal
cortical thicknesses in 22 patients aged 18 to 56
years.2 No reduction in cortical thickness in the
older patients was observed although it was not
commented on in the paper. This is contrary to the
findings in post-menopausal women in whom there
is a progressive reduction in BMC with age. If BMC
had been reduced by 1 % per annum in the patients
with Turner's syndrome we would have expected to
see it even with the relatively small numbers studied.
It had not been our clinical impression that the
fracture rate in Turner patients was noticeably,
different from normal subjects of similar age.
Unfortunately, it is not possible to draw firm
conclusions from the analysis of fractures in this
study because of the small numbers. However, the
incidence of fractures of the distal radius does
appear to be lower than the incidence in post¬
menopausal women and is comparable, in fact, to the
incidence in women of similar age. A lower than
expected fracture rate was also noted by Preger
et al2 in a group of over 50 Turner patients.
In conclusion, this study quantifies the bone
mineral content in patients with Turner's syndrome.
The absence of any reduction in BMC with age and
no clear evidence of an increase in frequency of
fractures both suggest that if osteoporosis is a
Bone demineralisation in patients with Turner's syndrome
complication of Turner's syndrome it should not be
thought analogous to the osteoporosis that occurs in
post-menopausal women. It would not, therefore,
be possible to justify the regular use of long term
oestrogen therapy in patients with Turner's syndrome
on the grounds of 'osteoporosis'.
We wish to thank Novo Diagnostic Systems for the
loan of the Osteodensitometer, Mrs D McKinna for
secretarial services, and Miss D Lytton of the
Department of Medical Illustration.
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Total body calcium in
rheumatoid arthritis: effects of
disease activity and
corticosteroid treatment
D M REID, N S J KENNEDY, M A SMITH,
PTOTHILL, GNUKI
Abstract
Rheumatoid arthritis may be associated with generalised
as well as periarticular osteoporosis. To assess the extent
of bone loss and the influence of corticosteroid treatment
total body calcium was measured by in-vivo neutron
activation analysis in 63 patients with rheumatoid
arthritis treated with non-steroidal anti-inflammatory
drugs alone and 31 treated with additional low-dose
corticosteroids. The results were compared with those in
40 normal controls matched for age, sex, and menopausal
state. There were significant reductions in mean total
body calcium in the group treated with non-steroidal
anti-inflammatory drugs (5-3% in men; 6-8% in women)
and greater reductions in the corticosteroid-treated
patients (11-5% in men, 15-5% in women). The reduction
was correlated with disease duration and activity in the
patients treated with non-steroidal anti-inflammatory
drugs alone. Measured total body calcium was signifi-
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cantly less than the values predicted when this relation
was used in the corticosteroid-treated patients. The data
suggest that increased bone loss in patients with rheuma¬
toid arthritis treated with corticosteroids is attributable
to drug treatment rather than disease activity.
Many patients with rheumatoid arthritis treated with
low-dosage corticosteroids and some postmenopausal
women with the disease are likely to be at risk from the
complications of osteoporosis.
Introduction
Rheumatoid arthritis is thought to be associated with generalised12
as well as periarticular osteoporosis, but considerable uncertainty
exists regarding the extent of bone loss and its relation to the
duration of disease, disease activity, and additional corticosteroid
treatment. Most previous studies of osteoporosis in rheumatoid
arthritis have used radiological or photon absorptiometric
methods.2 These techniques have the disadvantage of using
single bone sites and may be particularly misleading in a disease
associated with severe and variable localised periarticular
osteoporosis. The only accurate method of measuring total bone
mass in vivo is to measure total body calcium using neutron
activation analysis.3 To assess bone mass in rheumatoid arthritis
and its relation to duration of disease, disease activity, and drug
treatment we measured total body calcium in sizable groups of
patients treated with non-steroidal anti-inflammatory drugs
alone and with additional corticosteroids and compared the
results with those obtained in controls matched for age, sex, and
menopausal state.
Subjects and methods
We measured total body calcium in 63 patients (29 men, 34 women)
with definite or classical rheumatoid arthritis4 treated with non¬
steroidal anti-inflammatory agents alone and in 31 patients (nine men,
22 women) who were receiving in addition low-dosage corticosteroids
(<10 mg prednisolone/day) (see table). The results were compared
with those from 40 normal control subjects (20 men, 20 women).5
Serum calcium, phosphate, and protein concentrations and alkaline
phosphatase activity were measured in all subjects, and those with
abnormalities of calcium metabolism or medical conditions associated
with secondary osteoporosis were excluded.
Total body calcium was measured by in-vivo neutron activation
analysis. Patients were irradiated for 20 seconds from front and back,
while standing in a rigid polyethylene activation enclosure, using
/
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neutrons from the Edinburgh MRC cyclotron. They were then
transferred to a shadow shield whole-body counter, where the gamma
radiation from calcium-49 induced from stable calcium-48 by neutron
capture was measured for 20 minutes. The patient's total body
calcium (in grams) was calculated by comparison with the energy
spectrum from an activated anthropomorphic phantom containing a
known quantity of calcium. Repeated measurements of the phantom
gave a long-term precision of 1-8% for a radiation dose of 13 mSv
(1-3 rem). Mean total body calcium (±1 SD) in the control population
was 1142-7 ±133-8 g in men and 820-5 ±124-5 g in women. Individual
results were expressed as a percentage of the expected normal value
for the patient's skeletal size (arm span) and menopausal state. The
spread in the normal range was 7-8% in male controls and 6-5% in
female controls.5
Clinical assessments undertaken at the time of measurement of total
body calcium included measurements of articular index,6 functional
state,7 Westergren erythrocyte sedimentation rate, duration of early
morning stiffness, and rheumatoid factor titre.8 Statistical analysis of
results was performed using Student's t test for unpaired variables
and by multiple linear regression analysis. The Mann-Whitney test
was used for data not normally distributed and for small samples. All
patients gave informed consent, and ethical approval was obtained
from local and national committees.
Results
The table shows details of age, duration of disease, variables of
disease activity, and corticosteroid dosage in the patients studied.
Comparison of the results obtained in the control and patient groups
(fig 1) showed a significant reduction in mean total body calcium in
patients receiving non-steroidal anti-inflammatory drugs alone (men
5-3%, p<0-05; women 6-8%, p<0-01). Mean total body calcium was
further reduced in patients receiving low-dosage corticosteroids
compared with controls (men 11-5%, p<0-01; women 15-5%,
p <0-001) and in women receiving low-dosage corticosteroids com¬
pared with those receiving only non-steroidal anti-inflammatory drugs
(8-7%, p<0-02).
In patients receiving non-steroidal anti-inflammatory drugs total
body calcium was not significantly correlated with any single index of
disease activity or duration. Multiple linear regression analysis,
however, showed a weak but significant correlation between total body
calcium and a composite index of articular index, functional state,
erythrocyte sedimentation rate, rheumatoid factor titre, and duration
of disease (r=0-34, p<0-01) in 56 patients who had not received gold.
A similar correlation was shown in 26 of the patients receiving
corticosteroids (r = 0-64, p<0-01), in whom there was also an inverse
correlation between total body calcium and articular index (r= —0-60,
p<0-01).
When the equation obtained by multiple linear regression analysis
in patients receiving only non-steroidal anti-inflammatory drugs was
used the mean total body calcium in patients receiving additional
4
Mean age and variables ofdisease in patients studied {ranges given in parentheses)
Men Women
NSAID* Steroids NSAID* Steroids
(n = 29) (n = 9) (ri = 34) (n = 22)
Age (years) 51-7 53-6 52-4 561
(29-70) (32-70) (25-70) (34-69)
Duration of disease (years) 8-5 5-7, 8-2 12-3
(0-8-28) (1-5-10) (0-6-30) (3-33)
Erythrocyte sedimentation rate
(mm in first h) 35-9 31-9 39-5 35-0
Rheumatoid factor (1/titre)
(1-115) (2-104) (2-105) (4-137)
392 566 345 432
(0-1280) (0-1280) (0-2480) (0-1280)
Articular index 10-6 9 14-8 10-6
(0-21) (0-18) (4-31) (1-23)
Functional state 2-14 1-89 1-99 2-00
(1-4) (1-2) (1-2-5) (1-3)
Prednisolone (mg) 6-1 6-3
(4-6-9-5) (4-10)
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fig 1—Total body calcium expressed as percentage of expected normal
value (mean ± 1 SD) in male and female controls and patients with rheumatoid
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FIG 2—Relation of total body calcium, expressed as percentage of mean
normal value with daily dose of prednisolone (mg) in patients with rheu¬
matoid arthritis treated with corticosteroids.
corticosteroids predicted from the duration of disease and variables
of disease activity was found to be 93-6±3-7% (range 87-5-102-3%).
This was significantly higher (p< 0-005) than the measured value in
this group and similar to the measured value (93-2 ±10-9%) for men
and women in the group taking non-steroidal anti-inflammatory
agents alone. No significant differences were found in erythrocyte
sedimentation rate, functional state, and rheumatoid factor titre
between the group receiving non-steroidal anti-inflammatory drugs
alone and additional corticosteroids, although the duration of disease
was 25% higher (p<0-02) and the articular index 20% lower (p<0-05
in the group receiving corticosteroids.
In patients receiving corticosteroids total body calcium was closely
correlated with the mean daily dose of prednisolone (r=—0-66,
p<0-001) (fig 2) but not with duration of treatment or the total
steroid dose (daily dose x duration of treatment).
Discussion
These studies show a significant reduction in mean total body
calcium in patients with rheumatoid arthritis who had not
received corticosteroid drugs and strongly suggest that the
reduction in bone mass is an integral feature of the disease. The
only previous studies of total body calcium in patients with
rheumatoid arthritis showed conflicting results. In a small
preliminary study Zanzi et al9 found no reduction in seven
women who had not received corticosteroids, while Kennedy
et al10 found an 18% reduction in 32 women compared with
hypertensive controls. No details of drug treatment preceding
the study were given in the latter paper.
'JL
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By using localised methods of skeletal measurement several
previous studies have suggested a relation between bone loss
and duration of disease in rheumatoid arthritis,11-13 while others
have been unable to confirm this.14-16 Most studies in which
radiological or absorptiometry methods have been used,
however, have suggested a relation between bone loss and
variables of disease activity including erythrocyte sedimentation
rate13-15 and rheumatoid factor titre.13
Unfortunately, there is no good method by which overall
disease activity over a period of time can be assessed. The
composite index used in this study included the erythrocyte
sedimentation rate and rheumatoid factor litres as indicators of
disease activity at the time of measurement of total body calcium
as well as functional state and duration of disease, which also
reflect the clinical state over a prolonged period. Although the
correlation between total body calcium and the composite index
of disease duration and activity in patients who had not received
corticosteroid treatment was relatively weak, it did permit total
bone mass in the steroid-treated patients to be predicted. The
striking discrepancy between measured and predicted total body
calcium in the steroid-treated group suggests that loss of bone
mass in these patients is directly attributable to the drug
treatment and not a function of more prolonged or severe under¬
lying disease. Some previous studies using less sophisticated
methods have failed to show a relation between osteoporosis
and corticosteroid treatment in patients with rheumatoid
arthritis,111517 and it has been suggested that low-dosage
treatment may be free from this risk and that improved mobility
attributable to the use of corticosteroids may have the effect of
reducing bone loss. Most studies, however, have shown evidence
of increased bone loss in patients with rheumatoid arthritis
treated with corticosteroids,9 1818 although this has not been
correlated with steroid dosage. The finding that daily cortico¬
steroid dosage is correlated with reduction in total body calcium
while duration of corticosteroid treatment is not is consistent
with the hypothesis that the histochemical changes and catabolic
effects of corticosteroids on bone are most pronounced early in
the course of treatment.19 20
Previous measurements of total body calcium in women with
symptomatic postmenopausal osteoporosis have shown mean
reductions of 16 and 18% greater than expected values.3 21 This
would seem to suggest that despite low mean daily doses of
prednisolone (men 6-1 mg; women 6-3 mg) some male patients
with rheumatoid arthritis treated with corticosteroids (mean
reduction in total body calcium of 11-5%) and many female
patients (mean reduction 15-5%) are at risk of osteoporotic
complications. As a group patients treated with non-steroidal
anti-inflammatory drugs alone, with a mean reduction in total
•J
7
body calcium of only 5-3% in men and 6-8% in women;, are
probably not at high clinical risk of complications ofosteoporosis.
Since, however, the range of the reduction was wide ( — 20% to
+ 12% in men; —33% to +19% in women) and many patients
with rheumatoid arthritis are postmenopausal women, probably
many individual patients~who 'have not received corticosteroids
will sustain clinically important reductions in skeletal mass.
Although there has been an isolated report of spontaneous
fractures in patients with rheumatoid arthritis who had not
received corticosteroids,22 there is clearly a need for epidemio¬
logical studies of the incidence of fracture in patients with this
disease.
These studies also suggest that it will be important to try and
establish the pathological basis of reduced bone mass in patients
with rheumatoid arthritis as well as to determine to what extent
this is the result of local and generalised osteoporosis.
This work was supported by grants from the Scottish Hospital
Endowment Research Trust and the Arthritis and Rheumatism
Council. We are indebted to the Medical Research Council for use of
the cyclotron at the Western General Hospital, Edinburgh.
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Abstract. The bone mineral content (bmc) of the spine can be measured from the
attenuation of two photon beams. An equation was derived for the theoretical precision
of bmc measurement and validated experimentally. Though 1!3Gd was found to possess
the better energy combination, the precision due to the photon energy levels using
241Am,137Cs was only 1.5 times the value obtained from 153Gd. The available photon
outputs from 241 Am and 153Gd were investigated and with a 12 mm diameter disc source
a theoretical precision of 1% could be obtained with source strengths 20GBq "41Am or
5 GBq 153Gd in a 40min and 20 min patient scan respectively. There was no great
advantage in either energy combination when the problems of fat or patient dose were
considered. Given the disadvantages of 153Gd, its cost and availability, 243Am,137Cs can
be used as a practical alternative to measure spine bmc from a reconstructed bone mineral
image.
1. Introduction
Dual-photon absorptiometry (dpa) to measure bone mineral content (bmc) was first
proposed by Reed (1966). Subsequently interest concentrated on the forearm and
single-photon absorptiometry became the method of choice (Cameron and Sorenson
1963, Christiansen and R0dbro 1977). More recently the technique of dpa has been
used to measure the bmc of the spine, the site of most clinical interest, (Mazess et al
1974, Roos and Skoldborn 1974, Wilson and Madsen 1976, Price et al 1977, Condon
et al 1979, Krplner and Pors Nielsen 1980, Wahner and Dunn 1980, Smith et al
1983) and whole body (Price et al 1977, Peppier and Mazess 1981), the second energy
being used to compensate for variations in the thickness of overlying soft tissue.
The photon energies at 60 keV and 660 keV from 241Am and 137Cs respectively
have been used by Roos and Skoldborn (1974) and Condon et al (1979). More
commonly the radionuclide 153Gd, with effective energies at 44 keV and 100 keV has
been used (Mazess et al 1974, Wilson and Madsen 1976, Krplner and Pors Nielsen
1980, Wahner and Dunn 1980, Smith et al 1983). The reason for this is that it has
become generally accepted that 153Gd possesses the optimum energy combination for
such work. Mazess et al (1974) state that 153Gd is optimal for bones larger than the
radius and ulna, citing the theoretical work of Judy (1971). However Judy (1971)
concludes that the optimum lower energy for dpa is between 30 keV and 40 keV for
a thickness of soft tissue of only 5 g cm"2. Peppier and Mazess (1981) state that 153Gd
is optimal, citing the theoretical work of Hanson (1974) and Watt (1975). Hanson
(1974), however, compared l53Gd with 125I,241Am for thicknesses of soft tissue ranging
r Present address: Department of Medical Physics, Essex County Hospital, Colchester, Essex, England.
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up to 10 gem-2. Watt (1975) does show the optimum lower energy to be 40 keV,
but for a total sample thickness of only 15 g cm-2 and an upper energy of 400 keV.
The suggestion that 153Gd possesses the optimum lower energy is therefore interpreted
from calculations using thicknesses that are of the order of half that found in human
subjects in the region of the lumber spine. In addition, none of the theoretical analyses
included all the variables associated with the bone mineral measurement.
Although I53Gd may have nearly the optimum energy for bmc measurements of
the spine, it has a relatively short half-life of 240 d compared with 458 yr for 241Am.
In addition, 153Gd is more expensive and less readily available than 241Am. The cost
of 153Gd, which has to be replaced annually, is therefore considerably greater than
241 AAm.
Two factors, however, cause 241Am to have a much lower photon output per unit
volume than 153Gd. The first is its much longer half-life. The second is the photons
emitted per disintegration, 36% for 241 Am and 110% for the lower energy of 153Gd.
For a given output at the lower energy a much larger volume of 241Am is therefore
required and self absorption becomes significant. It is accepted that to reduce the
error due to repositioning without excessively increasing the patient dose, the best
method to measure spine bmc is to scan the patient and construct a bone mineral
image which includes the region of the spine to be measured. The exact region of
interest, for example the lumbar vertebrae L2, L3 and L4, can then be selected from
the computer-processed bone mineral image. Such a technique requires sufficient
resolution and sensitivity to produce an adequate bone mineral image. If narrow
collimation of the source is used to produce the image then the maximum possible
photon output from 241Am is much lower than from a 153Gd source, the activity of
which is typically 37 GBq(l Ci). However previous work using 153Gd with lower
activity of 7.4 GBq(200 mCi) (Smith et al 1983), showed that sufficient resolution to
distinguish the separate lumbar vertebrae could be obtained with collimator sizes
larger than had been used previously allowing the possibilities of higher activities of
241Am to be considered.
This study was undertaken firstly to establish the optimum energy combination
for dpa of the spine at realistic soft tissue and bone thicknesses, secondly to compare
the relative merits of the energy combinations from 153Gd and 241Am,137Cs and thirdly,
given that adequate images can be produced with larger collimation than has been
generally used, to determine whether 241Am can produce a high enough photon output
for dpa. The results would then determine whether 241Am,137Cs could be used in
practice as an acceptable alternative to 153Gd.
2. Methods
The content of either component of a two-phase system (e.g., bone and soft tissue)
can be obtained from the attenuation of two suitable monoenergetic photon beams
through the system, combined with the unattenuated count rates. For in vivo measure¬
ments of the spine a third phase, fat, is present. The assumption is made that the fat
content is evenly distributed across the body. The bmc of the spine is therefore
calculated using a region adjacent to the spine as the 'background' region, rather than
the unattenuated through-air count rate (Roos et al 1980).
The relative merits of different energy combinations, irrespective of the actual
count rate, were obtained using the following equations for the theoretical variance
of the bmc measurement:
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The measurement of bmc is obtained from four values
/x = total counts from energy 1 (lower) over the spine
12 = total counts from energy 2 (upper) over the spine
Iigd = total counts from energy 1 over the soft tissue background
12gd = total counts from energy 2 over the soft tissue background
using the equation
Mb = KMlX*d/h)-K0 ln(f1gd//2)] (1)
where
A/b is the bmc in g cm"2
Ka =Ms2/(MbllU's2-M'b2Msl)
K& = /Xsi//X,2
,u. is the mass attenuation coefficient (cm2 g"1).
Subscripts s, b, 1 and 2 refer to soft tissue, bone and the lower and upper energies
respectively. Also
h = */i - xo I2 and itgd = */^gd - xo i1gd
where */i and *1 ?gd are the actual measured counts and xo is the contribution from
the upper energy in the region of the lower energy referred to as the crossover
correction (Smith and Tothill 1982).
The variance of the bmc measurement is given by
where
IT = total counts at energy 1 through air—similarly IT
A = exp(/L6slrs + fibitb) = iT/h
B = expOus2/s + Aib2tb) = IT/h
C = exp(M5lrs) = /f//igd
D = exp(fis2Ts) = lT/l\sd
fb = thickness of bone (g cm"2); this is equivalent to Afb in equation (1)
ts = thickness of soft tissue overlying bone
Ts = thickness of soft tissue adjacent to bone
/air / yair2 /h ■
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\(C2/D+A2/B)(xo+xo2)/ ' 1 '
As would be expected the variance of the bmc is a function of sensitivity; in the
case of the equation above, of the unattenuated lower energy count rate. However




where 4> will be referred to as the comparative error function (cef) and which is
independent of the count rate. The cef will be proportional to the coefficient of
variation (cv) of the bmc measurement, which is usually defined as the precision or
reproducibility.
The theoretical error analysis of spine bmc measurement using the equations above
was performed for a range of energies, bone mineral values and soft tissue thicknesses.
The range of the lower energy was 30 keV to 80 keV, the range of the upper energy
100 keV to 800 keV. Soft tissue values ranged from 5 g cm-2 to 30 g cm-2 and the
bone mineral from 0.6 g cm-2 to 1.4 g cm-2. The values for the bone mineral covered
the range detected in patients and normal volunteers (Hansson and Roos 1980, Riggs
et al 1981). The mass attenuation coefficients, derived from the data of Sorenson
and Cameron (1974), are listed in table 1, the soft-tissue values being 85% muscle
and 15% fat. When simulating 153Gd, energies of 44 keV and 100 keV were used
with z = 1. The value of z = 1 is higher than from the theoretical emissions but is the
approximate ratio that has been observed from encapsulated sources (Peppier and
Mazess 1981, Smith and Tothill 1982).
Table 1. Mass attenuation coefficients (cm2 g ')
'"Gd 241Am, I37Cs
44 keV 100 keV 60 keV 660 keV
Mb 0.790 0.203 0.402 0.076
Us (15% fat) 0.241 0.170 0.204 0.086
Mm 0.245 0.170 0.205 0.086
Mf 0.216 0.170 0.195 0.086
To examine whether 153Gd possesses the ideal energies for spine bmc measurement,
the cef was determined over the energy ranges mentioned previously. The bone
mineral values and soft tissue thicknesses used were more realistic than those used
in previous analyses. The relative advantage, if any, of 153Gd over 241Am,137Cs due
to the photon energy levels was investigated by studying the ratio of the cefs,
0Am.cs/C^Gd* The effects of the bone mass, soft tissue mass, xo and method of
background calculation on the cef ratio and the optimum value of z for 241Am,137Cs
were investigated.
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The theoretical precision of spine bmc measurement using the 153Gd and 241Am,
137Cs was compared with experimental reproducibility measurements on phantoms
and normal volunteers. A 12 mm diameter sealed 153Gd disc source (ref. no X.92/1,
Amersham 1981) of activity 2.5-5.5 GBq(68-150 mCi) was used. The stainless steel
'window' for the source was specified as 0.2-0.25 mm. The 241Am,137Cs combination
used a 5 mm diameter spherical 241Am source of activity 7.4 GBq(200 mCi) (ref. no
X.108, Amersham 1981). Again, the window for the source was stainless steel,
0.2-0.3 mm thick. The 137Cs was a 2 mm diameter, 0.93 GBq(25 mCi) spherical bead
placed behind the 241Am. Bone mineral content measurements of the spine were
obtained using a dual headed rectilinear scanner, the J&P Multipoise II, with Nal
crystals 10 cm diameter and 5 cm thick. The top crystal was retained in use whilst
the source was placed in the position of the lower one. The minimum scan speed was
5 mms"1 with a stepping distance of 4 mm, so an average spine scan of 12 cm by
20 cm took 20 min. Two matrices of the high and low-energy transmission scans were
stored on computer. At the end of the scan these could be combined to produce a
two-dimensional bone mineral image of the lumbar spine on a colour tv display.
Regions of interest around the vertebrae and a suitable background region could
then be chosen. A variety of collimator sizes were used to vary the count rate and
resolution though the separation remained constant at 0.4 m. In all cases there was
sufficient resolution to define a region of interest around L2, L3 and L4.
Two types of phantom were used for experimental reproducibility measurements.
The first consisted of the bones of a spine and pelvis encased in paraffin wax 15 cm
thick. The bones were obtained from a cadaver and had a normal bmc (1.0 g cm-2).
The second was an anthropomorphic phantom consisting of a human skeleton encapsu¬
lated in tissue-equivalent rubber with a front to back thickness in the lumbar spine
region of 22.5 cm. The bmc was lower than normal (0.8 g cm-2) as was also confirmed
by total body neutron activation analysis (Kennedy et al 1982). The precision of bmc
measurements on human subjects was obtained from sets of two repeated measure¬
ments, separated by at least a week, on a number of normal volunteers. A single
experienced operator analysed the scans used for the precision estimation so that the
results would not contain any inter-observer error. Using equation (2) and measured
values of A, B, C and D, the theoretical precision was calculated in all cases for
comparison.
When comparing the two energy combinations the error due to fat must be
considered. In equation (1) the assumption is made that the percentage of fat in the
soft tissue is the same in both the background region and over the spine. The value
for p.s used assumes 15% fat and 85% muscle. If, however, there is a varying proportion
of fat in the two regions then an error is introduced into the bmc calculation. To
estimate the error in the bmc due to fat, associated with the two different energy
combinations, the following equations were used in which the components of soft
tissue, fat and muscle were considered separately:
11 ^Xp( M-bl^b /Ufltf)
II — 12* exp( — IXm2tm — /U.b2fb~ P-tltf)
/?gd =rf exP(-Mmirm-M„rf)
Ib2gd =lf exp(-HnaTm-fiaTi).
Substituting in equation (1)
tbl b2) (^m (^f
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where
Tm, Tf = thickness of muscle and fat (g cm-2) adjacent to the bone
tm, t{ = thickness of muscle and fat overlying the bone
V-m, /j.f = mass attenuation coefficients of muscle and fat at energies 1 and 2.
Other factors in the equation have been defined previously.
The mass attenuation coefficients listed in table 1 were used and the values Tm,
Tt, tm and tt were varied. The calculated bmc was compared with the true value tb
for both energy combinations.
The two energies can also be used to estimate the percentage fat in the background
region adjacent to the spine. The error in the fat estimation due to counting statistics
was calculated using equation (2), substituting the appropriate bone mineral param¬
eters with those for fat and the soft tissue parameters with those for muscle. This
enabled the precision of the percentage fat estimation to be obtained. The major
source of error in the accuracy of the fat estimation is due to inaccuracies in the mass
attenuation coefficients which are known typically to three decimal places. The
constant Ka, which in the estimation of fat content becomes Mm2/(MfiMm2_Mf2Mmi)>
is affected most by errors in fx. The maximum variation in the estimation of the fat
content was therefore calculated using the values of /x in table 1 plus and minus 0.0005.
The patient skin dose from the sources described previously was measured. An
ionisation chamber was placed on the bed and surrounded by tissue-equivalent
material. The dose was measured whilst the scanner operated in the same mode as
was used for spine measurements.
Having obtained a comparison between 153Gd and 241Am,137Cs intrinsic to the
photon energy levels, experimentally validated the theoretical precision estimation
and considered the effect of fat and dose, the question of available count rate was
investigated. The error due to counting statistics in dpa is determined principally by
the lower energy count rate. For spine bmc measurements the source would have a
single circular hole collimator, so a disc shaped source would give the highest output
per unit volume. The degree of self absorption is negligible in a 153Gd source but
significant in a 241Am source. The photon output for various sizes of 241Am and I53Gd
sources of different activities was investigated. The photon output was measured using
the two sources and detector described previously plus in addition a 12 mm diameter
11.1 GBq(300 mCi) 241Am source (ref. no X.92/0, Amersham 1981) with 0.2-
0.25 mm stainless steel window.
Previous research into dpa of the spine had shown that adequate resolution,
sufficient to define the space between the lumbar vertebrae on a bone mineral image,
could be obtained using a 12 mm diameter source collimator, a 20 mm square detector
collimator and a separation between the two of 0.4 m (Smith et al 1983). The
theoretical precision of spine bmc measurement for different activities of I53Gd and
24'Am was calculated using values of I\" that could be obtained from commercially
available sealed sources. The variation of precision with source activity was calculated
assuming a 12 mm diameter disc source and source collimator, 20 mm square detector
collimator, 0.4 m separation and a scan area of 12 cm by 20 cm. The time taken to
scan this area was assumed to be 20 min or 40 min. The average area over L2, L3
and L4 was calculated from six volunteer scans, and theoretical precision was calculated
for both a subject with normal spine bone mineral and soft tissue thickness and the
'worst' type of patient, one with dimineralised bone and a large thickness of soft tissue.
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tower photon energy (keV)
Figure 1. Variation in cef for a range of lower and upper energy values. Curve A, 100 keV; B, 200 keV;
C, 400 keV; D, 600 keV.
3. Results
The optimum energy combination to minimise the cef for spine bmc measurements,
assuming the optimum value of z, was found to be approximately 43 keV and 180 keV
for a bone mineral of 1.0 g cm-2 and a soft tissue thickness of 20 g cm-2. The variation
in cef is shown in figure 1 for a range of lower and upper photon energies. It can
be seen that though there is a well defined minimum at approximately the same lower
energy level, the upper energy level has little effect on the cef.
The results of the cef ratio for 241Am,I37Cs and 153Gd are shown in figure 2. A
xo value of 4% was used and the assumption was made that the area to define the
background level on the bone mineral image was the same as that used for the bone
mineral region. Also shown in figure 2 is a histogram showing the distribution of
Thickness of soft tissue (g cm"2)
Figure 2. Ratio of cef for a range of soft tissue thicknesses, bmc values of 0.6, 1.0 and 1.4 gem-2 are
used. Dashed line: z = 1 for 24lAm,l37Cs and I53Gd. Dotted line: z = 1 for I!3Gd, optimum z for
241Am,I37Cs. A histogram showing the variation in soft tissue thickness is also shown.
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anterior to posterior thicknesses in the lumbar region of 180 patients and normal
subjects. It can be seen that for measurements of the spine, though 153Gd may possess
nearly the optimum lower photon energy, the intrinsic error due to the photon energies
using the energy combinations from 241Am,137Cs is only about 1.5 times greater than
the error obtained using 153Gd. The value of the xo was found to have little effect
on the cef ratio; for example if the bone mineral is 1.0 gem-2 and the soft tissue
thickness is 20 g cm-2 then a xo of 6% will increase the cef ratio by 3.8% and a xo
of 2% will reduce it by 6.4%.
Figure 3 shows the variation in z, the optimum ratio of the two values of z.
Thickness of soft tissue (g cm 2)
Figure 3. Variation in optimal value of z with soft tissue thickness, bmc value of 1.0gem"2 and xo
values of 2%, 4% and 6% are used.
The results in table 2 show how well the theoretical error agrees with the experi¬
mental reproducibility. The large 4 cm diameter detector collimator used with 241Am
and the wax phantom showed the effect of increasing the 241Am photon output. With
this size collimator it was possible to distinguish the lumbar vertebrae on the bone
mineral image of the phantom but not of the human subjects.
The error due to fat is shown in figures 4(a) and 4(b). It can be seen that with
both a constant proportion of fat and different amounts of soft tissue and with different
proportions of fat and the same amount of soft tissue the error in bmc is worse using
153Gd by a factor of 1.3 compared with 241Am,137Cs. The precision of the fat estimation
(cv) using the two energies in the region adjacent to the spine improves as the total
soft tissue thickness decreases and the percentage fat increases. For a total soft tissue
thickness of 20 gem-2, 15% fat and IT = 108, the precision of the fat estimation
using 153Gd is 1.7% and using 241Am,137Cs is 3.8%. The maximum error in the fat
estimation due to the assumed inaccuracies of the mass attenuation coefficients varies
with the percentage fat content. With 15% fat the maximum error is 8% and 20%
and with 30% fat the maximum error is 2.5% and 6.5% for 153Gd and 241Am,137Cs
respectively.
The skin dose was found to be 123 p,Sv when the 1S3Gd activity was
10.6 GBq(286 mCi). The dose from the 7.4 GBq(200 mCi) 241Am plus
0.93 GBq(25 mCi) 137Cs combination was 14 p.Sv.
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Table 2. Theoretical and experimental precision using phantoms and normal volunteers,
(i) Anthropomorphic phantom using I53Gd.
Collimation CV (%)
Number of
Detector Source Measured Predicted measurements
(cm x cm) (mm)
2x2 13 1.1 1,2 10
o<NX 2.0 1.5 10
2x2 8 2.1 1.8 10
2x2 6 2.5 2.4 10
(ii) Wax phantom using 153Gd and 241Am,137Cs.
CV(%)
Detector Number of
Source collimation Measured Predicted measurements
241Am,137Cs 4 cm 0.6 0.90 10
133Gd 2 cm x 2 cm 0.4 0.37 10
(iii) Normal subjects using 133Gd and 241Am,137Cs
CV(%)
Number of
Source Measured Predicted measurements
!41Am, I37Cs (Condon et a! 1979) 2-3 2.64 12
1S3Gd (Tothill et al 1981) 0.95 0.96 10
Figure 4. Variation in calculated bmc with non-uniform distribution of fat in background and over spine,
(a) True bmc 1.0gcm"2, attenuation coefficients assume 15% fat. Percentage fat is constant over bone
and in background but amount of soft tissue in background is 25 gem"2 and over bone is 15 gem-2, (b)
Amount of soft tissue is constant, 20gem"2, and true bmc 1.0gem"2. Percentage fat over bone and in
background is different. In each case, curve A, li3Gd; curve B, 241Am,137Cs.
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Figure 5. Variation in photon output with activity for disc sources of !llAm with different diameters.
Various factors were found to affect the detected count rate from 241Am and
153Gd. It can be seen from figure 5 that the theoretical self absorption within a disc
source is a major problem with 241Am. The problem of self absorption is not significant
however for 153Gd, there being less than 1% with a source activity of 56 GBq(1.5 Ci).
The stainless steel window of the source encapsulation was assumed to be 0.225 mm
thick giving an attenuation of 19% and 39% at 60 keV and 44 keV respectively. An
additional source of photon attenuation in the source is caused by the fact that 241Am
is mixed with a ceramic which does not form a perfect disc when set but has one
concave face. This results in a reduction of approximately 15% in the photon output.
An improvement in the output from a sealed source can be achieved if a 1 mm Be
window is used. This will cause an attenuation of only 3% for both radionuclides.
The photon output from the sealed source is also significantly attenuated in the
housing around the Nal crystal, approximately 15% and 35% at 60 keV and 44 keV
respectively.
The theoretical variation of precision with source activity is shown in figure 6.
The value of IT used is obtained from the theoretical output assuming attenuation
by the factors described above and with a 1 mm Be window rather than stainless steel.
The time spent over L2, L3 and L4 was taken as 357 s and 750 s for 20 min and
40 min patient scans respectively. It can be seen that with the collimation used, 153Gd
has an acceptable theoretical precision of less than 1.0% at activities down to
5 GBq(135 mCi). This is also the case when an activity of more than 20 GBq(540 mCi)
of 241 Am is used with a 40 min scan time.
4. Discussion
The theoretical analysis of the variance of the bone mineral estimation is presented
in a more comprehensive form than in previous studies. Wooten (1971) ignored the
effect of xo and assumed four different optimum count times through bone and the
adjacent background at the two energies, and also different optimum values of z.
Hanson (1974) in his analysis ignored the xo, the error due to the background
estimation and the ratio of the two energies. Roos (1974) dealt more thoroughly with
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Source activity (GSq)
Figure 6. Variation in theoretical precision (cv) with activity of 153Gd or 241 Am. {a) 20 g cm-2 soft tissue,
1.0 gera"2 bone, 20 min scan, (b) 25 gcm"2 soft tissue, 0.8 g cm"2 bone, 20 min scan, (c) 25 gem" soft
tissue, 0.8 g cm"2 bone, 40 min scan.
the various factors but his analysis was very specific to his particular technique and
he did not present a single equation of the total error that was generally applicable.
The relative error function (ref) proposed by Judy (1971) and Watt (1975) also
ignored the xo, assumed that the background is estimated from the unattenuated
beams and that the ratio of the two energies was unity. In fact the ref is a special
case of the cef presented in this paper with xo = 0, z = 1 and C = D - 1. When these
values were inserted into the equation for the cef, identical results to those given in
the paper by Watt (1975) were found.
The theoretical analysis confirms that 153Gd possesses the ideal lower energy for
spine bmc measurement, though the upper energy is rather lower than the optimum.
Given that the upper energy is 100 keV, however, the actual ratio of the photon
outputs is reasonably close to the optimum value. Though intrinsically the energy
combination of 153Gd is superior to 241Am,137Cs, the precision in bmc measurement
is only increased by a factor of 1.5 if the latter is used. This suggests that 241 Am,
137Cs is a practical proposition if a high enough output can be obtained.
Neither 153Gd nor 24IAm,137Cs showed any clear advantage when the problem of
fat was considered. Though 153Gd estimates the fat content in the background region
with greater precision and accuracy than 24!Am,137Cs, a greater error is introduced
in the bmc calculation using 153Gd if the fat is not uniformly distributed over the spine.
There is also no particular advantage between the two energy combinations when
the patient dose, which is very low in both cases, is considered. The skin dose to the
patient from dpa of less than 150 p.Sv is far lower than other quantitative techniques,
such as neutron activation analysis, where the dose can be of the order of 30-60 mSv
(Al-Hiti ei al 1976, Smith and Tothill 1979).
For clinical studies into metabolic disorders of the bone, such as osteoporosis, the
precision of the technique needs to be around 2%, so the theoretical precision based
on counting statistics should be ideally around 1%. Using the 2 cm square detector
collimator and a 12 mm diameter disc source, which has been shown to give adequate
resolution of the bmc image, theoretical and experimental results (figure 6 and
720 MA Smith et al
table 2) showed that this degree of precision could be obtained with a 20 min scan if
at least 5 GBq(135 mCi) 1I3Gd were used. Clearly the sensitivity of 241Am could be
increased by reducing the scan speed, but it is our experience that 40 min is about
the maximum time that a patient will endure without becoming restless. Using the
same collimation and a 40 min scan time, it is possible to achieve this precision if at
least 20 GBq(540 mCi) 241Am are used.
The cost of 241Am is considerably less than 153Gd, though the cost of the latter
does vary in different countries. In Great Britain the cost of a 37 GBq(l Ci) 241 Am
12 mm disc source with a Be window would be of the order of £2000 compared with
£7000 for the same activity of 1S3Gd. Given that 153Gd needs to be replaced about
every 12 months, there is a considerable financial advantage in developing apparatus
which uses 241Am. In addition the availability of 133Gd is irregular.
The results in this paper show that activities down to 5 GBq(135 mCi) 153Gd can
be used suggesting that a 37 GBq(l Ci) 153Gd source could be used for about two
years. To use activities over this range, the size of the collimation would have to be
increased during the two year period to avoid dead-time errors at high activity and
to give a high enough count rate at low activity. This would alter the geometry and
also necessitate the use of different xo values (Smith and Tothill 1982) which could
introduce errors into the bmc measurement. If longitudinal patient studies are to be
undertaken, such as the study of osteoporosis covering a period of many years, then
it would be desirable to use a technique whose, parameters remain constant.
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Resume
Etude comparee du 153Gd et du couple 2,11 Am,13'Cs pour Ies mesures d'absorption dans la colonne
vertebrale en double energie.
Le contenu mineral de l'os (bmc) peut etre mesure dans le rachis a partir de l'attenuation de deux faisceaux
de photons. Une formule a ete etablie pour I'estimation theorique de l'incertitude qui affecte la mesure du
bmc, et elle a ete validee experimentalement. Bien que le "?3Gd presente la meilleure combinaison
d'energies de photons, I'incertitude due aux niveaux d'energies des photons du couple 241Am,137Cs est
seulement 1,5 fois plus importante que ceile correspondant au ,53Gd. Les flux de photons disponibles avec
le 2"Am et le 1S3Gd ont ete mesures et, pour une source ayant la forme d'un disque de 12 mm de diametre,
une incertitude theorique de 1% peut etre obtenue lors de l'examen d'un patient avec 20 GBq de 241 Am
(duree 40 min) et 5 GBq de 153Gd (duree 20 min). Aucun avantage important n'apparaft avec 1'une ou
l'autre des combinaisons d'energies pour la dose re?ue par le patient ou les problemes poses par la graisse.
Aussi, compte-tenu des inconvenients du l53Gd, en particulier son prix et sa disponibilite, il peut etre
remplace en pratique par le couple 21IAm,I37Cs pour la mesure du bmc dans la colonne vertebrale a partir
d'une image reconstruite du contenu mineral de 1'os.
Zusammenfassung
Vergleich zwischen 153Gd und 241Am/l37Cs fur 2-Photonenabsorptiometrie der Wirbelsaule.
Der Knochenmineralgehalt (KMG) der Wirbelsaule kann durch die Schwachung zweier Photonenstrahlen
gemessen werden. Eine Gleichung fur die theoretische Genauigkeit von KMG-Messungen wurde abgeleitet
LS~Gd or 241Am,13'Cs for spine bmc 721
und experimentell bestatigt. Obwohl 153Gd die giinstigere Energiekombination besitzt, ist die Genauigkeit,
die durch die Photonenergieniveaus bei Verwendung von 24IAm/l37Cs erreicht wird 1.5 mal groj3er als die
fur 153Gd erhaltenen Werte. Die verfiigbaren Photonenemissionen von 241Am und 153Gd wurden untersucht
und mit einer Flachenquelle von 12 mm Durchmesser konnte eine theoretische Genauigkeit von 1 % erreicht
werden mit Quellstarken von 20 GBq 241Am oder 5 GBq I53Gd in einem 40- bzw. 20-miniitigen Patienten-
Scan. Es gab fur beide Energiekombinationen keine groJ3en Vorteile bei der Beriicksichtigung der Fett-
oder Patientendosis. Wegen der Nachteile von 153Gd, Kosten und Verfiigbarkeit, kann 24IAm/137Cs als
praktische Alternative zur Messung des KMB der Wirbelsaule aus einem rekonstruirten Bild des Knochen-
minerals verwendet werden.
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but they have misrepresented the procedures of others and have alluded to intra-
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Intra-laboratory variations using dual-photon absorptiometry
The Editor,
Sir,
We welcome the letter by Mazess et al (previous letter), which provides further
justification for our belief that technical problems in dual-photon absorptiometry
(dpa) need to be explored. In our recent scientific note (Smith and Tothill 1982) we
stated that there were intra-laboratory differences between cross-sectional studies of
vertebral bone mineral content (bmc) in normal women as measured by dpa. Two
groups have reported an increase in the rate of loss of bmc from the spine at the time
of the menopause (Krplner and Pors Nielsen 1982, Smith et al 1983) whereas two
other groups have not (Madsen 1977, Riggs et al 1981). Examples from two groups
are shown in figure 1 illustrating this fairly fundamental disparity. Our own normal
data (Tothill et al 1983) show that the units used to express the bmc, whether in
grams (Krplner and Pors Nielsen 1980) or g cm'2 (Riggs et al 1981), do not alter any
age relationship. Nowhere in our scientific note did we state that the differences
illustrated in figure 1 were due to the crossover corrections; we simply stated that 'It
is not known whether this discrepancy between the various methods is due to differ¬
ences in methodology or in the populations studied. Before accepting the latter the
possibility of the former must be thoroughly investigated.'
We considered just one technical aspect of bmc measurement by dpa, the crossover
correction, and though it was recognised that this would be influenced by both the
Nal crystal and scatter within the patient it was considered unnecessary to separate
the two components. There is a dearth of information in the literature about methods
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Figure 1. Variation in bmc of the lumbar vertebrae with age as measured by A, Krelner and Pors Nielsen
(1982) in 70 normal women, and B, Riggs et at (1981) in 105 normal women. ±1 standard error about
the mean for each decade is shown with the exception of the oldest women in A when the range 70-90
years is used.
used to determine the crossover correction. Mazess et al (1974) state that copper
and aluminium were used to filter out the lower energy radiation. Other authors
however (Wilson and Madsen 1977, Krplner and Pors Nielsen 1980, Wahner and
Dunn 1980, Peppier and Mazess 1981, Riggs et al 1981) do not mention the absorber
used to determine the crossover correction. It is not true that aluminium does not
preferentially attenuate the 70keV peak (Mazess et al 1983). Aluminium may be
superior to copper but 5 cm of the former will attenuate the 70keV peak 2.6 times
more than the 100 keV peak, hence our rather complicated simulation of the upper
end of the 153Gd spectrum. Our empirical technique provided a satisfactory alternative,
but would need to be validated for other apparatus.
Although previous literature of dpa techniques omitted many technical details,
contradictions do appear to exist in the crossover correction values. Peppier and
Mazess (1981) used a detector collimation of 8 mm x 25 mm and stated that the
crossover correction varied with patient thickness from 1.8% to 3.4% whereas Wilson
and Madsen (1977), using an even larger detector collimator of 12.5 mm x 37.5 mm,
stated that the crossover correction was constant at 3%. Wahner and Dunn (1980)
and Riggs et al (1981) used 6 mm detector collimation, the smallest used for dpa,
but obtained crossover corrections of 6% and 4-6% respectively. The variation in
crossover correction of 4-6% (Riggs et al 1981) was stated to be dependent on the
source although no reason is apparent. The high value of 6% (Wahner and Dunn
1980) was due to the thin 1 mm Nal crystal used. If a thicker crystal were used which
detected the 100 keV peak efficiently then this value would be reduced to about 2.5%.
In the apparatus used by Kr0lner and Pors Nielsen (1980) however, which has a large
detector collimator of 13 mm, a crossover correction of only 1% was used (personal
communication).
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In our original scientific note (Smith and Tothill 1982) and in this letter we do
not intend criticism of any particular method of dpa for vertebral bmc measurements.
Explanations may exist for many of the intra-laboratory differences but they need to
be investigated with a degree of scientific thoroughness which hitherto has been absent.
Michael A Smith and Peter Tothill
Department of Medical Physics
and Medical Engineering,
Royal Infirmary, Edinburgh EH3 9YW,
17 March 1983 Scotland
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Dual photon absorptiometry of the spine with a low activity
source of gadolinium 153
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Abstract
Apparatus and data-processing techniques were developed
to measure the bone mineral content (BMC) of the lumbar
spine. 153Gd was used as the dual photon source with an
activity down to 7 GBq, lower than that adopted by other
workers. The compromise between resolution and sensitivity
was optimised. A reproducibility in normal subjects of 1.5%
(coefficient of variation) was obtained. Normalisation
procedures using parameters of the scan image and other
indicators of body size such as span were developed, and
reduced the coefficient of variation between normal subjects to
10% for men and 8% for pre-menopausal 1 women. The
absolute values of BMC are similar to those reported by
others. Cross-sectional studies in women demonstrated an
accelerated loss of BMC after the menopause.
Absorptiometry is well established as a method for
measuring bone mineral. If a uniform overall thickness
can be achieved, for example by using a water bath, and
a two-phase system assumed, a single photon technique
is adequate. Dual photon techniques have been used for
some time to allow for varying thicknesses or an extra
phase, and more recently have been applied to the study
of the spine, the area of trabecular bone of most interest
in diseases such as osteoporosis.
For the first measurements of bone mineral content
(BMC) of the spine Roos and Skoldborn (1974) used the
60 keV radiation from 241 Am and 660 keV gamma rays
from 137Cs. They did not rely on retrospective choice of
the site of analysis from a bone mineral image, but
identified the scan position from a prior radiograph.
Subsequent spine BMC measurements have generally
used the radiations from 153Gd, complex mixtures of X
and y rays effectively giving energies of 44 and 100 keV
(Mazess et al, 1974; Wilson & Madsen, 1977; Price et al,
1977; Krolner & Pors Nielsen, 1980; Wahner & Dunn,
1980; Smith et al, 1983a). These authors have mostly
selected the appropriate vertebrae from the processed
image.
We set out to develop a scanning and data processing
system for dual photon absorptiometry (DPA) of the
spine. We were able to obtain only a lower-activity,
larger-diameter 153Gd source than had been used by
previous workers and so had to investigate different
* Present address: Department of Medical Physics, Essex
County Hospital, Colchester, Essex.
compromises between sensitivity and resolution. An
appropriate collimation having been chosen,
measurements were made of spinal BMC in a group of
normal volunteers to establish the degree of variation
and to provide a baseline against which to judge
abnormality. Methods of normalisation of the data for
body size were investigated. The results are presented
here and compared with others from the literature.
Methods
A standard dual-headed radionuclide scanner (J. & P.
Engineering Ltd.) was adapted for transmission
scanning. The 153Gd source was mounted in the lower
head and was initially of 18-5 GBq (500 mCi); its
activity had decayed to about 7 GBq when the
measurements on normal volunteers were made. The
source was a disc, diameter 12 mm, in a stainless steel
capsule (Amersham International X 92/1). The initial
photon output was quoted by the supplier as 7 x 10s
photons/s/steradian at 100 keV. The output at 44 keV
was found to be about the same, there being appreciable
attenuation in the 0.25 mm thick stainless steel exit face.
The detector was the standard 10 x 5 cm overhead
Nal crystal of the scanner, which moved in synchronism
with the source. The collimator face separation was
40 cm. The minimum reliable scanner speed of 5 mm
s ~1 was used, with a stepping distance between scans of
4 mm. A variety of single parallel-hole collimators, each
of length 5 cm, was fitted to the source for
measurements on a phantom, but once the optimum
conditions had been determined a collimator of 13 mm
diameter was used for all measurements on subjects.
The detector collimator was 7.5 cm long and fixed at
20 mm square.
Two pulse-height analysers with window settings 32-
56 keV and 75-125 keV were used to select the gamma-
ray energies. Some of the results were obtained by
recording data on a Digidek tape recorder for off-line
transfer to a PDP 12 computer. Later a Cromemco
microcomputer and TV monitor were interfaced to the
scanner. Programs were written to correct for dead-time
when necessary and the contribution from the higher
energy radiation to the lower energy detection channel
(the cross-over). The latter arises partly from scatter in
the subject and partly from interactions in the detector
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crystal; the correction was found to vary with patient
thickness. To derive the cross-over with 153Gd it is
necessary to filter out the lower energy peak; the
presence of a low abundance 70 keV peak creates
complications (Smith & Tothill. 1982). The corrections
were determined for each collimator combination used.
The bone mineral was calculated for each 4 mm cell
using the equation derived by Roos and Skoldborn
(1974)
((pi/h) Psi ln (^02/(2)
where PsiPbi
Mb = bone mineral mass per unit area
(1)
= mass attenuation coefficient of soft tissue (s)
and bone (b) at the lower energy (1) and higher
energy (2)
I0 = intensity of unattenuated beam
I = intensity of transmitted beam
Re-arranging equation (1),
(fisi 1" h-Vs2 In/j)
-(Hsl In I02-I2s2 In ]01)
P&Pbl fslfib2
(2)
In the soft-tissue area lateral to the spine, Mb = 0, and
the second bracketed term containing the unattenuated
beam intensities is equal to the first bracketed term.
That area can be taken to constitute a background level
above which the bone mineral values are calculated, and




The equations as presented here assume that soft
tissue is homogeneous, whereas in practice it consists of
mixtures of lean and adipose tissue which vary between
patients. If the thickness of fat were uniform, the only
error introduced would be in the values of ns chosen.
Such uniformity is most unlikely, and non-uniformity
leads to an incorrect choice of baseline (Roos et al,
1980). However, in common with other workers, we
ignore the errors introduced by this factor.
The attenuation coefficients used in our calculations
were derived from attenuation measurements through
water and hydroxyapatite, and were as follows:
psl = 0.218, ps2 = 0.152, gbl = 0.71, fib2 = 0.21
(all in cm2 g ').
The ratio ns2/nsi is particularly important, as it was
found from phantom measurements that the adoption
of an incorrect ratio in the calculations led to an
apparent change of bone mineral with water depth. Our
ratio of 0.697 is close to the values used by other
workers, even though individual values of attenuation
coefficients may differ, perhaps due to different
assumptions about the composition of soft tissue and
bone mineral.
The bone mineral image is displayed on a colour
Fig. 1.
Monochrome display of bone mineral image.
monitor (Fig. 1). The original scan, over an area of
about 12 cm wide and 20 cm long (taking about 20 min
to perform), is positioned to include part of the pelvis, to
facilitate identification of vertebrae on the image. Three
lumbar vertebrae are included, cursors being positioned
manually at the top of L2 and the bottom of L4. All
cells in a vertical column between these limits are
summed and a horizontal profile plotted (Fig. 2).
Horizontal baselines are defined either side of the
vertebrae, their selection adjacent to the bone edge
being facilitated by vertical cursors. The bone mineral
values are then integrated above the line joining the
baselines. The results are expressed as a total in the
three vertebrae, as bone mineral per unit length or unit
area.
After reproducibility studies had been performed with
anthropomorphic phantoms the optimum collimations
were then used for repeated measurements on nine
normal volunteers aged 21-58 years. Two
measurements were made on separate days on each
830
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Fig. 2.
Profile of bone mineral content across vertebrae L2^4.
subject. Each bone mineral image was analysed by three
operators.
The 153Gd source with optimum collimation has
been used to measure spine BMC in 24 normal women,
aged 21-61 years, and 18 normal men aged 21-58 years.
As there is a measure of subjectivity in the selection of
the area of interest in the bone mineral image, all scans
were analysed by the same operator.
The radiation dose to the skin was measured with a 1
litre ionisation chamber and found to be 140 pGy when
the 153Gd activity was 12 GBq.
Results
From the experiments on models it was found that
the precision improved as the sensitivity was increased
by using larger diameter collimators, in spite of the
worsening resolution (Table I). The experimental
coefficients of variation were derived from 10 repeated
measurements on an anthropomorphic phantom. The
theoretical precision was based on counting statistics,
taking into account the photon outputs at the two
energies, the collimator geometries, the thickness of soft
tissue, the bone mineral content, the detector efficiencies
and the crossover correction. Details of the calculation
are given elsewhere (Smith et al, 1983b).
TABLE I
Experimental and theoretical precision using an
anthropomorphic model of a human skeleton in tissue-
equivalent rubber. 10 measurements. detector collimator
fixed at 20 x 20 mm
Mean B B/L B/A
Sex No. age g gem"1 g cm"2 BMI
M 18 33.9 62.1 5.51 0.98 1.00
(10.3) (14.4%) (11.2%) (11.4%) (9.8%)
F(all) 24 41.2 51.2 4.95 0.94
(12.8) (20.1%) (16.9%) (16.7%)
F(sJ 50y) 18 36.7 54.5 5.23 0.98 1.00
(11.4) (15.8%) (12.7%) (12.3%) (7.5%)
The results of the repeated measurements on normal
subjects, using the collimators that gave the highest
precision in phantoms, were calculated as the average
coefficients of variation (CV) obtained by dividing the
differences between two measurements on each subject,
expressed as a percentage of the mean, by 1.128 (Crow
et al, 1960). The mean CV for operator 1, who had more
experience than the others, was 1.0%, for operator 2,
1.5% and for operator 3, 3.3%.
The BMC values for the 42 normal subjects are
summarised in Table II. In column 4 is the total mass of
bone mineral in grams (B) in lumbar vertebrae 2, 3 and
4 as defined by the rectangle selected from the bone
mineral image. For column 5 the total BMC values
were divided by the length (L) of the rectangle in cm
(along the spine) to give B/L. A further division by the
width of the rectangle yielded the figures for BMC per
unit area (B/A) in column 6. The best reproducibility
was found by selecting the boundaries of the rectangle
at the edge of the profile peak as illustrated in Fig. 2.
The width of the rectangle was then such as to exclude
the extremities of the transverse processes. A small
amount of bone mineral was therefore included in the
soft-tissue background. This leads to an inaccuracy
analogous to that arising from non-uniform fat
distribution.
The use of B/L or B/A gives a measure of
normalisation for - body-size, but further relationships
were sought, in the hope of minimising the variations in
the values for The normal groups. The best correlation
for the men and for the women aged 50 or less was
between B/L and span. This linear relationship was used
to derive formulae to give predicted BMC (B/L)p for
normal subjects.
For women (B/L)p = 5.42 x S — 3.50,
r = 0.81, p < 0.001
For men (B/L)p = 5.73 x S — 4.61,
r = 0.48, p < 0.05
where
S = span in metres.
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BMC per unit length (B/L) plotted against age for normal
women. Error bars represent standard error of the mean for
each decade.
We can define a bone mineral index (BMI) as the
ratio of B/L to (B/L)p for individual subjects. The mean
values of the BMI are included in the last column of
Table II. Normalisation using span was slightly better
for B/L than for B.
When BMC was plotted against age for men, no
correlation was found. For women there was a
progressive loss of BMC with age above about 50 years.
For example, B/L is plotted against age in Fig. 3,
without normalisation for span. As there are relatively
few points and a fair amount of scatter, a degree of
smoothing has been obtained by calculating the mean
BMC cm-1 for each decade. The same method of
presentation, without data points or error bars, is used
in Fig. 4a, to illustrate the different normalisation
procedures and for comparison with other published
results, the means for the first decade being set to 100%.
A further indication of age-related bone loss in
women was obtained by correlating BMC with years
post-menopause (T). Only for the ratio BMI was the
correlation significant (r = —0.63, p < 0.05, n = 11), the
linear regression equation being BMI =
0.995 — 0.017 x Y, corresponding to a rate of loss of
1.7% per annum soon after the menopause.
Discussion
The main difference between our measurements of
spine BMC and those of others using a similar
technique was that the activity of our 153Gd source was
much lower, only about 7 MBq when most of the
measurements on normal subjects were performed,
compared with about 40 GBq in common use. Krolner
and Pors Nielsen (1982b) quote the lowest activity
employed, considering their source to be usable down to
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Fig. 4.
BMC plotted against age for normal women, mean results per
decade, a (above) present authors' results expressed in different
ways, b (below) results derived from other publications.
and measurements on models that an acceptable
precision (around 1%) could be obtained with this
lower activity, using a coarser collimation to maintain
sensitivity (Smith et al, 1983b). The results presented
here confirm this finding in repeated measurements on
normal subjects, the coefficients of variation of 1.0% and
1.5% for operators 1 and 2 being close to the theoretical
CV based on counting statistics. The CV of 3.3%
obtained by operator 3 is less acceptable, but he was
inexperienced in the analysis, and we have found that
practice brings a rapid improvement in the consistency
of area selection.
The acceptable precision obtained with our activity
means that a 20 GBq source could be used for about a
year and 50 GBq for twice as long.
Another way in which our source differed was that it
had an active diameter of 12 mm. The specific activity of
153Gd is such that self-absorption of the X rays is not a
limitation with smaller sources, and other workers have
used lower diameters, giving a better resolution. Some
have also improved resolution by using a smaller
detector collimation. Our demonstration that
satisfactory results can be obtained with a 12 mm
source is not so important for I53Gd, but is vital if
241Am is considered for the lower energy photon beam.
The long half-life of 241Am, which makes it so attractive
and economical a source, means that its specific activity
is low. It is only possible to obtain sufficient photon
output from 241Am to give the required statistical
precision if a diameter of at least 12 mm is used (Smith
et al, 1983b).
Our measured radiation doses are similar to those
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published by others. For example, Krolner and Pors
Nielsen (1980) quote a skin dose of 0.1 mGy and Wilson
and Madsen (1977) approximately 0.02 mGy. In any
case the doses are low enough to permit repeated
observations in a wide category of subjects.
The BMC results for normal subjects are presented in
Table II in different forms to allow comparison with
other published results. Each form has its merits. As
Krolner and Pors Nielsen (1980) have pointed out, the
total BMC in a number of vertebrae (usually the second,
third and fourth) is influenced least by vertebral crush
fractures, which compress the vertebrae into a shorter
length. On the other hand, no normalisation for body
size is provided by this presentation and the consistency
of the measurement is most critically dependent on the
choice of boundaries between vertebrae. The total
height of the three vertebrae is about 100 mm,
corresponding to 25 scans at our 4 mm spacing. An
inconsistency of boundary selection by one line, which is
difficult to avoid, leads to an error of about 4%. This
error can be much reduced, and some measure of
normalisation for body size obtained, by expressing
results as BMC per unit length. The penalty of this
method is that crushed vertebrae may thereby appear to
have a raised bone mineral content.
An advantage in expressing the result in terms of
BMC per unit length is that the length is easily defined
and so intercomparison of results using different
techniques can be made. This may not be so if the result
is expressed in terms of BMC per unit area, because the
width of the vertebrae can be expressed in several ways.
Our method was chosen to give the best reproducibility
of selection of region of interest. Increasing the width of
the chosen rectangle will not, beyond a certain level,
affect the BMC value but will progressively decrease the
BMC per unit area. Some centres do not use a rectangle
but an irregular region of interest, calculated using an
edge detection program. Thus though it may be possible
for the different techniques to obtain comparable BMC
or BMC per unit length values, there is likely to be
considerable variation between values of BMC per unit
area. This is illustrated in the results shown in Tables II
and III.
Using our apparatus, the mean width, which was
affected by the relatively coarse collimation, was about
5.5 cm; this is somewhat greater than the average width
of the vertebral bodies, but less than the overall width of
the transverse processes. By this exclusion we slightly
underestimate the total bone mineral, but include all the
trabecular bone of the bodies. The selection of a width
large enough to encompass the whole bones would
reduce the precision and the value of normalisation by
width. The use of a finite beam width and scanning
speed leads to an additional underestimate of BMC
(West & Reed, 1970; Watt, 1973) but in common with
others making measurements of the spine, we do not
attempt to apply corrections.
Table II shows that the CV for the normal population
studied was highest when total BMC was used
(column 4). A reduction was obtained, as might be
expected, when normalisation by length or area was
applied (columns 5 and 6). The least variation was found
when the additional factor of span was incorporated to
give the predicted BMC per unit length, with which the
measured value could be compared (column 7).
Our results can be compared with others from the
literature. As all investigators have demonstrated a loss
of BMC with age in women, it was thought best to
present the mean values for the populations studied,
together with the mean ages. These results are
summarised in Table III, which can be compared with
our Table II.
Roos et al (1980) relied on prior X-radiography to
select a single vertebra and performed a single profile
scan with a combined 241Am/137Cs beam.
The remaining authors used 153Gd, but Madsen
(1977) did not select the vertebrae from a bone mineral
image, relying instead on a fixed scanning length of
10 cm starting at the level of the iliac crests. Riggs et al
(1981) used lumbar vertebrae 1-4 and determined the
area used for normalisation from an edge-detection
program applied to the images. Krolner and Pors
Nielsen (1982a) integrated profiles to obtain total BMC
in vertebrae L2^t; although they express their results in
arbitrary units with the dimensions of mass, it is clear
from an earlier paper (Krolner & Pors Nielsen, 1980)
that these units are equivalent to grams of
hydroxyapatite.
It is seen from Tables I and II that our results are
very similar to those already published.
TABLE III
Mean values of lumbar bone mineral content reported by various authors
Mean Vertebrae BjL B/A
Authors Sex No. age studied B g cm"1 gem"2
Madsen (1977) F 41 61 10 cm length 4.5 0.85
Roos et al (1980) M 18 63.4 L 3 4.9
Riggs et al (1981) M 82 52 LI—4 1.22
F 105 55 Ll^l 1.08
Krolner & Pors Nielsen
(1982a,b) F 70 50.5 L2-4 44.5
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An examination of the loss of bone mineral from the
spine with increasing age in women is important, as
somewhat different patterns have been reported from
the various cross-sectional studies considered here.
Madsen (1977) fitted a linear regression to B/A over the
whole age range, with a slope of 0.40% per annum at
age 60. However, by re-analysing the data from his
graph, it can be seen that there is no evidence of a loss
below the age of about 50. For women over 50 a linear
regression has a correlation coefficient of 0.565, n = 31,
p < 0.001, with a slope of 0.75% per annum at
age 60.
Hansson and Roos (1980) measured the bone mineral
per unit length in single vertebrae removed at autopsy.
They correlated B/L with age using a linear regression,
showing a loss of 1.0% per annum at age 60. However,
only 4 of the 18 women were below 50 years of age and
the data do not permit deductions about possible
changes of slope.
Riggs et al (1981) also used a single linear regression,
this time of B/A against age, but justified it statistically,
there being much larger numbers and no significant
difference in the slope pre- and post-menopause. The
rate of loss was 1.0% per annum at age 60.
Krolner and Pors Nielsen (1982a) considered that the
distribution of lumbar BMC of normal pre-menopausal
women showed skewness, as logarithmic transformation
reduced the moment coefficient. However, analysis of
their data shows that the skewness was not statistically
significant. They found that BMC of pre-menopausal
women was not related to age, whereas a significant
reduction was found in the post-menopausal group,
with an annual loss of 1.4%. They investigated several
linear and polynomial regression equations, but chose
to fit data to a gamma variate function, although a
better fit was not obtained thereby. The function serves
well enough at higher ages, but has the disadvantage
that it introduces a maximum in the curve at about the
age of 35. This is not in accord with the data and it
seems a pity to distort the possible conclusions.
The data plotted in the four publications reviewed
above have been analysed in the same way as our own
data, mean values of BMC for each decade of age being
plotted against the mean age in Fig. 4b.
Our own results, such as those presented in Figs. 3
and 4a, do not contain sufficient numbers or cover a
wide enough age range for detailed analysis, but support
the view that there is an increased loss of lumbar bone
mineral after the menopause. Fig. 4a demonstrates that
the normalisation procedure adopted does not affect the
pattern of loss, suggesting that differences in Fig. 4b are
due to some other cause.
When sufficient normal women have been measured,
it should be possible to define the predicted normal
lumbar BMC for a given age and size, as has been done
for total body calcium (Cohn et al, 1976; Kennedy et al,
1982). The annual losses of lumbar bone mineral in
post-menopausal women summarised here are not
greatly different from those reported for total body
calcium, 1.1% (Cohn et al, 1976) and 1.5% (Kennedy et
al, 1982).
The age-dependence of lumbar bone mineral in men
has been reported by fewer authors. Hansson and Roos
(1980), again using autopsy specimens from 15 subjects,
found the slope of a linear regression of B/L against age
to be the same as for women in terms of g cm-1. Taking
into account the higher mean BMC of the men, the
proportional loss was lower, 0.76% per annum at age
60.
Riggs et al (1981) analysed the variation of lumbar
BMC with age in 82 men. They found a small loss, of
less than 0.2% per annum, with a significance of
p < 0.05. With smaller numbers studied and a more
restricted age range, it is not surprising that we
demonstrated no change with age. Once again these
results are similar to those from total body calcium
determinations (Kennedy et al, 1982).
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Book review
Porphyrin Photosensitization (Advances in Experimental
Medicine and Biology Vol. 160). Ed. by David Kessell and
Thomas J. Dougherty, pp. ix + 294, 1983 (Plenum Press, New
York/London), S42.50..
ISBN: 0—306—41193-8
For many years tumour tissues have been known to loca¬
lise porphyrins, although the biochemical reasons for this are
not understood. Nevertheless this finding is being exploited
clinically both by using haematoporphyrins as photosensitisers
as a means of eradication of tumours (PRT) and to aid tumour
localisation. In 1981 a workshop was held in which workers
involved in fundamental studies on porphyrin chemistry,
physics and photobiology, along with those using porphyrins
clinically, were brought together. This book contains the
contributions of the participants and is an extremely useful
source of information on the topic for all scientists and
clinicians interested in this field of knowledge.
A series of articles on clinical aspects of haematoporphyrin
photoradiation therapy is followed by a paper concerning the
dosimetry of light in tissue by Doiron et al and a general
review of photobiological considerations in photoradiation
therapy by J. A. Parrish, both of which should be of
widespread interest. The latter half of the book includes papers
on the photochemical and photobiological mechanism of
action of haematoporphyrin derivatives, including a report of
a study by Michael Berns and co-workers using fluorescent
analysis of cells with a laser light source. Each chapter ends
with a useful list of references, so that people with no prior
knowledge of the subject can use this as an original source of
information.
D. J. G. Davies.
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Abstract. In vivo neutron activation analysis was used to measure total body sodium and
chlorine in 18 male and 18 female normal adults. Corrections for body size were developed.
Normalisation factors were derived which enable the prediction of the normal levels of
sodium and chlorine in a subject. The coefficient of variation of normalised sodium was
5.9% in men and 6.9% in women, and of normalised chlorine 9.3% in men and 5.5% in
women. In the range examined (40-70 years) no significant age dependence was observed
for either element. Total body sodium was correlated with total body chlorine and total
body calcium. Sodium excess, defined as the amount of body sodium in excess of that
associated with chlorine, also correlated well with total body calcium. In females there
was a mean annual loss of sodium excess of 1.2% after the menopause, similar to the loss
of calcium.
1. Introduction
Total body neutron activation analysis can be used to determine the absolute amounts
of certain body elements and also changes in these levels with time. At present,
elements which may be measured by this technique include calcium, sodium, chlorine,
phosphorus and nitrogen.
Absolute levels of total body sodium (TBNa) with or without total body chlorine
(tbCI) in normal adults have been determined using neutron activation analysis by
Chamberlain et al (1968), Rudd et al (1972), Ellis et al (1976) and Aloia et al (1980).
Where appropriate the results of these studies and the data presented in this paper
will be compared and discussed. TBNa has been shown to change in several disease
states, e.g., renal failure (Cohn et al 1972), hypertension (Boddy et al 1978) and
osteomalacia (Hosking et al 1972), and so techniques which allow the accurate
evaluation of TBNa and tbCI are of considerable interest. For these to be of diagnostic
significance it is necessary to establish normal ranges and develop normalisation
procedures.
Most of the sodium in the body is extracellular, fairly rapidly exchangeable and
associated with an equivalent amount of chlorine. The sodium in bone exchanges less
rapidly and the chlorine concentration is much lower. The presence of a slowly-
exchangeable pool of sodium has been demonstrated by the differences between the
|| Present address: Department of Medical Physics, Ninewells Hospital, Dundee, Scotland.
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values for exchangeable sodium as measured by isotope dilution techniques and total
body sodium as measured by chemical analysis (Forbes and Lewis 1956) or by neutron
activation analysis (Chamberlain et al 1968, Boddy et al 1978).
2. Methods
In the technique, the subjects are exposed to a beam of partially moderated fast
• • 23 / 24 37 38
neutrons which induces amongst others the reactions, Na(n, y) Na, Cl(n, y) CI,
48Ca(n, y)49Ca, 31P(n, a)28Al and 14N(n, 2n)13N. The neutron source used for patient
activation was a cyclotron producing neutrons of mean energy 6.5 MeV (Williams et
al 1979). During irradiation the subject was positioned in a moderator kiosk which
optimises the uniformity of activation of sodium and chlorine. The subject was then
transferred to a shadow-shield whole-body counter where the y-ray spectrum, covering
the energy range 0 to 4 MeV, was recorded on a multichannel analyser. The data
were analysed by fitting five standard spectra obtained from the activation of sodium,
chlorine, calcium, phosphorus and potassium to the smoothed subject spectrum in the
energy range 1.0 to 3.4 MeV, using a least squares technique (Smith andTothill 1979).
Corrections to eliminate the effects of variations in activation and detection efficiency
with body size and position were then made, allowing the TBNa and tbCI content in
grams to be determined accurately.
The technique of total body neutron activation analysis used in this study has been
described in detail, with reference to measurements of calcium, by Kennedy et al
(1982). The corrections were determined for each element using phantoms of several
sizes, but there were no significant differences between those for calcium, sodium and
chlorine. The coefficient of variation (cv) for repeated measurements of an
anthropomorphic phantom was 2.1% for sodium and 4.3 % for chlorine for an absorbed
dose equivalent of 13 mSv. The phantom contained known amounts of sodium,
chlorine, calcium, phosphorus, potassium and nitrogen, and there was no significant
dependence of the counts obtained per gram of element on the ratio of the various
elements in the phantom. Although no attempt was made in this study to determine
total body nitrogen levels, a physiological amount of nitrogen (1960 g) was contained
in the phantom. The importance of including nitrogen has recently been emphasised
by Spinks and Bewley (1982).
Although this technique requires little patient preparation, it is important to check
that the subject is not wearing thermal underwear which may contain significant levels
of chlorine.
Since the chlorine space approximates extracellular fluid volume and the ratio of
Na to CI in the extracellular fluid has been estimated, the amount of sodium in excess
of that associated with the chlorine space may be defined as the sodium excess value,
NaES, (after Ellis et al 1976) and can be expressed in grams as
NaFS = TBNa-0.78 tbCI
where TBNa and tbCI are in grams. It is assumed that NaES represents most of the
sodium resident in bone.
3. Results
3.1. Normal values
TBNa and tbCI measurements were made on a group of 36 normal volunteers, 18
male and 18 female, betweeen 40 and 70 years of age. All the subjects were active
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and in good health. None had any history of disease that might be expected to
influence their TBNa and tbCI levels, and all had normal blood and urine biochemistry.
There was a considerable spread in the TBNa and tbCI results for both groups (see
table 1). For the males the TBNa ranged from 74.8 g to 99.4 g with a mean of
83.7 g±8.2% (cv) while the tbCI ranged from 61.8 g to 93.4 g with a mean of
71.7 g± 11.3%. The TBNa for the females ranged from 55.1 g to 75.9 g with a mean
of 62.0 g±9.2% while the tbCI ranged from 46.5 g to 65.8 g-with a mean of 53.4 g±
10.2%.




Height (m) 178.3 (4.8) 160.9 (4.0)
Weight (kg) 81.3(12.0) 62.5 (17.7)
Lean body mass (kg) 59.3(11.7) 39.9(12.6)
Age (y) 54.3(16.5) 56.7(10.9)
Sodium (g) 83.7 (8.2) 62.0(9.2)
Chlorine (g) 71.7(11.3) 53.4(10.2)
Sodium excess NaES, (g) 27.7(12.2) 20.5 (19.9)
NaES/kg calcium (g) 24.4(9.1) 24.9(17.5)
3.2. Normalisation procedures
As the total composition of the various elements in the body is related to the subject's
build, the dependence of the measured TBNa and tbCI on height, weight, lean body
mass (lbm) (calculated from the weight and skinfold thickness measurements), age
and number of years post-menopause was investigated by multiple linear regression
analysis.
For males, this gave a formula for predicted total body sodium (TBNap) in grams
TBNap = 19.2 (LBM)a26(height)0'71 (r = 0.72, P < 0.001)
and predicted total body chlorine (tbC1p) in grams
tbC1p= 11.3(lbm)°'37(height)0'57 (r = 0.58, P < 0.05).
Height is measured in metres and lbm in kilograms. Similar equations were obtained
when weight was used instead of lbm.
TBNap= 19.1(weight)a23(height)0'81 (r = 0.69, P< 0.001)
tbC1p = 8.9(weight)°'40(height)0'56 (r = 0.60, P < 0.05).
No significant dependence of TBNa and tbCI on age was observed. The biological
variation in normal TBNa and tbCI due to body build could be reduced by expressing
the results in terms of the ratios TBNa/TBNap and tbC1/tbC1p. This reduced the cv
in the male controls to 5.8% for sodium and 9.2% for chlorine.
For the female controls, multiple regression analysis gave,
TBNap = 13.1 (LBM)°'34(height)0'63 (r = 0.72, P < 0.001)
tbC1p = 5.2(LBM)°'59(height)0'33 (r = 0.84, P < 0.001).
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As with the male controls, similar equations were obtained when weight was substituted
for lbm
TBNap = 19.1(weight)°'16(height)109 0 = 0.72, P < 0.001)
tbC1p=9.8(weight)0'3 x(height)0'88 (r = 0.81, P < 0.001).
No significant dependence on age was observed for either element. Using the ratios
TBNa/TBNap and tbC1/tbC1p the cv for sodium was 6.9% and for chlorine was 5.5%.
The TBNa and tbCI results for both male and female subjects are presented in
figure 1. There was a good correlation between the TBNa and the tbCI results for
males (r = 0.89, P < 0.001) and females (r = 0.70, P < 0.005) and when the sexes were
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Figure 1. Relationship between total body sodium and total body chlorine. The regression line is calculated
from male and female data combined.
Total body sodium was also found to be dependent on the subject's total body
calcium (TBCa) (r = 0.67, P < 0.01). The TBCa results for these subjects were reported
by Kennedy et al (1982). Significant dependence for tbCI on TBCa was found only
for men (r = 0.49, P < 0.05).
There was a correlation between NaES and TBCa (figure 2). The relationship
derived was
NaES= 19.9 TBCa+ 4.5 (r = 0.79, P< 0.001)
where NaES is measured in g and TBCa in kg, and the mean NaES per kg of TBCa was
found to be 24.4 g for males and 24.9 g for females.
Although no correlation was found between TBNa and age, NaES was found to be
correlated with years post-menopause in females (r = 0.50, P<0.05) with an annual
loss of NaES after the menopause of 1.2%. No significant dependence of NaES on
age was observed for the male volunteers.
4. Discussion
The mean values of TBNa g/kg body weight for males, 1.03, and females, 0.99, are
in good agreement with those values determined by Ellis et al (1976) of 1.08 for
o male
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Figure 2. Relationship between sodium excess and total body calcium. The regression line is calculated
from male and female data combined.
males and 0.98 for females. However the mean values of tbCI g/kg body weight for
males, 0.88, and females, 0.85, are lower than those of Ellis et al (1976) of 0.99 for
both sexes.
No dependence of either TBNa or tbCI on age was observed for either sex. Over
the age range covered by this study, 40 to 70 years, this is largely in agreement with
Ellis et al (1976), which is the most comprehensive of the other studies, although
they did observe a slight decrease in TBNa in elderly females. Even when the varying
body build of the subjects in this study was taken into account by plotting TBNa/TBNap
and tbC1/tbC1p against age, no significant correlation was obtained for either sex.
The annual loss of NaEs after the menopause of 1.2% is not significantly different
from the loss of 1.5% per annum in TBCa in the same subjects (Kennedy et al 1982)
and implies that an approximately equal percentage of calcium and sodium is lost
from bone per year after the menopause. The lack of significant dependence of NaES
on age for the male volunteers agrees with a similar result for TBCa.
The mean level of 24.3 g of NaES per kg of TBCa for males agrees well with that
determined by Ellis et al (1976), for a similar age range, of 24.0 g/kg TBCa. However,
their mean value of NaES for females, aged 40-70 y of 15.3 g/kg TBCa, and that of
a later study by the same group, of 16.0 g/kg TBCa for females aged 50 to 59 y (Aloia
et al 1980) are considerably lower than the 24.9 g/kg TBCa of our study. Ellis et al
do not comment on the surprising difference they found between the sexes of the
relationship of sodium excess to total body calcium.
The results from this study imply that the sodium excess represents around 33%
of the TBNa for both male and female normal volunteers. This compares with values
of 27% for males by Rudd et al (1972), 18% for males by Chamberlain et al (1972)
and 27% for males and 23% for females by Ellis et al (1976).
The total body levels of sodium and chlorine determined in this study are in broad
agreement with other studies, e.g., Anderson et al (1968), Rudd et al (1972) and Ellis
et al (1976), and again suggest that the levels quoted by the International Commission
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on Radiological Protection (ICRP 23) of 100 g for a 70 kg man for sodium and 95 g
for chlorine are overestimates.
The narrow ranges for normal subjects that we have observed and the equations
for predicting TBNa and tbCI should allow the technique of total body neutron
activation analysis of sodium and chlorine to be a useful diagnostic procedure.
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Resume
Niveaux normaux du sodium et du chlore du corps entier par analyse par activation neutronique.
Nous avons utilise 1'analyse par activation neutronique in vivo pour mesurer le sodium et le chlore du
corps entier chez des adultes normaux (18 hommes et 18 femmes). Nous avons introduit des corrections
tenant compte des dimensions du corps. Nous en avons deduit des facteurs de normalisation permettant
de predire les niveaux normaux du sodium et du chlore chez un sujet. Le coefficient de variation du sodium
normalise est de 5,9% chez l'homme et 6,9% chez la femme, et celui du chlore normalise est de 9,3%
chez l'homme et de 5,5% chez la femme. Pour les deux elements, nous n'avons observe aucune dependance
significative vis a vis de l'age dans la tranche d'age examinee (40-70 ans). Le sodium du corps entier est
correle avec le chlore et le calcium du corps entier. L'exces de sodium, defini comme la quantite de sodium
du corps en excedant par rapport a celui associe au chlore, est aussi bien correle avec le calcium du corps
entier. Chez les femmes, on observe une perte moyenne annuelle du sodium en exces de 1,2% apres la
menopause, similaire a la perte en sodium.
Zusammenfassung
Normaler Ganzkorper-Natrium- und -Chlorspiegel mit Hilfe der Neutronen-aktivierungsanalyse.
Der Ganzkorpergehalt an Natrium und Chlor wurde bei 18 mannlichen und 18 weiblichen normalen
erwachsenen Probanden mit Hilfe der in ufuo-Neutronenaktivierungsanalyse gemessen. Korrektionen fur
die KorpergroJ3e wurden entwickelt und Normierungsfaktoren wurden abgeleitet, die die Voraussage des
normalen Natrium- und Chlorspiegels bei einem Menschen ermoglichen. Der Schwankungskoeffizient des
normierten Natriums war 5.9% bei Mannern und 6.9% bei Frauen. Der Schwankungskoeffizient des
normierten Chlors betrug bei Mannern 9.3% und bei Frauen 5.5%. Im untersuchten Bereich (40-70
Jahre) wurde fur keines der beiden Elemente eine signifikante Altersabhangigkeit beobachtet. Das
Ganzkorper-Natrium ist mit dem Ganzkorper-Chlor und dem Ganzkdrper-Kalzium korreliert. Der
Natrium-Uberschuji, definiert als die Menge an Korper-Natrium, die fiber den mit dem Chlor verbundenen
Anted hinausgeht, ist ebenfalls eng mit dem Ganzkorper-Kalzium korreliert. Bei Frauen wurde ein mittlerer
jahrlicher Verlust des Natrium-Uberschujles von 1.2% nach der Menopause festgestellt, ganz ahnlich wie
der Verlust an Kalzium.
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Abstract
Total body calcium (TBCa) was measured using a cyclotron
for in vivo neutron activation analysis (IVNAA) in 20 healthy
women, 15 women with vertebral compression fractures,
and 8 women with wrist fractures. The precision of the tech¬
nique, using phantoms, was 1.8% for a dose of 13 mSv. A
formula for predicted TBCa (TBCap) was derived from the 20
normal women based on span and years postmenopause.
The coefficient of variation of TBCa after normalization in
the normal women was 6.6%. The mean TBCa values for the
vertebral and wrist fracture groups were 69% and 84% of
TBCap for women at the time of the menopause. The low
TBCa in the wrist fracture group was attributable to post¬
menopausal bone loss. Of the low TBCa in the vertebral
fracture group, about half the loss could be attributed to
postmenopausal age and half to other factors.
Key Words: Activation-Analysis-Osteoporosis.
Introduction
In vivo neutron activation analysis (IVNAA) is an established
technique for measuring total body calcium (TBCa) and has
been described by five other groups (Chamberlain et al., 1968;
Cohn et al., 1976a; Palmer et al., 1968; Spinks et al., 1977;
Kennedy et al., 1979) as well as by ourselves (Kennedy et al.,
1982). Since 99% of TBCa is present in bone (Heany, 1963),
IVNAA can be used to measure bone mass and in this way
avoid the errors in sampling from different parts of the skele¬
ton. Two other groups have reported TBCa in women with
postmenopausal osteoporosis (Chesnut et al., 1977, Cohn
et al., 1974).
In this report we describe a formula for predicting TBCa
from the span and postmenopausal age based on a study of 20
normal women. This formula is then used to compare the bone
mass of women with vertebral or wrist fractures with their ex¬
pected bone mass. The degree of osteopenia associated with
these two types of fracture is also calculated.
Patients and Methods
Twenty women aged 46-66 years were selected from volunteers who
answered requests circulated in the hospital, in a factory, in the local
press, and on BBC Radio Scotland. The criteria for selection were
based on age (40-70 years) and the absence of a past history of back
pain, fragility fractures, artificial menopause, rheumatic, hepatic, renal,
or endocrine diseases, exposure to steroid or anticonvulsant therapy,
or excessive alcohol intake. Screening tests to exclude occult malab¬
sorption and disorders of calcium metabolism or of renal or hepatic
function were undertaken as follows: serum or plasma calcium,
phosphate, magnesium, alkaline phosphatase, albumin, parathyroid
hormone, 25-hydroxycalciferol, iron, iron-binding capacity, ferritin,
vitamin B12 and folic acid, urinary calcium, phosphate, magnesium,
hydroxyproline and creatinine clearance, and a full blood count.
Eight women with wrist fracture, aged 56-69 years, were selected
from a consecutive series of patients attending the orthopedic clinic.
Selection was made on the same basis as for the volunteers. Measure¬
ments of TBCa and of plasma and urine as for the normal women were
made 1 year after the fracture.
Fifteen women aged 48-71 years were referred to the endocrine
clinic for medical therapy of their vertebral osteoporosis. Back pain
had been present for less than 2 years in 11 of the 15 women. At least
two collapsed vertebrae were seen on a lateral radiograph of the
thoracolumbar spine in all patients. No selection was made of these
patients, and the same investigations as already described were per¬
formed together with isotope bone scans and bone biopsy when
indicated.
TBCa was measured by IVNAA using the MRC, cyclotron in
Edinburgh (Williams et al., 1979) as the source of neutrons. The in¬
duced radiation was measured using four sodium iodine detectors
mounted in a whole-body counter. Computer analysis of the spectrum
and the value of a standard irradiated simultaneously with the subjects
gave the TBCa in 49Ca counts. The long-term precision, based on
anthropomorphic phantom measurements, was 1.8%;(coefficient of
variation, CV) for a dose of 13 mSv (1.3 rem) (Kennedy et al., 1982). The
effect on measurement efficiency due to variation in body size was _
determined experimentally. Calcium counts were converted to grams
of calcium using a correction formula from phantom measurements.
Biologic variation due to size and age was then reduced using multiple
regression analysis of height, arm span, weight, age and years
postmenopause, and lean body mass (°/o body fat was obtained using
skin calipers) (Durnin and Womersley, 1974). The factors relating most
closely to TBCa were found to be arm span and years postmenopause.
Informed consent was obtained from all patients. The study proto¬
col was approved by the Hospital Ethics Committee and by ARSAC
(Administration of Radioactive Substances Advisory Committee).
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Results
The TBCa in normal women was 820 ± 124 g (mean ± stan¬
dard deviation, SD). This gave a CV of 15.1% before any
allowance was made for span or postmenopausal age. The
greatest reduction in variance was achieved using the following
formula to obtain the predicted TBCa (TBCap):
TBCap = as1-69e"°'015y (r = 0.90, P < 0.001)
where:
TBCap is in grams ■
a= 399
s = arm span in meters
y = years postmenopause
fhe arm span not only related more closely to TBCa than height
out also eliminated the error due to loss of height associated
with vertebral fractures. The formula applied to peri-
menopausal women and to women up to 22 years post-
menopause. The regression is based on an exponential loss of
Done mass starting at the time of the menopause. The esti¬
mated rate of bone loss was 1.5% per year. The ratio
"BCa/TBCap has been defined by Cohn et al. as the calcium
atio (Cafl) (Cohn et al., 1974) and for our normal women was
.00 with a CV of 6.6%.
The TBCa in women with vertebral and wrist fractures was
I49 ± 87 g and 787 ± 72 g, respectively (mean ± SD). The
alues of span and postmenopausal age are shown in Table I.
i the women with wrist fractures the CaR was 1.00 ± 0.10,
/hich was normal (Fig-1)- Six of the 15 women with vertebral
acture had postmenopausal ages greater than 22 years. This
/as the greatest postmenopausal age among the normal
/omen; the formula for TBCap cannot be extrapolated to
over the women in this group who were more than 22 years
ast the menopause. In the remaining 9 women the Cafl
'as 0.87 ± 0.06, significantly lower than in normal women
3 < 0.01). Factors that may have contributed to this excessive
one loss were identified in 5 of the 9 patients, namely,
rednisolone therapy for polymyalgia rheumatica, phenytoin
lerapy for epilepsy, previous history of thyrotoxicosis, atrophic
astritis, and moderate impairment of renal function (creatinine
earance 20 ml/min).
When TBCa was normalized for span alone (TBCa/as169),
2., y = 0 in the equation for TBCap, an estimate of osteopenia
the patients with fractures could be made by comparing the
dues with the CaR of the normal women (Fig. 2). The
3Ca/as169 for women with vertebral and wrist fractures
id for normal women were 0.69 ± 0.06, 0.84 ± 0.08, and
38 ± 0.11, respectively (mean ± SD). All the women with
rtebral fractures had values less than 0.78, but 3 of the 8
)men with wrist fractures and 5of the 20 normal women also
d values below 0.78.
>le I. Span and postmenopausal age in normal women and
women with vertebral and wrist fractures. The years
postmenopause in the vertebral fracture group were






eal women 20 1.65 ± 0.07 8.9 ± 7.0
sbral fracture 15 1.66 ± 0.07 21.9 ± 8.4














Fig. 1. Calcium ratio (CaH) in normal women (O), women with wrist
fracture (A), and women with vertebral fracture (□). Horizontal lines
























Fig. 2. Total body calcium normalized for span (TBCa/as1'69) in
normal women (O), women with wrist fracture (A), and women with
vertebral fracture (□). Horizontal lines are mean Ca„ ± 2 SD for
normal women.
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Discussion
TBCa for the normal women (820 ± 124 g) was similar to that
reported by Cohn et al. (1976b), namely, 804 ± 106 g for
normal women aged 50-59 years. The TBCa for women with
vertebral fractures (649 ± 87 g) resembled that described by
Chesnut et al. (1977) (mean 688 g ± 94 g) and Cohn et al.
(1974) (mean 590 g ± (108 g). However, some of the patients
in the latter two groups did not have vertebral compression
fractures but only demineralized vertebrae.
Different formulae for TBCap have been reported. Cohn et
al. (1976b) use age from birth, height, and total body potas¬
sium: the latter two also may be age dependent. Nelp et al.
(1972) predict TBCa from the cube of the patient's height. In
the present report it was noted that span was more effective
than height in reducing variance, and we would prefer to use
span, as it is unaffected by the height loss due to vertebral
compression fractures.
The CV of TBCap in normal women was 6.6% as compared
with 7.1% reported by Cohn et al. (1976b). The latter group
found that the rate of bone loss after the age of 55 years was
1.1% per year compared with the rate of 1.5% per year after
the menopause in our group.
The Cafl was 0.87 in the women with vertebral fractures,
similar to the value of 0.82 found by Cohn et al. (1974). An early
menopause in these two groups of women may explain in part
their osteopenia. Additional factors, including a low TBCa at
the time of the menopause or an accelerated loss of bone after
the menopause, must also have been present. The normal
CaR in the women with wrist fractures suggests that they
were not specifically prone to fracture compared with other
postmenopausal women.
Expressions such as TBCa/as1,69 to describe the degree of
osteopenia have not been reported previously. Although the
sample size of 15 was small, in this group of women vertebral
crush fractures occurred when total body calcium was below
80% of that predicted from span alone, i.e., TBCa/as169 less
than 0.78. However there was some overlap of these values
with the other groups of women. It may be possible, therefore,
to predict those women likely to sustain a vertebral fracture and
to recommend treatment, estrogens, for example, aimed at
preventing further loss of bone mass.
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resume
Le calcium corporel total (Ca CT) a ete mesure par activation neutronique in vivo avec I'aide d'un cyclotron chez 20 femmes en bonne sante, 15 femmes
ayant un tassement vertebral et 8 femmes atteintes de fracture de I'extremite inferieure du radius. La precision de la technique, evaluee sur des
fantomes, est de 1,8 pour cent pour une dose de 13 mSv. Une formule permettant de predire le CaCT a partir du delai ecoule depuis la menopause a ete
calculee pour les 20 femmes normales. Le coefficient de variation du CaCT apres normalisation est de 6,6 pour cent dans la population temoin. Les
valeurs moyennes du CaCT dans le groupe avec fracture vertebrale et dans celui avec fracture du radius etaient respectivement egales a 69 et 84 pour
cent du CaCT des femmes au moment de leur menopause. Le CaCT reduit dans le groupe avec fracture du radius peut etre attribue a la perte osseuse
post-menopausique. La reduction du CaCT dans le groupe avec tassements vertebraux peut etre imputee pour moitie environ a I'etat post-
menopausique et pour moitie a d'autres facteurs.
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Bone mass in nodal primary generalised
osteoarthrosis
D. M. REID, N. S. J. KENNEDY, M. A. SMITH, P. TOTHILL, AND G. NUKI
From the Rheumatic Diseases Unit, Northern General Hospital, Department ofMedicine, Western General
Hospital and Departments ofMedical Physics and Medical Engineering, Western General Hospital and Royal
Infirmary ofEdinburgh, University ofEdinburgh
summary Previous studies of patients with primary osteoarthrosis of the hip have suggested an
increase in bone mass compared with control populations. Nodal primary generalised osteoarth¬
rosis is known to have a strong familial tendency. To test the hypothesis that this tendency might
also lead to increased bone mass, total body calcium has been measured by in-vivo neutron
activation analysis and cortical area calculated from measurements of metacarpal indices in 15
female patients with primary generalised osteoarthrosis. The results have been compared with
those from 12 healthy controls matched forage, menopausal status, and skeletal size. No significant
differences were noted in the total body calcium or cortical area measurements between the 2
groups either before or after correction for skeletal size and menopausal status. No relationship
was found between the grade of radiological osteoarthrosis in the hand and either bone mass
parameter. Bone mass would not appear to be an important factor in the aetiopathogenesis of
nodal primary generalised osteoarthrosis.
Osteoarthrosis (OA) is not a single disease but rather
a pattern of biomechanical failure of joints1 which
may be secondary to a variety of disorders of bone or
articular cartilage. Although most theories of the
pathogenesis of OA are based on primary alterations
in the articular cartilage,2 Radin et al.3i have sug¬
gested that the progressive wear of fibrillated articu¬
lar cartilage seen in 'primary' OA results from stiffen¬
ing of the subchondral bone. Clinical support for such
a hypothesis comes from the observation that
pathological changes of OA are unusual in femoral
heads removed from patients with fractured necks of
femur5 and that bone mass appears to be increased in
patients with primary OA of the hip when assessed by
measurements of metacarpal indices6 or photon
absorptiometry.7
To examine this hypothesis further we have asses¬
sed bone mass in female patients with nodal primary
generalised osteoarthrosis by measuring total body
calcium and metacarpal indices and comparing the
results with controls matched for age, skeletal size,
and menopausal status.
Patients and methods
Fifteen female patients with nodal primary
Accepted for publication 23 February 1983.
Correspondence to Professor G. Nuki, Rheumatic Diseases Unit,
Northern General Hospital, Ferry Road, Edinburgh EH5 2DQ.
generalised osteoarthrosis (PGOA) fulfilling the
criteria defined by Kellgren and Moore8 and 12
asymptomatic healthy women matched for age,
skeletal size, and menopausal status have been
studied. Serum calcium, phosphate, alkaline phos¬
phatase, and albumin were measured in all subjects
by standard methods, and persons with abnormalities
of calcium metabolism or medical conditions known
to b'e associated with secondary osteoporosis were
excluded.
Total body calcium (TBCa) was measured by in-
vivo neutron activation analysis. Patients were
irradiated for 20 seconds from front and rear, while
standing in a rigid polyethylene activation enclosure,
by means of neutrons from the Edinburgh Medical
Research Council Cyclotron. The patients were then
transferred to a shadow-shield whole-body counter,
where the gamma radiation from calcium 49Ca
induced from stable 48Ca by neutron capture, was
measured for 20 minutes. The patient's TBCa in
grams was calculated by comparison with the energy
spectrum from an activated anthropomorphic phan¬
tom of human dimensions containing a known quan¬
tity of calcium. Repeated measurements of the phan¬
tom gave a long term precision of 1-8% for a radia¬
tion dose of 13 mSv (T3 rem).9 The mean TBCa ± 1
SD in the control population was 842-0 ± 142-7 g.
Individual results were expressed both in grams and
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as a percentage of the expected normal value for the
patient's skeletal size (arm span) and menopausal
status. After correction for arm span and menopausal
status the spread in the normal controls expressed as
the coefficient of variation was reduced to 6-3%.
Metacarpal indices were measured by a variation
of the technique described by Dequeker.10 A single
posteroanterior radiograph of the hands was taken at
a uniform 1 metre tube-to-film distance using non-
screen film. Morphometric measurements were per¬
formed at the right 2nd, 3rd, and 4th metacarpals.
The length of each metacarpal was determined with a
millimetre rule, and the external diameter (D) and
the internal diameter (d) of the midshaft of the cortext
were measured to the nearest 0-1 mm by means of a
needle-tipped direct reading Vernier caliper. The
cross-sectional cortical area was then calculated from
the formula 7t/4 (D2-d2), but omitting ir/4 by con¬
vention. The final figure was expressed as a mean of
the 3 metacarpals. The precision of the technique,
evaluated from 2 radiographs take at daily intervals
in 10 young normal controls, was 2-0%. The mean
cortical area in the control population was 46-3 mm2,
with a range from 37-5 to 52-9 mm2.
The severity of radiographic osteoarthritic changes
at the distal and proximal interphalangeal joints of
each digit and at the carpometacarpal joint of the
thumb was graded from 0 to 4 according to the
criteria of the Atlas of Standard Radiographs.11 A
composite score was derived from the sum of the
changes in each of the above joints giving a possible
score of 0-80 considering both hands. All patients
gave informed consent, and approval was obtained
from local and national ethical committees.
Results
Details of age, menopausal status, span, height, and
osteoarthrosis score for patients and controls are
shown in Table 1. The results of TBCa and cortical
Table 1 Mean age, menopausal status, span, height and
osteoarthrosis score in patients with PGOA and controls;
range given in parentheses
PGOA Controls
n = 15 n =12
Age (years) 58-5 55-5
(47-68) (46-65)
Years after menopause 8-5 6-9
(0-20) (0-22)
Arm span (cm) 166-2 1631
(155-183) (150-175)
Height (cm) 162-2 1.59-8
(156-5-170) (151-173)
Osteoarthrosis score 36 3
(11-64) (0-9)
Table 2 TBCa expressed in grams and as a percentage of
normal and cortical area in PGOA patients and controls.
Mean values ± SD with the range given in parentheses
PGOA Controls
n = 15 n = 12
TBCa in grams 830-6± 129-0 842± 142-7
(590-2-1053-7) (596 0-1036-1)
TBCa-% or normal 99-5± 11-5 100+ 6-31
(83-0-120-1) (88-7-110-4)
Cortical area in mm2 47-0+6-4 46-3±5-2
(36-1-56-0) (37-5-52-9)
area in the 2 groups are shown in Table 2. The mean
TBCa in control and PGOA groups showed almost
identical values, both when expressed in grams and
when expressed as a percentage . of the expected
normal values for the patient's skeletal size
and menopausal status. Mean cortical area
measurements in the 2 groups again showed no
significant difference.
Total body calcium was highly significantly corre¬
lated with cortical area (r = 0-722, p<0-001). TBCa
and cortical area were not correlated with the osteo¬
arthrosis score (TBCa: r = -0-289, cortical area: r =
-0-173). There was no different in any of the indices
of bone mass between patients who had or had not
received nonsteroidal anti-inflammatory drugs.
Discussion
These studies suggest that there are no significant
differences in total bone mass (measured by TBCa)
or local bone mass (measured by cortical area) in
patients with PGOA compared with matched con¬
trols. Statistical analysis of the data shows that mean
differences in TBCa normalised for skeletal size and
menopausal status s7-2% and cortical area s9-9%
would have been significant at the 95% level in
groups of this size.
Previous studies have only measured bone mass in
patients with primary osteoarthrosis of the hip. Foss
and Byers6 first suggested that bone density
measured by metacarpal indices was increased in
patients with primary OA of the hip when compared
with age matched normal subjects, but data on the
skeletal size and extent of generalised osteoarthrosis
in the patient group were not included. Roh et aid2
found an increase in periosteal diameter (external
cortical diameter) and cortical area in primary OA of
the hip compared with an age matched normal range,
but the differences in females may well have been
attributable to increased skeletal size. More recent
studies have failed to confirm such increases in bone
density using measurements of cortical area and cor¬
tical thickness13 or cortical area related to cross-
sectional area.14
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Photon absorptiometric methods have been used
to estimate metacarpal7 and radial bone mineral con¬
tent7 1315 in patients with primary OA of the hip. The
results have been conflicting: one study appeared to
show an increase in bone mineral content of 13% at
cortical and 23% at trabecular sites,7 one showed an
increase at a trabecular site alone,15 and one showed
no increase at either site.13
There are several possible explanations for the
differences shown in these studies. The use of a stick
as support might cause an increase in local bone mass,
and this was eliminated in only 2 of the studies.715
More important, patients and study groups have not
been closely matched for skeletal size in any of the
studies where increased bone mineral has been
shown. In 2 of them the osteoarthrotic groups were
indeed taller than the controls.712
No previous studies have corrected for meno¬
pausal status. As it is recognised that bone loss
in females occurs at a rate of 1-1%16 to 1-5%0 per
annum after the menopause and at a much slower
rate before (0-37%),16 the small changes in the bone
mineral content of the skeleton shown in some of the
above studies may simply be related to different
menopausal status.
Our failure to show increased total skeletal bone
mass in patients with PGOA makes it very unlikely
that bone mineral content is important in the aetio-
pathogenesis of this genetically determined condi¬
tion. Nevertheless, these findings do not rule out the
possibility of local increases in bone density in areas
adjacent to affected joints, or very small increases in
total bone mass.
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Changes in Total Body Calcium after Renal Transplantation
Effect of Low-Dose Steroid Regime
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Abstract. Total body calcium was measured in 8 men and 4 women, aged 20-51 years, undergoing kidney
transplantation. The initial measurement was made within 8 weeks of operation and subsequent measurements up to
33 months postoperatively. Transplant rejection was prevented by low-dose prednisolone therapy (20 mg/day). 2
patients underwent parathyroidectomy for hypercalcaemia, and their total body calcium increased by 29 g (3%) and 66
g (8%). In the remainder the mean annual change was -0.9% (3.7, SD) over an average follow-up period of 17 months.
This fall in total body calcium was statistically insignificant and was smaller than that previously described in patients
treated with higher doses of steroids.
Introduction
Total body calcium (TBCa) can be used to measure
long-term changes in calcium balance. We have applied
this technique to 12 patients undergoing kidney trans¬
plantation. Previous prospective studies have shown that
bone mass falls by between 5 and 7% in the 1st year after
transplantation [Lindsay et al., 1976; Aird and Pierides,
1977]. However, these studies used higher doses of ste¬
roids than those used in the present study.
Patients and Methods
8 men and 4 women aged 20-51 years (mean 35.9) were studied.
They had been on maintenance haemodialysis for 4-54 months
(mean 23). The causes of renal failure were chronic glomeruloneph¬
ritis (6), polycystic kidney disease (2), chronic pyelonephritis (1),
obstructive nephropathy (1), malignant hypertension (1), and Good¬
pasture's syndrome (1). 2 patients had hypercalcaemia due to secon¬
dary hyperparathyroidism at the time of operation, 1 had alumi¬
nium-induced osteomalacia, and 1 had osteomalacia treated with
alphacalcidol. 7 patients had arterial wall calcification.
9 patients received kidneys from cadavers and 3 from related
donors. Antirejection treatment was given as described by McGeown
et al [1977]. Azathioprine was given at a dose of 3 mg/kg/day and
prednisolone at a dose of 20 mg/day. Subacute rejection episodes
(average of 1 per patient, range 0-3) were treated with prednisolone
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200 mg/day and reduced to 20 mg/day over 10 days. This dose was
reduced to 10 mg/day over 10-33 months, unless chronic rejection
developed (2 cases), and then the dose was increased to 20 mg/day.
TBCa was measured by in vivo neutron activation analysis using
a cyclotron as the source of neutrons [Kennedy et al., 1982]. This
method has a precision in anthropomorphic models of 1.8% for a
dose of 13 mSv. Formulae have been described for predicting TBCa
(TBCap) from height in men and from arm span and years
postmenopause in women [Kennedy et al., 1982]. The ratio of TBCa
to TBCap is the calcium ration (CaR) and the mean value ± standard
deviation (SD) for 20 healthy men was 1.000 ±0.062 and for 20
women 1.000 ±0.066. Initial measurements were made in the week
prior to surgery in the 3 patients receiving kidneys from related
donors and within 8 weeks of surgery in the remainder. Subsequent
measurements were made at about 6-month intervals for up to 33
months (mean 17 months). Patients gave informed written consent,
and the study was approved by the hospital ethics committee and the
Administration of Radioactive Substances Advisory Committee.
Plasma calcium values were available immediately prior to ope¬
ration and were subsequently measured monthly along with magne¬
sium, protein, and creatinine. Plasma phosphate values were also
available from before operation, and plasma parathyroid hormone
(PTH), and plasma 25-hydroxyvitamin D were measured when the
initial TBCa measurement was made; measurements were repeated
at the end of the study. Radiographs were taken when considered
appropriate by the physician in charge.
A paired t test was used to analyze the changes following kidney
transplantation. Comparison with controls were made using the
unpaired t test. Plasma alkaline phosphatase and 25-hydroxyvi¬
tamin measurements were log^-transformed prior to statistical anal¬
ysis.
Eastell/Kennedy/Smith/Tothill/Anderton
Table I. Initial TBCa results in patients undergoing renal trans¬
plantation
Table II. Initial plasma biochemistry and changes following
renal allotransplantation in 10 patients
Men
TBCa. g
Renal failure 1,006 685
Controls 1,143 821
CaR
Renal failure 0.93* 0.82***
Controls 1.00 1.00
*p<0.05; ***p < 0.001 (unpaired t test).
Variable Initial Mean change, P
value %
Alkaline phosphatase, U/l 72.2 -54 NS
Phosphate, mmol/I 1.69 -51 <0.02
Calcium, mmol/l 2.34 8 <0.05
Magnesium, mmol/l 1.26 -29 <0.002
Parathyroid hormone, g/1 0.82 -71 NS
NS — Not significant.































Fig. I. Changes in CaR in men (O) and women (■) following
renal allotransplantation. Broken lines indicate 95% confidence
limits for male and female controls.
Fig. 2. Changes in plasma creatinine (.) and the mean daily dose
of prednisolone (-) in 12 patients after renal allotransplantation.




Initial values for TBCa and CaR are shown in table I.
The mean initial CaR values in the 8 men showed a 7%
reduction below the mean for male controls and in the 4
women an 18% reduction below the mean for female
controls. 3 of the 4 women and 2 out of the 8 men had CaR
values less than 2 SD below the mean for the controls.
The 2 men who underwent parathyroidectomy 4 and
20 months after renal transplantation had increases in
TBCa of 66 g (8%) over 10 months and 29 g (3%) over 18
months. In the remainder the mean change was calcu¬
lated from the initial and final measurements and was
-0.9%/year, with 95% confidence intervals of
-3.2-1.4%/year (fig. 1).
Biochemistry.
The initial biochemistry results are shown in table II.
The elevated plasma creatinine fell gradually, but never
into the normal range (fig. 2). 2 patients underwent para¬
thyroidectomy, and so their data are excluded from the
following results.
Plasma alkaline phosphatase and phosphate (table II)
and plasma magnesium (fig. 3) all fell into the normal
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Fig. 3. Changes in plasma calcium and magnesium in 10 patients
after renal allotransplantation. Broken lines indicate laboratory
reference ranges.
months such that the mean value was at the upper limit of
the reference range for the 30-month follow-up period
(fig. 3). sf 2.. cu/ikf-
Discussion
The annual reduction in TBCa of0.9% was not statisti¬
cally significant and was much smaller than the 7% fall in
metacarpal bone density described by Lindsay t1 al. [1976]
in the 1st year after renal transplantation. Aird and Pier-
ides [1977] showed a fall of 5.1-5.4% in lower femur
density over a similar period. Both groups used a higher
dose ofsteroid, and this could account forthe more rapid
bone loss compared with the changes in the present
study.
The insignificant change in TBCa contrasts with the
dramatic biochemical changes. The time course of the
return of plasma alkaline phosphatase, phosphate, and
magnesium to normal, along with a reduction in plasma
PTH almost to normal, corresponds with the bone biopsy
findings of Bortolotti et al [1977], They showed that the
marrow fibrosis, excess osteoid, and increased bone re¬
sorption had resolved by 16-20 months after renal allo¬
transplantation.
The persistent mild hypercalcaemia has been de¬
scribed in 21% of the 386 patients reported by Chatterjee
et al. [1976], David et al. [1973], Ibelse t al. [1978], and Leet t
al. [1973]. It is associated with normal or raised plasma
PTH levels [Kleerekoper et al., 1975]. This elevation may
be due to the persistently impaired renal function. Le-
mann et al. [1979] have shown that plasma PTH rises when
creatinine clearance falls below 50-80 ml/min (0.83-1.33
ml/s).
The initial low TBCa differs from the findings of
others. Cohn et al. [1975] and Denney et al. [1973] reported
normal mean TBCa values in patients on haemodialysis
for chronic renal failure. The type of bone disease was
reported to affect TBCa, the lowest values being found in
those with osteomalacia and normal or high values in
those with hyperparathyroidism. In the present series the
low TBCa may be due to a higher frequency of osteomal¬
acia, but unfortunately bone biopsies were not per¬
formed.
The healing of renal osteodystrophy after renal allo¬
transplantation might be expected to be associated with
an increase in TBCa, particularly in the patients with a
predominantly osteomalacia type of bone disease. In the
present series this effect was countered by the osteopae-
nic effect of the steroids. Ectopic calcification was pres¬
ent in more than half the subjects, but was always con¬
fined to blood vessel walls and was unlikely to have
contributed much to TBCa [Denney et al., 1973]. Once the
renal osteodystrophy has healed, the action of the ste¬
roids is unopposed and may be potentiated by the com¬
monly associated mild hyperparathyroidism. This might
account forthe findings of AndresenandNielsen[\9%2] of
a low bone density in patients 67 months after renal
transplantation; the mean value ofbone mineral concen¬
tration of the radius and ulna was 25% below age- and
sex-matched controls.
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Abstract. Total body calcium was measured using in vivo neutron activation analysis in
156 patients with rheumatic diseases at six-month intervals. Evidence of seasonal variation
was sought by relating deviation from a linear change to the month in which the measure¬
ment was made. A cyclic regression fitted to the data had an amplitude of 0.25% but a
significance of only P = 0.08. The calcium balance studies of Malm were re-analysed to-'
quantify the seasonal variation he had demonstrated in one group of men. The deduced
variations of body calcium were highly significant, with a phase and amplitude very similar
to the regression of our data. Both analyses differed from two previous reports of seasonal
variations of part-body bone mineral of much greater amplitude and different phase.
1. Introduction
In 1958 Malm demonstrated a seasonal variation of calcium balance in a group of
subjects maintained on a fixed intake over a long period (Malm 1958). This finding
is compatible with subsequent studies of the seasonal variation of associated measure¬
ments of calcium biochemistry (Smith et al 1964, Stamp and Round 1974, Robertson
et al 1974).
There have been two reports of direct measurements of bone mineral in limited
parts of the skeleton which also showed seasonal variation (Aitken et al 1973, Krplner
1983). There do not appear to have been any studies of such an effect in the whole
skeleton. As we have been carrying out longitudinal studies of total body calcium
over an appropriate period it seemed worthwhile to examine the data for evidence of
seasonal variation. Such a variation would be of direct physiological interest and also
relevant to the interpretation of longitudinal studies of total body calcium.
2. Method
Total body calcium was measured by in vivo neutron activation analysis using a
cyclotron source (Kennedy et al 1982). Corrections were applied for body size. The
long term precision with anthropomorphic models was 1.8% and with patients 2.9%
(Tothill et al 1984) for a dose-equivalent of 13 mSv. Three or four measurements of
total body calcium were made at intervals of six months in 156 patients with various
rheumatic diseases treated with a variety of agents (Reid et al 1984). 96 patients had
rheumatoid arthritis, 9 psoriatic arthropathy, 19 primary generalised osteoarthrosis,
14 polymyalgia rheumatica and 18 ankylosing spondilitis. Permission was obtained
from the local ethical committee and the Administration of Radioactive Substances
Advisory Committee and the patients gave informed consent.
0143-0815/86/040361 +07S02.50 © 1986 The Institute of Physics 361
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The rate of change of total body calcium was assessed by fitting a linear regression
to the points for each patient. The possibility of a seasonal variation of total body
calcium was investigated by relating the deviation of each point from the regression
line to the month in which the measurement was made. Comparisons were made
between mean deviations for monthly and three-monthly periods. In addition, a cyclic
regression was fitted to the data.
Malm (1958) had demonstrated the existence of a seasonal variation of calcium
balance by relating the proportion of 'better, poorer and intermediate' retentions to
the month in which the observations were made. Such a method of analysis does not
lend itself to the assessment of the significance or magnitude of the differences, so his
data were subjected to re-analysis by the same techniques as were applied to our own.
3. Results
Our study commenced in mid 1980 and continued through 1983, although only 27
measurements were made in the last year. When mean deviations for each month of
the study were plotted, no consistent pattern of variation was seen. As any seasonal
changes were likely to be small compared with the spread of the data, results for each
calendar month throughout the whole period were combined. The mean results for
all subjects are shown in figure 1. Average deviations for each month are given, with
^standard errors. In addition, mean values are given for three-month periods. There
is no significant difference between the mean values for any two months or quarters;
the standard deviations and numbers of subjects were such that a difference of 0.7%
in mean total body calcium between two three-month periods would have been
significant at P = 0.05.
JFMAMJJASOND
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Figure 1. Variation of total body calcium with calendar month in which the measurement was made. Points
are mean deviations from the regression line for each month, with standard errors. Blocks relate to means
and standard errors for three-month periods. All subjects are included.
An expression of the form x = a + b cos(t + c) was fitted to all 590 observations
using a least-squares method, x is the percentage deviation, t the month of the year
and a, b and c are the parameters of the equation, a represents the mean value of x,
b the amplitude of the oscillation and c the phase angle. The best-fit curve was
x = -0.002 + 0.253 cos(30t-19.37). (1)
The correlation coefficient was r = 0.070, with a significance of P = 0.08.
The correlation coefficient provides a measure of the amount by which the residual
variance of the data is reduced by the regression; in this case the reduction is barely
significant.
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A curve was also fitted to the mean monthly deviations
x = 0.032 + 0.187 cos(30f — 8.93). (2)
The regression (r = 0.44) had a significance of P>0.1, reflecting the undue weight
placed on the results from July, a month in which fewer than average measurements
were made.
The data were also considered separately for women before and after the menopause
and for men. No significant differences (at P < 0.05) between monthly or three-monthly
mean values were seen and cyclic regressions were not significant. As mean rates of
change were different in some of the disease and treatment groups (Reid et al 1984)
the possiblity of seasonal variation was also examined in each of the groups separately.
No evidence of such variation was found.
Malm (1958) considered seasonal variations of calcium balance in two groups of
men studied for at least eight months. The first consisted of 16 men on a daily calcium
intake of 950 mg. Over the whole period of study all but one of the subjects was in
positive calcium balance. To quantify the variation, the mean of all 14-day calcium
balances determined in a particular month was evaluated, together with its standard
error. The results are plotted in figure 2(a). The three-month totals are also included.
The numbers of observations varied slightly, averaging 31 per month. The difference
between the highest positive balance in August and the lowest in April was significant
(P<0.05). When quarterly totals are considered the mean balances in the period
July-September were greater than those in January-June, also with P<0.05. The
significance of the differences was calculated using tables of the Studentised range
(Snedecor and Cochran 1980).
A cyclic regression was fitted to the data, the equation being
y = 73.9 + 45.0 cos(30t + 86.6) (3)
where the units of y are mg d~' of calcium and t is in months. The correlation coefficient
o 1
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Figure 2. Malm's calcium balance data. Points are mean balances for each calendar month, with standard
errors. Blocks relate to means and standard errors for three-month periods, (a) 16 men maintained for at
least eight months with an intake of 950 mg d~'; the full curve is the cyclic regression fitted to the data, (b)
10 men maintained for at least eight months with an intake of 450 mgd-1.
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is r = 0.90 and the regression is highly significant (P < 0.001); the amplitude is 45 mg d"1.
The curve is included in figure 2(a).
Variations in total body content of calcium can be obtained by integration of
equation (3), giving
z = 2.251 + 2.58 sin(30l+ 86.6) (4)
where z is the change in calcium content in g since the beginning of the year. The
linear term reflects the overall positive balance of the subjects. The cyclic term has
an amplitude of 2.6 g, with the phase shifted by three months compared with equation
(3), so that the maximum positive deviation from a linear change occurs in December
and the maximum negative deviation in June. The cyclic part of the regression is
plotted in figure 3.
Figure 3. Cyclic regressions fitted to deviations from a linear change: A, total body calcium from Malm's
balance data; B, total body calcium measured by us; C, metacarpal bone mineral reported by Aitken et at;
D, spine bone mineral reported by Krplner.
The other group in which Malm claimed to have observed seasonal variation of
calcium balance contained ten men maintained on a diet of only 450 mg d-1. The
mean monthly and three-monthly balances are plotted in figure 2(b). None of the
differences between means was significant. The best-fit cyclic regression, y =
—44.5 + 7.73 cos(30l+ 91.7), was also not significant (r = 0.29, P >0.1). Although this
regression was not statistically significant, it may be noted that the phase was very
similar to that observed for the high-level-intake regression.
4. Discussion
The first suggestion of possible seasonal variation of calcium balance came from
McCance and Widdowson (1943). However, they made the finding in only three
subjects. Malm (1958) demonstrated such an effect with more certainty by long-term
balance studies on groups of subjects in a Norwegian state penitentiary, using closely
controlled calcium intakes. Our study was the first to examine seasonal changes of
total body calcium by direct measurement. The results suggest such a variation, but
do not demonstrate it with a high degree of statistical significance.
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Our re-analysis of Malm's data shows the magnitude and significance of seasonal
variation based on long-term balance measurements. For the group of 16 men with a
high calcium intake, the seasonal variation was highly significant. The maximum
deviations of total body calcium from a linear change were 2.6 g. The calcium content
of Reference Man is 1000 g (ICRP 1975) and our own measured mean value is 1143 g
(Kennedy et al 1982) so that such an amplitude represents only about 0.25% of total
body calcium. The dispersion of our results ofTBCa measurements explains the difficulty
that we have in detecting a change of this magnitude with any degree of significance.
Nevertheless, although of marginal statistical significance, the curve fitted to our data
is very similar in amplitude and phase to that derived from Malm's data. Both curves
are included in figure 3.
Malm's observation of an apparent seasonal variation in the group of ten men with
a low calcium intake was not, in fact, statistically significant.
The previous reports of the direct measurement of seasonal changes of bone mineral
in humans have examined only a part of the skeleton. Aitken et al (1973) showed that
the metacarpal mineral content of 48 post-menopausal women was 3.8% higher in the
period May-August than in November-February. A cyclic regression fits very well to
their data, with amplitude 2.3% and a maximum in July (figure 3).
Krplner (1983) similarly reported an increase of 1.7% in the lumbar spine bone
mineral content of 26 normal women (nine of them post-menopausal) during July-
September compared with January-March. There was a mean annual loss of 1% in
this group and Krplner assessed the seasonal variation from deviations from a linear
regression in the same way as we have. He fitted a cyclic regression equation, the
amplitude of which corresponded to 1% of the spine bone mineral, with a maximum
in August. This curve is also plotted in figure 3, which demonstrates that the two
observations of bone mineral variation in parts of the body exhibit a greater amplitude
than our deductions about total body calcium from Malm's balance data. They also
show a different phase, with the maximum occurring about five months earlier.
Our results are not incompatible with Malm's observations. They are, however, at
variance with the part-skeleton results; we could easily have detected changes of the
magnitude reported by Aitken et al (1973) and Krplner (1983) if they had applied to
the whole skeleton. It may be that seasonal variations are only apparent at certain
bone sites. The greater variation in the spine than in the whole body might be thought
to be due to the more rapid turnover of trabecular bone. However, the amplitude was
even greater in the cortical bone of the metacarpals. It would perhaps be unwise to
draw too many conclusions from different populations examined by different tech¬
niques.
We have to consider whether the likelihood of seasonal variation of TBCa in our
patients might be different from that for normal subjects by virtue of their disease.
Our population consisted of groups of patients, the majority of whom suffered from
rheumatoid arthritis or primary generalised osteoarthrosis. Previous studies have shown
that patients with these diseases do not have any disturbance of vitamin D metabolism
(Bird et al 1980, 1982) and none of our patients had any abnormality of elementary
calcium biochemistry. All were ambulant out-patients and it seems unlikely that the
rheumatic diseases could affect any seasonal variation in calcium balance by either of
the mechanisms that have been suggested, i.e. variable exposure to sunlight (Aitken
et al 1973) or reduced exercise in winter (Krplner 1983).
One of our motives for undertaking this study was conern that seasonal variations
might influence the interpretation of our longitudinal studies of TBCa. With the numbers
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of our observations and their variance, the magnitude of any such seasonal variation
is such that it does not complicate that interpretation.
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Resume
La variation saisonniere du contenu en calcium du corps entier.
Les auteurs ont mesure, a six mois d'intervalle, le contenu en calcium du corps entier par analyse de
l'activation neutronique in vivo sur 156 patients presentant des troubles rhumatismaux. Une variation
saisonniere evidente a ete recherchee en reliant l'ecart a un changement lineaire au mois durant lequel la
mesure etait faite. Une regression cyclique ajustee aux donnees a presente une amplitude de 0,25% mais
une significativite de seulement P = 0,08. Les etudes par Malm de l'equilibre en calcium ont ete analysees
de nouveau pour quantifier la variation saisonniere qu'il avait demontre chez un groupe d'hommes. Les
variations deduites du contenu en calcium du corps etaient hautement significatives, avec une phase et une
amplitude tout a fait comparables a celles obtenues en ajustant la regression a nos donnees. Les deux
analyses differaient de deux precedents rapports sur les variations saisonnieres du contenu mineral osseux
dans certaines parties du corps, presentant une amplitude beaucoup plus grande et une phase differente.
Zusammenfassung
Die jahreszeitliche Schwankung des Ganzkorperkalziums.
Mit Hilfe der in vivo Neutronenaktivierung wurde das Ganzkorperkalaium bei 156 Patienten mit rheuma-
tischen Erkrankungen in 6-Monats-Intervallen gemessen. Es wurden Hinweise fur jahreszeitliche
Schwankungen gesucht, indem man die Abweichung von einer linearen Anderung in Beziehung setzte zu
dem Monat, in dem die Messungen gemacht wurden. Eine zyklische Regression, mit der die Daten angepaOt
wurden, hatte eine Amplitude bei 0.25%, aber eine Signifikanz von nur E = 0.08. Die Kalzium-Gleich-
gewichtsstudien von Malm wurden re-analysiert, um die jahreszeitlichen Schwankungen zu quantifizieren,
die er in einer Gruppe von Mannern gefunden hatte. Die abgeleiteten Schwankungen des Korperkalziums
waren hochsignifikant mit einer Phase und Amplitude, die sehr ahnlich waren, wie die Regression
der vorliegenden Daten. Beide Analysen unterscheiden sich von friiheren Berichten jahreszeitlicher
Schwankungen des Teilkorperknochenmineralgehaltes von viel groBerer Amplitude und unterschiedlicher
Phase.
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Bone Mass in Ankylosing Spondylitis
DAVID M. REID, JEREMY J. NICOLL, NORMAN S. J. KENNEDY, MICHAEL A. SMITH,
PETER TOTHILL, and GEORGE NUKI
Abstract. To assess bone mass in ankylosing spondylitis (AS) we have measured total body cal¬
cium, bone mineral content of the lumbar spine and metacarpal indices in groups of patients
with AS. Mean total body calcium was reduced by 5.3% (p < 0.05) in 20 patients compared
with controls. The mean annual loss of bone, assessed over an 18 month period in 17 patients,
was 2.9% (p < 0.001). Compared to controls, bone mineral content was increased by 28%
(p < 0.05) in 8 male patients while metacarpal indices were normal in 18 male and female
patients. The results of total body calcium measurements give support to the hypothesis of
a minor increase in bone turnover in AS. The increased bone mineral content in the male pa¬




Although vertebral osteoporosis was originally considered
to be an early radiological sign of ankylosing spondylitis
(AS)1-2, it is now recognized to occur as a late feature of the
disease process3'4. Spontaneous fractures, a common
consequence of vertebral osteoporosis, appear to be
uncommon in AS, occurring only once in 212 patients in one
report5. However, another group of investigators found 2
spontaneous fractures in a series of 50 patients, and the
majority of subjects were said to have mild axial and
appendicular osteoporosis6.
To shed light on the presence and site of bone loss in AS
we have measured total bone mass by total body calcium in
patients with AS and related the results to those of vertebral
bone mass measured by dual photon absorptiometry,
peripheral bone mass measured by metacarpal indices and
radiographic disease status measured by syndesmophyte
count.
MATERIALS AND METHODS
Patients. We measured total body calcium in 20 randomly selected patients
(14 men, 6 women) with AS as defined by the New York criteria7 and
compared the results with 52 age matched normal control subjects (27 men,
25 women). From within the total group 10 patients with AS (8 men, 2
women) had a single estimation of lumbar spine bone mineral content, 18
(13 men, 5 women) had a single measurement of metacarpal indices and
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BONE MASS
SYNDESMOPHYTES
8 (7 men, 1 woman) had a syndesmophyte count. These patients were selected
solely on willingness to attend for bone mass assessment. Bone mineral
content results . were compared with 36 normal control subjects (18 men,
18 women) and metacarpal indices with 45 normal controls consisting of
. 24 asymptomatic volunteers (12 men, 12 women) and 21 patients with
primary generalized osteoarthritis (3 men, 18 women) who had been shown
to have normal total bone mass8.
Total body calcium measurement was repeated on 3 or 4 occasions over
an 18 month period in 17 patients with AS (13 men, 4 women).
Serum calcium, phosphate, proteins and alkaline phospatase were measured
in all subjects and those with abnormalities of calcium metabolism or medical
conditions associated with secondary osteoporosis were excluded.
Methods. Total body calcium was measured by in vivo neutron activation
analysis as described9. Neutrons produced from the Medical Research
Cyclotron were.directed at a patient standing in a rigid activation enclosure.
The gamma rays produced by the reaction48 Ca(n,y)49 Ca were measured
in a whole body counter and compared with the results from a phantom
to give a figure for total body calcium in grams. For longitudinal studies
the measurement was repeated 3 or 4 times over an 18-month period and
a regression line drawn through the values of total body calcium. From the
slope of the regression line, the rate of change of total body calcium was
calculated and expressed as a percentage of the initial value. In the initial
studies the figure for total body calcium in grams was normalized for skeletal
size (arm span) for both sexes and menopausal status in women using the
regression formulae previously published9. The in vivo precision of the
technique was 2.9%10 for a radiation dose of 13 mSv.
Bone mineral content of the lumbar spine was measured by dual photon
absorptiometry with an adapted dual headed rectilinear scanner using153 Gd
as a dual energy source". The bone mineral image was displayed on a
colour monitor and cursors placed at the top of lumbar vertebrae 2 (L2)
and at the bottom of L4. The bone mineral content of the area within the
cursors was calculated and divided by the vertical length to give bone mineral
content in g/cm. The in vivo precision was reduced to 1.0% by an experienced
operator. Predicted bone mineral content in patients with AS was calculated
using the formula derived from the linear relationship found in normals
between span and bone mineral content/unit length".
Metacarpal indices were measured by a variation of the technique described
by Dequeker12. From nonscreen radiographs of the hands taken at a fixed
1 m source to film distance, the length (L) of the 2nd, 3rd and 4th metacarpals
of the right hand were measured. At the mid-point of each metacarpal the
external diameter (D) and the internal diameter (d) of the cortex were
measured using a Vernier caliper. The mean cortical area as a percentage
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of surface area [(D2-d2)/DL] was then calculated. The precision of the
technique, evaluated from 2 radiographs taken at daily intervals in 10 young
healthy controls was 2.0%.
The formation of bony bridging between the lateral and anterior borders
of adjacent lumbar vertebrae from LI to L5 was measured from
posteroanterior and lateral films of the lumbar spine. Syndesmophytes were
graded on a 0-3 scale with 3 equal to complete bony bridging. A final
syndesmophyte count was recorded as a mean of the values at the 12 sites
measured. Hence, no syndesmophytes would score 0 and a bamboo spine 3.
Statistical analysis was performed by Students's t test for unpaired
variables. For small numbers and data not normally distributed, Wilcoxon's
rank sum test and Kendall's rank correlation test were used.
RESULTS
Details of sex and age in controls and patients undergoing
each assessment of bone mass are shown in Table 1. The
results of normalized total body calcium, bone mineral
content and metacarpal indices expressed as a percentage of
normal are shown in Figure 1. Total bone mass was reduced
by 5.3% (p<0.05) in AS compared with controls, when both
sexes were considered together. The reduction was greater
in the 6 female patients (9.7%,p<0.05) than in the males
(2.4%), although the difference between the sexes did not
reach statistical significance.
Bone mineral content of the lumbar spine was increased
by 28% (p<0.05) in the 8 male patients measured but
reduced in the 2 females. Metacarpal indices were normal
in male and female patients with AS (Figure 1).
Details of disease duration and activity are shown in Table
2. None of the bone mass indices were related to disease
duration or activity as measured by duration of early morning
stiffness and erythrocyte sedimentation rate (ESR). The rate
of change of total body calcium did not correlate with the
change in the disease activity indices and was not related to
the duration of disease. In addition, none of the bone mass
indices was significantly related to the syndesmophyte count
(mean + 1SD = 1.15 + 0.85), when male and female
Table 2. Results ofdisease activity indices expressed as the
mean initial and mean change (± 1 SD) in male andfemale
patients with AS undergoing measurements of total body
calcium.
Male Female
Duration of disease 12.1 ± 6.8 14.3 ± 10.4
(years)
Initial EMS 20.0 ± 25.9 114.2 + 107.7
(min)
Change in EMS + 3.5 ± 14.3 -46.2 ± 41.9
(min)
Initial ESR 24.8 ± 23.0 48.7 ± 40.4
(mm/h)
Change in ESR (mm/h) -5.5 ± 19.5 -31.7 + 35.0
(EMS = duration of early morming stiffness; ESR=erythrocyte
sedimentation rate)
patients were considered together. As syndesmophytes might
be expected to increase spinal bone mineral, the difference
in percentage of expected bone mass at lumbar and total bone
sites (i.e., % bone mineral content - % total body calcium)
was compared to the syndesmophyte count and a significant
correlation was found (tau=0.571, p<0.01).
The annual rate of loss of total body calcium in the 17
patients with AS completing the longitudinal study (Table
3) was 2.9% (p<0.01), a figure not entirely explained by
the large loss in the 4 female patients (5.2%), the male
reduction also being significant.
Table 3. The mean (± 1 SD) annual rate loss of total body
calcium in male and female patients with AS
Sex No. Annual Rate of Loss Significance
Males 13 2.2 ± 2.6% p<0.01
Females 4 5.2 ± 4.4% -
Both 17 2.9 ± 3.2% p<0.01
Table 1 .Sex, mean age and years post menopause (YPM) ± 1 SD in groups ofpatients
with AS and controls undergoing total body calcium (TBCa), bone mineral content of the
lumbar spine (BMC), metacarpal indices (MI) and syndesmophyte count (SC).
AS Patients Controls
Sex No. Mean Age YPM No. Mean Age YPM
TBCa
Males 14 41.7 ± 9.7
Females 6 39.7 ± 8.1 3.5 ± 5.9
27 48.3 ± 13.1




44.0 ± 10.4 - 18
40.0 ± 11.3 7.0 ± 9.9 18
33.9 ± 10.3
36.7 ± 11.4 3.2 ± 5.4
MI
Males 13 42.6 ± 9.5 - 15
Females 5 37.2 + 7.5 4.2 ± 6.3 30
46.6 ± 13.6






















H ffl I I Mean ± 1SD
A Male
# Female
NS PC0.05 P<0.05 P<0.05 NS NS
Fig. 1. Results of normalized total body calcium expressed as a percentage of normal, bone mineral content of the lumbar spine expressed as a percentage
of that predicted for each individual and metacarpal indices expressed as a percentage of the normal controls for male (A) and female (•) patients with
AS. The open blocks represent the mean ± 1 SD of the normal control subjects for each bone mass measurement. Significance values refer to the difference
between patients and control values for each measurement.
to the theory of a minor absolute reduction in bone mass as
there was a significant annual loss of bone in males (2.2%)
despite the young mean age of the group (42.6 years). Ethical
considerations precluded the collection of control data for
sequential measurements of bone mass, although previous
work with the technique has shown an estimated annual
reduction of total body calcium of only 0.7% in men over
the age of 50 with no recorded loss before that age'6. The
rate of bone loss was not related to the activity of disease
which tended to diminish during the study period.
If there is a reduction in total bone mass and an increased
rate of bone loss, it is of interest to speculate where this might
occur. Bone mineral content of the lumbar spine in 8 male
patients was increased by 28% compared to controls but this
increase is almost certainly explained by excess bone
formation. The syndesmophyte count was correlated with the
difference between the expected bone mass in the vertebrae
and the total body while it was not related to lumbar spine
bone mass alone. Hence, there is a strong suggestion that
the increase in vertebral bone mineral content is caused by
the presence of syndesmophytes. Using our current methods
it is impossible to eliminate the effect on vertebral bone mass
of syndesmophytes which become ossified when fully
developed17. It remains possible that the vertebral bodies
themselves are relatively osteopenic as suggested in
pathological18 and radiological studies1'2-6. The bone mineral
content of the lumbar spine of the 2 female patients was
markedly reduced and this is in keeping with the reduced
total bone mass of the female patients.
DISCUSSION
In vivo methods of bone mass assessment have not previously
been reported in patients with AS. However, radiographic
studies have suggested that osteoporosis occurs both in the
axial and appendicular skeletons6, and using the technique
of 24-h whole body retention of diphosphonate, bone
turnover has been shown to be increased13. In our study
total body calcium has been shown to be slightly, but
significantly, reduced in patients with AS although much of
the reduction occurred in the small group of female patients.
In general the female patients had slightly more active disease
than the males as measured by ESR and duration of early
morning stiffness. However, as the differences did not reach
statistical significance and the indices were not related to the
results of total body calcium, it is not clear whether the
slightly more active disease in females accounts for the lower
bone mass. Although this small group of female patients was
younger than controls, the age difference did not reach
statistical significance using nonparametric tests. Total bone
mass falls with age, but we have failed to show a relationship
between age and total body calcium in normal premenopausal
females either in this study or in previous work9. The lack
of such a relationship has been suggested by other workers
who only include an age correction factor for those women
over the age of 551415. Accordingly it seems very unlikely
that the difference in mean age between patients and controls
accounts for the substantial differences in total body calcium.
Longitudinal total body calcium assessment gave support
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The reduction in total body calcium in AS does not appear
to be explained by reduced vertebral bone mass or by
appendicular bone loss as metacarpal indices were normal
in our patients. In order to be more certain of the site of bone
loss it would be desirable to assess total, axial and
appendicular bone mass simultaneously in the same groups
of patients with AS and controls. This was not possible in
our study.
•The causes of increased bone loss in AS are unknown.
Vertebral immobilization and changes in blood flow could
be implicated, but the humoral factors responsible for
increased turnover of vertebral bone have yet to be identified.
Both immunoreactive parathyroid hormone (PTH)19 and
biologically active PTH20 have been found to be elevated in
some patients with AS but, in the absence of overt signs of
hyperparathyroidism, both studies suggested that end organ
failure might be responsible for the biochemical abnormality.
We did not measure PTH values in our patients but we did
not find any evidence of abnormal calcium biochemistry in
our patients, and the only patient found to have a transient
elevation in serum calcium was omitted from the analysis
reported above. Many other biological mediators of bone
resorption have recently been identified. From among these
bone resorbing lympokines, interleukin 1, prostaglandins and
vitamin D metabolites are all mediators that deserve further
investigation in chronic inflammatory disorder such as AS.
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PAPERS AND SHORT REPORTS
Corticosteroids and bone mass in asthma: comparisons with
rheumatoid arthritis and polymyalgia rheumatica
D M REID, J J NICOLL, M A SMITH, B HIGGINS, P TOTHILL, G NUKI
Abstract
Bone mass has previously been shown to be reduced at peripheral
bone sites in patients with bronchial asthma receiving cortico¬
steroids. To assess whether total bone mass is reduced in asthma
total body calcium was measured by in vivo neutron activation
analysis in patients receiving various treatments for asthma and
compared with results from normal controls and patients with
rheumatoid arthritis and polymyalgia rheumatica. Compared
with controls total body calcium was reduced by 13-6% (p<0-001)
in patients with asthma receiving daily oral corticosteroids but by
only 9-0% (p<0-005) in a similar group of patients who had
received oral calcium supplements at the start of their cortico¬
steroid treatment. Total body calcium was also reduced in a
group of patients receiving only inhaled corticosteroids (8-8%;
p<0-001) but not significantly reduced in a small group of
patients with asthma who had never received these drugs. When
compared with controls a group of patients matched for age and
for dose of corticosteroids given for rheumatoid arthritis had a
similar reduction in total body calcium to the patients with asthma
receiving daily oral treatment (17-7%; p<0-001), but no such
reduction was shown in patients with polymyalgia rheumatica.
These findings suggest that the risk of bone loss with low dose
oral corticosteroids is similar in asthma and rheumatoid arthritis.
Further work is required to assess the clinical relevance of small
losses ofbuue associated with the use of inhaled corticosteroids.
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Introduction
Since Cushing's original description of the syndrome in 1932 it
has been recognised that supraphysiological concentrations of
endogenous corticosteroids are associated with excess bone loss.'
The introduction of cortisone as a therapeutic agent was followed
very shortly by case reports of spontaneous fractures during
treatment,2 and subsequently radiological osteoporosis was re¬
ported at various skeletal sites.34 The cause of corticosteroid
induced osteoporosis is now better understood5 but there remains
controversy about the dose and duration of treatment with synthetic
corticosteroids necessary to induce osteoporosis.6'8 Whether or not
bone loss can be prevented by altering the route or timing of drug
administration8 9 remains uncertain. There is also continuing
controversy whether patients with some diseases may be less
susceptible.10"13
As there is a relative paucity ofdata on bone mass in asthmatics we
have carried out measurements of total body calcium in groups of
patients with bronchial asthma treated with oral and inhaled
corticosteroids and compared the results with those in people who
have not received steroids. The results were also compared from
those from patients with rheumatoid arthritis and polymyalgia
rheumatica receiving regular oral corticosteroid treatment and from
controls matched for age and sex.
Patients and methods
We measured total body calcium in 70 patients with asthma (28 men, 42
women). The total group was subdivided according to current and previous
treatment. Group 1 consisted of23 patients (eight men, 15 women) who were
receiving regular oral corticosteroids and had been doing so for at least two
years. Group 2 consisted of a further 13 patients (two men) who were also
receiving regular oral corticosteroids but who had received oral calcium
supplements as calcium lactate gluconate three tablets a day (elemental
calcium dose 1 "2 g daily) at the start of their corticosteroid treatment and for
two to 20 years thereafter. Group 3 consisted of 22 patients (11 men) whose
only regular corticosteroid treatment was given by the inhaled route either as
beclomethasone 100 ug four times daily or as betamethasone 200 pg four
times daily. Sixteen patients (six men) in group 3 had also received a mean of
2-2 booster courses of oral corticosteroids, usually beginning with 40 mg
prednisolone daily and reducing to nothing over seven to 10 days. Group 4
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consisted of 12 patients (seven men) who had never received corticosteroids
either by inhalation or by the oral route.
The results from the four groups of patients with asthma were compared
with those from 40 controls (20 men).141S The results from patients in group
1 were further compared with those from 27 patients (eight men) with
definite or classical rheumatoid arthritis,16 matched for daily dose of
prednisolone, and 12 patients (3 men) with polymyalgia rheumatica17 who
were receiving similar daily doses of oral corticosteroids.
All patients and controls who had abnormalities of calcium biochemistry
or medical conditions known to be associated with secondary osteoporosis
were excluded.
The corticosteroid dose for each patient was calculated retrospectively
from the case records, supplemented when necessary by information from
the patient. The total dose prescribed was expressed as the daily dose of
prednisolone or equivalent averaged over the duration of treatment. Data on
booster courses of the drugs were taken both from the case records and by
direct questioning of the patient.
Total body calcium was measured by in vivo neutron activation analysis
using the Edinburgh Medical Research Council cyclotron. Patients were
irradiated with neutrons for 40 seconds while standing in a rigid polyethy¬
lene activation enclosure. Patients were then transferred to a shadow shield
whole body counter, where y radiation induced by the reaction calcium-48
(n, y) calcium-49 was measured for 20 minutes. The patient's total body
calcium was calculated in grams by comparison with the energy spectrum
from an activated anthropomorphic phantom of human dimensions con¬
taining a known quantity of calcium. Repeated measurements of the
phantom gave a long term precision of T8% for a radiation dose of 13 mSv
(T3 rem).14 Normalisation was carried out by expressing individual results
as a percentage of the expected normal value for the patient's skeletal size
(arm span) in both sexes and menopausal state in women.14 The in vivo
=precision of the technique was 2'9%.18
Statistical methods—Results were analysed by Student's t test for unpaired
variables. The Mann-Whitney test was used for data not normally dis¬
tributed and for small samples. By using Chauvenet's criterion"—a
statistical technique designed to eliminate extreme values considered to
occur by chance—two grossly aberrant total body calcium values from a
woman in each of groups 1 and 2 were removed, leaving a total of 68 patients
with asthma, whose results are reported.
(13-6%; p<0-001), group 2 (9-0%; p<0'005), and group 3 (8'8%; p<0-001).
There was also a significant difference in mean total body calcium between
groups 1 and 4 (8'1%; p<0-05). No significant differences were found
between men and women.
No correlations were shown between the duration of disease and total
body calcium in any of the four groups with asthma nor between the duration







P< 0-001 p<0-005 p< 0-001
FIG 1—Total body calcium of patients with asthma expressed as percentage
of mean of control population. Shaded area represents normal values (mean
and 1 SD). In group 3 open symbols represent patients never given oral
corticosteroids. Bars are means.
TABLE II—Sex ratio, mean age, years postmenopausal, and details of corticosteroid
treatment in controls and patients with asthma, rheumatoid arthritis, and polymyalgia
rheumatica. (Mean values expressed with 1 SD in parentheses)
Results
Table I gives details of age, duration of disease, corticosteroid and oral
lalcium treatment, and total body calcium values in grams in the four groups
)f patients with asthma. Patients in group 4 were significantly younger
ABLE I—Sex ratio, mean age, years postmenopausal, duration of disease, and
'eatment in patients with asthma. (Mean values expressed with 1 SD in parentheses)
Rheumatoid Polymyalgia
Group 1 Group 2 Group 3 Group 4
(steroids alone; (steroids + (inhaled steroids; (no steroids;
e> II NJ calcium; n=12) n=22) n= 12)
ex ratio (M:F) 8:14 2:10 11:11 7:5
=ge (years) 54-1(11-7) 60-8(8-2) 55-6(12-5) 37-9(10-4)
!o of women pre-/ 6/8 1/9 3/8 4/1
postmenopausal
ears postmenopausal 5-0(7-3) 11-4(9-7) 10-0(8-2) 0-5(1-1)
•uration of 23-3(18-1) 30-6(13-3) 15-8(16-3) 12-0(15-2)
disease (years)
teroid dose (mg/day) 6-8(1-9) 8-9(1-4) — —
'uration of steroid 12-5(6-4) 18-0(3-8) — —
treatment (years)
o of boosters [range] — — 2-2 [0-18]* —
uration of calcium — 10-6(6-8) — —
treatment (years) •
otal body calcium (g) 863(173) 787(151) 894 (160) 1029(116)
Inly 16 patients in group 3 given booster courses.
<0'001) than those in the three other groups. Duration of disease was
eater in group 2 than in group 3 (by 14-8 years; p<0'05) and group 4 (by
I'6 years; p<0'01). Patients in group 1 had received a lower dose of
ednisolone (by 2T mg/day; p<0-01) and for a shorter period (by 5 *5 years;
CO'05) than those in group 2. Prenormalisation values for total body
Icium in controls were 1142-7 (1SD 133-8) g for men and 820-5 (124-7) g
r women, as previously reported.14
Comparison of normalised results obtained in the control and asthma
oups (fig 1) showed a reduction in mean total body calcium in group 1
Controls Asthma arthritis rheumatica
(n=40) (n=22) (n=27) (n= 12)
Sex ratio (M:F) 20:20 8:14 8:19 3:9
Age (years) 56-0(7-5) 54-1(11-7) 52-0(11-8) 58-7(10-2)
No of women pre-/postmenopausal 2/18 6/8 7/12 1/8
Years postmenopausal 8-8(6-7) 5-0(7-3) 6-8(7-3) 11-8(7-1)
Steroid dose (mg/day) — 6-8(1-9) 6-6(1-9) 7-7(1-5)
Duration of steroid treatment (years) — 12-5(6-4) 5-1(4-4) 3-7(3-3)
Total body calcium (g) 982(206) 863(173) 761 (155) 822 (173)
Table II gives details of sex ratio, age, corticosteroid treatment, and total
body calcium values in group 1 patients with asthma and patients with
rheumatoid arthritis and polymyalgia rheumatica. No significant differences
were found between the patient groups with regard to age or corticosteroid-
treatment except that the patients with asthma had received oral steroids for
longer than the patients with rheumatoid arthritis (7 4 years; p<0-001) and
polymyalgia rheumatica (8'8 years; p<0-001).
Comparison of normalised results in these three groups with controls
showed a reduction in mean total body calcium in patients with rheumatoid
arthritis (17-7%; p<0-001) but none in those with polymyalgia rheumatica
(fig 2). Compared with the group with polymyalgia bone mass was reduced
in the patients with asthma (13"2%; p<0-02) and rheumatoid arthritis
(17-3%; p<0-001). The apparent difference in mean total body calcium
between the patients with asthma and those with rheumatoid arthritis did
not reach statistical significance (0-1 >p>0"05).
The reduction in total body calcium was not related to the duration of
treatment or the total steroid dose (daily dose X duration) in any of the
groups but was correlated with the mean daily dose of prednisolone in those
patients with rheumatoid arthritis (r=—0-605; p<0-001).
Discussion
Oral corticosteroid treatment has previously been associated with
reduced bone mass in patients with bronchial asthma.810 These
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studies compared treated patients with normal controls using
different measurements of forearm bone mass. Though unlikely,
the possibility that bone mass might be reduced in asthma as a
consequence of the disease itself was not considered. As bones
contain 99% of the body's calcium content20 it is a reasonable
assumption that total body calcium is a measurement of total bone
mass, particularly as it is extremely well correlated with the total
bone mineral content of the skeleton measured by dual photon
absorptiometry.21 Hence this study confirms that reduced total bone
mass does occur in patients with bronchial asthma treated with daily
oral corticosteroids (group 1) when compared both with age
matched normal controls and with young asthmatics who had never
received steroids (group 4). Though this latter group was
significantly younger than the controls, other studies have failed to
show a relation between total body calcium and age in men or
premenopausal women," suggesting that the loss of bone in group 1























fig 2—Total body calcium of patients receiving corticosteroid treatment
expressed as percentage of mean of control population. Shaded area represents
normal values (mean and 1 SD). Bars are means.
The reduction in mean total body calcium of 13-6% in group 1
was substantial. Postmenopausal patients with crush fractures have
a mean reduction in total body calcium of 16-20%,22 24 suggesting
that many patients with asthma treated with steroids are at risk of
osteoporotic fractures. Indeed two patients in group 1 had sustained
at least one atraumatic crush fracture before the measurement of
total body calcium and a further patient had recurrent problems
with multiple rib fractures.
Prevention ofcorticosteroid induced osteoporosis in patients with
asthma, rheumatoid arthritis, and other diseases remains a severe
therapeutic problem.5 The use of alternate day corticosteroid
regimens has not been shown to be advantageous.910 In this study
five patients in groups 1 and 2 who had received an alternate day
regimen of corticosteroids for the first two to five years of treatment
had a total bone mass which did not differ from that of patients who
had received continuous daily treatment.
Despite higher daily doses and a longer duration ofcorticosteroid
treatment a small group of patients (group 2) who had received oral
calcium supplements at the start of treatment had a slightly greater
mean total body calcium than those in group 1 (4'6%; 0T>p>0"05).
This suggests that the use oforal calcium supplements alone given at
the start of corticosteroid treatment should be further investigated
as a possible means ofpreventing osteoporosis. Other studies aimed
at overcoming the calcium malabsorption known to be associated
with corticosteroid treatment25 have shown some benefit with
25-hydroxy vitamin D26 but not with 1,25-dihydroxy vitamin D.27
The use of inhaled corticosteroids in asthma is almost certainly
associated with a reduction in systemic side effects compared with
oral treatment28 29 but suppression of the hypothalamic-adrenal axis
may occur with large doses.50"32 There is little doubt that the main
portion of the aerosol dose is deposited in the mouth and
swallowed,33 allowing gastrointestinal as well as pulmonary absorp¬
tion. The finding that total body calcium was reduced in patients in
group 3 by a mean of 8 "8% compared with controls is therefore of
concern. Sixteen of the 22 patients had received booster courses of
oral corticosteroids, and such intermittent treatment has been
associated with minor reductions of bone mass in patients with
asthma.8 The six patients who had never received oral treatment,
however, had some of the lowest individual values of total body
calcium (fig 1). This suggests that inhaled corticosteroids might be
at least in part responsible for the reduction in group 3. The
widespread and increasing use of high dose corticosteroid inhalers34
suggests that further studies of bone mass in patients so treated
should be undertaken. The pending development of inhaled
corticosteroids which have an improved topical to systemic ratio33 35
should be encouraged.
The effects of corticosteroids on bone mass in patients with
asthma, rheumatoid arthritis, and polymyalgia rheumatica were
compared (fig 2). Both patients with asthma and those with
rheumatoid arthritis had reduced bone mass compared with patients
treated for polymyalgia rheumatica but we were unable to confirm
previous studies," 12 including our own preliminary data,13 which
suggested that corticosteroid treated patients with rheumatoid
arthritis were more susceptible to bone loss than patients with
asthma treated with similar daily doses. This study shows a small
reduction in mean total body calcium (4" 3%) in steroid treated
patients with rheumatoid arthritis compared with asthmatics. As we
have previously shown that total body calcium is reduced by 5"0-
6 "8% in patients with rheumatoid arthritis who have never received
corticosteroids,15 this reduction in bone mass may be attributable to
the effects of the disease process, which causes appreciable bone loss
at peripheral sites.36
Total body calcium is inversely related to the daily dose of
prednisolone in patients with rheumatoid arthritis (r=— 0*605;
p<0-001). This finding raised the hypothesis that corticosteroid
induced bone loss might occur early in the course of treatment,15 and
a recent longitudinal study has lent support to this theory.37 Lack of
a similar relation between total body calcium and daily steroid dose
in asthma may reflect the wider fluctuations in individual steroid
doses in these patients.
The explanation for the normal bone mass in patients with
polymyalgia rheumatica is not clear. Women with polymyalgia
rheumatica were older than those in the two other groups and the
magmtude of the corticosteroid induced bone loss may not be
apparent because of the substantial yearly T5% correction after the
menopause.14
At present there is little convincing evidence for increased or
decreased susceptibility to corticosteroid induced bone loss in
patients with asthma or rheumatoid arthritis, though the position in
patients with polymyalgia rheumatica may require further studies
including larger numbers of subjects.
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Total and peripheral bone mass in patients with psoriatic
arthritis and rheumatoid arthritis
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SUMMARY Psoriatic arthritis is thought to be associated with periarticular osteoporo¬
sis while rheumatoid arthritis may be associated with generalised as well as periarticular
bone loss. To assess the extent of total and peripheral bone loss in these two diseases, total
body calcium was measured by in vivo neutron activation analysis and peripheral bone mass
was assessed by metacarpal indices in age-matched patients with psoriatic arthritis and
rheumatoid arthritis treated with nonsteroidal anti-inflammatory drugs alone. In compari¬
son with age and sex-matched normal controls, total and peripheral bone mass was normal
in psoriatic arthritis. There were significant reductions in total (6.2°7o in men; 7.9% in
women) and peripheral (10.9% in men; 12.8% in women) bone mass in patients with
rheumatoid arthritis compared with controls. Peripheral bone mass was significantly corre¬
lated with the degree of radiographic damage in male and female patients with rheumatoid
arthritis. The mean annual loss of total body calcium was insignificant in psoriatic arthritis
(0.6% in men; 1.9% in women) but markedly greater in rheumatoid arthritis (4.4% in men;
2.7% in women). The data suggested that total and peripheral bone loss is greater in
rheumatoid arthritis than psoriatic arthritis. Substantial reductions in peripheral bone mass
in patients with rheumatoid arthritis not receiving corticosteroids may account in part for
the small reductions in total bone mass.
Key words: Psoriatic Arthritis, Rheumatoid Arthritis, Bone Mass, Total Body Calcium,
Metacarpal Indices.
INTRODUCTION
There is little published information on
the bone mass of patients with psoriatic ar¬
thritis (PA), although local osteoporosis is a
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recognised radiological feature (1). This is
not the experience of all investigators (2) and
it is certainly limited in extent compared to
that occurring in rheumatoid arthritis (RA)
(3), where periarticular osteoporosis is an
early radiological sign (4). Generalised os¬
teoporosis is not thought to be a feature of
PA (5) although it may occur in RA even in
the absence of corticosteroids (6,7). To our
knowledge no investigators have applied the
in vivo methods of bone mass assessment to
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patients with PA. As part of a large survey
of bone mass in rheumatic diseases, we have
have measured total bone mass, by total bo¬
dy calcium, and peripheral bone mass, by
metacarpal indices, in a small group of
patients with psoriatic arthritis and com¬
pared their results with those from a group
of age and sex-matched patients with rheu¬
matoid arthritis treated with nonsteroidal
anti-inflammatory drugs alone.
PATIENTS AND METHODS
Twelve patients (6 males, 6 females) with
PA, meeting the suggested diagnostic crite¬
ria of Wright and Moll (3), were enrolled in
the study. All patients had a peripheral ar¬
thritis conforming to the PAj PA3 and PA4
sub-groups recognised by Moll and Wright
(8). No patient had clinical evidence of
spondylitis or sacro-iliitis (sub-group PA5)
nor were there any patients with arthritis
mutilans (sub-group PA2). All patients were
sero-negative for rheumatoid factor and
were receiving therapy with nonsteroidal an¬
ti-inflammatory drugs (NSAID) alone. No
patient had received oral corticosteroids,
suppressive anti-rheumatic drugs or immu¬
nosuppressive therapy.
Initial total body calcium (TBCa) has
been assessed in the 12 patients with PA and
compared with that of 45 patients (23 males,
22 females) with RA who were receiving
NSAID alone and 36 controls (19 males, 17
females) (Table I).
The annual rate of change of TBCa has
been assessed in 9 of the PA patients (5
males, 4 females) and compared with that of
13 age-matched patients (6 males, 7
females), with RA receiving NSAID alone
(Table II).
Metacarpal indices have been measured in
11 of the PA patients and have been com¬
pared with results from 37 age and sex-
matched patients (17 males, 20 females) with
RA receiving NSAID alone and 27 controls
(13 males, 14 females) (Table II).
TBCa was measured by in vivo neutron
Table I Male/Female ratio, mean (± 1 standard deviation) age, yearsR post menopause and indices of disease
activity in controlsa and patients with psoriatic arthritis (PA) and rheumatoidn arthritis (RA) included in
initial total body calciumg measurement. Ranges given in parentheses. Statistical differences between PA
and RA patients shown when signficant
Controls Psoriatic Arthritis Rheumatoid Arthritis
(n = 36) (n= 12) •OII
Male/female ratio 19/17 6/6 23/22
Age 45.2±11.4 41 .5 ±12.2 47.0 ±9.2
(years) (24-59) (26-69) (25-59)
Pre/post-menopause 8/9 5/1 13/9
Years post menopause 5.6 + 2.9 19 5.4±4.0
(2-11) (2-11)
Disease duration — 7.1 ± 6.8 7.0±7.1
(years) (1-24) (1-30)
Functional status — 1.6±0.5* 2.1 ±0.6*
(1-3) (1-4)
ESR — 18.8 + 12.1* 35.4± 30.1*
(mm in 1st hour) (2-40) (1-115)
EMS — 56.0± 72.5 79 .8 ±89.7
(minutes) (0-240) (0-300)
Articular Index — 5.4± 6.9* 12.4± 5.7*
(0-22) (0-21)
[ESR = erythrocyte sedimentation rate: EMS = duration of early morning stiffness: * = P<0.01].
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Table II Mean age and years post menopause in controls and patientsR with psoriatic arthritis (PA) and
rheumatoid arthritis (RA)a undergoing measurements of metacarpal indices (MI) and then rate of
change.in total body calcium (cTBCa).
Controls Psoriatic Arthritis Rheumatoid Arthritis
Men Women Men Women Men Women
MI (n= 13) (n = 14) (n = 6) (n = 5) (n = 17) o<NII
Age 44.1 45.4 42.7 41.6 48.0 45 .9
(years) (26-60) (22-59) (32-57) (26-69) (29-59) (25 -58)
Pre/post-menopause — 8/6 — 5/1 — 12/8
Years post menopause — 5.8 — 19 — 1.8
(1-11) (2-11)
Controls Psoriatic Arthritis Rheumatoid Arthritis
Men Women Men Women Men Women
cTBCa — — (n = 5) (n = 4) (n = 6) (n = 7)
Age 44.8 36.7 46.8 48.4
(years) (37-57) ( 31-45) (32-59) (34-57)
Pre/post-menopause — — — 4/0 — 3/4
Years post menopause — 0 — 7.2
(2-16)
Range shown in parentheses
activation analysis. Patients were irradiated
for 40 seconds while standing in a rigid
polyethylene activation enclosure, with
neutrons from the Edinburgh Medical Re¬
search Council Cyclotron. The patients were
then transferred to a shadow-shield whole-
body counter, where gamma radiation indu¬
ced by the reaction 48Ca(n, 8 )49Ca was mea¬
sured for 20 minutes. The patients' TBCa in
grams was calculated by comparison with
the energy spectrum from an activated an¬
thropomorphic phantom of human di¬
mensions containing a known quantity of
calcium. Repeated measurements of the
phantom gave a long term precision of 1.8%
for a radiation dose of 13mSv (1.3 rem) (9).
Individual results were expressed as a per¬
centage of the expected normal value for the
patient's skeletal size (arm span) in both
sexes and menopausal status in women (9).
The rate of change of TBCa was calculat¬
ed from 3 or 4 measurements of TBCa un¬
dertaken at 6-monthly intervals over an 18-
month period. The TBCa in grams was plot¬
ted against time and from the slope of the
regression line, the rate of change of TBCa
was calculated and expressed as a percentage
of the initial value. The in vivo precision of
the technique, calculated from the deviation
of individual points from the lines of re¬
gression representing the change in TBCa
with time, was 2.9% in a large group of
patients with rheumatic diseases (10).
Metacarpal indices were measured by a
variation of the technique described by De-
queker (11). A single postero-anterior radio¬
graph of the hands was taken at a constant 1
metre tube-to-film distance using nonscreen
film. Morphometric measurements were per¬
formed at the right 2nd, 3rd, and 4th meta¬
carpals. The length of each metacarpal was
determined with a millimetre rule and the
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external diameter (D) and the internal
diameter (d) of the midshaft of the cortex
were measured to the nearest 0.1mm by
means of a needle-tipped direct reading
Vernier caliper. To correct partially for the
variation in skeletal size in the patient popu¬
lation, cortical area as a percentage of sur¬
face area [(D2-d2)/DL] was calculated and
the final figure expressed as a mean of the 3
metacarpals. Patient data were expressed as
a percentage of the mean value of the con¬
trol population. The precision of the tech¬
nique, evaluated from 2 radiographs taken
24 hours apart in 10 young controls, was
2.0%(12).
Statistical analysis of results was per¬
formed using Student's t-test for unpaired
variables. The Wilcoxon rank sum test was
used for data not normally distributed and
for small samples.
RESULTS
Details of male/female ratio, age, me¬
nopausal status and disease activity for the
patients and controls undergoing initial total
body calcium (TBCa) are shown in Table I.
The patients with RA had more active dis¬
ease in respect of their mean erythrocyte se¬
dimentation rate, their functional status and
their articular index. The age of the patients
going on to complete 3 or 4 measurements
of TBCa and those patients and controls
who had metacarpal indices measured are
included in Table II.
The results of initial TBCa measurement
in males, females and both sexes together
are shown in Table III. Patients with PA
had a mean TBCa value which did not differ
significantly from controls. Although the
RA patients had reduced TBCa compared
with PA patients, the results did not reach
statistical significance. The RA patients did
have reduced TBCa compared with controls
and this reached signficance in females and
both sexes when considered together. No re¬
lationship was found between age and TBCa
in controls, patients with PA or patients
with RA after the effect of the menopause
was excluded.
The annual rate of change of TBCa in PA
and RA patients is shown in Table IV. There
was a significant mean annual loss of TBCa
in the RA patients (-3.7%, p<0.005). The
numbers in the PA group were small but the
mean rate of change of TBCa was not signi¬
ficant in the male (-0.6%), the female
(-1.9%) or the total group (-1.1%). The ap¬
parent difference between the rate of change
of TBCa in RA and PA patients just failed
to reach statistical significance (0.1 >_
p>0.05). Annual change in TBCa was not
related to disease duration or any one index
of disease activity in the PA or RA groups.
The mean metacarpal indices for controls,
PA and RA patients are shown in the figure.
Cortical area as a percentage of surface area
(D2-d2/DL) was normal in the small groups
of male and female PA patients but signifi¬
cantly reduced in the groups of male and
Table III Mean (= 1 standard deviation) initial total body calcium (TBCa), expressed as a percentage of the
expected normal value, in male and female controls and patients with psoriatic arthritis and rheumatoid
arthritis.
Controls Psoriatic Arthritis Rheumatoid Arthritis
Males 100.4± 11.4 98.5±7.9 94.2 ± 10.2
Females 99.0 ±8.0* 99.8± 11.1 91.1±10.8*
Total 99.7 ±9.9** 99.1 ±9.7 93.3 ± 10.5**
[* = P<0.02: ** = P<0.005]
Statistical difference between controls and patients with rheumatoid arthritis shown were significant.
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Table IV Mean initial total body calcium (TBCa) expressed in grams and as a percentage of the expected normaI
value in patients with psoriatic arthritis and rheumatoid arthritis. Mean annual change in TBCa
expressed as a percentage of the initial value in male, pre-menopausal and post-menopausal female
patients. Range for each measurement shown in parentheses.
Psoriatic arthritis Rheumatoid arthritis
(n = 9) (n = 13)
Initial TBCa 1022.4 913.5
(grams) (821-1275) (638-1196)
Initial % TBCa 100.4 92.7
(90.1 - 121.4) (74.3 - 106.2)
Psoriatic arthritis Rheumatoid arthritis
(n = 9) (n = 13)
Annual change in TBCa
Males -0.6% -2.2%
( + 3.6 to -4.1) ( + 0.9 to -6.0)
Pre-menopausal -1.9% -2.4%
females ( + 0.5 to -4.3) (-0.1 to -4.4)
M-Post-menopausal — —4.8%
females (— 2.6 to —7.1)
Males + females -1.1% -3.7%
female RA patients both in comparison with
controls (males: 10.9%, p<0.01; females:
12.8%, p<0.01) and patients with PA
(males: 10.6%, p<0.02; females: 14%,
p<0.02). D2-d2/DL was not related to dis¬
ease duration or any one index of disease
activity in PA or RA with the exception of
the Steinbrocker X-ray status (13) which was
inversely related to the index in RA patients
(r= -0.35, p<0.05). Metacarpal indices
were not related to age or years post-meno¬
pause in controls or patients with the ex¬
ception of the female RA patients where
there were significant relationships with age
(r=-0.50, p<0.05) and years post-meno¬
pause (r = -0.65, p<0.01).
DISCUSSION
The results of initial total body calcium
measurements strongly suggest that total
bone mass is normal in patients with pso¬
riatic arthritis. Such a suggestion is in
keeping with a previously published view (5)
and is given further support by the longitu¬
dinal study where the mean change in TBCa
in the 9 patients with PA was only 1.1%.
This was not statistically significant and as
the figure also includes any loss of bone with
age, the lack of significant change gives sup¬
port to the hypothesis that psoriatic arthritis
is not usually associated with generalised os¬
teoporosis.
Local osteoporosis is a radiological
feature of psoriatic arthritis (1) but we were
unable to detect any local bone as measured
by metacarpal indices (Fig. 1). However, in
the patients with rheumatoid arthritis local
bone mass was markedly reduced and was
statistically less than that in psoriatic arthri-











































Fig. 1: Cortical area as a percentage of surface area [(D2-d2)/DL] of the 2nd, 3rd and 4th metacarpal bones in male
(a), pre-menopausal (•) and post-menopausal (o) female controls and patients with psoriatic and rheumatoid
arthritis. Results expressed as a percentage of the mean of the controls.
tis. Similar trends were seen in the cross-
sectional measurement of TBCa and also in
the rate of change of TBCa, with RA
patients showing reduced bone mass and a
greater rate of bone loss than patients with
PA. These results give support to the hypo¬
thesis that PA is a more benign condition as
far as bone is concerned (3). Our PA
patients had significantly less active disease
than the RA patients and this may account
for the differences in bone mass measure¬
ments, raising the possibility that biological
mediators of bone resorption may be present
in greater concentration in RA than in PA.
The reduction in local bone mass in RA is
greater, in percentage terms, than the re¬
duction in TBCa. Although the patients and
controls having both bone mass measure¬
ments carried out were substantially the
same, there were some who did not undergo
both measurements especially amongst the
controls. Nevertheless, the substantial re¬
duction in metacarpal indices (males:
10.9%, females: 12.8%) suggests a marked
degree of local bone loss in RA which, if
present in all peripheral bones, might
account in part for the reduction in total
bone mass shown in this study (males:
6.2%; females: 7.9%). A previous study
where peripheral and total bone mass has
been measured in the same group of patients
showed an 8% reduction in total body bone
mineral but a 19% reduction in the bone
mineral content of the forearm (14).
We have previously reported the lack of
relationships between TBCa and any one
index of disease duration and activity in
patients with RA (15). In addition no
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relationship was found in this study between
TBCa and Steinbrocker X-ray status. How¬
ever, metacarpal indices have been shown to
relate to X-ray status in RA (16) and this has
been confirmed in our present study.
Peripheral bone loss in RA does seem to
be related to the long-term disease activity
and may account for some, if not all, of the
reduction of TBCa. However, further work
using improved methods of local bone mass
assessment and relating any changes noted
to total bone mass in the same groups of
patients and controls will be required before
this suggestion can be substantiated.
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Abstract
The aims of this study were to measure the deficit in
total body calcium in patients with primary hyperpar¬
athyroidism and to observe whether this deficit was re¬
versed by parathyroidectomy. Total body calcium was
measured in five women and three men preoperatively,
and the mean was found to be 11% below that of age-
and sex-matched controls after normalization for post¬
menopausal age and body size (P < 0.01). Following
parathyroidectomy, repeat total body calcium measure¬
ments showed an increase of 7.1% over an average pe¬
riod of 14 months (P < 0.03). In patients with primary
hyperparathyroidism, total body calcium returns to¬
ward normal following surgical removal of the ade¬
noma.
Key Words: Primary Hyperparathyroidism-Parathy-
roidectomy-Total Body Calcium-ln Vivo Neutron Acti¬
vation Analysis.
Introduction
Bone mass may be reduced in primary hyperparathy¬
roidism. This has been found using techniques, such as in
vivo total body neutron activation analysis (Cohn et al.,
1973), photon absorptiometry of the radius (Pak et al.,.
1975, Pozzi-Mucelli et al., 1983; Posen et al., 1985), the
lumbar spine (Seeman et al., 1982), and the third meta¬
carpal (Genant et al., 1973), x-ray spectrophotometry of
the radius and ulna (Dalen and I Ijern, 1974), and quantita¬
tive computed tomography of the first and second lumbar
vertebrae (Pozzi-Mucelli et al., 1983). These noninvasive
techniques have shown mean reductions in bone of about
10% compared with age-matched controls. Low mean
bone mass has been described in bones that are predomi¬
nantly trabecular (Seeman et al., 1982; Pozzi-Mucelli et al.,
1983) as well as in bones that are predominantly cortical in
type. However, two studies have shown normal trabecular
bone volume in bone biopsy specimens taken from post¬
menopausal women with primary hyperparathyroidism
(Marcus et al., 1984; Charhon et al., 1982).
The skeleton is made up.of approximately 80% cortical
bone and 20% trabecular bone (Johnson, 1964). There¬
fore, total body calcium measurements are affected by
changes in both trabecular and cortical bone, and the ap¬
plication of this measurement ( = total body calcium) to pa¬
tients with primary hyperparathyroidism should be appro¬
priate. However, two studies of the effect of surgery for
primary hyperparathyroidism on total body calcium have
shown no overall beneficial effect (Cohn et al., 1973;
Hosking et al., 1972). This is in contrast to prospective
studies of regional bone mass, which have shown a bene¬
ficial effect of parathyroidectomy on bone density (Dalen
and Hjern, 1974; Genant et al., 1973; Leppla et al., 1982).
We report here the effect of parathyroidectomy on total




Eight patients with surgically proven primary hyperparathyroidism
were studied. Age, sex, and clinical information are shown in
Table I. Four of the five women were postmenopausal (1-11
years). The weight of the adenomata ranged from 0.17 to 1.59 g.
Subperiosteal erosions were present on the hand radiograph of
only one patient.
Twenty healthy women (aged 57.5 ± 6.5, SD) and 20 healthy
men (aged 54.4 ± 8.8, SD) acted as controls.
Methods
Height was measured by wall-mounted ruler, arm span by wall-
mounted graph paper, weight by Avery beam balance, and skin¬
fold thickness by Harpenden calipers. These measurements were
used in the normalization of total body calcium (Kennedy et al.,
1982).
Biochemistry. Plasma and urinary calcium were measured by
atomic absorption spectrophotometry and plasma alkaline phos¬
phatase by the aminoantipyrene method. Immunoreactive para¬
thyroid hormone (iPTH) was measured by a modification of the
method of Woo and Singer (1974) (hormone antiserum complex
precipitated by donkey antiguinea pig antiserum), which used
polyvalent antibovine PTH antibody directed mainly against N-ter-
minal PTH.
Total body calcium (TBCa). TBCa was measured by in vivo
neutron activation as previously described (Kennedy et al., 1982).
The method has a reproducibility of 1.8% (coefficient of variation
of repeated measurements on phantoms) and a radiation dose
equivalent of 1.3 rem (13 mSv). The reproducibility in vivo is 2.9%
(coefficient of variation of repeated measurements on humans,
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Table I. Laboratory results in eight patients with primary hyperparathyroidism.
Patient * Clinical Plasma Ca Plasma iPTH Plasma ALP Urine Ca TBCa Change in
No. Age Sex Features (mg/dl) (ng/l) (IU/1) (mg/24 h) (g) CaR TBCa (g)
1 55 F Flypertension
Wrist fracture
11.1 2.20 141 492 672 0.720 80
2 61 F Renal calculi
Maturity-onset
diabetes mellitus
10.3 0.53 88 460 697 0.911 142
3 46 F Peptic ulcer 10.2 0.19 54 188 691 0.920 50
4 49 F Peptic ulcer
Polyuria, fatigue
10.2 0.41 64 480 663 0.716 106
5 50 F Duodenitis 10.8 0.39 53 224 720 0.908 -26
6 64 M Renal calculi
Peptic ulcer
10.4 0.32 54 384 971 0.922 29
7 42 M Renal calculi 10.6 0.31 65 516 1209 1.038 -9
8 37 M Renal calculi
Gout
Patients (n = 8)
11.4 0.38 71 412 1004 0.983 101
Mean 10.6 0.44 70 395 820 0.890 59
SD 0.4 124 206 0.115 59
Controls (n = 40)
Mean 9.5 0.16 51 208 1.000
Mean ± 2SD 9.0-10.1 <0.33 30-80 8-408 0.870-1.130
P <0.001 <0.001 <0.01 <0.01 <0.01 <0.03
Tothill et al., 1984). TBCa can be predicted from height in men
and arm span and years postmenopause in women (Kennedy et
al., 1982). The TBCa is expressed as a ratio of the observed to the
predicted value (calcium ratio, CaR). The reference range of CaR
was calculated from the 40 control subjects (mean ± 2 SD) and
was 1.00 ± 0.13.
Statistical methods. The patient and control groups were com¬
pared by the Wilcoxon Rank Sum test. Changes following para¬
thyroidectomy were compared using the paired t-test. The rela¬
tionships between TBCa and biochemical measurements were
assessed by linear correlation. Data for alkaline phosphatase and
iPTH were analyzed after In-transformation.
Results
Biochemistry. The results are shown in Table I, in which
patients are compared with age-matched controls. In ad¬
dition to the expected elevation in plasma calcium and
iPTH, there were also increases in plasma alkaline phos¬
phatase activity and urinary calcium excretion. Following
parathyroidectomy plasma calcium fell into the normal
range or below (1 patient), and plasma alkaline phospha¬
tase activity fell by a mean of 22 IU/I (P < 0.05).
Total body calcium. The mean TBCa was 828 g (±206 g,
SD). The mean CaR was 0.890 (±0.115, SD), that is, after
normalization for body size and postmenopausal age there
/vas an 11 % reduction in bone mass (P < 0.01). Two of the
sight patients had results below the 95% confidence in-
ervals of CaR in controls (Fig. 1).
TBCa was remeasured 6-24 months (mean 14 months)
after parathyroidectomy (Fig. 1). The mean increase was
59 g (range -29-142 g), equivalent, to a mean rise of
M% in TBCa (P < 0.03). Only two of these eight patients
lad elevated plasma alkaline phosphatase activity pre-
iperatively.
The weak relationships between the change in TBCa
ind initial urinary calcium excretion (r = 0.40), plasma ai¬
rline phosphatase activity (r = 0.50), plasma iPTH (r =
0.22), and CaR (r = -0.41) did not reach statistical signifi¬
cance (P > 0.05).
Discussion
Cohn et al. (1973) found a mean CaR of 0.89 in nine pa¬
tients with primary hyperparathyroidism, a result identical
to that reported here. However, in the five patients they
remeasured following parathyroidectomy there was no
overall rise in TBCa. Similarly, Hosking et al. (1972) mea¬
sured TBCa in 10 patients with primary hyperparathy¬
roidism, and following parathyroidectomy half the patients
showed a fall in TBCa, and in one this reduction was 30%.
The patients studied by these groups had more severe hy¬
percalcemia [mean plasma calcium 11.9 (Cohn et al.,
1973) and 12.3 (Hosking et al., 1972), compared with 10.6
mg/dl in the present study] and higher plasma alkaline
phosphatase activity. In patients with more severe hyper¬
calcemia the osteopenia may not be reversible.
Three groups have reported increases in regional bone
density following parathyroidectomy. In each study the
size of the increase was similar to that reported in the
present study. Pak et al. (1975) measured bone density of
the distal radius by single photon absorptiometry and
found normal values in men and premenopausal women
and a 22% reduction in the bone density of postmeno¬
pausal women. The same group (Leppla et al., 1982) re¬
ported that after parathyroidectomy in postmenopausal
women, as in the group of patients with primary hyperpar¬
athyroidism as a whole, there was a rise in bone density of
6.4% at 1 year. Over the following 2 years there was no
further rise.
Genant et al. (1973) measured bone density of the third
digit by photon absorptiometry and found a mean reduc¬
tion of 13%. One to three years following parathyroidec¬
tomy there was a 7% rise in bone density. Dalen and Hjern
(1974) measured bone density of the distal radius and
ulna by x-ray spectrophotometry and found a mean reduc-
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Fig. 1. Change in calcium ratio (CaH) following surgery for pri¬
mary hyperparathyroidism in men (■) and women (•).
perparathyroidism may be associated with fragility frac¬
tures, such as vertebral crush fractures. For example, we
found that the mean CaR in 14 women with postmeno¬
pausal osteoporosis and vertebral crush fractures was
0.87 (Eastell et al., 1983), a value similar to that found in
the present study. Dauphine et al. (1975) found an in¬
creased prevalence of vertebral crush fractures in a case-
control study of patients with primary hyperparathyroidism.
Most of the patients with vertebral crush fractures in the
latter study were postmenopausal women. The increase in
total body calcium following parathyroidectomy may lower
the risk of fracture.
Although all the patients in the present study had
plasma calcium values of less than 12 mg/dl, most of them
had complications of primary hyperparathyroidism. The
results of this study may not apply to patients with mild,
asymptomatic primary hyperparathyroidism. However,
they do emphasize the need for a randomized, controlled
trial of the effect of parathyroidectomy on bone mass in
such patients.
tion of 9%. One year after parathyroidectomy bone mass
at this site had increased by 11.7%.
In a recently reported retrospective study Posen et al.
(1985) found a 16% reduction in the density of the nondo-
minant forearm measured by photon absorptiometry com¬
pared with age- and sex-matched patients who had un¬
dergone successful surgery for primary hyperparathy¬
roidism.
What is the mechanism of increased bone mass fol¬
lowing parathyroidectomy? Bone biopsy specimens taken
from patients with primary hyperparathyroidism show an
increase in the proportion of bone surfaces that are en¬
gaged in resorption. According to Parfitt (1980) the re¬
sorption phase leads to a transient deficit in bone mass,
which is restored almost completely after the osteoblastic
formation phase has finished. This ordinarily occurs in 2-3
months. In states of increased resorption there is a pre¬
dictable increase in this transient pool of missing bone.
Parathyroidectomy would cause an abrupt decrease in re¬
cruitment of resorption units, but those units already en¬
gaged in resorption would complete their remodeling
cycles. This would explain why Leppla et al. (1982) found
that the rise in bone density was almost complete at 6
months after parathyroidectomy. We were not able to de¬
lineate the time course of the change in total body calcium,
since the dose of radiation used precludes multiple mea¬
surements.
Can the change in bone mass following surgery be
predicted? No attempt was made by the three groups who
have shown changes in regional bone mass to relate the
changes to biochemical variables or initial bone mass. We
were unable to predict changes in TBCa from baseline
biochemical measurements or CaR.
The reduction in bone mass in patients with primary hy-
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BONE LOSS IN RHEUMATOID ARTHRITIS AND
PRIMARY GENERALIZED OSTEOARTHROSIS:
EFFECTS OF CORTICOSTEROIDS, SUPPRESSIVE
ANTIRHEUMATIC DRUGS AND CALCIUM
SUPPLEMENTS
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N. BROWN1, P. TOTHILL2 and G. NUKI1
1Rheumatic Diseases Unit, Northern General Hospital, Department of Medicine, Western
General Hospital, and 2Department of Medical Physics and Medical Engineering,
University of Edinburgh, UK
SUMMARY
The annual rate of bone loss in rheumatoid arthritis (RA) and primary generalized osteoarthrosis (PGOA)
was determined by measurement of total body calcium (TBCa). The mean annual rate of bone loss in 24
patients with RA treated with nonsteroidal anti-inflammatory drugs (NSAIDs) alone was 3.4%. This rate
of bone loss was not reduced in ten RA patients responding to suppressive antirheumatic drugs (4.3%) or
seven patients receiving oral calcium supplements (4.5%). The mean annual rate of loss of TBCa in 19
patients with PGOA was 1.6%, a figure which probably represents age-associated bone loss. The rate of
bone loss in PGOA was significantly less than that in RA patients not receiving corticosteroids. The mean
annual rate of change of TBCa in 30 RA patients receiving corticosteroids (+0.7%) was significantly less
than that in any of the other RA groups despite an initial normalized bone mass which was significantly less
than in those RA patients receiving NSAIDs alone. The data supported the hypothesis that bone loss
occurred early in the course of corticosteroid therapy and thereafter the drugs might have a protective
effect on the loss of bone in RA.
Key words: Bone loss. Total body calcium, Rheumatoid arthritis, Osteoarthrosis, Corticosteroids,
Suppressive antirheumatic drugs.
Total bone mass has been shown to be reduced
in rheumatoid arthritis (RA) [1-3] and further
reduced by low-dose corticosteroid therapy
[2, 3]. However, there is no literature on the rate
of total bone loss in this disease although loss of
bone from metacarpal sites has been shown to
occur at rates of 2-4% per annum in patients
receiving nonsteroidal anti-inflammatory drugs
(NSAIDs), corticosteroids or penicillamine
[4,5].
Initial cross-sectional studies reported by us
gave some support to the hypothesis that excess
bone loss induced by corticosteroids occurred
early in the course of therapy [2]. To test this
hypothesis and to examine the effects on the rate
of bone loss of oral calcium supplements and
suppression of the disease process with anti¬
rheumatic drugs, we now report the results of an
18-month longitudinal study of total body cal¬
cium in RA. The results have been compared
with those from patients with primary
Submitted 24 September; revised version accepted 15
December 1985.
Address correspondence to Dr. D. M. Reid, City Hos¬
pital, Urquhart Road, Aberdeen, AB2 1NJ.
generalized osteoarthrosis (PGOA) in whom
total bone mass has been found to be normal [6].
METHODS
Patients
Seventy-one patients (30 males, 41 females)
with definite or classical RA [7] underwent three
or four measurements of total body calcium
(TBCa) at 6-monthly intervals over 18 months.
Twenty-four patients continued NSAIDs alone,
30 patients continued treatment with low-dose
corticosteroids, ten patients commenced
therapy with suppressive antirheumatic drugs
(SARDs) in the form of gold or penicillamine
and seven patients commenced oral calcium sup¬
plements (OCS) in the form of calcium lactate
gluconate (Sandocal) one tablet t.d.s., giving an
elemental calcium dose of 1.2g/day. Those
treated with SARDs responded clinically to the
medication. All patients in the RA groups were
receiving NSAIDs. A group of 19 patients (2
males, 17 females) with PGOA also had three or
four measurements of TBCa and have been
included as a 'disease control group'. Eight of
these were receiving NSAIDs during the study
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TABLE I
Clinical and Therapeutic Details
RA+NSAIDs RA+SARDs RA+steroids RA + OCS PGOA
Number 24 10 30 7 19
Male/female 10/14 5/5 10/20 5/2 2/17
Pre/postmenopausal 3/11 4/1 5/15 1/1 2/15
Age (range) years 55.9 42.5 52.3 53.7 58.4
(32-70) (25-62) (25-69) (48-55) (47-68)
Years postmenopause (range) 10.4 0.2 8.8 6 9.8
(0-21) (0-1) (0-22) (0-12) (0-30)
Male/female ratio, mean age and menopausal status of patients with primary generalized osteoarthrosis (PGOA) and
rheumatoid arthritis (RA) treated with nonsteroidal anti-inflammatory drugs (NSAIDs) alone, additional suppressive
antirheumatic drugs (SARDs), additional corticosteroids or additional oral calcium supplements (OCS) completing the
18-month study period (range shown in parentheses).
while the other 11 were treated with simple anal¬
gesics. All patients gave informed consent, and
ethical approval was obtained from local and
national committees.
Clinical and serological measurements
These were undertaken at each 6-monthly
visit for TBCa estimation and included measure¬
ments of duration of early-morning stiffness,
functional status [8], articular index [9], ESR
and rheumatoid-factor titre [10]. A Steinbrocker
radiographic grading [8] was determined from a
hand radiograph at the beginning of the study.
All patients had renal and liver function tests
and calcium and phosphate biochemistry at the
beginning of the study.
Total body calcium measurements
Our method for a single measurement of total
body calcium (TBCa) has been fully reported
[2, 11]. TBCa was carried out by in-vivo neutron
activation analysis and calibration obtained by
comparison with an anthropomorphic phantom.
A figure for TBCa in grams was produced with
an in-vitro precision of 1.8% [11] and an in-vivo
precision over a period of 18 months of 2.9%
[12]. Individual results in the cross-sectional
studies were reported as a percentage of the
expected normal value for the patient's skeletal
size (arm span) and menopausal state derived
from measurements in 40 normal subjects [11],
Longitudinal analysis was undertaken by cal¬
culating a best-fit linear regression for the three
or four measurements of TBCa in grams. After
deviant points were omitted using Chauvenet's
criterion [13], the rate of change of TBCa was
calculated from the slope of the regression line
and expressed as a percentage of the initial
value. Analysis demonstrated that the assump¬
tion of a linear fit was reasonable. In the long¬
itudinal analysis no correction was made for the
patient's skeletal size or menopausal status as
the subjects acted as their own controls.
Statistical analysis
This was performed using Student's t test for
paired and unpaired variables. The Mann-
Whitney test was used for small samples.
RESULTS
The male/female ratio, age and menopausal
status of the 71 RA and 19 PGOA patients who
completed the longitudinal study are shown in
Table I. There was a preponderance of females
in all groups with the exception of the RA +
OCS group. Patients in the RA + SARDs group
were significantly younger than the NSAIDs
(13.4 years, p < 0.02), the steroid (9.8 years, p <
0.05) and the PGOA (15.9 years, p < 0.005)
groups.
Indices of disease duration and activity as well
as details of corticosteroid therapy are displayed
in Table II. The mean disease duration in the
SARDs group was shorter than the other treat¬
ment groups but not significantly. However, the
initial mean ESR in the SARDs group was sig¬
nificantly higher than that in the NSAIDs
(34mm/h, p < 0.025), steroid (32.7 mm/h, p <
0.05) and OCS (41.4 mm/h, p < 0.01) groups.
The ESR fell significantly in the SARDs group
during the study period (—32.8 mm/h, p <
0.001) but none of the indices changed signifi
cantly in the other groups.
The results of initial TBCa, expressed as a
percentage of the expected normal values, are
shown in Fig. 1. All the patients who continued
with NSAIDs and who were to commence
SARDs or OCS are contained in the RA plus no
steroid group. The steroid-treated group had a
significantly lower initial TBCa than the group
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TABLE II
Changes of Disease Activity
RA + RA + RA + RA +
NSAIDs SARDs steroids OCS
Number ■ 24 10 30 7
Duration of 10 6.2 10.3 10.2
disease (range) (1-35) (1.5-15) (1-38) (2-27)
Initial ESR 27.7 61.7 29 20.3
±20.8 ±38.0 ±27.1 ±13.1
Change in ESR +5.7 -32.8 +0.7 -3.9
±22.1 ±19.4 ±20.6 ±12.4
Initial A.I. 12.7 14 8.7 8.9
±6.2 ±7.9 ±6.4 ±2.7
Change in A.I. -1.9 -6 -1.9 -1.4
±6.2 ±8.5 ±4.6 ±5.3
Initial E.M.S. 45.4 113 45.3 91.7
±52.1 ±107 ±76.6 ±124
Change in
E.M.S. + 1 -36 -3.6 -57
±96.8 ±85.9 ±51.4 ±111
Initial F.S. 2.0 2.3 1.8 1.6
±0.3 ±0.5 ±0.5 ±0.5
Radiographic 2.6 2.4 2.6 2.4





SARDs or OCS groups. In the steroid group
there was no significant relationship between the
rate of change of TBCa and the daily dose or
duration of steroid therapy. The mean rate of
change of TBCa was similar in males and
females in all of the RA groups.
The 41 RA patients not treated with cortico¬
steroids (i.e. the NSAIDs, SARDs and OCS
groups combined) had a significantly increased
rate of bone loss compared to the steroid group
(—4.3%, p < 0.001) and the PGOA group
(—2.0%, p < 0.025) although the latter group
did show a significant annual loss of TBCa
(-1.6%, p < 0.01).
The corticosteroid-treated patients have been
sub-divided into those taking a low dose of pred¬
nisolone (=£5 mg/day) and a moderate dose of
the drug (5.1-10 mg/day). Details of disease
activity indices and corticosteroid therapy for
the two subgroups are shown in Table III. All
disease activity indices were greater in the mod¬
erate-dose group. The initial bone mass of the
two groups was not significantly different but
there was a significant difference between the






Results of disease activity indices expressed as the mean
initial and mean change in the index with the standard
deviation. No change in functional status or radiographic
grade occurred during the study.
NSAIDs = nonsteroidal anti-inflammatory drugs;
SARDs = suppressive antirheumatic drugs; OCS = oral
calcium supplements; ESR = erythrocyte sedimentation
rate (mm/h); A.I. = articular index; E.M.S. .= duration of
early morning stiffness in minutes; F.S. = functional
status.
who had not received corticosteroids (4.6%, p <
0.05) and the patients with PGOA (12.5%, p <
0.01). Both RA groups had a significantly
reduced mean TBCa compared with the 40
normal controls previously reported [2, 11].
Comparison of the rate of change of TBCa in
the four RA groups (Fig. 2) showed that they all
had significant mean annual losses of TBCa
(NSAIDs: 3.4%, p < 0.001; SARDs: 4.3%, p <
0.01; OCS: 4.5%, p < 0.01) with the exception
of the steroid group. There were no significant
differences between the annual rates of change
of the NSAIDs, SARDs and OCS groups but all
of these lost more calcium than the steroid group
(NSAIDs: 4.1%, p < 0.05; SARDs: 5.0%, p <
0.01; OCS: 5.2%, p < 0.02). There was no tend¬












Fig. 1.—Initial normalized total body calcium (TBCa)
expressed as a percentage of normal in male (A) and
female (•) patients with rheumatoid arthritis (RA) who
were receiving nonsteroidal anti-inflammatory drugs
(NSAIDs) alone or additional oral corticosteroids at the
onset of the study. TBCa of patients with primary
generalized osteoarthrosis (PGOA) are shown for com¬
parison. Normal range displayed in the hatched area as
the mean ±1 standard deviation.
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RA + RA + RA + RA+OCS PGOA
NSAID SARDS Steroids
(n=24) (n=10) (n=30) (n=7) (n=19)
% Mean -3.4 -4.3 +0.7 -4.5 -1.6
tL
° P < 0.02
Fig. 2.—Annual rate of change of total body calcium (TBCa) expressed as
a percentage of the initial value in male (A), and premenopausal (•) and
postmenopausal (O) female patients with rheumatoid arthritis (RA) treated
with nonsteroidal anti-inflammatory drugs (NSAIDs) alone, suppressive
antirheumatic drugs (SARDs), oral corticosteroids or oral calcium sup¬
plements (OCS) as well as in patients with primary generalized
osteoarthrosis(PGOA).
of change in the moderate-dose group (—2.3%
per annum) did not differ significantly from that
in the NSAIDs, SARDs or OCS groups.
The annual rate of change was not related to
disease duration or any one index of disease
activity in any of the four groups. There was no
difference between the rate of change of TBCa
in those patients with seropositive or seronega¬
tive disease.
Annual change in TBCa was not significantly
correlated with age or years postmenopause in
females or age in males. However in the females,
when considering 5-year postmenopause
cohorts, the highest mean annual loss of TBCa
was in the 5 years immediately after the meno¬
pause (0.1-5 years) both in the RA patients who
did not receive corticosteroids (n = 6: 4.0%) and
in the PGOA patients (n = 5: 3.2%).
DISCUSSION
Total bone mass has been shown to be reduced
(by 5-8%) in patients with RA treated with
NSAIDs alone and further reduced (by 11-15%)
with low-dose corticosteroid therapy [2,3], Both
these studies were cross-sectional and the rate of
bone loss was difficult to estimate, particularly as
there was no relationship between duration of
disease and total bone mass. Our longitudinal
study reported here is the first account of the rate
of loss of total bone mass in RA. The mean
annual rate of loss of calcium in patients treated
with NSAIDs alone was a substantial 3.4% per
annum. Although the rate is similar to the 2-4%
previously shown in longitudinal studies of
photon absorptiometry of the forearm [4] and
metacarpal indices [4,5], these bone sites are
close to areas of potentially inflamed synovium
and therefore might lose bone at a faster rate
than the total skeleton.
The annual rate of loss of TBCa in the RA
patients receiving NSAIDs alone was greater
than one would have expected from our cross-
sectional study where TBCa was reduced by
5.3% in males and 6.8% in females [2]. How¬
ever, in this study, the annual rate of loss of
TBCa was relatively increased by expressing it as
a percentage of the individual's initial value and
also by omitting the age and menopausal correc¬
tions of our original studies [2,6]. Furthermore,
RA patients with more advanced, destructive
disease may have an increased rate of bone loss
[4] and hence loss of TBCa would tend to accel¬
erate with time.
Loss of bone with age is greater in women than
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TABLE III
Age, Years Postmenopause and Mean Indices of
Disease Activity and Corticosteroid Therapy (±1
Standard Deviation) in Those taking Low (=S 5 mg
Prednisolone/Day) and Moderate (5.1-10 mg




Male/female ratio 8/12 2/8
Age 48.8 59.1 p<0.02
±13.9 ±8.4
Years postmenopause 7.1 11.2 NS
±8.5 ±6.4
Duration of disease 6.9 15.1 NS
±4.6 ±12.6
Initial ESR (mm/h) 20.6 45.7 NS
±15.2 ±37.6
Initial A.I. 6.4 13 p<0.01
±5.1 ±6.6
Initial E.M.S. (min) 17.7 100.5 p<0.01
±35.4 ±105.8
Functional status 1.5 2.2 p<0.001
±0.5 ±0.7
Radiographic grade 1.8 3.3 p<0.001
±1.1 ±0.7
Prednisolone dose 4.9 7.4 p<0.001
(mg/day) ±0.2 ±1.4
Duration of therapy 3.2 7.3 NS
(years) ±2.2 ±6.9
' ESR = erythrocyte sedimentation rate: A.I. = articular
index; E.M.S. = duration of early morning stiffness; NS =
not significant.
men [14], particularly immediately after the
menopause [11,15]. Rather surprisingly the
mean rate of loss in our study was similar in
males and females in all groups (Fig. 2). There
was a tendency for those nearest to the meno¬
pause to have the greatest rate of loss of TBCa.
In the light of these observations and because
the groups were reasonably matched for years
postmenopause, normalization for post-
menopause time was not justified. The explana¬
tion for the substantial loss of bone in male RA
patients is not clear. While there is a slow fall in
bone mass with age in men it has been estimated
at only 0.7% per annum after the age of 50 [16].
As the rate of bone loss is likely to be linear in
males [17] and therefore we were not surprised
to find no relationship between bone loss rates
and age in men. Nevertheless, the rate of bone
loss in males with RA must include an effect of
ageing. We have shown total bone mass to be
normal in PGOA [6], therefore the rate of bone
loss in this condition was attributed to ageing.
The number of men measured was too small to
comment on the rate of bone loss. It is reassuring
to note that the mean loss of 1.5% per annum in
women was very similar to the annual reduction
in total bone mass in women found in cross-
sectional studies of TBCa [11,16].
The rate
, of bone loss in RA patients not
treated with corticosteroids was significantly
greater than in patients with PGOA, suggesting
that bone loss, in excess of that due to ageing, is a
feature of the former disease.
There were no significant differences between
the annual loss of TBCa in the three nonsteroid-
treated RA groups. The failure to demonstrate a
reduction in the rate of bone loss in those
responding to gold or penicillamine, or those
taking calcium supplements was supported by
finding no diminution in the rate of bone loss.
The failure to prevent bone loss with SARDs is
disappointing. Preliminary data had suggested
that both gold [18-20] and penicillamine [21]
might limit the degree of radiological destruc¬
tion after a year of treatment. Indeed pen¬
icillamine may reverse the local bone loss
associated with RA as measured by metacarpal
indices [5, 22]. Penicillamine is a lathyritic agent
which inhibits collagen cross-linking and syn¬
thesis, and theoretically could hasten the
osteoporotic process by inhibiting collagen
maturation in bone [23]. However, there was no
significant difference in our study between the
Low dose prednisolone Moderate dose prednisolone
(n =20) (n =10)
Initial TBCa Annual change Initial TBCa Annual change
Fig. 3.—Initial normalized total body calcium (TBCa)
expressed as a percentage of normal and annual rate of
change of total body calcium (TBCa) expressed as a
percentage of the inital value in male (A), premenopausal
(•) and postmenopausal female (O) patients with rheu¬
matoid arthritis (RA) who were receiving low (S5 mg/day)
and moderate (5.1-10 mg/day) doses of prednisolone.
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rate of loss of TBCa in those treated with pen¬
icillamine and gold.
The failure to prevent bone loss with oral cal¬
cium supplements is less surprising although oral
calcium is thought to reduce the rate of bone loss
in postmenopausal osteoporosis [24] and in
corticosteroid-treated patients with rheumatoid
arthritis [25], The difference may be due to cal¬
cium malabsorption in postmenopausal
osteoporosis [26] and in corticosteroid-induced
bone loss [27] but not in RA [28]. However, a
recent study has shown a mild degree of calcium
malabsorption in early disease [29]. All our
patients had RA for at least one year. Alter¬
natively, most of the bone loss in RA patients
treated with NSAIDs alone may take place at
peripheral skeletal sites which may not be ame¬
nable to reversal by oral calcium supplements.
The data from the corticosteroid-treated
patients give strong support to our hypothesis
that bone loss due to prednisolone or its deriva¬
tives occurs early in the course of therapy [2],
This hypothesis is consistent with studies of the
catabolic and histochemical effects of cortico¬
steroids on bone in both animals [30] and
humans [31,32] and also with longitudinal
studies of metacarpal indices [4] and bone histo-
morphometry [33] in RA and other diseases.
The failure of the steroid-treated patients to
lose bone (Fig. 2) despite their initial reduced
bone mass (Fig. 1) is perhaps surprising. It might
reflect a tendency for those individuals with the
lowest initial TBCa to lose the least bone [4].
However, we were unable to detect a relation¬
ship between the initial bone mass and the rate
of loss in the steroid- or nonsteroid-treated
patients. A more exciting possibility is that
corticosteroid therapy might limit the degree of
local bone damage at periarticular sites by
reducing disease activity. Such a suggestion was
made initially in the Medical Research Council
trials of corticosteroids [34, 35] and has been
given support in more recent studies [36,37],
The subgroup of steroid patients who had
received moderate doses of prednisolone (5.1-
10 mg/day) had significantly greater mean loss of
bone than the low-dose treated group (Fig. 3).
The moderate-dose group was significantly
older, had more severe disease and were signifi¬
cantly less mobile than the low-dose subgroup.
These facts may explain the greater mean loss of
TBCa in the former group of patients rather than
their steroid therapy. Despite long-standing
severe disease, the small group of patients
receiving more than 5 mg of prednisolone daily
still had a lower rate of bone loss than the other
RA patients. It is conceivable that cortico¬
steroids, used in the treatment of RA, could
induce bone loss early in the course of therapy,
perhaps at an axial site, and thereafter prevent
destructive bone loss at appendicular bone sites.
Longitudinal studies assessing bone mass at both
these bone sites and relating any loss to altera¬
tion of erosion formation will be necessary to
explore such a hypothesis.
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Abstract. A single photon absorption imaging technique has been developed to assess the
bone mass of the hand, especially in patients with rheumatoid arthritis or bronchial asthma.
A modified rectilinear scanner images the hand by transmission scanning in a water bath
with a 7.4 GBq ,25I source. A microcomputer is used to calculate the bone mineral
distribution, and the total bone mineral content (bmc) of the hand is determined from
that distribution. The precision (coefficient of variation) of the measurement is 1.9%. A
control population of 20 men and 58 women has been studied to determine normal variations
in hand bone mineral content with age, sex, body size, hand volume and years since
menopause. The normal men are found to have an average hand bmc of 25.1 g with a
coefficient of variation (cv) of 22%, which is reduced to 12% by normalising for body
size using span. The normal women had an average hand bmc of 18.0 g± 15%. The cv
is reduced to 13% by normalising for span and years post-menopause.
1. Introduction
Single-photon absorptiometry (spa) is an established technique for the measurement
of forearm bone mineral content (bmc) using 125I as the isotope source (Cameron et
al 1968), but until now it had not been applied to the measurement of hand bone
mineral. Neutron activation analysis is also used to measure bone in vivo and has
been applied to the hand (Catto et al 1973, Maziere et al 1979). Maziere et al (1979)
compared activation analysis of hand calcium using 252Cf (132 controls, 45
osteoporotics) with spa measurements of bmc in the radial epiphyses (37 controls, 13
osteoporotics) and found a strong correlation between the two. They preferred the
naa technique, which gave a coefficient of variation of 2.4% for repeated measurements
on ten controls compared with 3.6% for the spa. Some spa measurements on patients
were abandoned because results could not be reproduced. Maziere's preference for
naa of the hand was based upon the site of measurement rather than upon the
technique. The radiation absorbed dose equivalent to the hand was 7.5 mSv. Smith
et al (1981) compared part-body neutiun activation analysis of the forearm with spa
of the radius 5 cm proximal to the styloid process, and found the two techniques to
be equally sensitive in vivo methods for monitoring changes in calcified bone.
Total bone mass has been shown to be reduced by 5-8% in patients with rheumatoid
arthritis who have been treated with non-steroidal anti-inflammatory drugs alone
and further reduced in those patients receiving additional corticosteroid therapy
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(Reid et al 1982, Als et al 1983). The site of bone loss in rheumatoid arthritis remains
in doubt, although substantial reductions in peripheral bone mass may in part account
for small reductions in the total bone mass in patients who have not received cor¬
ticosteroids (Reid et al 1986). Substantial reductions in peripheral bone mass may
relate both to periarticular osteoporosis and marginal bone erosion, which are radiologi¬
cal signs of rheumatoid arthritis (Bywaters 1960), especially in regions of the skeleton
where small joints are involved, such as the hand. A method of evaluating hand bone
mass could be useful not only to clarify the site of bone loss in ra but also as a
potential measurement of long-term disease activity and to monitor treatment.
Apparatus was therefore designed to apply the technique of spa with its established
potential for precision and low radiation doses and its simple nucleonic requirements
to the measurement of hand bone mineral.
2. Method
A J & P Multipoise dual-headed rectilinear scanner (J & P Engineering Ltd) is rotated
until the scanning frames are vertical and modified by the addition of a rigid frame
attached to one Nal detector (10 cm diameter, 5 cm thick) carrying a collimated 125I
source. The 1 mm diameter sealed source has an activity of 7.4 GBq on delivery and
is used until it has decayed to about 1.5 GBq. The positions and orientation of the
collimated source are adjusted to maximise the detected count rate. The detector
collimator is circular with a diameter of 4 or 5 mm; the larger diameter being used to
maintain the count rate as the source decays. The change of collimator does not
degrade the image. No dead time correction is necessary. The hand is placed in a
water bath at 35 °C between the source and detector (figure 1). Various widths of rigid
air-filled perspex boxes are placed in the tank alongside the hand to reduce the water
thickness as much as possible for an individual. Consideration was given to problems
associated with rheumatoid arthritis when designing the apparatus, the most important
feature being that some patients would be unable to straighten their fingers. For this
reason the (flexed) hand is held immobile in the tank by water-filled balloons, rather
than a rigid frame, for the duration of the scan. The apparatus is designed to scan
the left hand at a speed of approximately 0.5 cm s_1 and a cell size of 4 mm, giving a
total scan time of around 15 min.
The detected transmitted counts are collected into a 64 x 64 matrix by a Cromemco
microcomputer. This transmission image (shown in figure 2(a)) is used to calculate
a bone mineral image (figure 2(b)) by applying the following equation pixel by pixel:
= [Pb/(mbPb ~ M-sPs)] ln V7
where MB is the bone mass per unit area, pB and ps are densities (g cm-3) (the subscript
'B' indicating bone mineral and 'S' soft tissue or water) and p.B and p.s are mass
absorption coefficients (cm2g_1) of the bone mineral and soft tissue or water, respec¬
tively. The values used are those given by Cameron et a! (1968). I0 is the background
intensity; this is determined from three regions of interest as shown in figure 2(a), and
I is the transmitted intensity.
A rubber tourniquet is loosely applied around the wrist, 3 cm proximal to the radial
styloid. The position is found using a specially made set of dividers. This band is
clearly seen in the images (figure 2) and is used to define the limit of the hand. Total
hand bmc is the sum of all pixels inside a region of interest, as shown in figure 2(b).
Hand volume, distal to the marker band, is measured by the displacement of water.
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Figure 1. J & P rectilinear scanner modified for hand scanning. A 1 source is mounted on a bracket
facing the detector. The hand is placed in a water bath (35 °C) and held still by two water-filled balloons.
A marker band is placed around the wrist, 3 cm proximal to the radial styloid.
3. Experimental results
Two to six repeat measurements were performed on ten volunteers on separate occasions
over the life of a source (approximately five months), giving a precision (coefficient
of variation) of 1.9%. The absorbed dose, measured using thermoluminescent
dosimetry, was 6 p.Gy per scan.
The limit ofmeasurement, 3 cm proximal to the radial styloid, was chosen arbitrarily.
Figure 3 shows the variation in total bmc by movement of the upper limit for a typical
male hand. Hand bone mineral is not unduly influenced by the position of the limit,
and the relationship is linear. Errors introduced in the result by repositioning the
marker band are incorporated in the precision measurement.
The measurement of hand bmc is quite a sensitive function of the measured
background level; a 1% change in background giving a 2% change in hand bmc for
an average female hand with a bmc of 19 g. The background count rate is well
estimated; the counts in the three background regions give a coefficient of variation
of 0.1% and the integral non-uniformity is less than 0.5%. This slight non-uniformity
results from bowing of the tank walls when it is filled with water. More importantly,
fat attenuates less than water or soft tissue and fat around the hand will give a locally
raised background level. Increased transmission around the wrist may be clearly seen
on some transmission images. The worst case seen, in a 109 kg female patient, shown
in figure 4, gave an increased transmission of 15% at the side of the wrist. Using a
simple cylindrical anatomy this gives a maximum localised error over the bone of 1.5%
in transmitted counts or 3% in the bmc. However, this underestimate of the bmc is
non-uniform, being directly dependent on an individual's fat distribution, and cannot
be accurately measured. The effect is not included in the precision measurement as it
predominantly affects the accuracy rather than the reproducibility.
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Figure 2. (a) Regions used to determine the background level on the transmission image. (b) Region used
to determine hand bmc using the bone mineral image. The apparently very dense band around the wrist
is the marker.
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Figure 3. Variation of hand BMC with position of wrist limit marker.
4. Normalisation procedures
To establish a range of normal values for hand bmc, 78 normal volunteers were
measured: 20 males (four aged 20-29, seven aged 30-39, two aged 40-49, four aged
50-59 and three aged 60-69) and 58 females (thirteen aged 20-29, seven aged 30-39,
fourteen aged 40-49, twelve aged 50-59, eight aged 60-69 and four over 70). All the
subjects were active, in good health and without any history of disease that might be
expected to influence bone metabolism. The variation in hand bmc and in size is
shown in table 1. The females ranged from 12.9 to 25.6 g with a mean of 18.0 g± 15%
(cv), while the males ranged from 14.6 to 34.9g with a mean of 25.1 g±22% (cv).
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Table 1. Data for normal controls. Means and standard deviation.
Post-menopausal
Male (sd) All female (sd) women (sd)
Number 20 58 23
Age (years) 43 (=14) 46 (±16) 62 (±8)
Years post-menopause — — 12.5 (=9.6)
Span (m) 1.85 (±0.09) 1.69 (±0.06) 1.66 (±0.06)
Hand volume (ml) 430 (=63) 327(±39) 336 (±37)
Hand bmc (g) 25.1 (±5.5) 18.0 (=2.7) 16.7 (±1.9)
The dependence of measured hand bmc upon size parameters (hand volume, arm
span, height and weight) and age was investigated using multiple regression analysis.
The more significant results for men are shown in table 2(a) and for women in table
2(b). For women, years post-menopause is considered as an alternative age parameter.
The biological variation in bmc due to size and age could be reduced by expressing
the subjects' results as a ratio bmc/bmcp. bmcp is a predicted value obtained by using
equations derived from the multiple regression analyses and is given in tables 2(a)
and (b). These tables also contain the coefficients of variation (cv) of bmc/bmcp for
the control population when these predictive expressions are applied.
For men (table 2(a)), hand bmc is found to correlate equally well with hand volume
and arm span. However, the correlation with age alone is poor (r = 0.25, P > 0.3), and
the addition of age does not improve the correlation with either span or volume.
Amongst the female controls the biological variation was initially smaller (cv =
15%) (table 1), but correlations with size and age parameters were much weaker and
hence a much smaller reduction in the cv was achieved by normalisation. Hand bmc
correlates with span (r = 0.36, P<0.01) or height (r = 0.32, P< 0.02) alone but not
with volume alone. For women, both age (r = 0.33, P < 0.02) and years post-menopause
(r = 0.31, P < 0.02) correlate with hand bmc and may be combined with a size parameter
to improve the result. When this is done, age results in the lowest cv, giving 12.5%
with volume and 12.2% with arm span. However, the most significant correlation
(r = 0.48, P = 0.001) is for span and years post-menopause, a combination which gives
a cv of 12.8%.
Figure 5 is the result of plotting hand bmc normalised using the expression given
for span in table 2(b) (bmcp = 9.12S1'29) against age. By chance, all women over 50
are post-menopausal. The linear regressions are shown for the whole population, the
pre-menopausal women and the post-menopausal women. The population as a whole
shows a loss of 0.25% hand bmc per year with a significance P<0.05. The pre¬
menopausal group show an increase which is not significant and the post-menopausal
group show a loss of 0.4% hand bmc per year which is also insignificant.
5. Discussion
Single-photon absorptiometry can be usefully employed to make precise measurements
of hand bmc and hence to study local bone loss. It is relatively insensitive to variations
in placing and replacing the marker band, the effect of which is incorporated in the
precision estimate. Fat deposits around the hand or wrist will result in a small
inaccuracy in some patients.
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Table 2. (a) Normalisation of male hand bmc for age and size parameters, showing the equations for the
predicted hand bmc (bmcp) with coefficient of variation (cv) of the normalised controls, correlation
coefficients (r) and significances (P). Correlation with age alone was poor (P>0.3) and has been omitted.
(6) Normalisation of female hand bmc for age and size parameters, showing the equations for the predicted




parameters None Age (A) in years
Hand bmcp = 2.12 x 10~2 V1 •7 bmc = 1.63 x io"2V1'23e°ool7A
Volume cv — 11.8% cv= 11.7%
(V) in r = 0.81 r = 0.82
millilitres P< 0.0001 P <0.0001
Span (S) bmcp = 3.07S3 42 bmcp = 3.07 s3-4te0,002! A
in cv= 11.9% cv= 11.9%
metres r = 0.80 r = 0.80
P< 0.0001 P< 0.0002
Height bmcp = 3.28 Hy6 bmcp = 2.49 H381 e° 00384
(H) in cv = 15.0% cv = 14.3%
metres r = 0.67 r = 0.72
P< 0.001 P< 0.002
(b)
Age parameters
Body size Years post-menopause
parameters None Age (A) in years (Y) in years
None bmcp = 20.02 e-° 0027/4 BMCp = 18.32 e-0005iy
cv= 12.6% cv = 13.9%
r = 0.33 r = 0.31
P < 0.02 P<0.02
Hand BMCp= 11.03 V'12 bmcp = 4.47 v°'265 e 0 003'1A BMCp = 5.37 V021 e-000tY
volume cv = 28.4% cv = 12.5% cv= 13.9%
(V) in r = 0.07 r = 0.40 r = 0.36
millilitres P> 0.2 P<0.02 0<0.03
Span (S) BMCp = 9.12 S1'2® BMCp= 12.45 5° " e-° °026A BMCp = 9.40 S1-2® e-°0052v
in cv = 13.8% cv= 12.2% cv= 12.8%
metres r = 0.36 r = 0.43 r = 0.48
P<0.01 P<0.01 P = 0.001
Height (H) BMCp = 10.0 H1'20 bmcp= 12.8 H0 90 e'00023A BMCp = 11.3 H100 e-° 0045y
in cv= 14.2% cv= 18.0% cv= 13.6%
metres r = 0.32 r = 0.44 r = 0.42
P < 0.02 P<0.01 P<0.01
The variation in the control populations may be reduced by normalising for size
and age. In the male controls there is no significant loss of hand bmc with age, and
normalising for either span or hand volume gives an appreciable reduction in the
coefficient of variation. We had thought that, since any variation due to mispositioning








• ••• 0 o
n n1—" -—■•-
-» *.
• • • •
u v
■ o o
















Figure 5. Variation of hand BMC normalised using span alone with age in female controls. •, pre¬
menopausal—the full line represents the best fit to the data and has a gradient = 0.16% yr"1, significance
P> 0.2; O, post-menopausal—the full line representing the best fit with a gradient = -0.41% yr"1, significance
P> 0.2. The broken line, representing the best fit to all the data, has a gradient^ -0.24% yr"1, significance
P <0.05.
of the marker band would be present in both the hand bmc and volume measurements,
normalising for volume would help eliminate this source of error. However, if such
an effect is present it is masked by the greater biological variation (15%) in this
parameter, probably due to differences in soft tissue. The benefits of normalising the
female control results are much less, with only a 2-3% reduction in cv although, since
there is less biological variation initially, the normalised male and female controls
have very similar cv.
The range of hand bmc obtained agrees well with the results found by Maziere et
al (1979) who found 4.5-16 g of calcium distal to the radial and ulna styloid. Catto
et al (1973) gave results for four patients in the range 5.9-13.6 g.
The normalisation procedures used by Maziere and co-workers are more direct,
being based on an estimate of hand bone volume from a plane radiograph, and in the
20-60 age range they find a cv of 9% in men and 11% in women. However, this
normalisation procedure is not open to us since we cannot expect to be able to flatten
our patients' hands to obtain a suitable radiograph.
Age related loss of hand bmc is more apparent amongst the females although, as
shown in figure 5, the rate of loss is small and the statistical significance is poor. These
loss rates are much less than those reported previously for total body calcium where
a post-menopausal loss of 1.5% per year was observed (Kennedy et al 1982). The age
decade data given by Maziere et al (1979) for hand calcium suggest a loss rate of 1.3%
per year amongst post-menopausal women if the menopause is assumed to occur at
an age of 50. Dequeker (1976) used various hand bone indices from radiogrammetry
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which suggest a loss rate of just under 1 % per year following the menopause. However,
none of these measurements are directly comparable, nor is it possible to calculate the
significances from the published data.
The apparent change in the hand bmc loss rate at menopause, together with the
improved correlation, leads us to use span and years post-menopause for normalising
our female hand bmc. Span alone will be used for the male data.
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Resume
Mesure du contenu mineral des os de la main par absorptiometry a photon unique.
Les auteurs ont developpe une technique d'imagerie d'absorption a photon unique pour evaluer la masse
osseuse de la main, en particulier pour des patients atteints de polyarthrite rhumatoi'de ou d'asthme brochique.
Les images de la main ont ete obtenues sur un scintigraphe a balayage modifie, par des mesures de
transmission dans un bac d'eau utilisant une source de l25I de 7,4 GBq. Un micro-ordinateur permet de
calculer la distribution minerale dans l'os, et le contenu mineral total des os (bmc) de la main est determine
a partir de cette distribution. La dispersion des mesures est de 1,9% (coefficient de variation). Une population
de controle de 20 hommes et de 58 femmes a ete etudiee afin de determiner les variations normales du
contenu mineral osseux de la main en fonction de 1'age, du sexe, de la taille du corps, du volume de la
main, et du temps ecoule apres la menopause. Les hommes normaux (temoins) ont un bmc moyen de la
main de 25,1 g avec un coefficient de variation (cv) de 22% qui peut etre amene a 12% en normalisant par
rapport a la taille du corps, estimee avec 1'empan. Les femmes normales (temoins) ont un bmc moyen de
la main de 18,0 g± 15%. Le cv est reduit a 13% en normalisant par rapport a l'empan et le temps ecoule
apres la menopause.
Zusammenfassung
Messung des Knochenmineralgehaltes der Hand mit Hilfe der Einzel-Photon-Absorptiometrie.
Ein Einzel-Photon-Absorptions-Abbildungsverfahren wurde entwickelt, um die Knochenmasse der Hand
zu bestimmen, insbesondere bei Patienten mit rheumatischer Arthritis oder Bronchialasthma. Ein modifizier-
ter Scanner bildet die Hand ab durch Transmissionsabtastung in einem Wasserbad mit einer 7.4 GBq
125I-Quelle. Ein Mikrocomputer wird verwendet zur Berechnung der Verteilung des Knochenminerals und
der Gesamtknochenmineralgehalt (KMG) der Hand wird aus dieser Verteilung bestimmt. Die Genauigkeit
(Variationskoeffizient) der Messung betragt 1.9%. Eine Kontrollpopulation aus 20 Mannern und 58 Frauen
wurde untersucht, um die normalen Schwankungen im Knochenmineralgehalt der Hand in Abhangigkeit
von Alter, Geschlecht, KorpergroBe, Handvolumen und ggf. Jahre nach der Menopause zu bestimmen. Bei
normalen Mannern wurde ein KMG der Hand von 25.1 g festgestellt, mit einem Variationskoeffizienten
(VK) von 22%, der auf 12% reduziert wird durch Normierung von KorpergroBe und Handspanne. Bei
normalen Frauen wird ein KMG von 18.0 g ±15% gefunden. Der VK wird auf 13% reduziert durch
Normierung der Handspanne und der Jahre nach der Menopause.
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1. Introduction
In vivo neutron activation analysis is an important established technique for determin¬
ing body elemental composition. It may be used to determine both the absolute amount
of some body elements or changes with time (Cohn 1981).
The MRC cyclotron in Edinburgh has been used as a neutron source for total body
neutron activation analysis (tbnaa) of calcium (Kennedy et al 1982), sodium and
chlorine (Kennedy et al 1983) using the reactions 48Ca(n, y)49Ca, 23Na(n, y)24Na and
37Cl(n, y)38Cl respectively.
We have derived absolute quantities of calcium and sodium by identifying and
correcting for the body dimensions that affect the efficiency of activation and gamma-ray
measurement (Kennedy et al 1982). However, it is often of more importance, par¬
ticularly when measuring calcium, to determine changes within a patient over a long
period of time.
The ability to detect such changes in body elements depends upon the reproducibil¬
ity or precision of the method. This is defined as the coefficient of variation of repeated
measurements over varying periods of time. The precision quoted by various centres
making tbnaa estimations of total body calcium (TBCa), based on measurements of
phantoms or cadavers, is shown in table 1. No measurements have yet been published
of the long term in vivo precision of tbnaa based on repeated patient measurements.
Since the typical dose is about 10 mSv it would not be ethical to activate human subjects
repeatedly solely to obtain this information. However if patients are being measured
over a long period of time to monitor either their bone loss as a result of disease or
a change in bone calcium as a result of treatment, it is possible to use these results to
obtain a measurement of the long term precision of tbnaa in vivo.
2. Method
One hundred and fifty nine male and female subjects participated in a clinical study
to investigate bone loss in various rheumatic diseases. These patients attended for
tbnaa on three or four visits, six months apart, over a period of up to 18 months. On
§ Present address: Rheumatology Department, City Hospital, Urquhart Road, Aberdeen, UK.
|| Present address: Department of Medical Physics, Ninewells Hospital, Dundee, UK.
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Table 1. Precision and dose for TBCa and TBNa measurements.
TBCa TBNa Dose
Neutron precision precision equivalent
source (%) Method (%) (mSv) Authors
Cyclotron 2-3 8 measurements
of 1 cadaver
— 15+ Chamberlain et al
(1968)
Neutron 1.7 5 measurements — 6.4+ Cohn et al (1970)
generator of 1 phantom
Cyclotron 2 11 measurements
of 3 cadavers
— 20+ Nelp et al (1970)
14 Pu-Be 1.1 Phantom — 2.8+ Cohn et al
(1972,1976)
Two neutron 2.9 35+ measurements — 10 Boddy et al (1973)
generators of various phantoms
Cyclotron 2 Cadaver — 10 Spinks et al (1977)
Cyclotron 1.8 13 measurements
of 1 phantom
2.1 13+ Kennedy et al
(1982, 1983)
Neutron 3.6 43 measurements — 5 Burkinshaw (1985)
generator of 1 phantom
over 14 months
Neutron 3.0 5 measurements 1.9 10 Sharafi et al
generator of 1 phantom (1983)
t A quality factor or relative biological effectiveness of 10 is given in the references cited.
each occasion they attended, simultaneous measurement was made of TBCa, total body
sodium (TBNa) and total body chlorine (tbci). The patients were activated in their
normal clothing. This means that no reliable interpretation can be placed on the tbci
estimates as these are influenced by the chlorine content of their clothes, especially
due to the use of thermal underwear in winter.
Corrections were applied for patient height, body thickness and fat layer and for
air gap in the irradiation chamber (Kennedy et al 1982, 1983). Observed counts were
related to those from a sodium standard irradiated at the same time and overall
reproducibility was monitored by periodic activation of an an anthropomorphic model.
As a consequence of their disease or treatment, the patients' TBCa and TBNa might
be expected to change with time and this was observed in most patient groups (Reid
et al 1984). In calculating the in vivo precision, it was assumed that the changes would
be linear over the period concerned. The results of patients who attended three or
four times were analysed by fitting a linear regression to the TBCa and TBNa results
plotted against time. The coefficient of variation of the deviation of the points from
the regression line was calculated assuming a normal distribution and (n— 2) degrees
of freedom, where n is the number of visits for that patient. Individual points which
deviated by more than 3.4 standard deviations from the regression line were eliminated
by applying Chanvenet's criterion (Documenta Geigy 1956). The mean of these
coefficients of variation is taken to be the in vivo precision.
3. Results
After elimination for non-attendance and the application of Chauvenet's criterion,
which removed 15 points, 590 points remained representing 156 patients with three or
four TBCa results. The distribution of coefficients of variation is shown in figure 1.
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Figure 1. Deviation of TBCa results from regression (mean = 2.91, median = 2.76, mode = 2.25).
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Figure 2. Deviation of TBNa results from regression (mean = 3.63, median = 3.30, mode =2.25).
The in vivo precision is 2.9% compared with a precision of 1.8% obtained by repeated
activation of an anthropomorphic model over a period of three months.
158 subjects with three or four TBNa results remained. The distribution of coefficients
of variation is shown in figure 2. This gives an in vivo precision of 3.6% compared
with a precision of 2.1% obtained from measurements of an anthropomorphic model.
4. Discussion
tbnaa is in regular use for determining body composition. In longitudinal studies it
has successfully demonstrated changes in total body minerals as a result of disease or
its treatment (Eastell et al 1985, Gruber et al 1984). Longitudinal studies have been
over a variety of periods mainly in the range of six months to two years.
The application of tbnaa, however, requires a knowledge of the precision of the
estimate. In the past this has been obtained from phantoms activated within a relatively
short period of time. These models must represent the patient both in chemical
composition and in the distribution of the elements. This has led to the development
of complicated models, such as those of Oxby and Brooks (1979). Our technique of
estimating the precision overcomes the limitations of anthropomorphic models. All
the uncertainties in a single estimate are incorporated together with any long term
variations in patient parameters (e.g. weight) and in the equipment. The assumption
of linear changes in calcium and sodium seems to be reasonable (Tothill et al 1984)
but if the changes are non-linear then the method is likely to overestimate the coefficient
of variation. The true precision would then be better than that estimated by this
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method. The distribution of the deviations from the regression lines are shown in
figures 1 and 2. The use of the mean to describe the coefficient of variation is a
conservative choice.
Inspection of table 1 shows that our in vitro precision compares favourably with
that obtained by other authors. The difference observed between long term measure¬
ments in vivo and measurements based on the phantom (2.9 and 1.8% respectively for
TBCa, and 3.6 and 2.1% for TBNa) is not surprising. Corrections for patient size and
movement, neutron beam shape, and irradiation and measurement timing may not be
completely adequate. The precision is still very satisfactory and allows the study of
the effects of disease or treatment to be made with relatively small groups.of subjects.
We cannot tell how much deterioration of precision is to be expected with other systems
as no previous estimates have been made in vivo. Cohn (1982) has reported a precision
of 2.6% over a 4-5 year patient study compared with a phantom precision of 1% but
without details of how this was measured. Some centres are able to use anthropomor¬
phic models to monitor precision over long periods (Burkinshaw 1985) but this may
not fully allow for effects due to changes in the patients' weight or body build between
activations.
Acknowledgments
We should like to thank Mrs Norma Brown, Mrs E M Law, Mr J R Williams and the
staff of the MRC Cyclotron Unit in Edinburgh. The research was funded by the
Scottish Hospitals Endowment Research Trust and by the Arthritis and Rheumatism
Council.
References
Boddy K, Holloway I and Elliott A 1973 Int. J. Appl. Radiat. Isot. 24 428-30
Burkinshaw L 1985 Private communication
Chamberlain M J, Fremlin J M, Peters D K and Philip H 1968 Br. Med. J. 2 581-3
Cohn S H 1981 Med. Phys. 8 145-54
1982 Calcif. Tissue Int. 34 433-8
Cohn S H, Dombrowski C S and Fairchild R G 1970 Int. J. Appl. Radiat. Isot. 21 127-37
Cohn S H, Shukla K K, Dombrowski C S and Fairchild R G 1972 J. Nucl. Med. 13 487-92
Cohn S H, Vaswani A, Zanzi I and Ellis K J 1976 Am. J. Physiol. 230 143-8
Documenta Geigy 1956 Scientific Tables (Basle: Geigy) 5th edn p 47
Eastell R, Kennedy N S J, Smith M A, Tothill P and Anderton J L 1985 Nephron 40 139-42
Gruber H E, Ivey J L, Baylink D J, Matthews M, Nelp W B, Sisom K and Chesnut C H 1984 Metabolism
33 295
Kennedy N S J, Eastell R, Ferrington C M, Simpson J D, Smith M A, Strong J A and Tothill P 1982 Phys.
Med. Biol. 27 697-707
Kennedy N S J, Eastell R, Smith M A and Tothill P 1983 Phys. Med. Biol. 28 215-21
Nelp W B, Palmer H E, Murano R, Pailthorp K, Hinn G M, Rich C, Williams J L, Rudd T G and Denny
J D 1970 J. Lab. Clin. Med. 76 151-62
Oxby C B and Brooks K 1979 Phys. Med. Biol. 24 440-2
Reid D M, Nicoll J, Brown N, Kennedy N S J, Smith M A, Tothill P and Nuki G 1984 Br. J. Rheumatol.
23 116-7
Sharifi A, Pearson D, Oxby C B, Oldroyd B, Krupowicz D W, Brooks K and Ellis R E 1983 Phys. Med.
Biol. 28 203-14
Spinks T J, Bewley D K, Ranicar A S O and Joplin G F 1977 J. Radioanal. Chem. 37 345-55
Tothill P, Nicoll J J, Kennedy N S J, Smith M A, Reid D M and Nuki G 1984 Osteoporosis ed C Christiansen,
C D Arnaud, B E C Nordin, A M Parfitt, W A Peck and B L Figgs (Copenhagen: Glostrup Hospital
Press) pp 217-8
23
PREDICTION OF FRACTURE HEATING IN THE TIBIA
BY QUANTITATIVE RADIONUCLIDE IMAGING
M. A. SMITH, E. A. JONES, R. K. STRACHAN, J. J. NICOLE, J. J. K. BEST, P. TOTHILL, S, P. F.HUGHES
From the Royal Infirmary, Edinburgh
The uptake of 99mTc-iVlDP was studied in 73 patients after a tibial fracture. The image obtained five
minutes after injection during a period between one and four weeks after fracture was found to be related to
(he incidence of non-union after six months. A ratio of 1.3 between the uptake at the fracture site and at
normal bone adjacent to it predicted non-union in an individual patient with a sensitivity of about 70% and a
specificity of 90%.
It has been recognised for many years that there is an
increased uptake of bone scanning agents at the site of a
fracture and there have been several reports on bone
scans as indicators of fracture healing. Various radionu¬
clides such as 32P (Tucker 1950), 85Sr (Bauer and
Wendeberg 1959; Muheim 1973), 87mSr (Illingworth and
Schiess 1971; Johanssen 1973) and 18F (Riggens et al.
1974) have been used to investigate fracture healing
without a great deal of success. Technetium 99m-
phosphate compounds such as 99mTc-Sn-pyrophosphate
(Lund et al. 1978) have also been investigated but it is the
compound 99mTc-methylene diphosphonate (MDP)
which seems the most promising in the investigation of
fracture healing (Hughes 1980).
Most of the research using MDP has concentrated
on the qualitative assessment of scans recorded at two to
four hours after injection. Matin (1979) and Desai et al.
(1980), however, showed that there was increased uptake
at fractures sites. Auchincloss and Watt (1982), in a study
of fractures of the lower leg, demonstrated a significant
relationship between uptake at the fracture site and time
to union; they suggested that the two-hour scan may be of
value in the prediction of delayed healing, though there
was a considerable degree of overlap between the groups
M. A. Smith. MSc, t'hD, Senior Lecturer
Department of Radiological Sciences, United Medical and Dental
School, Guy's Hospital, St Thomas Street, London SI-1 9RT, England.
E. A. Jones, MSc, Senior Physicist
R. K.. Strachan, PRCS, Lecturer
J. J. Nicoll, PhD, Senior Physicist
J. J. R. Best, FRCP. FRCR, Professor of Medical Radiology
P. Tolhill, PhD, FlnstP, FRSE. Reader in Medical Phvsics '
S. P. F. Hughes, MS. PRC'S F.d. FRCS. FRCSI, 'Professor of
Orthopaedic Surgery
Departments of-Medical Physics and Medical Engineering, Orthopae¬
dic Surgery and Medical Radiology, The Royal Infirmary, Edinburgh
F.II3 9YW, Scotland.
Requests for reprints should be sent to Mr M. A. Smith.
;c; 1987 British Editorial Society of Bone and Joint Surgery
0301 620.X 87/3099 S2.00
in their study. However, Jacobs et al. (1981) and Gregg,
Bursoum and Clayton (1983) came to the opposite
conclusion. The only previous report on MDP uptake
very soon after injection was a small study (Jacobs et al.
1981) which demonstrated a relationship between the
rate of uptake and time to union.
It has been shown that the MDP uptake at two to
four hours after injection is a function of both regional
blood flow and bone formation (Lavender et al. 1979).
Given the relatively slow transfer of MDP from blood
through the bone fluids to bone itself with a peak at about
one hour (Hughes et al. 1978; Maklerand Charkes 1980),
the uptake of MDP soon after injection should be largely
dependent on blood flow alone. If the interruption of
blood flow in the bone is the reason for the number of
tibial fractures which fail to unite, then MDP uptake,
particularly soon after injection, could be a valuable
predictor of non-union. If bone blood flow is the
predominant factor, then it is important that studies be
made when the reactive increase in blood flow is
maximal.
Previous studies using MDP to investigate fracture
healing (Jacobs et al. 1981; Auchincloss and Watt 1982)
have demonstrated that various indices are related to the
time to union. Our aim was to conduct a prospective
study to investigate the differences in early uptake of
MDP between patients obtaining union in normal time
and those developing non-union. We hoped to develop a
technique which could predict non-union soon after
fracture in order to allow consideration ol an early
prophylactic operation.
PATIENTS AND METHODS
All patients aged from 16 to 55 years with a fractured
tibia and a normal contralateral limb admitted to the
Royal Infirmary. Edinburgh from January 1982 to July
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Table 1. Details of the 73 tibial fractures included in the study
Number
Fracture of tibia and fibula 62






















1984 were considered for this study. Exclusions were
those with severe multiple injuries and those who
declined to take part. In all, 86 patients were accepted
into the series, but 13 were subsequently withdrawn
because of clinical problems or failure to attend. We
accepted all types of tibial fracture (Table I) and all
methods of management. There were 27 patients aged 15
to 19 years, 36 aged 20 to 29 years, 12 aged 30 to 39 years
and 11 aged from 40 to 55 years.
In addition to the routine of management, each
patient was examined by the same orthopaedic surgeon
at monthly intervals in order to assess the state of healing
of the fracture. He had no access to the results of the bone
scan but, using a combination of radiographic and
clinical criteria, recorded each patient as showing union,
delayed union or non-union. Normal union was recorded
for the fractures which had united within four months,
and delayed union where fractures had united between
four and six months. Non-union was recorded for those
fractures which had not united by six months.
Our aim was to perform quantitative bone scans at
two, six and 12 weeks after the injury. These times were
chosen for a number of reasons. After a fracture there is
an immediate decrease in blood supply to that bone; this
is followed by an increase which reaches a maximum
after 10 to 14 days in the canine tibia (Paradis and Kelly
1975; McCarthy and Hughes 1984). This increased blood
flow is associated with new bone formation as the
fracture heals. Two weeks after injury is a suitable lime
with respect to the mobility of the patient, and is also the
time when the increased blood flow should reach a
plateau. Operation for failure to unite is commonly
considered after about 12 weeks; Jacobs el al. (1981)
were able to show a difference in uptake between cases of
delayed and of non-union at this lime. We therefore
performed a scan at 12 weeks and also at tin intermediate
time to assess the healing process. The work of Lund et
al. (1978) suggested that six weeks was an appropriate
time.
At each visit, each patient was given an intravenous
dose of 200 MBq of 99mTc-MDP; this is one-third of the
dose normally given for a routine bone scan. Before the
injection the radioactivity of the syringe was measured
by scintillation counter against a 99n'Tc-MDP standard
which was approximately 1% of the injected activity.
The patient was positioned supine on a scanning bed
below which a gamma camera had both lower legs in its
field of view. A Technicare 110 gamma camera with a
high sensitivity collimator and an MCS-560 computer
processor were used. The 99mTc-MDP was administered
as a bolus injection in the right antecubital fossa and was
flushed through with 20 ml of saline. A dynamic series of
30 x 10 second images were obtained from the time of
injection for 300 seconds. After this a static image was
collected from 300 to 800 seconds post-injection. This
static image was termed the "early uptake". After about
two hours the patient returned to the scanning room and
was positioned as before. A 300 second static scan was
then collected which was termed the "late uptake". This
late uptake scan was obtained with the same gamma
camera but with a medium resolution, lower sensitivity
collimator. After each early and late uptake scan the
99mTc-MDP standard was placed in the centre of the
collimator field and measured for 100 seconds so that the
absolute uptake at the fracture site could be determined.
The results from the bone scans were analysed using
the computer to measure the radioactivity within regions
of interest (Fig. 1). These were defined as: A, round the
Diagram to show the regions of interest A. B. C and D in
iclation to the site ,of the fracture.
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fracture site; B, over normal bone on the contralateral
limb at the corresponding level; C, over normal bone
above the fracture site; and D, over a corresponding
region on the contralateral limb. When the fracture was
too high in the tibia for enough normal bone to be
available above it, region C, and therefore region D also,
were chosen in normal bone below the fracture site. The
selection of these regions of interest was made by the
same author (EAJ) on each occasion after study of a
radiograph of the fractured bone. The late uptake scan
was often used to assist in the retrospective choice of the
regions for the early scan. The measurement of MDP
uptake from the images and the assessment of fracture
healing were both performed double-blind. The ratios of
A/B, A/C, C/D and (A/B) +- (C/D) were noted, after
each result had been normalised for area. The latter two
ratios were measured for comparison with the results of
Auchincloss and Watt (1982). The attenuation of
141 keV gamma photons through the plaster on a
fractured leg was between 3% and 5%, which is too small
to distort the ratios significantly.
Since our results depended on the choice of the
regions of interest, both intra-operator and inter-
operator variations were investigated. The scans of 20
patients were re-analysed six months after the initial
analysis by the original observer (EAJ) and the variation
between measured uptakes at the fracture site were
noted. Inter-observer variation was assessed by an
independent re-analysis of the most appropriate ratio by
a second observer using all the scans (JJN). Differences
in the sensitivity and specificity of the technique
between the two observers were noted. The sensitivity of
the prediction of non-union was defined as the propor¬
tion of patients developing non-union who could have
been correctly identified. The specificity was defined as
the proportion of patients obtaining normal union who
could have been correctly predicted.
In addition, activity profiles along the length of the
bone in the fractured leg were investigated. We also
studied the automatic determination of the region of
interest by the computer, and a range of computer
programs was developed to define this region. After the
operator had identified the approximate position of the
region of high uptake at the fracture site, the program
then included all pixels which showed more than a given
percentage of the maximum uptake; cut-off' levels of
70%, 80% and 90% were investigated.
RESULTS
Of the 73 patients admitted into the study, not all
attended on all three occasions. Although it had been
intended to obtain scans at two weeks, precise timing
was not possible, so we analysed scans taken at the "first
visit" from between one and four weeks after fracture.
Two patients had evidence of infection at the time of
scan and these results were excluded since infection is
known to increase MDP uptake (Hughes et ai. 1986).
There were fewer exclusions from the results of scans
taken between five and eight weeks after fracture,
referred to as the "second visit", or between 10 and 15
weeks after injury, the "third visit".
The mean ratios obtained at each visit for the three
groups of patients are listed in Table II. As would be
expected, the ratios of most interest (A/B and A/C) tend
to decrease in the patients who eventually showed non¬
union. For these ratios, the "non-union" group has a
lower mean than the. "union" group for both the early
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Table III. The t value and sign
groups with union and with non
ilicunee of the difference between the
union (Table II) for the ratios A C and
A, 13 on early and late uptake
Ratio t value of difference Significance
first visit
Early uptake- A/C 3.2 p < 0.005
A, B 1.3 NS
Late uptake A/C 3.5 p < 0.005
A, 13 0.8 NS
Second visit
Early uptake A,C 0.2 NS
A/B 1.7 NS
Late uptake A,C 2.6 P < 0.05




A/C 2.1 P <
A/B 1.6 NS




and hue uptake at each visit. Table 111 records the
significance of the difference; between the union and the
non-union groups for each of the three visits and for the
different ratios. As expected from other reports, there is
frequently a significant difference between the groups
designated union and non-union.
However, the degree of overlap between the results
from these groups is more important; an indication of
this overlap can be obtained from comparison of the /
statistic for each group. The t values indicate that the
best separation between the union and non-union groups
can be obtained from the A/C ratio at the first visit. The
only other significant differences between groups
(p <0.05) were obtained from the A/B -=- C/D ratio of
the late uptake, recorded at the first visit and the second
visit. Moreover, at the first visit the best separation of all
was that obtained by using the A/C ratio of the "early





The results of the early uptake A/C ratio at the
first visit related to the time to union. The dashed
line represents the ratio 1.3.
A/n late upt.iKe
second visit




Results for the late uptake A/B ratio at the second
visit related to the time to union.
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Tabic IV. T he sensitivity and specificity ol early uptake A/C" ratio at the first visit in predicting non-union using three different ratios as cut-oil
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the late uptake A/C ratio was higher than the corre¬
sponding early uptake ratio, this was due to very high
A/C values in the union group at late uptake even though
separation was not as good. The possibility of improving
the separation by using both early and late A/C ratios at
the first visit was investigated. The product of these
ratios gave no better separation between the groups than
the early uptake A/C ratio at the first visit on its own.
The late uptake A/B ratio at the second visit is shown in
Figure 3.
The absolute uptake in region A, as a percentage of
the injected activity, was calculated but no significant
differences were found between the union and non-union
groups at either the early or late uptakes at any of the
three visits. No significant differences between the
groups were found when the rate of uptake immediately
after injection was calculated from the initial series of
dynamic images.
The predictive value of the two-week, early uptake
A/C ratio was investigated. The intra-observer variation
in the analysis of these results was found to be a mean of
6% between the measured uptake at the fracture site on
two occasions six months apart. More important,
however, is the inter-observer variation, as the
investigator's choice of the region C will have important
implications. The sensitivity and specificity of the early
uptake A/C ratio at two weeks was calculated
independently by two of the authors using different A/C
cut-off values and the results are given in Table IV. As
expected, there are differences in the ratios and these are
reflected in the variation in the sensitivity and speci¬
ficity. It appears that a cut-off value of 1.3 for the ratios
provides an acceptable compromise between sensitivity
and specificity. Sensitivity varied from 63% to 84°/ and
the specificity was from 91% to 88% for the two
operators. Neither the use of longitudinal profiles or of
computer programs to define the region of interest
provided any improvement over a skilled operator, and,
in fact, the results were significantly worse.
The timing of the early scan at the first visit is
important in relation to the time of injection but less so
with regard to the time since fracture. In eight patients,
upiake was measured from a 15-minute dynamic series of
nmig.es; this showed a steady increase in the activity at
the fracture site, and there was little variation from
patient to patient (Fig. 4). This finding suggests that the
A/C ratios illustrated in Figure 2 are likely to differ
significantly if the measurements are performed at a
different time after injection of the isotope.
The variation of early uptake A/C ratio with time
since fracture in patients having normal union is
illustrated in Figure 5. During the period from one week
to four weeks after fracture there was no correlation
between the A/C ratio and the time since fracture. Four
patients had scans even earlier, between one and seven
days after fracture, though these results were not
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Fig. 5
Results lor the early uptake A/C ratio at the first visit related to time since fracture. The
open circles represent patients who were imaged less than one week after injury and
were not included in the detailed analysis.
a very low ratio whereas those scanned after six days had
results similar to those of the other patients. We
concluded that the timing of the first scan after fracture
is not particularly crucial to the ratio. Inspection of the
bone scan images showed no appearance which was
indicative of union or non-union, and in particular, no
evident cold spots were seen in the scans of patients who
proceeded to non-union.
DISCUSSION
Our results suggest that a quantitative MDP bone scan
can help to predict non-union, but that the contralateral
normal bone, as used by previous workers, does not
provide a useful control site. Enough separation between
the groups to enable a prediction to be made in an
individual patient can only be achieved by using a
normal ration in the same limb as control.
One hypothesis is that, since disruption of the bone
blood flow may be related to non-union, the early uptake
result, which is predominantly related to blood flow, will
be a better predictor than the late uptake, which is
related to both blood How and bone formation. This
hypothesis can be extended, since it also explains why
Lhe greatest separation between the increased bone blood
flow in bones which will unite, and its reduction in bones
which will fail to unite, will be obtained at around the
time of the maximum increase of blood flow. This period
is likely to be nearer two weeks after injury than six or 12
weeks, and this explains our findings.
After a fracture blood flow increases to the whole of
the bone, not just to the fracture site. This is why the use
of a control region in the fractured limb rather than, as
commonly chosen, a region in the contralateral normal
leg, can compensate for variations between patients of
the overall increase in blood flow. Thus the A/C ratio will
reflect variations in uptake at the fracture site alone. This
may explain the smaller spread of the A/C ratios in the
group obtaining union (coefficient of variation 23%) as
compared with the A/B ratios of 42%.
Our results are in broad agreement with those of
other workers. The mean values of the A/B -r C/D and
C/D ratios agree well with those reported by Auchincloss
and Watt (1982), and the inverse relationship they found
between the late uptake C/D ratio at six weeks and the
time to union is also confirmed. Auchincloss and Watt
(1982) state that this finding is "difficult to rationalise
and no data are available to explain this observation". A
possible explanation is that the fracture produces a
general increase in blood flow and activity at C is
increased relative to D. As the fracture heals, blood flow
decreases and uptake at C decreases; failure to unite may
result in the continued higher activity at C, resulting in
the increased C/D ratio for those with non-union. This
theory is substantiated by our results; the C/'D ratio is
similar in the union group at two weeks to that in the
non-union group at six weeks.
Jacobs et al. (1981) also used a control region in the
fractured limb and investigated early uptake, but our
uptake curves over the first 15 minutes (Fig. 4) are
significantly different from the example given in their
paper. We do not agree that the uptake between 7 min
and 15 min is a "linear phase" which is "more an index
of the affinity of the bone for phosphate and thus
correlated with bone formation". Our images of the late
uptake from one day to three weeks after fracture
confirm the findings of Gregg et al. (1983) that "neither
the presence of a cold spot nor any other scintigraphic
feature could be correlated with the progress or time to
fracture union". It must be noted, however, that we were
using a high sensitivity collimator with consequent low
resolution.
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The early uptake A/C ratio at the first visit
demonstrates a separation between patients proceeding
to union and those who develop non-union, and there are
acceptable levels of sensitivity and specificity at a cut-ofT
level of 1.3, even when different operators are analysing
the results. However, the same data has been used both
to develop and to assess the accuracy of the various cut¬
off values, so the values for sensitivity and specificity
may be over-optimistic. There is therefore a need to test
the technique in a further prospective study.
There are important practical implications for the
timing of measurements. The fact that the best results
were achieved as early as two weeks after fracture would
allow changes to be made in the management of the
patient far earlier than by other methods and these
changes could reduce the mean time to union. The
routine application of the technique is relatively easy
because the "early uptake" can be investigated in only 10
minutes of the patient's time. The proportion of our
patients recorded as suffering non-union was higher, at
20%, than the 13.5% quoted in a larger study by
Ramadier et al. (1981). The reason is probably that we
defined non-union as failure at six months; this is an
important interval for clinical decision on further
management. Auchincloss and Watt (1982) used the
terms delayed union or unsatisfactory union for these
patients and also had a lower incidence (11.5%) than in
our study. This difference may be due to the higher
proportion of severely injured limbs in our study: we had
16% and 66% respectively in Groups III and II (Ellis
1958) compared with 9% and 33% in Auchincloss and
Watts' series.
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Abstract
Two hundred and twenty-five premenopausal women were
studied to evaluate age-related changes in trabecular bone
mass. Measurements were made at the lumbar spine and
femoral neck by dual photon absorptiometry. It was found
that spinal bone density increased significantly from the 20s
to reach a peak in the mid-30s. Identical trends were ob¬
served in total bone mass and bone mass normalized by
length. Bone loss then proceeded at a rate of 1% per year,
and by the early 50s, 10% of peak spinal density was lost.
There was no peak in femoral neck density; loss commenced
in the late 20s and continued at a rate of 0.4% per year. The
cumulative premenopausal loss from the femur at 9% was
comparable to that in the spine. It is concluded that signifi¬
cant amounts of trabecular bone are lost from both the spine
and femoral neck before the menopause. The implications of
these findings for the prevention of osteoporosis are dis¬
cussed. ^
Key Words: Bone density-Dual photon absorptiometry-
Menopause.
Introduction
Age is well recognized as an important determinant of
bone density, but the natural history of age-related bone
loss remains controversial. In women, cortical bone den¬
sity shows little or no diminution until the menopause
which is followed by a period of rapid bone loss (Riggs et
ai. 1981). Advances in technology have led to the introduc¬
tion of dual photon absorptiometry and quantitative CT
scanning and these techniques make it possible to measure
bone density at the spine and femur, the clinically impor¬
tant sites where osteoporotic fractures tend to occur.
These areas have a significant trabecular bone component
and evidence is accumulating that cortical and trabecular
bone exhibit different patterns of loss.
Three patterns of age-related changes in trabecular
bone have been described. Riggs et aL (198l)demonsirated
loss commencing in "young adulthood" arid continuing in
a linear manner throughout life. A second model suggests
that trabecular bone behaves in a similar way to cortical
bone; it is maintained until the menopause when loss com¬
mences (Aloia et al. 1985; Sambrook et al. 1987). Other
groups have shown that trabecular bone mineral reaches a
peak in the tnid-30s. and this is followed by a progressive
Table I. Characteristics of the study population.
Age group Height (m) Weight (kg) Pill use (year)
(years) n mean ± SD mean ± SD mean
18-22 •v. 5J 1.65 ± 0.06 59JO ± 8.07 ; 1 5
21-25 69 1.63 ± 0.14 58.90 ± 7.11 ■ yr. ; - . JA
24-28 41 1.65 ± 04)6 57J8 ± 12.0 2.9
27-31 33 1.63 ±0.21 61.79 ± 10.0 2.9
30-34 27 1.66 ± 0.06 63.44 * 9.59 3.1
33-37 19 1.62 ± 0.08 62.17 ^ 11.5 2.3
36-40 28 1.62 ± 0.05 57.00 ± 17.0 2.0
39-43 30 1.62 ± 0.05 62.20 ± 9.99 1.8
42-46 23 1.63 ± 0.05 64.83 ± 8.36 2.0
45-49 17 1.60 ± 0.04 65.90 ± 11.2 2.5
48-52 15 1.56 ± 0.02 75.00 ± 14.3 1.9
1
2 A. Rodin et al.: Premenopausal bone loss in spine and femur
loss (Krolner and Pors-Nielsen 1982; Cann et al. 1985). The
aim of the present study is to establish the pattern of age-
related alterations in trabecular bone in normal Caucasian
women. An understanding of these changes may suggest
alternative approaches to the prevention of osteoporosis.
Patients and Methods
Patients
The study population consisted of 225 Caucasian women
whose ages ranged from 18 to 52 years. Women were re¬
cruited from the hospital staff and from outpatient clinics;
approximately 50% of volunteers in each age group were
staff members. They were all premenopausal with regular
menstrual cycles. Subjects had no relevant medical his¬
tory. and in particular, there was no history of bone or joint
disease. None of the women were taking medication
known to influence bone density. Women with a daily cal¬
cium intake of less than 500 mg, as assessed by question¬
naire, were excluded as were those with a history of an¬
orexia nervosa. In all cases, body mass index was <25
(weight in kilograms/(height in meters)2). The character¬
istics of the study population are shown in Table I. Height
and weight were similar in all age groups with the excep¬
tion of the oldest group which was significantly shorter and
heavier than other age groups. Current and past pill users
were included in this study; we have previously shown that
combined oral contraception does not influence bone den¬
sity (Rodin et al. 1987).
All subjects gave informed consent for the study and
approval was granted by the Ethical Committee, Guy's
Hospital, London.
Methods '".-A-'.
Individuals attended for densitometry on entry to the study
and there was no grouping of measurements with time ac¬
cording to age. All scans were performed and analyzed by
the same technician. Bom: mineral was measured at the
lumbar spine (L2-L4) and at the neck of femur by dual
photon absorptiometry using a Novo 22a dual photon ab-
sorptiometer. Total bone mineral (BM), bone mineral per
unit length (BM/L) and bone mineral per unit area or bone
mineral density (BMD) were measured at both sites. The
units used were respectively, grams hydroxyapatite (gHA),
grams hydroxyapatite per unit distance between the top of
L2 and the bottom of L4 (gHA/cm) and grams hydroxyapa¬
tite per unit area of L2 to L4 (gHA/cm2) as measured by
the edge detection algorithm. Reproducibility data was ob¬
tained by repeated measurements in 10 subjects at both
sites at 12-week intervals, giving a precision of 2.2% for
BM, 2.6% for BM/L and 2.0% for BMD in the lumbar
spine, and 2.2% for BMD in the femoral neck.
In the analysis of the data subjects were grouped ac¬
cording to age. Overlapping 5 year groups were formed
(18-22 years; 21-25 years; 24-28; 27-31; 30-34; 33-37;
36-40; 39-43; 42-46; 45-49 and 48-52). The mean BMD
and standard error of mean were calculated for each group
and plotted against the mean age for that group. Non-linear
regression analysis was also performed on the whole data
set. In order to confirm that the observed trends were inde¬
pendent of normalization, non-linear regression analysis
was also performed on the BM and BM/L data in the spine.
The significance of the difference between BMD at dif¬
ferent ages was assessed using Students t test for unpaired
data. To further analyze the significance of any visually
identifiable peak linear regression, analysis was performed
and rate of change in bone density was calculated.
Results
Second and higher order polynomial fits confirmed the ex¬
istence and position of a peak in spinal BMD. Further con¬
firmation was provided by the data on BM and BM/L (Fig.
1). The data were significantly correlated with a curve with
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Fig. 1. Spinal BM, BM/L and BMD plotted against age for 225
premenopausal women. Second order polynomial fit shown.
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correlation with a linear fit. There was a 5% increase in
spinal bone density between the age groups 18-22 and
33-37 which was significant (p = 0.03). This was followed
by a progressive decline at a rate of 1.0% per year. By the
early 50s. 10% of peak spinal bone mass was lost and this
represented a significant fall (p = 0.016) (Fig. 2).
A different pattern was exhibited by the femoral neck,
the raw data of which showed a linear correlation with age
(r = 0.31. p < 0.001). No improvement in fit was obtained
using a second or higher order polynomial. Our study did
not demonstrate a peak in femoral bone mass and loss of
mineral commenced in the late 20s. The rate of loss was
slower than that seen in the lumbar spine at 0.4% per year,
however, by the early 50s, 9% of femoral bone mass was
lost which represented a significant premenopausal fall (p
= 0.012) (Fig. 3).
Discussion
In this study, we have demonstrated that significant pre¬
menopausal bone loss occurs from both the lumbar spine
and neck of femur. Spinal bone density increases in the 20s
to reach a peak in the mid-30s and then falls in an almost
linear fashion. The femoral neck shows a different pattern
of bone loss: peak density is presumably attained at an ear¬
lier age which cannot be defined from the present data.
The rate of loss is slower than that seen in the spine, but as
bone loss commences at an earlier age, by the late 40s the
cumulative loss from peak density at both sites is compa¬
rable.
Previous studies offer conflicting evidence about the oc¬
currence of premenopausal bone loss and the patterns of
age-related changes in bone mineral. In a cross-sectional
study of 105 normal women, Riggs et al. (1981), found that
bone loss from the vertebrae begins in young adulthood
and is linear. However, the bulk of evidence now conflicts
with this early model. Krolner and Pors-Nielsen (1982) ex¬
amined lumbar spine bone mineral content in 70 women in
relation to age. By Fitting the data to a gamma variate func¬
tion they showed a maximum spinal density at 34 years,
but this method of statistical handling has been criticized
(Tothill et al. 1983). Their own results support the view that
there is increased loss of spinal bone mineral after the
menopause, but insufficient numbers prevent detailed
analysis in premenopausal women. This limitation also ap¬
plies to other studies. Nilas and Christiansen (1987) carried
out a cross-sectional study of 178 healthy women and
found no evidence that substantial premenopausal bone
loss occurs from any site. Hansson and Roos (1986) in
agreement with our findings, noted a continuous age-re¬
lated decrease of spinal bone density after the age of 35.
Mazess et al. (1987) with a heterogeneous study population
of 892 women derived from seven centers found a 10% de¬
crease in spinal density in the decade preceding the meno¬
pause. A similar pattern was shown for femoral bone den¬
sity. Schaadt and Bohr 11988). in a recent study, found that
the bone mineral content of the femoral neck decreased
linearly from the 30s. Premenopausal bone loss is also sug¬
gested by histomorphometric studies (Meunieret al. 1973:
Marcus et al. 1983) and by postmortem investigations
(Weaver and Chalmers 1966: Arnold 1973). The differing
descriptions of age-related changes in trabecular bone are
probably explained by technological differences, differ¬
ences in data handling and differences in the sample sizes
between the groups. Sambrook et al. (1987) pointed out the
pitfalls of using cross-sectional data to draw conclusions
about longitudinal changes in a population, and they em¬
phasized the importance of adequate sample size.
Our data and results from previous studies provide a
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Fig. 2. Spinal BMD plotted against age in 225 premenopausal women. Mean BMD was calculated for 5 year overlapping groups and
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Fig. 3. Femoral BMD plotted against age for 225 premenopausal women. Mean BMD was calculated for 5 year overlapping groups and
plotted against the mean age for that group.
ular bone occurs before the menopause. The finding of a
peak in spinal bone density is supported by similar trends
in BM and BM/L suggesting that this phenomenon is inde¬
pendent of area normalization. The significant increase in
spinal bone density between the 20s and mid-30s may have
important implications for the prevention of osteoporosis
in later life. In addition, our study provides further evi¬
dence that trabecular bone at different anatomical sites ex¬
hibits different patterns of age-related density changes, but
the reason for this variation is not fully understood.
The possibility that these patterns of changes in trabec¬
ular bone are biased by secular trends needs consideration.
It seems unlikely, however that the rise in spinal density
seen between 18 years to the mid-30s could be due to such
influences. The relatively short time scale argues against a
secular effect. However, we cannot rule out the possibility
that the differences between those at the age extremes of
the study population are influenced by secular effects.
The mechanism of early bone loss remains unclear. The
importance of oestrogen in maintaining skeletal bone mass
is well established and there is evidence for accelerated
bone loss after oophorectomy (Cann et al. 1980) or fol¬
lowing a natural menopause (Gennant et al. 1984). Oes¬
trogen replacement therapy is effective in preventing post¬
menopausal bone loss (Lindsay et al. 1976). However, the
menopause is preceded by a transition phase which is char¬
acterized by rising gonadotropin levels and falling total
oestrogen output from the ovaries (Sherman et al. 1976). It
therefore seems likely that the patterns of endocrine
changes will vary between individuals, and we suggest that
genetic and environmental factors interact to influence the
timing and profile of the hormonal fluxes associated with
the menopause. A proportion of women will therefore be-
comge relatively oestrogen deficient before the cessation
of their menses, and it is well known that some develop
vasomotor instability and genital atrophy during the cli¬
macteric. It has been suggested that this relative deficiency
of oestrogen may contribute to the loss of trabecular bone
in premenopausal women (Johnston et al. 1985). It is pos¬
sible that this effect contributes to spinal bone loss which
commences in the mid-30s, but it does not adequately ex¬
plain the pattern of loss seen in the femoral neck.
Prevention of osteoporosis is an important goal, and
while hormone replacement therapy in the early premeno¬
pausal years is of proven efficacy (Lindsay et al. 1976), our
findings raise the possibility that prophylaxis in premeno¬
pausal women should be considered. Two potential ap¬
proaches are suggested: (a) spinal bone density increases
in the young woman until the mid-30s, and if this can be
enhanced the peak spinal bone density can be maximized;
(b) if bone loss in the climacteric can be prevented or re¬
duced, women would again reach the menopause with a
better reserve. Exercise and calcium supplementation may
be suitable strategies, but before any measures can be rec¬
ommended they must be fully evaluated and ultimately
they must be shown to reduce fracture risk.
Acknowledgment: We would like to acknowledge the assistance of
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Abstract. The reproducibility of two methods of measuring broadband ultrasonic attenuation
(bua) in the calcaneus have been studied. An improvement in reproducibility in vivo from 9.6%
to 2.8% between old and new techniques has been observed. Measurements of the calcaneus
using bua were correlated with measurements ofbone mineral density measured by dual energy
x-ray absorptiometry in the lumbar spine, femur and total body and bone mineral content in
the distal and proximal forearm measured by single photon absorptiometry. For the older bua
technique the correlation coefficients ranged between r = 0.27 and r = 0.34. For the newer
bua technique the correlation coefficients ranged between r = 0.49 and r = 0.62 and were all
significant (PCO.OOl).
1. Introduction
Osteoporosis affects an increasing fraction of the elderly population and can result in
fractures of the wrist, spine and hip. Bone loss is more rapid from these sites of high
trabecular content (Genant and Cann 1981). Non-invasive bone measurement for the
management and diagnosis of osteoporosis is currently carried out using single photon
absorptiometry (spa) of the forearm (Cameron and Sorenson 1963), dual photon
absorptiometry (dpa) of the spine (Roos and Skoldborn 1974) and more recently by dual
energy x-ray absorptiometry (dexa) of the proximal femur, lumbar spine and total body
(Mazess et al 1989). Whilst all these methods are reasonably precise and accurate they do
expose the subject to ionising radiation and they only measure the area density (g cm-2) of
the bone.
Langton et al (1984) suggested that measurement of broadband ultrasonic attenuation
(bua, dB MHz-1) of the calcaneus can give a direct interpretation of the structure of the
bone as well as bone density. The calcaneum is chosen as it is a site containing a high
percentage of trabecular bone and may have a composition similar to other bones, such as
the vertebrae and femur, which are more commonly measured for bmd. Poll et al (1986)
later suggested that a reproducibility figure for this method of 3.9% could be obtained by
measuring both heels and taking the average bua value. Since then, other workers have
obtained improved reproducibility values in vitro for the method of 2.2% (McKelvie et al
1989) and 2.4% (McCloskey et al 1990a). The majority of the bua measurements reported
by other workers were made using the original commercial machine which measured bua,
the Walker Sonix UBA 1001, which has since been superseded by the Walker Sonix UBA
575.
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In this study we examine the reproducibility of both the old and new techniques for
measuring bua in the calcaneus and correlate them with spa of the forearm and dexa of the
lumbar spine, femur and total body. The normal variation of the newer bua technique and
comparison with dexa of the spine and femur is also assessed in a group of women in whom
we measured bua of the calcaneus and bmd of the femur and spine on the same day.
2. Methods
2.1. Ultrasound equipment
We measured bua in the right heel using two machines, the Walker Sonix UBA 1001 and
the Walker Sonix UBA 575. With the UBA 1001, the patient sits with his/her foot in a room
temperature water bath between two fixed 25 mm diameter transducers, both resonant at
1 MHz, one acting as a transmitter, the other as a receiver. The aim was to position the
foot accurately so that the calcaneus lay between the two transducers. A series of short
bursts of varying ultrasound frequency from 200 - 600 kHz in 16 kHz steps is transmitted
through the water without the foot in the bath and the transmitted amplitude at each
frequency recorded. A similar series of measurements is made through the water with the
heel inserted in the bath. As the difference between the ultrasound signal amplitude for
water and for water plus heel at each frequency sample point is due to the attenuation
caused by the heel, an attenuation spectrum can be constructed. The slope of the best
straight line fitted to this spectrum (dB MHz"1) is the reported measurement of bua. The
measurement is repeated until three consecutive values are obtained that are within
0.5 dB MHz-1 of each other. This usually takes about 3 min, the delay probably being
caused by air trapped in the pores which is released in this period.
The fundamental basis of the UBA 575 is the same as the UBA 1001 but several changes
in technique have been made. The transducers have been changed to 19 mm diameter with
500 kHz resonant frequency and signal amplitudes are recorded at 12 equally spaced
intervals between 200 and 600 kHz. The heel is still placed in a water bath but now the
transducers are made to carry out a rectilinear scan of nine sample points on a 3 x 3 grid
in a region of 22 mm x 22 mm located around the region of minimum density in the
calcaneus. This region was located by the manufacturers from a study of x-ray films of the
calcaneus. The calculation of bua at each of these sample points is done as previously but
the nine values obtained are subjected to a weighted averaging algorithm to produce a single
value for bua. The total measurement time is about 5 min.
2.2. Wetting agents
One problem with bua measurement in water is that air nucleates on the skin and surface
hair forming bubbles at the interface between skin and water. These bubbles cause
anomalous attenuation and can be a source of unreliability in the results. To overcome this
a wetting agent is added to the water and this releases the absorbed air within the water
and on the skin. The detergent recommended by the manufacturer is not widely available
and we had to select another capable of giving reliable results. The detergents (and
concentrations) that we tested were Ark (4%), Ecover (2%,4%), Quadralene (6%,8%),
Stardrops (1%,2%) and Triton X100 (2%). The last of these is a commercial wetting agent
and the remainder household detergents. Ark and Ecover were abandoned as they produced
a precipitate in the water bath which was opaque to ultrasound. Triton X100 was not used
after an initial trial as it tended to gel at room temperature. Using each of the other solutions
we made five measurements of bua using the UBA 575 on each of three phantoms of
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different bua (described in section 2.3). In each case a pooled coefficient of variation (cv)
was calculated and used as an indicator of reproducibility.
Prior to the reproducibility studies we found two other sources of variability in bua
measurement which could be easily removed. The first of these was due to talcum powder
on the feet of patients. This causes a precipitate in the water bath and can be removed by
prebathing the foot before immersion in the scanner. The second source of variability was
due to body oils or creams applied to the heel which can be removed with an alcohol swab
prior to scanning.
2.3. Reproducibility
The in vitro reproducibility studies were performed using phantoms, representing high,
medium and low values of bua which are made by Walker Sonix and are constructed from
room temperature vulcanised silicone in which glass beads are suspended. The phantoms
were stabilised in the scanner so that there was a minimal change in position and orientation
between scans. On the UBA 1001 37 measurements were made on two phantoms (high and
medium bua) over 13 months. On the UBA 575 64 scans were made on all three phantoms
over a period of three months.
The in vivo reproducibility studies were performed using cooperative volunteers who
were measured repeatedly with a reasonable time interval between measurements. On the
UBA 1001 three volunteers were studied on 13 occasions with an interval of about a month
between measurements. On the UBA 575, five volunteers were studied on five occasions
with an interval of one day between measurements. In addition, the short term
reproducibility in vivo was measured from two scans made within five minutes of each other
on 30 female volunteers, the foot being removed from the bath and dried between scans.
The effects of the various detergent solutions as described in section 2.2. was determined
prior to the evaluation of reproducibility of the UBA 575.
2.4. Bone mineral measurement using absorptiometry
We measured bmc in the forearm at two sites using a Nuclear Data 1100A scanner. This
spa technique uses an 125I source of 5.5 - 7.4 GBq activity. The patients' arm is held in a
water bath and the scanner finds the site at which the radius and ulna are separated by an
8 mm gap. From this point five scans are carried out at 4 mm intervals proximally and four
scans at 2 mm intervals distally. The proximal and distal groups of scans are each averaged
and the measurement at each of these two sites is given as bone mineral content normalised
for both fat cover and bone width and expressed in arbitrary units which can be converted
to g cm-2. Nilas et al (1985) report a reproducibility of 1 - 1.5% (coefficient of variation)
for the two forearm scan sites. The skin entrance dose associated with this technique is
between 30 and 50 fiSv.
To measure bmd in the spine, femur and total body we used a Lunar Radiation DPX
scanner. The dexa technique uses a filtered x-ray tube to obtain the dual energy beam
required. The scanning and analysis procedures on this scanner are controlled by the
manufacturers software version 3.2. The measurements we use are the bone mineral
densities (bmd g cm-2) of the lumbar spine (L2-L4), femoral neck, trochanter, Ward's
triangle, and total body. The reproducibility obtained by us for the spine, femur and total
body in vivo are 1.2%, 1.7% and 0.7% respectively. The skin entrance dose per scan
associated with these techniques is 14 jtSv each for spine and femur and 1 /iSv for a total
body scan.
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2.5. Statistical methods
For reproducibility measurements the coefficient of variation has been calculated. With sets
of paired data this is obtained from an analysis of the squares of the differences. For multiple
measurements on subjects the overall cv is obtained from a pooled variance. This analysis
and the calculation of the correlation coefficients was obtained using Statgraphics v3.0 as
were the tests for normality and the pooled Students t-test.
3. Subjects
On the UBA 1001 we made bua measurements on 264 women aged 19 to 81 years (group
1), comprising 131 asymptomatic normals, 83 patients with endocrine disorders, 12 with
asthma and 38 volunteers who were unclassified. Of these women, 261 had spine and femur
bmd and 60 had total body bmd measurements, spa of forearm was also carried out on 249
of these women.
We made bua measurements using the UBA 575 on 191 women aged 22 to 79 years
(group 2), comprising 112 asymptomatic normals, 60 patients with endocrine disorders, 6
with osteoarthritis and 13 volunteers who were unclassified. Of these 190 had spine and
femur bmd and 114 had total body bmd measurements. Forearm bmc measurements were
made on 103 of these women. On the occasions when measurements were made on the same
patient using different techniques they were carried out at the same visit.
The above measurements were made for use in a study of the correlation between the
different techniques of bone measurement and so no exclusions were considered merited.
To study the normal variation ofeach of the methodologies when applied to the same group,
a subset of 70 women aged 50 to 59 years (group 3) was selected from group 2. These
women were taking part in an hormone replacement therapy study and had presented for
prophylactic screening with no symptoms of bone disease and comprise the whole of this
age group. On groups 1 (UBA 1001) and 2 (UBA 575) we performed correlation analysis
between bua and each of the bmd and bmc measurement techniques described above. For
group 3 we calculated mean and standard deviation (sd) for the measurements obtained
using each technique and for each technique we also calculated the coefficient of variation
within the group.
4. Results
In the assessment of the wetting agents the pooled values of cv over the three phantoms
measured on the UBA 575 for Quadralene (6%,8%) were 0.52% and 1.99% respectively and
for Stardrops (1%,2%) were 2.00% and 0.39% respectively. On the basis of these results
we determined to use Stardrops (2%) in our future patient work.
The in vitro reproducibility measured in phantoms over a period of 13 months on the
UBA 1001 was 3.1%, on the UBA 575 the equivalent reproducibility value measured over
a period of 3 months was 2.2%. We measured reproducibility in vivo over a 13 month period
on the UBA 1001 to be 9.6%. On the UBA 575 the reproducibility measured over a 5 day
period was 2.8%. In addition to the above reproducibility measurements we measured the
reproducibility in vivo on the UBA 575 in the short term to be 3.5%.
Summary statistics for subject groups 1 and 2 for each of the measurement techniques
used are given in table 1. The smaller samples used for total body bmd in groups 1 and 2
and the forearm spa samples drawn from group 2 were checked to ensure that the mean
value of bua in these samples was representative of the bua of the group from which they
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Table 1. Summary statistics for group 1 (UBA 1001) and group 2 (UBA 575) for heel bua (dB MHz"1), bmd
(g cm"2) at various sites, bmc (g cm"') in the forearm, height (cm) and weight (kg) comprising sample size (n),
mean, standard deviation (sd), minimum and maximum values.
Group 1 Group 2
n Mean sd Min Max n Mean sd Min Max
Heel bua 264 96.7 20.9 28.2 157.2 191 62.5 14.2 26 99
Spine bmd 261 1.054 0.200 0.503 1.543 190 1.057 0.204 0.520 1.579
Femoral
neck bmd 261 0.879 0.148 0.520 1.333 190 0.868 0.152 0.518 1.343
Trochanter
bmd 261 0.719 0.122 0.366 1.052 189 0.711 0.131 0.421 1.051
Ward's bmd 261 0.743 0.191 0.318 1.290 190 0.752 0.194 0.292 1.213
Total body bmd 60 1.088 0.100 0.887 1.276 114 1.095 0.110 0.786 1.463
Proximal
forearm bmd 249 1.315 0.246 0.750 1.840 103 1.358 0.227 0.800 1.840
Distal
forearm bmc 249 0.969 0.199 0.540 1.510 103 0.977 0.194 0.540 1.450
Height 264 160.5 6.5 144 176 191 160.5 7.5 135 177
Weight 264 63.5 11.4 43 107 191 62.6 10.4 35 93
were drawn. Pooled r-tests revealed no significant differences in bua values between any of
these samples and the group mean values. The correlation coefficients of the different
techniques for groups 1 and 2 and their significances are given in table 2. None of the
variates used in the correlation analysis departed significantly from being normally
distributed. Scatter plots of the correlated variates did not depart from linearity confirming
the validity of the use of correlation analysis. It can be seen from table 2 that although the
correlations between bua and other measurements in group 1 are significant, they are all
relatively weak. Group 2 shows an improvement in the correlation coefficients all of which
are highly significant.
The spread of the normal data in group 3 using the different techniques is given in table
3. Examination of the evs of the various measurements reveals little difference between the
spread of the normal range using the different techniques. The cv of heel bua is, however,
the largest.
Table 2. Correlation coefficients (r), for group 1 (UBA 1001) and group 2 (UBA 575), for various bone mineral
measurement techniques compared to bua in the right calcaneus, with significance values (P) and sample sizes
(n). bmd is measured in g cm"2.
Measurement
technique
Group 1 Group 2
r P n r P n
Spine bmd 0.34 <0.001 261 0.61 <0.001 190
Femoral neck bmd 0.27 <0.001 261 0.60 <0.001 190
Trochanter bmd 0.33 <0.001 261 0.58 <0.001 189
Ward's triangle bmd 0.29 <0.001 261 0.62 <0.001 190
Total body bmd 0.31 <0.02 60 0.54 <0.001 114
Proximal forearm bmc 0.30 <0.001 249 0.49 <0.001 103
Distal forearm bmc 0.29 <0.001 249 0.55 <0.001 103
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Table 3. Summary statistics for heel bua (dB Mhz ') and bmd (g cm 2) comprising mean, standard deviation
(sd) and percentage coefficient of variation (cv) for group 3.
Measurement
technique Mean sd cv
Heel bua 65.61 12.45 18.98
Lumbar spine
bmd 1.06 0.15 14.58
Femoral neck bmd 0.87 0.12 13.96
Trochanter bmd 0.72 0.11 15.53
Ward's triangle bmd 0.75 0.13 17.39
5. Discussion
The reproducibility figures obtained suggested an improvement with the UBA 575 over the
earlier UBA 1001. This was particularly demonstrated by the in vivo data. However, the
in vivo reproducibility data from the two machines are not entirely comparable due to the
differences in time intervals used. The possible presence of a gradual variation in bua using
the UBA 1001 over the 13 month period was investigated by a further analysis of the data.
The reproducibility was assessed from the differences between successive measurements;
this gave a value of 9.4% suggesting that the relatively poor reproducibility was not due
to a gradual long term variation. The improvement in precision in the UBA 575 equipment
is probably due to several factors including a change in resonant frequency of the
transducers, a change to rectilinear scanning, the addition of a foot restraint, the selection
of wetting agent and the thorough cleaning of the foot before placement in the water bath.
Many groups have tried to correlate bua of the calcaneus with different bone
measurement techniques at other sites. With spa of the distal forearm correlation
coefficients of r = 0.8 (Poll et al 1986), r = 0.77 (McCloskey et al 1990b) and r = 0.64
(Rossman et al 1989) have been demonstrated. A study has also been reported which showed
no correlation between bua of the calcaneus and spa of the forearm (Resch et al 1990). For
dpa of the femoral neck Rossman et al (1989) report a correlation coefficient of 0.41 whilst
for the lumbar spine they give r = 0.66. For the spine McGloskey et al (1990b) give
r = 0.72. For all these previously reported studies reasonable numbers (n between 44 and
72) were used for the correlations.
Quantitative computed tomography (qct), a technique developed in different forms by
Cann and Genant (1980) and Ruegsegger et al (1976) has revealed a quite strong correlation
(r = 0.85) between bua of the calcaneus and forearm cortical bone mineral content, but
a far weaker relationship (r = 0.66) with trabecular bone mineral in the same limb (Hosie
et al 1987). However when bua and qct are carried out at the same site correlations of
r = 0.92 in excised os calces (McKelvie et al 1989) and r = 0.80 in calcaneal core samples
(McCloskey et al 1990a) have been observed. Both of these groups report correlations of
bua with physical density of approximately 0.8. However McKelvie et al (1989) rejected
a large proportion of their calcaneal core samples (15%) before correlating physical density
with bua. In the studies using qct the group sizes for correlation analysis ranged between
24 and 28.
The 25 mm core samples measured by McCloskey et al (1990a) were the same diameter
as the ultrasound transducers which may result in significant diffraction artefacts. The core
samples used above were ail taken from similar sites where the structure and orientation
of trabeculae could be expected to be similar. Evans and Tavakoli (1990) used samples taken
from different regions of bovine femora excised at random angles, thus a difference in
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structure and orientation between samples could be expected. This is probably why they
observed such a weak correlation (r = 0.33, n = 27) between bua and physical density.
Unless substantial scattering of the ultrasound beam is occurring the trabecular orientation
should make little difference to the measurement of attenuation. Evans and Tavakoli (1990)
also considered samples with a range of density (1.15 - 1.4 g cm-3) which had a higher
upper limit than other workers. At higher densities errors in the measurement increase,
which would diminish the correlation further.
Comparison of our correlation coefficients, of bua with other techniques, for group 1
(UBA 1001) and group 2 (UBA 575) shows a significant improvement in correlation with
the newer of the two methods of measuring bua. This improvement is probably attributable
to the improvement in reproducibility leading to less variability in bua measurement with
the newer method. When we compare the correlations of group 2 bua with other techniques
to those correlations reported by other workers, with the exception of the femoral neck
(Rossman et al 1989), all our correlations are weaker, although we have substantially larger
groups.
The weak correlations that have been obtained in our study could be due to either or
both of the following factors: (i) bua values may reflect, in some way, both density and
structure. We may, therefore, not expect the correlation with only bone density to be
particularly good, (ii) The correlation between bone density in the calcaneus and other sites
in the body may not be particularly strong.
Other methods of assessing the utility of bua measurements have been suggested in
terms of diagnostic predictive power. Several workers observe that those patients at high
risk of fracture can be sorted from the normal population (Langton et al 1984, Miller and
Porter 1987, Johnson and Porter 1987). Murray et al (1987) showed that patients with
osteoporosis could be identified, Fordham et al (1987) that patients with rheumatoid
arthritis differed from controls and Jones et al (1987) that active and sedentary groups could,
be separated. The problem still remains that, although groups can be separated, given a
single measurement of bua it is often difficult to assign an individual to a group with any
degree of confidence.
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1. Introduction
Single photon absorptiometry (spa) was first suggested by Cameron and Sorenson
(1963) for the measurement of bone mineral content (bmc) in the distal forearm
in vivo and quickly gained currency as a quantitative method of bone mineral measure¬
ment giving a precision of approximately 2% with a radiation dose of approximately
0.15 mGy similar to the dose for a forearm x-ray film exposure. Adaptations of the
method to measure the neonatal forearm met with some success (Steichen et al 1980,
Greer et al 1982) but until 1986 (James et al 1986b) an instrument designed specifically
to measure the forearm bones of premature neonates had not been constructed. With
a dose to the subject of only 0.03 mGy and accuracy of 5% this machine enabled
growth and mineralization data to be obtained for fetal mineralization (Ryan et al
1988), osteopenia of prematurity (James et al 1986a) and the repletion of mineral in
osteopenia of prematurity (Congdon et al 1990).
Unfortunately a subset of preterm babies were too sick to be amenable to this
measurement technique as they could not be moved from incubator to measuring
instrument. In many situations it is important to measure bmc in these babies at this
very early stage and to continue to monitor it in order to evaluate the efficacy of both
treatment and feeding regimes. To study such babies in the incubator it would be
necessary to construct a hand-held instrument which was portable, compact, light and
accurate. Such a device should only expose the baby to a low radiation dose. It was
felt that an isotope transmission device with a radiation sensitive charge coupled device
(ccd) camera offered the likeliest solution to the problem.
2. Methods
The development of ccd video cameras which are sensitive to a range of x and y ray
energies (Arndt and In'T Veld 1988) suggested a method of measurement of bmc in
the forearm using video techniques. The schematic diagram of an idealized version of
0031-9155/92/061391+ 07S04.50 © 1992 IOP Publishing Ltd 1391
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such a system is shown in figure 1. The ideal system would consist of an isotope source
of monochromatic -y-ray photons of sufficient intensity located close to the arm to
make the system as compact as possible. Correction for geometric distortion could be
carried out relatively easily. The forearm would be enclosed in a parallel-sided soft
tissue equivalent bolus material to provide a fixed thickness path in which the only
changes in transmitted intensity would be due to changes in equivalent bone thickness.
The radiation sensitive ccd video camera would convert each y-ray photon arriving
at the detector into a visible light photon which is converted to a specific charge on
the ccd. The video circuitry produces a TV frame every 40 ms in which the grey level
of each pixel is representative of the charge per element on the ccd. This information
is digitized using a frame grabber under computer control. With the frame grabber
operating in real time, the area to be measured could be viewed on the monitor before
the data was captured. Each captured frame would then be added into a frame store
until there were sufficient counts per pixel to reduce the measurement variance to an
acceptable level.
The feasibility of using a ccd camera was investigated using a model of the neonatal
forearm and the following apparatus. The ccd video camera was a Phototonic Science
X-ray Imager on loan for a day from the manufacturers. This camera has a detector
quantum efficiency (dqe) of 10-12% for energies of 5 to 200 keV covering the photopeak
of 125I at 27.5 keV. The effective detector pixels are 80 p,m square working into the
ccd by light pipe coupling to give 753 x 581 pixels. Digitization and sequential frame
addition was carried out using a PC Vision Plus 8 bit frame grabber having two
512x512 pixel frame stores, controlled by an IBM PC using ITEX PC plus software.
The limit of an 8 bit frame store meant that in practice in order to avoid overflow we
could only collect 32 frames which is equivalent to an integration period of 1.28 s. The
source used was an 125I 1 mm point emitter of activity 1.13 GBq.
The forearm was modelled by a water-filled syringe of 21.7 mm diameter located
74.3 mm from the source and 14.0 mm from the detector surface with two aluminium
tubes of diameters 3 mm and 2 mm having a wall thickness of 0.15 mm suspended
centrally in the water. These sizes were typical of neonatal forearm bone sizes measured
on x-rays. The forearm model was measured in air without a soft tissue equivalent









Figure 1. Schematic diagram of an idealized system for measuring BMC in the neonatal
forearm.
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correct for geometric distortion and differences in intensity caused by the cone beam
geometry in the system.
3. Theory
With reference to the transmission image, the bone mass per unit area (MB) can be
calculated pixel by pixel by the application of the following equation:
= Lpb/(PbPb — PsPs)] 1) MB = kBln(I0/1) (1)
where kB = pB/ (pBpB — PsPs)- Pb and Ps are the mass absorption coefficients for bone
mineral (2.40 cm2 g-1) and water or soft tissue (0.35 cm2 g-1) respectively. pB and ps
are the values of density for bone mineral (1.85 gem-3) and water or soft tissue
(1.00gem-3). I is the intensity through 'bone' and I0 is the background intensity. In
the neonatal forearm phantom, bone has been replaced by aluminium having a density
of 2.6989 g cm-3 and a mass absorption coefficient of 4.00 cm2 g-1, thus we can calculate
Ma the mass of aluminium per unit area.
We wished to study the relationship between the precision of the technique and
the exposure time so that the minimum investigation time is achieved. This is particularly
important in the measurement of preterm neonates. The variance of the mass per unit
area is given by




I + Io 1/2
cr(MB) = kB(-jj^) . (2)
4. Results
The transmission image in figure 2 results from the capture of 32 frames of the neonatal
phantom with the experimental system described above. Cursor regions A and C are
60x200 pixels (4.8x16 mm), cursor B is 80x200 pixels (6.4x16 mm) just covering
the width of the larger aluminium tube in the phantom. These represent reasonable
useful sizes for cursors in vivo. The equivalent mass of aluminium was calculated taking
the mean of regions A and C for the background intensity I0. Substituting into equation
(1) produces a value of 0.0909 g cm-2 for MA. This compares well with the known
value of Ma of 0.0864 ±0.0093 g cm-2; a difference of 5.3%.
The variation of the intensity across the phantom bone was studied using a region
250 pixels long but only 2 pixels wide. The plot of intensity across the aluminium
phantom is shown in figure 3. This may be a more appropriate method of analysis in
vivo as interpolation using the through tissue counts may give a more accurate
estimation of the background count intensity.
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Figure 3. Linescan data for measurements of counts made across the neonatal torearm
phantom plotted against distance expressed as pixel number between regions A and C.
Substitution into equation (2) gives a value for cr(MA) of 0.0009 g cm""2. This is
equivalent to a coefficient of variation (cv) of 0.99%. The computed skin entrance
dose for the experimental system with a 1.13 GBq source and an integration period of
1 second is 0.046 jxGy, computed from measurements made on a 3.5 GBq source in a
similar configuration, several orders of magnitude less than the other techniques
mentioned in the introduction. The variation of the theoretical precision versus time
and dose for a 3.7 GBq activity source is shown in figure 4. This shows that at 3.7 GBq
















Figure 4. Graph of the percentage error in the measurement of ma as a function of dose
(p,Gy) and time (seconds).
it could be possible to reduce the integration period to as little as 3 seconds and still
have a theoretical measurement error of less than 0.5%.
5. Discussion
While the physical size of the neonatal forearm means that an increase in cursor size
is unlikely to be achieved, reduction in the measurement error could be brought about
in a number of ways. The source we used in this evaluation was depleted and use of
a fresh source of 7.4 GBq would increase the photon flux by at least a factor of 6. The
position of the source in the experimental system is by no means optimal as the distance
away from the object tends to make the system too cumbersome for use in an incubator.
Moving the source closer to the object would also have the added advantage of
increasing the flux and reducing the exposure time required. The use of a ccd camera
working at video rate into an 8 bit frame grabber and frame store produces a grey
level limit of 256 levels per pixel effectively limiting exposure time to 1.28 s with the
photon flux available to us before overflow started to occur. The exposure time will
be reduced with a higher flux source but will still only give a grey level resolution of
256 levels. An increase in grey level resolution could only be achieved by the use of
a higher resolution frame grabber of 12 or 16 bits. Further, the system that we used
in the feasibility experiment is by no means ideal as the addition of each captured
frame into the frame store took about 30 seconds. This limit could be overcome in
two ways. Firstly, by staying with the same technology and using higher resolution
frame grabbers and stores with virtually instantaneous summation facility, which
although increasing the cost considerably would allow the retention of real time viewing
of the measurement site. The second possibility is to switch from real time video mode
to still camera mode where the x-ray sensitive ccd is operated in integrating mode,
exposed for a fixed period and then the charge is read off and converted to a digital
signal directly representing photon events per pixel. This system loses the ability to
view the measurement site at the time of measurement and suffers the further disadvan-
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Figure 5. Image of the sum of 32 frames of raw data obtained from measurement of the
distal and middle inter phalangeal joint of the middle finger in an adult.
tage of requiring to be cooled to liquid nitrogen temperatures to suppress electronic
noise in the device. Both these techniques would allow us to increase exposure time
to 10 s which we feel is the limit imposed by subject movement.
It may be possible to avoid using a bolus for the baby's arm altogether if we can
adequately fit a line representing the background intensity. If this cannot be done
satisfactorily then the tissue equivalent bolus need not be parallel sided. It may be
possible to produce a short source to detector distance and a non-linear bolus geometry
which could compensate for any variation in path length.
Although the technique was originally envisaged for the measurement of neonatal
bmc there is no reason why it should not be extended to the adult appendicular
skeleton. Figure 5 shows an image of the distal and middle inter-phalangeal joint of
the middle finger of an adult captured using the evaluation system. The manufacturers
have indicated that they could reduce the size of the video camera to 164 mm, with
the drive electronics housed up to 1 metre away, making it feasible to place such a
system in an incubator. In either neonates or adults this technique could provide a
quick and accurate method of measuring bmc in the appendicular skeleton which may
be adapted to suit many measurement environments and different measurement sites.
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SUMMARY
The association of OA with increased bone mass is controversial. This study measured BMD at the hip and spine and total
body bone mineral (TBBM) by dual energy X-ray absorptiometry, and BMD at the distal forearm by single photon
absorptiometry in 20 post-menopausal women with primary generalized OA. The data were compared with those from 89
normal controls. Osteoarthritic women had significantly increased BMD at the spine (P<0.001), distal forearm (P<0.05)
and increased TBBM (F<0.01), but no difference was seen at the femoral neck. These differences were not explained by
obesity. The influence of mobility is discussed.
Key words: Dual energy X-ray absorptiometry, Single photon absorptiometry, Spine, Distal forearm, Femoral neck.
Although the negative association between OA of the
hip and femoral neck fracture is well recognized [1-4], it
is not clear whether patients with OA have greater bone
mass than normal people. A number of studies have
been performed comparing bone mass in patients with
OA of the hip with controls, but results are conflicting,
perhaps due to the selection of subjects, the different
techniques and sites used for bone measurement, and
the heterogeneous nature of OA of the hip [3-6].
Fewer studies have been performed in patients with
primary generalized osteoarthritis (PGOA) but results
are also conflicting. Studies using metacarpal morphom¬
etry) and neutron activation analysis to measure total
body calcium [7], quantitative computed tomography
of the forearm [8] and single photon absorptiometry of
the forearm [9] have shown no difference between
osteoarthritic subjects and controls. However a
relationship between trabecular bone volume in iliac
crest biopsies and radiological grade of OA at the hand
was found in one post-mortem study [10].
The aim of our study was to assess BMD at potential
osteoporotic fracture sites (lumbar spine, distal forearm
and hip) and total body bone mineral (TBBM) in
women with PGOA and compare this with data from
normal women.
PATIENTS AND METHODS
Twenty postmenopausal women aged 52-79 yr
(median 68 yr), attending a rheumatology clinic for
treatment of PGOA were recruited. All women had
clinical and/or radiological OA affecting three or more
groups of joints as described by Kellgren and
Moore [11], Details of joint involvement are given in
Table I. Women with hysterectomy were excluded as
age of menopause was unknown although one woman
with simultaneous hysterectomy and bilateral oopho-
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rectomy was included. Women with a history of disease
or drug therapy potentially affecting bone mass were
also excluded e.g. diabetes, thyroid disease, oral steroid
therapy, anticonvulsant treatment. Although women
with fractures were not specifically excluded, none were
known to have vertebral or hip fractures and only one
had a previous Colles' fracture. A second patient sus¬
tained a Colles' fracture after the study was completed.
Six patients used one or more sticks for walking and two
of these six also used wheelchairs for outings. Data from
89 normal postmenopausal women aged 50-79 yr
(median 62 yr) recruited locally from hospital and uni¬
versity staff and randomly from a list ofpostmenopausal
women attending an inner city general practice were
used as controls [12]. Women with hysterectomy, thy¬
roid disease and other endocrine disorders, liver, kidney
or chronic gastrointestinal disease, known osteoporotic
fracture, impaired mobility or who had received steroid,
hormone replacement therapy or other treatment
potentially affecting bone, were excluded from the con¬
trol population. All study and control subjects were of
Caucasian origin.
BMD (bone mineral content/bone width, arbitrary
units) was measured at the distal forearm by single
photon absorptiometry. Bone mineral content (BMC,
g) and BMD (g/cm2) were measured at the lumbar spine
(L2L3L4) and femoral neck by dual energy X-ray absorp¬
tiometry using a Lunar DPX Bone Densitometer
TABLE I
Joint Involvement in Osteoarthritic Patients
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TABLE IV
Relationships Between Age, HAQ Score and Bone Mineral Measurements in Osteoarthritic Women Given as the
Coefficient of Correlation
Spine Femoral Forearm





Forearm -0.75 0.52 0.66
BMC/BW ** * **
TBBM -0.68 0.60 0.72 0.61






*o *On O -0.70
BMC, Bone mineral content; BW, bonewidth; TBBM, total body bone mineral content; HAQ, Stanford Health Assessment
Questionnaire.
* P <0.05; ** P <0.01; *** P <0.001.
showing this was not simply a local effect due to artefact.
Mean lumbar BMD was 7.3 g higher in osteoarthritic
patients than controls, whilst mean TBBM was 132 g
higher in osteoarthritic patients than controls (Table
III). The possible contribution of degenerative disease
in the lumbar spine to the difference in TBBM is there¬
fore small. In addition there was a strong correlation
between lumbar BMD and distal forearm, femoral neck
and TBBM measurements.
We conclude that women with PGOA have greater
bone mass than controls at the distal forearm and spine
and greater TBBM, although bone mass at the femoral
neck is not increased. These differences are not due to
obesity. It is possible that impaired mobility in the
osteoarthritic women could explain the lack of differ¬
ence in bone mass at the femoral neck. The cause of the
increase in bone mass in women with PGOA is
unknown, but the results of this study would support the
hypothesis that oestrogen excess may be involved in the
pathogenesis of OA [20].
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TABLE II
Age at Menopause and BMI in Osteoarthritic Women and
Controls
Osteoarthritic Controls
Age at menopause (yr) 48.4 ± 6.1 49.2 ± 4.0
BMI (kg/nr) 26.8 ± 4.1 24.9 ± 3.9
Results are expressed as means ± s.d.
(Lunar Radiation Corporation, Madison, WI, USA).
TBBM (g) was also measured by this technique.
Osteoarthritic patients completed a Stanford Health
Assessment Questionnaire (HAQ) [13] in order to
assess their functional ability.
Statistical analysis
Within group data were correlated using Spearman
rank correlation (rho). Data on age of menopause and
BMI from osteoarthritic women and controls were com¬
pared by separate variance f-tests. Differences in spine,
femoral neck, distal forearm and TBBM measurements
between the two groups were compared using an unbal¬
anced analysis of covariance with age as covariant and
significant difference of the F statistic for the elevation
was tested after the regression lines were shown to have
similar slopes.
All data were analysed on Unistat IV statistical
software.
RESULTS
There was no significant difference in age at meno¬
pause or BMI between osteoarthritic women and con¬
trols (Table II). Women with OA scored a mean of 0.81
± 0.64 (s.d.) on the HAQ.
BMC and BMD were significantly higher at the spine
(.PcO.OOl) and BMD at the distal forearm was also
increased (P<0.05) in osteoarthritic women compared
with controls. TBBM was higher in the osteoarthritic
group (PcO.Ol). BMC and BMD at the femoral neck
were not significantly increased in osteoarthritic women
(Table III).
Relationships between bone mineral measurements,
age and HAQ score are shown in Table IV. There was a
significant negative correlation between HAQ score
and spinal, femoral neck, forearm and TBBM measure¬
ments. There was a significant positive correlation of
HAQ score with age.
DISCUSSION
Women with PGOA have more bone at the distal
forearm and spine and greater TBBM than controls,
althoughno significant increase in bone mass was seen at
the femoral neck in osteoarthritic women. These differ¬
ences were not due to obesity as BMI was similar in con¬
trol and study groups.
Some of the osteoarthritic women had impaired
mobility and it is possible this may have influenced bone
mass at the femoral neck, reducing differences from
controls. Certainly the HAQ score correlated nega¬
tively with bone mineral measurements, but as age was
also related to HAQ score this should not be over inter¬
preted. It is of interest that muscle strength has been
shown to predict bone mass in the femur and forearm,
but not the spine in healthy postmenopausal
women [14]. A regional increase in BMD adjacent to an
osteoarthritic joint has been proposed as a mechanism
for increased bone mass in OA [15]. If this theory is cor¬
rect, the low prevalence of OA of the hip in our study
population (Table I) could provide an alternative
explanation for the lack of difference at the femoral
neck from controls. However, this theory would not
explain the increased BMD at the distal forearm in
osteoarthritic women.
Neither osteoarthritic women nor controls had a rou¬
tine lateral lumbar spine X-ray. The presence of osteo¬
phytes and degenerative disease at the facet joints can
produce artefacts affecting lumbar BMD measure¬
ments [16], although the extent to which these measure¬
ments are affected is controversial [15]. Spinal
osteophytes are present in the majority of'normal' post¬
menopausal women [17, 18],butaccountforonly4% of
the variance in lumbar BMD [17], However, only half
this effect is artefactual and lumbar osteophyte score is
related to femoral BMD [17). Exclusion of subjects
from a study population because of degenerative
changes may thus potentially bias the study group. In
men, osteophytes make a greater contribution to lum¬
bar BMD [19], perhaps because of lower age-related
bone loss, or sex differences in osteophyte
formation [18].
Although we cannotexclude an influence of degener¬
ative diseaseaon lumbar BMD, not only was bone mass
increased at the spine, but also at the distal forearm, and
TBBM was also elevated in the osteoarthritic group
TABLE III
Comparison Between Bone Mineral Measurements at the Spine, Femoral Neck, Distal Forearm and Total Body Bone
Mineral in Osteoarthritic Patients and Controls
OA, n = 20 Control, n = 89 /•■-statistic
Spine BMC (g) 48.8 ± 9.8 41.5 ± 9.3 12.24***
BMD (g/cm2) 1.12 ± 0.18 1.00 ± 0.17 1139***
Femoral neck BMC (g) 4.34 ± 0.68 4.13 ± 0.78 2.79 N.S.
BMD (g/cm2) 0.87 ± 0.12 0.85 ± 0.13 2.80 N.S.
Distal forearm BMC/BW 0.94 ± 0.18 0.90 ± 0.16 5.52*
(arbitrary units) (n = 18) (n = 89)
Total body bone mineral (g) 2377 ± 350 2245 ± 305 y ii**
(« = 20) II U> SO
BMC, Bone mineral content; BW, bonewidth.
Results expressed as means ± s.d.
* P <0.05; ** P <0.01; *** P <0.001.
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Abstract
Reference ranges used in dual energy X-ray absorptiometry (DXA) have previously used piecewise linear fits
to the whole data set for spine or femur bone mineral density (BMD) as a function of age. In a study of 329
Caucasian normal women we present a refinement to the normal range by fitting straight lines between
quinquennial mean values of BMD for each site measured (lumbar spine, femoral neck and Ward's triangle).
From the age of 40 years onwards the premenopausal women demonstrated minimal loss of BMD whereas
postmenopausal women showed a rapid loss amounting to 27% in the lumbar spine, 27% in the femoral neck
and 38% in the Ward's triangle region in the age range under examination. Comparison of quinquennial
means for pre and postmenopausal women in age bands 45-49 years and 50-54 years shows that at these ages
postmenopausal BMD is significantly lower than premenopausal BMD (P < 0.05). This finding suggests that
separate normal ranges should be used for pre and postmenopausal women. As reduction in the production
of oestrogen is a major factor in postmenopausal bone loss and oestrogen function is related to years since
menopause (YSM), a more logical way of displaying postmenopausal normal BMD ranges would be in terms
of YSM rather than chronological age. Such data are given in this paper.
The measurement of bone mineral has long been
recognized as important for the study of osteoporosis.
Originally instruments were developed to measure bone
mineral in the forearm (Cameron & Sorenson, 1963) but
in the early 1980s techniques were developed to measure
the sites of most clinical interest directly, i.e. the spine
and femoral neck. The techniques for measuring the
spine and femoral neck use the same basic principle; the
differential attenuation that occurs between bone and
soft tissue when gamma or X-ray photons of two
different energies pass through the body. A measure¬
ment of the relative attenuation, coupled with the mass
attenuation coefficient gives a measurement of the bone
mineral. The region is studied by moving the source and
detector in a rectilinear motion across the patient and
producing an image in which each pixel is representative
of the mineral content. The integration of the data over
the appropriate region of interest (ROI) gives the bone
mineral content (BMC) in grams.
Though the BMC for a given anatomical ROI may be
an important parameter in its own right it is clear that
its value will be dependent upon the size of the indivi¬
dual; large subjects will tend to have a higher BMC than
Received 21 February 1992 and in finalform 16 December
1992, accepted 18 January 1993.
small subjects. To compensate for this the BMC is
divided by the area of the bone obtained from the image
to produce bone mineral density (BMD) in units of g
cm-2. It should be noted that the BMD is not the
measurement of volume density but is the area normal¬
ized BMC. BMD appears to have become the measure¬
ment of choice but care must be taken with its use.
Early instruments used two gamma ray energies
obtained from isotope sources, initially a combination
of 241Am and 137Cs and subsequently 153Gd which
became the basis of a number of commercial systems.
The isotope techniques for measuring BMD were
referred to as dual photon absorptiometry (DPA)
(Reed, 1966). This gave a reasonable precision at about
8% (Tothill et al, 1983) but often the quality of the
images was poor and in many patients it was difficult to
identify the areas to measure. A significant improvement
in signal-to-noise ratio in the image was obtained with
the use of X-ray tubes as the photon source (Sartoris et
al, 1985). The more recent development is referred to as
quantitative digital radiography (QDR) or DXA
(Mazess et al, 1988). The two abbreviations refer to the
same basic principle and we shall adopt the latter irres¬
pective of the commercial system used. The improved
photon output of DXA over DPA results in benefits in
terms of improved resolution, improved precision or
shorter scan times.
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Variation in lumbar spine andfemoral neck bone mineral measured by DXA
The initial spine BMD results showed a significant
variation in age relationship with different systems
(Smith et al, 1983). At the time it was thought that there
could be some national differences in BMD although
technical explanations were also felt to be a possibility.
It must be remembered that the BMD is the ratio of the
BMC to the area of the bone. It is quite conceivable that
different techniques can calculate the BMC reliably but
that different algorithms used for edge detection, to
calculate the area of the bone, are likely to differ signific¬
antly from system to system. As a consequence it may
be the denominator in the ratio, i.e. the area, that is the
principal cause of variation between different systems.
The variation in BMD of the spine and femoral neck
using either DPA or DXA in Caucasian females in
several countries is illustrated in Figures la and lb. The
data was extracted from the references listed in Table I
which also gives the age range of each of the studies and
the number of subjects involved. There are discrepancies
between the data from each country, which may reflect
differences in either the control population or the tech¬
nique used. However, much depends upon the size of
the data set and consequently the statistical model that
can justifiably be used. This study was initiated to
enable us to obtain a comprehensive normal range of
BMD values for Caucasian females in the United
Kingdom (UK). It was also recognized that an indivi¬
dual may suffer a crush fracture which is caused by a
vertebral body having a lower BMC and may result in a
lower than normal vertebral area. In such a situation the
BMD, which is the ratio of the two, can appear in the
normal range. As a consequence the normal data were
analysed to obtain the vertebral area in the normal
population which could be used to give an indication as
to whether BMD or BMC values should be used in the
assessment of that individual.
Methods
Reference subjects
The reference sample for the spine BMD measure¬
ments consisted of 329 women aged between 20 and 81
years, of whom 174 were premenopausal and 155 were
postmenopausal. The mean age at menopause was 49.1
(4.5) years, the figure in brackets is the standard devia¬
tion. For the femur measurements the sample consisted
of 327 women from the above set aged between 21 and
81 years of whom 173 were premenopausal and 154
were postmenopausal with a mean age at menopause of
49.1 (4.4) years. The women were recruited mainly from
hospital and university staff by advertising locally and
from the list of a local general practitioner (GP). The
GP contacted every third woman on his list of
Caucasian females in the age range 55-80 years and
invited those with no known disorders to participate in
the study of whom approximately 30% attended. On the
basis of responses to a questionnaire women with endo¬
crine disorders, adrenal disorders, malignancy, chronic
gastrointestinal or liver disease, Paget's disease,
diabetes, rheumatoid arthritis or renal stones were
excluded. Women on steroid therapy, hormone replace¬
ment therapy, anticonvulsant drugs, sodium fluoride,
heparin, thyroxin or with a history of hip, spine or wrist
fracture or extended immobilization were all excluded.
The exclusion also extended to women who had under¬
gone hysterectomy or oophorectomy and subjects with
histories of drug or alcohol abuse. Spine X-rays were
not taken in this study for ethical reasons so that some
women who may possibly have asymptomatic vertebral
wedge or crush fractures were not identified and thus
not excluded. It is recognized that the reference data
presented in this study is not a statistically representa¬
tive sample of the local population. In particular there is
no representation of non-Caucasian races and there will
Table I. Major studies using DPA or DXA listed chronologically including first author, number of subjects, measurement site and
age range
First author Year Number Site Age range
(years)
Riggs 1981 105 Spine 20-89
Krolner 1982 70 Spine 19-88
Tothill 1983 24 Spine 21-61
Guesens 1986 156 Spine 20-85
Hansson 1986 214 Spine 35-80
Mazess 1987 892 Spine/Femur 20-79
Nilas 1987 178 Spine 29-78
Elders 1988 286 Spine 46-55
Pocock 1988 179 Spine/Femur 20-83
Ribot 1988 510 Spine 25-70
Schaadt 1988 113 Spine/Femur 20-89
Stevenson 1989 284 Spine/Femur 21-68
Aloia 1990 376/257 Spine/Femur 20-80
Elliott 1990 462 Spine/Femur 20-84
*Hall 1990 165 Spine 4-80
Rodin 1990 225 Spine/Femur 18-52
All DPA scans except *which is DEXA.
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Figure I. BMD (g cm-2) in the lumbar spine (a) and the femoral neck (b) of Caucasian women plotted against age (years) gathered
by different measurement centres throughout the world. (9 • Leeds 1991 refers to this paper.)
be a higher proportion of social classes I, II and III than
will be present in the local population.
Scanning techniques and scan analysis
Scanning was carried out using a Lunar DPX
machine on sites in the femoral neck and lumbar spine
(Mazess et al, 1989). Analysis of the scans was carried
out using the manufacturer's software version 3.2. The
effective dose equivalent for each examination is 1 /rSv
and was measured by the local radiation protection
service.
Precision
Precision is defined as the ability of a method to
obtain the same value with repeated measurements.
In vivo precision represents variations in patient posi¬
tioning and instrumentation errors, while in vitro preci¬
sion is determined by instrumentation error alone. 15
subjects (seven male, eight female; mean age 43 years)
had lumbar spine and femur scans on two occasions
with an interval of 28-90 days (mean 55 days) between
scans. The coefficient of variation (CV) for the lumbar
spine, femoral neck and Ward's triangle was 1.18%,
1.69% and 3.13%, respectively. The manufacturer's
aluminium spine and femur phantoms were scanned five
times per day for 7 days in a low attenuation plastic
tank filled with a nominal fat solution (25% isopropyl
alcohol, 75% water) to a depth of 15 cm to measure the
in vitro precision. The CV for spine, femoral neck and
Ward's triangle regions of the phantoms was 0.45%,
1.00% and 0.84%, respectively.
Data analysis
A number of different analyses were undertaken to
obtain normal data that could be used for comparison
with patients who may have a degree of crushing of one
or more of the vertebrae. If this is not known then the
total BMD of L2-L4 may give an erroneous result. The
total area of L2 + L3 + L4 was noted. In this paper we
present the normal results as means and standard devia¬
tions. For comparison with the normal ranges of the
commercial company (Lunar Corporation) straight lines
were fitted to the normal data. The assumption has been
made by the company that there is constant BMD early
in life and then two different linear rates of loss later in
life. Least squares techniques are used to identify the
slopes of these losses and the break points, i.e. the age at
which the rate of loss changes.
Results
The results for the normal vertebral BMD and asso¬
ciated areas are given in Table II, grouped into 5 year
age bands for all women and separately for pre and
postmenopausal women. The data for BMD of the
fetporal neck and Ward's triangle regions are given in
Table III, grouped in the same way. The BMD data for
spine, femoral neck and Ward's triangle are given,
grouped into 5 year bands of years since menopause
(YSM), in Table IV. The results of the variation of
BMD with age are shown graphically in Figure 2a for
the spine, Figure 3a for the femoral neck and Figure 4a
for Ward's triangle. In each case the figure contains the
raw data, the quinquennial mean values and straight
lines joining those mean values. The results of the
variation of BMD with YSM are shown in Figure 2b
for the spine, Figure 3b for the femoral neck and
Figure 4b for Ward's triangle. In each case the figure
contains the raw data, the mean value of BMD for the 5
year band and straight lines joining the mean values.
Further investigation of the effect of the menopause
was carried out by comparing the mean BMD values in
the three quinquennia, 40-44.9 years, 45-49.9 years and
50-54.9 years, in the lumbar spine, femoral neck and
Ward's triangle. Pooled Student's r-tests show that in
the 40-44.9 year band there is no significant difference
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Figure 2. BMD (g cm-2) in the lumbar
spine plotted against (a) age (years),
unbroken line joining means for all
women, upper broken line joining means
for premenopausal women, lower broken
line joining means for postmenopausal
women, and (b) years since menopause
(YSM) for postmenopausal women.
between the pre and postmenopausal groups, in the
45-49.9 year quinquennia the difference between the
two groups at all three sites is highly significant (P <
0.001) and in the 50-54.9 year band is still significant
(P < 0.05). The importance of separating reference data
into premenopausal and postmenopausal groups is
highlighted by this finding.
The results of comparing the linear fits to the data
Table II. Mean and standard deviation values for measurements made on lumbar vertebrae L2 to L4 of area, BMC and BMD
listed for all women and for pre and postmenopausal women by age band including the number in each group
Ageband Number Spine area Spine BMD
(years) (cm2) (g cm-2)
All Pre Post All Pre Post All Pre Post
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Figure 3. BMD (g cm"2) in the femoral
neck plotted against (a) age (years),
unbroken line joining means for all
women, upper broken line joining means
for premenopausal women, lower broken
line joining means for postmenopausal
women, and (b) years since menopause
(YSM) for postmenopausal women.
with the commercial company's normal range showed
negligible differences between the two data sets (Mean
Z-score of differences 0.062). However, it should be
noted that the results from Leeds were included in the
data base of the commercial company and account for
some 36% of the data used to construct their spine
normal range and about 43% of the data used in the
construction of their femur normal range.
Table III. Mean and standard deviation values for BMD measurements made in the femoral neck and Ward's triangle regions
listed for all women and for pre and postmenopausal women by ageband including the number in each group
Ageband
(years)




All Pre Post All Pre Post All Pre Post
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Figure 4. BMD (g cm-2) in Ward's
triangle plotted against (a) age (years),
unbroken line joining means for all
women, upper broken line joining means
for premenopausal women, lower broken
line joining means for postmenopausal
women and (b) years since menopause
(YSM) for postmenopausal women.
Discussion
Both the spine and femur data display an effect
caused by the menopause with the end point BMD
value of the premenopausal data being higher than the
starting point data of the postmenopausal data in each
case (Figures 2a, 3a, 4a). A small study by Tothill et al
(1983) demonstrated an increased loss of bone from the
spine after the menopause but this study was not
supported by a larger study from Hansson & Roos
(1986). By comparing the BMD values of premeno¬
pausal women who are over 45 years of age with the
BMD values of postmenopausal women within 5 years
Table IV. Mean and standard deviation values for BMD
measurements of the lumbar vertebrae (L2-L4), femoral neck
(FBMD) and Ward's triangle (WBMD) listed for
postmenopausal women by YSM including the number (n) in
each group
YSM n SBMD n FBMD WBMD
(years) (SD) (SD) (SD)
(g cm 2) (g cm 2) (g cm 2)
0-4.9 42 1.091 41 0.886 0.771
0.155 0.137 0.158
5-9.9 41 0.987 40 0.845 0.716
0.157 0.110 0.125
10-14.9 18 0.965 20 0.827 0.673
0.218 0.127 0.153
15-19.9 20 1.019 19 0.815 0.665
0.128 0.081 0.099
20-24.9 17 1.042 17 0.823 0.658
0.117 0.092 0.112
25-29.9 11 0.941 9 0.759 0.602
0.193 0.208 0.220
> 30 6 0.816 8 0.756 0.623
0.212 0.134 0.184
of menopause we can establish whether or not this
difference is significant. The outcomes of these tests are
given in Table V. It can be seen that in every site
measured the difference between the two groups is
highly significant, ranging from 7.9% to 11.3%.
In this set of data (Table II) peak BMD in the spine
occurs in the 35-39.9 year band with very little loss
taking place in the premenopausal women from the time
at which peak BMD is attained onwards. In the UK this
is earlier than the ages reported by Hall et al (1990) but
consistent with the findings of Rodin et al (1990). In
other countries we find agreement only with Elliott et al
(1990). Krolner & Nielsen (1982), Schaadt & Bohr
(1988), Guesens et al (1986) and Ribot et al (1988) all
find that the peak occurs earlier. Postmenopausally the
pattern is more confusing (Figure 2b) with a 10 year
Table V. Results of Student's t-tests comparing spine BMD
(SBMD), femoral neck BMD (FBMD) and Ward's triangle
BMD (WBMD) in two groups of women; premenopausal older
than 45 years and postmenopausal within 5 years of
menopause, for whom percentage differerence is given,
including mean, standard deviation (SD) and number of









SBMD Mean 1.218 1.091 0.00009 10.4
(gm cm-2) SD 0.138 0.155
n 47 42
FBMD Mean 0.962 0.886 0.007 7.9
(gm cm-2) SD 0.121 0.137
n 47 41
WBMD Mean 0.869 0.771 0.002 11.3
(gm cm-2) SD 0.135 0.158
n 47 41
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band of loss followed by a 10 year period of apparently
little change, then loss taking place from this time
onwards. When we look at this data set as a whole
(Figure 2a) the pattern is simpler, showing a rise of
BMD during the 20-40 year age range with peak density
achieved in the 35-39.9 year band. This is followed by a
steady loss amounting to about 27% in the following
42.5 years. This is consistent with the total bone loss of
25% reported by Hall et al (1990) in UK populations
covering the same age range as our data. In other
countries where Caucasian female populations covering
the same age range have been studied, percentage bone
losses have been closely comparable with ours with one
striking exception. Riggs et al (1981) reported a loss of
47% in the BMD of lumbar vertebrae LI to L4 but the
age range in their study is from 20 to 90 years.
In the femoral neck (Table III) peak BMD is attained
in the 25-29.9 year band with bone loss proceeding at a
negligible rate before the menopause. Postmenopausally
we observe a steady loss with years since menopause,
the total loss in the period considered being some 27%.
In the UK the total bone loss of 26% reported by
Stevenson et al (1989) agrees with our data although
they do report the loss phase starting at less than 30
years of age. Elsewhere in the world the data of Mazess
et al (1987) (25%) compares closely with this data
whereas Elliott et al (1990) report a lower age for both
attainment of peak bone mass (20-25 years) and for
onset of loss (25-30 years). Pocock et al (1987) also
report loss starting earlier (mean age 25 years) than our
estimate but proceeding at a comparable rate to achieve
a slightly higher total loss (30%) by age 83 years.
In Ward's triangle, peak BMD is attained in the
25-29.9 year age band with loss commencing in
the 30-34.9 year age band. Once again the premeno¬
pausal bone loss from this time is negligible.
Postmenopausally, however, the bone loss is steady and
rapid by comparison with the femoral neck, with total
loss in the period amounting to some 38%. This very
high rate of loss would make Ward's triangle an attrac¬
tive site for measurement if the in vivo precision could
be improved.
The data display two stages of bone loss consistent
with the classification of Type I and Type II osteopor¬
osis (Riggs & Melton, 1983). Type I is most active in the
15-20 years immediately after the menopause when the
rate of loss can be as much as three times higher than
normal. The loss is predominantly from trabecular bone
and manifests itself in the form of vertebral and Colles'
fractures. Type I osteoporosis is apparently linked to
oestrogen deficiency in some, as yet unclear, way.
Type II osteoporosis is apparent in women over 75
years of age and presents in the form of vertebral wedge
fractures and hip fractures. The mechanism of loss is
related to senescence with loss taking place in both
cortical and trabecular bone.
The value of considering the vertebral geometry can
only be assessed following a study of patients with a
variety of established symptoms of osteoporosis; this
analysis is currently being pursued. Our preliminary
findings suggest that when a patient is referred for a
bone mineral measurement the vertebral geometry
should be considered in addition to the BMD.
Normal ranges should be developed which split data
for pre and postmenopausal women. As reduced
oestrogen levels are associated with postmenopausal
bone loss and oestrogen levels decline with years since
menopause it may be more logical to express postmeno¬
pausal normal ranges in terms of YSM rather than
chronological age.
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Endosonography in Obstetrics and Gynecology. By G
Bernaschek, J Deutinger and A Kratochwil, pp. xii + 187, 1990
(Springer Verlag), DM248.00.
ISBN 0-387-508285
Endosonography in Gastroenterology, Gynecology and Urology.
By G Feifel, U Hildebrandt and N J Mortensen, pp. 217, 1990
(Springer Verlag), DM248.00.
ISBN 3-540-505032
Endosonography. Ed. by Bruno D Fornage, pp. iv+186, 1990
(Kluwer Academic Publishers), £77.00.
ISBN-0-7923-00475
Endosonography—the use of specially designed ultrasound
probes for insertion into various body orifices—is a significant
advance in the practice of ultrasonography. High frequency
transducers can be placed close to the organ of interest in order
to generate high resolution images which can dramatically
increase the yield of clinically useful information.
These probes are now offered by nearly all ultrasound
equipment manufacturers and most ultrasound departments
are being asked to provide an endosonographic service. There
is clearly a need for books which can provide instruction on
techniques and advice on image interpretation, and the
appearance of these three volumes in the bookshops is timely.
The first book listed above has three authors—Bernaschek,
Deutinger and Kratochwil—and is written as a conventional
textbook providing a comprehensive coverage of all
applications of endosonography in obstetrics and gynecology.
It is well written and is systematic in its approach. It is well
illustrated and all the scans are presented in a uniform format
using a standardized presentation of scan planes, and there is a
good selection of references to the literature.
The same publishers, Springer Verlag, have produced the
second volume, edited by Feifel, Hildebrandt and Mortensen.
This is a collection of six entirely separate review articles, each
with its own author or team of authors. As well as covering the
history and physics/instrumentation of endosonography, there
are chapters on the upper GI tract, rectum, prostate and
gynecology. The coverage is selective and both the style and
presentation of images are non-uniform.
The third book is edited by Bruno Fornage who has enlisted
the help of 17 co-authors. It has a broad scope, covering upper
and lower GI tract, urological, gynecological and obstetric
applications, but is rather patchy and variable in the depth of
its coverage, e.g. transvaginal Doppler techniques receive only
cursory mention. The orientation of the scans varies both
within and between chapters and the quality of some of the
illustrations is disappointing.
In conclusion, most ultrasound departments will be looking
for a teaching and reference text on endosonography in
obstetrics and gynecology, and the book by Bernaschek,
Deutinger and Kratochwil is to be highly recommended. For
departments and libraries looking for a book giving an
overview of all applications of endosonography, Fornage is
recommended, while this reviewer has difficulty in identifying a
prospective market for Feifel et al.
H C Irving
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Abstract. The propagation mechanisms of ultrasound in trabecular bone are poorly understood
and have been the subject of extended debate; also, the reproducibility of ultrasonic
measurements on bone in vivo using commercial ultrasound heel-scanning devices is such that
the interpretation of the obtained data is difficult. In this paper we describe recent developments
in the pioductiun of a bone-mimicking material which is well suited to the task of routine
monitoring of commercial ultrasound bone scanners. The materia], based on a standard epoxy
resin is fabricated to a pre-determined porosity value by the inclusion of a marrow-mimicking
material thereby introducing a known and controlled mean pore size.
Measurements of the velocity and attenuation of the material have been performed over
a range of porosity values from 10% to 80% in the frequency range 500-900 kHz; also,
broadband ultrasonic attenuation (bua) values have been obtained from commercial equipment.
The material displays velocities in the range 1844-3118 m s-1 and attenuation ranging from 7.0
to 17.7 dB cm"1 at 500 kHz.
1. Introduction
The rapidly increasing use of ultrasound to detect and monitor bone pathology, in particular
osteoporosis, has led to the development of several commercially available devices. Such
devices typically measure the rate of change of attenuation of ultrasound with frequency
(broadband ultrasound attenuation or BUA) between 0.2 and 0.6 MHz, and also the velocity
of sound (Langton et al 1984, 1990).
Currently, at least two of the commercial manufacturers offer phantoms for use with
their own scanners. However, at best these devices are suitable for monitoring temporal
changes in scanner performance. There is no independently validated data on their acoustic
parameters and in one case the machine is set in a different mode before the phantom can
be used because the acoustic properties differ significantly from those of the os calcis. In
neither case is there any attempt to simulate the architecture of the heel nor is it certain
that the phantoms themselves have good long-term stability. There is a clear requirement
for a phantom, constructed from a material which will mimic acoustically the properties
of ultrasound in trabecular bone in this frequency range. Such a phantom would enable
intercomparisons to be made between results from different commercial ultrasound bone
systems and provide the necessary calibration for long term longitudinal patient studies.
Furthermore, the propagation of ultrasound, particularly in trabecular bone, is still poorly
understood and so there is a need for a material which could be used to simulate bone in a
controlled, reproducible and realistic manner.
This paper describes a new material, made from a mixture of an epoxy resin and gelatine
which mimics the speed and attenuation of sound through trabecular bone and which can
be formed into a phantom of a specific size and shape.
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2. Trabecular-bone-mimicking material
2.1. Requirements of the material
The bones of the human skeleton can be divided into two types: cortical bone and cancellous,
or trabecular, bone. The latter has a porous structure made up of cortical trabecules, the
pores being filled with bone marrow.
Cortical bone is relatively straightforward to mimic, as it has a homogenous, compact
structure. Trabecular bone, having a composite structure is more problematic. The size,
shape and concentration of pores varies between skeletal sites; the proportion by volume
which is marrow is known as the porosity. Hence there is a requirement for the bone
phantom material to be able to mimic porosity in a controllable way. We therefore
aimed to have a two component material, one component being ultrasonically equivalent
to cortical bone, and the other equivalent to bone marrow. The two components were to
be geometrically arranged in a manner comparable to trabecular bone with variable, but
controlled, porosity.
The specification for the two materials was that they should match the velocity and
attenuation of cortical bone and marrow over as wide a range of conditions as possible.
Unfortunately there is significant variation in the reported values for both parameters for
cortical bone and almost no data for either quantity in bone marrow. Table 1 summarizes
some of the published values, although in all but one case, these refer to animal samples.
Table 1. The ultrasonic characteristics of the constituents of trabecular bone. Note, all data are
from bovine bone samples except the data marked with an asterisk (*) which are from human
bone. ± values refer to 1 standard deviation.
Velocity Attenuation at 1 MHz
Material (m s~') (db cm-1) Reference
Cortical bone 3461 ± 104 8.36 ± 1.37 Tavakoli (1991)
Cortical bone 3250 ± 196* — Andre et al (1980)
Cortical bone — 6.9 ±0.6 McKelvie and Palmer (1987)
Bone marrow 1435 ± 10 0.50 ± 0.05 Tavakoli (1991)
2.2. Materials to simulate cortical bone and marrow
An extensive search for synthetic materials possessing similar ultrasonic characteristics to
those of cortical bone and marrow was made using the techniques described below. This
concluded that the optimal values were not achievable. However, materials were found
which gave a reasonable match.
The cortical bone mimic is a two-part epoxy compound normally used for the
encapsulation of electrical components. It is available commercially as Araldite CW
1302 liquid epoxy resin and is used in conjunction with Araldite HY 1300 hardener in
the proportions recommended by the manufacturer. Its ultrasonic velocity is within the
published values for bone, although the attenuation coefficient is about 50% less (see table 2
below).
A number of materials were identified as potential marrow mimics but most were
rejected since no practical means could be found of creating the required structure when
dispersing in the epoxy compound. It was therefore decided to evaluate the use a
gelatine/water mixture in the proportions of 11 g of dry gelatine to 150 ml of water. This
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concentration was chosen as a compromise between the increased mechanical stiffness
at higher concentrations and the lower sound velocities at lower concentrations. This
concentration has useful mechanical properties as it can be formed into relatively stable
pore-shaped granules, but has the disadvantage that its attenuation coefficient is an order of
magnitude too low and its velocity some 6% too high. Nevertheless it was hoped that this
would prove to be of little significance as the high acoustic losses in trabecular bone are
more dependent on the scatter arising from the geometrical arrangement of its constituents
than absorption by the constituents themselves; also, the discrepancy in velocity should be
reduced in the composite material. The acoustic properties of the materials are displayed
in table 2.
Table 2. The ultrasonic characteristics of the constituents of the bone phantom (Truscott et al
1993). The ranges quoted refer to standard deviation values.
Attenuation at 1 MHz
Material Velocity (m s_1) (dB cm"')
Bone mimic 3168 ± 8 3.7 ± 0.3
Marrow mimic 1519 ±3 0.051 ±0.004
2.3. Manufacture of the trabecular bone material
The two components were combined so as to resemble the structure of cancellous bone in
the following manner. Firstly the gelatine was extruded twice through a 1.12 mm mesh to
produce roughly cubic granules of side approximately 1 mm. This was then added to the
liquid epoxy in volumes, calculated by means of weight and density, to give the required
porosity and then mixed until a uniform distribution of gelatine particles had been achieved.
The material was then de-gassed in a vacuum chamber at 3 Torr to remove any air pockets,
then poured into moulds and left to harden.
This process, which is the subject of a patent application, produces a material consisting
of gelatine pores enclosed in a matrix of epoxy. This differs from trabecular bone in as
much as the gelatine cavities are essentially separated from each other (giving a so-called
closed cell structure). In trabecular bone the cells are interconnected giving an open cell
structure through which the marrow can flow. Figure 1 compares the cross sections of a
sample of 60% porosity, the head of a femur and a lumbar vertebra.
Eight samples having porosities in the range 10% to 80% were made. The volumes of
epoxy and gelatine required to give the various porosities were obtained by weighing, these
weights being calculated after careful measurement of their densities. Values of the porosity
of each sample were then obtained by relating their density to those of their constituents.
All density measurements were made using Archimedes' principle.
3. Measurements on the trabecular phantom material
3.1. Instrumentation
Velocity and attenuation measurements at different frequencies were carried out using the
experimental set-up shown in figure 2. This consists of a cubic ultrasonic water tank of
side 15 cm with two identical 0.75 MHz broadband transducers centrally mounted in cut¬
outs on opposite faces so as to be in direct contact with the water. A 2% solution of a
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Figure 1. Cross sections of a lumbar vertebra, (left), the bone phantom (centre), and the head
of a femur (right).
Pulser JTil Sample T2





Figure 2. Block diagram of the experimental set-up.
proprietary detergent (Stardrops) was added to improve wetting. Transducer T1 is excited
by a 1 kV pulse of duration 0.1 /zs. This produces a broadband ultrasound pulse of length
approximately 7 /zs. The output from transducer T2 is captured by a digital oscilloscope
and then transferred to floppy disc via an IEEE-488 interface and computer.
3.2. Velocity
The velocity of ultrasound in the phantoms was determined using the 'time of flight' method
where the difference in the time taken for an ultrasound pulse to travel between the two
transducers both with and without a sample of known thickness in place is noted. The
velocity can then be calculated using the equation
dsVw
Vs = . ST/WA (1)ds VwAt
where Vs is the velocity of sound in the sample, Vw is the velocity of sound in water, ds is the
sample thickness and At is the (time of flight in water only) — (time of flight with sample
present). The measured ultrasonic velocities of the phantom material were compared with
two theoretical velocities. The first uses the relationship described by Wyllie et al (1956)
Quantitative ultrasound trabecular bone phantom 1681
who suggested that the ultrasonic velocity in a porous material could be predicted by the
equation
where Vp is the predicted velocity in the material, Va is the velocity in the matrix material,
Vi, is the velocity in the pore material and 0 is the porosity of the material.
This equation was derived by analysing the times taken for a pulse to traverse a
composite material made up of two slabs possessing different acoustic velocities. The
porosity is defined in terms of the slab thicknesses and thus the equation is essentially
one-dimensional.
The alternative hypothesis which we propose is that the velocity may change linearly
with volume fraction and would therefore be more accurately predicted by the simpler
expression
Here the predicted velocity is directly dependent on the porosity (i.e. the relative volumes
of pore and matrix materials) and as such should correspond more closely to the structure
of the phantom material. There are potentially a number of other formulations but, in this
case, a reasonable agreement with experiment was found with this simple version.
3.3. Attenuation
When assessing the ultrasonic attenuation in a material, allowance has to be made for
reflection losses at the water-sample interfaces. This was achieved by measuring the
transmitted amplitude for a number of thicknesses of each sample. It was assumed that
the reflection losses would be constant for each thickness and hence changes in received
amplitude would be due solely to losses within the sample.
The reduction in sample thickness was achieved by milling. This ensured that the
sample faces were parallel and hence kept the experimental errors to a minimum; also, care
was taken not to reduce the sample thickness to a degree where reverberations of ultrasonic
pulses inside the sample would affect the amplitude measurements. A thickness range of
8-20 mm was found to be acceptable.
The received pulses were digitized and subjected to a fast Fourier transform (FFT). This
produced a spectrum from which amplitudes at different frequencies could be obtained.
The attenuation coefficient of the phantom was determined graphically. This involved
plotting 201ogIO(amplitude) at a given frequency against sample thickness in cm. The slope
of the lesullant straight line should therefore be equal to the attenuation coefficient, a, given
in dB cm""1, thus;
Vp = Va(l - <p) + Vb0. (3)
(4)
where ds\ and dsj are sample thicknesses and A \ and A2 are the signal amplitudes at those
thicknesses.
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3.4. Broadband ultrasonic attenuation (BUA)
Commercial BUA devices generally measure the rate of change of attenuation with frequency
between roughly 200 kHz and 600 kHz although the technique has only been applied to
specific measurements on the os calcis (Langton et al 1984). However, although an attempt
is made to correct for water and diffraction losses, the sample thickness is not taken into
account. Furthermore, there is an implicit assumption that the attenuation is linear with
frequency over that range. The equipment used for our attenuation measurements had a poor
signal to noise ratio below 400 kHz and therefore results are given within the frequency
range 500-900 kHz. Although this is not ideal, we were able to confirm the validity of the
data by measuring BUA values in a commercial BUA scanner as described below.
In this study the BUA value was measured in a number of our samples using a commercial
device (Walker Sonix UBA 575). These samples were all rectangular blocks of dimensions
50 mm x 50 mm x 20 mm and were positioned with the 20 mm axis parallel to the ultrasonic
Porosity (%)
Figure 3. The relationship between porosity and velocity for the phantom, and predicted
velocities ( ) according to Wyllie et al (1956), and ( ) proposed. Error bars (indicating
± one standard error of the mean) lie within data symbols.
4. Results and discussion
The variation of velocity in the trabecular phantom material for different values of porosity
is shown in figure 3. It can be seen that the measured velocities seem to correspond
better to the predicted velocity using equation (3) rather than equation (2). Ideally, the
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lower limit of these values would be reduced further to provide a more comprehensive
coverage of the range of velocity values quoted for trabecular bone (see table 3) although
the range of reported values is large (McKelvie and Palmer 1987, Miller et al 1993). This
could be achieved by replacing the gelatine with another material of lower velocity, and
we are currently exploring a number of options. Since pulsed ultrasound was used for
the measurement of velocities, the possibility of some dispersion cannot be entirely ruled
out. Similarly, there was some initial concern about the possible errors due to non-linear
propagation. This was investigated by sending pulses with amplitudes differing by 10 dB
through the same material under the same conditions. The received signals were Fourier
transformed and compared. Above 1 MHz, differences of up to 1 dB were found, the data
points below 1 MHz had identical values within the limits of experimental precision and it
was concluded that non-linear errors were negligible.
35
0.9 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8
Sample Thickness (cm)
Figure 4. Example of the determination of attenuation coefficient of the 50% porous sample at
(♦) 0.5 MHz and (■) 0.75 MHz. The respective gradients and r2 values are (♦) 11.45, 0.99
and (■) 17.57, 0.99.
As stated above, the attenuation coefficient, a, at each frequency, was determined using
a range of thicknesses as shown in figure 4. A linear least-squares regression was applied
to the data points, the gradient of which gave the attenuation coefficient, a, in dB cm-1.
The correlation coefficient r2 had values for all samples ranging from 0.83 to 0.99 with a
mean value of 0.97. The attenuation coefficients obtained for the various samples over a
range of porosities and frequencies, including those of 0% porosity (pure epoxy) and 100%
porosity (pure gelatine), are displayed in figure 5. It can be seen that whilst the attenuation
A J Clarke et al
0 10 20 30 40 50 60 70 80 90 100
Porosity (%)
Figure 5. The relationship between the porosity and attenuation coefficient of the material.
in very low and very high porosity samples is relatively small it increases as the porosity
is changed and passes through a peak at roughly 50%.
The results for bua obtained from the Walker Sonix UBA 575 are displayed in figure 6.
The general shape of the data points shows a similarity to those in figure 5, both peaking
at around 50% porosity.
It is too early to report on the long-term stability of these phantoms, although we are in
the process of carrying out the relevant measurements. However, it is clear that some form
of encapsulation is needed to prevent the gelatine from drying out. Present signs indicate
that if a thin shell of epoxy is added, it not only provides a suitable seal but it also mimics
the outer cortical shell. The temperature dependence of the values is also relevant since
some equipment operates at 37 °C while others use room temperature. We have performed
tests on the temperature dependence of the 80% porosity phantom which indicate that it has
a temperature coefficient of roughly —1.5 m s_1 per °C for velocity and —0.06 dB MHz-1
per °C for bua.
As mentioned previously, much work has been done on the ultrasonic characteristics
of bone taken from various sources, both human and animal. The most pertinent results,
however, are those relating to large volumes of cancellous bone, as it has been suggested
that these would be more sensitive to changes in bone metabolism (Langton 1984). A
comparison of the results from previous work (McKelvie and Palmer 1987) and those
from the present study is shown in table 3. The data were obtained from bone mimics
with porosities in the range 47%-76% and cancellous bone with densities quoted as being
between 940 kg m-3 and 1170 kg m-3.
Quantitative ultrasound trabecular bone phantom 1685
Table 3. A comparison of the ultrasonic characteristics of the bone mimic and real bone.
Bone mimic Trabecular bone
Attenuation at 0.5 MHz (dB cm ') 7.0-17.7 6.0-16.0a
Velocity (m s-') 1844-3118 1465b-2084c
bua (dB MHz"1) 24-76 26-99d
a Tavakoli (1991).
b Miller et al (1993).
c McKelvie and Palmer (1987).
d Truscott et al (1992).
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Figure 6. The relationship between the porosity and the bua of the material. Error bars indicate
one standard error of the mean.
The peak in the attenuation at 50% porosity implies that the highly attenuating nature of
the material is predominantly due to the scatter arising from the geometrical arrangements
of its constituents; this is often referred to as the 'architecture' of trabecular bone. This
seems not to have been reported in ultrasonic studies of real bone, probably because the
full range of porosities is not readily available in biological samples.
The location of the peak in attenuation at 50% porosity could be explained as follows.
A standard pore size was used for all samples, the porosity being altered by changing
the pore density. It seems likely, therefore, that at high densities there is a degree of
connectivity between adjacent pores. Now if, as mentioned above, the attenuation is due
to inhomogeneities in the material, we can consider these inhomogeneities to be gelatine
pores in an epoxy matrix on one side of the peak (0%-50%) whereas on the other side
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(50%-100%) it is the gelatine which forms the continuous phase with particles of epoxy
forming the scatterers. It is then not unreasonable to assume that the attenuation in both
cases should be a maximum when the number of scatterers per unit volume is a maximum.
It is clear that this is not an entirely accurate model for cancellous bone, where changes in
both pore size and density take place. This may mean that in trabecular bone the attenuation
peak occurs at a porosity other than 50%.
As previous workers have shown, the attenuating properties of the os calcis diminish
with decreasing density (McCloskey et al 1990, McKelvie and Palmer 1987). Now it can
be assumed that in this case density and porosity are inversely proportional and hence the
attenuation in the os calcis decreases with increasing porosity. If, therefore, the attenuation
coefficients of various porosities of trabecular bone display a similar peak to that given by
the phantom, then the porosity of the os calcis should be greater than 50%. Although several
studies into the properties of the os calcis have been undertaken, no direct information on
its porosity was found. Density values obtained by means of the Archimedes' principle
are available. However, these measurements can be unreliable if great care is not taken to
exclude all air from the sample or if there is a degree of uncertainty about the nature of
the pore-filling material. For example, McKelvie and Palmer (1987) measured the density
of samples of os calcis to lie in the range 940 to 1170 kg m~3, despite the density of
marrow being (970 ± 60) kg m-3 and that of cortical bone (1990 ± 27) kg m~3 (ICRP
1975). Nevertheless, in general the densities of the os calcis always give a porosity well in
excess of 50%. This is also relevant when considering the BUA values obtained. Several
reports (Evans and Tavakoli 1990, Tavakoli and Evans 1991) have concluded that there is
a high correlation (0.8 to 0.9) between trabecular bone density and BUA in vivo and in vitro
and therefore changes in porosity, and hence also density, over a wide range may not be
particularly relevant in the os calcis where there appears to be a relatively small range of
values.
The existence of a peak in attenuation as the porosity is changed means that a lower
than normal attenuation measurement at a particular skeletal site cannot be interpreted as
an indication of osteoporotic bone without knowledge of the porosity of that bone. In fact,
if attenuation measurements of a particular bone either fall on the 'wrong' side of the peak
or straddle the peak this would lead to false conclusions being drawn as to the condition of
the bone.
The nature of the ultrasonic attenuating mechanism in porous materials is the subject
of debate. Two models have been suggested, one based purely on multiple scatter and the
other including losses due to viscoelastic mechanisms first described by Biot (1956, 1962).
Biot theory treats attenuation as an effect of the viscous forces that are created as fluid is
moved though the porous matrix. The theory therefore requires a fluid filled, permeable
structure rather than the closed cell structure filled with semi-solid gelatine which comprises
the phantom. Since our inclusions are of the order of 1 mm in diameter and the wavelength
is similar, then it is inevitable that scatter will be significant. In fact, it seems probable that
it is the dominant mechanism in this phantom material.
The trabecular phantom material displays ultrasonic characteristics which are similar to
those of trabecular bone, both velocity and attenuation being highly dependent on porosity;
also, the range of velocities, attenuation coefficients and BUA values achievable match those
found in real bone.
It seems probable that the dominant attenuating mechanism is scatter due to the
material's closed cell structure. Varying the porosity while using standard pore sizes
changes the number of scatterers and hence changes the attenuating characteristics. The
number of scatterers could also be altered by varying the pore size whilst keeping the
Quantitative ultrasound trabecular bone phantom 1687
porosity constant. Hence it is possible that for this material the attenuation and velocity are
independently variable, although further work is required in order to verify this. Another
important potential development is the introduction of anisotropy into the phantom material.
This would be readily achievable by using gelatine strands aligned in some way rather than
the isotropic cubes described here. Such a material would have the advantage of being able
to mimic the directionality of the structures in the os calcis, thereby making the phantom
more realistic. However, in clinical practice, the os calcis is always examined in the same
plane and therefore anisotropic influences should be minimal. Work to investigate this is
now underway.
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Summary
OBJECTIVE Our clinical practice has been to offer treat¬
ment with cyclical disodium etidronate and high dose
calcium supplements (1500-1600 mg/day) to all female
patients with osteoporosis who are unable or unwilling to
take hormone replacement therapy (HRT), and male
osteoporotics. In a retrospective study we compared the
effect of this treatment on measures of bone mineral over
a 12-month period in women with post-menopausai and
secondary osteoporosis. We also assessed its effects in
10 male osteoporotics.
DESIGN A retrospective analysis of 83 consecutive
patients with osteoporosis who completed 12 months of
treatment with disodium etidronate and calcium and who
had a dual energy X-ray absorptiometry (DEXA) scan at
baseline and following 12 months of therapy.
PATIENTS The study included 73 women (45 post-meno-
pausal and 28 secondary osteoporotics) and 10 men with
established osteoporosis as shown by spinal and femoral
bone mineral densities (BMD) > 2 standard deviations
(SD) below young normals, and radiological evidence of
osteoporosis.
MEASUREMENTS Each patient had routine biochemistry
at baseline, an X-ray of thoracic and lumbar spine and a
DEXA scan of lumbar spine (L2-L4) and femoral neck.
The DEXA scan was repeated following 12 months of
therapy.
RESULTS There was no difference between increase
in spinal BMD in the post-menopausal (5-7%) versus
Correspondence: Dr S. M. Orme, Department of Diabetes, Royal
Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK.
secondary osteoporotic group (6-7%). There was a
significant increase in spinal BMD at 12 months in the
10 male osteoporotics (9-0%, P < 0 01). No overall
change in femoral neck BMD was noted.
CONCLUSIONS Cyclical disodium etidronate given with
high dose calcium supplements is equally effective in
increasing spinal bone mineral density in post-menopau-
sai and secondary osteoporosis. It also results in a
significant rise in spinal bone mineral density in male
osteoporotics. Whether this produces a reduction in
fracture rates is unknown.
Osteoporosis is characterized by an absolute decrease in the
amount of bone, leading to an increased number of fragility
fractures principally of the vertebrae, proximal femur and
distal radius. Bone loss occurs because of an imbalance
between bone resorption and formation, with the former
exceeding the latter (Eastell et al., 1988). Measures of bone
mass correlate inversely with fracture rate (Jensen et al.,
1983). In post-menopausal women oestrogen deficiency, and
consequently negative calcium balance, is a major cause of
osteoporosis (Nordin & Morris, 1989; Nordin et al., 1991).
In patients with secondary osteoporosis due to thyrotox¬
icosis or steroid therapy, bone resorption is stimulated and
intestinal calcium absorption is inhibited (Meunier et al.,
1984; Baran & Braverman, 1991). In steroid induced
osteoporosis, bone formation is also inhibited by a direct
effect on osteoblasts (Bressot et al., 1979). Anti-resorptive
therapy combined with adequate calcium supplementation
would therefore be a rational therapy for these forms of
osteoporosis.
Bisphosphonates have complex actions on bone. They act
mainly as anti-resorptive agents, limiting the accession of
osteoclast precursors to bone, the formation of osteoclasts
(Boonekamp et al., 1986) and direct bone resorption by
mature osteoclasts (Carono et al., 1990). They may also act
through osteoblasts affecting their proliferation and
inhibiting the secretion of osteoclast stimulating factors
(Khoker & Dandona, 1989). They have been shown to
provide protection against osteopaenia in a rat model
(Wronski et al., 1991). In a clinical study, the bisphosphonate
(3-amino-1 -hydroxypropylidene)-1,1-bisphosphonate (APD)
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given continuously with 1 g of calcium supplements per day
has been shown to increase vertebral bone mineral density in
patients treated with corticosteroids (Reid et al., 1988).
Tiludronate has shown a more modest benefit when given
continuously without calcium supplements in post¬
menopausal osteoporosis (Reginster et al., 1989). More
recently, well designed clinical trials have reported that
400 mg of disodium etidronate daily, given for 2 weeks,
followed by 500 mg of calcium supplements for 11 weeks, in
repeated cycles over 2 and 3 years, resulted in an increase in
spinal bone mineral and reduced the rate of vertebral
fractures in post-menopausal osteoporosis (Storm et al.,
1990; Watts et al., 1990).
Our clinical practice has been to treat all patients with
established osteoporosis, who are not suitable for, or who
refuse, hormone replacement therapy (HRT) (including
secondary osteoporosis and male patients) with repeated
cycles of disodium etidronate, 400 mg per day for 2 weeks
followed by at least 1500mg of calcium supplements per
day for 11 weeks (recommended daily requirement for
post-menopausal women, Consensus Development Con¬
ference, 1987). In a retrospective study, we have compared
the effect of this treatment on spinal and femoral bone
mineral in a group of post-menopausal women with that
in a group of women with secondary osteoporosis. We
have also evaluated its effect on 10 male patients with
osteoporosis.
Patients
The study contained 45 women with post-menopausal
osteoporosis (mean age 64-4 ± 1 -2 years) and 28 women
with secondary osteoporosis (mean age 60-5 ± 1-9). Mean Z
scores at baseline in these groups were comparable (see
Table 1). The group with secondary osteoporosis included
patients with previous thyrotoxicosis (8), on oral steroid
therapy (7), and with early surgical menopause (13). All
other causes of secondary osteoporosis (such as coeliac
disease, anorexia nervosa and acromegaly) were excluded
because they represented only single cases. We also included
10 males with osteoporosis (see Table 2); the causes were,
idiopathic osteoporosis (7), hypogonadism (2) and previous
gastric surgery (1). Male patients with hypogonadism were
on stable treatment with testosterone supplements for at
least 1 year prior to treatment with etidronate; their
treatment was not altered during the period under study.
Osteoporosis was defined as a spinal or femoral Z score of
> 2 SD below young normals or X-ray evidence of
osteoporosis, such as vertebral body collapse. Vertebral
collapse was defined as a reduction in the height of the whole
or anterior vertebral body of > 20%. In a number of cases
Table 1 Details of female patients
Post-menopausal Secondary
women osteoporosis Significance
(n = 45) (n = 28) P
Age 64-4 ± 1-2 60-5 ± 1-9 NS
Age at
menopause 46-2 ± 0-7 43-0 ± 1-1 <; 0-001
Years since
menopause 16-7 ± 1-3 16-5 ±2-0 NS
Height (cm) 155-8 ±0-9 155-1 ± 1-5 NS
Weight (kg) 56-6 ± 1-5 57-3 ±2-3 NS
Z-score*
spine -3-45 ±0-20 -3-25 ±0-28 NS
femur -2-39 ±0-18 -2-51 ±0-19 NS
Paired t-test (mean ± SEM).
* Number of SD below young normals.
spinal Z scores were artefactually increased by vertebral
collapse or abdominal aortic calcification, in which case
patients were classified as osteoporotic by virtue of X-ray
evidence of vertebral collapse.
Patients were excluded from the study for the following
reasons: co-treatment with hormone replacement therapy
(3), inability to take calcium supplements (2), and treatment
with minocycline (which may bind calcium/etidronate in the
gut) for acne (1). Treatment was generally well tolerated
with only two patients who were unable to take calcium
supplements withdrawing.
Methods
All patients had a clinical assessment, routine biochemical
tests to exclude metabolic bone disease or other causes of
osteopaenia, and standard spinal X-rays at baseline. They
Table 2 Details of male patients
Male osteoporotic
(n = 10)
Age 49-5 ± 5-4
Height (cm) 163 0 ± 10-2
Weight (kg) 68-3 ± 8-0
Z score*
spine -3-59 ± 0-28
femur -1-19 ±0-52
Mean ± SEM.
* Number of SD below young normals.
Clinical Endocrinology (1994) 41 Etidronate and osteoporosis 247
each underwent a DEXA scan (Lunar Corporation,
Madison, Wisconsin, USA) of the lumbar vertebrae (L2-
L4) and femoral neck (reproducibility in normal controls
1-18% in spine and 1-69% in femur) (Truscott et al., 1993).
Z score (number of SD below young normals) was derived
from a study of 329 normal women (Truscott et al., 1993)
and 122 normal men (unpublished data) from the local
population. Measurements were performed at baseline and
after 12 months treatment in all cases.
Treatment consisted of disodium etidronate (400 mg to be
taken in the middle of a 4-hour fast at night for 2 weeks),
followed by 1500-1600 mg of calcium supplements per day
for 11 weeks. The calcium supplements were given according
to patient preference. Each patient started on Sandocal
(calcium lactate gluconate/calcium carbonate, Sandoz)
400 mg twice during the day and 800 mg at night initially.
Twelve were changed subsequently to Calcichew (calcium
carbonate, Shire Pharmaceuticals) 500 mg thrice daily as
they found the initial treatment unpalatable. Each cycle was
repeated every 3 months.
Statistics
Statistical analyses were performed with paired Student's
/-test or Wilcoxon signed rank test. Comparisons of more
than two data sets were done by one-way ANOVA with
the Bonferroni adjustment when comparing individual
groups. All data were expressed as mean ± SEM. Level of
significance was set at a P value of < 0-05.
Table 3 Measures of bone mineral in post-menopausal and
secondary osteoporotic women at baseline and 12 months
Table 4 Comparison of BMD in sub-groups of patients with
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Steroid therapy (n = 7)
Spinal BMD 0-608 ± 0-08
Femoral BMD 0-606 ± 0-08
Early surgical menopause (n = 13)
Spinal BMD 0-844 ± 0 04













Wilcoxon signed rank test (mean ± SEM).
BMD, Bone mineral density (g/cm2).
Results
There was no significant difference between the post¬
menopausal women (n = 45) and those with secondary
osteoporosis (n = 28) in terms of age, years since menopause,
height, weight or Z scores at baseline (see Table 1). The
secondary osteoporosis group tended to have an earlier
menopause, 43-0 ±1-1 years versus 46-2 ±0-7 years
(P < 0-01). The spinal Z scores in all three groups were
not significantly different (ANOVA F= 0-3033), but the
femoral neck Z scores were significantly higher in the male
group (Table 2) when compared with the post-menopausal
and secondary osteoporotic groups (P < 0-05, P < 0-01
ANOVA; Bonferroni correction) (Table 1).
Spinal BMD and bone mineral content (BMC) rose in all
groups (Tables 3 and 5). Percentage changes in BMD and
BMC in the post-menopausal women and secondary
osteoporotics were not significantly different (Fig. 1).
There was no change in spinal area (L2-L4) between
baseline and 12 months in either the post-menopausal or
Table 5 Measures of bone mineral in 10 male osteoporotic patients
at baseline and 12 months









0-867 ±0-033 P< 0-005
38-35 ±2-38 P < 0-005
0-806 ± 0-041 NS
4-32 ± 0-204 NS
Paired /-test (mean ± SEM.)
BMD, Bone mineral density (g/cm2); BMC, bone mineral content
(g hydroxyapatite).
Wilcoxon signed rank test (mean ± SEM).
BMD, Bone mineral density (g/cm2); BMC, bone mineral content
(g hydroxyapatite).
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Fig. 1 Percentage changes in |§], BMC and □, BMD in a, post¬
menopausal women and b, secondary osteoporotics following 12
months of therapy. *P < 0-005; **P < 0-0001.
secondary osteoporotic groups (37-25 ± 0-65 vs 37-20 cm2
±0-61; 38-9 ±104 vs 38-85cm2 ± 0-98). There was no
significant difference between percentage increase in spinal
BMD (ANOVA F= 0-906) or spinal BMC (ANOVA
F= 1-557) between groups (Figs 1 and 3). There was no
significant change in femoral neck BMC or BMD in any of
the groups studied (Tables 3 and 5). As femoral Z score in
the male group was significantly higher than in the female
groups they were not compared.
Baseline spinal BMD was significantly lower in the steroid
group compared with the post-thyrotoxicosis and post¬
surgical menopause groups (ANOVA, Bonferroni correction
-









Fig. 2 Percentage changes in BMD in secondary osteoporotics.
□ , Spine; femur, a, Post thyrotoxicosis (n = 8); b, steroid
therapy (n = 7); c, surgical menopause (n = 13). *P < 0-05;
**P<0-01.
14 p
( a ) ( b )
12 -
-it-
Fig. 3 Percentage changes in BMC and □, BMD in a, spine;
b, femur in 10 male patients. *P < 0-005.
P < 0-05, P < 0 01) (Table 4). Femoral neck BMD at
baseline was also significantly lower in the steroid group
compared with the post-surgical menopause group, but not
the post-thyrotoxicosis group (ANOVA, Bonferroni correc¬
tion P < 0-05) (Table 4). Spinal BMD increased in all sub¬
groups of secondary osteoporosis (Table 4). Percentage
changes in spinal BMD were not significantly different in the
sub-groups of secondary osteoporosis (ANOVA F = 2-786)
(Fig. 2). Flowever, there was a significant difference between
percentage changes in femoral neck BMD between groups
(ANOVA F=4-18, P< 0-05) (Fig. 2) with a significant
increase in the post-thyrotoxicosis group (P < 0-05) and a
'borderline' increase in the early surgical menopause group
(P = 0-052) (Fig. 2, Table 4). Both groups were significantly
different from the steroid group (P < 0-05, P < 0-05
ANOVA, Bonferroni correction). No patient suffered an
extra-axial fracture during the study period. We have no
data on spinal fracture rate.
Discussion
The increase in spinal BMD and BMC in post-menopausal
women and secondary osteoporotics were comparable and
significantly different from baseline. The mean increases in
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BMD and BMC in both groups were similar and the mean
spinal areas (L2-L4) were unchanged. This indicates a real
increase in bone mineral and not an artefactual increase in
BMD produced by further vertebral collapse.
In the two major studies previously referred to (Storm et
al., 1990; Watts et ai, 1990) the former quoted a 5-3%
increase in spinal BMC at 3 years and the latter a 5-2%
increase in BMD at 2 years. A recent study (Miller et al.,
1991) has shown a 15-7% increase in spinal BMD over 2
years in 47 post-menopausal women treated with a similar
regimen to that of Watts et al. (1990) except that they may
have received a higher dose of calcium and vitamin D (total
daily calcium intake 1500mg/vitamin D 400-800IU). A
subsequent similar study (Silberstein et al., 1992) has
reported a mean increase of 6-6% in spinal BMD at 12
months, despite removing 15 of 42 patients from analysis
due to technical difficulties in measuring BMD in spondylotic
spines and 3 patients for not responding to treatment. All
crushed vertebrae were excluded from analysis. They
reported a mean increase in femoral neck BMD of 4-8%
in 28 of 42 patients who 'responded' to treatment, with a fall
in femoral neck BMD of 3-9% in the 14 'non-responders'.
Watts et al. (1990) excluded from analysis any vertebra
which suffered a crush fracture either at baseline or during
the study. Their results show a greater than 1 % increase in
spinal BMD in the control group which is contrary to the
well recognized decline in spinal BMD in post-menopausal
osteoporotics shown in longitudinal studies. This increase in
the control group was not found by Storm et al. (1990) who
did not exclude any vertebra from analysis and quoted
spinal BMC. Watts's regimen was similar to Storm's except
for phosphate pretreatment (2g per day for 3 days) to
stimulate 'osteoblast activity' prior to the commencement of
etidronate. Both studies showed evidence of a reduction in
the incidence of spinal fractures compared with controls. No
consistent increase in femoral BMD was found by Watts et
al. (1990) and all three femoral neck fractures which
occurred in the study period were in the two treatment
groups. Storm et al. (1990) did not report any hip data.
We have found no overall changes in femoral neck BMD
or BMC at one year. However, there appeared to be a small
increase for patients with previous thyrotoxicosis, with a
value of borderline significance for those with an early post¬
surgical menopause. The lack of any significant change in
bone mass at the femoral neck could be interpreted as a
beneficial effect in view of the expected bone loss at this site
in most of the patients studied. The less marked benefit of
anti-resorptive therapy on the femoral neck may result from
the lower percentage of trabecular bone and higher
percentage of cortical bone in the femoral neck, compared
with the vertebrae. Evidence suggests that cortical osteo¬
clasts are less sensitive to etidronate than trabecular
osteoclasts (Chappard et al., 1991).
In conclusion, cyclical disodium etidronate given with
high dose calcium supplements results in a significant
increase in spinal bone mineral density and content in
post-menopausal osteoporotics, women with secondary
osteoporosis and male osteoporotics. The increase may be
greater than that produced by a lower daily dose of calcium,
but direct comparisons between studies is not possible. The
impact of this treatment regimen on fracture rate is not
known.
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A portable system for measuring bone mineral density
in the pre-term neonatal forearm
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Abstract
Current systems used to measure bone mineral content (BMC) in the neonate have the major drawback that
the child must be well enough to be moved to the scanner. Consequently, low birth weight pre-term neonates,.,
a group at particular risk of mineral compromise, cannot be measured. This paper describes a portable
neonatal bone mineral device capable of measuring bone mineral in the incubator. It uses a radiation sensitive,
charge coupled device (CCD) to acquire a bone mineral image enabling bone mineral to be measured at
various sites. It measures bone mineral density (BMD) with a precision of 5.5 mg cm"2 in vivo, reduced to
7.5 mg cm"2 when repositioning between scans is taken into account. The procedure takes under 5 min with
an image acquisition time of 30 s and an absorbed radiation dose to skin of 6 pSv. Calibration has been
undertaken with aluminium foils of differing thickness to confirm the linearity of the system throughout the
intended measurement range. A regression line fitted to the data demonstrated linearity and correlation
between BMD and aluminium thickness with r=0.99 (< 0.0001). Preliminary measurements on pre-term
neonates show values of BMD ranging from 43 to 115 mg cm"2 in babies aged 23-41 weeks post-conception.
These figures are within the linear range of the system.
Improvements in neonatal intensive care have resulted
in increased survival rate of very premature babies of
less than 28 weeks gestation. The incidence of osteopenia
of prematurity has been shown to be in excess of 50%
in these particular infants [1]. This high incidence may
be explained by the fact that the fetal skeleton is most
intensively mineralized during the third trimester of preg¬
nancy when ahout 70% (30 g) of calcium may be incor¬
porated [2, 3]. This means that the very premature
infant tends to have low bone mineral content (BMC).
Conventional feeding regimes lead to far lower mineral
accretion rates than those achieved in utero [4], Because
of the need to understand and overcome this problem
both calcium metabolism and skeletal mineralization of
the human fetus and neonate have been the subject of
intensive study [5] but the lack of a simple, accurate
and safe means of determining BMC has been a limiting
factor in progress in the field.
For many years radiography was used but radiographs
appear normal until a deficit in BMC of the order of
20% is present [6], Lack of consistency in sequential
radiographs due to variations in both exposure and
development parameters mean that this technique is
unsuitable for following infants undergoing different
nutritional regimes. The application of photon absorpti¬
ometry to the determination of BMC in infants by
Steichen et al [7] in 1978 was a major advance in the
Received 2 November 1995 and in revised form 8 February
1996, accepted 6 March 1996.
field as it allowed the direct measurement of bone min¬
eral content without the intermediate use of film with all
its problems.
Neonatal bone, even at term, contains only relatively
small amounts of mineral, typically 0.2 gem"2 [8], To
measure these very small amounts of mineral, we built
and validated the first machine designed specifically to
measure the very small bones in the neonatal forearm
[9], Using this instrument we then went on to define
osteopenia of prematurity [10], to describe the pace of
mineral incorporation into bone in utero [11] and also
after birth [12], This system also allowed us to measure
mineralization in a number of pathological conditions
[13] and different nutritional regimes [14], Prior to this
we described the apparent resolution of osteopenia of
prematurity in pre-term babies [15]. One major problem
with this study was that the babies had to be well enough
to be moved to the measuring instrument. The size of
the samples and sensitivity of the instrument meant that
a difference of less than or equal to 15% between normal
term and premature babies at 71 weeks post-conception
would not have been statistically significant. This latter
problem could have been addressed by increasing the
size of the study groups but the problem of moving the
babies to the scanner proved more intractable. The sick¬
est pre-term babies were not and could not be included
in our studies using the, then, current technology. These
babies, typically, fail to thrive and have mineralization
patterns markedly different from those of premature
babies who are well at birth and normal for dates.
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A system measuring neonatal forearm bone
Lyon et al [16] reported a system for the measurement
of bone mineral in babies who were ill enough to warrant
intensive care. This system required the observer to
obtain two X-ray films of the forearm at 40 kV and
120 kV using a mobile X-ray unit. The films were sub¬
sequently digitized using a light box and video camera
and a form of dual energy X-ray absorptiometry was
carried out. More recently Williams et al [17] have been
using this technique to measure premature babies in the
incubator. Although offering a method which causes
minimal disturbance to the baby, the problems associ¬
ated with film radiography still affect this system and
are reflected in the reproducibility in phantom measure¬
ments of between 6% and 9.2% noted by the authors.
This technique underestimates the value of bone mineral
in phantom sets by between 15.6% and 18.5%. They
also give no suggestions as to why this inconsistency in
the underestimate occurs, but it is obviously a major
problem with this technique. All estimates of repro¬
ducibility and accuracy are based on phantom work and
one would anticipate that these values would deteriorate
in vivo.
This paper describes a new measurement instrument
which is: (1) portable; (2) compact enough to be placed
in the incubator; (3) fast enough in operation to cause
minimal disturbance to the neonate; (4) capable of imag¬
ing a section of the forearm in a reproducible manner;
(5) low dose enough to allow measurements to be made
at frequent intervals. Apart from the obvious advantages
in the solution of the problem which made the design
desirable, several other advantages accrue. As we can
measure a neonate almost immediately after birth we
should be able to separate the maternal in utero effects
on mineralization, such as placental insufficiency, from
the environmental effects experienced post-partum. Such
a system would also allow the effects of differing
nutritional regimes to be assessed whilst the baby is in
the incubator. Similarly the effects of various therapies,
on bone, could be monitored at regular intervals.
Apparatus
Equipment design
It is usual for forearm bone mineral scanners to meas¬
ure bone mineral across a region, often scanning a larger
region to identify an appropriately reproducible site. In
adults, the point of separation between the distal radius
and ulna has often been used. In neonates, little is known
about mineralization along the bones of the forearm and
so we had no preconceived notion about the optimum
site for measurement, both in terms of reproducibility or
clinical value. For this reason it was felt that it would
be ideal to obtain a map of bone mineral values of a
relatively large proportion of the distal forearm.
The equipment was developed using a radiation sensi¬
tive charge coupled device (CCD) camera which offered
the following advantages:
(1) A two-dimensional (2D) image of bone mineral con¬
tent of the distal and mid-forearm could be obtained.
(2) No scanning mechanism and so no moving parts
would be involved. Thus the technology could be
robust enough to be portable within a neonatal
intensive care unit.
(3) The device could be sufficiently compact to fit into
an incubator.
(4) The sensitivity of radiation sensitive CCDs would
allow sufficient data to be acquired in 1 or 2 s with
a low radiation dose [18].
The block diagram for the system is shown in Figure 1.
Photons are produced at 27.5 keV by the decay of an
125I point source of half life 60 days. A cone beam of
photons from the source is passed through the baby's
forearm which is held in a water bolus between two
parallel sheets of Perspex. Photons are differentially
absorbed by bone of varying mineral content and hence
the photon beam falling on the front part of the detector
has different intensities per unit area. Each of these inten¬
sities will be inversely proportional to the bone mineral
in the beam.
A bone mineral equivalent image can be calculated on
a pixel by pixel basis by the application of the equation:
Mb^CPBAABPB-PsPSJ] InCfo/l)- (1)
where /rB and ps are the mass attenuation coefficients for
bone mineral (3.1704 cm2 g-1) and water/soft tissue
(0.48016 cm2 g_l) respectively. pB and ps are the density
values for bone mineral (3.225 gem-3) and water/soft
tissue (1.0 g cm-3) respectively. / is the photon intensity
of an image pixel of the sample. I0 is the photon intensity
in the same pixel through the water bolus alone. MB
represents bone mass per unit area and is in units of
g cm-2 above the soft tissue/background level (which is
an arbitrary baseline).
To calculate BMC (grams) the bone image must be
integrated within a region of interest (ROI) and an equiv¬
alent area in the non-bone background subtracted. The
area normalized BMC (BMD) can then be calculated by
dividing the BMC by the area of the ROI. Because of
the mass attenuation coefficient used these values are in
grams of hydroxyapatite.
Most other single photon absorptiometry (SPA) adult
forearm BMC techniques do not use two separate acqui¬
sitions. In this system the IQ data are acquired mainly
to compensate for the different radiation path length
which results from using a point source with a 2D detec¬
tor array rather than a single collimated detector.
Consequently, with a sample of uniform thickness in the
beam, the acquired image of the signal intensity would
be maximum at the centre and gradually decrease radi¬
ally towards the edge of the image. This is due to the
increase in radiation path length with distance from the
centre (the inverse square law effect) coupled with an
increase in sample thickness as the radiation beam passes
through with increasing obliquity. The contribution of
both these effects could be calculated mathematically
from the precise geometry of the apparatus and correc¬
tion could be made to the image. However, it was felt
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Figure 1. Block diagram of apparatus.
that the use of an IQ image would be more reliable for
longitudinal studies as the precise equipment geometry
could change over a long time period.
Equipment construction
A Photonic Science X-ray Imager is used; this is a
high performance X-ray sensitive video camera, con¬
sisting of a thin polycrystalline layer of gadolinium oxy-
sulphide on a fibre optic substrate, optically coupled to
a high resolution, low light level, intensified CCD imager.
The active imaging area is a .50 mm diameter circle and
the captured image region is a rectangular region 40.mm
wide by 30 mm deep. A thin aluminium foil in front of
the gadolinium oxysulphide scintillator makes the
imager light-tight allowing operation under normal
ambient lighting conditions. Using an image intensifier
and coherent fibre optic components the image is trans¬
ferred from the scintillator to a solid state (CCD)
image sensor.
The camera electronics produce an output signal in
the form of a monochrome composite video signal of 1
volt peak to peak into a 75 Q load complying with
Comite Consultatif Internationale de Radiodiffusion
(CCIR) video standards. This video signal provides the
input to a Data Translation DT2867 integrated image
processor and precision frame grabber with a 16 bit full
image buffer (Data Translation, Marlboro, MA, USA).
This card, which is controlled by a 80486 personal com¬
puter running at 66 MHz, is capable of real time image
capture. We use it to capture images of 768 pixels across
a video scan line and 512 pixels (lines) in the frame with
an effective pixel size of 52 pm square, from which we
use a region of 32 mm by 24.5 mm. The digital image
may be viewed in real time before data accumulation
takes place. When positioning is satisfactory a simple
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button press will start data collection by adding captured
frames to the frame store until an image with sufficient
detail is obtained. These data are then stored as a 16 bit
image file and archived on a 1.6 GB hard disk drive for
later analysis; an image of the water bolus on its own is
also captured and stored for use as background in the
calculation of a bone mineral image. The specification
for this system was determined after a previously
reported feasibility study [18].
The internal construction of the system is shown dia-
grammatically in Figure 2 and illustrated in Figure 3(a).
The 125I source, 2 mm diameter, of initial activity 200
mCi, is held in a shielded container. In front of the
container is a simple shutter operated by a self contained
subminiature time delay relay unit controlled by a timer
dial and push button shutter release. The source, which
has a half life of 60 days, is renewed at 120 day intervals.
Constant path length is maintained by the Perspex sided
forearm and bolus holder located between the source
and the camera. Source-to-detector distance is 9 cm and
the source-to-sample distance is approximately 6.2 cm
with 3.5 cm between the faces of the forearm holder. The
bolus is a water filled condom which is wrapped around
the forearm. It fills the space between the Perspex sides
of the positioning device. An air gap between the pos¬
itioning device and the detector minimizes the effect of
scatter in the image. The video output, camera power
and control signals are coupled between computer and
instrument via an insulated cable at the rear of the unit.
Electrical construction and safety are consistent with
IEC 601/1 and comply with all regulations for safety of
the patient and operator. In use, the instrument is
encased in a non-conducting Perspex casing giving elec¬
trical isolation to both user and subject. The size of the
instrument is 52 cm by 20 cm. The controlling computer
The British Journal of Radiology, June 1996
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Figure 2. Diagram of apparatus design.
vemSmsassik
Figure 3. (a) Photograph of apparatus without protective cover. 125I source container (1), shutter (2), bolus holder (3), camera
(4). (b) Photograph of apparatus in incubator with baby.
is an IPC Porta PC P5-486 with docking station (IPC
Corporation (UK), Lancashire, UK) having a footprint
of 37 cm by 27 cm working into a Panasonic 5 inch
monochrome monitor of size 15 cm by 25 cm
(Matsushita Electric Industrial Co. Ltd, Osaka, Japan).
This compact controlling system is mounted on a small
trolley to improve mobility. The scanner is shown in use
in an open incubator in Figure 3b, where it may be seen
how compact the instrument is. This figure shows an
open incubator in order not to obscure the view of the
instrument in use. It is equally functional in a closed
incubator.
Data acquisition software, which controls both the
camera and the DT2867 frame grabber and frame store,
was supplied by Photonic Science, the manufacturer of
the X-ray imager. The software allows the user to specify
real time viewing of the video image on the monitor,
thus permitting the positioning of the forearm before
data collection is commenced. Data collected are
specified as a number of consecutive "grabbed" video
frames added into the frame store. Any number of frames
between one and 9999 may be specified but the user
should be careful that no pixels overflow (they have a
16 bit limit). Once a satisfactory image is obtained it
may be named and saved to disk. Files are later trans¬
ferred to an archive and analysis system based on a
DAN 66 MHz 486 desk top PC system with 1.6 GByte
hard drive.
Data analysis
A typical digital image is shown in Figure 4. Working
on a pixel by pixel basis a bone mineral image is
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Figure 4. Bone mineral image with cursor positioned for data
analysis.
calculated and, if required, displayed. Visible bone parts
of the image are actually the mineralized section of the
radius and ulna. Bone mineral values can be obtained
by integrating through an ROI placed in this mineralized
section. Currently we are investigating methods for plac¬
ing.the ROI and as a guide have developed a "T" shaped
cursor which the operator can place with the bar of the
"T" at the end of the mineralized portion of the radius
and the tail of the "T" along the axis of the bone as
shown in Figure 4. The operator can then opt to position
the ROI either at a fixed distance from the end of the
bone or at a percentage of the bone length from its end.
The length of the radius can be calculated by measuring
the palpated distance between the ulnar styloid process
and the olecranon and applying the regression equation
established by James et al [9], Results in this paper have
been obtained using an ROI 1.5 mm x 5 mm located
1 cm from the mineralized end of the radius axial to
the shaft.
Calibration and preliminary validation
The system was checked for linearity in the biological
range of interest by measuring aluminium foil. Differing
numbers of pieces of 15 pm thick aluminium foil were
placed in a water bath in the scanner, measures of its
J G Truscott, R Milner, P C Holland et al
thickness were obtained, and BMD equivalent values
were calculated. These are shown plotted against the
number of foils in Figure 5. Linear regression analysis
applied to these points demonstrated a correlation
coefficient of 0.999 (p <0.0001) indicating a high degree
of linearity in the mineral range of interest.
The reproducibility of the system was measured in vivo
by two experiments. In the first of these two consecutive
measurements were made on a set of 20 subjects without
repositioning the forearm between scans. In the second,
16 subjects were scanned twice with the arm being
removed from the system between scans. The precision
was then calculated for each case using the method out¬
lined by Bland [19]. This gave values of 5.5 mg cm"2
(8%) and 7.5mgcm~2 (11%) respectively. The whole
measurement procedure for a single scan took 5 min of
which 30 s was patient acquisition time.
The absorbed radiation dose to skin associated with
a single acquisition is approximately 6 pSv. This dose
was calculated based on an air kerma rate of 30 pGy
h"1 GBq"1 at 1 m [20] which allows for both y and
X-radiation. It should be remembered that this dose is
given to a small portion of the forearm when comparing
it with the typical dose for a paediatric chest X-ray of
40 pGy. As the forearm contains only skin, bone and
muscle and the beam impinges on a very small region
of the forearm the effective dose to the subject is
negligible.
After establishing this linear relationship and the pre¬
cision of the system we went on to measure pre-term
babies at a range of gestational ages from 23 weeks to
41 weeks.
The measurement procedure was well tolerated by the
babies studied. All measurements were made at less than
48 h of age and included babies of extreme prematurity
undergoing mechanical ventilation. None of them
showed any physiological evidence of distress or deteri¬
oration in their condition during the image collection.
Despite their requirement for intensive care, the most
immature babies were often easier to measure than their
more mature counterparts as they tended to be less
active. More active babies required more patience to
Density
Figure 5. Theoretical bone mineral equivalent using aluminium
foils versus calculated BMD. The horizontal dotted lines indi¬
cated the approximate range of BMD values for neonates.
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Assessment of Renal Osteodystrophy
in Dialysis Patients: Use of Bone
Alkaline Phosphatase, Bone Mineral
Density and Parathyroid Ultrasound in
Comparison with Bone Histology
Abstract
Bone biopsies were studied in 73 patients to determine if a two-site radio-
immunometric assay for serum bone alkaline phosphatase (BAP), total serum
alkaline phosphatase (ALP), serum intact parathyroid hormone (iPTH), hand
X-rays, regional bone mineral density (BMD) measurements and parathyroid
enlargement detected by ultrasonography could accurately predict renal osteo¬
dystrophy. In the patients studied 57 had hyperparathyroid bone disease, 4
mixed renal osteodystrophy, 3 adynamic bone disease, 1 osteomalacia and 8
normal histology. Serum BAP, ALP and iPTH correlated positively with min¬
eral apposition rate, osteoblastic, osteoid and eroded surface. In the diagnosis
of hyperparathyroid bone disease serum iPTH was the most sensitive investi¬
gation, detecting 81 % ofpatients at a level >100 pg/ml but with a specificity of
only 66%. Serum BAP was more sensitive, 70% at a level of > 10 ng/ml, than
serum total ALP, 30% at a level of 300 IU/1, with similar specificities, 92 and
100%, respectively. Ultrasound detection of an enlarged parathyroid gland
had a sensitivity of 64% and a specificity of 100% for the diagnosis ofhyperpa¬
rathyroid bone disease. Hand X-rays had a poor sensitivity, 47%, but a high
specificity, 92%, for the detection of hyperparathyroid bone disease. The
majority of patients had regionai BMD values within the normal reference
range and this test was of poor discriminatory value. The non-invasive mark¬
ers were unable to distinguish between patients with low turnover, mild hyper¬
parathyroidism and patients with normal histology. In conclusion the mea¬
surement of serum iPTH is a useful screening tool for the detection of hyper¬
parathyroid bone disease which can be confirmed by the finding of a raised
serum BAP or parathyroid enlargement. For definitive diagnosis, however,
the gold standard remains bone biopsy and at present one cannot recommend
any non-invasive method as an adequate substitute.
KARGER
E-Mail karger@karger.ch
Fax+ 41 61 306 12 34
http://www.karger. ch
© 1997 S. Karger AG, Basel
0028-2766/97/0754-0412$ 12.00/0 ~
This article is also accessible online at:
http://BioMedNet.com/karger
Dr. R.G. Jones
Department of Chemical Pathology and Immunology
Old Medical School
GB-Leeds LS2 9JT (UK)
Introduction
Bone disorders resulting from abnormalities in miner¬
al metabolism are common in patients with renal disease,
and their diagnosis and treatment remains a considerable
challenge to clinical nephrologists [1]. A reliable diagnosis
of metabolic bone disease can be obtained from a transil-
iac bone biopsy, but this is an invasive procedure un-
suited for repeated routine use. Biochemical and radio¬
logical investigations are used to try to identify high and
low turnover renal osteodystrophy (ROD). Hand X-rays,
despite their poor sensitivity, have traditionally been
used to detect hyperparathyroid bone disease [2], Serum
intact parathyroid hormone (iPTH), even though not a
direct product of bone metabolism, is currently accepted
as the most clinically useful marker of high turnover
ROD [3, 4]. Adynamic bone disease, which is being diag¬
nosed with increasing frequency in chronic renal failure,
is particularly difficult to establish with traditional mark¬
ers of bone turnover [5, 6]. The inability to diagnose met¬
abolic bone disease accurately in uraemic patients from
serum biochemistry has led to continuing work to devel¬
op plasma markers of bone turnover. Serum osteocalcin
and collagen breakdown products are renally excreted
and although they accurately predict bone turnover in
non-renal and pre-dialysis patients, due to the interfer¬
ence of breakdown products their use is limited in dialy¬
sis patients [7, 8].
Alkaline phosphatase (ALP), a product of osteoblasts,
has a long history as a marker of bone turnover in meta¬
bolic bone disease [9], Common routine measurement of
serum total ALP lacks specificity for bone disease due to
the inclusion of the activity of all isoenzymes, principally
from liver, bone, gut and kidney in biochemical assays
[10]. Serum bone-specific alkaline phosphatase (BAP) has
shown a greater correlation with abnormal histology in
renal failure than serum total ALP [11], but the accurate
measurement of specific isoenzymes has required compli¬
cated separation techniques based upon electrophoresis,
whereas more routine methods of isoenzyme separation,
including thermal stability, have provided only a qualita¬
tive differentiation of limited clinical value [12-14], The
recent development of a direct radio-immunoassay, using
two monoclonal antibodies to BAP, enables a more pre¬
cise assessment of osteoblastic activity [15],
The aim of the present study is to determine the rela¬
tive efficacy of certain non-invasive techniques to diag¬
nose renal bone disease using histologically and histomor-
phometrically defined bone biopsies. In particular, the
use of BAP as a plasma biochemical index ofbone forma¬
tion, regional bone mineral density (BMD) measurement,
hand X-ray analysis, and ultrasound examination of the
neck for parathyroid enlargement was evaluated.
Subjects and Methods
Patients
Seventy-three patients (39 male; 34 female) were recruited, in this
cross-sectional study, from the dialysis units of Leeds General Infir¬
mary and St. James's University Hospital (age range 23-78 years,
median 48; time on dialysis 0-14 years, median 3). All patients were
medically stable with no changes in therapy for at least 6 months
prior to their biopsy. In the 3 months preceding their biopsy there
was no change in the dosage or method of administration of vitamin
D, although there were minor modifications of dietary phosphate
and phosphate binders. Bone biopsies were performed on 39 patients
with a known elevated serum iPTH, 32 prior to entering a trial of
pulsed calcitriol, and 7 at the time of parathyroidectomy. Thirty-
three patients were biopsied when an opportunity arose for a general
anaesthetic, 19 at the time of transplantation, 9 when peritoneal dial¬
ysis catheters were inserted or repositioned, and 5 at the time of mis¬
cellaneous operations unrelated to dialysis. A single patient with clin¬
ical features of chronic aluminium overload and a positive desfer-
rioxamine stimulation test was biopsied to assess the severity of alu¬
minium deposition prior to treatment. Forty-six patients were on
peritoneal dialysis and 28 were on haemodialysis. Table 1 lists the
causes of end-stage renal failure in the subjects. All patients gave
informed consent and the study was approved by the local Ethics
Committees ofboth hospitals.
Bone Histology
Anterior iliac crest bone biopsies were taken from the 73 patients,
20 of whom had received tetracycline double labelling; 250 mg of
oxytetracycline was taken twice daily for 4 days, followed 10 days
later by 150 mg of demeclocycline twice daily for 4 days, and bone
biopsy 4 days later. Biopsies were taken using a Sheffield trephine
with a 7-mm diameter bore (Bolton Surgical Services Ltd., Sheffield,
UK). All patients were under general anaesthesia with 2% Marcaine
locally infiltrated and a 100 mg diclofenac suppository for analgesia.
Patients tolerated the procedure well but there was one case ofpersis¬
tent haemorrhage (which settled when packed) and two wound infec-
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tions requiringantibiotics. All biopsies underwent histological exami¬
nation, 57 were examined histomorphometrically, fragmentation
during the collection process making the rest unsuitable for the latter
procedure.
The tetracycline-labelled specimens were fixed immediately in
70% alcohol, while the remainder were fixed in 10% phosphate-buff¬
ered formalin, pH 7.3. Undecalcified specimens were dehydrated in
alcohol, cleared in xylene and embedded in methyl methacrylate.
Sections, 10 gm thick, were cut on a Jung k heavy duty microtome
(Reichert-Jung, Heidelberg) and stained for histomorphometry [16]
with either 1 % toluidine blue stain for 30 min or a modification of
the Goldner stain [4], In addition, sections 5-7 gm thick were stained
with 1% solochrome azurine, pH 5, for approximately 18 h for the
identification and localisation of aluminium impeding the bone sur¬
face [17], The relative surface extent of aluminium staining was sub¬
jectively assigned as <10% (normal-low A1 deposition), 10-33%
(low-moderate A1 deposition), 33-60% (moderate-high A1 deposi¬
tion) and >60% (extensive A1 deposition) [17], Other sections were
stained with haemoxylin and eosin for routine histological examina¬
tion. Histomorphometry was possible on 57 biopsies using a semi¬
automatic image analysing system OsteoMeasure (OsteoMetrics Inc.,
Atlanta, USA) and an epifluorescence microscope with ultraviolet
light for the analysis of the tetracycline labels. In addition to the rela¬
tive bone area within each specimen, a comprehensive range of for¬
mation and resorption variables was measured without prior knowl¬
edge of the corresponding biochemistry. On the basis of the histology
the biopsies were classified according to the following criteria:
(1) normal bone biopsies: no evidence of increased or decreased
bone turnover and normal osteoid distribution and thickness;
(2) adynamic bone disease: low bone formation rate with flat
osteoblasts, few osteoid seams and rare osteoclasts and resorption
cavities;
(3) osteomalacia: low and diffuse uptake of tetracycline, wide and
extensive osteoid seams from which cuboidal-shaped osteoblasts are
often absent and rare osteoclasts and resorption cavities;
(4) mixed renal osteodystrophy: combination ofosteomalacia and
hyperparathyroidism with poor mineralisation and wide and exten¬
sive osteoid seams in conjunction with increased numbers of cuboi¬
dal-shaped osteoblasts, osteoclasts and resorption cavities indicative
of hyperparathyroidism;
(5) hyperparathyroid bone disease: (a) mild - localised areas of
increased osteoblastic and osteoclastic activity, a slight increase in
osteoid tissue and resorption cavities but no evidence ofperitrabecu-
lar fibrosis; (b) moderate - more general increase in osteoblastic and
osteoclastic activity, with increased osteoid tissue, resorption cavities
with clearly defined but limited peritrabecular fibrosis; (c) severe -
extensive osteoblastic and osteoclastic activity with increased osteoid
tissue, usually of normal thickness, resorption cavities which are
increased in both extent and depth, areas of woven bone and exten¬
sive peritrabecular fibrosis.
BiochemicalAnalysis
The following biochemical measurements were made on stable
patients under standard conditions: serum calcium, phosphate, bio-
carbonate, and total ALP (range 100-300IU/1; BM Hitachi Autoana-
lyser, Boehringer Mannheim, Poole, Dorset, UK), serum iPTH (Ni¬
chols Institute, normocalcaemic range 11-55 pg/ml) and serum BAP
(Tandem OSTASE Hybritech, San Diego, Calif., USA, reference
range <19 ng/ml), serum aluminium (atomic absorption, Perkin-
Elmer, reference range 0.00-1.85 p.mol/1). Standard calcium was cal¬
culated by the equation of Payne et al. [18]: Std Ca = Ca + (40 -
albumin) x 0.025.
The samples were drawn from peritoneal dialysis patients imme¬
diately prior to their biopsy and for haemodialysis patients these
samples were taken prior to dialysis. There was no significant differ¬
ence in their serum calcium, phosphate, bicarbonate, total ALP and
iPTH between these study samples and the routine pre-dialysis sam¬
ples taken to monitor the adequacy of dialysis. In the 15 patients who
underwent fine needle aspiration of their parathyroid glands, there
was no significant difference between the biochemical values drawn
prior to their gland aspiration and those taken prior to bone biopsy
which was performed after the glands were sampled.
BMD Measurement
BMD of the lumbar spine (L2-L4), right femoral neck and total
body were determined in 65 patients prior to biopsy, by dual energy
X-ray absorptiometry (DEXA) using a Lunar DPX-L bone densitom¬
eter (Lunar Radiation Co., Madison, Wise., USA). Software version
1.3y was used for analysis of spine and femoral neck with extended
research mode selected for total body analysis. Results were ex¬
pressed as Z scores, the number of standard deviations of the mea¬
sured value from age- and sex-predicted normal values obtained
from a local population, reference range ± 2 SD [19]. Single photon
absorptiometry of the dominant arm was performed using a Nuclear
Data (ND1100A) bone densitometer. Bone mineral measurements
were made at sites distal (approximately 25% trabecular bone) and
proximal (approximately 7% trabecular bone) to an 8-mm gap
between the radius and ulna [20]. Scan analysis was made using Y03
software. Z scores were derived by comparison with a local control
group.
RadiographicAnalysis
Hand X-rays were performed on all patients prior to biopsy.
Images were obtained using a mammographic technique (Fuji MA
Mammography cassette loaded with CEA MA Mammography film,
processed through a Kodak X-OMAT Processor). All X-rays were
examined by a single radiologist blinded to histology. The severity of
acro-osteolysis of the terminal phalanx and subperiosteal erosions
were graded in each case and radiological evidence of hyperparathy¬
roidism was considered if grade 2 acro-osteolysis or grade 1 subper¬
iosteal erosions were present [21, 22],
Ultrasonography
High resolution ultrasound of the neck was performed on 53
patients, prior to biopsy (Ultramark 9 with a L10-5 MHz linear array
broadband transducer, Advanced Technology Laboratories, Both-
well, Wash., USA) by 2 radiologists blinded to histology. The detec¬
tion limit was 0.016 cm3. Since normal parathyroid glands could not
be detected, identification of parathyroid tissue was considered a
positive scan. Each gland was measured in three dimensions (X, Y,
Z) and the volume calculated, assuming it to be an ellipsoid [23J. In
15 patients cytological examination of ultrasound-guided fine needle
aspirates confirmed the presence of parathyroid cells whilst elevated
aspirate iPTH concentrations indicated a functioning adenoma.
All results are expressed as mean ± SD with Student's t test and
Pearson product-moment correlation used as appropriate, using AS¬
TUTE statistical calculator computer program.
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Table 2. Bone biopsy results with ancillary biological and biochemical data
Histology n Age Time on Standard Phosphate Bicarbonate Total ALP Bone ALP iPTH Serum
years dialysis calcium (0.8-1.2 (22-26 (100-300 (0-19ng/ml) (11-55 pg/1) aluminium
years (2.2-2.4
mmol/1)
mmol/1) mmol/1) IU/1) (0.0-1.85
gmol/1)
Normal 8 52.8± 12.1
Adynamic 3 54.0± 10.6
Osteomalacia 1 48
Mixed 4 51.5 ± 3.5
Mild HPT 11 42.7 ±12.2
Moderate HPT 17 43.6 ± 12.3
Severe HPT 29 48.6 ± 13.6°
1.5 ±0.9 2.46 ±0.23 1.83±0.23 21.7±3.0 147±63 4.24±1.68 99 + 102 0.36±0.12
1.7 ±1.1 2.43 ±0.18 1.98 ± 0.31 15.6 ±2.6 161 ±53 9.9±3.3 140±187 0.59±0.49
1 2.5 1.59 25.6 116 6.9 28 0.28
1.3 ± 0.5 2.56±0.28 2.3±0.2 20.0±2.4 161 ±43 7.02± 1.6 68±70 0.38±0.12
3.5 ±4.6 2.42 ±0.1 1.89±0.14 19.8±3.2 126±35 5.73±2.7 54±27 0.52±0.27
3.1 ±3.6 2.39±0.03 2.01±0.43 20.2±4.8 237±78** 15.8±10.4* 405±232** 0.75±0.35
4.1 ±3.7 2.5 ±0.25 2.06±0.55 20.7±4.4 361 ±190** 43.9±31.5** 780±455** 0.80±0.48
Results are shown as mean ± SD. Reference values and units for each parameter are indicated.
Statistically different values when compared with the patients with normal histology are shown as
*
p < 0.05; ** p < 0.01; *** p < 0.001. HPT = Hyperparathyroidism.
Table 3. Histomorphometric and histodynamic data for the study population
Histology n Bone volume Osteoid Osteoid Total osteoid Osteoblast Eroded Osteoclast Mineral
BV/TV volume thickness surface surface surface surface appositional rate
OV/BV O. Th OS/BS Ob. S.BS ES/BS Oc. S/BS MAR
(23.19±4.37%) (1.48±0.93%) (10.34±2.1 pm) (12.10±4.64%) (3.9 ±1.94%) (4.09±2.33%) (0.69±0.61% ) (0.63 ± 0.2 pm/day)
Normal 6 22.38±7.64 1.63±2.51 8.82±2.09 7.37±10.97 0.51 ±0.21 3.14±3.47 1.14± 1.13
Adynamic 2 20.91 0.45 7.68 3.41 - 5.79 1.62
21.59 0.59 11.1 4.94 0.77 -
Osteomalacia 1 23.04 13.19** 19.17** 32.59** 0.56 1.36 0.159
Mixed 3 31.39± 15.12 8.57±3.71** 14.89±3.74* 43.12± 11.31** 0.24 2.49±2.74 1.62 0.86
Mild HPT 9 22.24±4.94 1.91 ±2.00 10.98±2.34 8.1 ±6.96 0.68±0.25 2.12±2.63 0.43±0.28 0.58±0.14
Moderate HPT 12 21.77±4.56 6.49±4.34* 11.47±2.98 25.49± 16.41 1.35 ±0.99 6.66±3.23 1.69± 1.17 1.21 ±0.43
Severe HPT 24 23.37±7.02 12.05±8.69** 16.39±7.35** 37.96± 16.66** 2.53±2.51** 9.73±4.64** 2.46±2.46 1.11 ±0.47
Values are shown as mean ± SD. Where the number of patients is <2 individual values are given.
Statistically different values when compared with the patients with normal histology are shown as
*
p < 0.05; ** p < 0.01; *** p< 0.001. HPT = Hyperparathyroidism.
Results
Histology
The histological results classification of the 73 bone
biopsies with ancillary biological and biochemical data
are shown in table 2. There were 57 patients with predom¬
inant hyperparathyroid bone disease which included 1
patient with severe hyperparathyroid bone disease and
severe aluminium deposition. There were 4 patients with
mixed ROD and 4 patients with low turnover ROD, com¬
prising 3 adynamic and 1 case of osteomalacia. There
were 8 patients with normal bone histology. The high inci¬
dence of hyperparathyroidism in this study can be ac¬
counted for by patient selection. There was no statistical
difference in age between histological subgroups. Hyper-
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parathyroid patients tended to be on dialysis longer than
other histological subgroups, although this reached signif¬
icance only between severe hyperparathyroid and normal
histology.
The histomorphometry of the 57 undamaged bone
biopsies is shown in table 3. The patients with normal and
mild hyperparathyroidism on bone biopsy had histomor¬
phometric parameters comparable with the range of the
normal population included in the Osteo Measure soft¬
ware package and with our own previously published
data. One of the adynamic biopsies had a raised osteoclast
surface but the overall histomorphometric and histologi¬
cal picture was that of low bone formation. In the absence
of aluminium staining a diagnosis of adynamic bone dis¬
ease was reached by the 2 observers independently.
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Table 4. The correlation between the biochemical markers of
bone turnover and histomorphometric variables
Total ALP Bone ALP PTH
Total osteoid surface 0.44** 0.58*** 0.46**
Osteoid thickness 0.22 0.35* 0.31*
Osteoblast surface 0.51*** 0.49** 0.37*
Eroded surface 0.40** 0.36* 0.51***
Osteoclast surface 0.16 0.16 0.20
Mineral appositional rate 0.42** 0.54*** 0.49*
The data is presented as the r values obtained by Pearson prod¬
uct-moment correlation. Statistically significant values are shown as
*p<0.05; **p<0.01; ***p<0.001.
The incidence of bone surface aluminium deposition
was low; 7 patients (9.6% of the 73 biopsies) had mild
deposition, 2 (2.7%) had moderate deposition and the
patient with clinical aluminium toxicity had severe depo¬
sition. At the time of biopsy 11 (15%) were being pre¬
scribed aluminium phosphate binders, although 35 (48%)
had been prescribed aluminium hydroxide at some time
on dialysis. Mean serum aluminium levels were within
the reference range for all histological groups. The patient
with severe aluminium depositions had been prescribed
aluminium hydroxide for 9 years as a phosphate binder
with a serum aluminium within the normal range
throughout this time. Persistent bone pain and myopathy
raised the clinical suspicion of aluminium toxicity, which
was confirmed by a desferrioxamine stimulation test and
a bone biopsy. There was no correlation between the
severity of bone aluminium deposition and serum alu¬
minium.
Histopathological examination of the marrow revealed
2 unsuspected cases of non-Hodgkin's lymphoma.
Biochemistry
There was no statistically significant difference in plas¬
ma standard calcium, phosphate and bicarbonate concen¬
trations between the subgroups studied, mean levels lying
within the adult reference range. Mean serum iPTH levels
were raised in all subgroups except the patient with osteo¬
malacia. Mean serum total ALP and BAP levels were
within the reference range for all subgroups except those
with severe hyperparathyroidism. Moderate and severe
hyperparathyroidism showed significant elevated serum
iPTH, total ALP and BAP when compared with patients
with normal histology (table 2).
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Serum BAP, total ALP and iPTH all correlated signifi¬
cantly with mineral apposition rate, osteoid surface, os¬
teoblast surface and eroded surface (table 4). There was a
low degree of correlation between the osteoclast surface
and the plasma markers of bone turnover. There was a
wide variation in the values for osteoclast surface within
the histological groups as exemplified by the adynamic
patient described previously which the authors are unable
to explain.
In the diagnosis of hyperparathyroid bone disease a
serum iPTH >100 pg/ml had a specificity of 66% and a
sensitivity of 81 %. A serum BAP >10 ng/ml had a speci¬
ficity of 92% and a sensitivity of 70%. A serum total ALP
>300 IU/1 had a specificity of 100% but a sensitivity of
30%. When the investigations were used in combination a
serum iPTH >100 pg/ml and a serum BAP >10 ng/ml
produced a specificity of 100% and a sensitivity of 66%. A
serum iPTH >100 pg/ml and a serum total ALP >300
IU/1 had a combined specificity of 100% but a sensitivity
of 30%.
Bone Mineral Density
BMD for each histological group is shown in table 5.
Mean Z scores for each histological subgroup, except for
the spinal measurements for patients with mixed ROD,
were within 2 SD of a matched control population.
Patients with normal bone histology had a negative mean
Z score in the axial skeleton reflecting a loss of mineralisa¬
tion. There was a negative relation between severity of
hyperparathyroid bone disease and BMD in all regions
measured. Patients with mixed, mild and moderate hy¬
perparathyroid bone disease had a higher mean axial
BMD measurement than patients with normal histology
or adynamic bone disease. In the forearm there was an
increasing differential loss of BMD between the proximal
and distal forearm with increasing severity of hyperpara¬
thyroid bone disease which reached significance in pa¬
tients with severe hyperparathyroidism, p < 0.005.
Radiology
There was no radiological evidence of hyperparathy¬
roid bone disease in the histologically defined mild sub¬
group. Four moderate patients and 23 severe patients had
radiological evidence of hyperparathyroid bone disease
on hand X-rays (table 6). There was no significant differ¬
ence between the detection rate of subperiosteal erosions
and acro-osteolysis in patients with hyperparathyroid
bone disease. The specificity of a positive hand X-ray for
the diagnosis of hyperparathyroid bone disease was 92%
and the sensitivity 47%. When combined with a serum
Fletcher/Jones/Rayner/Harnden/Hordon/
Aaron/Oldroyd/Brownjohn/Turney/Smith
Table 5. Regional BMD expressed as a Z score ± SD
Histology Number Spine Femur Total body Distal Proximal
forearm forearm
Normal 7 0.38±0.21 -0.87±1.1 -0.93+1.4 -0.87 ±1.2 -0.83± 1.2
Adynamic 1 1 -0.86 -0.57 -0.23 -1.85
Mixed 4 2.85± 1.98 -0.09±1.1 -0.10±0.78 0.01 ±1.58 -0.17±2.12
Mild HPT 9 0.49± 1.1 -0.4±1.3 0.05±0.56 0.03±1.0 -0.16±0.9
Moderate HPT 15 -0.06±1.3 -0.24±0.87 -0.32±1.27 -0.5±1.4 -0.81 ± 1.5
Severe HPT 25 -0.77± 1.6 -0.95 ±0.9 -1.44± 1.5 -1.23± 1.5 -1.94± 1.9
HPT = Hyperparathyroidism.
Table 6. Radiological evidence of
hyparathyroidism in hand X-rays from
the study population
Histology Number Acro-ostcolysis Subperiosteal erosion
grade I grade III grade I grade II
and II and III
Normal 8 8 0 8 0
Adynamic 3 2 1 2 1
Osteomalacia 110 10
Mixed 4 4 0 4 0
Mild HPT 10 10 0 10 0
Moderate HPT 17 14 3 13 4
Severe HPT 29 10 19 6 23
HPT = Hyperparathyroidism.
iPTH > 100 pg/ml the specificity and sensitivity remained
the same.
Parathyroid enlargement was only detected in patients
with hyperparathyroid bone disease (Table 7). There was
no correlation between parathyroid gland volume and
serum iPTH levels. The specificity of the detection of an
enlarged parathyroid gland in the diagnosis of hyperpara¬
thyroid bone disease was 100% with a sensitivity of 68%.
When combined with a serum iPTH > 100 pg/ml the spec-
ificity and sensitivity remained the same.
Discussion
The histological response of bone to the metabolic dis¬
order of chronic renal failure is modified by age, sex,
underlying renal pathology, duration of chronic renal fail¬
ure, exposure to aluminium, medication and mode of
dialysis, leading to considerable individual variation in
Table 7. Detection of parathyroid enlargement by ultrasound in
the study population
Histology Number Parathvroid Volume, cm3
enlargement (mean ± SEM)
not detected
detected
Normal 5 5 0 -
Adynamic 1 1 0 -
Osteomalacia 0 0 0 -
Mixed 3 2 1 0.02
Mild HPT 6 5 1 0.07
Moderate HPT 12 7 5 0.09 ±0.03
Severe HPT 26 2 24 0.30±0.48
HPT = Hyperparathyroidism.
Assessment ofRenal Osteodystrophy Nephron 1997;75:412-419 417
type and severity of ROD [24], An accurate histological
diagnosis may be provided by a bone biopsy but, because
bone is a dynamic organ, the nature and severity of any
pathology may change with time. Regular, repeated bone
biopsies are generally an unacceptable method of moni¬
toring ROD due to the degree of discomfort suffered by
the patients. The measurement of plasma biochemical
markers of bone metabolism are used frequently to dis¬
criminate between high and low turnover metabolic bone
disease in non-renal patients. However, ROD is more dif¬
ficult to accurately diagnose using non-invasive methods,
particularly in the early stages, because traditional bio¬
chemical markers lack specificity and their metabolism
may be altered in the presence of uraemia [25],
In this study BAP, total ALP and serum iPTH corre¬
lated significantly with histomorphometric measure¬
ments ofosteoblastic activity. In patients with normal his¬
tology, low turnover and mild hyperparathyroid bone dis¬
ease there was no significant difference in serum BAP,
total ALP and iPTH levels. Markers of bone turnover
were unable to differentiate the bone pathologies in these
patients. It was surprising that the histomorphometric
parameters within these subgroups were all within the ref¬
erence range, despite the clear diagnostic histological dif¬
ferences. A serum iPTH greater than 55 pg/1, the upper
reference limit for normocalcaemic non-renal patients,
was the most sensitive investigation for the detection of
hyperparathyroid bone disease. A mean serum iPTH of
54 pg/1 was observed in the mild subgroup, several
patients with clear histological disease having 'normal'
iPTH values, i.e. <55 pg/1. However, a mean serum cal¬
cium of 2.41 mmol/1 for this group suggests that there is a
failure of PTH suppression within this group and the
selection of an isolated value for iPTH without regard to
prevailing calcium levels is inappropriate. We do not have
enough data in the present study to identify an appro¬
priate index value which would combine calcium and
iPTH values. In any event, lowering the limit below 55
pg/1 to increase sensitivity of detection of the mild cases
proves unacceptable due to the loss of specificity. An ele¬
vated mean serum iPTH was also found in several
patients in the adynamic, normal and mixed ROD sub¬
groups, reducing the specificity of a raised serum iPTH
for the diagnosis of hyperparathyroid bone disease.
The normal reference range for serum BAP is quoted
as less than 19 ng/ml, but in this study all but 1 of the
patients with low turnover or normal histology had a
serum BAP of less than 10 ng/ml. A serum BAP greater
than 10 ng/ml gave a sensitivity similar to serum iPTH
but with a greater specificity for the diagnosis of hyperpa¬
rathyroid bone disease where all the subgroups were
included.
BMD measurements were made in only 1 patient with
adynamic bone disease and this study cannot comment
on the diagnostic value of DEXA scanning to distinguish
between high and low turnover ROD. Within the hyper¬
parathyroid group there was a negative correlation be¬
tween increasing severity of hyperparathyroid bone dis¬
ease and BMD, although the mean values in all three sub¬
groups were within 2 SD of a matched control population.
DEXA scanning has little value in the diagnosis of hyper¬
parathyroid bone disease, but it may have the potential to
monitor its progress once it has been histologically diag¬
nosed. Confirmation would require a longitudinal study.
Increased bone turnover leads to cancellisation ofcortical
bone leading to a loss of bone volume principally in the
appendicular skeleton [24]. The proximal forearm has a
higher proportion of cortical bone than the distal forearm
[26], Increasing severity of hyperparathyroidism caused a
greater differential loss of BMD in the proximal than the
distal forearm, which was statistically significant in the
patients with severe hyperparathyroid bone disease. The
forearm, which reflects the changes in bone turnover
occurring with hyperparathyroidism, can therefore be
used for repeat measurements rather than subjecting the
patients to total body scanning.
Using a higher cut-off of iPTH of 100 pg/1 gave a speci¬
ficity of 66% and sensitivity of 81 %, the loss of sensitivity
being attributable to the number of patients with mild
bone disease who had normal or only marginally elevated
iPTH values.
Parathyroid volume measured at the time of parathy¬
roidectomy has been shown to correlate with the maximal
iPTH secretion, the shift in calcium set point and with the
duration and severity of renal failure [27], Advances in
ultrasound technology have improved the sensitivity and
specificity of detection of the parathyroid glands. In this
study the detection of an enlarged parathyroid gland was
more sensitive and specific than for the diagnosis of
hyperparathyroid bone disease than the radiological
changes on a hand X-ray. Ultrasonography would be the
appropriate radiological investigation to confirm the
diagnosis of hyperparathyroid bone disease in patients
with an elevated iPTH.
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Conclusions
At present there are no humeral markers or radiologi¬
cal markers capable of totally replacing a bone biopsy in
the diagnosis of ROD. The measurement of serum iPTH
was the most sensitive test in detecting hyperparathyroid
bone disease but was not highly specific particularly when
considering early and mild disease. When raised serum
iPTH was combined with an elevated BAP or the detec¬
tion of an enlarged parathyroid gland, the specificity of
the diagnosis was increased. The use of a number of non¬
invasive investigations, combined with sound clinical
judgement, may detect metabolic bone disease when
present in the majority of patients, although a minority
may still require a bone biopsy.
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Regional bone mineral density after orthotopic liver
transplantation
S. Hyder Hussaini3 Brian Oldroydb, Sheena P. Stewart6, Fiona Roman6,
Michael A. Smith6, Stephen Pollard3, Peter Lodge3, John G. O'Grady3 and
Monty S. Losowsky3
Objectives Although there is a fall in lumbar spine bone
mineral density (BMD) after liver transplantation, little is
known about femoral neck or total body BMD. Therefore
we determined: (a) the proportion of patients with pre¬
existing hepatic osteopenia before transplantation and (b)
the effects of transplantation on global and regional BMD.
Design Retrospective analysis of BMD measurements of
patients before and up to 2 years after liver transplantation.
Methods BMD was assessed by dual energy X-ray
absorptiometry in 56 patients, before and at regular
intervals after liver transplantation, for up to 24 months, to
measure total body, lumbar spine (L2-L4) and femoral
neck BMDs.
Results Pre-transplant, 23% of patients had osteoporosis
(a negative Z score > 2). Paired data before arid after
transplantation revealed no change in total body BMD.
However, there was a fall in lumbar spine BMD (1.04 ± 0.03
to 1.02 ± 0.03 g/cm2; P < 0.04) at 1 month after
transplantation. The reduction in lumbar spine BMD was
seen up to 12 months, BMD at 18-24 months being similar
to pre-transplant values. Femoral neck BMD also fell
I
(0.96 ± 0.06 to 0.83 ± 0.04 g/cm2; P < 0.03), but only after
6-9 months, thereafter remaining below pre-transplant
values until the end of the follow-up period.
Conclusions Although osteopenia is common in patients
with liver disease, total bone density does not fall after
transplantation. Nonetheless regional lumbar spine and
femoral neck bone density does fall after transplantation
with a risk period for femoral neck fracture which may
extend for up to 2 years. Eur J Gastroenterol Hepatol
11:157-163 © 1999 Lippincott Williams & Wilkins
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Introduction
Patients with chronic liver disease suffer from bone
disease [1—3]. Osteomalacia occurs particularly in pa¬
tients with cholestatic disease and is secondary to
vitamin D deficiency [4,5]. Reduced bone mineral
density (BMD), known as osteopenia, is present in up
to 40% of patients with chronic liver disease [6,7],
Osteopenia results in a two-fold increase in the rate of
axial spinal and appendicular peripheral spontaneous
bone fracture in patients with chronic liver disease
compared to healthy controls [6].
Orthotopic liver transplantation (OLT) is an estab¬
lished treatment for patients with end-stage chronic
liver disease with 1 year survival rates for elective
patients of over 90% [8]. In some patients undergoing
liver transplantation, pre-existing bone disease may
deteriorate due to factors such as prolonged bed rest,
immobilization [9] and immunosuppressive therapy
[10-12]. Nonetheless, good graft function after liver
transplantation might be expected to overcome the
osteoporotic effects of the underlying liver disease. The
initial studies of bone disease following liver trans¬
plantation have found a high rate of atraumatic bone
fracture [13-15] and a fall in BMD immediately after
transplantation [14,16,17]. However, long-term studies
suggest an overall improvement in BMD following
transplantation [14,17]. Immunosuppressive regimens
utilizing relatively high doses of steroids, especially in
the early post-operative period, may in part have been
responsible for these high fracture rates post-trans-
plantation [13,17]. Osteopenia in the non-transplant
population is a heterogeneous disorder with marked
anatomical regional variations in bone density [18-20],
The initial studies of BMD after transplantation
focused on the changes of lumbar spine BMD
[14,16,17], which consists of predominantly trabecular
bone. Only one small series has examined the effects of
0954 -691X © 1999 Lippincott Williams & Wilkins
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OLT on regional bone density [21]. Therefore, in a
cohort of patients undergoing OLT for end-stage
chronic liver disease we determined the following: (a)
the proportion of patients with pre-existing hepatic
osteopenia before transplantation and (b) the effects of
transplantation on global and regional BMD. Further¬
more, we assessed whether duration of hospital stay,
dose of steroids, number of rejection episodes, presence
of cholestatic liver disease, age and sex were potential
risk factors for post-transplant osteopenia.
Methods
Patients
We retrospectively identified all patients who under¬
went dual energy X-ray absorptiometry (DEXA) scan¬
ning before and after liver transplantation between
September 1989 and December 1994. Fifty-six patients
(33 female) with end-stage chronic liver disease were
identified, with a mean age of 51 ± SEM 1.5 y (range
24-69 y). Some of the patients studied have been
reported in a separate, but related study concerning the
changes in body composition after liver transplantation
[22]. Thirty-three patients had cholestatic liver disease, -
24 with primary biliary cirrhosis (18 female), seven with
primary sclerosing cholangitis (three female), and two
with secondary biliary cirrhosis (two female). A total of
nine patients had alcohol-related cirrhosis (three female)
and five had chronic autoimmune cirrhosis (four fe¬
male). Of the remaining 10 patients, three had crypto¬
genic cirrhosis (two female), four had neoplastic disease
(one female), one patient had hepatitis B cirrhosis and
one suffered from alpha-1 antitrypsin deficiency.
All patients were diagnosed on the basis of biochemical,
immunological or serological markers, together with
liver histology when appropriate. The diagnosis of
cryptogenic cirrhosis was made if a liver biopsy demon¬
strated cirrhosis with no diagnostic features, with the
exclusion of excess alcohol intake and following labora¬
tory findings of: (a) no autoantibodies and normal
immunoglobulins (to exclude autoimmune liver dis¬
ease), (b) negative viral serology for hepatitis B and C
and, (c) normal studies for iron, copper and alpha-1
antitrypsin. All patients with primary biliary cirrhosis
received 100 000 units intramuscular of vitamin D
(calciferol) per month.
Transplantation details
Clinical data were available in 43 patients with regard
to disease severity before transplantation. Six of the 43
patients were Child-Pugh [23] class A, 33 were class B
and 4 were class C. All patients were given triple
immunosuppressant therapy consisting of cyclosporin
(or tacrolimus in seven patients), azathioprine and
prednisolone. In 41 patients details of steroid dosage,
duration of hospital stay and number of rejection
episodes were available. Patients received a median
dose of prednisolone of 20, 12.5, 10, 7.5, and 7.5 mg at
time intervals of 1, 2-5, 6-9, 12 and 18—24 months,
respectively. The mean duration of hospital stay after
transplantation was 32 ± 7 days (range 14-96 days;
median 28 days). Ten (25%) patients had an episode of
cholestasis after transplantation due to a bile duct
stricture or cholestatic hepatitis. Only five (8%) patients
experienced an episode of post-transplant hepatitis.
One patient who was re-transplantedfor recurrent
hepatitis B did not receive any prednisolone post¬
operatively, to minimize the risk of hepatitis B recur¬
rence.
Controls
A group of 329 women (age range 20-81 y) and 115.
men (age range 20-78 y) were recruited locally as
controls [24]. Subjects with a history of prolonged
immobilization, fractures affecting the hip, spine or
wrist, medical conditions or on medication known to
affect BMD were excluded as control subjects. :• '.v;
Bone mineral density measurements
Total body, lumbar spine (L2-L4) and right femoral
neck BMD were measured by dual energy X-ray
absorptiometry using a Lunar DPX Bone Densitometer
(Lunar Radiation Corporation, Wisconsin, USA). Analy¬
sis of the bone scans was made using the manufac¬
turer's software (version 3.6) which calculated bone
ineral content (g) and bone area scanned (cm2).
Hence BMD was calculated (g/cm2) and Z scores
derived subsequently, corrected for age and sex, were
used in data analysis. The Z score for BMD is the
number of standard deviations above or below the
mean BMD for an age and sex-matched normal popula¬
tion. Patients were assessed before transplantation, at 1,
2-5, 6-9, 12 and 18-24 months after transplantation.
Statistical analysis
The number of patients stucjied at each of these time
periods was variable. Thus, bone mineral content was
analysed as paired data for each time period compared
to pre-transplant values, and tested for statistical
significance with the paired /-test. P values of < 0.05
were considered to be statistically significant.
To determine possible risk factors for osteopenia,
patients were stratified into those with negative Z
scores % 1. The World Health Organization defines
osteopenia as a BMD of > 1 SD below the mean for a
healthy young population [25], Since we wished to
compare patients with liver disease with controls of the
same sex and similar age, we defined osteopenia as
BMD > 1 SD below that for an age and sex-matched
control population, that is a negative Z score of > 1.
Osteoporosis was defined as a negative Z score of > 2.
Risk factors for osteopenia, i.e. severity of liver disease,
age, gender and cholestatic chronic liver disease, were
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compared before and after transplantation with the
non-parametric heteroscedastic /-test. Further possible
risk factors for osteopenia, namely duration of hospital
stay, dose of steroids and numbers of rejection episodes
were then compared in those with and without osteope¬
nia after transplantation using the non-parametric
analysis. Since multiple analyses, to determine risk
factors for bone disease, were performed on the same
dataset before and after transplantation, only P values
of < 0.01 were taken as demonstrating a significant
difference. The results were expressed as mean va¬
lues ± standard error of the mean (SEM), unless other¬
wise stated. Excel software version 5.0 (Microsoft
Corporation, 1 Microsoft Way, Redmond, WA 98052-
6399) was used to analyse data.
Ethical Considerations j t
The study was approved by the Ethics Committee of
St James's University Hospital.
Results ; \*f..
Pre-transplant bone mineral density
The data for total body, lumbar spine and femoral neck
BMD for controls and patients in all subjects and
stratified for gender are shown in Fig. 1. The total body
BMD of 1,15 ±0.01 g/cm2 in controls was significantly
greater than the BMD of 0.62 ± 0.15 g/cm2 in patients
(P < 0.001).. Similar differences were seen for lumbar
spine (1.16 ± 0.02 vs 0.49 ± 0.15 g/cm2; P < 0.001)
and femoral neck (0.94 ± 0.02 vs 0.52 ± 0.i3 g/cm2;
P < 0.002) BMD in controls and patients, respectively. •
As can be seen from Fig. 1, the pattern of osteopenia
was unchanged when stratified for gender, although the
difference in BMD was more marked between women
and their controls.
The number of patients with osteoporosis defined as a
negative Z score of > 2 or osteopenia defined as a
negative Z score of > 1 is shown in Fig. 2. A total of 13
(23%) of 56 patients studied had osteoporosis, i.e. either
total body, lumbar spine or femoral neck negative Z
scores of > 2. However, the numbers of patients with
total body, lumbar spine or femoral neck osteoporosis
was variable, highlighting the fact that the osteoporosis
was rather heterogeneous. Whole body DEXA results
"
detected only an extra two patients to those with
osteoporosis at either femoral or lumbar spine sites.
The prevalence of osteopenia was far greater than that
of osteoporosis, with 32 (57%) of 56 patients with either
total body, lumbar spine or femoral neck negative Z
scores of > 1. No additional patients with osteopenia
were detected with whole body DEXA scanning.
Pre-transplant deternoinants of osteopenia
Although total body BMD for patients with cholestatic
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Male subjects
Total body Lumbar spine Femoral neck
The data for total body, lumbar spine and femoral neck absolute bone
mineral density! (g/cm2) of patients (■) and controls (a) in all subjects
and stratified for gender. The mean values are represented by the bars
with the SEM8 depicted as lines. Any statistical differences between
controls and patients are shown as the following: * P < 0.03;
**P< 0.007; ***P< 0.0001.
patients with non-cholestatic liver disease (1.15 ±0.02;
P < 0.002), this difference was not statistically signifi¬
cant when corrected for age and sex as Z scores
(-0.90 ± 0.26 vs -0.70 ± 0.96; P = 0.07). Similarly no
significant difference was seen in lumbar spine (—0.96
± 0.22 vs —0.63 ± 0.19) or femoral neck (—0.57 ± 0.30
vs —0.32 ± 0.23) Z scores from patients with cholestatic
and non-cholestatic liver disease, respectively.
No significant differences in Z scores were observed
between patients with a Child-Pugh (CP) score of < 7
(range 5-7; median 7) and those with a CP score > 7
(8-13; 9.5)' for: (a) total body (-0.52 ± 0.25 vs -0.48 ±
0.34); (b) lumbar spine (—0.72 ± 0.20 vs —0.75 ± 0.29);





The regional variation in bone density is depicted as the number of
patients with osteoporosis (negative Z score of > 2; ■) or osteopenia
(negative Z score of > 1; □). The histogram shows the number of
abnormal Z scores at: total body (TB), lumbar spine (LS) or femoral
neck (FN) sites; total body alone or combined lumbar spine and femoral
neck measurements and as combined total body, lumbar spine or
femoral neck measurements.
or (c) femoral neck (—0.63 ± 0.25 vs —0.17 ±0.47)
BMD.
Bone mineral density after liver transplantation
The paired data for BMD after transplantation are
given in Fig. 3. The numbers of patients studied at 1,
2-5, 6-9, 12 and 18-24 months were 30, 23, 26, 17 and
If patients, respectively. Total body BMD fell slightly
at 2-5 months from 1.12 ±0.03 to 1.11 ± 0.03 g/cm2,
although this just failed to reach statistical significance





Time after OLT (mo)
Immediately after transplantation, there was a fall in
lumbar spine BMD, which persisted over the next 12
months. However in the 11 patients studied before and
18-24 months after transplantation no difference in
BMD was observed. In contrast to lumbar spine BMD,
there was no fall in femoral neck BMD immediately
after transplantation. Nonetheless, significant reduc¬
tions in femoral neck BMD were observed after 6-9
months which were sustained at 18-24 months after
OLT.
Symptomatic non-traumatic fractures
The patients included in this study did not undergo
systematic axial and spinal screening, radiology to
determine the rate of asymptomatic fractures. However,
the rate of symptomatic bone fractures was 11% (six of
56 patients) at 2 years. The details of the fractures with
BMD before and at the time of fracture are given in
Table 1. Only one patient with primary biliary cirrhosis
(PBC) experienced a fracture of the lumbar spine, the
remaining five patients sustaining femoral neck frac¬
tures. All the patients were female, four with PBC, five
over the age of 50 years. Four patients had negative Z
scores > 0.5 pre-transplantation and all had a negative
Z score > 0.5 at the time of fracture.
Post-transplant determinants of osteopenia
No differences in BMD were found between patients
stratified for age, gender, disease severity or disease






















Time after OLT (mo)
18-24
Paired data of bone mineral density (g/cm2) expressed as
mean ± SEM before and after orthotopic liver transplantation (OLT) for
total body, lumbar spine and femoral neck measufijfrraots. Paired data
that show a significant fall in bone mineral density are shown' as
follows: *P< 0.05; **P< 0.004.0, Pre-OLT;E2, post-OLT.
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Tabla 1 Atraumatic fractures after liver transplantation
Z score at 3ite of fracture
Age Time post¬
Patient (y) Disease Site of fracture transplantation (mo) ' Pre-transplantation At time of fracture
1 58 PBC LS 4 -0.56 -0.56
2 44 CC . FN 12 0.40 -0.77
3 65 PBC FN 24 -2.12 -1.98
4 52 PBC FN 2 -0.88 -1.62
5 59 ALD FN 8 -0.20 -0.86
6 59 PBC FN 9 -2.86 -2.82
Demographic details of the six female patients who experienced symptomatic atraumatic bone fractures after livgr transplantation at
either femoral neck (FN) or lumbar spine (LS) sites with Z scores corresponding to the site of fracture before transplantation and at
a time period nearest to the time that the bone fracture occurred. PBC, primary biliary cirrhosis; ALD, alcohol-related liver disease;
CC, cryptogenic cirrhosis.
time interval nor the duration of hospital stay was study which examined both femoral and lurr)!)^ ,,,
significantly different in patients with or without BMD after transplantation [21]. A possible
osteopenia (i.e. negative Z scores of > 1) post-trans- for the discordance in the fall of femoral h
plantation. Overall, 18 (44%) of the 41 patients had lumbar spine BMD may have been the large Uffja IBB
between one and three episodes of acute cellular used in the early time periods. Thus a subc/$ f mH!e.
rejection with no significant difference in the number femoral BMD in the 2-5 month period may hflyMUj in
of rejection episodes between those with or without missed. Nonetheless using this time scale we wmdmfeh
osteopenia. able to 'demonstrate a significant fall in lum^a/-! Itl il
BMD in the early post-transplant period. Fer^Wlplhe
DiSCUSSiOn bone density 2 years after OLT was still sigpuvf|66k
Our results confirm that there is a loss of BMD after lower than pre-transplant bone density. Thuf aiwitly
liver transplantation [14,16,17,26]. However, we have period for bone fracture may extend beyond till (Idk
reported the effects of transplantation on both trabecu- year and perhaps still exists 2 years followi/fyj/i fifst
lar and cortical bone, rather than trabecular bone alone plantation.
[14,16,17,26]. We consider this to be important since
osteopenia is a heterogeneous disorder with variable The regional variation in osteopenia before #/«.>
bone density depending on the site examined [21]. transplantation, observed in the current study, h|* rfktr
documented previously in studies of bone Ip^ tjf&th
The paired data did show a significant, though small, liver disease patients with osteoporosis [18-^'/'(6ft-
fall in lumbar spine bone density, confirming the bar spine is predominantly made up of trabee^jL/j/{/fft-
findings of other groups [14,16,17,26]. Thereafter there whilst proximal femur consists of mainly ftfe,
was no improvement over pre-transplant values in Trabecular bone has a higher turnover rate c^au/Mmb.
lumbar spine BMD up to 24 months post-transplanta- cortical bone [27] which may account iof Wm tti
tion. In contrast to our data, Eastell et al. [17] found variation in bone loss. 'Whal
that lumbar spine BMD returned to the pre-operative
values by about 12 months and was convincingly great- The regional loss of bone density without ^ ;
er than pre-transplantation BMD by 2 years. The delay total BMD has been demonstrated previp^Mif in
in recovery of lumbar bone density that we found renal [28] transplantation, but has not been r
confirms the observations of Arnold et al. [14], who following liver transplantation. Following n^fnodd
documented an early fall in BMD within 3-6 months, plantation these changes have been att^c//ifh$-
which thereafter remained unchanged in the majority differing regional skeletal responses to to
of patients up to 24 months after liver transplantation. [29,30] or a redistribution of bone coofjm/ntibti
However, long-term studies of bone density are re- trabecular to cortical bone sites [30], T)^
quired to determine the degree of reversibility of post- findings of an initial fall of lumbar spine bon^; Ydfit
transplant osteopenia, especially in transplant pro- and subsequent fall in femoral neck bone
grammes which use long-term corticosteroid therapy. little change in total body BMD support the ito^^ith
that there is a redistribution rather than abspjyi^mdSis
The timing of the changes of bone density in the bone following transplantation. However, Ym of
femoral neck was different to that in the lumbar spine, practice, the measurement of total BMD, ip jjdpnfeal
with a fall in femoral BMD after transplantation, lumbar spine and femoral neck BMD, is tb
confirming regional differences in another, smaller, benefit/since only two further cases of
..Hi / Wms1
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were detected before transplantation and no overall
changes in BMD were seen after transplantation.
The regional variations in bone density shown in the
current study, together with the definitions used for
osteopenia and osteoporosis, demonstrate the difficulty
in defining the exact prevalence of bone disease
patients with chronic liver disorders. In the current
series, 23% of our patients had osteoporosis and 57%
were osteopenic, although the exact figures would vary,
depending on which region of the body was studied.
Although these prevalence rates are comparable to
earlier data [6,7], we would suggest that both lumbar
spine and femoral neck BMD need to be assessed in
order to accurately determine the prevalence of osteo¬
penia in patients with chronic liver disease.
The small numbers of patients with cholestatic liver
disease in our study, together with the fact that these
patients received early transplantation and vitamin D
supplementation prior to transplantation, may account ~
•:' for thex absence of a relationship between cholestatic ..
disease and bone density found by some [31], but riot
all,.authors [17,32]. Furthermore, the short duration of -
hospital stay and relatively low dose of steroids admin-"'
istered were probably responsible for these factors not
being implicated in the development of post-transplant
bone disease. The median CP scores for the group of
patients with mild (7) and those with moderate severity
(9.5) liver disease were similar, with only four patients
with class C disease. This skew in the distribution of
disease severity towards milder disease may account for
the similar BMD in patients with mild or moderate
severity chronic liver disease before transplantation.
Since patients were not investigated systematically for
evidence of asymptomatic fractures, we believe that
the low fracture rate of 11% in the current series
underestimates the true asymptomatic fracture rate.
Others have reported a fracture rate of 20-65% in the
first year of transplantation [13-15,17,33], However, an
alternative explanation for the low fracture rate is the
relatively small magnitude of the reduction in BMD
after transplantation. The quantitative fall in lumbar
spine BMD was lower than some reports [13,15,17],
although similar to others [14]. Moreover a recent study
[34] reported no reduction in bone density in 82
patients undergoing transplantation. We speculate that
••{ the reason for the diminished reduction in BMD after
transplantation, compared to a decade ago, is a conse¬
quence of earlier liver transplantation, shorter hospital
stays and the use of steroids in lower dosages (with
steroid withdrawal in some programmes).
nVc^nclusion, although osteopenia is common in pa-
ffl^|^ith chronic liver disease, total bone density®^t;fall after transplantation. Nonetheless regional
8B£w;,<&- •• • '■
mm-- ?: ■ . *
lumbar spine and femoral neck bone density does fall
after transplantation with a risk period for femoral neck
fracture which may extend for up to 2 years. However
the magnitude of the fall in bone density after trans¬
plantation has declined over the last decade. This
suggests that the prevalence rate of asymptomatic
fracture should be reassessed with the use of modern
transplantation techniques.
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Abstract. Two non-invasive methods of bone measurement were, for the first time,
compared at the same part-body site. Bone calcium, using in vivo neutron activation
analysis, and bone mineral, using photon absorptiometry, were measured in the forearm in a
group of renal patients. A highly significant correlation was obtained from absolute values
(r = 0.91) which was reduced after normalisation (r = 0.75). Percentage changes, over
periods totalling 31.3 patient years, were also highly significantly correlated (r = 0.61,
P < 0.001). The precision of the techniques accounts for the spread of the bivariate data and
the estimated line of the true relationship was not significantly different from the line
described if the percentage changes measured by the two techniques were equal. The two
basic techniques were shown to be equally sensitive in vivo methods for monitoring calcified
bone in patients suffering from metabolic bone disease.
1. Introduction
In metabolic bone disorders such as renal osteodystrophy, osteomalacia and osteo¬
porosis, the loss of calcified bone will increase the tendency to fracture. It is therefore
necessary to establish a means of quantifying any such bone loss, both for the routine
management of patients and also to evaluate possible therapeutic regimes.
The two most precise non-invasive techniques of investigating the bone status are
neutron activation analysis (naa) and photon absorptiometry, naa has been used
clinically to measure both whole-body calcium and part-body calcium whilst photon
absorptiometry has been used principally to measure the bone mineral content (bmc) of
the forearm. The two techniques measure similar, though not identical, parameters.
naa measures purely calcium; photon absorptiometry, on the other hand, reflects total
mineral content, usually in a small volume of bone.
Comparisons have been made in clinical studies between absolute values, normal¬
ised values (a correction being made to eliminate the variation in patient size) and
fractional changes over a time period using the two techniques. Highly significant
correlations have been found between absolute photon absorptiometry and both
whole-body and part-body naa (Chesnut et al 1973, Cohn et al 1974, 1975, 1976,
Harrison etal 1974, Manzke et al 1975, Naik et al 1977, Zanzi etal 1978, Maziere etal
1979). As both techniques give values that are dependent on the size of the patient,
these correlations are to be expected. The correlation coefficients were reduced when
normalisation procedures were adopted in an attempt to correct for the size of the
patient (Cohn et al 1974, 1975, Manzke et al 1975). The significant correlations that
exist after normalisation may reflect the inadequacies of the normalisation procedures
rather than demonstrating any relationship between the techniques themselves.
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The most important comparison is therefore between changes measured over a
period by the two methods. All such comparisons reported so far have failed to
demonstrate any significant correlation (Harrison et al 1974, Aloia et al 1975, Cohn et
al 1975, 1976, Dabek et al 1977) though 'reasonable agreement' was found in one
study (Harrison et al 1974). It must be noted that different body sites were used for the
two techniques so the lack of correlation could therefore reflect the different rates of
change in bone at different sites in the body rather than differences between the two
methods.
This study seeks to obtain a valid comparison of the two methods by comparing
absolute, normalised and percentage changes measured by photon absorptiometry and
naa at the same part-body site, measurements of the forearm being correlated in a
long-term clinical study.
2. Methods and patients
The main purpose of our research work has been the development and evaluation of
naa to measure forearm calcium. Care was taken in the design and construction of the
apparatus to obtain a high level of precision. Photon absorptiometric measurements
however were performed using available apparatus which had been constructed many
years earlier in our workshop with the aim of monitoring bone mineral content in renal
patients.
2.1. Part-body naa
The calcium in the forearm was activated using two 252Cf neutron sources positioned
one either side of the forearm. The induced 49Ca activity was then measured by two
15 cmx 10 cm Nal detectors, also in a bilateral arrangement (Smith and MacPherson
1977, Smith and Tothill 1979). The irradiation apparatus had initially been designed to
measure only changes in forearm calcium. Three repeated measurements were per¬
formed at each visit producing a precision of the calcium measurement of 1.8%. At the
final visit an additional measurement was performed using the apparatus which was
more suitable for absolute calcium measurements. Immersion of the forearm in a water
bath (Smith and Tothill 1979) eliminated the variation in the sensitivity of activation
due to soft tissue around the bone. The precision of a single measurement of absolute
forearm calcium was 2.6%. To normalise for body stature the absolute calcium values
were divided by the cube of the patient's height, this factor giving the smallest spread of
the data from a series of normal forearm measurements (Tothill et al 1979).
The bilateral geometry effectively eliminated errors due to minor patient move¬
ment. The design of the apparatus, with the arm always held rigidly in the same arm
rest, eliminated any subjective choice of the measurement site and hence inter-operator
error. The efficiency of activation and detection are not uniform along the length of the
forearm, the combination approximating to a normal distribution of full width at half
maximum of 14 cm centred 19 cm from the centre of the fist. It is therefore not
appropriate to express the results in grams of calcium. The measurements are
'absolute' in the sense that the 49Ca counts recorded depend only on the mass of calcium
and its distribution along the sensitive volume, and not on such factors as the thickness
or composition of overlying tissue. The results are expressed as 'calcium counts',
corrections being derived for such factors as source decay by measurements on a
calcium standard.
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2.2. Photon absorptiometry
The bone mineral content of the radius was measured using the techniques described by
Cameron and Sorenson (1963). Calipers were used to define the measurement site
5 cm from the styloid process after which the forearm was positioned horizontally with
the inside of the forearm uppermost in a water bath. A 1.665 GBq (45 mCi) 241Am
source and Nal detector with a collimation of 0.5 cm x 1.2 cm, scanned across the
radius, counting for 5 s every millimetre (approximate count rate, 6 x 103 cps). Three
repeated scans across the radius were performed and the data were stored on punched
tape for computer analysis. The precision of the bmc measurement on normal
volunteers was approximately 3.5%. The width of the radius, obtained by plotting the
bmc values across the forearm, was used as the normalisation factor.
It is recognised that neither the site nor the source were ideal for bmc measure¬
ments. The former was used to be consistent with previous studies whilst the latter was
used for financial reasons. Our method of photon absorptiometry was more prone to
patient movement and repositioning errors than naa; in addition, varying amounts of
overlying fat would affect the bmc measurements.
Only about 10% of the bone at the 5 cm site is trabecular (Melsen etal 1979) so both
naa and photon absorptiometry are measuring predominantly cortical bone.
2.3. Patient group
Nineteen renal patients undergoing chronic haemodialysis at home were followed for
22 months in a study to evaluate the effect of dialysate calcium levels and treatment with
la-hydroxycholecalciferol. The same naa apparatus was used to measure the forearm
calcium at times 0, 8 and 22 months to determine the percentage changes over the first
8-month and then subsequent 14-month period. Changes in bone mineral content by
photon absorptiometry were also measured over the same periods. Of the 19 patients
at the start of the study, 18 were measured at eight months and the surviving 16 at 22
months. In addition absolute forearm calcium was measured at 22 months.
Absolute and normalised part body calcium and bone mineral content were
correlated in 16 patients and percentage changes were correlated from 34 sets of data
totalling 31.3 patient years. Regression analysis of the second kind (Documenta Geigy
1970) was performed on the data and P > 0.05 was taken to be non-significant. Having
performed the regression analysis on the percentage changes measured by naa and
photon absorptiometry a x2 value was calculated which established whether the known
errors of the two methods could account for any observed spread of the bivariate data
about a straight line (see Appendix 1).
3. Results
The results of the absolute measurements are displayed in figure 1 and the results of the
percentage changes in figure 2. As it is the percentage difference between the two sets
of measurements which is plotted in figure 2, the error becomes the precision x V2, i.e.
5.0% and 2.6% for bmc and naa respectively. The estimated line of the true
relationship (see Appendix 1) is displayed. This would only correspond to the major
axis of the ellipse (figure 2) if the precisions of the two techniques were identical.
Tolerance ellipses (P = 0.05) are displayed with the data and the results of the
regression analysis are given in table 1. The result of the x2 analysis of the data in figure
2 was x2 = 36.2 (P = 0.30).
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Figure 1. Correlation of absolute bone mineral content (bmc) measured by photon absorptiometry against
forearm calcium measured by naa.
% change
in bmc
Figure 2. Correlation of percentage changes in bone mineral content (bmc) by photon absorptiometry
against percentage changes in forearm calcium by naa. Estimated line of true relationship is displayed.
Table 1. Correlation coefficients.
n r P
Absolute values 16 0.91 <0.001
Normalised values 14 0.75 <0.01
Percent changes 34 0.61 <0.001
n = number of sets of patient measurements.
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4. Discussion
This group of renal patients proved to be an ideal one to correlate naa with photon
absorptiometry because not only did they have a wide variation in absolute naa values-
but also some large percentage changes over the period of the study. The naa results
are supported by clinical findings; a highly significant inverse correlation (/■ = —0.84,
P< 0.001) was found between the normalised forearm calcium and the duration of
dialysis and the patients receiving la-hydroxycholecalciferol were shown to increase
significantly their forearm calcium during the study (Winney et al 1977, Smith et al
1979, 1981).
The correlation coefficient r = 0.91 for absolute values falling to r = 0.75 after
normalisation agrees very well with the values found in comparisons between whole
body naa and forearm photon absorptiometry (Cohn et al 1975, Manzke et al 1975)
and is better than values obtained by Maziere etal (1979) and Harrison etal (1974) who
compared forearm photon absorptiometry with part-body naa of the hand and trunk
respectively. The decrease in the correlation coefficient from 0.91 to 0.75 after
normalisation suggests that the high correlation between absolute values is due to a
large extent to the size of the patient. As neither of the normalisation factors are
perfect, the true correlation is probably lower still. This inability to eliminate
completely the effect of stature means that the most important information can only be
obtained by comparing the changes measured by the two techniques.
There are two important questions that need to be answered from the analysis of the
percentage changes. Firstly, are changes in calcified bone measured by naa and photon
absorptiometry related and, secondly, if this is so, which is the more sensitive method.
This study is the first to show a highly significant correlation (r = 0.61, P< 0.001)
between changes measured by naa and photon absorptiometry. In addition the ,y2
value obtained showed that the errors of the techniques could account for the spread of
the bivariate data. This is further demonstrated by the fact that 80% of the data points
in figure 2 are within one standard deviation of the estimated line of the true
relationship, suggesting that the scatter about the line is due to the known measurement
errors. Consequently, if a perfect correlation between the methods did exist, the data
would not be distributed along a straight line but in an ellipse of comparable width to the
one obtained in this study.
Information about which of the two methods is the more sensitive is obtained from
the estimated line of the true relationship of the data (figure 2). This line crosses the
axes extremely close to the origin and the slope of the line appears to suggest that naa is
the more sensitive, as would be expected due to the better precision of the method.
However, the 95% confidence interval of the line contains the line Y = X so the line
through the origin with slope unity is not significantly different from the estimated line
of the true relationship of the data.
The discussion must now be extended to consider how the results from our specific
methods of naa and photon absorptiometry can be used to draw more general
conclusions about the two techniques. In our hands naa has a better precision,
although figures of 1% have been quoted for some photon absorptiometry apparatus
(Christiansen and Rodbro 1977). If, in figure 2, the bmc had the same precision as naa
then the line of relationship would be the major axis of the ellipse, which has a slope of
0.95. Thus naa and photon absorptiometry, generally speaking, are equally sensitive
in vivo techniques for monitoring bone status in the forearm in patients suffering from
metabolic bone disease. An implication of the findings is that the lack of correlation of
6 MA Smith et al
changes found by others is due to real physiological differences between parts of the
body and not to the use of alternative measurement techniques.
Appendix 1.
The equation to calculate\2 to test whether the specified error variances of the naa and
photon absorptiometry measurements are large enough to account for the observed
spread of the bivariate data about a straight line (Sprent 1966) is as follows:
Let
(5X)2 = error variance of x-axis
where
Sx = precision of naa measurement x V2.
Similarly for the y-axis for photon absorptiometry.
Then
2 Syy—2bSXy+b Sxx ^
T = /c ^ xui<c A (" ~1 deirees of freedom)(Sy) +b (Sx)
where




sxx = I (xi - x)2, Syy = X (y< - y )2
SXy =Z(x,-x)(y,-y).
b is the slope of the estimated line of the true relationship between x and y.
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Resume
Comparaison en une meme partie du corps de l'analyse par activation neutronique et de la mesure par
absorption des photons.
Pour la premiere fois, une etude comparative de deux methodes non-invasives de mesure de l'os ont ete
comparees, en une meme partie du corps. Nous avons mesure, au niveau de l'avant-bras, dans un groupe de
patients ayant une atteinte renale, le calcium osseux, en utilisant l'analyse par activation neutronique in vivo
et l'os mineral, en utilisant la mesure par absorption des photons. Nous avons obtenu une correlation
hautement significative pour les valeurs absolues (r = 0,91), celle-ci diminue apres normalisation (r = 0,75).
Les changements en pourcentage, sur une periode totale de 31,3 annees-malades, sont egalement correles de
maniere hautement significative (r = 0,61), P<0,001). La distribution de ces donnees bivariates est
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expliquee par la precision des techniques. La ligne de regression estimee a partir des vraies valeurs ne differe
pas significativement de celle obtenue en supposant que les changements en pourcentage mesures par les deux
techniques sont egaux. Nous avons montre que ces deux techniques de base, de surveillance in vivo de l'os
calcifie, chez des patients souffrant de maladies osseuses metaboliques, ont une sensibilite egale.
Zusammenfassung
Ein Vergleich zwischen Neutronenaktiviersungsanalyse und Photonenabsorptiometrie bei gleicher Teilkor-
perlage.
Zwei nicht-invasive Methoden zur Messung am Knochen werden bei gleicher Teilkdrperlage verglichen. Mit
der in vivo Neutronenaktivierungsanalyse wurde das Kalzium im Knochen, mit der Photonenabsorptiometrie
der Mineralgehalt des Knochens im Vorderarm von Nierenpatienten gemessen. Aus den Absolutwerten
(r = 0.91) erhielt man eine hochsignifikante Korrelation, die nach der Normalisierung (r = 0.75) reduziert
wurde. Prozentuale Anderungen waren ebenfalls hochsignifikant korreliert (r = 0.61, P = 0.001). Die
Genauigkeit, die man erhalt durch das Spreizen der zweidimensionalen Werte und die geschatzte Linie der
wahren Beziehung, war nicht sehr verschieden von der Linie, wenn die gemessenen prozentualen
Anderungen bei beiden Techniken gleich waren. Es wird gezeigt, dal3 beide Techniken gleich empfindliche in
vivo Methoden zur Darstellung verkalkter Knochen sind bei Patienten, die an einer Stoffwechselkrankheit
leiden.
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Sir,—Your recent leading article (4 April,
p 1096) draws conclusions with which we
cannot entirely agree. Certainly patients who
undergo surgery for peptic ulcer are at
increased risk of dying prematurely. This was
the conclusion in our article to which you
refer,1 and was re-emphasised in an extended
study (on 779 males aged 30-59 years operated
on from 1947 to 1965) recently presented to the
British Society of Gastroenterology. Over a
15-32-year follow-up period highly significant
increases in mortality occurred in all age
groups. In both studies we found that the major
contribution to this excess mortality was
provided by diseases which have close asso¬
ciations with cigarette smoking (carcinoma of
the lung and oesophagus, ischaemic heart
disease, and chronic bronchitis and em¬
physema2). In our experience gastric carcinoma
was no more common than predicted for an
age-matched Scottish population. Eighty-four
per cent of the patients studied were smokers
prior to operation and this proportion of
smokers remains unchanged among our
patients now undergoing highly selective
vagotomy.
Surgically treated ulcer patients as a group
are heavy cigarette smokers. The crucial
question therefore is not whether 5 % or more
of the survivors of the "gastrectomy bonanza"
will subsequently develop carcinoma of the
stomach but whether patients coming to
surgery can be persuaded to cease smoking.
Otherwise the trend towards premature death
will not diminish with the abandonment of
gastrectomy and patients undergoing highly
selective vatogomy will die as prematurely as
their gastrectomised predecessors.








Department of Medical Physics,
Royal Infirmary,
Edinburgh EH3 9YW
1 Din NA, Small WP. Gut 1974;15:335.
2 DoH R, Peto R. Br Med J 1976 jii: 1525-36.
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LATE MORTALITY AFTER SURGERY FOR PEPTIC ULCER
A. Hugh McLean Ross, M.B., Ch.B., Michael A. Smith, Ph.D., John R. Anderson, M.B., Ch.B.,
and William P. Small, Ch.M.
Abstract To examine the claim that life expectancy is
reduced after curative peptic-ulcer surgery, we studied
mortality and its causes in 779 men with peptic ulcer treat¬
ed surgically between 1947 and 1965. The minimum fol¬
low-up period of survivors was 15 years.
There was an excess mortality in the three major age
groups (30 to 39, 40 to 49, and 50 to 59 years at operation),
as compared with the general population (P<0.001), with
a mean shift of 9.1 years in the survival curve. Surgery
was not the direct cause of death. In particular, the eight
THE long-term survival of patients who undergocurative surgery for peptic ulcer has attracted
relatively little recent attention.1 In 1958 Krause
showed that patients tended to die prematurely in the
years after Polya gastrectomy2; the major contributors
to this excess mortality were tuberculosis, carcinoma
of the gastric remnant, suicide, and alcoholism. In the
same year Balint confirmed that the number of deaths
from pulmonary tuberculosis was significantly in¬
creased after gastric surgery; this report also added
ischemic heart disease and carcinoma of the lung to the
list.^ Other diseases since linked with gastric surgery
include carcinoma of the esophagus,4 certain neuro¬
logic disorders,5 and gallstones.6
The general increase in life expectancy since the
reports of Krause and Balint, together with earlier
claims that patients who had undergone surgery for
ulcer were bad risks in life-insurance terms,7 prompted
us to review the mortality trends in men undergoing
curative peptic-ulcer surgery.
The aims of our study were twofold: to determine
whether there was still a tendency for patients to die
prematurely after a successful peptic-ulcer operation,
and if so, to determine which factors contributed to the
excess mortality.
Methods
The records of all men between 30 and 59 years old who under¬
went peptic-ulcer surgery in the Western General Hospital between
1947 and 1965 were reviewed. These records are completed at the
time of surgery and updated at regular intervals thereafter by stand¬
ardized questionnaires or personal interviews.
Three categories of patients were excluded from the analysis:
those who died within one year of surgery, those who underwent
simple closure of a perforated ulcer, and those in whom peptic ulcer
subsequently recurred.
The patient's age at operation, the date of operation, the type of
operation, the smoking status at operation, the age at death, and the
cause of death were recorded. The cause of death in patients who
died at home during the study period was taken as the underlying
cause registered on the death certificate.
Of the 856 patients in the series, 77 (9 per cent) were excluded
either because their records were incomplete or because they were
lost to follow-up by the end of 1979. The study population therefore
comprises 779 patients. By the end of 1979, 360 patients had died.
From the Gastric Follow-Up Clinic and Gastro-lntestinal Unit, Western General
Hospital. Edinburgh, and the Department of Medical Physics and Engineering,
Royal Infirmary of Edinburgh. Address reprint requests to Mr. Small at the Gastric
Follow-Up Clinic, Out-Patient Department, Western General Hospital, Crewe
Rd., Edinburgh EH4 2XU, Scotland.
deaths from carcinoma of the stomach were no more than
expected. Excess mortality was due to smoking-asso-
ciated disease, which accounted for 200 deaths.
Eighty-three per cent of the patients were cigarette
smokers.
We conclude that substituting highly selective vagotomy
for gastrectomy will not lead to improved survival, because
80 per cent of patients now having operations for ulcer are
heavy cigarette smokers. (N Engl J Med. 1982; 307:519-
22.)
Six hundred seventy (86 per cent) of the 779 patients were treated
by gastrectomy, and 101 (13 per cent) by drainage with or without
vagotomy.
Method of Analysis
Actuarial survival curves were constructed to assess the mortality
rate for each of three 10-year age groups: 30 to 39, 40 to 49, and 50 to
59 years at operation. These curves were compared with curves of
expected survival calculated for the general population from life-
table figures obtained from the Faculty of Actuaries of Edinburgh
and appropriate to the period and the age groups under study. All
patients were included in the calculation of the percentage surviving
at 5, 10, and 15 years after surgery. In order to calculate the percent¬
age surviving 20 and 25 years after surgery, subgroups of patients
who underwent surgery before 1955 were used. The numbers of
patients in the subgroups from 30 to 39, 40 to 49, and 50 to 59 years
old were 85, 157, and 132, respectively.
The expected numbers of deaths from individual diseases were
obtained from figures published by the Registrar General for Scot¬
land (RGS).8 For this purpose, the study group was not divided into
the three groups used for the survival analysis. Two methods of
calculating the expected number of deaths were used. When avail¬
able from the RGS statistics, the death rate (expressed as the num¬
ber of deaths per year per 100,000 population) was used. Data were
analyzed in three five-year periods from 1965 (when input into the
study group had ceased and the size of the group was 701 patients)
until 1980. The age spectrum of the study group for each such period
was calculated in 10-year intervals and combined with data from the
RGS for the same age decades. The RGS data used were those for
the middle year of each period (1967, 1972, and 1977). The three
causes of death analyzed by this method were ischemic heart dis¬
ease, chronic bronchitis and emphysema, and carcinoma of the lung.
For the causes of death for which the death rate per 100,000
population was not published, a second method was used. The study
group was split into five periods from 1955 to 1980. As before, the
RGS figures used were those for the middle year of each period,
considered in 10-year age intervals. For each disease, the number of
deaths per year recorded in the RGS figures was expressed as a
percentage of the total number of deaths from all causes in the same
age group. This was then combined with the total number ofdeaths
in the corresponding age group of the study population for the
particular five-year period, resulting in the expected number of
deaths from a particular cause. This method of analysis alone was
applied to six causes ofdeath: carcinoma of the stomach, carcinoma
of the pancreas, carcinoma of the esophagus, carcinoma of the colon
and rectum, suicide, and cirrhosis of the liver. It was also employed
for ischemic heart disease, chronic bronchitis, and carcinoma of the
lung for the period from 1955 to 1965, when death rates expressed as
deaths per year per 100,000 population were not published. Both
methods of analysis took account of variations in causes of death
with age and time.
When appropriate, the chi-square test was used to assess signifi¬
cance. When the expected number of deaths was less than five and
the chi-square method was consequently invalid, the probability
was calculated directly from the equation of the binomial distri¬
bution.9
Reprinted from the New England Journal of Medicine
307:519-522 (August 26), 1982
Figure 1. Survival Curves for the Three Age Groups (30 to 39, 40 to 49, and 50 to 59
Years at Operation).
Curves for expected survival were calculated from general-population data obtained
from the Faculty of Actuaries of Edinburgh.
Results
When the life-table survival curves for each of the
three age groups studied are compared with the sur¬
vival curves predicted for the general population, it is
seen that the study population had a significant in¬
crease in mortality rate (Fig. 1) (P<0.001 in each age
group). Figure 2 shows the death rate per year for each
age group at operation over the first 15 years after the
the operation. The curve for the study group (which
includes a figure for 20 to 29-year-old patients who
underwent surgery for peptic ulcer during the same
period) is shifted to the left, indicating premature mor¬
tality; the mean shift of the curve is 9.1 ±0.1 years.
Table 1 shows the number ofdeaths from individual
diseases by age group during the study.
Deaths from diseases that have been identified as
having close associations with smoking,10 diseases that
have been related to the sequelae of gastric surgery,2
and other diseases with significant variations from the







Figure 2. Death Rates for Each Age Group during the First 15
Years after Surgery.
The study group is represented by the dashed line, and actuarial
data by the solid line. The figures include data for patients be¬
tween 20 and 29 years old who underwent surgery in the same
period.
Eighty-three per cent of the patients were cigarette
smokers at the time of operation.
There were eight deaths from carcinoma of the
stomach; the average time from gastrectomy to death
from carcinoma was 18.9 years.
There were significant increases in the numbers of
deaths from cirrhosis of the liver, suicide, carcinoma of
the colon and rectum, and carcinoma of the pancreas.
Discussion
Since Krause2 first identified the increased risk of
premature death in the years after peptic-ulcer sur¬
gery, this finding has been confirmed by others.3'11'12
Earlier, the nature of the link between the increased
incidences of ischemic heart disease, of tuberculo¬
sis, 13 of carcinoma of the lung, esophagus, or stomach,
of suicide, and of alcoholism after peptic-ulcer sur¬
gery was not always clear. However, the growing real¬
ization of the part played by smoking in the causation
of a number of these diseases clarifies the rela¬
tion of gastric surgery to shortening life expect-
ancy.10'14'15
Our study confirms a tendency for patients who
have undergone a curative ulcer operation to die pre¬
maturely in the years after the operation. The shorten¬
ing of life expectancy was approximately nine years —
a figure similar to that calculated several years ago
with some of the population data presented here."
The trend toward premature death occurred in each
age group at operation that we studied.
Thus, persons who have had surgery for ulcer are
indeed bad risks in life-insurance terms. The question
is why.
Of the four causes originally shown to be related to
gastrectomy, pulmonary tuberculosis has now been
virtually eliminated. We could attribute only two
deaths to this disease.
An increased incidence of gastric carcinoma after
gastrectomy has been reported,16"18 but we found that
it was no more common than predicted for an age-
matched Scottish population. Stalsberg19 suggested
20-29 30-39 40-49 50-59 60^69
AGE AT OPERATION (YEARS)
MEAN CURVE
DISPLACEMENT
= 9.1 i 0.15 years
that the increase in incidence occurs only 15 years or
more after surgery; before then, the incidence may be
decreased.20 The average interval between gastrecto¬
my and death from gastric carcinoma was 18.9 years in
our study, so that insufficient time may have elapsed.
If a subsequent increase does occur, its contribution to
the overall excess mortality will be small.
Thus, of Krause's original four contributors, only
alcoholism (as measured by liver cirrhosis) and sui¬
cide have in our experience contributed to the excess
mortality. But numerically the excess was small. The
major contribution was from the diseases that are
closely associated with smoking. In men these diseases
are identified as carcinoma of the lung and other respi¬
ratory sites, carcinoma of the esophagus, tuberculosis,
chronic bronchitis and emphysema, pulmonary heart
disease, aortic aneurysm, hernia, and ischemic heart
disease.10 In our study tuberculosis, hernia, and aortic
aneurysm accounted for only three deaths. Overall,
deaths due to the other five diseases were significantly
more common than predicted for an age-matched
Scottish population (P = 0.025), although individual¬
ly these increases over the predicted values did not
reach statistical significance. In particular, the num¬
ber of deaths from ischemic heart disease, though in¬
creased, was not significantly different from the pre¬
dicted value. Doll and Peto have shown that in men
the link between ischemic heart disease and smoking is
Table 1. Causes of Death According to Age Group.*
Cause of Death Age Group at Death (Yr)
total 30-39 40-49 50-59 60-69 70-79 >80
no. ofdeaths
Ischemic heart disease 128 1 4 36 65 19 3
Carcinoma of the lung 47 — 1 8 28 10 —
Cerebrovascular accident 29 — 2 5 13 9 —
Chronic bronchitis and
emphysema
22 — — 4 14 4 —
Bronchopneumonia 21 — — 5 7 6 3
Carcinoma of the colon and
rectum
16 — 1 2 11 2 —
Carcinoma of the pancreas 11 — 3 2 5 1 —
Suicide 10 — 4 3 1 2 —
Carcinoma of the stomach 8 1 — 1 4 1 1
Accident 8 — 2 4 2 — —
Hepatic cirrhosis 7 — 2 3 2 — —
Peripheral vascular disease 6 — - 2 2 2 —
Carcinoma of the prostate 5 — — — 3 2 —
Pulmonary embolism 5 - 2 3 — —
Other malignant diseases 21 — — 12 5 3 1
Other gastrointestinal
diseases
4 — — 1 2 1 —
Other respiratory diseases 3 — - 2 - 1 —
Other vascular diseases 3 — 1 1 1 — —
Miscellaneous 6 — 1 2 - 3 —
* Diseases that caused five or more deaths in the series are listed individually.
Table 2. Actual and Predicted Numbers of Deaths from
Individual Diseases, 1955-1979.*
Cause of Death No. of Deaths P Value f
ACTUAL PREDICTED
Ischemic heart disease and





Carcinoma of the lung and
other respiratory sites J
47 35.7 0.05




Carcinoma of the stomach 8 10.4 NS
Suicide 10 3.0 <0.05
Cirrhosis 7 2.2 <0.05
Carcinoma of the colon and
rectum
16 8.9 <0.01
Carcinoma of the pancreas 11 3.9 <0.01
*Diseases with established links with smoking, diseases traditionally linked with gastric
surgery, and other diseases with significant differences from the predicted number of
deaths are listed.
fNS denotes not significant.
^Smoking-associated disease.
strongest under the age of 45.10 In patients over this
age, the connection with smoking becomes weaker.
Since the majority of our patients had the operation in
their 40s, this may explain the insignificance of the rise
over the predicted values.
Confirming the findings of others,19,21 we found no
significant increase in carcinoma of the esophagus. Al¬
though suicide and alcoholism are both traditionally
regarded as potential sequelae ofgastric surgery, both
have established connections with smoking status.
Possibly, they are related to the patient's psycholog¬
ical background as well as the need for peptic-ulcer
surgery.
Carcinomas of the colorectum and of the pancreas
were significantly increased in our study population,
and these are also related to smoking status, although
in the case of colorectal carcinoma the association is
limited to carcinoma of the rectum.10 No connection
between these diseases and gastric surgery has been
described, to our knowledge.
Thus, we found that diseases known to be related to
smoking contributed more toward mortality than dis¬
eases traditionally linked with the sequelae or gastric
surgery.
Eighty-three per cent of our patients were habitual
cigarette smokers at the time of operation, and few
ceased to smoke after surgery. The trend continues
into the 1980s. Eighty per cent of our male patients
presently undergoing highly selective vagotomy for
chronic peptic ulceration are cigarette smokers, and
this is occurring in a population in which the propor¬
tion of male smokers is diminishing. Clearly, the men
who come to surgery for duodenal ulcer represent a
select group.
Recently it has been suggested that the crucial ques¬
tion determining the fate of patients undergoing sur¬
gery for peptic ulcer is whether 5 per cent or more
will subsequently have gastric-remnant carcinoma.22
Should this occur, it will have relatively little impact
on the problem of premature death after peptic-ulcer
surgery.23 Of much greater numerical importance is
the problem of premature death caused by diseases
associated with cigarette smoking. Despite reductions
in the number of men in the general population who
smoke, no such reduction is apparent in the group of
patients with chronic peptic ulceration who require
surgical treatment. The increase in premature death
after surgery that cures ulcer will therefore continue,
and since this increase is unrelated to the operation,
the move from gastrectomy toward more conservative
physiologic operations will not be followed by a signifi¬
cant improvement in life expectancy.
We are indebted to the staff of the Gastric Follow-Up Clinic and
the Department of Medical Physics and Engineering for their in¬
valuable assistance during this study, and to Prof. Sir Richard Doll
for his helpful comments.
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Late mortality after vagotomy and
drainage for duodenal ulcer
Sir,—In their report (5 May, p 1335) on d" g
survival of 711 patients who underway1 J
truncal vagotomy and drainage for PePaC|
ulcer Mr P C H Watt and others refer to our ft
previously published study of 779 men und#' J
going surgery for peptic ulcer mainly WJ
gastrectomy.1 Direct comparison is
possible. The Belfast series included men an j
women patients, our series was restricted ®|
men. The inclusion of women may expln®|
the discrepancy between actual /predict1?!
ratios (APR) for lung cancer (Belfast 3d|f
Edinburgh 1-32). The actuarial curves shd'hji
greater reduction in survival for women
men. To compare the two studies it would J
interesting to know the significance levels £
survival and for individual disease incide° ^
for the group of men only.
BRlTIsH MEDICAL JOURNAL VOLUME 289
Whatever the reason for any discrepancies
tvVeen the calculated APRs in Edinburgh
, Belfast, there is clearly a real difference
. the number of deaths due to gastric'
cinoma, which accounts for 7-1% of all
deaths in the Belfast study, compared with
nly 2-2% in the Edinburgh study. As all
tients had vagotomy and drainage in the
Belfast study compared with less than 13%
in the Edinburgh study, the type of operation
may explain the difference, though longer
follow up may be required before increases
are seen after gastrectomy.
Hone the less, of greater importance is the
confirmation by Watt et al of the much larger
contribution to excess mortality from disease
having close associations with smoking
(ischaemic heart disease, lung and oesophageal
carcinoma, and chronic bronchitis).' One
hundred and forty one of their patients died
of these conditions while only 16 died of
gastric carcinoma, emphasising the need to
influence smoking habits if late mortality is to
fall appreciably.
Finally, they confirm our finding of a
statistically significant excess mortality from
colorectal carcinoma following gastric surgery
(APR 1'8, p = 0 01). Although not a major
contributor to excess mortality, the increased
incidence of colorectal carcinoma is academi¬
cally stimulating in the search for factors of
aetiological importance in the development of
such tumours.






Edinburgh EH4 2XU ;
1 McLean Ross AH, Smith MA, Anderson JR, Small
WP. Late mortality after surgery for peptic ulcer.
N Engl J Med 1982;307:519-22.
z Doll R, Peto R. Mortality in relation to smoking:
20 years observations on male British doctors.
Br Med J 1976 ;ii: 1525-36.
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Metabolism of Sodium Pentosan Polysulphate
in Man - Catabolism of lodinated Derivatives
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Summary
An iodinated derivative of the heparin analogue SP54 has been
prepared and used in conjunction with unlabelled SP54 to study
the catabolism and organ distribution of this potential antithrom¬
botic agent in healthy human volunteers. As observed previously
with 125I-heparin, we found that the 125I-SP54 was rapidly cleared
from the circulation, returning later in a desulphated form. Organ
distribution studies with 123I-SP54 suggested that the liver and
spleen were major sites of desulphation. Gel filtration and
Polybrene binding showed the presence of sulphated mac-
romolecular SP54 and desulphated macromolecular and depoly-
merised SP54 in post-injection urines. No depolymerised material
was present in plasma suggesting depolymerisation occurs in the
kidney.
Introduction
Studies have demonstrated that heparin analogues which are
relatively inactive in vitro may be potent anticoagulants in vivo
and have led to a reappraisal of such properties (1, 2, 3). Pentosan
polysulphate (SP54) is a semisynthetic linear polymer of (1—>4)
linked (3-D-xylopyranose residues which contains s 1.8 sulphate
groups per monosaccharide unit and has a mean molecular weight
of 6,000 daltons. It is less active than heparin in vitro but exhibits
marked anticoagulant activity after injection in man. Several
workers have shown that the inhibition of factor Xa activity in
vivo is greater than obtained with a similar weight of injected
heparin while thrombin inhibition is less (4, 5, 6, 7). Fischer et al.
have also demonstrated that inhibition of factor Xa generation
may be an important mechanism of SP54's activity (8). Such
results have prompted clinical trials of the antithrombotic efficacy
of SP54 which suggest that it can prevent postoperative throm¬
boembolic complications (9, 10).
We have, therefore, investigated the catabolism of SP54 in
man in view of its potential clinical use as an antithrombotic drug.
Studies on the catabolism of heparin and its analogues have been
previously hampered by the lack of a labelled molecule combining
high specific activity with retention of biological activity but we
have described the preparation and use of an iodinated derivat-
ised heparin which possessed both properties (11). We have used
a similar approach with SP54 by preparing a derivative containing
tyrosyl residues via which the molecule can be iodinated using the
conventional chloramine T method.
" Correspondence to: Dr. I. R. MacGregor, Scottish National Blood
Transfusion Service, Headquarters Unit Laboratory, 2 Forrest Road,
Edinburgh EH1 2QN, Scotland, U. K.
The labelled SP54 has been used to study the catabolism of
SP54 after intravenous and subcutaneous injection in human
volunteers and to determine its organ distribution. The results
indicate that the catabolism of SP54 follows similar general
pathways to those previously described for heparin (11).
Materials and Methods
Derivatisation and Iodination of SP54
Gel filtered fractions of SP54 (Bene-Chemie,W. Germany) were
provided by Drs. Tangen and Granath, Pharmacia. Their mean molecular
weights were 3,000, 6,000 and 10,000 daltons as determined by low angle
light scattering.
Fractionated SP54 was converted from the sodium salt to the tetrabuty-
lammonium salt, freeze dried and dissolved in 0.5 ml dimethylsulphoxide
to a concentration of 40 mg/ml. It was then reacted with 14 mg of
carbonyldiimidazole at 56° C for 45 min following which 36 mg tyrosyl
hydrazide was added and allowed to react overnight at 20° C. The tyrosyl-
SP54 derivative was then converted to the Na+ salt by adding excess
sodium chloride, gel filtered on Sephadex LH-20 (Pharmacia, U.K.) in
distilled water, and finally freeze dried. Tyrosyl incorporation was
determined from the dry weight and absorption using a molar extinction
coefficient Ej^j, of 4.55 x 103.
10|ig aliquots of derivatised SP54 were iodinated with 125I or 123I
(Na125I and Na123I, carrier free, Amersham, U. K.) using the chloramine
T method of Greenwood et al. (12). The fraction of mean molecular
weight 6,000 was used in all metabolism experiments.
Characterisation of I25I-SP54
The molecular size distribution of 125I-SP54 was compared with that of
underivatised SP54 by gel filtration on a 95 x 3.6 cm column of Sephadex
G-50 (Pharmacia, U. K.). The column was developed with 13 mM
trisodium citrate, 150 mM NaCI, pH 6.7 and 8.3 ml fractions were
collected. The elution position of underivatised SP54 was determined by
measuring metachromasia with azure A (13), while that of the 125I-SP54
was measured by gamma counting (NE-1600 y counter, Nuclear Enter¬
prises, U. K.).
The labelled and underivatised SP54 preparations were chromatog-
raphed on a 7 x 5.6 cm column of protamine agarose using an exponential
gradient of 13 mM trisodium citrate, pH 6.7 containing from 0 to 3 M
NaCI and were detected as described above. Salt concentration was
measured conductimetrically.
Biological activity of derivatised SP54 was measured in an activated
partial thromboplastin time assay (APTT) in vitro by adding known
concentrations to a normal human citrated plasma pool (14). The APTT
calibration curve was compared with that obtained using underivatised
SP54.
Injection of I2SI-SP54 in Human Volunteers
Five healthy volunteers were fully informed of the procedures and aims
of the study. Their weights ranged from 52-77 kg (mean 68) and their ages
from 28-44 years (mean 34). Four subjects were injected intravenously
with either 0, 0.t,T, 7 or 50 mg SP54 containing 370 kBq 125I-SP54,-one-
subject receiving tracer alone and tracer plus 50 mg SP54 at an interval of
3 weeks. The fifth volunteer was injected subcutaneously with 50 mg SP54
containing 370 kBq 125I-SP54.The actual amount of injected radioactivity
was measured by counting a known fraction of the total volume of
injection. 30 mg potassiumiodide was given orally each day to the
subjects up to one week after injection. The unlabelled SP54 was an
unfractionated sample used clinically.
Blood samples were taken at various times after injection by clean
venepuncture from the antecubital veins and processed as described later.
Urine samples of measured volume were collected at known times after
injection.
Clearance ofI25I-SP54
Whole blood, platelet poor plasma (PPP), packed blood cells and urine
obtained at various times after injection were counted for radioactivity in
a gamma counter with the counts being corrected for background counts.
The binding capacity of 125I-SP54 for the polybasic chemical Polybrene
(Aldrich, U. K.) was determined by end over end mixing of 5 ml plasma
or urine with 0.2 ml of a slurry of Polybrene immobilised by linkage to
epoxy agarose 6B (Pharmacia, U. K.). The molecular size distribution
of125I-SP54 in plasma or urine was estimated by gel filtration on Sephadex
G-50 as described above.
Organ Distribution of 123I-SP54
Prior to injection, the syringe containing 10.0 MBq 123I-labelled SP54
and 1 mg unlabelled SP54 was measured against an 123I standard of
approximate activity 30 MBq. The subject was then injected in front of a
Scintag-Berthold gamma camera and a series of nine anterior views at
5 min intervals starting 7.5 min after injection, were stored on a Techni-
care MCS 560 computer processor. Immediately following this a single
5 min posterior view was recorded. The net detected 123I counts in the
liver and spleen were obtained for each image using variable regions of
interest on the computer. The absolute uptake, as a percent of the
administered activity, was obtained by relating the geometric mean of the
45 min and 50 min anterior and posterior image to the 123I standard which
was also counted using the gamma camera. The uptake in the liver plus
spleen was also measured at 3 hr and 43 hr after injection using a profile
scan on the whole body counter. The separate retention in the liver and
spleen at 3 hr and 43 hr could not be obtained because of the absence of
lateral resolution in the whole body counter profile. In all calculations of
the 123I retention, allowances were made for radioactive decay.
Results
Characterisation of IodinatecL SP54
In initial labelling* experiments with molecular weight fractions
of SP54, 125I was preferentially incorporated, on a weight basis,
into the lowest molecular weight fraction of 3,000 daltons. This
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Fig. 1 Clearance of 125I-SP54 from the circulation. Radioactivity was monitored in blood samples taken at various times after intravenous injection of
(nominal) 370 kBq 125I-SP54, with 50 mg SP54, A-A; with 7 mg SP54, O-O; with 1 mg SP54, A-A; with 0.1 mg SP54, and without unlabelled
SP54 □-□. 5 ml sample volumes were counted throughout.
Fig. 2 Absorption and clearance of 125I-SP54 in the circulation after subcutaneous injection. Radioactivity was monitored in samples taken at various
times after subcutaneous injection of (nominal) 370 kBq 125I-SP54 with 50 mg unlabelled SP54. Radioactivity in whole blood, A-A; in plasma, O-O;
and in packed cells, •-•. 5 ml sample volumes were counted throughout.
Fig. 3 Elution profile of gel-filtered radioactivity in plasma and urine obtained after i. v. injection of 125I-SP54. Radioactivity was measured in fractions
obtained after gel filtration of 5 ml plasma obtained at 320 min after injection of 370 kBq 125I-SP54, •-•; or 5 ml urine at 90 min after injection, O-O;
on a 95 x 3.6 cm column of Sephadex G-50 equilibrated with 13 mM citrate, 130 mM NaCI, pH*6.T. V0~=~void volume and Vs~= Solvent volume of the
column.
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reducing end of the molecule, rather than at free hydroxyl groups
throughout the molecule, since the charge density of each labelled
fraction was similar. Accordingly, a fraction of SP54 whose mean
molecular weight was 6,000 was used for derivatisation and
iodination and this exhibited a major elution peak coincident with
that of unlabelled SP54 upon gel filtration. A second peak of
radioactivity, which averaged 10% of the applied load, eluted in
the solvent volume of the Sephadex G-50 column. Tyrosine was
typically incorporated at 0.5 mole per mole of SP54.
Labelled and native SP54 eluted from protamine agarose at a
similar salt concentration of 1.7 M NaCl. Up to 14% of the
labelled material did not bind to the solid phase in 13 mM citrate.
Biological activity of the derivatised SP54 preparation of mean
molecular weight 6,000 daltons was assessed by prolongation of
the APTT of normal human plasma containing from 0-10 pg/ml
derivatised SP54 or unmodified SP54.The activity of the derivat¬
ised SP54 averaged 69% of the activity of unmodified SP54, tested
at three different concentrations.
Clearance of Injected 125I-SP54
Radioactivity was initially cleared from the blood with a half-
life of between 13-18 min at all i. v. doses except 50 mg where the
half-life was 45 min, assuming zero order kinetics (Fig. 1). 90% of
the radioactivity had been removed within 80 min of injection for
the lower doses and within 240 min for the highest dose. Most
remaining radioactivity was cleared in a second phase over the
next 24-96 hr. The clearance of 125I-SP54 from plasma and blood
was initially similar, but the radioactivity in plasma decreased
more rapidly than in whole blood, due to the progressive
association of 125I-SP54 with the packed cell fraction as shown in
Table 1.
After s. c. injection of 50 mg SP54 with 370 kBq 125I-SP54
radioactivity became detectable at 5 min post-injection and the
peak radioactivity in the blood occurred at 80 min as shown in
Fig. 2.
Table 1 125I-SP54 associated with plasma or packed cells
Time after injection
of 7 mg SP54 plus
370 kBq 125I-SP54 (min)
Radioactivity expressed as











Radioactivity due to plasma trapped in the packed cell fraction was
estimated and subtracted to allow the calculation of cell associated 125I-
SP54
injected dose (range 22-43%) and was not related to the dose of
unlabelled SP54.
Characterisation of 12SI-SP54 in Plasma and Urine
a) Affinity for immobilised Polybrene. The percentage of
radioactivity in plasma which bound to immobilised Polybrene
decreased with time after injection and the rate of decrease in
binding was less after 50 mg unlabelled SP54 than after the lower
doses (Table 2). 125I-SP54 with affinity for immobilised Poly¬
brene was present in urine samples obtained soon after injection
but not in later samples. Early urine samples contained more
Polybrene-binding material after injection of 125I-SP54 with 50 mg
unlabelled SP54 than for the lower doses of cold SP54. Thus in the
initial urine sampled 95 min after injection of 50 mg SP54, 78% of
the radioactivity bound to Polybrene agarose while in the urines
at 48 and 90 min after injection of 0.1 mg SP54 the binding was 43
and 9% respectively. With all doses the binding in urine was less
than 10% by 6 hr after injection.
Appearance of 125I-SP54 in Urine
Radioactivity was detectable in urine within an hour of i.v.
injection. The recovery of radioactivity in the urine within 24 hr
following both i.v. and s.c. injection averaged 31% of the
125,



















Fig. 4 Elution profile of gel-filtered radioactivity in urines obtained after i.v. injection of 125I-SP54 with 7 mg SP54. Radioactivity was measured in
fractions obtained after gel filtration of 5 ml urine obtained at 125 min, and 425 min, O-O after injection of 370 kBq 125I-SP54 with 7 mg SP54.
50% of the former and 3% of the latter sample bound to solid phase Poiybrene. Other details are as described in the legend to Fig. 3 except that the
eluting buffer contained 3 M NaCl.
Fig. 5 Distribution of 123I-SP54 in the liver and spleen after intravenous injection. The retention of 123I by the liver, and the spleen, O-O; was
assessed as described in the text after i.v. injection of 10.0 MBq 123I-SP54 with 1 mg SP54.
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Table 2 Relationship between binding of 125I-SP54 in plasma to immobi¬
lised Polybrene and time after injection showing the influence of
accompanying dose of unlabelled SP54
Dosage of unlabelled
SP54 (mg) injected
together with 370 kBq
125I-SP54
Time after injection (min)
10 20 40 80 160
_ 93 93 82 84 57 29
0.1 81 77 87 58 33 18
1 91 91 90 84 45 19
7 89 84 89 80 42 28
50 75 79 87 88 84 70
Binding shown as % of total counts added to binding system
b) Molecular size of 125I-SP54 in plasma and urine assessed by gel
filtration. Figure 3 shows the elution profiles of gel filtered plasma
and urine obtained after injection of 370 kBq 125I-SP54 in the
absence of any unlabelled SP54. Radioactivity in the plasma
sample obtained at 320 min after injection, eluted in a major peak
prior to the solvent volume demonstrating its macromolecular
nature. In contrast, radioactivity in a urine sample obtained
90 min after injection eluted almost entirely in the solvent volume
of the column, indicating that it was associated with low molecular
weight material (<1,000 daltons). Samples of urine obtained at
various times after injection of 125I-SP54 plus 7 mg unlabelled
SP54 were also gel filtered. Figure 4 shows the elution profile of
urines sampled at 125 and 425 min after injection. Radioactivity
in the first sample was associated both with macromolecular and
degraded material while that in the later sample was entirely
associated with low molecular weight material in the solvent
volume of the column.
Radioactivity bound to Polybrene-agarose after adsorption of
post-SP54 plasma (as described in section [a]) was eluted with 5 M
NaCl and gel filtered on Sephadex G-50 using 13 mM citrate
containing 3 M NaCl. The radioactivity eluted entirely before the
solvent volume indicating the absence of any low molecular
weight degraded material (results not shown).
Organ Distribution of 123I-SP54
123I-SP54 was prepared immediately before injection and
coeluted with unlabelled SP54 when filtered on Sephadex G-50.
88% of the labelled SP54 had high affinity for immobilised
Polybrene. After i.v. administration of 10.0 MBq 123I-SP54 with
1 mg unlabelled SP54 images taken at 5 min intervals from 7.5 to
47.5 min showed progressive uptake of 123I by the liver and spleen
(Fig. 5), such that at 50 min 60% and 7.5% of the dose respect¬
ively was associated with these organs. A profile scan at 3 hr post-
injection showed 60% of the activity in the liver plus spleen and
13% in the bladder. By 43 hr post-injection the liver plus spleen
retention was 37%. Urine collected over 18 hr post-injection
contained 35% of the administered activity while stools passed at
18 and 42 hr post-injection contained 0.13% and 0.07% respec¬
tively.
Discussion
Radioactively labelled heparin has been used by several groups
to study the metabolism of heparin in a number of species
(15-18). The most commonly used labels have been 35S and JH
both of which are rather unsuitable for use in man. The former
label is quickly detached from the polysaccharide chain during the
desulphation reactions and cannot be used to follow the subse¬
quent metabolism of desulphated material. The latter label is
hazardous and it is consequently difficult to administer sufficient
labelled material for accurate counting. We have previously
shown that iodination of a derivatised heparin resulted in a
labelled material of high specific activity which retained several of
the biological activities characteristic of heparin (11) and which
was suitable for injection in man.
A similar approach was chosen with SP54 and the following
criteria led us to conclude that the labelled molecule can be
successfully used as a tracer of SP54 metabolism in human
volunteers. Firstly, the derivatisation of SP54 involves activation
of ring hydroxyls or reducing end groups with carbonyl-
diimidazole to give an imidazolyl carbamate derivative which
reacts with tyrosyl hydrazide to yield tyrosine coupled to SP54 via
a urethane linkage (19). This linkage is very stable under the
conditions used in the chromatographic experiments and those
existing in plasma. Secondly, the labelled SP54 exhibited similar
affinities for protamine and Polybrene to native SP54 and the
molecular size distribution taking into account the effect of
substitution of the derivatising groups was also similar. Thirdly,
the labelled SP54 retained biological activity as assessed by the
APTT assay.
The kinetics of clearance of 125I-SP54 could not be accurately
determined due to probable redistribution following the bolus
injection. Even so it was clear that 125I-SP54 was removed from
the circulation more slowly when injected together with 50 mg of
unlabelled SP54. These results again point to the similar proper¬
ties of 125I-SP54 and native SP54, in this case competing for the
same mechanism of uptake from the blood-stream. A point of
inflection in the plasma clearance curves which was also previ¬
ously observed after injection of 125I-heparin (11) represents the
reappearance of 125I-SP54 or its degradation products from
extravascular sites.
Peak absorption of 125I-SP54 occurred after subcutaneous
injection at 80 min post-injection, and followed a similar time
course to that observed for biological activity in other studies (5,
6, 7, 8). These results demonstrate the suitability of the tracer for
following uptake and clearance of SP54 by the subcutaneous
route.
The redistribution of 35S-labelled SP54 from the plasma to the
packed red cells has been noted in the rat. In the present
experiments 30-40% of labelled material in later samples was
associated with cells (shown to be leukocytes by cell fractiona¬
tion) , but this total radioactivity only represented about 2% of the
injected dose. Binding to cellular elements of the blood is
therefore not a major metabolic pathway for SP54 clearance
which, like heparin, is probably mainly removed by the
reticuloendothelial system (20).
Gel filtration and Polybrene-binding experiments showed that
only macromolecular 125I-SP54 was present in plasma and that the
proportion with affinity for Polybrene decreased with time after
injection. We conclude that the material without affinity is
macromolecular desulphated SP54 and that the probable sites of
desulphation are the liver and spleen which are rich sources of
sulphatases (21). The 123I-SP54 imaging data supports this con¬
clusion since a major portion of the label became localised in
these organs.
From the absence of depolymerised 125I-SP54 in plasma it
appears that the kidney is the site of depolymerisation. Only
depolymerised label was found in the urine after injection of 125I-
SP54 alone while after injection of 125I-SP54 with high doses of
unlabelled SP54 both macromolecular label (some with affinity
for Polybrene) and depolymerised label was detected. These
results demonstrate the saturation of the desulphation and
depolymerisation mechanisms at pharmacologically relevant
doses of SP54. Such saturation has also been observed with
clinical doses of heparin (22), although the enzymic pathways for
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SP54 catabolism must differ from that of heparin due to structural
differences and remain to be defined.
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Correction Factors for Gravimetric Measurement of
Peritumoural Oedema in Man
B. A. BELL, M. A. SMITH, J. L. TOCHER & J. D. MILLER
University Department of Clinical Neurosciences, Western General Hospital, Crewe Road,
Edinburgh EH4 2XU, Scotland
Abstract
The water content of samples of normal and oedematous brain in lobectomy specimens from 16 patients with cerebral
tumours has been measured by gravimetry and by wet and dry weighing. Uncorrected gravimetry underestimated the
water content of oedematous peritumoural cortex by a mean of 1.17%, and of oedematous peritumoural white matter by a
mean of 2.52%. Gravimetric correction equations calculated theoretically and from an animal model of serum infusion
white matter oedema overestimate peritumoural white matter oedema in man, and empirical gravimetric error correction
factors for oedematous peritumoural human white matter and cortex have therefore been derived. These enable
gravimetry to be used to accurately determine peritumoural oedema in man.
Key words: Brain oedema, specific gravity, gravimetry.
Introduction
Interest in gravimetry of the brain began 135
years ago in Devon, with Sir Charles Bucknill's
measurements on the brains of deceased luna¬
tics'. A century after Bucknill's studies, Lowry
used gravimetry to study changes in brain
volume produced by freezing2, and in 1971
Nelson and his colleagues introduced micro-
gravimetry for the measurement of cerebral
oedema induced by water intoxication in
mice3. Nelson's technique was subsequently
refined in the cat4, and has been widely applied
to other animals and to man.
The estimation of tissue water content, and
hence oedema, from gravimetric measurements
requires the specific gravity of the tissue solids
to be known. This is a constant in oedema
produced by water intoxication3, but varies
when the oedema fluid contains protein, and
when the blood volume in the tissue changes5.
Marmarou and his colleagues derived a correc¬
tion for the white matter of the cat brain made
oedmatous by the direct infusion of serum,
which introduced an error in uncorrected
gravimetric water content measurements that
approached 4.5%5. This serum infusion oe¬
dema model is designed to simulate vasogenic
oedema in which vascular permeability to
plasma proteins is abnormal. Whilst it is
suggested that the correction factors derived
from these experiments might allow gravime¬
try to accurately measure water content in
cryogeiiically induced oedema, the possibility
that a different experimental model and differ¬
ent species may introduce new errors is
discussed, and no correction to account for
blood volume changes is made5.
An assessment of the accuracy of gravimetry
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to measure clinical brain oedema in man has
not been made, and this is what has been done
in the study reported here.
Patients and Methods
Neurosurgical operative treatment offered the
opportunity to measure brain water in 16
patients with intrinsic supratentorial tumours
of glial or metastatic origin. There were 14
men and two women, with an age range of
39-73 years (mean 58 years), and all were
investigated with preoperative CT (computed
X-ray transmission tomography) and NMR
(nuclear magnetic resonance) imaging of their
tumour. Surgery followed MRI (magnetic
resonance imaging) within 24 h, and 7 patients
had a frontal lobectomy, 4 a temporal lobec¬
tomy, and 5 an occipital lobectomy. The
lobectomy specimens were sealed in copolymer
film (Ethicon Ltd, Edinburgh, Scotland) to
prevent evaporative water loss, and taken
from the operating theatre to an adjacent
laboratory.
Eleven samples of oedematous peritumoural
cortex were obtained from the specimens, and
13 samples of oedematous peritumoural white
matter. Thirteen samples of normal cortex and
8 of normal white matter were obtained from
the poles of the lobectomy specimens in those
patients whose MRI showed a normal longitu¬
dinal relaxation time ( 7)) at the poles of the
lobe to be resected.
Each tissue sample was divided, and part of
it was weighed in its fresh state on a small piece
of dry aluminium foil that had an accurately
predetermined weight. The sample was then
dried in an oven at 80°C, and re-weighed at 24
h intervals until it reached a constant weight,
which was then recorded. The wet tissue
weight ( W) was obtained by subtraction of the
foil weight from the fresh weight, and the dry
tissue weight (D) by subtraction of the foil
weight from the dried weight. The wet tissue
weights ranged from 8.9 to 484.1 mg, with a
mean of 102.8 mg. Water content was ex¬
pressed as a percentage by weight of the fresh
tissue using the formula:
W-D
% water = X100
W
The remainder of each fresh tissue sample
was then divided into three portions weighing
approximately 5 mg each, and they were placed
in a calibrated layered oil density column for
specific gravity measurements3,4,5. Tissue
water content was calculated from the specific
gravity of fresh tissue (SG) using the equation:
weight of water m
b





and b = (Marmarou4)
SGsolids — 1
1
and SGsolids = (Nelson3)
(SG— 1) x W
1
DxSG
(SGsolids = derived specific gravity of the
solid component of normal brain tissue)
For our samples of normal brain, m = 4.688
and 6 = 3.688 for cortex, and m= 7.430 and
6 = 6.430 for white matter. These values are
similar to those derived for man by Takagi and
his associates6. Modified formulae were also
derived for man using Marmarou's theoretical
equations5 for both oedmatous cortex, where
?w = 8.145 and 6 = 7.005, and for oedematous
white matter, where m—15.905 and 6 =
14.566. (For the derivation of these values of
m and 6 please refer to the appendix).
Results
For the 13 samples of normal cortex, the mean
(± standard deviation) water content mea¬
sured by wet and dry weighing was 80.96%
(±0.86%), and derived from specific gravity
measurements was 81.01% (±0.92%). The
specific gravity of the solid component of
normal human cortex was 1.2711 (±0.0230).
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For the 8 samples of normal white matter, the
mean water content measured by wet and dry
weighing was 70.23% ( ± 0.88%), and derived
from specific gravity measurements was
70.25% ( ± 1.18%). The specific gravity of the
solid component of normal human white mat¬
ter was 1.1555 (±0.0086).
The specific gravity of the solid component
of the brain increased as peritumoural oedema
increased, for both cortex and white matter.
The rise in specific gravity of the tissue solids
was greater in cortex, where it averaged 0.0181
per 1% oedematous water increase (Fig. 1),
compared to an average rise of 0.0044 per 1%


















83 84 85 86
Wet/dry Water Content %


















For the 11 samples of oedematous peritu¬
moural cortex, the mean water content mea¬
sured by wet and dry weighing was 83.54%,
and derived from uncorrected specific gravity
measurements using Nelson's formula3 was
82.37%. The cortex results are presented
graphically in Fig. 3, and the progressive
underestimate of water content with increasing
oedema is apparent from the slope of the
regression line of the data (0.3841) compared
with the line of identity for the two different
measuring techniques which has a slope of
unity. For the 13 samples of oedematous
peritumoural white matter, the mean water
content measured by wet and dry weighing was
77.74%, and derived from uncorrected specific
gravity measurements using Nelson's formula3
was 75.22%. The white matter results are
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Fig. 2. Change in specific gravity of white matter solids
with increasing oedema.
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progressive underestimate of water content
with increasing oedema, although with less
error than in cortex, as the slope of the
regression line for the data (0.6068) is closer to
unity.
Discussion
Many workers who quantify cerebral oedema
with gravimetry have recognised the potential
for the errors highlighted by Marmarou and his
colleagues and have avoided calculating water
content from specific gravity measurements5.
They express their results directly as specific
gravity figures, and take a fall in specific
gravity to indicate cerebral oedema. This may
not always be a valid interpretation. Taking as
an example a 1 ml sample of normal human
white matter:
Example 1
Fresh weight = 1.0417 g
Specific gravity = 1.0417 g/lml = 1.0417
Dry weight =0.3104 g
Water content from wet
and dry weights =70.21%
Water content from
SG (Nelson3) =70.21%
For the same 1ml sample made oedematous by
adding 0.5ml of pure water to it:
Example 2
Fresh weight = 1.0417 + 0.5000 g = 1.5417 g
Specific gravity = 1.5417g/l.5ml =1.0278
Dry weight =0.3104 g
Water content from wet
and dry weights =79.87%
Water content from
SG (Nelson3) =79.87%
If 0.5 ml of normal human plasma containing
0.036 g of plasma protein is substituted for
water as the oedema fluid:
Example 3
Fresh weight = 1.5417 g + 0.0360 g= 1.5777g
Specific gravity = 1.5777 g/1.5ml =1.0518
Dry weight = 0.3104 g +0.0360 g = 0.3464 g
Water content from wet
and dry weights =78.04%
Water content from
SG (Nelson3) =63.41%
In these examples it has been assumed that
none of the protein from the plasma oedema
has been cleared from the oedematous tissue,
and the approximation that 1 ml water weighs
1 g at the temperature at which weighing was
performed has been accepted. With these
limitations, the extent of the error introduced
by plasma protein in oedema fluid is apparent
in Example 3, with an erroneous fall in water
content calculated using the uncorrected equa¬
tion3. This erroneous fall in water content
would also be construed from the measured
rise in specific gravity to 1.0518. Specific
gravity and water content derived by Nelson's
formula3 are directly mathematically related,
and the acceptance that calculated water con¬
tent figures are inaccurate means that the
underlying specific gravity figures are an
equally inaccurate indicator of oedema.
Specific gravity figures alone cannot there¬
fore be quoted when quantifying oedema, and
the derivation of a correction factor to allow
water content to be calculated from specific
gravity, as advocated by Marmarou and his
colleagues5, is essential for each particular
experimental protocol, or clinical aetiology. To
test whether Marmarou's corrections derived
from the serum infusion white matter oedema
model in the cat are applicable to clinical
peritumoural oedema in man, we have com¬
pared white matter water content measured by
wet and dry weighing, with water content
calculated from the specific gravity of the same
samples by Marmarou's derived equation cor¬
rected for man (Fig. 5). Marmarou's equation
progressively overestimates water content for
this type of oedema in man, as the slope of the
regression line for the data (1.3044) exceeds
unity. Deriving a corrected equation for human
cortex in accordance with Marmarou, a closer
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estimate of water content is obtained from
specific gravity measurements of oedematous
peritumoural cortex (Fig. 6).
Specific Gravity
Water Content %
70 72 74 76 78 80 82 84
Wet/dry Water Content %




Fig. 6. Oedematous cortex water content derived by
Marmarou's equation.
The reason why Marmarou's corrected
equation overestimates oedema in peritu¬
moural white matter relates to the degree of
the increase in the specific gravity of tissue
solids that occurs with increasing white matter
oedema. Marmarou assumes in his equations
that the protein content of vasogenic oedema
fluid equals that of serum. This latter assump¬
tion will lead to an overcorrection if in fact the
oedema fluid contains less protein than plasma.
This is highly likely in the case of peritumoural
white matter oedema in man, where the leak in
the blood brain barrier may be partially
selective and exclude some plasma proteins
from the oedema fluid. Some of the proteins
that are extravasated into the oedema fluid may
also be cleared from the tissue by reabsorption
into the vascular compartment, further reduc¬
ing the equilibrium protein content of the
fluid. The measured rise in the specific gravity
of tissue solids for a 1% increase in oedematous
water content is less for human peritumoural
white matter (0.0044 from Fig. 2) than for
peritumoural cortex (0.0181 from Fig. 1), and
this disparity between the two tissues is likely
to be accounted for by a lower protein content
of white matter oedema fluid compared to
cortex oedema fluid.
Empirical correction factors can be derived
from the regression line equations of our data
in Figs. 3 and 4. The error for oedematous
cortex shown in Fig. 3, can be corrected by
subtracting the constant (50.28) from the
uncorrected specific gravity derived water
content and multiplying the result by 2.603
(the reciprocal of the slope of the regression
line). The error for oedematous white matter
shown in Fig. 4, can be corrected by subtract¬
ing the constant (28.05) from the uncorrected
specific gravity derived water content and
multiplying the result by 1.648 (the reciprocal
of the slope of the regression line).
It must be stressed that these correction
factors are for uncorrected water content
derived from specific gravity measurements by
Nelson's formula3, and apply only to peritu¬
moural oedema in man. They cannot be
applied to animals, or where oedema in man
has been produced by pathological processes
other than a tumour. All measurements of
brain oedema, where the oedema fluid is not
pure water, must initially use wet and dry
weighing as a reference standard to allow the
derivation of correction factors for subsequent
gravimetric estimations. Gravimetry alone in
these circumstances cannot measure brain
oedema accurately, and the error is in the
specific gravity values themselves (Example 3)
as well as in the water content figures derived
from them by uncorrected equations.
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Appendix
Derivation of m and b for human brain, where the oedema
fluid is pure water, from Marmarou4:
SGsolids 1
m = and b =
SGsolids — 1 SGsolids — 1
For our samples of normal human cortex, mean
SGsolids= 1.2711, therefore:
1.2711 1
m= = 4.688 and b— = 3.688
0.2711 0.2711
For our samples of normal human white matter, mean
SGsolids = 1.1555, therefore:
1.1555 1
m = = 7.430 and 6= =6.430
0.1555 0.1555
Derivation of m and b for human brain, assuming the
oedema fluid contains the same amount of protein as
plasma, from Marmarou5:
Equation A105 m =
(Brain Water—Plasma Water) x (SGbrain x SGplasma)
(SGplasma—SGbrain)
Equation All5 b—
(Plasma Water X SGplasma) — (Brain Water X SGbrain)
(SGplasma—SGbrain)
For normal man, SGplasma= 1.0264 and Plasma Prote¬
in =0.0720 g protein/ml plasma7.
Plasma Protein 0.0720
Plasma Water = l = 1 = 0.9299
SGplasma 1.0264
For our samples of normal human cortex, mean Brain
Water=0.8096 g water/g brain (by wet/dry weighing),
and mean SG= 1.0422.








For our samples of normal human white matter, mean
Brain Water=0.7023 g water/g brain (by wet/dry weigh¬
ing), and mean SG= 1.0417.









The gravimetric method has been shown by many authors
to be a useful technique for measurement of brain tissue
water. It allows us to measure water content of small
samples rapidly and accurately and has considerable
advantages over conventional oven drying methods. This
article by Dr Bell and his colleagues, emphasises an
important point which is crucial to the correct application
of the gravimetric methodology. Specifically, one must
determine the nature of the edema fluid before using the
appropriate equations, which convert the gravimetric
measures directly to water content. In this study, it has
been shown that the fluid, which exudes from the tumorous
site in man, differs from that of serum. Thus, new
conversion factors are necessary in order to accurately
measure water content in adjacent tissue. Accordingly, it
would seem proper that studies of tumorous edema in man
utilise the equations described in this report. Complexities
arise when compressive effects of the tumor volume result
in barrier compromise or ischemia, in which case the
nature of the extracellular fluid is difficult, if not
impossible, to define. Under these circumstances, conven¬
tional wet/dry techniques share the same errors as
gravimetry and given a choice, the features of small
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Summary
OBJECTIVE We investigated interindividual differences in
the shape, slope and setpoint of the pituitary-thyroid axis
(PTA) in normal persons. Based on these physiological
data we propose a novel bivariate concept for the inter¬
pretation of thyroid function tests which is less biased by
interindividual differences in the PTA than the currently
used univariate approach.
DESIGN In two separate trials (A and B), healthy volun¬
teers were given small, increasing doses of T3 (7-5-45 fig/
day orally) over 5 days. The regulation characteristics of
the individual PTAs and the effects of age and gender were
assessed by general linear regression models. In addi¬
tion, serum samples were collected from normal persons
to establish the proposed bivariate approach for the
interpretation of thyroid function tests.
SUBJECTS The regulatory characteristics of the PTA
were determined in a total of 21 normal volunteers (eight
females, 13 males; age 24-49 years). Single blood sam¬
ples were collected from 257 normal volunteers. The
participants had no history of pituitary or thyroid disease.
MEASUREMENTS Free and total thyroid hormone and
TSH concentrations were determined in the serum. All
samples from one person were analysed in the same
assay in duplicate.
RESULTS A log-linear relationship between T3 and TSH
was found to describe best the individual PTA (multiple
r=0-96). However, significant differences in the setpoint
(P<0 00!) and to a lesser degree in the slope (P<0 05) of
the PTA were detected; this variability was not dependent
} Present address: Department of Medical Physics, University of
Leeds, Leeds General Infirmary, Great George Street, Leeds LSI
SEX, UK.
Correspondence and present address: Dr Christoph A. Meier,
Thyroid Unit. Room 4-767, University Hospital, CH-I211
Geneva 14, Switzerland.
on age or gender. Since these findings invalidate the
assumptions on which the current univariate interpreta¬
tion of thyroid function tests is based, we propose a novel
model for the evaluation of thyroid function tests derived
from the experimentally determined shape and average
slope of the PTA.
CONCLUSIONS The presence of significant age and
gender-independent interindividual variations in the set-
point of the pituitary-thyroid axis raises conceptual prob¬
lems with the current approach tor interpreting thyroid
function tests. An easy to use graphical bivariate repre¬
sentation of the normal ranges for thyroid function tests is
presented and exemplified by the thyroid hormone and
TSH measurements in a large reference population. This
concept should improve the diagnostic accuracy in the
borderline-normal, and particularly subclinical hypo¬
thyroid region of these hormone measurements.
To assess the thyroid function of a patient, the thyroid
hormone and TSH concentrations are measured in the
serum. The results are formally interpreted independently of
each other, i.e. by applying separate normal ranges for T3,
T4 and TSH levels (Caldwell et al., 1985; Klee & Hay, 1987;
Helfand & Crapo, 1990; Liewendahl, 1990; Surks et al.,
1990). Nevertheless, many clinicians intuitively reason that,
for example, a low-normal T4 level is more likely to be
indicative of early hypothyroidism when accompanied by a
high-normal rather than a low-normal TSH level. Presently,
however, no method exists which permits this knowledge to
be exploited quantitatively. The categorization of primary
thyroid disorders into subclinical and overt hypo and hyper¬
thyroidism is a direct consequence of this univariate
approach as shown in Fig. 1. Two fundamental problems are
raised by such a classification.
(1) When interpreting the thyroid function tests in a patient,
the thyroid hormone and TSH levels are implicitly
assumed to be uncorrelated in an individual normal
person within the normal range of the hormone concen¬
trations. If a correlation between these parameters exists,
the individual shape, slope and setpoint of this relation¬
ship influence the extension of the individual normal
range as represented by the maximally allowed varia¬
tions of thyroid hormone and TSH levels within the
normal range derived from a population (Fig. 1, see
legend) thus introducing an unpredictable bias.
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Fig. 2 Graphical representation of'the individual pituitary ■
thyroid axes. A curve of the shape T3 = M log(TSH) + N has been
fitted to the hormone levels of each individual person (mean
r = 0-96). Note the interindividuai differences in the regulation
characteristics and its influence on the individual normal range
(dashed lines represent the univariate normal range for the
hormone assays; see Subjects and methods), a, Individual axes
from study A (n= 14). b, individual axes from study B (n = l).
measure the FT4 serum levels within a range of 0-93 pmol/1,
the normal range being 9-24-5 pmol/1 (intra-assay CVs 9 and
4%, respectively). The concentration ofTSH was determined
with the ultrasensitive RIA-gnost hTSH assay using a
normal range of 0-3-3-0 mIU/1. The intra-assay CVs for
0-13 mIU/1 were 20 and 3% for 5 mIU/1.
Study B. The FT3 serum concentrations were measured
using the Amerlex-M RIA kit (Amersham Inc., UK) cover¬
ing a range of 0-40 pmol/1 with a normal range of 2-9 8-9
pmol/1. The intra-assay CV was 3% at 5-0 pmol/1. The
Amerlex-M Free T4 RIA was utilized to measure the FT4
serum levels within a range of 0-130 pmol/1, the normal
range being 9-4-25 pmol/1. The intra-assay CV was 4% at
14-8 pmol/1. The concentrations of TSH in the sera were
determined with the ultrasensitive Amerwell TSH immuno-
radiometric assay (monoclonal) using a normal range of
0-36-3-25 mIU/1. The sensitivity was better than 0-06 mIU/1
and the intra-assay CV for 0-8 mIU/1 was 4-4%.
All samples from one person were analysed in the same
assay in duplicate. The normal ranges given above are those
currently in use by the respective laboratories and were
utilized in Fig. 2.
Statistical methods
The data transformations, summary statistics, generalized
linear regression modelling, Wilcoxon signed rank test,
Kolmogorov-Smirnov and chi-squared goodness-of-fit tests
were carried out on an IBM-PC with SYSTAT 5-03 (Systat
Inc., Evanston IL, USA). Analysis of covariance with a
repeated measures design was used to compare the slope and
intercept of multiple regression lines (Neter el al., 1990).
Similar multiple regression models were specified to test the
influence of sex and age on the interindividuai differences in
the pituitary-thyroid axis. Unless stated otherwise the results
were expressed as mean + one standard deviation (x ± SD).
Results
Table 1 summarizes the hormone levels of the 21 persons
from studies A and B after the administration of the T3 doses
indicated. In study A, the TSH and FT4 concentrations had
already declined significantly on day 2. Until and including
day 4 the TT3 levels remained within the normal range
accompanied by steadily declining TSH concentrations,
demonstrating the continuous regulation of TSH by T3
within the normal range of the hormone concentrations.
Because a small threshold in the pituitary-thyroid regulation
could not be excluded from these data, this possibility has
been investigated by the measurement of the TSH levels
every 20 minutes after a single oral dose of 6 pg T3 was given
to a healthy person. This resulted in a decline of TSH levels
by 0-6 mIU/1 within 4 hours (duplicate experiment in one
person, controlled for circadian rhythmicity; data not
shown). Taking into account the slightly different dosage
regimen, study B showed a similar time course of the relative
hormone level changes.
The regulation characteristics of the individual feedback
axes were investigated by fitting a separate line through the
T3 us TSH data points of each person using multiple
regression with a repeated measures factor. The residual
mean squares were significantly lower when a regression line
was fitted through the log-transformed rather than the linear
TSH levels (P < 0-0005 in studies A and B); hence a
logarithmic curve described the individual relationship
between TT3/TSH in study A (multiple r = 0-97) and FT3/
TSH in study B (multiple r=0-95) well. However, a signifi-
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Fig. 3 Representation of the proposed
modified bivariate concept for the
interpretation of thyroid function tests.
The FT3 and TSH levels of 257 normal '2
individuals were plotted and a univariate
normal range box (dashed lines) based on
the 2-5th and 97-5th percentiles was
calculated. Three classic bivariate
confidence ellipses (for 95-45, 99-73 and
99-99% corresponding to the probabilities 9
of ±2 SD, +3 SD and +4 SD,
respectively) are shown in solid lines. The
zones (stippled lines) for + 2 SD, + 3 SD 5
and +4 SD derived from the proposed °
modified bivariate model have been £
calculated as described in the Appendix. 10
Essentially, for each person the FT3 and m
TSH levels are standardized and subtracted 2
to yield a new parameter ZD, which is
representative of the distance moved along
the average pituitary-thyroid axis. The 2
normal range for ZD is between ± 2 SD,
while the other lines ( + 3 SD, +4 SD) may
represent an empirical measure of the
probability to suffer from thyroid disease.
Contrary to the univariate and classical
bivariate approach, this concept allows for 0









feedback axis and its parallels as depicted in Fig. 3 and
described in detail in the Appendix. The average axis is
defined by the experimentally found logarithmic shape and
the average slope from study B. These zones provide several
advantages over the univariate normal range matrix as well
as over the bivariate confidence ellipses.
(1) They allow for differences in the setpoint of the pitui¬
tary-thyroid axis and are less sensitive to interindividual
variations in the slope of the axis than is the conventional
approach. It is apparent from the statistical analysis and
Fig. 2 that the variability in the setpoint is an important
factor for the interindividual differences in the regulation
axes. Although an ideal model would take into account
the slope of the axis in a given patient, this information is
obviously not generally available.
(2) Not only can the binary question, whether a pair of FT3
and TSH levels is within or outside the normal range, be
answered but an empirical measure of the piobability
that a patient with borderline abnormal thyroid function
tests suffers from early thyroid dysfunction may be
derived in prospective studies. This could prove particu¬
larly useful in a more refined classification of subclinical
thyroid disease, particularly for research purposes
(O'Malley el ai, 1989; Ross et a!., 1989; Tenerez et at.,
1990; Roden et al„ 1991; Wartofsky, 1991).
(3) The different stages of thyroid disease (e.g. normal-►sub¬
clinical hypothyroidism—► overt hypothyroidism) are
conceptually better represented in adjacent zones rather
than by the univariate matrix (Wehmann & Nisula,
1984) or concentric confidence ellipses.
The clinical usefulness of this zonal concept and the
assignment of probabilities for thyroid dysfunction to the
different zones needs to be established in future studies. Since
thyroid function tests are used simultaneously as the tools for
defining and diagnosing thyroid disease, only a large pro¬
spective study will establish a pattern of borderline abnormal
T3 and TSH levels which are associated with an increased
risk for thyroid disease. Nonetheless, in addition to the
theoretical considerations outlined above, indirect evidence
suggests that the proposed concept will prove clinically
useful. When the serum T4 levels from a large population of
patients with and without thyroid disease are plotted against
the logarithm of the TSH concentrations, the data points
form a distinct band of constant width along a linear
regression line representing the average regulation axis
(Spencer et al., 1990). It is evident that in such a situation
zones orthogonal to the normalized regression line would
represent a more adequate normal range than a univariate
box with no direct relationship to the regulation axis. The
clinical relevance of the modified bivariate model as depicted
SuDDlied bv The British Librarv- "The world's knowledae"
Clinical Endocrinology (1993) 39 Interpretation of thyroid function tests 10?
Chopra, I.J. (1991) Nature, sources, and relative biological signifi¬
cance of circulating thyroid hormones. In Werner and Jngbar's
The Thyroid (eds L. E. Braverman & R. D. Utiger), pp. 126-143.
J.B. Lippincott Company, Philadelphia.
Cotton, G.E., Gorman, C.A. & Maybcrry, W.E. (1971) Suppression
of thyrotropin (h-TSH) in serum of patients with myxedema of
varying etiology treated with thyroid hormones. New England
Journal of Medicine, 285, 529-533.
Helfand, M. & Crapo, L.M. (1990) Screening for thyroid disease.
Annals of Internal Medicine, 112, 840-849.
Klee, G.G. & Hay, I.D. (1987) Assessment of sensitive thyrotropin
assays for an expanded role in thyroid function testing: Proposed
criteria for analytic performance and clinical utility. Journal of
Clinical Endocrinology and Metabolism, 64, 461-463.
Larsen, P.R. (1982) Thyroid-pituitary interaction. New England
Journal of Medicine, 306, 23-32.
Liewendahl, FC. (1990) Assessment of thyroid status by laboratory
methods: developments and perspectives. Scandinavian Journal of
Clinical and Laboratory Investigation, 50, 83-92.
Neter, J., Wasserman, W. & Kutner, M.H. (1990) Applied Linear
Statistical Models Irwin, Boston.
O'Malley, B.P., Rosenthal, F.D., Exley, A., Falconer-Smith, J.F.,
Mahabir. J. & Woods, K.L. (1989) Low serum TSH with normal
total thyroid hormone levels: an indicator of free T4 excess.
Clinical Endocrinology, 30, 627-634.
Reichiin, S. & Utiger, R.D. (1967) Regulation of the pituitary-
thyroid axis in man: relationship of TSH concentration to
concentration of free and total thyroxine in plasma. Journal of
Clinical Endocrinology and Metabolism, 27, 251-255.
Roden, M., Nowotny, P., Vierhapper, H. & Waldhausl, W. (1991)
Diagnostic relevance of suppressed basal concentrations of TSH
compared with the negative TRH test in detection and exclusion
of hyperthyroidism. Acta Endocrinologica (Copenhagen), 124,
136-142.
Ross, D.S., Ardisson, L.J. & Meskell, M.J. (1989) Measurement of
thyrotropin in clinical and subclinical hyperthyroidism using a
new chemiluminescent assay. Journal of Clinical Endocrinology
and Metabolism, 69, 684-6S8.
Snedecor, G.W. & Cochran, W.G. (1989) Statistical Methods. Iowa
State University Press, Ames.
Spencer, C.A., LoPresti, J.S., Patel, A., Guttler, R.B., Eigen, A.,
S'hen, D., Gray, D. & NicolofT, J.T. (1990) Applications of a new
chemiluminometric thyrotropin assay to subnormal measure¬
ment. Journal of Clinical Endocrinology and Metabolism, 70,
453-460.
Spira, O. & Gordon, A. (1986) Thyroid hormone feedback effects on
thyroid-stimulating hormone. In Thyroid Hormone Metabolism
(ed. G. Hennemann), pp. 535-578. Marcel Dekker, New York.
Staub, J.J., Althaus, B.U., Engler, H., Ryff, A.S., Trabucco, P.,
Marquardt, K., Burckhardt, D., Girard, J. & Weintraub, B.D.
(1992) Spectrum of subclinical and overt hypothyroidism—effect
on thyrotropin, prolactin, and thyroid reserve, and metabolic
impact on peripheral target tissues. American Journal ofMedicine,
92, 631-642.
Surks, M.I., Chopra, I.J., Mariash, C.N., NicolofT, J.T. & Solomon,
D.H. (1990) American Thyroid Association guidelines for use of
laboratory tests in thyroid disorders. Journal of the American
Medical Association, 263, 1529-1532.
Tenerez, A., Forberg, R. & Jansson, R. (1990) Is a more active
attitude warranted in patients with subclinical thyrotoxicosis?
Journal of Internal Medicine, 228, 229-233.
Vice, P.A., Clark, F., Schardt, W. & Evered, D. (1976) Studies on the
control of thyrotropin secretion in normal man. Clinical Endocrin¬
ology, 5, 515-529.
Wartofsky, L. (1991) Use of sensitive TSH assay to determine
optimal thyroid hormone therapy and avoid osteoporosis. Annual
Reviews of Medicine, 42, 341-345.
Wehmann, R.E. & Nisula, B.C. (1984) Radioimmunoassay of
human thyrotropin: analytical and clinical developments. Critical
Reviews in Clinical Laboratory Sciences, 20, 243-283.
Supplied bv The British Librarv- "The world's knowledae"
 
1984, The British Journal of Radiology, 57, 1145-1148 December 1984
Technical note
The installation of a commercial resistive NMR imager
By M. A. Smith, M.Sc., Ph.D., J. J. K. Best, M.B., M.Sc., F.R.C.P. (Ed), F.R.C.R.,
R. H. B. Douglas, D.C.R.(D) and D. M. Kean, M.B., Ch.B., D.M.R.D., F.R.C.R.
NMR Imaging Unit, University of Edinburgh, Royal Infirmary, Edinburgh
(Received May 1984)
A whole body NMR imager has been installed in the
Royal Infirmary, Edinburgh for clinical evaluation. This
paper gives details of the installation of the first
commercial NMR imager to be sited in a hospital
environment in the United Kingdom.
NMR Imager
The NMR imager is the first production machine
manufactured by an Aberdeen-based company.* The
design of the imager is based on the "Mark II NMR
Imager" developed at Aberdeen Royal Infirmary.
Though the physical principles are the same, the
computer control circuits and much of the electronics
have been redesigned.
The water-cooled, resistive magnet consists of four
circular coils, horizontally mounted, producing a field
of 0.08T (1 Tesla = 10,000 Gauss) in the vertical
direction. The patient enters between the two larger
coils, which have a separation of 0.35 m, and lies inside
the patient tube which is 0.56 m diameter and 1.2 m
long. Wound round the outside of the patient tube are
the windings which produce the three orthogonal
magnetic field gradients. The RF coil has a slightly
larger diameter and is in the form of two linked
solenoids in the central region of the patient tube. The
overall dimensions of the imager, including the
radiofrequency (RF) shield are 2.35 m wide, 2.05 m
high and it weighs about 2000 kg. The patient couch
extends a further 2.65 m and it weighs 350 kg.
The RF and gradient amplifiers, temperature control,
power supply control and NMR lock are contained in
one cabinet with the power supply itself in another
cabinet. The power supply cabinet is also water-cooled
in parallel with the magnet. The imager is controlled by
a PDP 11 /23 + computer which drives the RF and
gradient amplifiers and also analyses the NMR signals.
This computer has two RL02 discs for storage and is
part of the operator's console, which in addition
contains a black and white monitor and a VDU with
keyboard. Images in the transverse, sagittal or coronal
plane are obtained using two-dimensional Fourier
transform, the "spin warp" technique (Edelstein et al,
1980). Saturation recovery and inversion recovery pulse
*M&D Technology Ltd, Unit 1, Whitemyres Avenue,
Mastrick, Aberdeen, AB2 6HQ, Scotland.
sequences are used with a suitable time between pulses
to give proton density and 7j images. The computer of
the operator's console is linked to a second PDP 11/23,
using a serial line, which acts as an independent
diagnostic console. The diagnostic console contains a
Winchester disc, an 8-inch floppy disc and a magnetic
tape unit for patient data storage, plus black and white
and colour monitors and a VDU with keyboard.
Site Preparation
The NMR imager is installed in a room which
previously had been a laboratory in the University
Department of Medicine. The room is part of a single-
storey, metal framed building, with girders of the metal
frame in the centre of the room. One adjacent room is a
store which contains some ferrous material, most of
which is rarely moved. In the room where the imager is
sited there had been a large treadmill which could be
lowered below floor level when not in use. Though this
contains a large amount of ferrous material it was not
removed but permanently floored over. The specifica¬
tions from M&D Technology Ltd. required that there
should be no ferrous material within 3 m of the centre
of the magnet. The material in the storeroom, the
vertical support girders and the treadmill are sited at
different positions around the magnet site but all are
just outside the 3 m limit (Fig. 1). The only ferrous
material within the 3 m limit which was removed was a
short length of steel trunking sunk into the floor and
two central heating radiators along the wall. The
laboratory cupboards at the end of the room nearest the
magnet are wooden with a metal frame but though they
are within the 3 m limit they were not removed.
A separate three-phase supply has been installed for
the NMR imager, computers and refrigerator unit.
Plastic trunking is used for the electricity cables within
the NMR room. Although a water supply was already
in the room, a larger 22 mm mains supply has been
installed from the adjacent laboratory to increase the
flow for the run-to-waste system. A 15 mm mains
supply was connected which ran outside the room to
the position of the refrigerator unit.
Other modifications made to the room, such as the
construction of a partition to create office space, are
included in our financial costs for the installation of the
NMR imager, though they are not specific for NMR.
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Plan view of the NMR Imaging Unit. A—rack containing
power control, temperature control, gradient and RF
amplifiers. B—power supply. C—operator's console. D—
photographic hard-copy device. E—diagnostic console. F—
refrigeration unit. G—laboratory bench with storage cup¬
boards. H—vertical metal girders supporting the building. J—
position of large metal treadmill stored below floor level. The
shaded rings indicate the position of the ring magnets within
the imager.
Machine Installation
Before the magnet was delivered, the refrigerator unit
was placed in position on a concrete plinth outside the
NMR room using a large crane. The suppliers of the
unit installed the plumbing necessary for the magnet
and power cooling system. A closed-loop water system
using 22 mm copper pipe was installed, linking the
magnet, power supply and refrigerator with junctions in
the flow pipe connected to the 22 mm mains supply,
and in the return pipe connected to a pipe which ran to
waste. Stopcocks can either isolate the refrigeration unit
or the mains and waste pipes, so that it is possible to
switch easily from one cooling system Lo the other.
The magnet was delivered in one piece with the four
coils on their supporting frame and the patient tube in
position. The magnet was lifted from the lorry, then
manhandled along a corridor and into the NMR room.
Part of the wall of the room was removed to allow
access. The base of the RF shield had already been fixed
into position and after the magnet had been pushed into
place the castors at the base of each leg of the frame
were removed. The magnet stands directly on a concrete
floor which forms the foundation of the building.
The magnet operates at 232 A and 100 V when
producing a field strength of 0.08 T. To obtain a
uniform magnetic field at the centre of the magnet it
had to be shimmed. Before this was done, all the
cabinets, computers and couch motor assembly, in fact
everything which contained ferrous metal, were sited in
their permanent positions as shown in Fig. 1. The
process of shimming the magnet involved making small
adjustments to the relative positions and orientations of
the four magnet coils and two sets of shimming coils. In
addition, small amounts of ferrous material were
attached to the magnet to make fine adjustments to the
uniformity. Unfortunately, at the end of the first
shimming procedure, a fault developed on the upper
large coil which had to be replaced. The upper coil was
lifted from the magnet using a winch and a frame
constructed around the magnet, then tipped onto its
side so that it could be rolled out of the room. The
replacement coil was installed in the same way. When
the magnet was shimmed once more, a uniformity of
126 ppm in a 44 cm diameter disc was obtained. After
the magnet had been shimmed, the RF shield was fitted
and the couch was fixed into position.
Operation of the Imager
The orientation of the coils of the magnet produces a
vertical magnetic field, so the fringe field is greatest
above and below the magnet, which in our case presents
no problem. Magnetic field contours, as low as









Plan and cross-sectional view of the NMR Imaging Unit
illustrating the fringe field (in Tesla) of the magnet. The lack of





can be seen that there is circular symmetry of the low
field contours even though there is ferrous material in
the vicinity of the magnet. The 0.0005 T (5 gauss)
contour is often quoted to signify the "limit" of the
fringe field though this value is far lower than the field
strength that might be hazardous to patients with
pacemakers or aneurysm clips.
The refrigeration plant successfully maintains the
magnet temperature between ?3°C and 25°C. The run-
to-waste cooling system also works successfully,
keeping the magnet at a temperature of about 26°C
with a constant water flow of 20 1/min.
ihe imager is designed with a "standby" mode ot
operation. This can be used at night to control the
current supplied to maintain the magnet at any desired
temperature with no water cooling. This is designed to
ensure that the core of the magnet is at the correct
temperature first thing in the morning for imaging.
There is also an NMR feedback device which uses a
small NMR probe in the imager to adjust the current
and voltage and so maintain a stable field. It is our
experience, however, that everything could be switched
off at night and that the NMR imager could be used
half an hour after switching on in the morning, even
with the NMR feedback device disconnected.
Cost of Tnstat.t.atton
The cost of ilie NMR unagei with lire independent
diagnostic console was £399,000, including three years'
warranty. Edinburgh received the first imager manu-
lactured by the company and as a consequence, it was
expected that there would be "teething troubles" with
the imager and that any new developments would be
evaluated in Edinburgh. The price paid for the system
may not therefore reflect the price of subsequent
systems.
The cost of site preparation was £6,500. The largest
item of the cost (£5,000) was for the installation of a
three phase electricity supply to the NMR Unit and the
associated wiring for the electricity supply to the power
racks and computers. The cost incurred was less than if
an X-ray CT body scanner had been installed rather
than an NMR imager, expensive radiation protection
measures not being required for the latter.
Summary
It has been demonstrated that a relatively low-cost
resistive NMR imager can be installed in a normal
hospital environment without many major or expensive
modifications. The magnet can be adjusted to give
adequate uniformity and there is sufficient RF shielding
to give good quality clinical images (Fig. 3). The fringe
field of the magnet of this system, which operates at the
lowest field strength of any commercial NMR imager,
does not present a problem to imaging unit staff
(NRPB, 1984).
The long term reliability and detailed specifications
with regard to image quality have yet to be determined.
These will be determined whilst the imager is being used
c
Fig. 3.
Images of the normal head and body using the two types of
RF coils: (a) proton density, (b) inversion recovery, (c)
calculated T1.
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for clinical studies as part of the national clinical
evaluation of NMR imaging supported by the Medical
Research Council.
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Environmental Radioactivity. NCRP Proceedings No. 5. pp.
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Measurements, Bethesda, Md. 20814 USA), $17.00.
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This publication contains the scientific and briefing sessions
of the 19th annual meeting of NCRP and the text of the 7th
Lauriston Taylor Lecture given by Merril Eisenbud.
A wide range of topics was covered in the scientific session,
including papers on the role of the environment and of natural
and man-made sources within it, assessments of radioactivity
at the Nevada test-site, in the atolls of the Northern Marshall
Islands and at the site of the Three-Mile-Island incident. There
were also contributions on environmental modelling, the
particular problems associated with long-lived radionuclides,
and the ever-present problem of waste disposal. The
concluding paper of this section summarised and discussed the
current criteria for setting dose-limits for the public.
Merril Eisenbud's lecture, "The human environment—past,
present and future" was an interesting and stimulating account
of environmental pollution, taken in a fairly broad sense. In
contrast to many recent papers on this topic, his treatment was
not gloomy, nor were his conclusions pessimistic. It is a pity
that his time limit only allowed him to touch on relatively few
aspects.
The scientific briefing session contained five papers; mostly
reviews of published reports, including that of the NRPB on
the Windscale release, the OECD report on the biological
behaviour of plutonium and allied transuranic elements, the
1982 UNSCEAR document and two upon USA legislation in
the fields of protection and radioactive waste. The proceedings
closed with some selected task-group reports.
As usual, the papers are well presented, and continue to
maintain the high standard we have come to expect from this
Council's publications. There is much in this volume that will
be of interest to those engaged in radiation protection and to
environmental health physicists.
John R. K. Savage.
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Candidate compounds in the toxicity hypothesis of Parkinson's
H disease.
|| (I) MPTP itself.
,v (II) Ramsden and Williams' proposal.
% (III) Fellman and Nutt's alternative.
(IV) l,2,3,4-tetrahydro-/3-carbolines. R, varies with the aldehyde or
:r ketoacid structure involved. R2 is H or CH3 derived from tryptamine or
| N-methyltryptamine, respectively. Alternatively, N-methylation may be
i possible after the cyclisation.
. N-methyl derivatives. This hypothesis can be tested by looking for
this substance in biological fluids from patients and by
pharmacological studies on compounds with neurotoxic activity
characteristic of parkinsonism. Although experimental difficulty
may arise from the variable C-l substitutions (Ri), this hypothesis
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BRAIN WATER IN CHRONIC ALCOHOLIC PATIENTS
MEASURED BY MAGNETIC RESONANCE IMAGING
Sir,—In magnetic resonance imaging (MRI) the Tt relaxation
time is related to the state of water in the tissue.1-The T! value,
measured in milliseconds, increases as the proportion of free to
bound water increases. MRI is therefore a potentially valuable
technique in the study ofbrain water during withdrawal ofalcohol
in chronic alcoholic patients. It has been used previously in such a
study2 which suggested that there was "decreased free water during
intoxication and an increase in brain water during alcohol
withdrawal", a somewhat surprising result that the authors
admitted was "at variance with current clinical practice which
emphasises the role ofdehydration in the syndrome and encourages
fluid replacement". We have repeated the study in a larger group of
patients, since the result could have implications for the treatment
of alcoholism.
The subjects were 9 chronic alcoholic patients (7 male, 2 female,
aged 29-60 years, mean 46) voluntarily admitted to hospital for
detoxification. They had been drinking at least 130 g ethanol per
day (mean 180 g per day) before admission and had a 5-15 year
history of alcoholism. None was clinically malnourished, or had
physical disorders other than raised liver enzymes in serum. Over
the first 5 days each patient received a normal diet, intramuscular
vitamin B supplement, and decreasing doses ofchlordiazepoxide. 9
normal controls, sex and age matched (range 26-62 years, mean 45),
were chosen from hospital staff; their alcohol consumption ranged
from total abstinence to the equivalent of 80 g ethanol per week.
Measurements were performed using a 0-08T resistive MRI
system.3 All patients were investigated on two occasions, at 24'h and
at 7-21 days after cessation of alcohol consumption; controls were
investigated once. Measurements ofTj were made from a calculated
Tj image of a 12 mm thick transverse section 10 mm above the
maximum diameter ofthe lateral ventricles. To define the T l in grey
and white matter in the frontal, parietal, and occipital regions small
regions of interest were defined—for grey matter 20 mm2 and for
white 69 mm2—and the mean ofsimilar regions in the left and right
hemisphere was noted. In addition the Tj value over the whole
brain, excluding the cerebrospinal fluid. (CSF), was measured. The
precision of T] estimation was estimated from four repeated
measurements on 3 normal volunteers over a period ofa month. The
T [ precision ofwhite matter was 2 • 8%, grey matter 4 • 9%, and the
whole brain, excluding CSF, 2-6%.
At 24 h Tj over whole brain was higher in alcoholic patients than
in controls (see figure). It then falls over the next 7 to 21 days. The
change in Tj in the whole brain in alcoholic patients correlated with
the time between abstinence and the second measurement








3001 24hrs 7-21 days
controls Patients
Tj values over whole brain of individual patients at 24 h and at 7 - 21
days after withdrawal of alcohol compared with age-matched
normal controls.
Mean±lSE is shown.
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in grey matter was 10-1 ms (SE = 6-9 ms) whereas the decrease in
white matter was only 0-6 ms (SE=4'0 ms). The decrease in Tj in
grey matter correlated with the duration of abstinence (r= -0-76,
p<0 • 05). Though the decreases in Tj over whole brain and in grey
matter in alcoholic patients were not significantly different from
zero, the reduction is significantly different (p<0-05) from the
increase previously reported by Besson et al.2
The preliminary results of this study suggest that chronic
alcoholic patients have a higher T[ value in the brain than do normal;
controls. This raised T! probably reflects an increase in free water
within the brain. During withdrawal from alcohol the T] drops,
probably because of a decrease in the brain water content. Our
findings contradict those ofBesson et>al2 but are consistent with the
generally accepted hypothesis that the brain becomes excessively
hydrated during chronic alcohol consumption and that abstinence
results in dehydration of the brain.
We intend to determine in more detail the differences between T]
in alcoholic patients and normal volunteers, whether the
subsequent reduction in T] is significant, and if so whether it
returns to normal values with prolonged abstinence. A larger
number of patients will enable the apparent difference in response
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ENDOCRINE ADJUVANT THERAPY FOR BREAST
CANCER
Sir,—The six-year follow-up analysis by the Nolvadex Adjuvant
Trial Organisation (NATO) of their comparison of tamoxifen with
no adjuvant therapy after surgery for early breast cancer (April 13,
p 836) focused on oestrogen receptor (ER) content of the primary
tumour and on patterns of first relapse. Data from the Ludwig
Breast Cancer Trials III and IV,1 in which one year of daily
prednisone 7-5 mg and tamoxifen 20 mg was compared with no
adjuvant therapy after surgery for node-positive postmenopausal
breast cancer, also cast light on these two issues.
In the Ludwig trials, 32% ofpatients whose ER status was known
had ER values below 10 fmol/mg (taken as the threshold of ER-
negativity in previous publications) and 23% had ER values below 5
fmol/mg, compared with 37% in the NATO trial. The higher
frequency ofER-negative tumours in the NATO trial might be due
to the (few) premenopausal patients included, the limited tumour
material available from node-negative patients, or the loss of
receptor content during harvesting and transport of the specimens
to the laboratory. The NATO investigators suggest that receptor
loss during handling would have yielded a higher percentage of
patients whose tumours contained less than 30 fmol/mg than that
observed. The higher percentage ofpatients in the NATO trial with
ER measurements below 5 fmol/mg cytosol protein almost certainly
included some whose tumours in fact contained higher levels of
receptor than that measured and who therefore benefited from
adjuvant endocrine treatment.
The investigators provide an analysis of events by first site of
recurrence and report that tamoxifen appeared to prevent both
local/regional and distant disease. This observation is in contrast to
the findings in the Ludwig trials III and IV, which indicated a
significant reduction of local and regional recurrences but not of
distant metastases.1,2 The raw recurrence data presented by NATO
show that the frequency of distant events was reduced by 17%
(15 • 1 % in the tamoxifen-treated group and 18 • 2.% in the controls).
On the other hand, the incidence of local/regional relapses (also
including second primaries which are reported together) was
reduced by 46% (7-5% in the tamoxifen group and 13-8% in the
controls). The table analyses type of recurrence by time in the
Ludwig trials. The reduction in mastectomy scar recurrences
appeared primarily within the first two years after randomisation,
while significant control of regional recurrence and some impact on
distant spread was only apparent beyond the first two years. The
two-year duration ofthe tamoxifen treatment in the NATO trial—in
contrast to only one year in the Ludwig trial—could therefore
account for the early evidence of a survival benefit in the adjuvant-
treated group. We do feel, along with our NATO colleagues, that
long-term follow-up is needed for a better comprehension ofthe real
effect of adjuvant endocrine treatment in early breast cancer.
A. Goldhirsch
R. D. Gelber
M. N. H. Tattersall
C.-M. Rudenstam
F. Cavalli,
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OESTROGEN RECEPTOR STATUS AND CELLULAR
COMPOSITION OF BREAST CANCERS
Sir,—In the continuing debate (April 27, p 876) about the
predictive value of oestrogen receptor (ER) concentrations in the
management of breast cancer1"3 we risk losing sight of a
fundamental flaw in conventional ER assay methods. ER
concentrations can now be measured precisely: regrettably the same
precision has not always been applied to the assessment of the
cellularity of the assayed tumour sample. Indeed, the tissue
homogenisation required for conventional assays prohibits any
assessment of cellularity or even verification that viable tumour is|j
present in the assayed sample.
Variations in tumour epithelial cellularity (clinically significant
ER is assumed to reside in the epithelial compartment of breast |g|
SITES OF FAILURE BY TIME TO FAILURE (AT 48 MO MEDIAN FOLLOW-UP TIME): LUDWIG STUDIES III AND IV
Site of failure
All failures Failure at <2 yr Failure at >2 yr
P + T Control P + T Control P + T Control i|
O O/E O O/E O O/E O O/E O O/E O O/E f
Mastectomy scar alone 24 0-64 46 1-42 16 0-56 38 1-50 8 0-90 8 i*i3
Contralateral breast alone 1 0-21 8 1-93 1 0-38 4 1-71 0 0-00 4 2-22
Regional±local 22 0-61 45 1-45 17 005 26 1-28 5 0-38 19 1-77
Distant 84 0-92 86 M0 60 0-95 59 1-05 24 0-84 27 1-20
2nd primary (not breast) 6 1-00 5 1-00 4 1-08 3 0-91 2 0-88
'
2 1*16
Death without recurrence 15 1-39 5 0-54 9 1-55 2 0-39 6 1-21 3 0-75
Total failures 152 0-81 195 1-22 107 0-85 132 1-17 45 0-75 63 1-32 ;
P + T= adjuvant endocrine therapy (prednisone+ tamoxifen) (n=320); control = observation only (n = 309). O=observed number ofevents; O/E ° ratio observed/expected number ofevents.
I
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Nuclear magnetic resonance in hypertrophic
cardiomyopathy
M BEEN, D KEAN, M A SMITH, R H B DOUGLAS, J J K BEST, A L MUIR
From the Nuclear Magnetic Resonance Imaging Unit, Royal Infirmary, Edinburgh
summary The large differences in the spin lattice relaxation times (Tj) of blood and myocardium
(measured by nuclear magnetic resonance) allow the heart to be visualised without the use of
contrast media. The findings using nuclear magnetic resonance in 11 unselected patients with
hypertrophic cardiomyopathy were compared with those in equal numbers of normal subjects and
patients with electrocardiographic features of left ventricular hypertrophy. In patients with hyper¬
trophic cardiomyopathy characteristic septal hypertrophy was noted together with variable and
sometimes pronounced hypertrophy of the left ventricular free wall, which is consistent with the
heterogeneous nature of this disease. The mean (SD) ratio of septal to free wall thickness was
1-5(0-8) for patients with hypertrophic cardiomyopathy, 0-8(0-2) for those with left ventricular
hypertrophy, and 0-9(0-2) for normal subjects. Although septal measurements by nuclear magnetic
resonance were greater than those obtained by echocardiography there was a significant correlation
between the two. Septal and free wall area were significantly smaller in normal subjects. There were
no differences in septal or free wall T( values between the three groups.
Non-gated nuclear magnetic resonance can detect septal and free wall hypertrophy. With the
addition of multiple slice acquisition, rapid estimation of myocardial mass will be possible allowing
the potentially important assessment of progression or regression of myocardial hypertrophy.
Hypertrophic cardiomyopathy is characterised- by
hypertrophy of myocardium, particularly of the inter¬
ventricular septum, without apparent cause. Disunct
histological appearances—such as cardiac muscle cell
disorganisation, again mainly of the septum—have
been reported.1 The diagnosis may be confirmed by
echocardiography if the typical features (systolic
anterior motion of the mitral valve, early aordc valve
closure, and disproportionate thickening of the sep¬
tum relative to the left ventricular free wall) are pres¬
ent. When few of the features are present or if
echocardiography is technically difficult than doubt
remains. In 1982 Goodwin suggested that angiocar¬
diography was still the most useful investigation.2
Nuclear magnetic resonance can be used for both
non-invasive visualisation of cardiac structures and
tissue characterisation; the second can be achieved by
using the spin lattice relaxation time (Tj). The large
Requests for reprints to Dr M Been, The Nuclear Magnetic
Resonance Imaging Unit, The Royal Infimary, Lauriston Place,
Edinburgh EH3 9YW.
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differences in the Tj values of myocardium and blood
allow clear separation between cardiac muscle and
cavity without the use of contrast medium.3
Using nuclear magnetic resonance we therefore
examined the appearances of hypertrophic car¬
diomyopathy by measuring septal and free wall thick¬
ness and contrasting T, values with those found in




Three groups were examined. The first consisted of
11 unselected patients attending a cardiac review
clinic with an established diagnosis of hypertrophic
cardiomyopathy based on clinical, echocardiographic,
and in two cases angiographic findings (Table 1). The
second group consisted of 11 patients with left ven¬
tricular hypertrophy based on the electrocardiog¬
raphic criteria of Romhilt and Estes,4 of whom nine
had World Health Organisation stage III hyperten¬
sion, one aortic stenosis, and one aortic coarctation.
.The third group consisted of 11 age matched healthy
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Table 1 Echocardiography and nuclear magnetic resonance measurements in 11 patients with hypertrophic cardiomyopathy



















1* 50 14 16 NO NO 14 4-38 23 4-07
2 55 24 15 NO YES 23 4-96 7 4-40
3 26 32 20 NO YES 32 7-35 20 7-17
4 52 30 12 YES YES 41 7-69 54 8-82
5 45 18 20 NO NO 26 5-14 23 7-17
6 19 30 16 NO NO 30 4-62 14 5-57
7* 48 20 18 NO NO 26 4-93 15 4-53
8 32 32 14 YES YES 46 9-03 41 8-39
9 68 15 12 YES YES 29 5-36 27 6-00
10 19 26 12 YES YES 37 8-21 20 5-67
11 45 14 12 YES YES 38 6-55 18 5-18
♦Sisters.
LV, left ventricular; SAM, systolic anterior motion.
volunteers drawn mainly from hospital staff. In all
cases consent was obtained and the study approved by
our institute's ethical committee.
NUCLEAR MAGNETIC RESONANCE
Nuclear magnetic resonance was carred out using a
commercial (M&D Technology) low field (0-08T)
resistive imaging system. Cardiac gating was not
used. Three transverse sections with a slice of 16 mm
were obtained from each subject with a separation of
20 mm between each section. The pulse sequence
used was an interlaced saturation recovery and inver¬
sion recovery sequence each with a repetition rate of
1 s and a tau value of 200 ms for the latter. For each
section four images were obtained at the end of the 4
min 16 s acquisition: proton density, calculated Tt,
inversion recovery, and a "difference" image (proton
density-inversion recovery). The inversion recovery
and difference images contain both T( and proton
density information. Of the four images, the calcu¬
lated T, image gave the best contrast between blood
and myocardium. The long term precision of Tt esti¬
mation using this particular technique has been found
to be 2-7% for a T, value of 300 ms.
The section giving best definition between septum
and left ventricular cavity was selected for each
patient and studied in more detail. Initially, an esti¬
mate of the mean and range of T, values for myocar¬
dium and ventricular blood was obtained in the 33
subjects. The mean (SD) T, value for myocardium
was 345(28) and for blood 635(124). The window on
tile T[ images was set so Lhai all pixels with a Tj value
>450 ms appeared uniformly bright enabling
myocardium and blood to be clearly separated.
Irregular regions of interest were drawn around the
interventricular septum and free wall of the left ven¬
tricle using the computer. Computer derived meas¬
urements of septal and free wall thickness and area
were made together with total cardiac diameter.
ECHOCARDIOGRAPHY
M mode and real time echocardiography were carried
out in the left oblique position within two weeks of
the nuclear magnetic study. Septal and free wall
diameters were measured from M mode recordings
using an Irex-3 phased array system with a 2-5 MHz
transducer in the groups with hypertrophic car¬
diomyopathy and left ventricular hypertrophy.
Recordings were made at end diastole at a level just
above the mitral valve. Septal and free wall thickness
were measured in three consecutive cycles and the
mean values noted for each subject. Five of the
patients with hypertrophic cardiomyopathy showed
systolic anterior motion of the anterior mitral leaflet
and seven some degree of early closure of the aortic
valve. None of these abnormalities was seen in
patients with left ventricular hypertrophy. Two
patients did not have echocardiographic features typi¬
cal of hypertrophic cardiomyopathy, the diagnosis
having been established at angiography (cases 1 and
5).
STATISTICAL ANALYSIS
A non-paired Wilcoxon rank test was used for com¬
parison between groups. Student's t test was used for
comparison of T, values between septum and left ven¬
tricular free wall with all groups combined.
Results
In eight patients with hypertrophic cardiomyopathy
nuclear magnetic resonance showed characteristic
appearances with pronounced septal hypertrophy and
a variable degree of left ventricular free wall hyper¬
trophy (Figs. 1 and 2). Table 1 shows the results and
patient details for the group with hypertrophic car-
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Table 2 Septal and left ventricular free wall spin lattice
relaxation times (T ,) in three groups ofpatients. Values are mean
(SD)
Septal Tx (s) Free wall Tx (s)
Normal subjects 374 (18) 331 (29)
Patients with ventricular
hypertrophy 355 (31) 333 (22)
Patients with hypertrophic
cardiomyopathy 352 (27) 342 (24)
diomyopathy. In those patients with secondary left
ventricular hypertrophy the free wall and septum
appeared of equal thickness, but the muscle mass was
greater than in normal subjects. The differences in
area and dimension between patients with hyper¬
trophic cardiomyopathy, left ventricular hypertro¬
phy, and normal hearts (Figs. 3 and 4) are summar¬
ised below.
SEPTAL AND FREE WALL THICKNESS
There was considerable variation in the thickness of
both septum and left ventricular free wall measured
by nuclear magnetic resonance in the group with
hypertrophic cardiomyopathy (Table 1). Although
septal measurements were greater than those obtained
with echocardiography there was a significant correla¬
tion between the two (r=0-71, p<0-001). The mean
ratio of septal to free wall thickness measured by nuc¬
lear magnetic resonance and M mode echocardiogra¬
phy was similar at 1-5(0-8) and 1-6(0-6) respectively.
The mean ratio of septal to free wall thickness as
measured by magnetic resonance imaging was 0-8(0-2)
for patients with left ventricular hypertrophy and
0-9(0-3) for normal subjects. In view of the variability
of this ratio in patients with hypertrophic car¬
diomyopathy, there was no statistically significant dif¬



































Hypertrophic Left ventricular Normal
cardiomyopathy hypertrophy subjects
Fig. 2 (a) Septal and free wall area and (b) ratio ofseptal to
free wall area in individual patients with hypertrophic
cardiomyopathy, those with left ventricular hypertrophy, and
normal subjects.
Fig. 1 Typical appearance of hypertrophic cardiomyopathy by nuclear magnetic resonance showing pronounced septal
hypertrophy (arrow 1) (a) with mild left ventricularfree wall hypertrophy (arrow 2) (case 10) and(b) with pronounced left
ventricular free wall hypertrophy (arrow 2) (case 8).
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SEPTAL AND FREE WALL AREA
There was a significant difference in septal area bet¬
ween normal subjects and both patient groups. Meas¬
ured area in normal subjects was 2-7 cm2 compared
with 4-6 cm2 (p<0-05) and 6-1 cm2 (p<0-05) for
patients with left ventricular hypertrophy and hyper¬
trophic cardiomyopathy respectively. Corresponding
values for left ventricular free wall area were 3-7 cm2,
6-3 cm2 (p<0-05), and 6-1 cm2 (p<0-05).
TOTAL CARDIAC DIAMETER
The diameter as measured from the right ventricular
border to the mid portion of the left ventricular free
wall was greater in both patient groups at 138(10) mm
and 130(14) mm for patients with hypertrophic car¬
diomyopathy and left ventricular hypertrophy respec¬
tively compared with 120(12) mm for normal sub¬
jects. The difference did not reach statistical
significance.
SPIN LATTICE RELAXATION TIME (T,)
Table 2 shows the mean values for Tr There was no
significant difference between patient groups,
although septal T, was consistently higher than free
wall T, for all groups (p<0-01).
Discussion
This study shows the ability of nuclear magnetic reso¬
nance to outline the interventricular septum and left
ventricular free wall and to, detect differences in
myocardial thickness in patients with increased after-
load and hypertrophic cardiomyopathy when con¬
trasted with normal subjects. The pronounced con¬
trast between flowing blood, which gives a high signal
intensity, and the chamber walls allows hypertrophy
to be demonstrated since there is also contrast bet¬
ween myocardium and surrounding tissues.
Within the group of patients with hypertrophic
cardiomyopathy large variations in septal area were
found. In those cases in which a diagnosis of hyper¬
trophic cardiomyopathy could confidently be made by
nuclear magnetic resonance the findings on echocar¬
diography were more impressive (Table 1). Our
unselected population of patients with hypertrophic
cardiomyopathy represented the full spectrum of the
disease, which is known to be heterogeneous.5 This
variability in septal and free wall size was detected
both by echocardiography and by nuclear magnetic
resonance.
Steiner, in outlining the applications and potential
of nuclear magnetic resonance in cardiac imaging,
described the concentric nature of left ventricular
hypertrophy in patients with hypertension and aortic
stenosis and the non-uniform septal and free wall
hypertrophy of hypertrophic cardiomyopathy.6
Although these patterns may occur in typical exam¬
ples, it is important to recognise that both the extent
and position of myocardial hypertrophy are variable
as illustrated by nuclear magnetic resonance (Figs. 1
and 2).
Stone et al recently reported the appearances of
hypertrophic cardiomyopathy obtained with non-
gated computed tomography using contrast medium
in nine patients.7 Visualisation of the septum was
good and showed the variability of the position of
maximal septal hypertrophy. Definition of the left
ventricular free wall was, however, poor and inadequ¬
ate for measurements. By using the differences in the
relaxation index Tj between flowing blood and ven¬
tricular muscle, nuclear magnetic resonance can allow
clear visualisation of both septum and free wall with¬
out the use of contrast agents.
It was not the purpose of this study to compare
nuclear magnetic resonance with echocardiography as
there is a large difference in their cost and stage of
development. There is also a wide variation in pur¬
chase and installation costs between different nuclear
magnetic resonance systems and the variables they
measure. The system we used is a low cost low magne¬
tic field system. Echocardiography has contributed to
the understanding of hypertrophic cardiomyopathy
(for example, in determining the cause and level of
obstruction when present8) and is of value in making
the diagnosis. Echocardiographic features are not,
however, specific individually.5 M mode echocardiog¬
raphy gives diagnostic information in over 85% of
patients, but precise measurements of left ventricular
dimensions are possible in only 60-65% of patients.9
Real time echocardiography improves diagnostic abil¬
ity, and because of its rapidity and widespread availa¬
bility echocardiography will remain the commonest
and most practical technique for confirming hyper¬
trophic cardiomyopathy. Nevertheless, nuclear
magnetic resonance is possible in most patients and
may be helpful in those in whom echocardiographic
quality is poor.
The differences observed between our three groups
were from images taken without cardiac gating. The
extent by which gating improves resolution in nuclear
magnetic resonance is not yet established. Some
reports have emphasised the need for cardiac gating to
obtain satisfactory anatomical information.10 Choyke
et al, however, have shown that images of diagnostic
quality were obtained without gating using single spin
echo sequences with a very short echo time (10-20
ms).11 In practice it gives a very similar echo time to
that used in our own system. They had noted pro¬
nounced degradation of the image with longer echo
times and concluded that the previous unfavourable
reports using non-gated techniques may have been
due to longer echo times used in other centres.
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The ability to obtain measurements of myocardial
area and thus by multiple slice acquisition to estimate
myocardial mass may prove valuable in the follow up
of patients with myocardial hypertrophy. Drug
treatment in both patients with hypertension and
those with hypertrophic cardiomyopathy should
ideally result in a reduction in muscle mass. The non¬
invasive nature of nuclear magnetic resonance makes
this an attractive method for long term assessment of
such patients.
This work was funded in part by the Medical
Research Council, Department of Health and Social
Security, the Scottish Home and Health Department,
University of Edinburgh, Melville, and the Wellcome
Trusts. MB was in receipt of a Squibb Cardiovascular
Fellowship.
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Two Examples of CNS Lipomas Demonstrated by
Computed Tomography and Low Lield (0.08 T)
MR Imaging
D. M. Kean, M. A. Smith, R. H. B. Douglas, C. N. Martyn, and J. J. K. Best
Abstract: The low field (0.08 T) magnetic resonance (MR) findings in two
lipomas of the central nervous system (CNS), one adjacent to the corpus
callosum, the other in the cervical cord, are described. The characteristic short
T1 of fat and the image acquisition in the sagittal plane permit accurate local¬
isation of these lipomas. Low field MR can provide images of diagnostic
quality in a number of CNS lesions. Index Terms: Central nervous system,
neoplasms—Nuclear magnetic resonance, techniques—Computed tomog¬
raphy.
Whereas the general trend seems to be toward
higher field magnetic resonance (MR) imaging, low
field imaging is being performed with satisfactory
results in a number of centers (1). We report here
on the usage of low field (0.08 T) imaging in the
cases of fatty tumors of the central nervous system.
MATERIALS AND METHODS
Magnetic resonance investigations were per¬
formed using a commercial low field (0.08 T) resis¬
tive imaging system, manufactured by M & D Tech¬
nology Ltd., which has been installed in the Royal
Infirmary, Edinburgh (2). A section 12 mm thick
was used and the pulse sequence was an interlaced
saturation recovery and inversion recovery, each
with a repetition time of 1,000 ms and inversion
time of 200 ms for the latter. Eor each section a
proton density image, inversion recovery image,
and a calculated T1 image were obtained in a total
acquisition time of 4 min 16 s.
CASE REPORTS
Case 1
A 32-year-old man was admitted after a seizure that
had occurred while he was asleep. He had a previous
From the NMR Imaging Unit, Department of Medicine, Uni¬
versity of Edinburgh, Royal Infirmary, Lauriston Place, Edin¬
burgh EH5 9YW, Scotland. Address correspondence and reprint
requests to Dr. D. M. Kean.
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history of seizures but had never received anticonvulsant
therapy. Plain posteroanterior skull radiography showed
a faint curvilinear calcification, deep in the left frontal
region, parasagittally. Computed tomography (EMI CT
5005) (Fig. 1) showed a large lesion of low attenuation
values in the region of the corpus callosum with a rim of
calcification anteriorly. With MR the sagittal inversion
recovery image (Fig. 2) showed a region of high signal
intensity closely related to the corpus callosum. The axial
calculated T1 image (Fig. 3) demonstrated the very short
T1 of this abnormality. All features seen in both CT and
FIG. 1. Case 1. CT scan of lipoma of corpus callosum.
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FIG. 2. Case 1. Sagittal inversion recovery MR image shows FIG. 3. Case 1. Calculated T1 image shows short T1 of li-
high signal intensity from lipoma. poma.
FIG. 4. Case 2. CT scan of cervical cord lesion.
FIG. 5. Case 2. Sagittal inversion recovery MR image shows FIG. 6. Case 2. Sagittal calculated T1 image shows short T1
high signal intensity from cervical lipoma. of lipoma.
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MR are in keeping with the diagnosis of lipoma adjacent
to the corpus callosum.
Case 2
A 57-year-old man had a 6 year history of increasing
spasticity of the right leg and unsteadiness of gait asso¬
ciated with more recent onset of clumsiness and loss of
sensation in both upper limbs. Myelography demon¬
strated an intradural, extramedullary mass lesion in the
cervical region (C2-C7). Figure 4 is a CT scan with in¬
trathecal metrizamide, at the level of the C4 vertebral
body. This showed the spinal cord compressed and dis¬
placed anteriorly by a large mass with low attenuation
values. The sagittal inversion recovery MR image (Fig.
5) showed a large abnormality extending from C2 to C7.
The T1 values, as demonstrated by a calculated T1 (Fig.
6), were very short, strongly suggesting that the lesion
contained fat tissue. The CT and MR findings were in
keeping with the diagnosis of lipoma. At surgery a lipoma
that was both adherent to and incorporated within the
cord was identified, biopsied, and subsequently shown to
be a lipoma.
DISCUSSION
These two cases illustrate that images of good
technical quality can be obtained using a low field
MR system. Further, the advantages of MR are
again demonstrated. In particular we may reem-
phasize the ability to accurately delineate midline
lesions by the use of sagittal plane imaging, and the
ability to image spinal cord pathology without the
injection of intrathecal contrast material. Finally,
we have shown that measurements of magnetic re¬
laxation times, in this case Tl, may be useful in
characterising lesions such as the two lipomas re¬
ported here.
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CHARACTERISATION OF ACUTE MYOCARDIAL
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Summary In studies with gated nuclear magnetic
resonance imaging, patients with recent
transmural myocardial infarction showed significantly longer
spin-lattice relaxation times (T[) in the infarct area than did
healthy volunteers or patients with non-ischaemic or chronic
ischaemic heart disease. 10 of the 13 patients had a T1 longer
than that found in any healthy subject or in any patient with
other heart disease. Changes in T! should prove useful in the
assessment of interventions designed to limit infarct size.
Introduction
proton magnetic resonance imaging is a non-invasive
technique with which body structure can be visualised in
multiple planes. It relies on the principle that protons in a
static magnetic field will tend to recover to their original
position after deflection by a radiofrequency pulse.
Anatomical information may be obtained by measuring
proton density, which will differentiate between tissues such
as muscle and lung.
Measurements of differences in the spin-lattice relaxation
time (T,) and of the spin-spin relaxation time (T2) allow
detailed tissue characterisation. These relaxation parameters
are influenced by the ratio of"free" to "bound" water within
the tisue.1 Oedematous tissue would thus have a longer T1
and T2 than normal tissue.
In dogs Tj and T2 are longer in infarcted than in normal
myocardium in'vitro.2'3 Differences in T, relaxation times in
acute myocardial infarction in man have not been recorded,
although an increase in T2 after acute myocardial infarction
has been reported.4
The prognosis after myocardial infarction depends on the
extent of myocardial damage and residual left ventricular
function.5 Current emphasis on intervention in myocardial
infarction designed to limit infarct size highlights the need for
techniques that can localise and define ischaemic and
infarcted myocardium.6 Since current methods of assessing
myocardial infarct size are imprecise,' require repeated blood
sampling,8 or involve the use of radioisotopes,5 we have
explored the use of gated Tl images to identify the position
and size of myocardial infarcts in man.
Patients and Methods
Patients
13 patients with a recent transmural myocardial infarction
diagnosed from electrocardiographic (ECG) evidence and the
finding of raised levels of heart muscle enzymes were studied 2-l'2
days after the onset of infarction! 8 patients had ECG evidence of
anterior, 3 ofinferior, and 1 ofpredominantly lateral infarction, and .
in 1 patient the site could not be determined from the
electrocardiogram. 6 patients received standard therapy in the
coronary-care unit for the first 48 h, and 7 received intravenous
thrombolytic therapy. A further 2 patients with subendocardial
infarction were also studied. The age range of patients was 37 to 68
years.
Transverse
Fig 1—The 12 areas into which the transverse and coronal scans
are divided.
The findings of the acute-infarct group were, compared with a
control population of a further three groups comprising 7 healthy
volunteers, 5 patients with chronic ischaemic heart disease and
previous infarction, and 5 patients with non-ischaemic heart
disease. The age range ofthese groups was similar to the group with
"acute infarction.
Magnetic Resonance Imager
The magnetic resonance imager in the Royal Infirmary of
Edinburgh is a 0- 08T resistive system (manufactured by M&D
Technology).9 It uses an interlaced saturation recovery and
inversion recovery sequence from which a T1 image is obtained.
Cardiac gating was achieved by triggering from the R wave of the
patient's ECG. Two electrodes were placed on the right side of the
trunk and connected to an optical coupling device for relay to the
ECG monitor. This prevented electrical interference between the
monitor and magnet. Triggering of the image pulse sequence could
be varied from every R wave to every second or third R wave to take
account of rapid heart rates. The pulse sequence allowed a
minimum delay of 230 ms between the upstroke of the R wave and
the position within the cardiac cycle to be imaged. Images were
obtained close to end systole to avoid the effect of intracavity blood
flow.
Imaging Procedure
The study was approved by the local ethical review committee,
and written informed consent was obtained from all participants.
All patients were in a stable phase at the time of imaging and able to
lie flat comfortably. A rapid (16s) ungated scan was done so that the
correct section of the left ventricle to be imaged could be selected.
Initially, only one or two full scans with an acquisition time of
between 4 and 6 min per section were obtained until we were
confident that patients who had recently sustained a myocardial
infarction were able to tolerate the procedure without evidence of
stress, such as an increase in heart rate. Imaging time was thereafter
increased to allow up to five sections per patient but was still
restricted to a maximum imaging time of 30 min per patient. The
procedure was well tolerated in all subjects.
Measurement of Tt
The T! image was transferred to a diagnostic console and
displayed in colour corresponding to the range of T] values. The
overall visual appearance was noted, and any obvious abnormalities
such as wall thinning, pericardial fluid, or obvious area of increased
myocardial Tj were recorded. For all studies the left ventricular
wall was divided into six areas for both transverse and coronal scans
(fig 1), and the T[ for each region was measured.
Results
The appearance of normal myocardium was of a uniform
Tt (fig 2), which was seen in both the healthy volunteers and
patients with non-i'schaemic cardiac disease. The mean Tj
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was 305±25 ms for normal volunteers, which was not
significantly different from the T, values for the patients with
non-ischaemic cardiac disease or old infarction but was lower
than for recent infarcts where the mean Tj was 329±60 ms
(p<0-01).
In the group with recent transmural infarction the most
dramatic finding was of distinct areas of increased T j in the
left ventricular wall (table I). The precise area ofmyocardium
involved varied from a localised region ofprolonged T l (fig 2)
to a more diffuse area ofpatchy increase in Tj. Differences in
TABLE I—MAXIMUM T, VALUES IN PATIENTS WITH RECENT
MYOCARDIAL INFARCTION
Time since Region of
onset of myocardium from
infarction Site of Max CK Max T, (SD) which T, was
(days) infarction (U/l) (ms) obtained (fig 1)
1 Inferior 484 508 (44) 11
2 Anterior 1915 371 (27) 5
3 Anterior 1169 457(14) 10, 4
3 Anterolateral 2206 324 (58) 1
5 Inferior 946 407 (24) 10
6 Anterior 2640 338(50) 3
7 Indeterminate 729 429 (19) 11
8 Inferior *' 449 (62) 9
8 Anterior 1660 434 (45) 9, 10
9 Anterior 2215 396 (58) 5
10 Anterior 2050 422 (38) 3
11 Anterior 1982 590 (92) . "3
12 Anterior 1585 419(51) 4
CK = creatine kinase.
*No CK measured; maximum aspartate aminotransferase 146 U/l.
TABLE II—MEAN AND MAXIMUM (±1 SD) T,
Mean Maximum
- T i (ms) T, (ms)
Normal volunteers ' 305±25 340±17
Non-ischaemic cardiac
disease 296±22 316±9
Old infarction 307±27 352±31
Recent infarction 329±60 426±70
maximum T { values between the groups were greater than
differences in mean Tj (table II). For patients with recent
infarction the maximum T, was 426±67 ms. This compares
with a maximum Tj of352±30 ms for old infarct (more than 2
months) (p<0-05), 316±9 for non-ischaemic cardiac disease
(p<0-01), and 339±17 for normal volunteers (p<0- 02). 10 of
the 13 patients with recent transmural infarction had a region
of myocardium with a T, longer than 390 ms, whereas none
of the other groups contained any areas ofmyocardium with a
T! longer than 390 ms. There was no significant difference in
the prolongation of T, between those treated with and
without thrombolytic therapy. Of the 3 patients with recent
infarction who did not show areas of increased T(, all had
only one or two sections scanned and it is possible that the
region of infarction may not have been included. No regions
of high T, were seen in the 2 patients with subendocardial
infarction. Unsuspected pericardial fluid was noted in 2
patients, pleural effusion in 1, and suspected early aneurysm
formation in 1. Patients with previous myocardial infarction
had changes such as ventricular dilatation and wall thinning
but no areas of increased T,A degree ofwall thinning was
also seen in 3 patients with recent infarction. In patients with
inferior myocardial infarction affecting the inferior border of
the left ventricle, the area of increased TL was often best
appreciated on the coronal scan, although it was present on
the lowest transverse section as a very broad area ofraised Tj.
Discussion
Using a magnetic resonance imager that gives accurate
measurements of the relaxation parameter T,, we have
demonstrated that recent myocardial infarction can be
visualised in man. We found an average 40% increase in Tj in
areas of suspected infarction in patients imaged between 2
and 12 days after the onset ofinfarction. A smaller percentage
increase in T1 was reported by Williams et al2 in biopsy
specimens of ischaemic tissue from dogs within 30 min of
experimental coronary occlusion. Our findings of increased
T! with recent but not with old infarction are in keeping with
the in-vitro measurements of Brown et al,10 who showed
prolongation ofT[ in canine myocardium 3 h and 4 days after
Eig 2—Gated T, coronal images of a healthy volunteer (left) and a man 8 days after inferior myocardial infarction (right).
The infarcted heart shows an area ofhigh T [ in the infero-apical region ofthe left ventricle above the.arrow. There is also a small amount ofpericardial fluid seen
as a rim of very high T,. ■ . .
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coronary occlusion, but at 21 days Tt was more variable, and
by 56 days it was shortened.
Higgins et al3 found a 14% prolongation ofT2 and a good
correlation with the percent water content in an experimental
model of myocardial infarction and have confirmed these
findings in man.4 In dogs, Wesby et al, having demonstrated
a change in spin echo signal intensity in vivo, reported 69%
prolongation of T2 in vitro. It is not yet possible to say
whether T, or T2 is superior either in vitro or in vivo. Most
magnetic resonance imaging systems are designed so that
images of high spatial resolution can be obtained, less
emphasis being placed on precise estimation ofT! or T2. In
such systems the spin echo pulse sequence is generally used
for cardiac imaging because it is technically easier to gate and
because it produces images ofgood spatial resolution. Using a
system such as this, T2-weighted images can be obtained and
T j and T2 values can be calculated, T; with generally poorer
accuracy and precision than T2. However, our method, using
inversion recovery, provides a more precise value for T].
Whether "U or T2 will in the end be the more useful remains
to be determined.
The ability to obtain serial sections through the heart
suggests that it should be possible to obtain an accurate
measure of infarct size with gated images in man. This is of
particular importance in assessing interventions designed to
limit infarct size. Thrombolytic therapy causes recanalisation
and improves blood flow and ventricular function but may
cause reperfusion damage or haemorrhagic infarction.12'13
Our studies have not revealed a significant difference in T[
values between patients treated conventionally and those
with documented coronary reperfusion, but the varying time
of imaging from onset of infarction make a more detailed
study necessary. With nuclear magnetic spectroscopic
analysis Slutsky et al14 found an increase in T, in excised
dogs' hearts after 3 h of ischaemia and a slight further
prolongation with reperfusion. Brown et al15 found a
differential effect of varying lengths of occlusion and
reperfusion on Tt values in canine hearts. With measurement
of T, it should be possible to follow the natural history of
myocardial infarction and to determine the effect of
intervention therapies, including coronary reperfusion.
Correspondence should be addressed to a. l. M., Department ofMedicine,
Royal Infirmary, Edinburgh EH3 9YW.
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Summary A monoclonal antibody (H17E2) against
placental alkaline phosphatase (PLAP) and
testicular placental-like alkaline phosphatase was labelled
with indium- lllandusedin radioimmunoscintigraphy of 15
patients known or. suspected to have germ-cell carcinoma of
the testis or carcinoma of the ovary or cervix. Good images of
neoplastic lesions were obtained in most patients with active
disease. In 1 patient with testicular teratoma and elevated
human chorionic gonadotropin who had a normal computed
tomography scan, the labelled antibody located microscopic
disease in a lymph node, which was then removed. No false
positive localisation was seen in patients with PLAP-negative
tumours or sites of inflammation. This method may be
helpful in the diagnosis, staging, and monitoring of PLAP-
positive neoplasms of testicular, ovarian, and cervical origin.
Introduction
radioiodinated polyclonal1'2 and monoclonal
antibodies3"8 have been shown to localise successfully in a
wide range of neoplasms. In-vivo dehalogenation and
antibody cross-reactivity with healthy tissues are limitations
of this method and may explain the low levels of radioiodine
detectable in resected tumours.9'10
We selected a new monoclonal antibody (H17E2)11 against
placental alkaline phosphatase (PLAP) and testicular
placental-like alkaline phosphatase which shows high
reactivity against PLAP-positive tumours and very low, if
any, reactivity against healthy tissues.12 For radiolabelling we
used indium-Ill, which has been shown to produce better
tumour-to-healthy-organ (except for liver) ratios than those
with radioiodine.13"16
Patients and Methods
15 patients, aged 21-70 years (mean 40 years), with testicular
(n = 8), ovarian (n = 6), and cervical (n= 1) neoplasms were studied.
Written, informed consent was obtained from all patients, and they
were skin tested for allergy to mouse antibodies before injection.
Monoclonal Antibody HI 7E211'12
This mouse IgGl reacts with placental alkaline phosphatase as
well as the leucine inhibitable form ofalkaline phosphatase found at
low levels in the healthy testis and which cross-reacts with the
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£ brain water measured in volunteers after
alcohol and vasopressin
We have reported that brain water levels in chronic
^alcoholics are raised during the acute phase ofwithdrawal and then
decrease over 7-21 days ofabstinence. We used magnetic resonance
•paging (MRI), the T, relaxation time being related to the amount
Tjjf free water in tissues.2 These findings are consistent with the
hypothesis that the brain, in the initial stage of withdrawal, is
ioverhydrated. Vasopressin may have a role in mediating these
-changes.3 We have attempted to reproduce these changes in healthy
gj|hinteers.
1 Four male and one female volunteers, mean age 32 (range 26-40),
with an average weekly consumption of 16 units of alcohol (range
42) had an NMR scan before and 45 min after the consumption of
a bottle ofspirits (14 units). The alcohol was consumed over 1 Vi
ours. This produced blood alcohol levels of 143-197 mg/dl at the
of the second scan and caused a mean increase in plasma
ilarity of 12 mmol/kg (after correction for alcohol). We used a
i-OST resistive MRI system.1
■ Measurements ofTt were made from a calculated T] image of a
fe j2 mm thick transverse section 10 mm above the maximum
^ ciiameter of the lateral ventricles. Measurements were made for the
left and right hemispheres ofthe whole section, excluding CSF, and
for individual small.areas ofgrey and white matter in the frontal and
occipital regions. Statistical significance of results was calculated
using Wilcoxon's paired rank test.
{.There was a significant decrease in Tj ofthe whole section (mean
3;7 ms, p<0-05) (table). In white matter there was a significant
decrease when frontal and occipital measurements were analysed
together (t = - 3 • 9 ms, p<0 ■ 05) and there was a similar trend in grey
#Siaiter (t= -6-4 ms, NS). The precision of T, in grey matter is
1
"(poorer than that ofwhite matter or ofthe whole brain.1 The change
*"
Tj is consistent with the observation that alcohol inhibits
ipressin and this promotes diuresis and dehydration in the short
;erm.
Three further volunteers (all male, aged 30, 31, and 32 yr) were
ien scanned daily at 0900 h for 4 days. Day 1 acted as a baseline and
ie volunteers took vasopressin 20 pi twice daily for the next 3 days,
produced a fall in mean sodium from 140 to 135 mmol/1 and in
'jMean plasma osmolarity from 292 to 281 mmol/kg. The Tt of
(frontal and occipital white matter increased by a mean of 4 -1 ms
(consistent'With an increase in free water). This increase just failed
:to reach significance at the 5% level. No general trend was noted in
grey matter or whole slice measurements.
ius we have demonstrated that we can alter T] acutely and in
5e direction we would expect if the change is due to alterations in
(he amount offree water in the brain tissue, although the magnitude
fthe change is about halfof that seen in chronic alcoholics.1 This
supports the view that changes in T, during withdrawal are due to
dynamic changes in water balance.
) Isosmotic overhydration has been noted4 in alcoholics and so have
(decreased levels of vasopressin in plasma and CSF.5,6 Eisenhofer
?(d Johnson7 found that in normal volunteers early suppression of
Tasopressin is followed by raised levels as the increasing plasma
asmolarity overcomes the direct suppression. Perhaps the
' mechanism of vasopressin release becomes reset in chronic
acoholism. These and other studies8'9 suggest that water retention,
mediated by raised vasopressin levels, may be responsible for some
the clinical features of alcohol withdrawal.
NMR is a safe, non-invasive tool for monitoring changes in tissue
hydration, and we plan to look next at changes in total body water,
fc)™, VALUES (ms) OF LEFT AND RIGHT HEMISPHERES BEFORE AND
gig AFTER CONSUMPTION OF 14 UNITS OF ALCOHOL
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vasopressin, aldosterone, and renin levels over a one week
withdrawal period, beginning while the patient is still intoxicated.
This research has important clinical implications—both for the
treatment of withdrawal symptoms and because of the possibility
that vasopressin is involved in the development of dependence on
and tolerance to alcohol,10 and because ofcase-reports ofimproved
memory in patients with Korsakoff's psychosis given a course of
vasopressin.
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cystic leucomalacia in preterm infant:
site of lesion in relation to prognosis
Sir,—In your July issue (p 137) we reported the very poor
outcome in infants with periventricular leucomalacia (PVL)
compared with those who had large intraventricular haemorrhages.
We did not distinguish between ischaemic lesions confined to the
periventricular areas and those extending further into the white-
matter. We have since studied another 7 cases and have become
aware of the prognostic importance of the distribution of these
lesions (figure). We suggest that the term "periventricular" should
be restricted to lesions adjacent to the ventricles in the area of the
centrum semiovale, trigone, and optic radiation. Lesions further
from the ventricles, at the depth of the sulci in the subcortical
region, should be classed as "subcortical leucomalacia" (SCL), on
the basis of the post-mortem angiographic studies ofTakashima et
al.1 Lesions are prominent in both the subcortical and
periventricular regions would be classed as "mixed".
Of the 17 infants studied so far (including the 10 previously
reported) 9 had extensive lesions in the periventricular area, 4 in the
subcortical region, and 4 were mixed. Although serial ultrasound
studies showed the same basic pattern for all lesions, in SCL the
areas of increased echogenicity tended to occur earlier after the
insult and were especially marked around the interhemispheric
fissure, and cysts occurred sooner and persisted far beyond 40
weeks' postmenstrual age.
PVL was seen in preterm infants below 32 weeks' gestation while
SCL tended to occur in older preterm infants. Takashima et al1
suggested that the distribution of the cystic lesions is related to the
maturity of the vascular supply. Another suggestion is that the
different energy metabolism in the various parts of the brain at
6.
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Technical note
ECG-gated Ty images of the heart
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1. Introduction
Magnetic resonance imaging (mri) has been usee} to investigate heart disease, either
studying abnormal anatomy or attempting to identify pathological alterations of
myocardial tissue. The anatomical studies have used cardiac-gated saturation recovery
or spin-echo pulse sequences with short time to echo (te), which produce reasonably
high spatial resolution images containing mainly proton density information (Longmore
et al 1985) or real-time echo planar imaging (Rzedzian et al 1983). For information
concerning tissue, particularly important for the investigation of myocardial infarction
(mi), it may be possible to identify abnormal pathology within the cardiac tissue using
the relaxation times Tx or T2.
In vitro measurements of excised dog hearts have shown that both Tl and T2
increase following recent myocardial infarction (Williams et al 1980, Higgins et al
1983). The changes in 7*, correlate with changes in the water content of the tissue
(Higgins et al 1983, Brown et al 1984, 1985) demonstrating that the initial increase in
T, and T2 is due to tissue oedema. The increase in Tx is then reversed as the region
of the heart wall is replaced by fibrous tissue (Brown et al 1984). Increases in T2 in
vivo following mi have been demonstrated in dogs (Wesbey et al 1984, Pflugfelder et
al 1985) and in man (Higgins et al 1984, McNamara et al 1985). In one of these studies
T, weighted images were also investigated but no increases in signal were detected
(Pflugfelder et al 1985).
There is a wide variation in the results of the magnitude of the changes in 7) and
T2 following infarction and also some disagreement concerning the relative merits of
Tj or T2 in the assessment of mi. We feel that the suggested superiority of T2 over Tx
is likely to be influenced by the fact that the mri systems used were not designed to
give accurate or precise Tx values (Pflugfelder et al 1985) or that the pulse sequence
combination used was more appropriate for T2 measurements than for Tx (Higgins et
al 1983). In order to assess the true value of in vivo Tx measurements of mi in man a
pulse sequence specifically designed for Tx measurement with high precision has been
gated with the cardiac cycle to produce gated Tx images.
2. Methods
A commercial 0.08 T resistive system, installed in a hospital environment for clinical
studies (Smith et al 1984), has been modified to produce cardiac gated T\ images. The
0031-9155/86/070771+08S02.50 © 1986 The Institute of Physics 771
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imager generally uses a fixed pulse sequence which produces a saturation recovery
image, an inversion recovery image and a calculated 7j image for each section in a
4min 16 s acquisition time. The imager uses an interlaced saturation recovery and
inversion recovery pulse sequence with tr= 1000 ms for both and ti = 200 ms for the
latter. One novel feature of the system, which makes it particularly suited to gated
cardiac imaging, is the use of an adiabatic fast passage (afp) pulse to invert the nuclei
in the inversion recovery sequence (Hutchinson and Smith 1983). This pulse is very
efficient at inverting the nuclei throughout the section imaged and it also has the
advantage that it is not slice-selective in the inversion part of the sequence. This latter
feature of the inverting afp pulse is important because of the necessarily long delay
between it and the subsequent 90° pulse, which is slice-selective, and which therefore
must be synchronised with the cardiac cycle.
The timing of the pulse sequence is controlled by two timing integrated circuits,
each with ten channels. In the normal mode of operation one of the timing channels
controls the tr interval, which can be fixed at a preset value. This counter works in a
free running mode and is automatically re-armed. For the gating sequence, this channel
is changed to one shot mode. A single pulse sequence can then be started under direct
software control by re-arming the appropriate channels. The computer used in the mri
system is a Digital PDP 11/23 + . The software was programmed to respond to a pulse
occurring on one of the status lines and a socket was fitted so that the system could
be triggered externally from either a cardiac or respiratory gating pulse.
To obtain an ecg pulse from a subject inside the nmr imager, care was taken to
reduce interference on the ecg signal from the rf pulses and also to minimise the
noise introduced into the system from any patient connections. It was decided to
monitor the ecg and use the R wave to determine the position of systole and diastole
in the cardiac cycle rather than the less precise method of using a peripheral pulse
from a region such as the finger. It was found that two electrodes placed one on either
wrist produced severe interference on the ecg signal from the rf pulse, ecg detection
in a perpendicular direction, with one electrode placed on the right shoulder and the
other electrode just above the right hip produced no measureable interference from
the rf pulses on the ecg signal. Conventional ecg electrodes were used in this position
as illustrated in figure 1, the leads being taped to the patient with Micropore to ensure
that there were no loops to pick up rf interference. The cables from the two electrodes
were twisted together and connected to a rechargeable battery-powered unit 1.2 m from
the centre of the magnet which converted the ecg to optical pulses so that it could be
transmitted along a 12 m optical fibre. The distance of the battery-powered optical
fibre unit from the central region of the magnet was found to be important. If the unit
were nearer the centre of the magnet the ferromagnetic material within the unit would
degrade the image; if the unit were further away then the electrode leads would act
as an aerial for the external rf interference. The optical fibre is connected to a unit
to convert the ecg signal into a form that can be fed into a conventional ecg monitor
(Kontron Micromon 7141), both of which are sited 4 m from the magnet. The monitor
has been modified to produce a pulse immediately after the detection of the QRS
complex.
The trigger pulse from the modified ecg monitor is fed into a microcomputer (BBC
model B) which in turn produces a pulse which is fed into the mri system computer
to trigger a single nmr signal acquisition. The microcomputer controls the delay
between the patient's R wave and the part of the cardiac cycle to be imaged. A window
setting can be used such that only R-R intervals within a certain range produce a
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Figure 1. Schematic plan view of subject in mri system. The positions of the ecg electrodes and leads
and the battery powered box, converting the ecg to optical pulses, are shown in relation to the subject and
the largest ring magnet.
signal for the mr system: thus ectopic beats are excluded. This is particularly important
for end diastolic images as the section is not imaged immediately after the R wave, as
is usually the case, but immediately before the succeeding R wave.
The timing of the T, gating sequence is illustrated in figure 2. There is a delay of
20 ms between the patient's R wave and the trigger from the ecg monitor due to the












Figure 2. Timing diagram for a gated 7j image showing inversion recovery and saturation recovery pulses
during the interleaved sequence. The trigger from the ecg monitor occurs 20 ms after the upstroke of the
R wave. The delay between the trigger pulse and the afp is controlled by the microprocessor and will be
different for each subject. A time from inversion (ti) of 200 ms is shown. The nmr signal is a field echo
occurring 10 ms after the 90° pulse.
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pulse is controlled by the microcomputer. The time from inversion (ti) can be altered
in the main mr acquisition program but is generally set at 200 ms. The time from the
trigger pulse and the 90° pulse is identical in both the saturation recovery and inversion
recovery parts of the pulse sequence. Thus in both types of pulse sequence resonance
occurs in the section at the same part of the cardiac cycle. The field echo occurs
approximately 10 ms after the 90° pulse. The shortest delay available between the
patient's R wave and the part of the cardiac cycle to be imaged is 230 ms, falling within
systole even in patients with heart beat rates as fast as 120 min"1. Signal acquisition
can be triggered from every heart beat, though for accurate T, estimation every other
heart beat is used in subjects with a heart beat rate faster than 70 min"1.
A Perspex phantom was used to check the gated Tx images. It contained three
layers of CuS04 solution, the central layer having a 7j of 330 ms and the outer layers
a 7) of 528 ms, and moved up and down with a maximum distance of travel of 5 cm. It
was driven by a stepping motor controlled by a microprocessor which enabled either
regular motion or motion which simulated an irregular R-R interval to be used. The
microprocessor also produced a trigger pulse at the start of each cycle. The frequency
of movement studied was 38-70 min"1, equivalent to the frequency of trigger pulses
obtained from human subjects, remembering that for heart beat rates greater than
70 min"1 a trigger pulse is produced on every second beat.
Results obtained from the moving phantom are given in table 1. It can be seen that
the precision of the calculated 7j, as demonstrated by the standard deviation of pixel
values within the region of interest used, is not degraded by movement. There is a
slight variation in 7j value with tr, as would be expected. However the variation is
within the long-term reproducibility (coefficient of variation) of 7j measurement which
is 2.9 and 6.5% for T, values 330 and 528 ms respectively.
An example of a cardiac-gated 7j image of a normal subject at end systole is
illustrated in figure 3 with an ungated image of the identical section for comparison.
The time to end-systole from the R wave was determined using echocardiography. The
3. Results
Table 1. Results obtained from phantom whr i moving at a fixed
frequency, at an irregular frequency and when stationary. The
Tx±2 sd refers to the mean 7\ within a region of interest±2
standard deviations of the 7\ values of the pixels within that region.
7\ + 2sd (ms)
Frequency tr



























Static Phantom 1000 330 ±30 528 ±90
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Figure 3. (a) Gated and (b) ungated transverse T, images of a normal human subject. The linear grey
scale covers the range 50 to 650 ms.
section thickness used was 16 mm and the acquisition time for the gated image just
under 4 min. The absence of signal from the anterior chest wall on the right-hand side
is caused by the ferromagnetic material in the screening of the cable of the ecg
connection. In the gated 7j image the region of the left ventricular wall can be seen
quite clearly with a uniform 7j value. In the ungated image there is no such region
of uniform 7j corresponding to the ventricular wall; the 7j value steadily increases
from the outer edge of the heart to the centre. Eight small regions of interest were
drawn encompassing the whole of the left ventricular free wall and the coefficient of
variation of the 7j values was found to be 3% in the gated image and 10% in the
ungated image.
At end-systole the 7j of the blood is fairly uniform. This is not the case in images
later in the cardiac cycle, particularly during early diastole, where the Tx of blood
varies considerably. The cause of this is illustrated in figure 4 which shows the
saturation recovery image at different stages during the heart cycle. It can be seen that
the image acquired at the beginning of diastole contains a region of very low signal,
caused presumably by the turbulence of the blood flowing into the ventricles. As the
signal level from this image is the denominator in the equation to calculate 7j, this
results in indeterminate values of 7j.
To date the technique has been used on 12 normal volunteers, many of these on
more than one occasion, 13 patients with hypertrophic cardiomyopathy and 32 patients
with mi, 7 within 4 days and the rest within 12 days of infarction. Occasionally the
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Figure 4. Gated saturation recovery images of a
normal subject (a) at end-systole, (b) during dias¬
tole, showing a region of low signal in the left ven¬
tricle as it is filling, and (c) towards the end of
diastole.
position of the two electrodes makes it impossible to produce a trigger pulse from the
cardiac monitor. On such occasions the electrode on the right hip is moved to the left
side of the patient and the cable to the electrode on the right shoulder is supported
away from the chest wall by foam pads so that no signal loss occurs in the region of
the heart. The use of this arrangement has improved the ecg signal sufficiently to allow
a trigger pulse to be produced in all but one patient. However, the position of the
electrode on the left-hand side of the patient causes interference on the ecg from the
rf or gradient pulses, depending on the size of the patient and consequent proximity
to the gradient windings or rf coil, which can cause unwanted trigger pulses. This
can be overcome by gating the signal acquisition on every second, third or fourth
pulse, depending on the type of interference. In some instances this can result in a
lengthening of the time for an acquisition of a single section.
Figure 5. Gated coronal Tt image of a patient with recent mi. The region of increased 7j, corresponding
to infarcted tissue, is indicated.
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Patients with recent infarction find the procedure acceptable, a complete investiga¬
tion of four transverse and one coronal section taking between 20 and 30 min. Regions
of increased 7\ have been found in the ventricular wall in patients with a recent infarct
(Been et al 1985) and an example is shown in figure 5.
4. Discussion
The ability to obtain ecg-gated T, images of sufficient quality and in a sufficiently
short time for clinical use has been demonstrated. The commercial system which has
been modified has been shown to be particularly suitable for obtaining such images. This
technique will be of value in assessing the use of in vivo Tx measurement to identify
abnormal pathology within the ventricular wall, particularly in patients with recent
infarction. Most other mri methods of investigating cardiac disease rely on the
identification of wall thinning or abnormal motion using gated spin-echo images, often
presented in cine mode. Such techniques can take a long time, particularly if the
complete left ventricle is to be studied, which may prove unacceptable for patients
with recent infarction. Moreover, echocardiography is already a well established and
readily available technique producing similar information.
Many patients with cardiac disease will have an irregular heart beat; even if ectopic
beats are not present then the R-R interval will vary during an investigation. Such a
variation can produce a significant error in the 7) estimation when a gated spin-echo
sequence with short tr is used. In contrast, our use of a gated inversion recovery
sequence with an inverting pulse that is not slice-selective ensures that the typical R-R
variations obtained from patients have little effect on the Tx values obtained.
It would be possible to obtain better linear spatial resolution by increasing the
section width, thereby increasing the signal size, or by signal averaging, which would
result in a considerably longer acquisition time. However, thicker sections have not
been used as these would increase the partial volume effect, which increases with
section thickness, as the heart is imaged in the transverse plane which itself is not
perpendicular to the ventricular wall. To minimise the time that the patient is inside
the mri system signal averaging is not performed.
Future improvements to the system will be the availability of oblique sections so
that the left ventricle can be imaged in a more appropriate plane, either perpendicular
to the ventricular wall or along the length of the ventricle through the apex.
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In view of the absence of conclusive evidence to support the
existence of non-thermal effects we retain our hypothesis that
the applied heat dose, which is dependent upon both the
temperature obtained and the exposure time, is the critical
parameter. In this case extensive thermometry is required to
ensure that the patient receives an effective adjunct treatment
to radiotherapy.
Yours, etc.,
J. van der Zee
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The absence of tissue specificity in MRI using in vivo
X, or T2 determination: true biological variation or
technical artefact?
The Editor—Sir,
The discovery by Damadian (1971) that malignant tissue
measured in vitro has a higher Tt than normal tissue acted as
the stimulus for the development of NMR imaging techniques.
In the beginning it was hoped that in vivo measurements of
relaxation parameters may uniquely identify different tissues or
the same tissue in different pathological states, perhaps
enabling the differentiation between normal, benign or
malignant tissue. However, by the time commercial magnetic
resonance imaging (MRI) systems became available in about
1982, the emphasis in MRI system design was generally not on
precise or accurate in vivo 7j or T2 determination but rather
higher resolution image production, the images being X, or T2
weighted. It is generally accepted now that neither X2 nor T2
are disease-specific, there being too great an overlap for
diagnostic purposes.
We feel that this conclusion may be erroneous. The spread
of X, or T2 values from a particular tissue may not be due
solely to the biological variation but instead may be
significantly expanded due to technical errors in their
calculation. There are a number of possible sources of error in
the in vivo relaxation parameter determination.
(a) The calculation of in vivo T1 from a saturation recovery
and an inversion recovery pulse sequence will have an
error if there is not efficient inversion in the latter
sequence. This will occur in all imaging systems when a
spatially selective 180° pulse is used or when there is
significant radiofrequency inhomogeneity across the image
plane. An exception is the system which uses an adiabatic
fast passage RF pulse (Edelstein et al, 1980), which
efficiently inverts all the nuclei.
(b) Some two-point methods of relaxation parameter calcula¬
tion are known to be imprecise; for example, two
saturation-recovery or two spin-echo sequences with
different TR or two inversion-recovery sequences with
different TI to calculate Tl and two spin-echo sequences
with different TE to calculate T2. More precise estimations
using such sequences require a larger number of points
each with a different TI or TE value to be used.
(c) The spin-spin and spin-lattice relaxation processes may
not be characterised by a single exponential.
(d) The width of the tomographic sections used in MRI,
particularly when values of X2 or T2 are being calculated,
can be as thick as 20 mm. As a consequence there can be a
significant partial volume effect. The partial volume effect
can produce a considerably reduced estimate of the X, or
T2 in a pathological lesion which has a higher value than
surrounding normal tissues unless the lesion was extremely
large. Much thinner section widths must, therefore, be
used for accurate in vivo X, or X, determination; the
thickness of the section should be about half the diameter
of any tissue under investigation and care must be taken to
position the section through the centre of the tissue.
(e) It is recognised that cardiac and respiratory movement
degrade the resolution of images; this can be avoided by
the use of gating techniques. However, not only does it
degrade image resolution, it will also produce an error in
the calculation of X, or X2 if the tissue is moving.
(f) There can be an error introduced due to subjective
operator variation in the choice of region for or T2
calculation.
Experience has shown that, as the techniques of in vivo Tt
and T2 determination are improved, so the spread in their
values from a particular type of tissue is reduced. Only when
the technical errors of X, and X2 measurement are eliminated
can we hope to draw any firm conclusions concerning their
specificity and consequent clinical use.
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Radioprotection by ascorbate in vitro: temperature-
dependent uptake
The Editor—Sir,
The role of glutathione in radioprotection has been much
investigated, but relatively little attention has been paid to
ascorbate, which is present at high concentrations in human
tumours (Kakar & Wilson, 1974; Moriarty et al, 1977). Both
glutathione and ascorbate can act as H-atom donors, although
ascorbate is more efficient in electron transfer reactions, and
both these reactions may be important in DNA repair
processes (Redpath & Willson, 1973; O'Neill, 1983; Willson,
1983). There have been some reports in the literature of
radioprotection by' ascorbate in vitro (Redpath & Willson
1973; O'Connor et al, 1977; Baverstock, 1979) but other
workers have found no effect of ascorbate on radiosensitisa-
tion by misonidazole (Koch et al, 1979).
As a part of an investigation into the radioprotective role of
ascorbate in vitro, we have measured the uptake of ascorbate
by V79 379A Chinese hamster cells incubated in Eagles'
minimum essential medium +10% fetal calf serum at various
temperatures. Figure 1 shows the concentration of ascorbate in
cells plotted against time of incubation under N2 at 4°C,
21.5°C and 36°C. The point we would wish to emphasise is the
marked temperature-dependence and slow time course of the
uptake, with essentially no uptake at 4°C, and intracellular
concentrations increasing for several hours at the higher
temperatures. In some radiobiological experiments the pre-
irradiation incubations are carried out at 4°C in order to
'educe toxicity. If the agent of interest is actively transported,
or is taken up slowly, both of which appear to apply to
ascorbate, a lack of effect could arise from poor intracellular
uptake rather than inactivity per se. Thus, Koch et al (1979)
We would recognise that in many MRI systems it is not
possible to eliminate all the sources of technical error,
particularly as there is often limited time available for patient
investigation. In the centres which adopt a pragmatic approach
to T, and T2 calculation and are investigating its use in the
clinical environment, knowing that, for technical reasons, the
values obtained may not be entirely accurate, we would
suggest that such quantitative values should be defined as Tf
and T2". The term Tl and T2 would be reserved for what is
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dose/Gy
Fig. 2.
Survival curves for cells irradiated under N2, in the absence or
presence of ascorbate. (a) (O) Hypoxic control, (#) 1 mM
ascorbate; protection factor (PF) = 1.14. (b) Cells incubated
with the inhibitor of glutathione (GSH) biosynthesis
buthionine sulphoximine (BSO) (0.1 mM) for 18 h: (□)
hypoxic control, (■) 0.2 mM ascorbate; PF = 1.15. (c) GSH
depleted cells + misonidazole (0.1 mM): (A) hypoxic control,
(a(c) 0.2 mM ascorbate; PF = 1.17. In each case, the PF is
quoted relative to the paired survival curve in the absence of
ascorbate.
showed that ascorbate at 5 mM had no effect on radiosen-
sitivity when the pre-gassing was carried out at 4°C. We have
iccently shown that if pre-incubation is at room temperature,
then ascorbate can afford significant protection in both control
and GSH-depleted cells (Fig. 2). Full details will be published
elsewhere. We would, therefore, like to take this opportunity
to emphasise the importance of measuring the uptake of any
Time (h)
Fig. 1.
Temperature-dependence of the uptake of ascorbate by cells
incubated with 0.5 mM ascorbate under N2. Error bars
indicate +SD.
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A Description of a Low Field Resistive Magnetic Resonance
Imaging System and its Application in Imaging Midline Central
Nervous System Pathology
D. M. KEAN, M. A. SMITH, R. H. B. DOUGLAS and J. J. K. BEST
NMR Imaging Unit, University of Edinburgh, Royal Infirmary, Edinburgh
A commercial low field magnetic resonance imaging
(MRI) system installed in the Royal Infirmary, Edin¬
burgh at the end of 1983 has since been used for the
clinical investigation of over 1000 patients. This system
uses an interlaced saturation recovery and inversion
recovery pulse sequence which yields four types of clini¬
cal image. A Tl weighted image has been found to be the
most sensitive for the detection of pathology. Several
examples of pathology with negative X-ray computed
tomography examinations including three examples of a
syrinx and two cases of tonsillar herniation have been
demonstrated using this system. It is suggested that the
system could provide a routine clinical service for imag¬
ing the central nervous system.
to noise ratio and consequently the best spatial resolu¬
tion of the four images, but since there is very little
difference between proton density in different normal
tissue types and between different pathological tissues
little pathological information is contained in this image.
The image is not a true proton density image as subs¬
tances with a very long Tl relaxation time like
cerebrospinal fluid will give very little signal due to the
incomplete relaxation of magnetisation between succes¬
sive pulses with a TR of 1 s.
The inversion-recovery pulse sequence employs an
adiabatic fast passage (AFP) radiofrequency (RF) pulse
to ensure complete 180° inversion of magnetisation
throughout the section of data collection. This differs
from more conventional 180° RF pulses where it may be
THE MAGNETIC RESONANCE UNIT
The past four years have seen considerable progress in
magnetic resonance imaging (MRI). In the majority of
this work imaging systems with field strengths of 0.15 T
and above have been used, though some clinical work
has been performed at 0.08 T (Hawkes et al., 1980;
Bydder and Steiner 1982; Bydder et al., 1982; Brant-
Zawadski et al., 1983; Bydder etal., 1983; Gamsu etal.,
1983; Herfkens et al., 1983; Hricak etal., 1983a; Hricak
etal., 1983b; Smith 1983; Worthington et al., 1983; Kean
etal., 1985). Since the major application of MRI appears
to be in the investigation of the central nervous system it
is necessary to produce satisfactory images of this system
with sufficient resolution and pathological contrast
within an acceptable patient investigation time.
90° 90°
A A
AFP 90° AFP 90°
■ A ■ A
(jj|(W tyl/l/v l\j\r~ signal
Fig. 1 - The NMR pulse sequence used in the M&D 800 imager.
The magnetic resonance machine is a low field 0.08 T
system manufactured by M&D Technology Ltd,
installed in the Royal Infirmary, Edinburgh (Smith et
al., 1984). It employs a resistive magnet whose magnetic
field is directed along the vertical axis. The design of the
system is closely based on the Aberdeen magnetic reso¬
nance imager (Hutchison and Smith, 1983) and uses an
interlaced saturation-recovery and inversion-recovery
pulse sequence (Fig. 1). The repetition rate (TR) and
time to inversion (77) are normally 1000 ms and 200 ms
respectively resulting in a total data acquisition time of
4 min 16 s for each section.
Four types of clinical image are processed for each
section (Fig. 2). The so called 'P' or 'proton density'
image (Fig. 3) is obtained from the saturation-recovery
pulse sequence which utilises a field echo with an echo-
delay time (TE) of 10 ms. This image has the best signal Fig. 2 - The four different types of image produced by the imager.
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Fig. 3 - A proton density image.
uncertain whether complete inversion through 180° has
been achieved. The inversion-recovery image can be
displayed by either a non-modulus or a modulus form of
display (Fig. 4). The inversion recovery image is Tj
weighted, allowing for discrimination between tissues of
different Tl values such as grey and white matter. The
contrast, that ic the difference in signal between two
different tissues, will vary with the time allowed for
longitudinal relaxation before a 90° pulse is applied
(77).
The 'D' or 'difference' image is obtained by subtract¬
ing the numerical data of the inversion-recovery pulse
sequence from the saturation recovery pulse sequence.
This image (Fig. 5) contains much of the spatial resolu¬
tion of the saturation-recovery image but its Tx weight¬
ing provides much more pathological information. This
Tl weighting will result in regions of prolonged 7) giving
a higher signal intensity. "
A calculated T1 image is obtained from the following
equation:
7\=200/ln {(2x'P')/'D'}
where 'P' and 'D' represent the pixel values in the
proton density and difference images respectively. This
image is often useful in confirming the presence of
pathology which is suspected on the 'difference' or
inversion-recovery image. The Tj calculation is precise
due to the complete inversion achieved by the AFP
pulse. The long-term in vitro precision over six months
varies from 2.3% (coefficient of variation) to 4.1% for
Tx values of between 163 ms and 416 ms respectively.
The in vivo precision is 4.9% for grey matter and 2.8%
for white matter (Smith etai, 1985). An example of a 7)
Fig. 5 - The 'difference' image.
(a) (b)
Fig. 4- (a) Modulus form and (&) non-modulus form of the inversion-recovery image.
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Fig. 8 - 'Fast' image showing high signal from flowing blood in the
sagittal sinus and around the thrombus in a cavernous aneurysm.
Fig. 6 - The calculated 7\ image.
image is shown in Fig. 6. The Tx values can be displayed
using a linear grey scale or colour coded display. The
pixel values on the grey scale and the colours on the
colour-coded display are directly related to the Tx value
in milliseconds.
THE MACHINE IN CLINICAL PRACTICE
The patient is positioned by means of a light source
and is transported into the magnet system on a motor-
driven couch. A smaller head coil is fitted into the larger
body coil for cranial examination. A 16 s 'fast' scan is
used to check the anatomical level before the 4 min 16 s
full data collection is begun. There is some T1 informa¬
tion in the 'fast' scan and this can show pathology such as
the subdural collection shown in Fig. 7. This is useful if
the patient is unable to cooperate or elderly when
chance of movement during the longer scan increases.
Fast scans, due to the short TR are also more flow
dependent and may be used to confirm the presence of
flowing blood within a lesion like an intracranial
aneurysm (Fig. 8). Subsequent transverse images above
Fig. 7 - 'Fast' image showing high signal from a subdural collection.
Fig. 9 - An anaesthetic trolley positioned close to the imager.
Fig. 10 - Midline sagittal proton density image showing tonsillar
herniation to the posterior arch of C2.
214 CLINICAL RADIOLOGY
or below the first image are then obtained by controlled
couch movement. Sagittal and coronal images can also
be obtained but at present these are only available
through the mid-sagittal and mid-coronal planes of the
imagingvolume. Slight adjustment to the position of this
plane in the midline of the imaging volume may be made
by alterations to the static magnetic field. These altera¬
tions however are limited and only permit about 1 cm
latitude. It is also possible, by moving the patient
slightly, to alter the position of the region of interest
being imaged.
As with other MRI systems claustrophobia may be a
problem, particularly with cranial examinations where
the head is more enclosed within the smaller head coil.
Gentle persuasion overcomes this problem in all but the
most severely claustrophobic. The overall total rejec¬
tion rate due to claustrophobia is 2%,
To date 49 children have been examined, eight of
these under general anaesthesia. Several problems are
posed in the administration of general anaesthesia in a
magnetic environment but these have been successfully
overcome. The problems are minimised by the low mag-
Fig. 12 - (a) A midline sagittal inversion-recovery image showing high
calculated Tx image showing the very short Tx of this lipoma compatible
al, 1985.)
' (b)
signal from a large lipoma in the cervical spinal cord, (b) Midline sagittal
with fat. The displacement of the spinal cord is also shown. (From Kean et
(a) (b)
Fig. 11 - (a) A midline sagittal proton density image showing central low signal in the cervical cord due to a syrinx cavity, (b) 'Normal' CT scan of the
same patient (L+100, W250).
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netic field. It is important that no metal is used in the
anaesthetic tubing, particularly at the mouthpiece.
Metal stethoscopes cannot be used but an oesophageal
stethoscope has proved ideal. A standard anaesthetic
trolley causes distortion of the main magnetic field when
it is in close proximity to the magnet and adjacent to the
RF shield next to the patient couch. Once an anaesthetic
trolley is in position however this distortion can be com¬
pensated for by adjusting the static magnetic field; and
provided it is not moved, the quality of the image is
unaffected (Fig. 9). A pulse monitor with a light-emit¬
ting diode detector around a digit may be used to moni¬
tor the pulse. It is important that all anaesthetic staff are
warned of the possibility of danger from projectile metal
objects in the proximity of the static field. This hazard
however is not so great a problem with a lower field
system than with higher field systems. In common with
all other MR systems, patients with pacemakers are not
(b)
Fig. 13 - (a) Midline sagittal 'D' image showing high signal from a
pontine glioma causing effacement of the 4th ventriclei (b) Coronal
inversion-recovery image showing very low signal i.e. long 7i from the
same pontine glioma.
allowed within the imaging suite and at present patients
with aneurysm clips are not imaged.
CLINICAL RESULTS
Craniovertebral Junction
To date 44 patients with suspected pathology in this
region have been examined. The assessment of
suspected pathology in this location is made particularly
easy by the use of the sagittal imaging plane. This allows
the position of the cerebellar tonsils to be accurately
defined and any downward displacement of these struc¬
tures to be easily assessed. Since cortical bone is not
visualised by MR the anterior and posterior margins of
the foramen magnum are not directly visualised but can
be inferred. The clivus, which contains fat, points to the
anterior margin of the foramen magnum and the fat in
the occipital diploe points to the posterior margin.
When the cerebellar tonsils are displaced inferiorly (Fig.
10) they are seen to herniate through the foramen mag¬
num and in this example are seen to approach the post¬
erior arch of the second cervical vertebra.
The presence of a syrinx can be rapidly demonstrated
by low-field MRI. Figure 11(a) demonstrates a low sig¬
nal from a syrinx cavity within the cervical cord. This
cavity contains CSF which on a proton density image
gives a low signal due to its very long relaxation time
when examined with a TR of 1 s. A moderate degree of
tonsillar herniation is also seen. The computed tomogra¬
phy (CT) examination, with intrathecal iopamidol (Fig.
lib), shows a normal sized cord and no evidence of a
syrinx.
A lipoma in the cervical cord is dramatically shown on
inversion recovery and calculated T, images (Fig. 12).
The short 7j of this lesion allows a diagnosis of lipoma to
be made. The anterior displacement of the cervical spi¬
nal cord is also well seen.
Brain Stem
To date 50 patients with suspected pathology in this
region have been examined. Lesions in the brain stem
cause a non-specific rise in relaxation times. Figure 13a
Fig. 14- Midline sagittal inversion-recovery image showing low signal
from a large brain stem infarct.
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demonstrates an expanding lesion in the pons, which is
effacing the 4th ventricle. The coronal image (Fig. 136)
confirms the intra-axial location of this pathology. Vas¬
cular lesions such as brain-stem infarcts are easily
demonstrated. Figure 14 demonstrates a region of low
signal on an inversion-recovery image corresponding to
prolonged Tl in a large brain-stem infarct. Figure 19
demonstrates a region of prolonged Tl in the pons in a
patient with clinical signs of brain-stem demyelination.
It must be pointed out that this 7j abnormality is not
specific and may also be seen in a small area of
ischaemia.
Corpus Callosum
This is another structure which is easily assessed by
MRI. Figure 16a demonstrates agenesis of the corpus
callosum with an associated lipoma. The transverse sec¬
tion (Fig. 166) shows the separation of the lateral ventri-
Fig. 15 - Transverse 'D' image showing high signal in the posterior
aspect of the pons due to an area of demyelination.
cles and the presence of a rounded short T1 lesion
anteriorly.
Pituitary Gland
To date 60 patients with suspected pathology in this
region have been examined. MRI does not demonstrate
the destruction of cortical bone by pituitary pathology
but the presence of most pituitary pathology is easily
demonstrated. A very large pituitary macroadenoma is
demonstrated in Fig. 17a; although demonstrated well
by X-ray CT (Fig. 176), it should be pointed out that this
examination required over 45 1.5 mm sections together
with intravenous contrast medium to provide such an
image. The spatial resolution of the MRI machine is at
present insufficient to demonstrate small pituitary
lesions like microadenomas.
DISCUSSION
The advantages of MRI in the investigation of the
CNS are now well known and many of these can be
obtained from a low-field system. There have now been
numerous publications demonstrating the use of MRI in
the central nervous system. All of these have shown that
MRI is the modality of choice in this region due to the
following features:
1. The variability of the pulse sequences give MRI flex¬
ibility and allows the examination to be tailored to
suit the particular clinical problem since these
sequences may be altered to provide more contrast
between normal and abnormal tissues which makes
MRI a more sensitive technique.
2. The lack of artefact, particularly streaking in the
posterior fossa, permits the demonstration of this
area along with the craniovertebral junction much
better than X-ray CT.
3. The direct acquisition of sagittal and coronal images
permits the rapid and accurate localisation of path¬
ology particularly at the cranio-vertebral junction
and in the brain stem.
Fig. 16 - (a) Midline sagittal inversion-recovery image showing high signal
showing low signal from the same lipoma. The separation of the lateral v
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(a) (b)
Fig. 17- (a) Midline sagittal 'D' image showing a large pituitary macroadenoma extending down into the sella. There is also considerable suprasellar
extension, (b) CT scan of the same pituitary macroadenoma (L+40, W150).
These advantages have been demonstrated on systems
with a higher field strength than the one described. We
believe that the low-field system described is capable of
producing excellent clinical results. The most obvious
disadvantage is the inferior spatial resolution compared
with high-field systems. This drawback may only be a
problem in examining regions such as the pituitary and
the internal auditory meatus. Signal averaging may
overcome this but this would mean a slightly increased
imaging time. Another drawback to the system at pre¬
sent is the lack of offset slices in the sagittal and coronal
planes. It is planned to upgrade the system with this
facility together with the addition of a facility for multi¬
ple simultaneous slice acquisition.
In conclusion, we feel that this imaging system, at
least when applied to the central nervous system, can
provide almost all the advantages inherent to MRI but
without many of the problems associated with higher
field, higher cost systems; and with the additions of
offset slices and multiple simultaneous slice acquisition
this system will be capable of providing a routine clinical
service in imaging the CNS.
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Technical note
A technique for velocity imaging using magnetic resonance imaging
By J. P. Ridgway, B.Sc., M.Sc. and M. A. Smith, B.Sc., M.Sc., Ph.D.
NMR Imaging Unit and Department of Medical Physics & Medical Engineering, University of Edinburgh,
Royal Infirmary, Edinburgh
(.Received October 1985 and in revised form December 1985)
Magnetic resonance imaging (MRI) is becoming well
established as a technique which both shows anatomy
and allows tissue characterisation. A further develop¬
ment of the technique allows the imaging of regular
movement such as blood flow and cardiac wall motion.
In particular, much effort has been put into developing
techniques for imaging flowing blood and deducing
such parameters as velocity and acceleration.
Early work by Singer (1959) described a technique of
blood flow velocity measurement using a "time-of-
flight" method. Velocity images have been obtained by
this method using a modified version of a spin-echo
pulse sequence (Feinberg et al, 1984). Normally, a slice
is excited using a selective 90° radio-frequency (RF)
pulse and an echo is produced at a later time by
applying a selective 180" pulse to the same slice. If
moving hydrogen nuclei have, in the meantime, moved
out of the slice, no signal will be returned from them,
resulting in a reduction in signal intensity from blood
vessels in the image. This is the spin washout effect. If,
however, the 180° RF pulse is applied to a slice
downstream, an echo signal will be returned from
excited nuclei having a velocity such that they coincide
with the second slice selection. In this way, a series of
images can be obtained, each corresponding to a certain
range of velocities.
The standard spin-echo technique can also be
exploited to produce flow-dependent signals in vessels
(Axel, 1984; Bradley et al, 1984; Waluch & Bradley,
1984). The effect, known as paradoxical enhancement,
results in vessels appearing to have a much higher
intensity than the surrounding tissue. This effect
becomes particularly noticeable for shorter repetition
times since freshly saturated nuclei moving into the slice
will give a stronger signal relative to the surrounding
stationary tissue, which is only partially saturated.
In a multi-echo sequence a phenomenon known as
even-echo rephasing is also present (Waluch & Bradley,
1984). The magnetic field gradient (subsequently
referred to as the gradient) used for slice selection and
the gradient used for readout are applied twice in a
spin-echo sequence. The first time they are applied,
nuclei dephase along the direction of the gradient; the
second time, they are applied with opposite polarity and
nuclei move back into phase along that direction. If the
nuclei are stationary then they will move back exactly
into phase with one another; however, if nuclei are
moving along a gradient direction they will have a
phase shift at the first echo, having only partially
rephased. This phase shift will be linearly dependent on
their velocity. All nuclei having the same velocity will
have the same phase shift on odd echoes but will have
zero phase shift on even echoes, the effect of the
gradients having been reversed provided the velocity is
constant. Thus, flow can be identified by comparing
first and second echo images. On the first echo, flowing
blood will appear to have a reduced signal while, on the
second echo, the signal will be of higher intensity. We
are, of course, neglecting dephasing effects caused by
spin-spin relaxation.
Since the non-zero phase shift on the first echo is
linearly dependent on velocity, it can be used to
measure velocity directly (Bryant et al, 1984; Moran &
Moran, 1984; Redpath et al, 1984; Van Dijk, 1984;
Moran et al, 1985; Wedeen et al, 1985). In most MRI
systems the signal is collected from two channels in
quadrature, yielding a real and an imaginary data set.
These are usually combined to calculate a modulus
image used for diagnosis. These two data sets can,
however, be used separately to produce a real or an
imaginary image, or can be combined to calculate a
phase image. All three of these contain phase
information which is normally discarded in the
calculation of the modulus image and it is this
information which provides a way of imaging velocity.
Although real and imaginary images have been used
to demonstrate imaging of velocity, they also contain
spin-density information (Moran et al, 1985). The
phase image is easiest to interpret and quantify since it
contains only motion information and represents a
direct linear map of a single velocity component. In
order to quantify the velocity measurements accurately,
standard spin-echo and field-echo sequences have been
modified by adding extra gradient pulses in the
direction of required velocity measurement.
To date, this has been done in two ways (Moran
et al, 1985); either two identical gradient pulses
separated by a 180° RF pulse are inserted, or a bipolar
pulse consisting of two successive gradient pulses equal
in magnitude and duration but of opposite sign is
inserted into the pulse sequence between the 90° RF
pulse and the readout gradient. The first of these
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gradient pulses dephases the nuclei in the applied
direction and the second pulse rephases them.
Stationary nuclei are all brought back into phase,
whereas for nuclei moving along the gradient the
rephasing is not complete, leaving them with a phase
shift proportional to velocity.
The accuracy of the technique is dependent on the
two gradient pulses having exactly the same duration
and magnitude over the imaging volume and on the
uniformity of the RF, gradient and static fields. A non¬
uniform field will introduce a spatially dependent phase
shift over the image (McVeigh et al, 1985; Norris,
1985b). A technique has been developed (Redpath et al,
1984) to overcome these difficulties by varying the size
of the flow-encoding pulses for a number of data
acquisitions and applying a 3D Fourier transform
technique to the whole set of data. The resultant set of
images will be coded in intensity, each corresponding to
a certain velocity range, and may be used to reconstruct
a simple velocity-coded image. A further limitation of
the techniques is that velocities corresponding to a
phase shift of greater than +180° or less than —180°
will lead to an ambiguity of velocity measurement. This
can be avoided by adjusting the magnitude of the
gradient so that the resultant phase shifts lie within the
range of + 180°. This paper presents a technique which
uses the calculated phase image as a direct measurement
of velocity. The problem of field non-uniformity is
avoided by using two separate pulse sequences and
subtracting the resultant phase images.
Method
The technique has been integrated into the standard
spin-warp imaging sequence (Edelstein et al, 1980) used
on an M&D 0.08 T resistive MRI system (Smith et al,
1984). The slice selection gradients, which are effectively
of bipolar form, were initially used to provide the phase
encoding for velocity components perpendicular to the
imaging slice (Fig. 1). In order to avoid the appearance
of phase shifts due to the spatial non-uniformities of the
fields, two pulse sequences were used to produce two
phase images which were subtracted to produce the
final velocity image. The two pulse sequences were
identical except that the timing of the rephasing
gradient was later in one than in the other. Phase errors
due to the time-independent inhomogeneities in the
main field and the RF field would be the same in each
case and would, thus, cancel in the final subtracted
image. The only remaining phase differences are due to
motion, such that for a given velocity component, v, in
the direction of the applied slice selection gradient, G,
the phase difference is;
•^difr = — yG'Tw'difT
where tv is the duration of the rephasing pulse, tm is
the difference in pulse separation for the two pulse
sequences, and y is the gyromagnetic ratio for protons
(Fig. 1).
All the computer processing is performed within the
acquisition program so that the subtracted phase
images are displayed 8 s after acquisition. An ungated
velocity image can be obtained in 64 s using a repetition
time (TR) of 250 ms. For in-vivo imaging, however, the
pulse sequences are gated (Been et al, 1985) in order to
look at an instantaneous velocity, and consequently
the imaging time is dependent on the heart rate.
Typically, one section will take about 4 min. The two
pulse sequences are interlaced so as to reduce the effects
of gross patient movement between scans. The
magnitude of the flow pulse gradient, G, is
1.25 mT m ~1. For the studies described here, the flow
pulse timing was such that rdifr = 2 ms and 7W = 2.4 ms.




















A simple adaption of the Aberdeen spin-
warp pulse sequence for imaging of
velocity through the slice by varying the
position of the rephasing gradient
(broken line) between positions 1 and 2.
Two corresponding phase images are









Velocity measurements have been calibrated using a
simple flow phantom consisting of a 1 cm-inside
diameter polythene tube surrounded by a bath of
2.5 mm solution of copper sulphate. The same solution
of copper sulphate was pumped through the tube at
various known constant rates. The mean flow velocity
for the tube was calculated and calibrated against the
mean phase shift found within the tube. A number of
normal volunteers have been imaged in the neck, thorax
and abdomen using the interlaced gated sequence. An
initial comparison with continuous wave Doppler
ultrasound at 2.5 MHz has been carried out in the
abdominal aorta using a Hewlett Packard 77020
Doppler imaging system. Using MRI, a number of
delays were used from the electrocardiogram R-wave in
order to plot the velocity in the abdominal aorta over
the systolic period of the heart cycle. The sample
volume for this measurement was taken at the centre of
the aortic diameter.
Fig. 3.
(a) A flow image of the neck using the pulse sequence of
Fig. 1. This image demonstrates the common carotids and the
vertebral arteries as the darker vessels, corresponding to a
negative phase shift, and the jugular veins as the lighter vessels,
corresponding to a positive phase shift. The surrounding
stationary tissue is displayed as mid-grey, (b) A flow image of
the thorax showing the ascending and descending aorta, (c) A
flow image of the abdomen showing aorta and inferior vena
cava. A line profile through both vessels clearly shows the
differences in velocities.
Velocity calibration of the flow measurement technique using
the pulse sequence in Fig. 1.
Results
The calibration of the velocity measurement shows a
good linear relationship between velocity and phase
shift (Fig. 2). Three examples of the volunteer studies
are shown in Fig. 3. These images display zero phase
shift as mid-grey, positive phase shift of 180° as white
and negative phase shift of 180° as black. Where the
values in the modulus image are below a certain
threshold the phase values are not calculated.
Figure 4 shows the velocity measurements taken in
the abdominal aorta compared with those taken from
continuous-wave Doppler ultrasound measurements.
There is a good agreement in profile shape and timing,
although the velocities appear to be lower in the case of
the Doppler measurements.
Discussion
It has been shown that velocity measurements are
possible on the low field imaging system at Edinburgh
with changes only to the pulse sequence and software
and without any improvements required on the field
homogeneity.
This technique, using phase as a direct measurement
of velocity, has advantages over the other techniques
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Fig. 4.
A velocity flow profile of the systolic period of the heart cycle
for the abdominal aorta comparing the results from 11 flow
images as shown in Fig. 3c, with results from Doppler
ultrasound measurements.
mentioned in the introduction due to its relative
simplicity in interpretation, processing and display. The
time-of-flight method is restricted to imaging of one
particular velocity range per image. Paradoxical
enhancement and even echo rephasing are not
quantitative measures of flow and can only be used to
identify whether flow is present. The 3D Fourier
transform method requires many flow encoding stages,
whereas the technique described here requires only two
sections to produce the final velocity image.
Initially, high flow velocities are being examined since
they occur in the larger, better defined vessels. Lower
velocities of the order of 1 cm s_I have been imaged by
the technique simply by extending the time tm.
However, if this becomes too large then inhomogeneities
in the field lead to loss of signal from the imaging slice,
so it would be necessary instead to increase the
magnitude of the flow gradient.
While peak velocity in the abdominal aorta can easily
be imaged, the peak velocity in the ascending aorta is
rather more difficult to image due to loss of signal
around high velocity gradients over the vessel cross-
section (Moran & Moran, 1984; Moran et al, 1985;
Wedeen et al, 1985). These large velocity gradients
result in a large range of velocities and, hence, a large
range of phase shifts being present in the same pixel
volume. This phase dispersion causes the signal from
the nuclei in the same pixel volume to cancel, resulting
in loss of signal, and is often seen as a dark line along
the inner surface of the vessel. This effect can be seen
even in standard pulse sequences, as the slice selection
and signal readout gradients induce accidental phase
shifts for nuclei moving in their direction. Of particular
importance is the case of mitral-valve stenosis where
high-velocity jets are present.
Methods have been suggested to overcome the phase
dispersion which causes this loss of signal (Le Roux &
Floch, 1985; Pattany & Naylor, 1985). It is proposed
to use an adaption of the compensating bipolar pulse
technique suggested by Le Roux and Floch, modifying
it for use with the basic spin-warp pulse sequence. The
compensating bipolar pulse is of opposite polarity to
that already in the sequence, so that the dephasing
effect is reversed. Figure 5 shows the suggested pulse
sequence for use in further work, incorporating
compensating bipolar pulses into the technique in all
three directions. At present, this is not possible to do
due to hardware limitations, although it is hoped to
implement it in the near future.
It has already been shown (Norris, 1985a) that
double bipolar pulses can be used to image accelera¬
tion. The greater the separation between the bipolar
pulses, the greater the phase shift for a given
acceleration. Thus, phase shifts due to acceleration can
be minimised by merging the two middle pulses of the
double bipolar flow pulse into one. The velocity
















A further adaption of the flow pulse
sequence of Fig. I for measurement of
blood flow velocity in all three orthogonal
directions. The gradient pulse sequences
in the slice selection and frequency
encoding directions have two bipolar
pulses to compensate for the phase





of the broken line pulses in Fig. 5 between positions 1
and 2. Using the previous notation, the expression for
phase shift is given by:
= yGv/wrdin-+yGarw(7twrdifr+/diff2)
where a is the constant acceleration.
Thus, for conditions where maximum acceleration
occurs in vivo (200 cm s~2) this would produce at most
a 10% error in velocity measurement, given that typical
velocities at this point are around 50 cm s_1.
It is proposed to extend the technique to the
measurement of flow in all directions in all phases and
to pursue further volunteer studies and initial clinical
trials. The technique will be compared directly with
results from Doppler ultrasound measurements where
possible.
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Abstract
A relationship has been demonstrated between nuclear
magnetic resonance (NMR) longitudinal relaxation times (Tj
values) obtained in vivo in both normal and oedematous
(peritumoral) brain tissue, and measurements of brain water
obtained by gravimetric analysis of operative samples.
Significant correlations were found in seven patients in both
cortex (r = 0.97, P < 0.001) and white matter (r = 0.92,
P < 0.001). These findings suggest that NMR may prove a
useful technique for monitoring brain oedema.
Nuclear magnetic resonance (NMR) values in body
tissue are considered to be related to total water content
and to the ratio between "free" and "bound" water (Go
& Edzes, 1975; Mathur-De Vre, 1984). Longitudinal
relaxation time (T^ lengthens in oedematous tissue and
in a variety of pathological conditions including
malignancy. Previous authors (Go & Edzes, 1975;
Naruse et al, 1982) have shown a linear correlation
between Tj of experimentally induced cerebral oedema,
measured by in vitro NMR spectrometry, and brain
water, calculated from the weight of wet and dry
tissues. The present study was performed in order to
examine the relationship between Tt values, obtained
from clinical NMR images of patients about to undergo
surgery for cerebral tumour, and brain water measure¬
ments obtained by gravimetric analysis of the excised
specimens, and also to establish whether Tj images can
be used to predict the degree of cerebral oedema.
Method
Patients
All seven patients examined had histologically
verified solitary tumours within the brain. Six were
gliomas and the seventh a metastasis from an
adenocarcinoma of lung. All patients were receiving
4 mg dexamethasone four times a day at the time of
imaging and surgery. Four of the patients received
200-500 ml 20% mannitol at the time of dural opening,
within 30 min of tissue excision. Six patients underwent
lobectomy and one patient had multiple needle biopsies
of tumour and peritumoral tissue. The excised
specimens were rapidly enclosed in "cling film" and
transported to the adjacent laboratory for measurement
of brain water content.
Imaging
All patients were scanned the day before surgery with
the M&D 800 NMR Imager at the Royal Infirmary,
Edinburgh (Smith et al, 1984). For each section an
interlaced saturation-recovery and inversion-recovery
pulse sequence was used with a repetition time of 1 s for
both, and in the latter a Tt (time to inversion) of
200 ms was used. The slice thickness was 12 mm and
the acquisition time 4 min 16 s. A calculated Tj image
was obtained from the saturation-recovery and
inversion-recovery images using a two point method.
This was felt to be adequate given that most tissues
exhibit a single exponential decay curve (Ling et al,
1980). The use of an adiabatic fast passage inversion
pulse ensures efficient inversion throughout the section.
The mathematical algorithm used produces sufficiently
accurate Tt values (Redpath, 1982) and the long term
precision of Tt values, measured over a 6 month period,
varies from 2.3% for T[ = 160 ms to 4.1% for
T, = 500 ms. Between four and eight sections were
collected from each patient.
Brain water measurements
Brain water content was measured by microgravi-
metry using small tissue samples from the lobectomy
specimens. The specific gravity (s.g.) of each sample was
determined by placing it in a layered gradient column of
a mixture of kerosene and bromobenzene oil, that had a
high specific gravity at the bottom and a low specific
gravity at the top (Marmarou et al, 1978). Two minutes
after insertion of the sample into the column, its depth
in the oil was measured, and the column was
subsequently calibrated by measuring the depth of
potassium-sulphate droplets of known specific gravity.
The water con Lent of each sample was then calculated
from its specific gravity using the formula:
sample s.g. — 1
g water/g tissue = 1 - —— -
(1 — 1/solids s.g.) x sample s.g.
derived by Nelson et al (1971). The s.g. of the normal
human cortex and white matter solids was determined
by wet-weighing 500 mg samples from five patients with
normal brain in their operative specimens, and then
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reweighing the same samples after drying to constant
weight at 80°C (Nelson et al, 1971).
The lobectomy specimens were sectioned in the
transverse plane. Three samples of peritumoral white
matter, each weighing about 10 mg, were taken from
each site. Each sample was measured in the layered
kerosene/bromobenzene density column (Marmarou
et al, 1978), and samples of normal cortex and white
matter, when present in the specimen, were similarly
measured. In two patients, macroscopically oedematous
cortex was also sampled. All gravimetric measurements
were completed within 15 min of excision of the
specimen, to minimise water loss from the tissues. The
lobectomy specimen was then fixed for subsequent
histological examination.
Analysis
The NMR images were reviewed by the same
radiologist and surgeon without reference to the
gravimetric data. The sites of tissue sampling had been
noted by the surgeon with reference to known
landmarks. Tx values for abnormal tissue were obtained
from those sites using the region of interest facility on
the diagnostic console. Values for normal tissue were
taken by the same method, wherever possible, within
the lobe which had been resected.
Results
A graph of Tt values plotted against brain water
readings for normal and oedematous tissue is shown in
Fig. 1. A significant correlation exists between the two
measurements for white matter (r = 0.92, P < 0.001),
and cortex (r = 0.97, P < 0.001). Statistical analysis of
the data (Smith et al, 1981) demonstrates that the errors
of the techniques account for the spread of the bivariate
data about the regression line (x2 = 36.9, P < 0.001).
Discussion
Brain tumours are often surrounded by a zone of
oedema. This form of oedema is regarded by Klatzo
(1972) as vasogenic, where oedema fluid emerges
through a defective blood-brain barrier and spreads in
the extracellular space of the white matter. This
preliminary in-vivo study confirms in patients with brain
tumours the linear correlation between brain water
content and NMR Tt values, previously reported in
experimental animal models. Our results, however,
highlight differences between white matter, where T,
increases rapidly as water content rises, and cortex,
where the increase is slower. In normal tissue the water
content of cortex is greater than that of white matter,
our finding of 10% agreeing closely with the 10-15%
reported by other authors (Mathur-De Vre, 1984). The
Tt of normal cortex is correspondingly longer than that
of normal white matter. Oedema fluid accumulating in
cortical tissue is taken up by the cells and is, therefore,
influenced by the intracellular macromolecules. The
water protons are "bound" in the hydration layer
around the macromolecules and this alteration in their
Fig. 1.
Graph of water content and NMR Tt values for cortex and
white matter. Linear regression line for normal and
abnormal cortex (no mannitol □, with mannitol ■).
Linear regression line for normal and abnormal white
matter (no mannitol O, with mannitol •).
dynamic state shortens their relaxation time (Mathur-
De Vre, 1984). In oedematous white matter more water
remains in the extracellular compartment. A lower rate
of collisions between molecules in this "free" state
results in a longer relaxation time. Previous authors,
working with rat brain in vitro, have attributed the
linear increase in Tj with water content to increase in
the "free" water (Go & Edzes, 1975). Although results
from our small sample must be interpreted with
caution, we have shown a less marked rise in cortex, in
keeping with the smaller rise in "free" as opposed to
"bound" water. It appears that NMR Tt values can be
used to predict the degree of cerebral oedema in white
matter, and possibly in cortex.
Four of our patients received intra-operative
mannitol. Measured water content in their peritumoral
white matter is lower than might be expected from pre¬
operative T[ readings. Magnetic resonance imaging
may prove a useful tool in assessing the effect of
mannitol and other agents on cerebral oedema.
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A SURFACE COIL DESIGN FOR A VERTICAL FIELD MRI SYSTEM
AND ITS APPLICATION IN IMAGING THE BREAST
M. A. Smith*t and D. W. PYEf
*NMR Imaging Unit and IDepartment of Medical Physics and Medical Engineering,
University of Edinburgh, Edinburgh, United Kingdom
The general design of a flat surface coil for use with a vertical field MRI system is discussed. A development
of the design for imaging the breast is used as a specific illustration. The phenomenon of "sympathetic resonance"
is described in which transmission and reception is performed on the standard body coil with the surface coil
disconnected, its presence amplifying the signal to the body coil from the region of interest. Results show that
better quality images can be obtained with the surface coil than with the standard body coil and that the sym¬
pathetic resonance mode overcomes to a large extent the limited field of view problem normally associated with
a surface coil. A threefold improvement in signal to noise ratio was obtained using the surface coil.
Keywords: Magnetic resonance imaging; Surface coils; Vertical main field; Sympathetic resonance; Breast T,
imaging.
INTRODUCTION
Tomographic images through human subjects are
obtained by magnetic resonance imaging (MRI) using
a combination of magnetism and radio-frequency
(RF) radiation. The RF coil or coils are either in the
form of a combined transmitter and receiver coil,
sometimes known as a transceiver, or separate trans¬
mitter and receiver coils. It is possible to obtain a sig¬
nificant improvement in the signal to noise ratio
(S/N) of the NMR signal by placing a smaller RF
coil, generally referred to as a surface coil, close to the
patient at the region of interest. Such a coil is gener¬
ally only a receiver coil, a much larger coil being used
as a transmitter. The improvement in S/N produces
images of a higher quality but over a restricted region
of the patient.
The simplest type of surface coil is a circular loop
of conducting material. As the RF field (Bi) must be
perpendicular to the main magnetic field (B0), there
is a restriction in the orientation of these surface coils.
Most MRI systems have a horizontal magnetic field
B0, which means that a circular surface coil can be
used in planes parallel to the patient couch. This is
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very convenient for imaging regions such as the orbit
or breast.1
When the main magnetic field B0 is in the vertical
direction, circular surface coils cannot be used in the
plane parallel to the patient couch. To image a spe¬
cific region of the body, different coil configurations
must be developed which produce the RF field Bx in
a horizontal plane.
An additional criterion to be considered in the
design of a surface coil when a vertical field MRI sys¬
tem is used is that the access for the patient in the ver¬
tical direction is generally more restricted than in
horizontal field systems. The form of coil for imaging
the breast or spine, for instance, must take up the
minimum amount of space in the vertical direction. In
particular, a flat spine coil would allow imaging with
the patient lying supine over it. A further criterion
which applies to all breast coils, irrespective of the
main field orientation, is that the axillary tail must be
imaged as well as the breast.
Although the general design discussed here is ap¬
plicable to imaging various parts of the body using a
vertical field system, and has been tested by us for
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imaging both breast and spine, there is particular clin¬
ical interest in Edinburgh in the former, and so the
technique is specifically illustrated here with the
design of a breast coil.
METHODS
A breast coil was developed for the M&D 0.08-T
vertical field resistive MRI system sited in the Royal
Infirmary, Edinburgh. The patient enters between the
faces of the two larger horizontal ring magnets; the
distance between the patient couch and the lower face
of the upper magnet is 33 cm. One advantage of the
vertical field orientation for the main magnetic field
is that solenoidal RF coils can be used, resulting in a
higher S/N than would be obtained from a similar
size saddle coil.2 The RF coil used for conventional
body imaging is a split solenoid, which is situated on
the outside of the patient tube containing the gradient
windings. The coil is electronically switched between
transmit and receive mode. Prior to the development
of surface coils, body images were obtained using a
16-mm section width. Calculated Tx maps were
obtained using an interleaved saturation recovery and
inversion recovery pulse sequenced with TR = 1000
ms for both and TI = 200 ms for the latter.
Coil design
At the operating frequency of 3.4 MHz the skin
depth in copper is less than 0.1 mm. As a consequence
it is possible to construct RF coils using copper tube
or ribbon. To reduce the resistance of the coil as much
as possible, surface coils were constructed using cop¬
per pipe with an outside diameter of 8 mm and a wall
thickness of 0.6 mm. To construct a surface coil, the
appropriate length of copper pipe was straightened
and then filled with fine dry sand. The pipe could
then be shaped by hand, the sand enabling fairly
sharp bends to be obtained without distorting the
pipe. Having shaped the coil, the sand was removed.
To tune the coil, fixed polystyrene capacitors and
nonmagnetic variable capacitors were used. Polysty¬
rene or polyethylene capacitors suffer less RF loss
than other types of capacitors. 300-fi twin feed cable
connected the breast coil to the standard M&D pre¬
amplifier. When rigid support was required, polycar¬
bonate was used rather than perspex because there is
less RF loss with the former.
The surface coils developed for our MRI system
used the principle illustrated in Fig. 1. The parallel
sections of conductor in the central region of the coil
carry current in the same direction resulting in a mag¬
netic field with a significant component perpendicu¬
lar to the parallel conductors. The return paths of the
coil are positioned far enough away from the central
region so that the RF field from them does not inter¬
fere with the central region. This type of coil can be
flat, and such surface coils have been constructed for
the spine and mediastinum.
The breast coil design was an extension of this
principle and is illustrated in Fig. 2. The breast coil
was connected as two loops in parallel and mounted
on an expanded polystyrene block in which a trough
Fig. 1. The transmitter coil produces an RF field Bf parallel to and along the long axis of the patient couch. The central
conductors of the flat surface coil produce an RF field B(* which is perpendicular to both B0 and Bf. The field B{* is pro¬
duced in the region of the central conductors of the flat surface coil; the rest of the flat surface coil is oval in shape, the
conductor being sufficiently far from the central region not to interfere with the RF field.
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Fig. 2. Prototype breast coil showing the surface coil shaped to fit round the breast when the patient lies prone on the coil
support. The curvature of the coil is sufficient for a wide range of breast sizes to be imaged.
was cut. A piece of high-density foam, 1 cm thick,
was then placed on top of the coil and the polystyrene
block to reduce capacitive coupling between the breast
coil and the patient. The subject lies prone with the
centre of the breast of interest positioned in the mid¬
dle of the parallel conductors.
The surface coil was not used to transmit RF radi¬
ation; the conventional solenoidal body RF coil was
used as a transmitter resulting in uniform spin excita¬
tion throughout the tomographic section. The or¬
thogonal orientation of the RF fields associated with
the transmitter coil and breast coil; which acted as the
receiver, reduced the degree of cross-coupling. The
presence of the breast coil did not significantly change
the resonant frequency of the body coil, nor was there
any interference on the breast coil from transmitted
RF radiation. The breast coil was tuned inside the
imager at the central position and connected to the
preamplifier which had a capacitive loading effect of
60 pF. The pixel size was reduced from 3.5 mm square
used for body imaging to 2 mm square and slice thick¬
nesses of 8-12 mm were used.
Coil performance assessment
To assess the performance of the breast coil, the Q
factor and the S/N were measured. Two methods
were used to determine the Q of the breast coil. The
first method to measure Q was performed during the
tuning of the breast coil. Two 15-cm-diameter circu¬
lar copper search coils were placed 20 cm apart, one
either side of the breast coil. One coil was connected
to a signal generator and frequency counter, the
former being set to the exact reference frequency of
the MRI system. The second coil was connected to an
oscilloscope and the capacitors of the surface coil
adjusted until maximum signal was obtained from the
oscilloscope. The Q of the coil was obtained from the
equation
Q = V3/max/(/, -f2) ,
where /max equals frequency of maximum signal, f
equals frequency above /max at which the signal am¬
plitude is reduced by a half and f2 equals frequency
below /max at which signal is reduced by half. The
second method of measuring Q employed a vector
impedance meter connected across the surface coil ter¬
minals to trace its impedance variation with frequency
about 3.4 MHz. This technique was useful for making
measurements of Q for both unloaded and patient
loaded conditions, search coils being difficult to apply
in the latter. All Q values were measured with the
breast coil in the imaging position inside the magnet.
A major aspect of our research in Edinburgh into
the use of MRI in the breast is the use of 7j in the
investigation of breast disease. As a consequence the
image S/N was obtained from the calculated 7j map
for specific section widths and at various distances
from the breast coil. The definition of S/N used for
evaluation and comparison of surface coils was
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S/N = mean 7j /SD ,
where the mean 7j was obtained from a region of
interest containing at least 80 pixels, and SD equals
the standard deviation of individual pixel 7j values
within that region.
Coil performance was assessed from images on
normal volunteers and also from images of a 7.5-cm-
diameter bottle containing CuS04 with a 7j of about
200 ms. The bottle was placed in the trough of the
breast coil and imaged in the same way as a human
subject.
Sympathetic resonance
The phenomenon which we have called "sym¬
pathetic resonance" was identified while testing the
breast coil. In the conventional surface coil mode the
breast coil was tuned to the imager resonant fre¬
quency (3.4 MHz) and acted as the RF receiver. How¬
ever, similar improvements to those obtained using
the conventional surface coil mode could be obtained
if the large body coil used for transmission was also
used for RF detection, with the breast coil still tuned
to the resonant frequency but not connected to the
preamplifier nor directly coupled to the imager elec¬
tronics in any way. Images were obtained using the
breast coil in this sympathetic resonance mode and
also, for comparison, with its connectors shorted so
that the coil did not resonate near 3.4 MHz. The prin¬
ciple of a sympathetic resonance coil is illustrated in
Fig. 3.
RESULTS
The Q of the patient breast coil for different situ¬
ations is listed in Table 1. As expected, there is a
reduction in Q when the coil is inside the imager and
Fig. 3. Schematic diagram demonstrating the coil used as
a sympathetic resonator. The larger RF coil is used for both
transmit and receive. The surface coil is tuned to the reso¬
nant frequency but is not directly coupled to the imager elec¬
tronics in any way.
a further reduction when the coil is loaded with a
human subject. There is an increase in Q when oper¬
ating in the sympathetic resonance mode, because the
coil is no longer damped by connection to the pream¬
plifier input.
As expected, there is a variation in sensitivity with
distance from the breast coil; this variation, however,
is less in the sympathetic resonance mode. The calcu¬
lated 7) map is obtained from a saturation recovery
and inversion recovery image in the usual way, both
images having the same signal depth variation. As a
consequence, when they are combined, the 7j map is
uniform with depth. However, the decreasing signal in
the original images results in a gradual decrease in 7j
S/Wwith distance from the breast coil. The variation
in S/N with depth is shown in Fig. 4 with the S/N for
the conventional body coil and head coil3 shown for
comparison. The section width used with the breast
coil is narrower than the 16 mm used for routine
patient body imaging. The S/N values at different
Table 1. Q values of the breast coil and normal body coil
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Fig. 4. Variation in S/N in the 7j image with distance
from the surface coil at different section thicknesses. For
comparison the signal to noise using the head coil and the
large body coil at different section thicknesses is shown.
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Fig. 5. r, images of the same normal breast using a slice thickness of 12 mm with (a) breast coil connected in the conven¬
tional manner, (b) breast coil connected in the sympathetic resonance mode and (c) conventional body coil.
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Table 2. S/N of a 7] image with section thickness
10 mm at two different distances from the surface coil.
It can be seen that the S/N is better when the breast
coil is connected in the conventional manner near
the coil but the sympathetic resonance mode is
superior at greater distances
S/N
5 cm from 9 cm from
coil coil
Receive on breast coil 25.8 14.6
Receive on body coil
(sympathetic resonance) 21.9 17.2
Receive on body coil,
breast coil shorted
(no sympathetic resonance) 9.6 8.6
depths for the breast coil connected in the conven¬
tional surface coil mode and also in the sympathetic
resonance mode are given in Table 2.
An indication of the improvement obtained using
the breast coil on a normal volunteer is illustrated in
Fig. 5. For comparison an image is shown using the
standard body coil but with the magnet gradients and
section width that were used for breast coil imaging.
The smaller pixel size and section width used with the
conventional body coil produce an apparently noisier
image, due to a 75% reduction in signal per pixel,
than would be obtained if it were used in its conven¬
tional mode. The improvement in image quality com¬
pared with the conventional body coil can be seen
clearly. This improvement is present when the surface
coil is connected in the two different modes though in
the sympathetic resonance mode the field of view is
larger. This is because the variation in sensitivity with
distance from the coil is less in the sympathetic reso¬
nance mode and so the image S/N does not deteri¬
orate so quickly.
DISCUSSION
It has been demonstrated that a surface breast coil
can be used with a vertical field MRI system to obtain
significant improvements in breast image quality. It
has also been shown that the depth response of a
breast coil can be improved when connected in the
sympathetic resonance mode. This is particularly
important when investigating regions of abnormal tis¬
sue near the chest wall or in the axilla.
It is hoped that the use of this breast coil will
enable 7) maps to be obtained in patients suffering
from breast disease with a much thinner section width
than could be obtained using the conventional body
coil. This will result in a much smaller partial volume
error in the Tx values obtained which may in the past
have been partly responsible for the degree of overlap
that was found in Tx values between normal and
abnormal tissue.4
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Cardiac gating in nuclear magnetic
resonance imaging
M. A. Smith
NMR Imaging Unit, Royal Infirmary, Edinburgh, UK
In order to obtain NMR images ofthe heart, and to measure blood
flow by NMR, the signal acquisition must be synchronized with
the patient's cardiac cycle. Some of the problems of detecting the
cardiac cycle within a strong uniform magnetic field without
introducing RF interference into the imaging system are discussed,
some general applications of cardiac gated NMR imaging are
presented.
keywords: nuclear magnetic resonance imaging,
cardiac gating, heart, flow.
Introduction
The basic principles of nuclear magnetic resonance
(NMR) have been explained in detail both in this Journal
[1] and elsewhere [2 and 3]. Essentially the technique
involves placing a sample, in our case a human subject, in
a strong constant magnetic field. Radiofrequency (RF)
radiation is applied at a specific frequency which causes
the proton nuclei within the body to resonate; the source
of radiofrequency radiation is then switched off and the
nuclei continue to resonate emitting RF radiation which
can be detected. The size of the NMR signal will be
influenced by the amount of protons present, i.e. the
proton density. There are two time constants which relate
to the exponential decay of two components of the
resonance and these are referred to as the relaxation
parameters Tj and T2. During the transmission and
subsequent detection of the RF radiation additional
magnetic fields are briefly applied to encode spatial
information within the NMR signal. These additional
magnetic fields are known as 'magnetic gradients'.
NMR images are produced using a series of RF pulses
and the timing and type of pulses used will result in the
amplitude of the detection NMR signal containing
information not only of the proton density of the sample
but also the T[ and T2. Thus different pulse sequences
can be used in magnetic resonance imaging (MRI) which
produce images of the body which contain either mainly
proton density information, T] information, T2 informa¬
tion or a combination of two or even three of these
parameters. The term 'weighted image' is often used to
indicate that the signal intensity of the image is mainly
influenced by one particular variable. For example in a
T2 weighted image there will be a lot of information
concerning the proton density but the image intensity will
also be influenced by the T2 of the tissue. A Ti image on
the other hand contains purely information related to the
T i of the tissue. Such an image is sometimes referred to as
a 'Tj map'.
The amount of T[ or T2 weighting in an image using a
particular pulse sequence will be influenced by the
separation between the pulses in the sequence. As the RF
pulses in these sequences are often slice selective,
difficulties can arise when attempts are made to synchro¬
nize the pulses with the cardiac cycle. Not only can the
amount of Tj or T2 weighting vary during a single scan,
thus distorting the final image, but the pulses may not all
occur at exactly the same part of the cardiac cycle and so
the motion of the heart may not be completely 'frozen'. In
addition, the motion of the heart may cause dephasing of
the NMR signal resulting in a loss of signal amplitude
and low intensity regions in the image.
Cardiac gating is important in MRI, not only to eliminate
cardiac motion and phase smearing (figure 1) when
imaging the heart, but also to image velocity and flow
within the body. It is possible to store velocity informa¬
tion in the phase of the NMR signal [4 and 5] resulting in
the production of a phase image the intensity of which is
related to velocity. Measurements of pulsatile flow in
vessels within the body can only be achieved using
cardiac gating.
Figure 1. An ungated saturation recovery image, with the ECG
leads usedfor gating connected, showing (1) the loss ofsignal due
to the ECG lead; (2) the 'phase smearing' in the vertical direction
caused by the motion ofthe heart. The absence ofsignal within the
left ventricle is caused by turbulence ofthe blood and is therefore not
a true representation of the ventricular cavity.
The term cardiac 'gating' is something of a misnomer in
MRI. In nuclear cardiology signals are emitted from the
patient all the time and the patients' ECG is used to
define a 'widow' or 'gate' in time during which signals are
recorded. Hence the image obtained is cardiac gated. In
MRI the image is built up from a number of different
NMR signals, usually 128 or 256. These signals are
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Figure 2. An ECG gated coronal spin echo image at end systole. This sequence produces an image containing mainly proton density
information but with high contrast between cardiac tissue and blood. (Courtesy of the National Heart and Chest Hospital.)
produced after a short burst of RF and magnetic gradient
pulses which are 'triggered' by the patient's ECG so the
NMR signal is obtained in the same part of the cardiac
cycle. It is sometimes argued therefore that the term
cardiac triggered image is more appropriate.
Detecting the position of the cardiac cycle
There are a number of problems which must be overcome
to synchronize the NMR image with the cardiac cycle:
(1) Care must be taken not to introduce an excessive
amount of ferromagnetic material into the MRI
system. The presence of ferromagnetic material will
disturb the magnetic field uniformity and hence can
degrade the image.
(2) Both the RF and magnetic gradient pulses can
produce interference on any system used to detect the
cardiac cycle which is situated inside the MRI
system.
(3) The MRI is very sensitive to RF noise and any leads
attached to the patient can act as aerials and
introduce unwanted noise into the system.
(4) Any system which is developed must not just work for
normal volunteers but must be able to tolerate a wide
range of abnormal ECGs, compensate for variations
in the patient's R-R interval and detect and reject
ectopic beats.
A peripheral pulse can be used to identify the cardiac
cycle. This has two advantages: the first is that there need
be no electrical contact with the patient, and, secondly,
any device attached to the patient need be no nearer than
0.5m to the section imaged. The main disadvantage of
this technique is that unlike an ECG it does not provide
such an accurate determination of the cardiac cycle [6].
Often in cardiac imaging it is required to trigger each
signal at end diastole but the delay which exists between
end diastole and a peripheral pulse can prevent such
images being obtained.
A patient's cardiac cycle is most accurately specified
using their ECG. It is possible to detect a patient's ECG
using two electrodes, one on either wrist. The advantage
of such an arrangement is that the electrodes and cables
are away from the region being imaged. The main
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disadvantage is that the ECG signal is low but also
interference can be detected from RF transmitter and the
gradient coils. In our vertical field MRI system it is
possible to detect a patient's ECG using two electrodes,
one placed on the right shoulder and one placed on the
right hip, which produces a larger signal and less
interference [7].
It is possible to use some conventional electrodes, which
do not contain sufficient ferromagnetic material to distort
the image, at low field strengths but in high field systems
the amount of ferromagnetic material may produce
significant distortion and carbon electrodes may be
necessary. Signal loss can occur around the electrode
leads (see figure 1) but as the lead is positioned away from
the heart, this is quite acceptable. The small local loss of
signal is probably due to eddy currents in the screening of
the cable; removal of the screening eliminates this signal
loss but increases the RF noise introduced into the
system.
Transfer of the ECG signal
It is sometimes possible to use a simple filter on the ECG
leads to prevent interference being introduced into the
MRI system. More common is the use of an optical fibre
to transmit the ECG signal. The two ECG leads from the
patient are connected to a device which converts the ECG
to optical pulses. In Edinburgh a battery-powered
module is used with rechargeable nickel-cadmium bat¬
teries. This rests at the side of the patient approximately
1,2m from the imaging section and level with the entrance
to the imager.
The optical fibre is then connected to a device, this time
several meters from the main part of the NMR imaging
system, which reconverts the optical pulses to an ECG
signal. The signal can then be connected to a modified
ECG monitor which produces a trigger pulse at the
R wave. A visual display of the ECG has been found to be
important to obtain the best position of the electrodes on
the patient and also to confirm that the R wave is being
detected. In addition the ability to monitor many cardiac
patients during the investigation is essential. It must be
remembered however that the ECG cannot be considered
as diagnostic because of the possible presence of RF and
gradient pulses.
Triggering the image acquisition
A NMR image is produced from a number of NMR
signals, each obtained with a different phase encoded
gradient. In non-gated images the time between each of
these signals will be constant for a particular acquisition.
However, the time will vary for different types of
acquisition typically from about 50ms to 4000ms.
In cardiac gated MRI the trigger pulse initiates a
sequence of RF and gradient pulses which produces an
NMR signal. The next trigger pulse initiates the produc¬
tion of the next signal and so on until an image is
produced. The time from the R wave to the start of each
NMR signal production can be altered so that the heart is
imaged at any point within the cardiac cycle. RF and
gradient interference can produce sharp spikes on the
ECG which can be detected as R waves in the ECG
monitor producing a trigger pulse. This can be overcome
in the software of the MRI system as any such pulses will
occur at exact times after the trigger pulse which initiated
the signal production. As a consequence pulses detected
at such times are ignored.
As in other cardiac gated imaging techniques trigger
pulses produced by ectopic beats or from R waves
following R-R intervals outwith a predefined range must
be ignored. This can be done using a microcomputer or
within the main MRI computer itself.
Applications of cardiac gated NMR imaging
In other cardiac imaging techniques there is usually only
one parameter which influences the image intensity. In
nuclear cardiology it is the isotope concentration, with
ultrasound it is tissue reflectivity, and in computerized
tomography it is X-ray absorption. In MRI the situation
is quite different as we have three separate parameters
which can influence the image produced. It is generally
true to say that images that are essentially images of
proton density can be used to demonstrate anatomy.
Pathology, on the other hand, can be imaged using the T]
or T2 relaxation parameters.
A cardiac gated image of the heart containing mainly
proton density information is shown in figure 2. A spin
echo sequence has been used which produces good
contrast between blood and cardiac tissue due to the
motion of the blood. Such an image would be used to
identify abnormal anatomy within the heart or to
calculate ventricular volumes and parameters such as
ejection fraction and stroke volume [8]. The trigger pulse
after the R wave can initiate a number of NMR signals
occurring at different parts of the cardiac cycle. The
sequence of images so produced, usually 8 or 16, can be
displayed in a cine loop mode at the end of acquisition.
Figure 3. A cardiac gated Ti map showing mainly the left ventricle
at end systole. The scale on the right-hand side of the image is
calibrated in milliseconds. Generally such images are viewed in
colour to highlight increases in the Tj parameter following
myocardial infarction.
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Figure 4. An ECG gated phase image just above the heart
demonstrating flow in the great vessels. Velocity perpendicular to
the transverse section is displayed in the image. Sections of the
image where there is no motion are displayed as mid grey. Velocity
in one direction is displayed lighter, whereas velocity in the opposite
direction is displayed darker. The intensity is linearly related to the
velocity.
This can be used to demonstrate abnormalities in
ventricular wall motion.
Cardiac pathology can be visualised using gated T x maps
as illustrated in figure 3. Two sequences are used to
calculate the Ti maps, both of which are gated. An
important example is the identification of myocardial
infarction which results in a local increase in tissue water
due to oedema. The anatomy of the heart may appear
quite normal even though the pathology is abnormal. The
relaxation parameters T; and T2 are both prolonged in
regions of oedema and consequently will identify regions
of recent infarction that would not be shown on a proton
density image [9 and 10]. This time the blood has a high
signal corresponding to a high Tj.
The application of cardiac gating in flow measurements is
illustrated in figure 4. Moving tissue will influence the
phase of the NMR signal; phase maps can therefore
be produced in which the image intensity is directly
related to velocity and direction. Fairly accurate esti¬
mates of flow can be obtained from these velocity
measurements and the technique may rival Doppler
ultrasound for some applications in the future. To
measure pulsatile flow, whether in blood or the CSF, the
sequence must be synchronized with the cardiac cycle.
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Summary Brain water content was measured in tissue
samples taken at operation from 19 patients
with intrinsic cerebral tumours imaged preoperatively by
magnetic resonance. A high correlation (r = 0-94,
p <0-0001) between white matter water content and the
longitudinal relaxation time (Tt) enabled water content to be
estimated from T, to within 4%. 11 patients received
dexamethasone and improved clinically but their T,, and
thus brain water content, was unchanged an average of 6
days later. Intravenous infusion of 20% mannitol in 11
patients significantly reduced T, in oedematous white
matter and tumour within 15 min of administration, and by
30 min the T i of oedematous white matter had fallen to a
mean of32-4 (SEM 7-1) ms, corresponding to a reduction in
water content of 1-4 (0-3)%.
Introduction
In 1919 Weed and McKibben1 showed that the brain
bulk of cats could be increased by intravenous infusion of
distilled water and decreased by hypertonic (30%) saline or
saturated sodium bicarbonate solution. They reported that
the cortical capillaries were distended and the intercellular
spaces were diminished, but did not examine changes in
water content. What are the physical effects of osmotic
agents on the brain? Some workers argue that mannitol does
not decrease brain water content, but rather changes
intracranial vascular calibre2 and reduces ventricular
cerebrospinal fluid (CSF) volume.3 Others report
measurements suggesting that mannitol can reduce brain
water content.4
In cerebral neoplasms there is relief of symptoms after
administration ofdexamethasone, and clinical improvement
is seen within 24 h. Initially it was thought that steroids
produced immediate clinical improvement by reducing the
oedema around the tumour, but papilledema was noted to
be slow to resolve.5 The water content of oedematous brain
biopsy samples from untreated tumour patients is higher
than in those treated with steroids for 4 days,6 but a rapid fall
in water content in an individual patient coincident with
clinical improvement has not been shown. Dexamethasone
and other glucocorticoids can reduce high intracranial
pressure in tumour patients, but the reduction lags behind
steroid administration and clinical improvement by days,7
although there is evidence that the viscoelastic properties of
brain tissue are changed within 24 h of the start of steroid
therapy.8,9 In acute head injury, no such changes are seen.10
Computed X-ray transmission tomography (CT) has
been used to assess brain water content changes after
dexamethasone, and although some investigators have seen
changes of about 3 Hounsfield units in oedematous white
matter 48 h after starting dexamethasone,11 changes in
density of this order are close to the resolution limits of CT
and are influenced by other factors besides water content.
Magnetic resonance imaging (MRI) is a better technique
than CT for the investigation of brain water. The
longitudinal relaxation' time (T,) is mainly determined by
the ratio of "free" to "bound" water within tissue.12 The
expected T, changes have been shown after alcohol and
vasopressin intake,13 and T, correlates with brain water
content in vivo.14
This study was undertaken to confirm the correlation
between T, and brain oedema in patients with intrinsic
tumours,14 to investigate water changes in the brain
following mannitol administration, and to examine with
MRI the effects of dexamethasone.
Patients and Methods
Brain Water Estimations
Brain water was measured in 16 men and 3 women aged 39-73 .
years (mean. 58) having neurosurgery for intrinsic supratentorial
tumours of glial (18 patients) or metastatic (1 patient) origin. The
site of the tumour allowed a frontal (7 patients), temporal (5
patients), or occipital (6 patients) lobectomy to be done, and biopsies
of peritumoural tissue were taken in 1 patient. The lobectomy
specimens were sealed immediately in copolymer sheet (Ethicon
Ltd, Edinburgh) to prevent evaporative water loss, were taken to a
laboratory adjacent to the operating theatre, and were cut
transversely as close as possible to the plane of a preoperative MRI
of the brain. Peritumoural white matter and, where possible,
peritumoural cortex, normal white matter, and normal cortex were
sampled from the lobe, and the positions of the samples were
marked.
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The samples were then placed in a calibrated layered oil density
column for specific gravity measurement and the calculation of
water content.15-17 In 16 patients halfofeach sample was placed in its
fresh state on a small piece of dry aluminium foil that had an
accurately predetermined weight. The sample was then dried in an
oven at 80°C and reweighed at 24 h intervals until it reached a
constant weight, which was then recorded. The wet tissue weight
(W) was obtained by subtraction of the foil weight from the fresh
weight and the dry tissue weight (D) by subtraction of the foil
weight from the dried weight. Wet tissue weight ranged from 8-9 to
484-1 mg, mean 102-8. Water content was expressed as a percentage
by weight of the fresh tissue with the formula: % water = (W — D)/
W x 100. Wet and dry weighing ofnormal samples ofbrain allowed
the derivation of the specific gravity of the solids ofhuman grey and
white matter. The specific gravity of the tissue solids is used to
calculate water content from the wet tissue specific gravity
measurements, and wet and dry weighing also allowed correction of
the error introduced by protein in the oedema fluid.18 The interval
between operative lobectomy and completion of the specific gravity
measurements was kept to less than 20 min in all cases, so as to limit
evaporative water loss from the tissue specimens.
Correlation of 7) with Brain Water
The patients had MRI the day before surgery by a 0-08 T vertical
field resistive MRI system (M & D Technology, Aberdeen).
Calculated T, maps were obtained by means of an interleaved
saturation recovery and inversion recovery pulse sequence with a
sequence repetition time of 1000 ms and a time from inversion of
200 ms. Transverse sections through the tumour were obtained,
each with a section thickness of 12 mm and an acquisition time of
256 s. Interrogation of the digitally stored T: map enabled T, values
to be measured in any region ofa tomographic section. Experiments
on normal volunteers showed that the precision of T,
measurements in the cortex and white matter was 5% and 3%,
respectively.19
All patients had their operations within 24 h of MRI, and in 6
patients mannitol was given peroperatively to control intracranial
pressure. 13 patients did not receive mannitol during surgery. After
operation, measurements of T, were made from the stored
preoperative MRI at sites corresponding as closely as possible to
those of brain tissue sampling. The correlation between the
measured T, and the water content of the samples was assessed by
least squares regression analysis, and confidence limits were
calculated for the regression line for white matter.
Changes in Ti with Dexamethasohe and Mannitol
11 patients with glial tumours were imaged before steroid
administration and were started on dexamethasone 4 mg 6-hourly
by mouth immediately after MRI. They had a second MRI 2-11
days later (mean interval 6), and Ti values for normal cortex, normal
white matter, peritumoural white matter, and tumour were
measured from the same positions on equivalent sections of the
pretreatment and post-treatment scans. All the dexamethasone
group had improved clinically by the time the second MRI was
done.
17 patients with glial tumours were imaged while having an
intravenous infusion of 0-9% saline, after which the infusion fluid
was changed to 20% mannitol in 11 patients. Over the next 15 min,
200 ml of infusion fluid was administered to each patient; further
MRIs were taken 15 min and 30 min after the control image. On
equivalent sections of the control, 15 min, and 30 min images, T,
values for normal cortex, normal white matter, peritumoural white
matter, and tumour were measured at fixed sites by two observers
who did not know whether the patient had received 20% mannitol
or placebo (0-9% saline), or the timing of the scan.
Changes in T, after dexamethasone or mannitol were assessed by
non-parametric statistics. Changes from zero were assessed by the
Wilcoxon signed rank test and, in the case ofmannitol, from patients
receiving a placebo infusion by the Mann Whitney test. Results
were regarded as significant if p <0-05.
Results
Comparison of Brain Water Estimations
In the 16 patients for whom there were wet and dry
weight brain samples in addition to specific gravity
estimations of brain water, gravimetry underestimated
tissue water content of oedematous white matter by a mean
of 2-4% and of oedematous cortex by a mean of 1 -2%.18
Correlation of Tx with Brain Water
In 19 patients there were nine samples of white matter
from normal areas of brain and twenty-one from
oedematous peritumoural areas. The nine samples of
normal white matter had a mean T, of 298 0 (SD 15-1) ms
and water content of69-7 (0-7)%, and these are the lowest 9
points on the graph in fig 1A. There was a high correlation
(r = 0-94, p< 0 0001) between T, and water content with
narrow 95% confidence limits. From the image of a single
patient the T! of white matter allows estimation of water
content to within 4%.
In 17 patients there were twelve samples of cortex from
normal areas of brain and eight from oedematous
peritumoural areas. The twelve samples of normal cortex
had a mean T, of 464-8 (SD 35-8) ms, and water content of
80-5 (0-8)%, and these are the lowest 12 points on the graph
in fig IB. Oedematous cortex was hard to identify in the
lobectomy specimens, since the distribution ofperitumoural
oedema is largely within white matter, as evident on CT as
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Fig 1—Correlation of white matter (A) and cortex (B) water content with T*! values.
Open circles, patients who had peroperative mannitol; regression line ; 95% confidence limits . (A) linear regression line slope = 0-043, constant
term = 57-13. (B) linear regression line slope = 0 031, constant term = 66-98.







Fig 2—Changes in Ti measurements after dexamethasone (A) and 15 min after mannitol administration (B).
c, normal cortex; w, normal white matter; aw, abnormal oedematous peritumoural white matter; t, tumour; open circles, patients given placebo.
well as NMR images. In addition the Ti of cortex was less
easy to determine than that of white matter because of the
proximity of the CSF in the subarachnoid space, with a
consequent partial volume effect, and the smaller area of
tissue for measurement on the NMR images. Nonetheless,
there was a correlation (r = 0-65, p < 0-002) between T, and
water content of cortex; but confidence limits were not
calculated because there were insufficient data from
abnormal tissue.
Changes in Ti with Dexamethasone
Dexamethasone had no significant effect on the Ti of
normal cortex and white matter, oedematous peritumoural
white matter, or the tumour tissue (fig 2A). We therefore
concluded that the water content of these tissues was
unchanged by dexamethasone and could not explain the
clinical improvement (seen in all patients) by any effect of
dexamethasone on the extent of brain oedema.
Changes in T! with Mannitol
Mannitol did have an effect in reducing the Tt of
oedematous peritumoural white matter and the Ti of the
tumour tissue, but did not have a significant effect on normal
white matter or cortex. After 15 min (fig 2B) the change in
the T! of the peritumoural white matter and tumour tissue
was significantly less than zero (-19-6, SEM 40 ms,
p<001; and -26-9, SEM 11 ;3 ms, p<0-05, respectively)
and for peritumoural white matter it was significantly less
than the values obtained during the placebo infusion
(pCO-01). 30 min after the intravenous infusion of 20%
mannitol was started (fig 3) the mean reduction in Tx of the
peritumoural white matter was 32-4, SEM 7-1 ms (p < 0-01)
and for tumour was 57-0, SEM 15-6 ms (p < 0-01). In both
peritumoural white matter and tumour the reduction in T,
i
c w aw t
3—Changes in Ti measurements 30 min after mannitol
ministration.
was significantly greater (p< 0-005) in patients given
mannitol than in those given placebo. The fall of 32-4 ms
corresponds to a reduction in water content of 1-4% within
the oedematous white matter.
Discussion
This study partly confirms the simple linear correlation
between brain water and Ti reported in animal models of
cytotoxic and cryogenic oedema.20 Within a given tissue
(cortex or subcortical white matter) brain water is linearly
related to T„ but the relaxation behaviour of the water
molecules in white matter seems to be different from the
behaviour of the water in cortex. The water within normal
cortical tissue is largely intracellular, the extracellular fluid
space being small. When white matter becomes
oedematous, water accumulates outside the myelin sheaths,
and although it can permeate between the myelin lamellae, it
remains largely extracellular.21 This extracellular oedema
fluid in white matter probably has a high free to bound ratio,
because of a low concentration of macromolecules in the
extracellular space of white matter.
Dexamethasone does not seem to change T, in intrinsic
tumours and the surrounding oedematous brain, or in the
normal brain remote from the tumour, within an average of
6 days ofadministration. The initial effect ofdexamethasone
must therefore be mediated by some mechanism other than
a change in the water content of the brain. Although resting
intracranial pressure is not reduced by steroid therapy for 48
to 72 h, patients are clinically better within 24 h and plateau
waves become less frequent. The lumped intracranial
elastance, as measured by pressure volume tests, shows a
return towards normal over 72 h, but the biggest change is
within the first 24 h.8-9 In patients with posterior fossa
tumours, the same clinical response follows steroid therapy
over the same time scale, with the disappearance of plateau
waves, and yet in these patients the cause of the raised
intracranial pressure is predominantly obstructive
hydrocephalus rather than brain oedema.22 This suggests
that the first change is an alteration in the viscoelastic
properties of brain tissue. The present study shows that
brain water is not reduced at this early stage, and to explain
the elastance changes some other mechanism, such as a
change in cerebral blood volume or alteration in the
structural properties of cell membranes, must be invoked.
The intravenous infusion of mannitol reduces T„ but
only in abnormal tissues (tumour and oedematous
peritumoural white matter). After rapid intravenous
infusion in normal cats, mannitol has been shown to produce
considerable pial arteriolar vasoconstriction within 5
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minutes of injection, with subsequent vasodilatation at 1
hour.2 The time course of this vasoconstriction closely
matches the reduction in intracranial pressure and blood
viscosity that mannitol is known to produce. Some workers
argue that the blood viscosity reduction is the primary
change and an autoregulatory mechanism is responsible for
the vasoconstriction.2 When autoregulation is impaired,
mannitol does not reduce intracranial pressure.23
Mannitol lowers haematocrit by drawing water
osmotically from tissues other than normal brain, because of
the high hydraulic resistance ofthe normal cerebral capillary
wall to water movement (thirty times higher than muscle
capillaries and three thousand times higher than mesenteric
capillaries).2,24 This would explain our finding of no change
in water content in the normal brain regions of our patients,
while in tumour and oedematous peritumoural white matter
the water content was reduced. In these abnormal regions,
the blood-brain barrier is known to be disrupted from the
appearance on contrast enhanced CT and pertechnetate
radionuclide scans. The hydraulic resistance of the
capillaries in these areas will be low, and mannitol would
seem from our findings to withdraw water osmotically from
these abnormal tissues.
Our results show that it is possible to estimate tissue water
from the T, value ofwhite matter with sufficient accuracy to
enable small changes in water content to be detected in vivo.
They suggest that the early effects of dexamethasone in
patients with brain tumours are not mediated by reduction
of cerebral oedema, and that mannitol does reduce water
content of oedematous brain, but not of normal brain.
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Summary The mechanism by which a synovial flare
occurred in a patient with rheumatoid
arthritis after intravenous infusion of iron-dextran was
investigated. After the infusion, serum and synovial-fluid
iron-binding capacity became saturated, giving rise to
low-molecular-mass iron chelates with the capacity to cause
oxidative damage ("bleomycin-iron"). At the same time
lipid peroxidation and the concentration ofoxidised ascorbic
acid (dehydroascorbate) increased in both serum and
synovial fluid, and red-cell glutathione fell. These changes
corresponded closely to an exacerbation of rheumatoid
synovitis. Hepatic function was transiently disturbed 7 days
after the infusion, reflecting hepatic oxidant stress within
the iron-loaded liver. Such changes provide clear evidence
that iron-catalysed oxidative reactions influence the
inflammatory process in human beings.
Introduction
The observation that the rheumatoid synovial membrane
contains greater than normal deposits of iron1 led to
speculation2,3 that iron-catalysed generation of toxic free
radicals may promote rheumatoid synovitis. The
superoxide anion radical and hydrogen peroxide, derived
from polymorphonuclear leucocytes (PMN) within the
synovial cavity or activated macrophages within the synovial
membrane, react together in the presence of transition-
metal catalysts (eg, iron) to form the highly reactive
hydroxyl radical.4 This radical is thought to oxidise lipids,5
proteins,6"8 ascorbic acid,9 and other biomolecules within the
joint and thus perpetuate inflammation. The oxidation
reaction depends on the presence of iron in a suitable form,
such as a low-molecular-mass complex (eg, ADP-Fe).4 As
long as iron in synovial fluid or serum is bound to transferrin
(serum transferrin is normally about 30% saturated)
catalysis of hydroxyl radical formation will not take place.4
Iron with the capacity to cause oxidative damage can be
detected by the bleomycin assay.10
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Abstract
The study of pulsatile cerebrospinal-fluid (CSF) flow may be
useful in diagnosis of certain forms of intracranial disease.
Previous techniques used to study CSF flow either are invasive
or do not allow accurate measurement. Magnetic resonance
imaging (MRI) offers a non-invasive method of studying the
CSF pathways. Our technique uses MR phase images and
allows quantitative measurement of flow velocities and
volume-flow rates. Four volunteers were studied at the level of
the second cervical vertebra (C2). The MRI pulse sequence was
gated from the R-wave of the subject's electrocardiogram and
12 scans were taken corresponding to different times in the
cardiac cycle. The variation in flow velocity throughout the
cycle was plotted, and maximum caudad and cephalad flow
velocities and flow rates were calculated. Good agreement was
found between three of the four volunteers. The mean
maximum caudad velocity was 2.91 cms"1 occurring at a mean
time of 190 ms after the R-wave. This corresponds to a mean
maximum flow rate of 4.13 ml s_1. The total imaging time for
each study was about 1 h. Technical developments, allowing
simultaneous acquisition of several images throughout the
cardiac cycle, will reduce this time significantly.
The cerebrospinal-fluid (CSF) pathways are particularly
difficult to study, and to obtain reliable information the
haemodynamic conditions must not be altered, for
example, by surgical intervention. Radiologists have,
for a long time, been aware of the pulsatile nature of
CSF flow at fluoroscopy during Pantopaque myel¬
ography and in cineradiology of myelography and
encephalography (du Boulay, 1966; du Boulay et al,
1972). Estimations of CSF flow using these techniques,
which were derived from observation of a television
monitor, were inevitably imprecise.
The appearance of flowing fluid using magnetic
resonance imaging (MRI) has been the subject of much
research, and various techniques have been developed
to demonstrate the velocity of blood flow. The effects of
blood flow on magnetic resonance (MR) images are
dependent on the pulse sequence used, and on the
velocity profile of the flow. They can be interpreted as
either an increase or decrease in signal compared with
stationary material (Axel, 1984; George et al, 1984).
The precise variation in signal intensity as a function of
velocity is dependent on many factors and is thus
difficult to predict.
The nuclear magnetic resonance signal has two
components which are referred to as the real and
imaginary parts of the signal. These two components
can be used to calculate both the modulus and the
phase of the signal for each pixel. It is the modulus
value that is normally used to obtain the standard
clinical MR images. It has been shown, however, that
phase images can also be used to quantify flow
velocities (Moran et al, 1985). Whereas the modulus
MR image contains information on proton density,
relaxation time parameters (7\ or Tf) and flow effects,
the phase image contains information on the velocity
and direction of flow, as well as phase shifts due to
magnetic-field inhomogeneity, chemical shifts, and
changes in magnetic susceptibility. The velocity
information is usually encoded by adding extra gradient
pulses into the pulse sequence (Bryant et al, 1984; Van
Dijk, 1984). Alternatively, the bipolar form of gradient
pulses which are part of the standard imaging sequence,
such as those used for slice selection, can be exploited to
provide velocity encoding (Ridgway & Smith, 1986).
The range of velocities to be measured can be altered by
changing the temporal separation of the two com¬
ponents of the bipolar pulse. Thus, peak velocities in
the ascending aorta, and slower venous flow, can both
be imaged using the same technique.
Pulsatile CSF flow has been demonstrated in the
cerebral aqueduct and pontine cistern using MRI by
showing a variation in signal intensity over the cardiac
cycle (Bergstrand et al, 1985). An inversion-recovery
pulse sequence was used in this study and though a
cyclical variation in intensity was shown, no direct
quantification of velocity or direction of flow was
possible. Phase imaging has not previously been used to
image pulsatile CSF flow.
The study describes the extension of a phase imaging
technique which was originally developed to measure
arterial flow in the body. The technique was modified to
measure slow flow in the head and neck.
Method
This study was performed using a 0.08 T resistive
MRI system manufactured by M&D Technology Ltd.
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The imaging technique acquires two phase images, each
having different velocity encoding, achieved by varying
the temporal separation of the dephase and rephase
components of the slice selection gradient (Ridgway &
Smith, 1986). The final velocity image is obtained by
subtracting these two images, thus eliminating any
phase shifts due to field inhomogeneity, chemical shifts
or changes in magnetic susceptibility. The technique
was modified to image at lower velocity ranges by
extending the separation of the bipolar slice selection
gradients in one of the velocity-encoding pulse
sequences. The difference in separation for the two
pulse sequences was thus extended from 2 ms to 12 ms.
The maximum measurable velocity, corresponding to a
phase shift range of ± 180°, was thus decreased from
120 cms-1 to 20 cms-1 making finer velocity
resolution possible. Further modifications involved the
inclusion of stronger gradients and the use of a smaller-
diameter RF coil, used routinely for head imaging.
The flow measurement was calibrated for mean flow
velocities in the range 1-11 cms-1. A simple con¬
tinuous-flow phantom was used, incorporating a tube
of inside diameter 10 mm, containing copper sulphate
solution with T1 = 250 ms. The phantom was fed from
a constant head tank and mean flow rates were
calculated by finding the time taken for a known
volume to pass through the phantom. The MRI pulse
sequence was triggered from an external source at a
repetition rate corresponding to a heart rate of 75 beats
min-1. Each scan was repeated three times and the flow
rate recorded before and after each scan.
Four volunteers were imaged, gating the pulse
sequence with the subject's electrocardiogram (ECG)
(Smith et al, 1986). Heart rates were monitored and
images were obtained with delays of 110, 140, 165, 190,
215, 240, 290, 390, 490, 590, 690 and 790 ms after the
subject's R-wave. More images were obtained during
the systolic period where the velocity variation
appeared to be more rapid. The total imaging time for
each subject was about one hour.
Prior to this study, one volunteer was imaged at 12
levels in the head and neck at the time during the
cardiac cycle when the peak velocity was attained. The
resultant images suggested that the peak velocity was
higher in the neck than in the head. Imaging too low in
the neck resulted in increasing loss of sensitivity with
distance from the head coil. As a compromise the level
chosen for the four volunteers was at the level of the
second cervical vertebra (C2).
The mean phase shift within the ring-shaped
subarachnoid space was calculated using two regions of
interest; the outer represented the boundaries of the
spinal canal and the inner, the spinal cord. From these
two regions the mean phase shift within the sub¬
arachnoid space and its area were determined. The
calibration curve was used to determine the velocity
from the phase shift, and the area of the subarachnoid
space was used to calculate flow.
In order to assess the reproducibility of the
and M. A. Smith
Calibration curve showing calculated mean velocity versus the
mean phase shift. The 95% confidence limits with which
velocity can be predicted from phase shift are also shown.
technique, expressed as a coefficient of variation, one
volunteer was scanned six times at the same level at the
time of peak velocity.
Results
The results of the velocity calibration are plotted in
Fig. 1, showing 95% confidence limits at
+ 0.92 cms-1. There was a significant correlation
(r = 0.998, p < 0.001) between the phase shift (degrees)
and the flow velocity (cm s"1).
A representative transverse section from one of the
normal volunteers is illustrated in Fig. 2, showing both
the modulus and the phase images. The CSF flow in the
subarachnoid space can be seen on the phase image as a
ring-shaped area. The displayed intensity of the phase
image is related to velocity. Velocity in the caudad
direction is represented by lighter shades of grey which
correspond to a positive phase shift (Fig. 3a). Similarly,
velocity in the cephalad direction is represented by
darker shades of grey which correspond to a negative
phase shift (Fig. 3b). Mid-grey represents zero velocity,
corresponding to zero phase shift.
All volunteers demonstrated pulsatile flow within the
subarachnoid space during the cardiac cycle and a
representative flow-velocity curve is shown in Fig. 4.
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Representative section of those used in the volunteer study showing (a) the modulus image and (b) the phase image. The CSF
flow is seen on the phase image as a ring of increased intensity (arrows). Also seen are left and right internal jugular veins.
Maximum flow rates, maximum flow velocities and time
to peak flow for all subjects are listed in Table I. At
intervening times during the cardiac cycle, flow
velocities were relatively small and their corresponding
phase shifts were not significantly different from phase
shifts measured in adjacent soft tissue. The maximum
variation in heart rate in any one volunteer was from 65
to 83 beats min^1.
The reproducibility of the repeated scan, analysed
once, was 14.4%. However, this figure includes the
error associated with the estimation of phase informa¬
tion from a single image which was found to be 8.7%.
The reproducibility of the technique itself is therefore
11.5%.
Discussion
This study not only confirms the ability of MRI to
demonstrate pulsatile CSF flow, but also demonstrates
Fig. 3.
Two representative phase images demonstrating the pulsatile nature of the CSF flow: (a) shows caudad flow (positive phase shift);
(b) shows cephalad flow (negative phase shift).
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Fig. 4.
Variation of CSF flow velocity
(cms-1) plotted against time
after the R-wave (ms). The set
of measured points are shown
as filled circles. The same set of
points was plotted (open
circles) in adjacent ECG cycles
to show the continuity of the
curve. In this case the average
R-R interval was 800 ms
(corresponding to a heart rate
of 75 beats min"1).
that phase imaging enables quantitative measurement
of flow velocity to be obtained with reasonable
accuracy. In addition, the direction of flow can be
assessed. The technique therefore has advantages over
methods which rely on signal intensity (Bergstrand et al,
1985). However, unlike Bergstrand, we have been
unable to demonstrate flow within the cerebral
aqueduct, though this may be due, in part, to the lower
signal-to-noise ratio that is obtained with the lower-field
system used in this study.
There is good agreement between the flow rates and
velocities obtained in three out of our four normal
subjects. Shorter sampling intervals would enable these
values to be established more accurately; currently the
"peak" caudad and cephalad velocities could be
underestimated. The variation in the time to peak CSF
flow velocity may be due to many factors including the
sampling time, i.e. time after R-wave, respiratory rate
or variation in heart rate.
At present, the total imaging time for each subject is
probably too long for routine clinical use. Simultaneous
multislice acquisition would substantially reduce total
imaging time but the spatial location of each section
would be different. Alternatively, the acquisition of
multiple images of a single section throughout the
cardiac cycle, as has been done in cardiac imaging
(Waterton et al, 1985) would also reduce imaging time.
This technique offers potential for the investigation of
disorders involving the CSF circulation. In the case of
complete obstruction, for example, pulsation distal to
the obstructing lesion will stop, but it will persist on the
cranial side. In addition, du Boulay (1966), using
myelographic techniques, observed that when the
subarachnoid space was narrowed but not obliterated
the amplitude of movement could be considerably
exaggerated. Magnetic resonance imaging offers a non¬
invasive method of studying the direction and velocity
of CSF flow in such patients.
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jj|The Editors do not hold themselves responsible for opinions expressed by correspondents)
Magnetic resonance flow imaging: a possible
method for distinguishing communicating
j| syringomyelia from cystic intraspinal lesions
. j The Editor—Sir,
Jjjglhe important radiological differential diagnosis of
^^syringomyelia is an intramedullary tumour. Magnetic
t resonance (MR) is now the modality of choice to image the
spinal cord and canal (Han et al, 1983; Yeates et al, 1983;
i'-'Norman et al, 1983). However, differentiation between the
i cerebrospinal fluid (CSF) contained within a syrinx and a
'
cystic tumour is a potential problem, as there may be little
v. difference in the relaxation parameters (7", and T2) or in the
fmorphology. One possible means of differentiating these
^conditions is to study CSF flow using a MR phase imaging
'^technique (Ridgway & Smith, 1986; Ridgway et al, 1987),
which has recently been developed to allow quantitative
mneasurement of flow velocities, including low values found in
£F flow.
We recently studied a 38-year-old lady who presented with a
Story of mild spinal-cord disturbance, suggestive of a
emyelinating disease. The MR scan showed a probable syrinx
tending from the level of the first cervical vertebra to at least
second thoracic vertebra, with some associated tonsillar
aiation (Fig. 1). Although in this case the demonstration of
xisting Chiari malformation established the diagnosis,
: images were obtained in order to detect CSF flow within
:ssyrinx. These were obtained in the transverse plane at the
el of the second cervical vertebra; the pulse sequence was
E from the R-wave of the subject's electrocardiogram and
ges obtained at 50, 225, 300 and 325 ms following the R-
ave. Both the time intervals and choice of level corresponded
®®f'those used in a previous study carried out on normal
volunteers (Ridgway et al, 1987). The cross-sectional area of
the syrinx was measured from the images and maximum
caudad and cephalad flow rates and velocities were calculated.
Pulsatile CSF flow was demonstrated within the syrinx
during the cardiac cycle (Fig. 2). A maximum caudad flow rate
of 1.27 ml s-1 was achieved at 300 ms following the R-wave.
This corresponds to a maximum velocity of 1.63 cms-1,
which was calculated from the area of the syrinx (0.87 cm2).
Cephalad flow was maximum at 50 ms with a flow rate of
0.64 mis-1 and a velocity of 0.86 cms-1. Due to cord
expansion, the subarachnoid space at the level imaged was too
small for accurate measurement of CSF flow outside the syrinx
to be obtained.
Magnetic resonance phase imaging offers a means of
studying the velocity and direction of flow in both normal and
pathological CSF circulation. It may prove to be useful non¬
invasive technique to distinguish communicating and non-
communicating forms of syringomyelia, including those
associated with spinal-cord tumours, posterior-fossa tumours
or cysts, and spinal-cord trauma.
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Fig. 1.
.Sagittal proton density image showing fusiform enlargement of
the spinal cord. The syrinx cavity is identified as a low-
intensity area, vertically orientated, running throughout the
length of the cord.
Fig. 2.
Transverse phase image at the level of the second cervical
vertebra. The flow within the syrinx is seen as an oval area of
increased intensity (arrow). Blood flow within the right deep
cervical vein is noted.
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Avoidance of ring artefacts in lumbar spine
computed tomography in obese patients
The Editor—Sir,
Central ring artefacts (Kowalski & Wagner, 1977) are
sometimes unavoidable on computed tomography (CT) in very
obese patients, even when meticulous care has been taken with
calibration (Seeram, 1982). This is because of low photon
transmission and consequent low signal-to-noise ratio (Haaga
et al, 1981). The spinal canal is often at the precise centre of
the axis of tomographic rotation and, thus, especially liable to
be obscured by such artefacts (Fig. 1). This can be avoided by
purposely positioning the patient slightly off centre within
the gantry aperture so that the spinal canal is removed from
the axis of rotation (Fig. 2).
Quantum mottle on the initial lateral scanogram is
indicative of low photon transmission and provides a clue that
deliberate off-centring may be beneficial.
Yours, etc.,
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Fig. 1.
Computed tomogram of the L5/S1 disc of an extremely obese
patient (W = 1024, L = +45). A central field of reconstruction
has been used with a magnification factor of 4.2. The central
ring artefacts obscure detail of the disc.
Fig. 2.
The patient has been moved 3.5 cm to the right. The ring
artefact is now over the left sacral alum. The degenerate L5/S1
disc is seen more clearly.
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Cerebral and Brain Stem Changes After ECT Revealed by Nuclear
Magnetic Resonance Imaging
A. J. MANDER, A. WHITFIELD, D. M. KEAN, M. A. SMITH, R. H. B. DOUGLAS and R. E. KENDELL
Nuclear magnetic resonance images of the brain were obtained in fourteen patients with
major depression during a course of ECT. The T, relaxation time rose immediately after the fit,
reaching a maximum 4-6 h later. The 7", values then returned to their original level; no long-
term increase occurred over the course of treatment. These results are consistent with an
extensive but temporary breakdown of the blood-brain barrier during ECT.
Nuclear magnetic resonance (NMR) is a long
established technique in physics and chemistry, but
relatively new in medicine. Nuclei in a constant mag¬
netic field can be made to resonate by the application
of an oscillating magnetic field in the radiofrequency
range. As the resonance decays to zero the radio-
frequency radiation emitted by the nuclei can be
detected; this is the basis of the NMR signal. The
time taken for the nuclei to return to their original
equilibrium position is the spin lattice relaxation
time, Tx.
In medical NMR imaging, the signal is usually
obtained from hydrogen nuclei (protons) within the
body. Since most biological systems consist of
70-90% water, it is these water protons that cause the
major component of the NMR signal. Solid tissues
have short Tl values, while relatively fluid tissues
have longer ones. The Tx of grey matter is signifi¬
cantly longer than that of white matter because of
their different fat:water ratios. 7j times can be
altered by changes in the ratio of 'free' to 'bound'
water in a tissue (Mathur De Vre, 1984) or in its total
water content (MacDonald et al, 1985). NMR is
therefore a useful tool for investigating possible
changes in the brain during a course ofECT, particu¬
larly as there is no ethical objection to scanning
patients repeatedly. Information obtained in this
way about changes in the brain induced by ECT may
also shed light on the intracerebral changes occurring
after spontaneous epiletic fits.
Method
Eleven patients (4 male, 7 female, mean age 49.6 years) had
an NMR scan before and after the administration of the
first treatment (scans 1 and 2) and again before and after a
later treatment (scans 3 and 4) of a course of ECT. A further
three patients (all female, mean age 40.3 years) had a scan
before and after their last treatment and then six further
scans during the 6 h following the treatment. One of these
had a final scan after 25 h. Of the total group of fourteen
patients, eleven had bilateral and three had unilateral elec¬
trode placings; all of them satisfied Research Diagnostic
Criteria for a major depressive episode (Spitzer et al, 1978).
Patients were excluded if there was a history of serious
head injury, brain damage, alcohol abuse or previous
radiological abnormality. None had received ECT in the
previous 6 months. A standard anaesthetic procedure
was used: methohexitone (60-100 mg) and suxamethonium
(30-80 mg). Four patients also received diazepam (2.5-
10 mg i.v.) before scan 2. The treatment was delivered
using an Ectron CC-100 machine, except in one case where
a Mecta machine was used. The post-ECT scan was per¬
formed as soon as possible after the patient had recovered
from the effects of the anaesthetic.
An M&D Technology Ltd 0.08 T resistive magnetic
resonance imaging system was used. For each scan, calcu¬
lated Tt images were obtained in three planes: a transverse
section 10 mm above the maximum diameter of the lateral
ventricles, a midline sagittal section of the brain stem, and a
coronal section through the parietal and temporal lobes. All
sections were 12 mm thick, and the pixel size was 2 mm2.
Measurement ofmean 7", of the entire area of the transverse
section (the grey and white matter together but excluding
the cerebrospinal fluid (CSF)) was made. The area of each
hemisphere to be sampled was delineated separately using
an irregular region of interest; a cursor was used to draw the
boundary of the area to be measured directly onto the image
of the section as it was displayed on the monitor. The mean
7j within the region of interest was calculated and
displayed. CSF has a high 7\, and is white on the coloured
display. It is therefore possible to exclude sulcal CSF by
ensuring that it is not included within the boundary of the
area to be sampled. In addition, the computer was pro¬
grammed to present the mean Tx of the tissues in this area
that were withm the range 60-600 ms. This range includes
grey and white matter, but not CSF, which has a much
higher value. This latter method also ensures that in the
small regions of interest sulcal CSF is not included in the
samples of grey matter that were analysed. Individual
small areas of Tx in the pons, mid-brain (at the level of the
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Table I
Change in T, ofthe transverse section
T,- ■ ms
Scan 1 Scan 2 Scan 3 Scan 4
Mean s.d. Mean s.d. Mean s.d. Mean s.d.
Unilateral (n = 3) 350 1 354 7 347 11 348 10
Bilateral (n = 8) 341 18 348 15 340 10 346 9
Total (n= 11) 344* 16 350* 13 342** 10 346** 9
*P<0.01; **P< 0.05; all other comparisons NS (Wilcoxon's paired rank test)
optic chiasma) and posterior corpus callosum (sagittal
section); frontal and occipital lobes (transverse section) and
parietal and temporal lobes (coronal section) were also
measured. Tr was measured at the mid-point of each area.
In each case the sample measured had a volume of 1.41 cm3,
except the mid-brain and posterior corpus callosum
(0.42 cm3).
To control for the effects of the general anaesthetic, five
volunteers (three male, two female, mean age 32.6 years)
had a transverse section scan before and 30 minutes after an
identical anaesthetic procedure.
Results
Patients had a mean of 5.4 treatments given at a mean
frequency of 2.4 per week prior to scan 3. As those having
unilateral ECT did not show any lateralisation ofchange in
Tj, unilateral and bilateral treatments have been analysed
together. There was no significant change in Tl in any of the
areas examined between the beginning and the end of the
course of ECT, i.e. when scan 1 was compared with scan 3
and scan 2 with scan 4.
In the transverse section there were significant differences
in the mean Ti of the whole section before and after the
individual treatments, i.e. between scans 1 and 2 and
between scans 3 and 4 (Table I). The mean change between
scans 1 and 2 was 6 ms (P <0.01). The rise after bilateral
ECT was larger (7.3 ms) than after unilateral ECT (4.0 ms),
although this was not significant, probably because of
the small numbers in the study. There was a smaller mean
increase in 7\ of 4 ms between scans 3 and 4 (P <0.05);
bilateral ECT produced a larger increase (6.7 ms) than
unilateral ECT (1.3 ms), although again this difference was
not significant. Patients were scanned sooner after the last
ECT (15.8+4 min, range 13-28 mins) than after the first
(30.9±16min, range 15-62 mins), probably because by
then they were less depressed and also familiar with the
technique (r = 2.69, d.f. = 19, P <0.02); this suggested that
the maximum rise in T1 may not have occurred within
15 min of treatment. This was shown to be so in the three
patients scanned six times during the six hours following
ECT (Fig. 1). In the patient scanned after 25 h the Tx time
had returned to below its starting value.




Time after ECT: h
Fig. 1 Change in mean Tl for the three patients scanned over the
six hours following ECT.
associated with a non-significant decrease in mean T1 from
340 ms (s.d. 9 ms) to 336 ms (s.d. 8 ms).
Of the nineteen individual small regions in the grey and
white matter, T1 was found to increase in ten between scans
1 and 2; there was a decrease in seven, and no change in the
other two. This increase was statistically significant in the
frontal and occipital white matter (P < 0.05) and in the left
temporal grey matter (P <0.01). For the 8 patients having
bilateral ECT only, there was a significantly decreased Tt
in the right occipital grey matter (P <0.01). Between scans
3 and 4 the T1 in eleven regions increased; there was a
decrease in six and no change in the other two.
Discussion
The mean T1 of the transverse section showed a
significant increase after treatment, both at the start
and end of a course of ECT, reaching a maximum
4—6 h after the fit. This was shortlived, and no
cumulative effects of ECT were noted. The increases
reported in this study are likely to be underestimates
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of the changes produced by ECT itself, since anaes¬
thesia alone was associated with a fall in Tx.
Measurement of the 19 small regions described
above added little further information. Most of the
T1 values in the transverse and coronal sections (20
of 32) increased following treatment. Because there
were 64 comparisons involved, it is likely that some
of the significant differences arose by chance.
The brain stem showed a non-significant fall in Tx
in five of the six measurements. This may be due to
the anaesthetic having a greater effect in this area,
and is especially interesting since the brain stem
reticular formation is involved in arousal.
Interpretation of changes in Tl is difficult. There
is no good evidence that ECT causes brain damage
(Meldrum et al, 1974; Galloway et al, 1981), and
recently necroscopy could reveal no pathology
attributable to ECT in a patient who had received
over 1250 treatments (Lippmann et al, 1985). Simi¬
larly, it is unlikely that these Tt changes represent
inflammation or brain damage, since they are
reversed so quickly. It is more likely that they are the
result of an increase in the total water content of the
brain. It is known that ECT produces a temporary
breakdown of the blood-brain barrier (BBB) and
that this is probably due to the concomitant increase
in blood pressure (Bolwig et al, 1977a) and cerebral
blood flow (Bolwig et al, 1911b). It is also known that
repeated convulsions at short intervals produce cere¬
bral oedema (Laursen et al, 1985). It has been shown
that macromolecules leak into cerebral tissue during
the temporary breakdown of the BBB induced by
ECT (Bolwig et al, 1977a). This would cause an
increase in the relative osmotic pressure of the brain.
After restoration of the BBB, movement of water
from blood vessels into the tissues would therefore
occur, and this would provide an explanation for the
rise in Tt over time. It is likely that similar changes
occur after spontaneous epileptic fits, although the
possibility that the observed changes in Jx are
induced by the electrical stimulus rather then by the
subsequent convulsive activity in the brain cannot be
excluded.
More work is needed to determine the duration
and magnitude of the change in Tx and to find out if it
is related to clinical improvement or the side-effects
of treatment.
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Serial changes in the T1 magnetic relaxation
parameter after myocardial infarction in man
M BEEN,* M A SMITH,ft J P RIDGWAY,} R H B DOUGLAS,f
D P de BONO,* J J K BEST,f A L MUIR*
From the Nuclear Magnetic Resonance Imaging Unit (Departments of *Medicine; fMedical Radiology, and
%Medical Physics and Medical Engineering, University of Edinburgh), Royal Infirmary, Edinburgh
summary A low field resistive nuclear magnetic resonance imaging system (0-08 Tesla) was used
to study the in vivo changes in the relaxation parameter Tx of the left ventricular myocardium
from the first day to six months after acute myocardial infarction in 41 consecutive patients
admitted to a coronary care unit. T2 maps were constructed from transverse and coronal images
at various times after infarction. Thrombolytic treatment had been successful in 28 patients.
Thirty three of the 34 patients studied within two weeks of infarction had a significantly increased
Tj value but this developed only after the third day in four. At day 1-3 the mean (1 SD) maximum
Tt was 413 (29) ms (n = 23) compared with 430 (41) ms (n = 22) at day 4^7, 433 (35) ms (n = 24)
at day 8-14, 420 (34) at one month (n = 22), 388 (39) (n = 20) at three months, and 361 (24)
(n = 14) at six months. The number of regions of interest with an increased Tx followed a similar
time course. Although the increase in Tt measured at three months correlated with the initial
maximum creatine kinase and with the left ventricular ejection fraction measured at one month,
the number of regions with abnormal T: from day 4 through to one month correlated best with
left ventricular ejection fraction. There was no significant difference in Tt between patients with
or without reperfusion. The rise in Tj over the first few days together with the prolonged time
course of T, increase suggests that the increase in Tt may reflect cellular infiltration as much or
more than tissue oedema.
It has been suggested that the magnetic relaxation
parameters Tj and T, which are associated with an
increase in free water content may be used to demon¬
strate tissue abnormalities.1 After experimental
canine myocardial infarction in vitro and T2 were
prolonged, and these changes correlated well with
increases in tissue water content.23 In vivo pro¬
longation of both Tj and T2 after myocardial
infarction has been confirmed in dogs4 5 and recently
in human beings.6 7 In dogs the changes begin
within 30 minutes of coronary occlusion2 and
become more pronounced with occlusions of one,
two, and three hours.2 5 Recently, Pflugfelder et al
described the serial changes in the intensity of the in
vivo signal in canine myocardial infarction8 but sim-
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Royal Infirmary, Edinburgh EH3 9YW.
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ilar studies in human beings have not been reported.
The purpose of the present study was primarily to
define the time course of changes in TL after acute
myocardial infarction in human beings.
Patients and methods
We studied 41 patients with transmural myocardial
infarction that was confirmed by both electro¬
cardiographic and creatine kinase changes. When¬
ever possible, imaging was carried out on day 1-3,
day 4-7, day 8-14 and one month, three months,
and six months after infarction. Serial imaging was
performed on 2-6 occasions (mean 3-4 per patient);
however, in two patients adequate images were
obtained on one occasion only. Consecutive patients
were selected provided that the imager was available,
the patient consented, and none of the following
exclusion criteria was present: current symptomatic
pulmonary oedema, continuing chest pain, major
2
arrhythmia within 12 hours, previous infarction in
the same electrocardiographic territory, or any myo¬
cardial infarct in the preceding year.
The study was approved by the local ethics review
committee and all patients gave written informed
consent.
Ten patients did not have thrombolytic treatment
and in a further three thrombolysis was found to be
unsuccessful at subsequent coronary angiography
(group 1). The remaining 28 patients (group 2) had
successful coronary thrombolysis with intravenous
anisoylated plasminogen streptokinase complex9
(n = 23) or recombinant tissue type plasminogen
activator (n = 5) (table 1).
The study population was heterogeneous in terms
of the site of infarct, rise in creatine kinase, and the
use and success of thrombolytic treatment (table 1).
Patients on thrombolytic treatment underwent early
coronary angiography to determine whether the
infarct related vessel was patent, and left ventricular
function was assessed by gated blood pool scan.10 In
all patients creatine kinase activity was measured
twice a day during their stay in the coronary care
unit.
The number of patients in group 1 (n = 13) was
smaller than that in group 2 (n = 28) because the use
of thrombolytic treatment increased during the
study and because non-reperfused patients tended to
be less well and were therefore more likely to be
excluded from this study.
MAGNETIC RESONANCE IMAGING TECHNIQUE
Patients were imaged with a 0-08 T vertical field
resistive magnetic resonance imaging system,
manufactured by M & D technology, installed in
the Edinburgh Royal Infirmary,11 and situated
between the coronary care unit and the angiography
laboratory. Calculated Tt maps were obtained by an
interleaved saturation-recovery and inversion-
recovery pulse sequence with a time from inversion
(TI) of 200 ms. Inversion was obtained with an
Table 1 Data (mean (1 SD)) on the study population





No of patients 13* 28
Anterior infarction 5 19
Inferior infarction 8 9
Age (years) 57(10) 53(10)
Peak creatine
kinase (U/l) 1889(800) 1947 (1334)
*Confirmed at angiography3 or assumed because thrombolysis was
not used.
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adiabatic fast passage inverting pulse rather than the
usual 180° pulse; this is particularly suitable for pre¬
cise Tl calculation because it efficiently inverts all
the nuclei within the section. In addition, it is not
slice selective which means that it inverts all the
nuclei within the heart and therefore does not have
to be synchronised with the cardiac cycle.
The patient's electrocardiogram was used to
trigger the imager such that the 90° pulse in both
the saturation-recovery and inversion-recovery
sequences occurred in the same part of the cardiac
cycle.12 A field gradient echo of 20 ms was used. The
minimum time from the R wave trigger at which
imaging can be performed is 230 ms, principally
because of the time from inversion (TI) values used.
Partly as a consequence of this, but also to obtain
tomographic sections ofmaximum myocardial thick¬
ness, images were obtained towards end systole. The
pixel size was 3-5 mm x 3-5 mm.
In an attempt to obtain comparable sections on
serial studies for individual patients we used the
following routine. After attachment of the electro¬
cardiographic leads we used an alignment marker to
position the patient on the couch. The lower edge of
the xiphisternum was used as the reference level.
The distance of subsequent couch movements was
recorded from the digital readout provided by the
system. Initial images were obtained with a 16 s
ungated saturation-recovery sequence as an anat¬
omical guide for the sections to be scanned. Having
optimised the image position and recorded its dis¬
tance from the xiphisternum we performed a gated
scan with a slice thickness of 16 mm. To encompass
the whole left ventricle, further scans were per¬
formed at two or three 15 mm levels cranial or caudal
to this or both, and the position was noted to allow
equivalent sections to be obtained at subsequent
imaging. .
A single coronal section through the left ventricle
was obtained. The most suitable imaging slice was
again selected from rapid ungated images, but in this
case the position was adjusted by slightly altering the
strength of the magnetic field. Despite the measures
described above, it is likely that changing left ven¬
tricular geometry over the six month period pre¬
vented serial imaging of exactly the same portion of
myocardium. For this reason we used the area of
highest T[ found in any region of interest in the
infarct territory for analysis.
The imager was triggered by each R wave for heart
rates <75/min and by alternate R waves for faster
heart rates. Patients who were scanned during the
first 48 hours while in the coronary care unit were
moved on a trolley equipped with a defibrillator, and
electrocardiographic monitoring was continued
throughout.
Magnetic resonance Tl changes after myocardial infarction 3
DATA ANALYSIS
For analysis of T; values, the myocardium was
divided into six sections for each image containing
the left ventricular myocardium and cavity. Figure 1
shows the areas into which the myocardium was
divided. values for each of the six sections of
every image were obtained by using the computer to
draw circular regions of interest within the myo¬
cardium. The largest circle that could be placed
clearly within the myocardium was used. The area of
interest selected was either 0-26 or 0-51 cm2, but
where wall thinning was considerable the smallest
available region of interest (0-08 cm2) was used. This
gives a T! value of the full thickness of the ventricu¬
lar wall but with a greater contribution from the
central portion of the myocardium. In nine patients
there was considerable thinning of the myocardium
in the infarct region (eight anterior, one inferior). To
avoid the possibility that measurements of myo¬
cardial T j from this region might be rendered inac¬
curate by inclusion of intracavitary signal (from
blood or thrombus) or extramyocardial signal (from
pericardial fat or connective tissue) the region of
interest was modified where necessary to encompass
the closest lateral position which lay clearly within
the myocardium. Attempts at obtaining a Tj value
from the narrowed segment illustrated the necessity
for this modification since minor inward or outward
adjustment of position resulted in major alterations
in Tj.
The maximum Tj value for each patient
investigation was noted as was the number of areas
with a Tt value >390 ms, the value previously
identified as the cut off between normal and infarcted
tissue.7 Values for non-affected myocardium were
then obtained as follows. On the first image showing
an increased Tt value (>390 ms) we selected the T1
value from an area anatomically remote from the site
of infarction to control for and give information
about the variability of T1 measurements with our
system. Tt values for this selected non-affected
region were noted for subsequent examinations.
The data were analysed in both a cross sectional
and longitudinal manner. In the cross sectional anal¬
ysis the maximum Tt for all patients at each time
period after infarction is presented as a mean and
1 SD. The variation in Tj with time since infarction
was studied by fitting a gamma variate curve to the
mean maximum Tt values at each time period and
calculating the regression coefficient. The maximum
Tj at day 1-3 was compared with the value obtained
from the non-affected region on the same scan by
means of a paired Student's t test. Linear regression
analysis was used to correlate the maximum Tt val¬
ues and the number of areas of increased Tj with left
ventricular ejection fraction and peak creatine kinase
Fig 1 (a) Regions of myocardium with greatest 7) value
in patients with anterior infarction. Each dot represents the
region with the maximum value for a single patient, (b)
Regions of myocardium with greatest value in patients
with inferior infarction.
activity.
Longitudinal analysis of the data was performed
by noting the change in T( at each study interval.
Results
Tj VALUES IN THE NON-AFFECTED AREA
For the group as a whole the mean Tt of the non-
affected myocardium at day 1-3 was 320 (19) ms.
There was no significant difference in the measured
Tt at any time in the non-affected region, the highest
mean value being 326 (18) ms at one month. The
range of T, values in the 41 patients over all time
periods was 274-382 ms, confirming our previous
observation that a cut off of 390 ms differentiates
between normal and infarcted myocardium.7
Ti VALUES IN THE AFFECTED AREA
Maximum Tt values
Table 2 shows the results for each patient at the six
times after infarction. Maximum Tj values always
occurred in an anatomical position consistent with
the electrocardiographic changes (fig la and b). But
the highest T( was not always seen in the same
region on serial imaging.
Cross sectional analysis of the data (fig 2) showed
that at day 1-3 T, was significantly higher in the
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CK Day 1-3 Day 4—7 Day I1-14 1 rnnth 3 mnth 6 mnth
1 39 Lateral Yes 111 480 — 476 462 397 399
2 45 Inferior Yes 1261 — 435 443 374 — —
3 64 Inferior No 1395 — — — 476 427 —
4 58 Inferior No 1230 415 404 447 454 410 378
5 70 Anterior Yes 1169 371 — 539 — — 348
6 55 Anterior Yes 2624 — 475 — 452 400 389
7 37 Anterior Yes 3117 366 — 409 399 377 —
8 49 Inferior No 1529 — 389 468 439 322 356
9 56 Inferior Yes 2076 — — — — 430 353
10 54 Anterior Yes 4578 428 507 455 451 408 366
11 60 Anterior Yes 789 414 472 483 402 — 364
12 46 Inferior Yes 2361 — 400 379 — — 344
13 60 Inferior Yes 1030 435 — — — — 356
14 67 Inferior Yes 799 378 386 — — 357 —
15 57 Anterior Yes 513 — 452 — — — —
16 48 Anterior Yes 2743 — — — 391 — 361
17 53 Anterior Yes 4565 414 402 420 453 478 372
18 61 Anterior Yes 3602 — — 474 — — —
19 57 Inferior No 1301 392 — 397 470 363 344
20 56 Inferior No 3156 410 — — — — —
21 73 Anterior No 699 431 469 468 — 346 385
22 49 Anterior No 2215 — — 400 358 358 —
23 42 Lateral Yes 3719 441 439 438 425 392 —
24 33 Anterior Yes 1736 442 502 — 405 — 412
25 57 Anterior Yes 247 429 387 — — — —
26 62 Anterior Yes 881 — 397 — — 371 359
27 40 Inferior No — — 460 390 — 360 350
28 42 Anterior Yes 1652 — — 396 — 423 338
29 56 Anterior No 3025 — — — — — 412
30 63 Inferior Yes 814 — — — — 364 343
31 52 Inferior Yes 1286 — — — — 393 347
32 58 Anterior No 2869 426 — — — — —
33 61 Anterior Yes 1701 — — 408 — — —
34 58 Anterior Yes 4372 435 396 — 424 438 376
35 58 Anterior Yes — — — — — — 374
36 58 Anterior Yes 203 402 428 372 429 — —
37 61 Inferior Yes 1303 390 365 393 390 346 —
38 44 Anterior No 2138 404 465 456 427 472 —
39 58 Inferior No 1216 374 394 469 387 383 —
40 73 Inferior No 1890 443 — 442 410 355 —
41 62 Anterior Yes 2723 371 441 443 384 392 —
(p < 0 0001). Tx continued to rise, reaching a peak at
day 8-14 before falling gradually towards normal.
Fig 3a-d shows images from one patient at increasing
intervals after infarction. The gamma variate curve
fitted to the change in peak gave a significant
correlation coefficient (r = 0-95, p < 0 001).
The results of longitudinal analysis, which com¬
bined the changes in individual patients, supported
the trend shown in fig 2.
Area of raised T1 (fig 4)
In this study 38 of the 41 patients had a maximum Tt
of > 390 ms. Of the 23 patients who had their first
scan between the first and third day after the onset of
infarction, five had no regions of interest with a T,
above 389 ms. In four of these, however, the Tt
subsequently rose to more than 390 ms by the time
of the second scan on day 4—7. Only one patient did
not demonstrate a Tj value above 390 ms on at least
one scan; the maximum Tj value in this patient was
386 ms.
The number of areas with significantly increased
T, varied greatly both between patients and at
different times. The same general pattern to that of
the peak T[ values was found. By six months only
two patients had any areas of Tt >390 ms.
COMPARISON OF REPERFUSED AND
NON-REPERFUSED GROUPS
The maximum T[ and number of areas of increased
T[ (above 390 ms) were not significantly different
between the two groups at any time period. Neither
was there any significant difference in T, values
between those patients in the reperfused group who
were treated early (within two hours) and those who
were treated later, although there was a trend
towards a more rapid fall in the number of areas of
raised T, in the group treated early.
IDENTIFICATION OF INFARCT SITE
For inferior infarcts the maximum T t was most
commonly seen on the coronal image (fig la) but
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Fig 2 Mean maximum Tl values (2 SE) after
myocardial infarction. Values were greater than the normal
mean maximum Tx (SE) at first imaging (day 1-3) and
tended to increase until the third imaging sequence (day
8-14); values only returned to the mean maximum T{
values seen in normal subjects six months after infarction.
maximum Ti values were more commonly seen on
the transverse views when there was an anterior
infarct (fig lb).
CORRELATION OF Tt WITH OTHER MEASURED
VARIABLES
Creatine kinase
Because inferior infarcts tended to have a smaller
peak activity of creatine kinase (1471 (581) vs 2162
(428) U/l) and left ventricular function was better
preserved (52 (7)% vs 32 (11)%), they were first con¬
sidered separately from anterior infarcts. There was
no significant difference in maximum T, values
between anterior and inferior infarction, however.
There was a correlation (r = 0-59, p < 0-01) between
the peak activity of creatine kinase and the maximum
Tj found at three months in the combined groups.
Left ventricular ejection fraction
There was a correlation between ejection fraction
and peak Tj values at one month (r = —0-57,
p < 0-05). The number of areas of increased T,
(> 390 ms) correlated with ejection fraction at 4-7
days (r = —0-63, p < 0 01), 8-14 days (r = —0-53,
p < 0-05), and at one month (r = —0-6, p < 0-02).
Discussion
After myocardial infarction Ti rises in the area of
infarction in almost all patients. There is no
significant change in Tt in the unaffected myo¬
cardium. This confirms reports of in vitro2 3 and in
vivo5 6 experimental studies and those in human
infarction.7 8 The changes may not appear or be
appreciable before four days after the onset of
infarction, and they reach a peak by the end of the
first week. While it is likely that there was some
increase in T, during the early stages of infarction in
all our patients, the magnitude of this increase was
not sufficient to permit reliable identification of
abnormal myocardium in every case. The values in
the five patients who did not have aT( > 390 ms on
their initial scan ranged from 366 to 378 ms com¬
pared with a mean 320 (9) ms in the normal
myocardium and they were within our previously
reported range for normal myocardium.
Our finding that maximum Tj values occurred at
about two weeks was unexpected. The reported close
correlation between Tt and water content2 suggests
that a more uniform and rapid increase in Tt would
be expected, because myocardial interstitial oedema
and mitochondrial swelling occur early after the
onset of infarction.13 The dissociation between the
timing of the peak T, and the expected peak of myo¬
cardial oedema formation may partly be explained by
the fact that Tt depends not simply on the total
myocardial water content but also on the binding
or interaction of water with biological macro-
molecules.1
The difference between our findings and previous
in vitro studies of early changes in T, is likely to
reflect the major differences between ischaemic
human myocardium and excised heart muscle. Not
only will the quantity of blood in the intramyocardial
vessels differ, as does the coronary anatomy, but in
addition there are differences in the state of binding
of water within cells. In living systems metabolic
processes continuously produce water and its biolog¬
ical state is regulated by cellular processes. That
such differences affect Tt has been demonstrated by
comparative in vivo and in vitro Tt measurements in
rabbits.14
Our results accord with the in vivo experimental
work of Pflugfelder et al who studied the serial
changes in relaxation parameters and signal intensity
in eight dogs after myocardial infarction.8 In one
animal the increase in signal intensity was only seen
4-6 days after infarction. The timing of peak signal
intensity was dependent on the pulse sequence used
but occurred between the fourth and thirteenth day.
Furthermore, these workers frequently found an
area of increased signal intensity on day 20 (the final
image) and they commented that the affected area
seemed to get smaller. Similarly in our study T,
values remained raised at one month and even in
some patients at three and occasionally six months,
but the number of areas of increased Tj fell more
rapidly.
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Fig 3 Sequential coronal images in a patient with inferior
(d) 3 months after infarction.
The presence of Tt prolongation for up to three
months confirms that factors other than myocardial
oedema are responsible. The classic histological
findings15 1C after myocardial infarction indicate that
neutrophils appear after about six hours and increase
rapidly after 24 hours, reaching a peak between the
third and fifth day.1517 Thereafter the number of
large mononuclear macrophages increases, reaching
a maximum at six weeks and subsequently declining.
Other cellular infiltrates also occur, as does prolif¬
d
infarction: (a) 3 days, (b) 14 days, (c) 1 month, and
eration of capillaries which reaches a peak between
3-6 weeks. The histological changes may vary in
the same patient at various times.17 These cellular
changes may influence magnetic resonance variables
but, as yet, precise histological correlations are not
possible. The possibility that Tj and T2 changes
may provide a method of obtaining in vivo informa¬
tion about pathogenesis is exciting and has received
some support from the recent finding that T2 cor¬
relates with the histological severity of rejection in
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Fig 4 Number of areas (mean (1 SE) ) of myocardium
with raised T\ ( >390 ms) after myocardial infarction.
The changes with time follow the same pattern as the
changes in maximum T].
heterotopic cardiac transplantation in dogs.18
Some studies have suggested that T, is better than
T[ for the identification of infarcted tissue, but this
may reflect different imaging sequences where the
pulse sequence combination used was more appro¬
priate for T2 measurements than for T,. Spin echo
sequences with a short time to recovery do not con¬
tain as much Tt weighting as an inversion-recovery
sequence. In addition, variation in a patient's RR
interval can influence time to recovery in the spin
echo sequence causing a variable Tj weighting and,
as a consequence, error in the I*! value. The constant
time for inversion used in our technique, coupled
with a non-slice selective efficient inverting pulse,
minimises the error in Tj caused by variation in the
RR interval.12
Ratner et al measured endocardial and epicardial
Tt and T2 and correlates these variables with per¬
fusion measured after 30 and 60 minutes of coronary
occlusion.19 They suggested that the magnitude of
change in T, and T, correlates with the extent of the
ischaemic insult. The magnitude of the ischaemic
insult is dependent not only on the duration of vessel
occlusion but also on vessel size, collateral flow, and
the rate of oxygen consumption which all modify the
response and determine the infarct size. In this clin¬
ical study our means of assessing infarct size were
limited. We used the peak creatine kinase activity as
a crude assessment of infarct size. There was a cor¬
relation with maximum T1; but only at one month.
Thus the maximum level of T[ seems to correlate
poorly with infarct size in clinical practice. Because
the kinetics of creatine kinase release are altered by
reperfusion we also measured left ventricular ejec¬
tion fraction at 8-10 days. All patients included in
this analysis presented with a first infarct and so the
reduction in left ventricular function provides some
information about infarct size. The number of areas
of increased T[ did correlate with the ejection frac¬
tion at 4-7 days, 8-14 days, and at one month. No
correlation was expected at day 1-3 or at three and
six months because some patients did not develop
changes until after the third day and by three months
the area of increased Tt was considerably reduced.
This correlation presumably reflects the amount of
myocardium affected by the ischaemic event. Thus
the extent of the area with abnormal Tt values seems
a better guide to infarct size than the magnitude of
changes in Tt. When this study was undertaken we
were unable to perform multiple slice acquisitions
but with this capability a precise determination of
the volume of infarcted tissue should be possible.
Studies of changes in T, in dogs after coronary
occlusion and reperfusion have suggested that Tj is
further prolonged by reperfusion,20 and an increase
in cellular swelling after reperfusion has been
reported.13 None the less, we found no significant
difference in maximum Tj between our reperfused
and non-reperfused patients. This may reflect a
balance between beneficial and harmful21 effects of
reperfusion; however, further analysis of our data
in which those given early and late thrombolytic
treatment were compared gives no evidence of this.
Because time to reperfusion is critically important22
to the effect of reperfusion, it might be expected that
the T[ values would be different in these groups.
There was no significant difference in maximum T j
or the number of areas showing raised Tj between
those treated within two hours and those treated
more than two hours after the onset of symptoms.
We noted a trend towards a more rapid fall in the
number of areas with a raised Tt in those treated
early. The small numbers in these subgroups and the
heterogeneity of the patients (in terms of the vessel
affected, the position of the lesion, rate of reper¬
fusion, extent of residual stenosis, collateral flow,
disease of other vessels and therefore of infarct size
and degree of continuing ischaemia) may be masking
real differences.
The factors which produce these alterations in T,
are complex and as yet we do not know whether
changes in Tt values reflect specific histological
8
findings. If the demonstrated changes reflect healing
then alterations in T, may provide an important
method for studying a neglected area in our under¬
standing of myocardial infarction.
This work was supported by the Medical Research
Council, The Wellcome Trust, and the Scottish
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Myocardial involvement in systemic lupus erythematosus
detected by magnetic resonance imaging
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Myocardial involvement in systemic lupus erythematosus is commonlyfoundat autopsy but seldom recognized
clinically or by routine cardiological investigations. As the magnetic resonance relaxation parameter, T1, is
altered by changes in tissue cellularity, we carried out magnetic resonance imaging in 10 patients with systemic
lupus erythematosus. Five had active systemic lupus erythematosus when assessed using the lupus activity
criteria count.
The mean ( + SD) T1 was 319+12 in normal volunteers and 321 + 10 in a second control group with
hypertrophic cardiomyopathy. In the group with systemic lupus erythematosus, there was a higher mean value
of 336 ms with a wider scatter of individual results (SD±22 ms). In the subgroup ofpatients with active
disease, T1 was significantly higher (349 + 24) than in either of the two control groups.
In addition, there was an inverse correlation between serum complement andmyocardial T1 in patients with
systemic lupus erythematosus. Myocardial abnormalities in systemic lupus erythematosus were demonstrated
by magnetic resonance imaging even where other non-invasive cardiac investigations were negative.
We conclude that Tl calculated from magnetic resonance imaging is often abnormal in systemic lupus
erythematosus andprobably indicates myocardial involvement.
Introduction
Myocardial abnormalities are frequently found
in post-mortem studies of patients with systemic
lupus erythematosus'1-31 and discovery of inflam¬
matory infiltration of the myocardial interstitium
led to the first description of systemic lupus ery¬
thematosus as a 'connective tissue disease''4!
The diagnosis of myocarditis in vivo, however,
has remained difficult to establish. The electro¬
cardiogram and chest X-ray are often abnormal in
systemic lupus erythematosus but do not clearly
differentiate myocardial and pericardial disease'5'6!
Echocardiography may be helpful particularly in
the assessment of myocardial function'7'8! but
cannot differentiate ischaemic from non-ischaemic
dysfunction and is of limited use in determining
tissue changes. Thallium imaging reveals perfusion
defects in patients with both active and inactive
disease'9! but little is known about the underlying
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mechanism. The lack of an adequate method for
non-invasive assessment of myocardial abnormali¬
ties has limited the understanding and recognition
of the myocardial component of cardiac involve¬
ment in systemic lupus erythematosus.
Magnetic resonance imaging may allow myocar¬
dial tissue characterisation. Although we reported
that the Tl was not altered in hypertrophic cardio¬
myopathy'10! these observations were made before
we had developed a satisfactory gating technique
for magnetic resonance imaging. Increases in the
magnetic resonance relaxation parameters, Tl and
T2, have been noted after experimental myocardial
infarction and relate to myocardial tissue water
content"1'12! We demonstrated an increase in Tl in
end-systolic images after myocardial infarction in
man'131 but the time of maximum change was at
about 14 days after infarction, suggesting that alter¬
ations in Tl may reflect cellular repair'14' rather
than myocardial oedema alone. This concept is
further supported by recent studies of the time
course of magnetic-resonance parameter changes
after coronary occlusion in both dogs'15' and
rabbits'16!
©1988 The European Society of Cardiology
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The purpose of the present study was to deter¬
mine whether the tissue characterisation provided
by magnetic resonance imaging could indicate the
presence of myocardial involvement in patients
with systemic lupus erythematosus and. thereby,
provide an index of myocarditis.
Methods
SUBJECTS
Ten female patients with established systemic
lupus erythematosus fulfilling the revised American
Rheumatism Association criteria'1'1 were studied.
Clinical details of the patients are illustrated in
Table 4. Nine patients were free of cardiac symp¬
toms at the time of study, although one of these had
a bioprosthetic mitral valve. The tenth patient was
in congestive cardiac failure and suffered from
recurrent supraventricular dysrhythmias.
Two control groups were also studied. The
first was an age- and gender-matched group of
eight normal volunteers drawn mainly from
hospital staff. The second group consisted of 10
age-matched patients with hypertrophic cardio¬
myopathy, seven of whom were female.
All patients and volunteers gave written,
informed consent prior to magnetic resonance
imaging.
INVESTIGATIONS
A clinical history was taken from all patients with
systemic lupus erythematosus and a physical
examination was performed by one physician
(BJT). Blood was taken for estimation of the full
blood count, immuno-reactive complement pro¬
teins C3 and C4, antibody to double stranded DNA
and circulating immune complexes. Disease activity
was then assessed using the lupus activity criteria
count, a validated index of disease activity which
comprises seven primarily clinical variables'18'19'.
The presence of two or more positive variables at
the time of study indicates active disease. Each
subject had a 12-lead electrocardiogram, M-mode
and cross-sectional echocardiography on the same
day as magnetic resonance imaging. The results
of the cardiac imaging were assessed by a second
clinician (MB) who was unaware of the clinical
assessment.
MAGNETIC RESONANCE IMAGING
Subjects were imaged in a low field (0-08 Tesla)
resistive imaging system (M&D Technology). An
interleaved saturation recovery and inversion
recovery pulse sequence was used to allow accurate
measurement of the magnetic relaxation parameter
Tl. Electrocardiographically triggered cardiac
gating was used as described previously'20'. Images
were obtained at end-systole with aquisition ofeach
image taking about 5 min. Four contiguous trans¬
verse slices, each of 16 mm thickness were obtained,
encompassing the left ventricle. A single coronal
scan was also obtained at a level that bisected the
left ventricle.
The Tl maps which make up the images were













LC 21 4 140/86 12-5
MJ 37 2 Alopecia 154/80 25 150
EG 48 2 Arthritis 140/88 15 —
JB 38 6 Arthritis 160/96 15 —
JW 57 14 Arthritis 138/80 2-5 —
CMcD 68 20 — 175/102 10 —
GD 33 4 Arthritis 150/80 — —
JM 51 10 — 160/80 12-5 —
AR 31 7 Cardiac failure 150/96 60 50
pericarditis, mucosal
ulceration, haematuria
AL 26 4 — 140/90 — —
Pred.. prednisolone: Aza.. azathiaprine; SLE, systemic lupus erythematosus
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then analysed by dividing each image of the left
ventricular myocardium into six regions of interest
to test for homogeneity of signal. From the T1
values obtained, a mean T1 of all regions of interest
for each subject was obtained and the maximum T1
in any section noted.
ECHOCARDIOGRAP HY
M-mode and cross-sectional echocardiography
were performed using a Hewlett-Packard phased
array system with a 3-5-MHz transducer. Left ven¬
tricular function was assessed from cross-sectional
images and measurement of myocardial thickness
and cavity size made from M-mode tracings.
STATISTICAL ANALYSIS
In addition to analysis between three clinical
groups, the group with systemic lupus erythemato¬
sus was further subdivided into those with and
without active disease based on the disease activity
Table 2 ECG and echocardiography findings in patients with systemic lupus erythematosus
ECHO
Patient , ECG
(yearS) SEPTUM L™E EDD ESD
LC 21 Normal 11 14 50 36
MJ 37 Normal 13 14 33 20
EG 48 Normal 11 12 56 30
JB 38 LBBB 12 12 64 56
JW 57 Normal 16 16 50 35
CMcD 68 Non-specific 13 20 44 24
T-wave changes
GD 33 Normal 12 14 50 36
JM 51 Left axis 13 16 63 45
Deviation
AR 38 AF, widespread 12 11 64 48
T inversion
AL 26 Normal 11 11 52 33
SLE, systemic lupus erythematosus: LBBB, left bundle branch block;AF, atrial fibrillation.
Table 3 Magnetic resonance T1 values in volunteers, patients with hypertrophic
cardiomyopathy and SLE (complement values are shownfor patients with SLE)
Mean T1 (ms) Complement
Vol. HCM SLE (C3 C4 adsDNA LACC)
321 311 313 (1-01 0-13 elevated 1 )
— 314 332 (0-83 0-23 normal 0 )
318 320 314 (0-55 0-16 elevated 2*)
334 333 366 (0-51 0-07 2*)
322 324 346 (0-53 0-07 elevated 2*)
— 333 339 (0-67 0-15 elevated 1 )
297 320 343 (0-69 0-09 elevated ?*)
332 321 320 (1-23 0-34 normal 0 )
314 318 377 (0-53 018 elevated 5*)
314 305 313 (0-99 0-27 normal 0 )
Vol., volunteers; HCM, hypertrophic cardiomypathy; SLE, systemic lupus erythe¬
matosus; ads DNA, antibody to double stranded DNA: LACC, lupus activity
criteria count.
*Active disease.





Figure 1 Mean T1 values in normal volunteers, patients
with hypertrophic cardiomyopathy and patients with sys¬
temic lupus erythematosus. O, Active disease.
score. Analysis of variance was used to establish
whether there was a significant difference between
the means of the initial three groups and also
between the means of the further subdivision into
four groups. Subsequent analysis was performed
using a non-paired ;-test to decide which group
means differed significantly12'1.
Correlation between T1 values and complement
levels was by linear regression analysis. Significance
was accepted at ^ < 0-05.
Results
CLINICAL FINDINGS
The clinical findings in the group with systemic
lupus erythematosus are summarised in Table 1.
Active disease, as indicated by a lupus activity cri¬
teria count of2 or more, was present in five of the 10
patients. Eight patients were on prednisolone and
two on azathiaprine. Clinical evidence of cardiac




Four of the group with systemic lupus ery¬
thematosus had non-specific electrocardiographic
abnormalities (Table 2). The presence of an abnor¬
mal electrocardiogram did not relate to disease
activity. On echocardiography, mild hypertrophy
of the interventricular septum and left ventricular
free wall was common (Table 2). Poor left ventri¬
cular function was confirmed in the patient with
cardiac failure and a dilated left ventricle with
moderate contraction was noted in the patient
with a mitral-valve replacement.
All patients with hypertrophic cardiomyopathy
had evidence of septal hypertrophy, usually with
some free-wall hypertrophy.
PERICARDIAL INVOLVEMENT
A small amount of pericardial fluid was noted on
the magnetic resonance image in two patients with
systemic lupus erythematosus, but was also seen in
two normal volunteers and in one patient with
hypertrophic cardiomyopathy. The pericardial
fluid was not detectable by echocardiography in
the normal volunteers or patients with systemic
lupus erythematosus but was noted in the patient
with hypertrophic cardiomyopathy (in whom the
effusion was larger).
Figure 2 Relationship between MR T1 and the C, component of
the complement in patients with SLE (r= —0-67, R<0-05).
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Figure 3 Transverse sections illustrating T1 values in (a) a normal subject and
(b) a patient with active lupus erythematosus. The colour bar shows the T1
values with the normal subject having T1 values of around 300 ms, but the
patient with lupus having a diffuse increase in T1 of around 360 ms.
I
MAGNETIC RESONANCE IMAGING
The individual mean left ventricular myocardial
T1 for each group is shown in Table 3. The mean T1
(1 standard deviation) for normal volunteers was
319+12 ms), similar to the group with hypertro¬
phic cardiomyopathy (321 ± 10 ms). For the group
with systemic lupus erythematosus the mean T1 was
higher at 336 + 22 ms, this difference being signifi¬
cant (/><0-05) when compared to the group with
hypertrophic cardiomyopathy (N= 10), but not
when compared to the normal volunteers (N= 8).
However, there was marked variability in T1 values
within the systemic lupus erythematosus group
(Fig. 1). Values were particularly elevated in those
with active disease as indicated by the lupus
activity criteria count. For this subgroup the
mean T1 was 349 + 24 as compared to 324+ 12 in
the subgroup with inactive disease (Table 3).
Analysis of variance demonstrated a significant
difference between the means at the 0-99 level.
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Subsequent analysis demonstrated that the sub¬
group with active disease was significantly different
to both the normal volunteer and hypertrophic
cardiomyopathic groups (PcO-Ol). In addition,
T1 showed a negative correlation with serum C3,
(r = 0-67, /><0-05) in the group with systemic
lupus erythematosus (Fig. 2). In the patients with
systemic lupus erythematosus and raised T1 values
the increase in T1 was diffuse (Fig. 3).
No abnormalities were seen in the electrocar¬
diogram or echocardiographs of the normal
volunteers.
Discussion
This study confirms our previous findings that
there is little variation in T1 in normal subjects
and the T1 is not abnormal in patients with
hypertrophic cardiomyopathy'13'101. Furthermore,
it demonstrates that the magnetic relaxation par¬
ameter is frequently, but not invariably, raised in
patients with active systemic lupus erythematosus.
The patients with systemic lupus erythematosus
were recruited from those attending an out-patient
clinic. They thus tended to have severe disease,
reflected by the fact that eight were on steroid
therapy (Table 1). However, of the five with
active disease at the time of the study, only two
had clinical, radiological, electrocardiographic or
echocardiographic evidence suggestive of myocar¬
dial involvement.
Badui et alP] found evidence of myocarditis in
only 14% of cases using routine non-invasive
investigations. Despite the selective nature of the
patient group, the fact that four out of the five
with active disease had a raised T1 suggests that
abnormalities in the myocardium in systemic lupus
erythematous are common. It is likely that
commonly available cardiac investigations are
insensitive to the detection of such myocardial
involvement. In two patients with markedly
prolonged myocardial T1 values the electrocardio¬
gram was entirely normal.
The possibility that the elevated T1 values might
be related to the slight increase in left ventricular
wall thickness found in the group with systemic
lupus erythematosus is discounted by the normal
values in the patients with hypertrophic cardiomyo¬
pathy who had marked myocardial hypertrophy.
Increases in myocardial T1 are not specific to
systemic lupus erythematosus. We have previously
reported increases in T1 following myocardial
infarction'13'. However, the pattern of increase is
very different in the two conditions. In myocardial
infarc.tion there is a localised area of increased Tl,
with values in the infarcted area rising above
390 ms. There is often associated wall thinning,
while the unaffected myocardium has a normal
appearance. In contrast, those patients with
systemic lupus erythematosus and raised Tl values
show a more diffuse pattern of Tl elevation, with
values usually not exceeding 400 ms (Fig. 3).
After acute myocardial infarction the time course
of the changes is for a localised abnormal area to
increase in size up to about 14 days after infarction.
There is a gradual return to normal values by six
months after the acute event. We have not yet been
able to make serial measurements in the patients
with lupus erythematosus.
The underlying mechanism for this increase in Tl
is not yet clear. Histological findings reported in the
myocardium of patients dying of systemic lupus
erythematosus include lymphocytic infiltration,
sometimes accompanied by myocardial oedema. In
addition to the changes following acute myocar¬
dial infarction'13' Tl also rises in acute rejection
following heterotopic cardiac transplantation'32'.
In both these conditions, as in systemic lupus
erythematosus, cellular infiltration is a prominent
histological feature and may directly or indirectly
be responsible for the increase in T1.
Although prolonged myocardial Tl values
appear to reflect overall disease activity, one patient
with active disease had a normal Tl. Although
we have no histological proof, increases in Tl
may specifically reflect myocardial involvement. It
is notable that the one patient with acute cardiac
failure had the highest Tl.
The likelihood is that increases in Tl documen¬
ted by this interleaved saturation recovery and
inversion recovery pulse sequence reflect altered
cellularity of the tissue being examined. The relaxa¬
tion parameters Tl and T2 depend on the precise
pulse sequence using in magnetic resonance
imaging. The pulse sequence used in our system
given a more precise estimate ofTl than in the more
common spin-echo pulse sequence, so some caution
has to be taken before applying these results to
measurements from other magnetic resonance
imaging systems. However, estimates of Tl values
from magnetic resonance imaging using inversion
recovery sequences may aid in the investigation of
other myocardial diseases such as myocarditis,
congestive cardiomyopathy, connective tissues
diseases other than systemic lupus erythematosus
and cardiac rejection after transplantation where
myocardial inflammation is suspected.
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Brain hydration during alcohol withdrawal in alcoholics
measured by magnetic resonance imaging
M.A. Smith, J.D. Chick*, H.M. Engleman, D.M. Kean, A.J. Mander, R.H.B. Douglas
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Twenty-seven patients had a first Magnetic Resonance Imaging (MRI) scan 1 — 3 days after stopping drinking and a second
approximately 2 weeks later with no change in whole brain T1 or T{ in selected brain areas. Six patients whose first scan was
over 36 h after the last drink underwent an increase in whole brain Tl in the interval to the second scan. The later the first scan
was performed the greater was the increase in Ty These results are compatible with a very early fall in brain water
immediately on cessation of drinking (perhaps due to a rebound increase of vasopressin activity) with a return to 'baseline'
after two weeks. A third scan after discharge from hospital in 23 individuals who had abstained from alcohol or drank very
little did not reveal any further significant change in brain Tr
Key words: brain hydration; alcohol withdrawal; magnetic resonance imaging
Introduction
Water retention within the brain has been
postulated as a contributant to some of the
clinical features of alcohol withdrawal in
chronic alcoholics [1]. In magnetic resonance
imaging (MRI), Tx relaxation time is related to
the state of water in the tissue [2]. The T value,
measured in milliseconds (ms) increases as the
proportion of free to bound water within the
tissue increases. In vivo Tx values have been
shown to correlate with the level of brain water
[3 — 5] and so may enable a study of brain water
during withdrawal of alcohol in chronic
alcoholics.
MRI was first used for the investigation of
chronic alcoholics by Besson and colleagues [6].
These authors suggested that brain water is
diminished during intoxication and increased
during alcohol withdrawal. Acute intoxication
in occasional drinkers results in a fall in whole
brain Ty compatible with the dehydration
*To whom correspondence should be sent.
which follows acute intake of alcohol [7],
Eisenhoffer and colleagues [1] suggest that
such an effect, if chronic, might result on
alcohol withdrawal in a rebound increase of
vasopressin activity, followed by a return to
baseline.
It was therefore hypothesised that whole
brain Tx in alcoholics would be seen to fall from
the level at 24 — 48 h following cessation of
drinking to a lower level ('baseline') some 2
weeks later. We were unable to perform Tx
measurements in the present study in
intoxicated alcoholics immediately prior to
admission and thus unable to study the early
part of the postulated pattern of changes (that
is, the putative rise in brain water and T).
Patients and Methods
Chronic alcoholic patients who were about to
be voluntarily admitted as inpatients for
detoxification to the Alcohol Problems Clinic,
Royal Edinburgh Hospital, were fully informed
about the study and invited to participate.
0376-8716/88/$03.50 ©1988 Elsevier Scientific Publishers Ireland Ltd.
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Twenty-seven patients (18 men, 9 women), were
admitted to this study. Their mean age was 44
years (range 26 — 63, S.E.M. 5.2). They were to
be scanned within 48 h of admission (day 1) and
again approximately on day 15. However, the
timing of scans varied according to the
availability of the scanner and the
requirements of the patients' participation in
the ward programme.
In connection with a separate study [8] of
cognitive impairment and MRI parameters,
results of a scan performed at approximately
day 15 were available in a further 42 patients.
These patients had not been scanned at or near
admission.
Patients had been drinking at least 130 g
ethanol/day before admission and had a 5 —15
year history of alcoholism. No patients were
included if they had a history of drug abuse, or
were clinically malnourished, or had physical
disorders other than raised serum liver
enzymes. Over the first 5 days each patient
received a normal diet, intramuscular multi¬
vitamin supplements and decreasing doses of
chlordiazepoxide to control withdrawal
symptoms.
Our procedures for measuring whole brain
T1 and Tl in regions of interest in the brain
have been described [9]. The inter-operator
reliability of our Tx measurements has been
reported [8]. Differences in T1 values between
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Fig. 1. Whole Brain Tx measurements with means according to length of time since last drink.
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Table I. Mean change in Tl from Scan 1 to Scan 2 (A = Tj (Scan 2) — Tj (Scan 1)).
All subjects Scan 1 within 36 h
of last drink




1.83 ± 9.46 -0.39 ± 2.04 8.50 ± 3.77
A Frontal
Grey
0.50 ± 17.51 - 1.833 ± 4.26 7.50 ± 6.08
A Parietal
White
0.83 ± 9.17 -0.39 ±2.12 4.50 ± 3.90
A Parietal
Grey
- 6.75 ± 22.21 - 11.17 ± 5.09 6.50 ± 8.17
A Whole brain 0.75 ± 8.89 1 00 1+ o 8.33* ± 2.04
n 24 18 6
♦Significantly greater iP = 0.012) than in those whose first scan was within 36 h of last drink.
compared using Student's f-test. Changes in Tj
in individual patients were assessed using a
paired Student's f-test.
Results
Three patients were unavailable for their
second scan. The mean whole brain Tx at the
first scan in the 24 patients who had a second
scan was 314 ms (range 283 — 338, S.E. 2.71). At
the second scan the mean Tx was also 314 ms
(range 283 — 334, S.E. 2.69). T1 measurements in
small areas of interest likewise showed no
significant change between scans. Figure 1
illustrates all our available data on whole brain
Tx in the withdrawal period. It includes the
subjects on whom only the first scan was done,
and subjects from our other study scanned only
at day 15 approximately. No trend suggestive
of a fall in whole brain Tt is visible.
Lest the hypothesised fall in Tj had been
early and had been followed by an early 'return
to baseline', an analysis of the change in Tj
between the first and second scan was made,
comparing those patients who had their first
scan within 36 h of the last drink to those whose
first scan was later. The 18 patients scanned
within 36 h had their second scan at a mean of
13.6 days later (range 9 — 16 days, S.E. 0.43) and
the six whose first scan was up to 48 h later had
their second scan at a mean interval of 12.3
days since the first (range 9 — 16, S.E. 1.15).
This interval was not significantly different CP
= 0.33).
In those whose first scan had been within 36 h
of the last drink, the difference between
whole brain Tx on the first and second scans
was insignificant (mean difference - 1.78 ms —
a fall — range -15 — +9, S.E. 2.01). A
significant increase occurred, however, in those
whose first scan had been up to 48 h later (mean
8.33 ms, range +2 1-14, S.E. 2.04; t = 4.08,
d.f. 5 P < 0.01). The difference between the
changes in these two groups of patients,
(between those scanned within 36 h of
admission and those scanned later), is
Table II. Correlation of TIME OF SCAN 1 (post admission) with CHANGE IN ?! from Scan 1 to Scan 2.
ff-values (* - P< 0.01) n = 24
A WB A FW A PW AFG A PG
TIME OF
SCAN 1 0.4048* 0.2434* 0.1080* 0.4076* 0.4242*
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significant (t - 2.73, d.f. 22, P — 0.012) (Table
I). The trend was visible but not significant in
each of the Ty measurements made in areas of
interest. The later the first scan was performed
after the last drink, the greater the change
between the first and second scans, as shown
by the correlation coefficients given in Table II.
In case our timing of the scans had resulted
in our missing any later changes in Ty, another
comparison was made. Four patients had the
second scan on the 9th or 10th day and 20
patients beyond the 10th day. There was no
significant difference when these groups were
compared in the mean change between the first
and second scans (2.25 ms, S.E. 5.28, range - 11
— +13 and 0.45 ms, range - 15 — + 14, S.E.
1.97, respectively; t = 0.36, d.f. 22, P = 0.72).
We had some further data after patients had
been discharged from the 2-week ward
programme. Seventeen patients from the
present study had a further scan 2 months after
discharge. There was also a scan at that point in
38 patients in the collateral study already
mentioned. The difficulty in using this data is
that we were not always certain whether or not
an individual had continued to abstain from
alcohol during that period. We examined the Ty
values in 23 individuals who had been scanned
at about day 15 and had a repeat scan at a mean
of 102 days and who as far as we could tell had
abstained during that period or drunk very
little. No significant change in Ty in any of the
regions of interest or in the whole brain was
noted. However, the trend in these apparent
abstainers in all our T measures was for a
slight increase, but with considerable
individual variation (for example, the mean
increase in whole brain Ty was 2.39 ms, range
— 11—(-19, S.E. 1.55 ms,?i = 23).
Discussion and Conclusions
The only possible way in which our data
would support the notion that there is a fall in
brain water following withdrawal from alcohol
is using the sparse data comparing the changes
in those scanned within 36 h of the last drink with
those whose first scan was later. Our data would
support a fall in Ty between 36 h and 84 h, with
a subsequent return to 'baseline' during the
next 10 days approximately. It would have to
be postulated, however, that individual
differences in 'baseline' T prevented this from
emerging in the data on the whole sample as
illustrated in Fig. 1.
Our data do not uphold the provisional result
which we obtained on our first 9 patients [9]. In
that paper, we reported a fall in whole brain Ty
which correlated positively with the length of
abstinence prior to the second scan. In our
present sample, the correlation between
change in whole brain Ty and interval to the
second scan was insignificant (— 0.09). Neither
were there significant correlations between the
change in Tx in the areas of interest and
interval to the second scan.
Further studies should comprise daily
measurements beginning on the day prior to
admission, when the patient is still drinking,
and continuing for 2 weeks.
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Magnetic resonance spectroscopy in vivo
D.A. Porter and M.A. Smith
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ABSTRACT
Nuclear magnetic resonance ( NMR) lias become an important non-invasive investigative technique in medicine and biology.
The most recent development has been the ability to perform magnetic resonance spectroscopy (MRS) in selected regions
within the human body. Such volumes can be selected by techniques which fall into the following broad catagories: surface
coil methods, surface coils with depth selection, volume selection and chemical shift mapping. The latter two methods use
magnetic field gradients, present on magnetic resonance imaging systems, to select the volume. MRS can be used
to measure phosphorus and proton metabolites and hence study tissue biochemistry in-vivo.
Keywords: Medical imaging, magnetic resonance spectroscopy, biochemical analysis.
INTRODUCTION
There has been a great deal of interest in the
application of nuclear magnetic resonance (NMR)
in the field of medicine and biology over the last 15
years. The initial interest was fueled by the develop¬
ment of techniques of magnetic resonance imaging
(MRI) so that now commercial MRI systems are
present in many hospitals and research centres. More
recently, developments in magnetic resonance
spectroscopy (MRS) have provided a non-invasive
technique for monitoring biochemical activity from
selected regions within the body.
Following the first observations of NMR in 1946
by Bloch1 and Purcell2, it has long been possible to
obtain in-vilro NMR spectra from small samples in
liquid or solid form. In 1974 it was demonstrated
that NMR can be used to study the major phos¬
phorus containing metabolites in isolated intact
tissues'1. With the development of larger bore high
field superconducting magnets came the possibility
of acquiring NMR spectra from animal and human
tissues in-vivo. Nuclei that can be studied by MRS
include phosphorus, protons and carbon, all ofwhich
play an important role in human biochemistry.
One important requirement for in-vivo studies is
spatial selection, so that spectra can be collected from
a well defined region within the body without
contamination by signals originating from tissues not
under investigation. After a short account of the basic
principles, this article reviews the techniques used to
meet the in-vivo objectives and presents examples of
human in-vivo NMR spectra.
PRINCIPLES OF MRS
In order to obtain NMR spectra, the sample to
be studied is placed in a strong magnetic field of high
homogeneity. The strength of this field is denoted by
B() and its direction is defined as thez axis. Interaction
between the magnetic moment of the nuclei and the
static field Bu results in the preferential alignment of
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the nuclear spins along the field direction. In this
way, a nuclear magnetization is produced along the
z axis. An individual nucleus, whose spin is inclined
at an angle to Blh will precess about the field direction
at a characteristic frequency:
oj = yB()
where oj is known as the Larmor frequency and
y is the gyromagnetic ratio for the particular nuclear
species.
This behaviour is analogous to the precession of
the axis of a gyroscope about the Earth's gravita¬
tional field. A radio frequency (RE) magnetic field
at the same frequency can be employed to tilt the
magnetization away from the z axis. This time
varying field, denoted by Bu is applied in a direction
perpendicular to B{). The magnitude and duration
of this RF excitation pulse determines the angle of
till, a, away from the z axis as follows:
tx = y BAl) d/
where is the pulse duration.
A 180' pulse leaves the nuclear magnetization
along the — z axis and a 90° pulse leaves it in the
xij plane. The continued precession of the nuclei
about B{) means that any xy component ofmagnetiza¬
tion present alter the RF pulse also precesses about
Bu. It is this rotating magnetization that is detected
by the induction of an electromotive force (EMF)
in a radio frequency receiver coil. The decay of this
signal is characterized by two time constants 7j and
T,. 7j is known as the longitudinal or spin-lattice
relaxation time and describes the relaxation of the
system to equilibrium with the nuclear magnetiza¬
tion along the z axis. T-> is the transverse or spin-spin
relaxation time and is a measure of the time during
which the individual nuclear magnetic moments that
contribute to the rotating xy magnetization remain
in phase with each other.
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The magnetic field experienced by the nuclei is
modified by aspects of its local environment such as
the distribution of electrons. As a result, different
compounds of the same nucleus will experience
marginally different B0 fields and consequently pro¬
duce resonances at slightly different frequencies. This
change in resonant frequency is known as a chemical
shift. Formally, the chemical shift for a compound
with resonant frequency, co, is given by:
chemical shift (p.p.m.) =— x 106
co0
co0 is the resonant frequency ofa reference compound
which is standard for a given nuclear type. Providing
the bandwidth of the RF excitation pulse is sufficient
to encompass the entire range of chemical shift for
a given nuclear type, the time signal produced by
the rotating xy magnetization contains information
about the relative signal intensity as a function of
chemical shift. This information is retrieved by
Fourier transformation of the time signal and allows
relative concentrations ofdifferent compounds of the
same nucleus to be inferred. In order to resolve the
different chemical shifts, a high degree of magnetic
field homogeneity is required. If this condition is not
met the resonant frequency of a nucleus with a given
chemical shift will vary significantly across the
sample and degrade resolution. Before data can be
acquired in an NMR experiment the magnetic field
Bu is adjusted until the required homogeneity is
produced. The field homogeneity can be monitored
by measuring the line width of a single resonance.
The resonance of proton nuclei in water molecules
are frequently used for this purpose. This process of
B0 field adjustment is known as shimming. For
imaging purposes a uniformity of 1 in 10° is sufficient
whereas for spectroscopy a uniformity of 1 in 10; is
required.
SURFACE COIL TECHNIQUES
In 1980 the first in-vivo NMR spectra were collected
from phosphorus compounds in skeletal muscle and
brain of intact rats, using a single turn circular RF
coil placed close to the skin4. The coil, which is tuned
to the appropriate resonant frequency, is positioned
so that the coil axis is perpendicular to the static
magnetic field B0. The coil is used both to send the
RF excitation pulse and to receive the subsequent
RF signal from the irradiated tissues. In conventional
in vilro NMR spectioscopy a saddle-shaped or sole-
noidal coil is used to provide a uniform B{ field over
the sample. Under these conditions, different regions
within the sample contribute evenly to the detected
signal. The inhomogeneous magnetic field associated
with a surface coil is used to confine the NMR signal
to a region close to the surface of the body. The
relative signal strength as a function of spatial
coordinates is determined by two factors. Firstly, as
a result of the principle of reciprocity3, the EMF
induced in the coil by the rotating magnetization at
a given point in the sample is proportional to the
magnetic field produced at that same point by unit
current flowing through the coil. Secondly, the pulse
angle following an RF excitation pulse varies across
the sample according to equation (1).
It therefore follows that the relative contribution
to the detected signal from a given point in the
sample, is proportional to a sin a, where a is the pulse
angle at that point. This behaviour can be used to
a limited extent to select regions at different distances
from the coil. Figure 1 shows the relative signal
received from points in a homogeneous non-con¬
ducting sample as a function of distance along the
coil axis when a 90° and 180° pulse are generated at
the coil centre. Frequency dependent attenuation of
the RF signals in conducting biological samples6 must
be considered for a more careful analysis. The
behaviour of the surface coil Bt field away from the
coil axis means that regions ofhigh sensitivity selected
by adjustment of pulse length have a complex shape.
It is not possible to achieve efficient depth selection
using simple radio frequency excitation pulses as a
result of surface contamination. This arises due to
the high B{ flux near the coil wire, where a large
range of pulse angles exist and where the inherent
sensitivity is high.
An example of a phosphorus spectrum from a
human calf muscle using a 6 cm diameter surface coil
is shown in Figure 2.
DEPTH SELECTION
A number of techniques have been developed to
improve the ability of surface coil methods to select
regions of tissue at different distances from the coil.
One approach has been to make the signal received
from a given point a stronger function of the pulse
angle at that point. In this way the signal is more
effectively localized to regions where the pulse angle
is close to 90°. This has been achieved by using a
series of multiple RF pulses to excite the nuclear
magnetization away from its equilibrium direction
along the z axis7. This contrasts with the simple NMR
experiment, outlined above, where a single RF pulse
is applied for this purpose.
distance along coil axis / radius
Figure 1 The relative signal strength received by a circular
surface coil as a function of the distance along the coil axis. The
two curves show how the pulse angle at the coil centre determines
thu-dcpthTroimwhich-maximurn-signaLis.receiued
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Figure 2 In-vivii phosphorus NMR spectrum collected from
human call' muscle using a 6 cm surface coil. The frequency
decreases from left to right and 0 p.p.m. corresponds to a
frequency of about 26 MHz at 1.5 T. The resonances arising
from the different phosphorus compounds arc labelled as follows:
Pi, inorganic phosphate; PCr, phosphocrcatinc; g, a, b ATP,
gamma, alpha and beta adenosine triphosphate
A number of different RF pulse sequences have
been used. An example of one of the less complex is
a follows: an initial RF pulse ofduration L is followed
by a second RF pulse of duration 21 before signal
acquisition. Four separate signal acquisitions are
performed in the same way, but the phase difference
between the two RF pulses is increased by 90° for
each acquisition; 180° phase adjustment of the
receiver is also required for alternate acquisitions.
Analysis of the motion of the nuclear magnetization
during this sequence shows that summation of the
four signals produces a signal whose magnitude7 is
proportional to oc siffia. Figure 3 compares this
dependence on pulse angle with that obtained from
the use of a single RF pulse for excitation.
Other multiple pulse sequences produce signals
that tire proportional to higher order trigonometrical
functions of the pulse length. This greater selectivity
to pulse length is accompanied by greater complexity
of the sequence and an increase in the number of
signal acquisitions required. The problem of avoid¬
ing contamination by signals from regions close to
the coil has also been addressed by multiple pulse
techniques".
The introduction of magnetic field gradient tech¬
niques provided a more efficient method ofselectively
receiving a signal from tissue at a given distance
below a surface coil. One technique which utilizes a
magnetic field gradient in conjunction with a surface
coil to produce spatial localization is DRESS (Depth
Resolved Surface Coil Spectroscopy)9. Superposition
of a linear magnetic field gradient upon the B0 static
magnetic field has the effect of making the resonant
frequency of the nuclei a linear function of position
along the field gradient. Hence, the application of a
narrow-bandwidth RF excitation pulse in the pres¬
ence of the magnetic field gradient only excites spatial
distance along coil axis / radius
Figure 3 A comparison of the spatially dependent signal received
using the multiple radio frequency (RF) pulse sequence outlined
in the text (curve 1) with that produced using a single RF
excitation pulse (curve 2). These theoretical curves arc plotted
for a 180" pulse angle at the coil centre. This pulse angle can
be varied to select regions at different distances from the coil
regions of nuclei within the appropriate range of
resonant frequency. In DRESS a magnetic field
gradient is applied perpendicular to the surface coil
plane. The use of a narrow-bandwidth RF excitation
pulse, such as an amplitude-modulated sine function,
then has the effect of confining the signal to a plane
perpendicular to the field direction and parallel to
the surface coil plane. Localization of the signal
within the plane is determined by the geometry of
the surface coil. The thickness of the selected plane
is dependent upon the magnitude of the magnetic
field gradient and the bandwidth of the RF pulse.
In this technique the effects of chemical shift must
be examined. Consider two compounds of the same
nucleus whose resonances are separated by Aca in the
field B0. The range of frequencies contained within
the narrow-bandwidth RF pulse corresponds to
slightly
different spatial regions for each of the two com¬
pounds. The spatial offset between the two regions
is given by:
where Gx is the field gradient in the x direction.
Clearly, the offset is minimized by using as large a
field gradient as possible.
The DRESS technique makes one further modifi¬
cation to the surface coil method of AIRS. Separate
RF coils are used for excitation and receiving. The
coil used for excitation is chosen to have a uniform
B\ field over the sensitive volume of the surface
receiver coil. A larger surface coil can be used for
the excitation. It is then possible to optimize the
signal strength received from the selected plane by
applying a 90° pulse to the sample. Pulse length
variation, and associated signal reduction, is in¬
evitable if the smaller surface coil is used for the
excitation. The Johnson noise received from the
sample is determined by the receiver coil dimensions.
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Hence, this coil arrangement detects no greater noise
than when a single send and receive coil is used.
VOLUME SELECTION
The first technique of volume selection was chris¬
tened topical magnetic resonance (TMR)'° and was
used to collect the first human in-vivo NMR spectrum
in 1981 from forearm muscle". Static high order
magnetic field gradients are superimposed upon the
magnetic field B0 to produce high field homogeneity
in one region only. The signal detected from this
region contains highly resolved frequency informa¬
tion, characterized by narrow lines in the spectrum.
The detector, which may be a surface coil, also
receives signals from the inhomogeneous parts of the
body elsewhere. This low resolution information can
be filtered out from the signal mathematically to
recover the signal originating from the region ofhigh
field homogeneity only. The complex nature of the
spatial variation of magnetic field means that the
volume selected in this manner is irregular and not
well defined. The technique is further limited by the
requirement that the homogeneous region can only
be produced at the centre of the main magnetic field.
This makes positioning of the localized volume a
difficult task. This method of spatial localization has
been superseded by others and is only of historical
interest.
More recently, techniques have been developed
that achieve localization of the detected signal to a
well defined volume, such as a cube, deep within the
body. The position and size of the volume is very
flexible and changes can be made without repo¬
sitioning of the subject under investigation. Such
methods employ pulsed field gradients that are used
in MR I. As in the DRESS technique, described
above, the combination of magnetic field gradients
and narrow-bandwidth pulses allows the excitation
of selected regions of nuclear spins. In DRESS a field
gradient is applied in one dimension only, confining
the signal to a plane. Field gradients applied in all
three dimensions can be used to confine the signal
further to a cube. NMR images of the body provide
a means of identifying the region from which a
spectrum is to be obtained. Then appropriate field
gradients and RF pulses are used to acquire localized
information from the desired location. The choice of
position of the volume is, however, restricted by the
sensitive volume of the receiver coil. A number of
methods for achieving volume selection have been
developed 7. Here we restrict ourselves to the
description of two techniques currently implemented
on our equipment ISIS1 and SPARS14.
ISIS (Image Selected In-vivo Spectroscopy) makes
use of slice selection in three orthogonal planes. A
slice selective 180° pulse applied to a sample leaves
the nuclear magnetization with its direction along
the — z axis in the selected slice and unperturbed
in the + z axis equilibrium direction elsewhere. Ap¬
plication of a non-selective 90° pulse, or detection
pulse, rotates the magnetization into the xy plane
across the whole sample. The magnetization then
rotates in the xy plane as described previously.
However, the magnetization in the ^elected slice
points in the opposite direction to that elsewhere in
the sample. As a result there is a 180° phase difference
between signals from the two regions so that signal
from the selected slice contributes negatively to the
total signal. A signal acquired from the same total
volume, omitting the 180° slice selective pulse has
positive signal contributions from the entire sample.
Hence, subtraction of the signal acquired with the
slice selection from that acquired without it results
in the summation of signal from the selected slice
and cancellation elsewhere.
In the ISIS technique this principle is extended
to three dimensions to achieve cancellation in all
regions except a selected cube. Three orthogonal field
gradients arc used to produce three selected slices
whose intersection is the required cube. The three
180° slice selective pulses are applied successively
before the detection pulse. The slice selective pulses
can be applied in any combination, ranging from
the omission of all three to the use of all three. When
no slice selective pulses are applied during the
preparation period, before the detection pulse, all
regions within the sample contribute positively to the
signal. If a single selective pulse is used, a single slice
perpendicular to the appropriate held gradient con¬
tributes negative signal as above. When two or
three slice selections are used, regions experiencing
zero or two 180° pulses contribute positively to the
signal and regions where one or three 180° pulses
have been applied contribute negatively. Signals
received using different permutations of the slice
selective pulses can be arithmetically combined to
cancel signal from everywhere except for the cube
formed by the intersection of the three planes, where
the signal is summed. Eight separate signal acquisi¬
tions are required to achieve this.
As with all techniques that incorporate selective
excitation using magnetic held gradients, the spatial
localization is a function ofchemical shift as described
by equation (2). In our case, a maximum magnetic
held gradient of 3mT/m means that A x is about
1 cm for the range of phosphorus compounds at
1.5 T. Although selective 180° pulses give the
optimum signal, the method of cancellation does not
depend on the pulse angles used. As a result ISIS
can be used in conjunction with RF coils, such as
surface coils, with an inhomogeneous B\ held.
SPARS (SPAtially Resolved Spectroscopy) uses a
more complex sequence of magnetic held gradient
and RF pulses to produce signals from the selected
volume in each signal acquisition. In this case the
method does rely on accurate pulse angles and a
homogeneous 5, held is required. Firstly, a non¬
selective 90° pulse is applied, rotating the magneti¬
zation into the xy plane. A combination of pulsed
magnetic held gradients and a 180° RF pulse are
then used to produce a phase coherence of the nuclear
spins in the xy plane. It is then possible to apply a
slice selective 90° pulse to rotate the spins within a
given slice back along the z axis. The remaining spins
in the xy plane become dephased as a result of the
position dependent resonant frequency created by
the magnetic held applied during the 90° selective
pulse. The sequence is repeated and slice selections
are performed in the other two dimensions. The
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consequence of this is to produce a r magnetization
in the selected cube only. A further 90° pulse is
applied, rotating this z magnetization into the xy
plane and producing a signal from the selected cube.
SPARS requires a longer preparation period prior
to. data acquisition than ISIS. As a result the
application of SPARS is unsuitable for compounds
with small T> relaxation times, when there is
unacceptable loss of signal between excitation and
detection. This is true of physiological phosphorus
compounds where T2 values can be as low as 10 ms.
In order to obtain phosphorus brain spectra
we have made use of both of the above techniques
in our MRI and spectroscopy system shown in
Figure 4. The human subject is fitted with a phos¬
phorus head coil that is positioned close to the head to
optimize sensitivity. The subject is then placed inside
the magnet with the head inside the proton imaging
coil. Figure 5 shows the position of the two RF coils
during the investigation. Firstly, an image is ac¬
quired, from which the position and size of the
Figure 4 The 1.5 T Gyroscan Magnetic Resonance Imaging
and Spectroscopy system manufactured by Philips Medical
Systems. In the foreground the operator can be seen in front of
the control console on top of which is the box used to adjust the
magnet shim. Through the window can be seen the patient couch
and magnet
Figure 5 Positioning of the RF coils about the head during
acquisition of a phosphorus spectrum from the brain. The
proton coil is used both to collect magnetic resonance images to
identify the region of interest and to acquire localized proton
signals used to shim the static magnetic field A,—
PPM
Figure 7 In-vivo phosphorus n.m.r. spectrum collected from the
brain of a healthy volunteer. The resonances arising from the
different phosphorus compounds are labelled as follows: PME.
phosphomonocstcrs; Pi, inorganic phosphate; PDE, phospho-
dicstcrs; PCr, phosphocrcatine; g, a, b ATP, gamma, alpha and
beta adenosine triphosphate
volume to be studied by AIRS is determined (see
Figure 6). The proton coil is then used to collect
localized proton signals from the volume of interest
using SPARS. The static magnetic field, B0, is
shimmed by varying the current through a series
of resistive coils around the magnet bore until the
required magnetic field homogeneity of 0.2 to 0.3
p.p.m. is obtained. ISIS is then used to collect a
localized phosphorus spectrum; the phosphorus coil
is used for both excitation and receiving. A phos¬
phorus spectrum obtained from a 5 x 5 x 5 cm cube
in the brain ofa normal volunteer is shown in Figure 7.
Figure 6 A magnetic resonance image is used to select a volume
in the brain from which a phosphorus NMR spectrum is obtained
wm , m a
566 J. Biomed. Eng. 1988, Vol. 10, November
Magnetic resonance spectroscopy: D.A. Porter and AI.A. Smith
CHEMICAL SHIFT MAPPING
In chemical shift mapping, instead of collecting
a single NMR spectrum from a selected region, a
map is produced of the spatial distribution of each
of the compounds of the nucleus under investigation.
One, two and three dimensional versions have been
implemented. In a one dimensional method a series
of spectra are obtained from a set of parallel planes.
In two dimensions an individual NMR spectrum is
associated with each pixel and, in three dimensions,
with each voxel.
Rotating frame zeugmatographv was initially pro¬
posed as a proton imaging technique18. In this form
the spatial distribution ofwater molecules is mapped,
but no chemical shift information is obtained. The
method has been modified to enable one-dimensional
chemical shift images to be obtained from the human
body 9. A one dimensional /ft field gradient, of
duration ft, is followed by a period, ft, of free
precession in the homogeneous static field /ft. A series
of acquisitions are performed, varying ft each time.
During the period ft, the nuclear spins rotate in a
plane containing the z axis. The total angle of the
rotation during ft is given by equation (1). The larger
the value of /ft the higher the frequency of this
rotation. Hence, for the linear /ft field gradient,
Fourier transformation with respect to ft yields a
frequency variable J\ which linearly describes posi¬
tion in the sample in a direction along the /ft field
gradient. Fourier transformation with respect to ft
provides the chemical shift information for each of
the spatial regions defined by Jx.
A second method for obtaining chemical shift
images uses pulsed magnetic field gradients. After
the nuclear spins have been excited into the xy plane,
an applied linear magnetic field gradient makes the
frequency ofpreeession of the nuclei a linear function
of position. When the field gradient is removed the
frequencies of precession are equal, although a small
variation exists dependent on the homogeneity of the
static field /ft. However, a phase variation exists in
the direction of the applied field gradient, so that
the spins are phase encoded with respect to their
positions. The signal is acquired, during a period of
free precession ft, after removal of the field gradient.
Subsequent signals are collected using different field
gradient strengths, so that the resulting phase varia¬
tion has a different spatial frequency each time. If
.'V signal acquisitions are performed, incrementing
the field gradient by the same amount each time, a
two dimensional data set is produced comprising the
A sets of acquisition times ft. Two dimensional
Fourier transformation of this data produces both
chemical shift and positional information. N spectra
are produced associated with :V slices perpendicular
to the applied field gradient. One dimensional chem¬
ical shift imaging using phase encoding techniques
was first applied to in-vivo animal studies in 198320
and in-vivo human phosphorus chemical shift images
were obtained in 1987-'.
By using three orthogonal field gradients for phase
encoding, three dimensional chemical shift images of
the human body have been produced2"'. All three
gradients are applied simultaneously to produce
phase encoding in all three directions. The number
of acquisitions performed is given by Aft x Ny x Aft,
where N, is the number of voxels in dimension i. As
above the field gradients are removed before signal
acquisition. Four dimensional Fourier transforma¬
tion produces information in three spatial directions
along with the chemical shift information. The
technique has been used in conjunction with a surface
coil to produce chemical shift images of phosphorus
in human liver22 with a voxel size of 2 x 2 X 2 cm.
SUMMARY
MRI has many applications in medicine and would
be the investigation technique of choice in a number
of clinical conditions. However, the role of MRS in
routine clinical practice is much less clear. Many of
the above spectroscopic techniques are currently
undergoing evaluation of their potential clinical
applications. Of particular interest is the non-in¬
vasive monitoring of pathological conditions and
their response to different therapeautic regimes
rather than the use of MRS as a diagnostic tool.
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Atherosclerosis of major arteries is a
very common disease in the Western
world, and the biggest single killer. It
also accounts for a considerable
morbidity resulting from the ischaemic
effects on a wide variety of organs,
leading to angina, transient ischaemic
attacks, claudication, rest pain etc.
Investigation of this disease has, for
many years, relied upon X-ray
angiography which produces high
quality images of the anatomy of the
arteries under study and enables
interventional therapeutic procedures,
most notably angioplasty, to be
performed.
However, X-ray angiography has
several important drawbacks. First, it
is necessary to inject a contrast
medium into the vascular system and,
even with the new low osmolar agents,
this is uncomfortable and not without
a significant morbidity and mortality.
Secondly, the patient is exposed to
X-radiation and, thirdly, as the
femoral artery is punctured, most
angiograms necessitate an overnight
hospital stay with the associated
financial implications.
X-ray angiography has been greatly
improved by digital subtraction
techniques which allow angiography to
be performed as an out-patient
procedure using small catheters, a
lower contrast medium dose and a
possible reduction in X-radiation dose.
Nevertheless, for all this, it still
remains an unpleasant, expensive and
potentially hazardous investigation.
Duplex ultrasound offers a non¬
invasive alternative with many
attractions. It is a truly non-invasive
technique, as no significant harmful
effects are known.
However, it too suffers from many
drawbacks.
Ultrasound is attenuated by gas and
bone, so that certain areas of the body
are less accessible and, although
B-scan ultrasound produces images of
Blood flow imaging by
magnetic resonance
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Summary. The effects of motion on magnetic resonance signals have been
utilized by many workers to produce quantitative and qualitative flow
data. The Philips MR flow package is able to provide both quantitative
flow information and angiographic images of blood vessels using the same
basic pulse sequence. The authors describe the use of this package in
studies of both normal volunteers and patients, and demonstrate its
potential as an accurate, non-invasive alternative to X-ray angiography
and as a widely applicable tool for measuring in-vivo blood flow.
vessels, the resolution is poor
compared to X-ray angiography. In
order to study a long vessel, a picture
has to be built up from several
images. Such scans are highly
operator-dependent and time
consuming, and it is sometimes
difficult to identify which vessel one is
imaging.
The volume of blood flowing per unit
of time through named arteries and to
individual organs is a very basic
physiological parameter. A non¬
invasive accurate in-vivo method for
measuring blood flow would be of
great value in both clinical and
research situations. The only npn-
invasive in-vivo technique at present
applied to measure blood flow
through individual arteries is Doppler
ultrasound. This has proved itself
accurate in those vessels which are
accessible to ultrasound.
However, an inherent problem in the
Doppler technique is that it does not
measure flow directly. Values for
instantaneous velocity are obtained,
which are then integrated throughout
the cardiac cycle to produce a figure
for time-averaged velocity. It is then
necessary to measure the cross-
sectional area of the vessel under
study in order to calculate flow. Thus,
this method involves several stages at
which errors may occur. The need for
accurate measurement of blood vessel
cross-sectional area is a particular
drawback as many vessels, not just
those within the head, are difficult to
image.
Other techniques have also been used
for in-vivo blood flow measurement.
For example, a limited degree of
success has been achieved using
radioactive isotopes, and quantitative
measurements from digital X-ray
angiography. However, these
techniques are invasive.
There is, therefore, a need for a rapid
non-invasive and accurate technique
for imaging the vascular system and
for performing quantitative blood flo\
measurements.
MR flow techniques
Flow effects on magnetic resonance
(MR) signals have been known for
over 30 years, and no sooner had the
first magnetic resonance images of the
human body been produced than
workers in several centres were
studying ways of exploiting these
effects to produce quantitative and
qualitative information on blood flow
MR angiography
One of the attractive features of
conventional X-ray angiography is the
production of a projection image of
the contrast-filled blood vessels within
the beam.
However tortuous the vessel may be,
it will be shown throughout its length
(albeit foreshortened in places).
Attempts to provide images of the
blood vessels using MR have generally
Fig. 1. The .FLAG pulse sequence.
a. Basic sequence.
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concentrated on simulating such a
projection image with a section thick
enough to contain all the vessels of
interest. These techniques have been
collectively termed MR angiography.
The first technique of MR
angiography relied on the different
degrees of phase dispersion within
voxels in different parts of the cardiac
cycle6-12. Van Wedeen13 used a
conventional 2D FT spin-echo
sequence. Two cardiac-triggered
images were acquired: one at systole
and the other at diastole. In diastole
the blood flow is relatively slow, so
there was no significant phase
dispersion, resulting in preservation of
the signal from the slow-flowing
blood. In the image acquired during
systole, however, significant phase
dispersion caused a reduction in the
signal intensity from the more rapidly
flowing blood. The signal from
stationary tissue was the same in both
images. Subtraction of the systolic
from the diastolic image resulted in an
MR angiogram.
A disadvantage of this technique is
that it will only work where the flow
is relatively strongly pulsatile. Vessels
in which there is a constant velocity
cannot be imaged. Probably a more
important disadvantage is the change
in position of some vessels in different
parts of the cardiac cycle. Such
movement of vessels will produce
registration errors when the images are
subtracted. A further disadvantage is
the variability in the phase dispersion
at a fixed point in the cardiac cycle in
a patient with vascular disease or with
a variable heart rate.
The general technique of MR
angiography, which overcomes the
problems mentioned above, produces
different velocity-dependent phase-
shifts in two images which can be at
the same phase of the cardiac cycle.
Stationary tissue will have the same
phase shift in each image resulting in
zero signal after subtraction. Careful
choice of the imaging parameters to
produce a phase shift of 180% at the
peak velocity likely to be found in the
region to be studied will give a
maximum signal within the vessel
following subtraction.
Van Wedeen et al.14 use a subtraction
of two SE sequences with an unpulsed
frequency encoded gradient and
different echo times. This variation of
TE produces the velocity-dependent
phase shift in the subtracted image.
Dumoulin et al.2 inserted an
additional bi-polar pulse during the
evolution period of a gradient echo
sequence. Data for two images were
acquired, the polarity of the additional
bi-polar pulse being reversed for the
second image. This reversal modulates
the phase of the moving spins but has
no effect on the stationary spins.
Groen et al.4 developed a sequence
with the acronym FLAG (Flow
Adjusted Gradients); this is the
technique we use, and..we shall discuss.,
it in detail below.
MR velocity-phase maps
The technique of using MR images to
ig. 2. MR angiogram of upper legs of normal volunteer. Note good
isualization of deep and superficial femoraI arteries, but motion artifact
bliteration of signal within the pelvis.
Fig. 3. MR angiogram of tower legs of normal volunteer. This is a
composite image taken by summing 6 images taken throughout the cycle.
antitate velocity was developed by Bryant et al.Moran
d Moran7 and Van Dijk". These early methods had
'ere limitations for clinical application, but there have
ce been a number of significant advances which make
lical use practical. Nayler et al.8 Ridgway and Smith9
i Young et al.15 utilized a field echo to increase the
lge of velocities that could be measured. Methods to
?rcome the phase dispersion, which can produce a loss
signal, were also developed8-9. The technique has also
in extended to measure very slow flow10.
-e FLAG sequence
the FLAG sequence additional bi-polar gradient pulses
added to a field echo sequence to compensate for the
3city-dependent phase shifts. Two images are acquired,
: where the bi-polar pulse compensates for velocity,
ing zero phase change in flowing blood, and the second
h the added bi-polar gradient changed in magnitude
ing a velocity-dependent phase shift. For MR
iography a thick section is selected and an additional
llow gradient is. applied in the- 'slice. selectLdirection to
hase the signal from stationary tissue. Complex
traction of the two images gives the required high
lal from flowing blood and zero signal from the
kground. For velocity-phase maps, thin sections are
selected and the separate phase images are subtracted.
The FLAG sequence is illustrated in Fig 1. In addition to
the standard sequence parameters such as slice thickness,
matrix size, TE flip angle etc., the following additional
operator-adjustable parameters are available: cardiac
triggered or continuous acquisition, direction of flow
sensitivity, velocity to give the maximum signal or phase
diffeience, and slice dephasing gradient.
Recently there have been a number of developments of the
FLAG sequence. The minimum echo time has been
reduced to enable thin-section phase maps of the aorta to
be acquired with less signal loss; this has also improved
the signal-to-noise ratio in MR angiograms.
In a further refinement of the FLAG sequence the flow-
sensitive and compensated acquisitions are interleaved
within the same cardiac cycle instead of at the same point
in adjacent cycles. Consequently the separation is reduced
from perhaps 800 ms to 50 ms, reducing the effect of
extravascular motion. This technique is referred to as
Rapid Sequential Excitation5.
Our work has been carried out on a Philips Gyroscan MR
system operating at 1.5T using the original FLAG
sequence, the short echo modification and also the rapid
sequential excitation version.
lm
Fig. 4. Comparison of X-ray and MR angiograms of a patient with a
block at the origin of the left peroneal artery.
a. X-ray angiogram.
b. MR angiogram demonstrating absence offlow in the left peroneal
artery.






In MR angiography, the acquisition sequence is normally
synchronized to the cardiac cycle in order to obtain images
at different times within the cycle. This is important in
regions such as the lower limb where the flow is very
pulsatile, but is not necessary in the carotid arteries where
the flow is continuously present throughout the cardiac
cycle. Using the standard FLAG sequence to assess flow in
the lower limb arteries, we normally collect images at 6
points throughout the cycle, at 75 ms intervals starting
50 ms after the R-wave. We have found a velocity setting
of 0.5 m/s to be optimal for the lower leg and cerebral
circulation, and 1.0 m/s for the upper leg.
The slice thickness is selected at the minimum which
ensures inclusion of all the vessels of interest. A maximum
thickness of 10 cm is satisfactory in most circumstances.
The direction of flow sensitivity can be set in either of the
two co-ordinate axes within the slice. One direction usually
suffices, but two directions are sometimes necessary if the
vessels are very tortuous. The thick slice under study may
be angled if necessary, which is especially useful for
examinations of the carotid bifurcation. We generally use
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Fig. 6. Comparison of X-ray and MR angiograms in a patient with
aortobifemoral trouser graft, and a block of the left superficial femoral
artery at its origin with reconstitution via collaterals from the deep
femoral artery to the popliteal.
a, b. X-ray angiograms.
c, d. MR angiograms.
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Fig. 7. Comparison of X-ray and MR angiograms in a patient with a
block of the right superficial femoral artery at its origin, and
reconstitution of the popliteal. There is also a short block of the left
superficial femoral artery at the adductor hiatus.
a. X-ray angiogram.
b. MR angiogram.
Fig. 8. MR angiogram, with sagittal view of the right side of head and
neck of a normal volunteer. This demonstrates the common, external and
internal carotid arteries, the siphon, the vertebral and basilar arteries and
the posterior superior sagittal sinus and transverse sinus.
Fig. 9. MR angiogram of the carotid bifurcation in a normal volunteer.








. ' V VT
'W • >j ..
i-r-jf ''
Fig. 10. Comparison of 3 cm thick midline sagittal MR angiograms in a
normal volunteer and a patient with occlusion of the superior sagittal
sinus.-
i. MR angiogram in a normal volunteer, using velocity encoding of 25
:m per second. Note good visualization offlow in the superior sagittal
sinus.
j. Same scan as Fig. 10a in a patient with occlusion of the superior
sagittal sinus. Note absence offlow signal from within the sinus.
matrix size of 256 x 256, a TE of 25 ms, a flip angle of
° and four measurements. A slice dephasing gradient is
ed to reduce signal from stationary tissue; the magnitude
this gradient depends on the thickness of the slice,
yestigation of the lower limb arteries from aorta to
furcation using the standard FLAG sequence takes 25
nutes for each position, the whole lower limb being
^ered in two positions making a total imaging time of
der one hour. Untriggered angiograms of the head and
:k can be obtained in under 10 minutes.
suits in the lower limb
ing the original FLAG sequence, high quality images of
femoral, popliteal and lower leg vessels were obtained
all normal volunteers (Figs 2, 3). The veins could be
dily distinguished from the arteries by their relative
msity at different phases through the cycle and there
e very few artifacts. However, as was also found by
Laat3, studies in patients were less satisfactory. The
ility of The images was lower In older patients and those
h more generalized disease. This is probably due to
ient motion.
ipite these difficulties we have obtained many
diagnostic studies, such as the example shown in Fig. 4.
Particularly high quality images were obtained in a series
of 10 patients with femoro-popliteal grafts. All the patent
grafts were clearly shown on the MR angiograms, as
illustrated in Figure 5.
The quality of the angiograms in the thigh and lower leg
was improved with the use of the new sequence with a
shorter TE. However, a major problem still remained, in
that the abdominal aorta and iliac arteries were impossible
to image adequately due to bowel and respiratory motion
(Fig. 2). Rapid sequential excitation showed a dramatic
improvement in the ability to image the iliac and aortic
bifurcation and, for the first time, we were able to
routinely visualize the lower aorta and the iliac arteries.
We have now used this sequence to study several patients,
with excellent results (Figs 6, 7).
Results in the head and neck
Nowadays, most carotid angiography is performed for the
detection of atherosclerosis (bifurcation and siphon) or
intracranial aneurysm. Non-invasive images with Doppler
can compete very strongly with X-ray angiography for
carotid bifurcation lesions, but cannot show concomitant
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Fig. 11. Velocity-phase mapping.
a. Spin echo transaxial scan through the ascending and descending aorta,
used to plan for phase maps.
b. MR phase map corresponding to Fig. 11a. This shows a fairly uniform
white signal indicating flow into the slice in the ascending aorta, and a
black signal indicating flow out of the slice in the descending aorta. The
background and the pulmonary artery show a mid-grey signal indicating
zero flow vector within the slice.
c. Sagittal MR phase map of ascending and descending aorta planned
from Fig. lib.
d. Colour coded MR phase map as in Fig. He, superimposed on the
correspondingly orientated spin echo image.
Fig. 12. Transaxial phase map of the neck showing the common carotid
arteries, vertebral arteries and the jugular veins.
iisease of the siphon or intracranial aneurysms.
vlR angiography could potentially image both areas
Fig. 8) and has been applied to imaging the carotid
lifurcation (Fig 9). Studies in this area, however, have
ieen disappointing for several reasons. First, there is
onfusing overlap of the signal from the jugular vein,
lecondly, the spatial resolution is not sufficient to detect
mall but nevertheless important lesions and, thirdly, flow
isturbances near the carotid bulb are common, causing
ignal loss even in normal volunteers.
'he ability of MR to image within the skull and to obtain
low information in two directions should allow it to be
sed to produce angiograms of the intracranial vessels,
fnfortunately, however, the spatial resolution of this
/stem is not yet sufficient to cope adequately with the
nail size of these vessels or to detect small but clinically
gnificant aneurysms. On the other hand, the cerebral
mous drainage is a large-volume, low-velocity system
hich can be usefully imaged with MR angiography. We
ave obtained high quality angiograms of the superior
igittal sinus in normal volunteers (Fig. 10a). In two
itients with proven thrombosis of the superior sagittal
nus we have demonstrated absence of flow (Fig 10b),
us confirming the diagnosis which is very difficult to




le same pulse sequences used to produce the MR
lgiograms can also be utilized to produce quantitative
lase images whereby the grey scale is proportional to the
locity of the blood, black lepieseating maximum flow in
ie direction, and white representing maximum flow in
e opposite direction. Mid-grey represents stationary
sue.
is important to realize that although both the
giograms and the velocity-phase maps are produced
ing the same pulse sequence, the variable parameters and
ta processing are very different so that it is not, in
ictice, possible to quantitate flow from an angiographic
age.
locity-phase maps have potentially more clinical use
in the MR angiographic technique described above,
dike Doppler methods, time-averaged flow can be
ermined directly by analysing a region of interest
;htly larger than the cross section of the vessel,
is not necessary to measure the exact area of the vessel,
t only the velocity profile within it. This can then be
■d to measure blood flow to individual organs. Time-
12
averaged or instantaneous velocity can be measured if
desired. Phantom experiments and comparison of our
technique with Doppler ultrasound studies in normal
volunteers have shown it to be accurate for quantifying
both time-averaged velocity and flow. Since clinically, and
in most research situations, the primary interest is in time-
averaged flow or velocity, there is no need to synchronize
the sequence to the cardiac cycle, and continuous
acquisition sequences are used in many vessels. This
significantly reduces the time needed for data acquisition
and processing - a typical study taking about 8 minutes
to acquire.
Results
Typical examples of cardiac-gated phase maps of the
thoracic aorta are shown in Figure lib and 11c. Phase
maps can be colour coded to give more immediate visual
impact of the direction of flow and, if desired,
superimposed on standard spin echo images (Fig. lid).
This is likely to have, its most important application within
the heart to study flow disturbances, arising, from
congenital defects.
We have used the technique to measure blood flow in the
common and internal carotid arteries (Fig. 12), middle
cerebral artery (Fig. 13b), renal artery and femoral artery.
;;;
109
Fig. 13. Velocity-phase mapping of the left middle cerebral artery.
a. Sagittal field echo image perpendicular to the left middle cerebral
artery before its division. This image is planned from a series of routinely
orientated transaxial spin echo head scans which, in almost all cases,
adequately demonstrate the course of the middle cerebral artery for
planning purposes. Note the high signal in the centre of the vessel at the
peak of the parabolic flow profile. Nearer the edges of the vessel there is
a large variation of velocities within each voxel which produces dephasing
and, therefore, loss of signal.
b. Corresponding phase map from which flow measurements are
obtained.
Results from the carotid and femoral arteries were
compared with Doppler ultrasound and good agreement
was achieved.
The sensitivity of the technique to velocity changes can be
of great help as an adjunct to the interpretation of MR
angiographic defects. An area of signal loss on an MR
ailgiogiam can be due to a stenosis (the high velocity
leading to signal loss) or an occlusion. Phase mapping can
more clearly define the problem in difficult situations.
(Fig. 14).
Conclusions
We now have a technique which, totally non-invasively
and with no contrast medium, provides a high quality
'projective' angiogram of all the major vessels of the
lower limbs in under one hour. Currently, the technique
has clinical applications in the diagnosis of peripheral
vascular disease and assessment of femoro-popliteal grafts.
X-ray angiography will continue, however, to offer the
potential for angioplastic intervention.
MR angiography has immediate application in the
investigation of cerebral venous sinus disease and long
term potential in the imaging of the intracranial arteries.
It is unlikely to ever compete with ultrasound in the
diagnosis of disease of the carotid bifurcation.
MR phase maps can measure flow and velocity accurately
and non-invasively through large and medium size vessels.
There is a huge potential clinical and research application
for the technique.
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Fig. 14. Comparison of X-ray angiography and MR velocity-phase
mapping in a patient with tight stenosis of the left externa! iliac artery.
a. X*ray angiogram.
b. MR thin section sagittal phase map along the left external iliac artery
demonstrating very high signal at the stenosis where the velocity is very
high. Note the dark signal in the iliac vein lying anterior to the artery.
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Technical notes
the softkeys (function keys) and would eliminate the
time-consuming transfer from the asymmetrical to the
symmetrical mode. If, for example, the xl field wire is
to be moved by a distance <5x the new value for dx is
dx + <5x and the couch has to be moved a distance <5x/2
such that x2 remains constant (Fig. 1). The same would
apply for the x2, y\ and y2 field wires.
This software modification would make it possible to
alter one edge of a symmetrical field without influencing
the remainder and would make a significant impact on
the length of time taken to perform the simulation
procedure, thereby reducing the likelihood of restless¬
ness and subsequent patient movement.
Magnetic resonance imaging of the infant heart at 1.5T
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Magnetic resonance (MR) has been found to be of value
in many fields of medicine but has yet to find an
established place in the study of diseases of the heart.
Published studies of the heart have demonstrated its
ability to identify areas of acute myocardial infarction
(Been et al, 1985b) and old infarcts (Higgins et al, 1984b),
lo recognize hypertrophic cardiomyopathies (Been et al,
1985a), pericardial effusions (Stark et al, 1984) and
constrictive pericarditis (Soulen et al, 1985). Il is, in
addition, possible to measure ventricular volumes
(Longmore et al, 1985) and images containing blood-
flow-related data can be acquired (Ridgway & Smith,
1986; Underwood et al, 1987).
Magnetic resonance imaging (MRI) has been
suggested to have a particularly valuable role in the study
of the anatomy of the congenitally malformed heart
(Higgins et al, 1984a) and imaging studies of a limited
number of cases have been published (Jacobstein et al,
1985a,b; Boxer et al, 1986; Didier & Higgins, 1986;
Didier et al, 1986; Fletcher & Jacobstein, 1986; von
Shulthess et al, 1986). However, in these studies from a
small number of research centres there is very little
experience in the use of MRI in infants. Since 90% of
patients with congenital heart disease present in the first
year of life (Hoffman & Christianson, 1978), if MRI is to
play a role in the investigation of congenital
cardiovascular abnormalities it is essential to be able to
image infants within the first year.
Imaging of the heart has generally been performed
using low- and medium-field strength magnetic
resonance systems with a field strength of 0.6 T or less
(Higgins et al, 1985; Didier et al, 1986; Smith et al, 1986;
Underwood et al, 1987). Cardiac triggering poses few
problems at these field strengths but it has been thought
that difficulties may arise with higher-field systems at
Address reprint requests to Dr M. A. Smith.
1.5 T and above. Despite this, however, the high-field
MR systems have a potentially important advantage for
the study of congenital heart disease in children; the
signal-to-noise ratio from these systems is higher than
from low- and mid-field systems resulting in improved
spatial resolution or shorter imaging times. Both these
advantages are particularly valuable in the study of
infants.
An alternative approach for paediatric imaging is to
use the echo-planar imaging technique (Rzedzian, 1983).
With this method the images can be obtained in 60-
120 ms, so that patient and cardiac motion are frozen. A
drawback with echo-planar imaging is that, as yet, the
image quality is poorer than that obtained using
triggered conventional imaging techniques at the same
field strength. In addition, the technique is not generally
available.
The research described in this paper set out to
determine the feasibility of investigating cardiovascular
abnormalities in young infants making use of the
improved spatial resolution that can be obtained with a
high-field MR system.
Imaging technique
The subjects were imaged using a 1.5 T whole-body
MR system manufactured by Philips Medical Systems
(Gyroscan). To image the heart or the great vessels, the
acquisition of the MR image must be synchronized with
the patient's heartbeat. To achieve this with a high-field
MR system, care must be taken over the positioning of
the electrodes. If the three electrodes are placed in the
conventional position used for triggering in other
imaging modalities, or in MRI at low- and medium-field
strengths, unacceptable distortion of the electro¬
cardiogram (ECG) is produced. The R wave is sharply
defined as required but the T-wave amplitude is greatly
increased and may be the same size as the R wave, thus
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Figure 1. Aortic coarctation in a 6-week-old infant. This section
shows clearly the relationship of the left subclavian artery (LSA)
to the stricture.
Figure 3. Infant aged 6 months with right lower lobe
consolidation. This coronal image demonstrates the
hyperinflated right lung with narrowing of the right main
bronchus (RB), shown on subsequent images to be caused by
the azygos vein and pulmonetry artery.
introducing the possibility of incorrect triggering from
the T wave. This distortion does not indicate a risk to the
patient because it is not caused by the magnetic field
disturbing the electrical conduction within the heart but
by the motion of conducting material, particularly blood
in the great vessels, in the high magnetic field. The
distortion is reduced to an insignificant level by placing
the three electrodes close together around the left nipple.
Pre-gelled disposable silver/silver chloride electrodes
(medicotest Q-10-A) were used and the ECG was
transmitted using a telemetry system. Specialized
electrodes, sometimes proposed for MRI, were not
required.
The standard proton radiofrequency (RF) transmit
and receive head coil was used. This is circular in cross-
section with an internal diameter of 32 cm. The size and
design of the coil enabled the infant to be positioned
inside without difficulty and visual contact was possible
if necessary throughout the investigation.
The infant was wrapped in a blanket and placed on a
thin, firm mattress, which was strapped in a semicircle
round the patient to restrict movement. The majority of
subjects were imaged supine. The first 12 babies to be
imaged were fed immediately prior to the MRI
investigation and the investigation was undertaken
without sedation. However, although this procedure was
successful in most cases, in some, time was needed for
them to settle during the investigation and this difficulty
increased as infants with more severe abnormalities were
studied. Consequently, most subsequent infants were
given sedation of 75 mg/kg chloral.
Simultaneous 5 mm sections were acquired using a
spin-echo sequence with, echo time (TE) of 30 ms and a
field of view of 200-250 mm. A matrix size of 256 x 256
was used but with each image being constructed from
180 signals instead of the usual 256. This resulted in a
reduction in scan time with only a slight reduction in
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Figure 2. Aortic hypoplasia in a !2-week-old infant. The MR
scan clearly demonstrates severe hypoplasia of the whole aortic
arch and descending aorta without any localized narrowing.
The patient's weakened medical condition and reduced lumen
made her a poor candidate for X-ray angiography.
Figure 4. Congenitally corrected transposition in a 10-month-
old infant. A smooth-walled anterior left ventricle (LV) and a
posterior trabeculated right ventricle (RV) are shown with
associated tricuspid (TV) and mitral valves (MV). Other images
in the series showed the pulmonary artery arising from the left
ventricle and the aorta from the right ventricle.
Technical notes
Figure 5. Tetralogy of Fallot in a 19-week-old infant. The
ventricular septal defect, valve cusps of the overriding aorta and
hypertrophied right ventricle are clearly seen.
spatial resolution in the phase-encoded direction. The
MR system was triggered on each heartbeat, even for
heart rates as high as 140 beats per minute. Once in
position, a series of sections was acquired in the
transverse direction from which the angles of obliquity
could be obtained. Double-oblique imaging was then
used to obtain the appropriate angulation, for example,
through the arch and descending section of the aorta.
Two signal averages were performed resulting in a
typical scan time for a set of seven sections of about
6 min. The total investigation time per patient varies with
the complexity of the congenital abnormality; typically,
it is currently between 60 and 90 min.
Measurements were performed on a high-contrast
resolution phantom and a line pair separation of 1.5 mm
and 0.95 mm was obtained in the phase-encoded and
frequency-encoded directions, respectively. The RF
power absorption for children of different age imaged
using the procedure are all below the maximum
recommended specific absorption rate (SAR) with a
typical value for a 6-week infant of 0.08 W/kg.
Results
The technique has been used to image over 40 infants
under the age of 12 months. Electrocardiogram
triggering was successfully achieved in all cases and
respiratory motion artefacts were not found to be a
problem. Constant observation of the patient from the
end of the magnet and monitoring of the ECG ensured
Datient safety. In one instance, an ill, oxygen-dependent
infant was imaged with the attendant clinician inside the
nagnet.
The technique has been successful in imaging a range
)f congenital disorders including coarctation of the aorta
rc = 22), atrial and/or ventricular septal defect (72= 14),
ransposition (77 = 5), Fallot's tetralogy (77 = 3) and
nultiple cardiac defects. Images were obtained
uccessfully from all patients and examples showing the
juality of images obtained are given in Figs 1 to 5.
Discussion
The superior signal-to-noise ratio obtained with a
ligh-field MR system enables good-quality, thin sections
to be obtained in a reasonably short time period, which
we fee! is particularly suitable for the investigation of
cardiac disease in the infant. Imaging soon after feeding
can eliminate the need for any sedation, but for reliable,
rapid throughput imaging, mild sedation is required. A
series of diagnostic quality images can be obtained in a
sufficiently short time to enable MRI to be considered as
a possible routine technique for cardiac investigation in
these children. Although a rigorous comparative study
with ultrasound has not yet been undertaken, our
experience suggests that the amount of anatomical detail
is at least equal to and generally greater than that
achieved using echocardiography. In a number of cases
MRI eliminated the need for an X-ray angiogram.
A study is cufrently in progress to determine the
clinical value of MRI in congenital heart disease in
infants.
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Magnetic resonance imaging at a high field strength
of ventricular septal defects in infants
E J BAKER, VICTORIA AYTON,* M A SMITH,* J M PARSONS, E J LADUSANS,
RH ANDERSON,f MNMAISEY,* M TYNAN, NUALA L K FAGG,{
p E OEVERALL§
From the Departments of Paediatric Cardiology, *Radiological Sciences; §Cardiothoracic Surgery; and
*Hislopathology, Guy's Hospital; and iCardiothoracic Institute, London
SUMMARY Magnetic resonance imaging at a high field strength has potential benefits for the study
of die heart in infants, which is when most congenital heart disease presents. Seventeen infants with
various anatomical types of ventricular septal defect were studied by this technique. Good quality,
high resolution, images were obtained in every case. There were no major practical problems. The
mo lology of the defects in all 17 hearts was displayed in great detail. In some instances, the
interpretation of the images resembled that of equivalent images from cross sectional echocar¬
diography. But this new technique allowed imaging in planes that cannot be obtained by
echocardiography. One particularly valuable plane gave a face on view of the inlet and trabecular
components of the septum. This allowed very precise localisation of defects in these areas. The
relation between the defects and the atrioventricular and arterial valves was exceptionally well
shown in various different imaging planes. One patient in the series had multiple trabecular defects
that were clearly shown.
M gnetic resonance imaging gives detailed morphological information about ventricular septal
deie. .;.
High resolution cross sectional imaging can provide a
precise description of the morphology of defects in
the ventricular septum,1 and echocardiography is a
useful investigation in patients with such defects. But
newer cross sectional imaging methods have not been
evaluated in the study of ventricular septal defects.
Gated cardiac magnetic resonance imaging, with
imag systems of low field strength, can detect
large defects in older patients.23 The structural
diagnosis of congenital heart defects, however, is
usually made in infants.4 This is the age group in
which new imaging techniques need to be evaluated.
We studied an unselected series of infants with
''arious types of ventricular septal defect by a mag¬
netic resonance imaging system that operates at high
field ength.
Path. ..s and methods
PATIENTS
We studied 17 infants with ventricular septal defects
Acquests lor reprints to Dr E J Baker, Department of Paediatric
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undergoing clinical assessment at Guy's Hospital
(table). The selection criteria were the presence of a
known ventricular septal defect and the availability
of the infant for imaging. They were aged between
three weeks and six months. All had a normal atrial
arrangement. Nine had normal cardiac connections.
In three there was a discordant ventriculoarterial
connection, and one of these infants also had a
discordant atrioventricular connection. Two cases
had double outlet from the morphologically right
ventricle, two others had pulmonary atresia, while
the final patient had a common arterial trunk. One
patient has since died and the heart has been
examined (patient 5). Another has undergone sur¬
gical closure of the defect (patient 17).
METHODS
The imaging protocol was described in detail else¬
where.' In all patients an initial series of sections was
acquired in the transverse plane of the body, encom¬
passing the whole heart. Typically, this required
seven sections. Subsequent imaging planes were
chosen in the light of the suspected cardiac abnor¬
mality and the position and orientation of the cardiac
structures as shown on these images. Imaging planes
Morphology demonstrated by magnetic resonance
3 mnth Large muscular inlet defect, multiple small muscular trabecular defects
4 mnth Double outlet of the morphologically right ventricle, anterior aorta, posterior pulmonary trunk overriding a
perimembranous confluent defect
3 wk Pulmonary atresia, aorta arising anteriorly from the right ventricle, no central pulmonary arteries, muscular outlet
defect
4 mnth Perimembranous confluent defect with overriding by the tricuspid valve and malalignment between the atrial
septum and the trabecular ventricular septum
3 mnth Double outlet of the right ventricle with the great arteries arising, side by side, the aorta to the right, complete
muscular infundibulum beneath both great arteries, defect with entirely muscular margins
6 wk Doubly committed juxta-arterial defect with muscular posteroinferior border, coarctation
4 mnth Pulmonary atresia with central confluent pulmonary arteries; aortic valve overrides a perimembranous outlet
defect
6 wk Perimembranous inlet defect with accessory tricuspid valve tissue partially closing it
3 mth Small perimembranous defect with accessory tricuspid valve tissue
1 mnth Muscular outlet defect, complete muscular subaortic infundibulum coarctation
5 mnth Discordant ventriculoarterial connection, muscular outlet defect with posterior deviation of the outlet septum and
subpulmonary stenosis
1 mnth Perimembranous confluent defect with overriding tricuspid valve, overriding aortic valve, and infundibular
pulmonary stenosis j
3 wk Perimembranous defect with overriding common arterial trunk
2 mnth Small perimembranous defect, coarctation ^
5 mnth Discordant ventriculoarterial connection, muscular outlet defect
1 mnth Discordant atrioventricular and ventriculoarterial connections; perimembranous outlet defect with overriding
pulmonary valve
6 mnth Single large muscular inlet defect
Results
Images of adequate quality for morphological study
were obtained in every patient. The electrocardio¬
graphic gating was also satisfactory* in all instances.
i
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Table Details of patients studied by magnetic resonance imaging at high field strength
Case No Age
oblique in one or two axes to the standard planes of
the body were used in every patient. The angles for
these planes were measured individually in each
patient from the earlier images. Optimum imaging of
the cardiac anomaly was achieved typically in total
imaging time of about 90 minutes.
Fig 1 Magnetic resonance image of oblique coronal section
in patient 1. The section includes the ventricular septum and
shows multiple muscular defects (arrows), the largest being in
the inlet septum. There is no defect in the outlet septum; it
appears to be defective because it curves backwards out of the
plane of the section.
Fig 2 Magnetic resonance image of oblique coronal section
in patient 17. There is a single large muscular defect
(arrow). The membranous septum was shown to be intact in
sections orthogonal to this; because it is thin it appears to oe
defective in this plane.
Magnetic resonance imaging of ventricular septal defects
Fig 4 (a) Magnetic resonance images of a sagittal cut of a
confluent perimembranous defect (patient 4). This shows the
outlet extension of the defect, with the outlet septum clearly
delineated (arrow), (b) Oblique transverse,four chamber,
cut in the same patient. There is a large perimembranous
defect between the ventricular inlets with malalignment
between the atrial septum and ventricular septum ' arrowsJ.
Fig 3 Magnetic resonance image of oblique transverse, four
char :T cut, in patient 2 showing that the defect between the
rent cular inlets is perimembranous (arrow). The defect is
"roofed" by the area offibrous continuity between the
atrioventricular valves, which are not offset.
The table lists the descriptions of the morphology
that were discernible from the magnetic resonance
images. The morphological criteria for the descrip¬
tion of ventricular septal defects have been described
in detail elsewhere.' In the two patients in whom
dir observation of the morphology of the defect
Fig 5 Magnetic resonance image of oblique sagittal cut to
show the septum in patient 6 who had a doubly committed
juxta-arterial defect. The area offibrous continuity between
the arterial valves is clearly shown (arrow). There is some
offsetting between the pulmonary and aortic valves in this
section.
was possible at necropsy or operation the magnetic
resonance description of the defects was confirmed.
Although the imaging planes used in each patient
were different, some general principles emerged. For
Baker, Ayton, Smith, Parsons, Ladusans, Anderson, Maisey, Tynan, Fagg, Deverall
The use of oblique imaging planes individually
tailored to the morphology seen in each case was
essential (figs 4, 5, and 6). The morphology of the
ventricular septal defects studied in this series was
very varied. There was no standard imaging protocol
that would have provided the best images in every
patient.
Discussion
This series contains examples of a wide variety of
anatomical types of ventricular septal defects. In
every patient, the magnetic resonance study provided
the morphological details to define the anatomy of
the defects present. The high resolution of the images
obtained, even in these small infants, compares
favourably with those from cross sectional echocar¬
diography. A unique feature of magnetic resonance
imaging is its capability to image in any plane
through the heart. There should in theory, therefore,
be no feature of the morphology of any ventricular
septal defect that cannot be determined within the
limits of resolution of the images. Further experience
will indicate whether this is indeed true. It is already
Fig 6 (a) Magnetic resonance image of a coronal cut to
show the bilateral infundibulum in patient 5. (b) An
equivalent incision in the same heart at necropsy. Ao, aorta;
PT,pulmonary trunk; LV, left ventricle; RV, right
ventricle.
instance, the oblique coronal plane was a particularly
valuable imaging plane (rotated around a vertical
axis, and also occasionally a left to right axis, in the
plane of the inlet and trabecular components of the
ventricular septum). This included a large part of the
septum within the 5 mm thick slice. This imaging
plane clearly showed the position of defects in the
inlet and trabecular septum and their relation to the
central fibrous body. This section needed careful
selection of the imaging plane and was not satisfac¬
torily achieved in every patient. In patient 1, such a
section clearly showed not only a large muscular inlet
defect, but also several small muscular trabecular
defects (fig 1). In contrast, in patient 17 a similar
image showed a single large defect with entirely
muscular margins in the inlet septum (fig 2). An
oblique sagittal plane rotated around both the ver¬
tical and anterioposterior axes was used to show the
ventricles in short axis. A four chamber image,
showing the inlet septum, was obtained from an
oblique transverse plane, rotated around the left to
right and anterioposterior axes (fig 3). Frequently,
even with large defects, the morphology could not be
clearly determined from standard imaging planes.
Magnetic resonance imaging of ventricular septal defects
clear to us that considerable experience is required in
choosing the best imaging plane in individual
pa ,-nts. We believe that the standard series of
imaging planes that have been described by others,6
have no place in the imaging of congenital malforma¬
tion's of the heart. The protocol in each patient has to
be matched to the observed anatomy. This is already
well established in echocardiography. The same
general principles about the interpretation of cross
sectional images of the heart apply to magnetic
resonance images.
po ITION OF THE DEFECT IN THE VENTRICULAR
SEPTUM
Magnetic resonance images in planes that are
equivalent to cross sectional echocardiography
imaging planes can be interpreted by the same
criteria.1 Thus the defect can be judged as solely
opening between the ventricular inlets, solely be¬
tween the subarterial outlets, or extending between
these areas, when they may be termed "confluent"
(fi 5). Although there are no examples in this series,
large isolated muscular trabecular defects should be
demonstrable in such planes. In addition, we showed
a new approach to imaging the ventricular septum
that is exclusive to the technique of magnetic reson¬
ance imaging. Sections in the plane of, and enclosing,
the inlet and trabecular components of the septum
produce images comparable to seeing these areas of
the septum directly. Defects in these areas can then
be recisely localised.
RELATION OF THE DEFECT TO ARTERIAL VALVES
Examples of muscular, perimembranous, and doubly
committed juxta-arterial defects all opening between
the subarterial outlets are included in this series. The
outlet septum cannot be shown face on in the same
way as the inlet and trabecular components of the
septum. This is because, in hearts with normal
connections, the septum curves posteriorly out of the
im. .ing plane. Despite this, extension of defects to
open between the subarterial outlets was exception¬
ally well shown. For example, the fibrous continuity
between aortic and pulmonary valve in a patient with
a doubly committed defect was very clear (fig 5). A
comparison of the necropsy specimen with the mag¬
netic resonance images in a patient with a bilateral
infundibulum shows how well this aspect of the
anaromy was shown (fig 6). Features such as over-
tic g of arterial valves and deviation of the outlet
septum were also well shown.
RELATION OF THE DEFECT TO THE CENTRAL
FIBROUS BODY AND ATRIOVENTRICULAR VALVES
The relation of defects to the central fibrous body
was shown in various planes. So perimembranous
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defects were readily distinguished from other
defects. Perimembranous defects extending into the
inlet septum and roofed by the atrioventricular
valves were well shown in a four chamber imaging
plane. In two patients in this series such defects were
associated with overriding of the tricuspid valve.
This was clearly shown (fig 4). In one of these,
however, there was echocardiographic evidence of
additional straddling of the tension apparatus of the
valve that was not evident on the magnetic resonance
images.
MULTIPLE DEFECTS
In one patient in this series, the magnetic resonance
images clearly showed multiple small trabecular
defects in association with a large muscular defect of
the inlet septum (fig 1). Only one trabecular defect
was shown in this patient on both Doppler colour
flow mapping and cineangiography. It is, therefore,
possible that magnetic resonance imaging will prove
of special value in detecting the presence of multiple
defects. Great care is needed to differentiate
trabeculations on the right ventricular surface of the
septum from true small trabecular defects. By fol¬
lowing the defects in contiguous sections from the
cavity of the left ventricle to that of the right we were
confident that in this patient they were true septal
defects. If this is not always done, trabeculations will
be falsely identified as septal defects.
THE PLACE OF MAGNETIC RESONANCE IMAGING
There are few practical problems with this imaging
technique. The patient must be prevented from
moving. We found that light sedation was sufficient
for this. The infant does not suffer any discomfort
during the imaging procedure and, if well prepared,
will generally sleep soundly. The heart rate is con¬
stantly monitored and the patient's colour and res¬
piratory motion can be observed from outside the
magnet. Cardiac gating was a potential problem
because of possible distortion of the electrocar¬
diogram. But we have not found any major difficulty
with this. Occasionally the position of the electrodes
has to be adjusted to give the best signal, but we have
always been able to obtain satisfactorily gating.
Magnetic resonance imaging can, therefore,
provide excellent images of ventricular septal
defects. Much of the information they contain is
comparable with that from cross sectional echocar¬
diography. The images, however, are of high resolu¬
tion, and new imaging planes that are not possible
with echocardiography can be used. This new tech¬
nique enables a very detailed assessment of the
morphology of ventricular septal defects to be made
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cineangiography in the assessment of infants with
ventricular septum defects.
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Magnetic resonance imaging of coarctation of the
aorta in infants: use of a high field strength
E J BAKER, VICTORIA AYTON,* M A SMITH,* J M PARSONS, MNMAISEY,*
E J LADUSANS, RH ANDERSON,f M TYNAN, A K YATES,J P B DEVERALLJ
From the Departments of Paediatric Cardiology, *Radiological Sciences, and %Cardiothoracic Surgery, Guy's
Hospital, and tNational Heart and Lung Institute, London
summary Nineteen infants with suspected coarctation of the aorta were studied with electrocar-
diographically gated magnetic resonance imaging on a 1-5 T whole body imaging system. In all
cases imaging was successful and produced diagnostic images of high resolution. Coarctation was
shown in 12 cases. The position and shape of the coarctation were well displayed by the magnetic
resonance images. In addition, they clearly showed the relation of the coarctation to arteries arising
from the aortic arch and to the length and diameter of the aortic isthmus and the distal aortic arch.
The anatomy was confirmed at operation in all 12 patients, except for two with a small ductus
arteriosus (arterial duct), which was not seen in the magnetic resonance images. In the seven
remaining patients, coarctation was excluded.
Magnetic resonance imaging produced high quality images that showed the anatomy better than
other non-invasive methods. It provided all the anatomical information required for surgical
correction.
Magnetic resonance has been promoted as an impor¬
tant advance in the imaging of congenital malform¬
ations of the heart and great vessels.1 As yet, however,
there is little evidence that it will either supplant or
supplement established imaging techniques. There is
no experience in very young children, the age group
in which most cases of coarctation now present.2 We
report our experience of imaging the aorta in a group
of infants with suspected coarctation with a high field
strength magnetic resonance imaging system. The
superior spatial resolution of such a system makes it
particularly suitable for this age group.
Patients and methods
PATIENTS
Nineteen infants, aged between three days and 10
months, were imaged (table). In every case there was
clinical or echocardiographic suspicion ofcoarctation
of the aorta. Infants who were in severe heart failure
that required intravenous inotropic support or ven-
Requests for reprints to Dr E J Baker, Department of Paediatric
Cardiology, Guy's Hospital, London SE1 9RT.
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tilation were not included; otherwise there were no
selection criteria. Four of the patients studied
(patients 4, 5, 6, and 10) subsequently had aorto-
grams. Surgical correction was performed in all
the cases in which coarctation was confirmed by
magnetic resonance imaging.
METHODS
The infants were fed just before the imaging
procedure and, ifnecessary, sedated with 75 mg/kg of
chloral hydrate. They were imaged by a 1-5 T whole
body imaging system (Gyroscan) manufactured by
Philips Medical Systems. Electrocardiogram elec¬
trodes were placed closely around the left nipple, an
arrangement that minimises the distortion of the
electrocardiogram produced by the movement of
blood within the high magnetic field. The electro¬
cardiogram was transmitted by a telemetry system.
The infants were wrapped in a blanket and their
movement was restricted by a firm foam mattress
curved in a semicircle around them. They were
imaged while supine in a 32 cm diameter proton head
coil.
Electrocardiographically gated sections (5 mm
thick), separated by 0-5 mm, were simultaneously
acquired by a spin echo sequence with an echo time of
97
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Table Details ofpatients studied
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Surgical
findings
Number Age Anatomy shown by magnetic resonance where different
1 3 wk Discrete shelf, mild isthmal hypoplasia Small arterial duct
2 3 wk Waist lesion, no isthmus, mild distal arch hypoplasia Agree
3 8 days Discrete shelf, severe isthmal hypoplasia, patent arterial duct Agree
4 17 days Mild isthmal narrowing, no coarctation —
5 6 days Discrete shelf, anomalous right subclavian artery proximal to coarctation Agree
6 2 mnth Anomalous pulmonary veins to coronary sinus, coarctation excluded —
7 5 days No coarctation —
8 6 wk Discrete shelf, mild isthmal hypoplasia, ventricular septal defect Agree
9 10 mnth Waist lesion, no isthmus
Hypoplasia of abdominal aorta, no coarctation
Agree
10 3 mnth —
11 3 days Normal aortic arch —
12 3 mnth Discrete shelf, mild isthmal hypoplasia Agree
13 1 mnth No isthmus, hypoplasia ofdistal arch, ventricular septal defect, subaortic infundibulum Small arterial duct
14 2 mnth Mild isthmal hypoplasia, discrete shelf, small ventricular septal defect Agree
15 10 days Mild isthmal hypoplasia, no coarctation —
16 2 mnth Severe isthmal hypoplasia, discrete shelf Agree
17 12 days Normal aortic arch —
18 7 wk Waist lesion, hypoplasia of distal arch, no isthmus Agree
19 6 wk Discrete shelf, distal arch and isthmal hypoplasia Agree
30 ms. The matrix used was 256 x 256, with a typical
pixel size of 0-75 mm. To reduce acquisition time we
used 180 phase encoding gradients instead of the
usual 256 to produce the image. Two acquisitions
of each phase encoding step were averaged. This
resulted in a typical scan time for one set of seven
sections of about six minutes.
In every case, the initial series of sections was in the
transverse plane of the body, encompassing the
structures between the arch of the aorta and the
diaphragm. This, typically, required seven to nine
sections. Subsequent imaging planes, oblique to the
standard planes of the body, were chosen to show the
area of suspected coarctation. The angles for these
planes, chosen individually in each patient, were
determined directly from the initial series of trans¬
verse images. The most valuable imaging plane for
the aortic arch was found to be an oblique sagittal,
rotated around a vertical axis, to show the aortic arch
(figs 1-5). Occasionally, the imaging plane had to be
additionally rotated around an anterioposterior axis
to show the aortic arch optimally. A coronal plane,
which showed the descending aorta, was also useful
in some cases.
In all the patients with coarctation, the area of
narrowing was shown in the oblique sagittal plane
and at least one other plane, either the transverse or
coronal. In most patients it was imaged in all three
planes.
Results
Images of diagnostic quality were obtained in every
patient. There were no imaging failures. In all
patients the electrocardiographic gating was satisfac-
Fig 1 A normal aortic arch in a three day old infant
(patient 11). This image is in an oblique sagittal plane
rotated around a vertical axis. There is some mild isthmal
narrowing but no coarctation. Cross sectional
echocardiography did not rule out the presence of coarctation.
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Fig 2 An oblique sagittal section in a three month old infant
with coarctation. There is a discrete shelf across the
descending aorta. The length of the aortic isthmus and the
relation of the coarctation to the left subclavian artery is
clearly seen. There is only very mild isthmal hypoplasia.
Fig 3 An oblique sagittal section in another patient aged 10
months with coarctation. In contrast with the anatomy in
figure 2, there is a waist like narrowing of the descending
aorta. The origin of the left subclavian artery arises at the
level of the coarctation and so there is no isthmus.
Fig 4 An oblique sagittal section in an infant with a very
long, hypoplastic isthmus (between the arrows). The
coarctation forms a discrete shelf rather than a waist.
tory. The diagnosis of coarctation was confirmed in
12 infants. It was excluded in seven. In the first case
in which it was excluded (patient 4), we lacked
experience in interpreting the magnetic resonance
images and so the clinical picture prompted inves¬
tigation by angiography. The aortogram confirmed
normal aortic anatomy. In all the subsequent cases
the diagnosis based on magnetic resonance imaging
was accepted. Angiography was performed in two
other negative cases (patients 6 and 10) to define
aspects of the cardiac anatomy other than the aortic
arch. In one positive case the arrangement of the
branches of the aortic arch was unclear. An aorto¬
gram was performed before surgical correction to
clarify this. The right subclavian artery arose
anomalously just proximal to the coarctation and, in
retrospect, this could be seen in the coronal images of
the coarctation in this patient. In all the remaining
positive cases, surgical correction was performed
without further investigation.
Surgical correction confirmed the anatomy in all
the patients with coarctation. But in two patients
small arterial ducts (ductus arteriosus) were found at
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Fig 5 An oblique sagittal section in an infant with
coarctation in the form of a shelf (lower arrow). There is no
isthmus and a dilated left subclavian artery (upper arrow)
can be seen arising just proximal to the shelf. In this case
there is considerable hypoplasia of the distal aortic arch
proximal to the origin of the left subclavian artery.
operation that were not seen in the magnetic reson¬
ance images. In practice this was not of clinical
importance. In one patient a large arterial duct was
shown by magnetic resonance imaging (case 3).
The presence or absence of obstruction in the
thoracic aorta could invariably be shown in the initial
transverse series of images. Further oblique sagittal
images were, however, obtained in all cases to display
the anatomy of the aortic arch clearly. From such
images the diameter and length of the aortic isthmus
were evident. The coarctation shelf, itself, gave a
very intense magnetic resonance signal in these T1
weighted images. Images obtained in the coronal
plane were valuable in defining the relation of the
coarctation to the vessels arising from the aortic arch,
particularly the left subclavian artery.
Discussion
To date magnetic resonance imaging of the heart has
generally been performed with systems that use low
and medium field strengths, < 0-6 T.34 It was
thought that it would be difficult to achieve cardiac
gating in strong magnetic fields such as 1-5 T. This is
because the electrocardiographic signal is distorted
by the flow of blood in the high magnetic field. But
the newer, high field strength imaging systems have a
potentially important advantage for the study of
congenital heart disease. The signal to noise ratio
from these systems is considerably better than from
those that use low and medium strength fields and so
a more favourable compromise between spatial
resolution and imaging time can be achieved. These
advantages are especially valuable when infants are
studied. A major criticism ofpublished reports is that
there is almost no experience in the use of gated
magnetic resonance cardiac imaging in infants.
Indeed, most workers specifically avoided imaging in
this age group. Because almost all patients with
congenital heart disease present in the first year of
life,2 the anatomical diagnosis of cardiac defects is
now generally performed in infancy. An imaging
technique, to be of value, must be capable ofproduc¬
ing high quality images in this age group.
As we have shown, magnetic resonance images can
define the position of the coarctation in the aortic
arch, its relation to the arterial duct and the arteries
arising from the arch, the length and diameter of the
aortic isthmus, and whether the coarctation is a
discrete shelf or a waist lesion.5 Identification of the
coarctation is greatly helped by the intensity of the
signal from the shelf itself. In infants, this is usually
made up of tissue originating from the arterial duct
(ductus arteriosus).6 We always made certain that the
shelf could be seen in images in at least two different
planes, thus ensuring it was not an artefact produced
by the oblique transection of the aorta. In practice,
this does not seem to be a problem. In none of our
normal patients were the appearances of the aortic
arch ambiguous.
We believe that our experience shows that high
field strength magnetic resonance imaging can con¬
sistently produce high resolution cardiac images in
infants. In this series, we have shown that it is
possible, with great clarity, to image the aortic arch.
The images were of much higher resolution than
those obtained with cross sectional echocardio¬
graphy.7 In addition, magnetic resonance imaging is
non-invasive and safe. It does not use any ionising
radiation. It provides all the anatomical information
required for surgical repair of the anomaly. It thus
has many advantages for studying this age group. Its
clinical role requires further evaluation.
This research was supported by the British Heart
Foundation. The imaging system was purchased
with the assistance of Sir Philip and Lady Harris and
the Special Trustees of Guy's Hospital,
References
1 Didier D, Higgins CB, Fischer MR, Osaki L, Silverman
Magnetic resonance imaging of coarctation
NH, Cheitlin MD. Congenital heart disease: gated
MR imaging in 72 patients. Radiology 1986;158:
227-35.
2 Hoffman JIE, Christianson R. Congenital heart disease
in a cohort of 19,502 births with long term follow up.
Am J Cardiol 1978;42:641-7.
3 Boxer RA, LaCorte M, Singh S, et al. Nuclear magnetic
resonance imaging in evaluation and follow-up of
children treated for coarctation of the aorta. J Am Coll
Cardiol 1986;7:1095-8.
4 von Shulthess GK, Higashino SM, Higgins SS, Didier
D, Fischer MR, Higgins CB. Coarctation of the aorta:
101
MR imaging. Radiology 1986;158:289-96.
5 Sinha SN, Kardatzke ML, Cole RB, Muster AJ, Wessel
HU, Paul MH. Coarctation of the aorta in infancy.
Circulation 1969;40:385-98.
6 Elzenga NJ, Gittenberger-de Groot AC, Oppenheimer-
Dekker A. Coarctation and other obstructive aortic
arch anomalies: their relationship to the ductus
arteriosus. Int J Cardiol 1986;13:289-308.
7 Smallhorn JF, Huhta JC, Adams PA, Anderson RH,
Wilkinson JL, Macartney FJ. Cross-sectional
echocardiographic assessment of coarctation in the
sick neonate and infant. Br Heart J 1983;50:349-61.
68
0145-6008/89/! 303-0512S2.00/0
Alcoholism: Clinical and Experimental Research
Vol. 13, No. 4
July/August 1989
Magnetic Resonance Imaging of the Brain in Alcoholics:
Cerebral Atrophy, Lifetime Alcohol Consumption, and
Cognitive Deficits
J. D. Chick, M. A. Smith, H. M. Engleman, D. M. Kean, A. J. Mander, R. H. B. Douglas, and J. J. K. Best
Magnetic resonance imaging of the brain in 69 detoxified alcoholics
revealed that relaxation time (Ti) in whole brain and in grey matter
and parietal white matter was greater than in age-matched controls.
In 48 patients, data on cognitive function and lifetime alcohol con¬
sumption were available. With age-controlled, lifetime consumption,
and impairment on performance in the cognitive test (a Category
Sorting Test) correlated positively with T, in whole brain and in
selected regions. Impairment in the cognitive test correlated with
increased T, in whole brain and white matter independently of cere¬
bral atrophy. Alcohol consumption patterns in the following 6 months
were unrelated to changes in 7V The excess water implied by the
elevated T, values may be intra- or extracellular. It is uncertain
whether or not 7, elevation in alcoholics is a marker of neuronal
damage. T, elevation appears to be a marker of one type of alcohol-
related cognitive impairment.
T^XCESSIVE DRINKING is associated with impaired
■*—1' cognition.1 There is evidence in some drinkers that a
defect in cognition predates the heavy drinking.2 However,
improvements in cognition occur in some alcoholics who
become abstinent.1-3 Also indicators of predrinking intel¬
ligence such as early academic attainment and retained
verbal skills suggest that the excessive drinking is at least
as much a cause of certain types of cognitive impairment
as a consequence thereof.1-2
Brain shrinkage is also well established,4j and modest
correlations between measures of shrinkage (especially
central shrinkage) and cognitive impairment have been
found.1-3 The cause of this-shrinkage is unknown. How¬
ever, the cerebellar atrophy of alcoholism is due at least
in part to neuronal death.6 Neuronal death may contribute
to the cerebral shrinkage of the alcoholic, a possibility that
was raised over 80 years ago.7 Animal studies have shown
that ethanol consumption can cause nerve cell dysfunction
and death.8"1'
A potential marker of nerve cell death in alcoholic
patients is, of course, the shrinkage visible in computer
tomographic (CT) scans. However, a search for another
marker seems justified since the correlations between cog-
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nitive impairment indices and CT measurements is, as
mentioned, modest at best. An alternative marker might
be provided by magnetic resonance imaging (MRI) of the
brain. Furthermore, the observation that the histology of
neuronal death may show oedematous cells12 suggests a
particular importance for MRI.
In magnetic resonance imaging of living tissue the pa¬
rameter known as T, relaxation time is related to the state
of water in the tissue.13 The 7j value, measured in milli¬
seconds, increases as the proportion of free to bound water
within the tissue increases. MRI scanning of brain in the
intact patient before neurosurgery has shown that in vivo
7j measurements predict the degree of brain hydration.14
Besson et al.13 were the first to report brain T, measure¬
ments in a small group of alcoholics but reported only on
change in the phase immediately after cessation of alcohol
intake.
The present study had four hypotheses: (a) that the
detoxified alcoholic brain some 2 weeks after the last drink
would be overhydrated compared to age and sex matched
non-alcoholics; (b) that in detoxified alcoholics the degree
of overhydration in the brain would be related to the total
lifetime consumption of alcohol; (c) that this overhydra¬
tion would predict cognitive impairment; (d) that ex¬
tended abstinence in the posttreatment phase would be
associated with reduction of overhydration and improve¬
ment in cognitive functioning.
SUBJECTS AND METHODS
Alcoholic patients admitted for detoxification to the Alcohol Problems
Clinic at the Royal Edinburgh Hospital were fully informed about the
purpose and procedures of the study and invited to participate. Signed
consent was obtained. The project was approved by the appropriate
Ethics of Research Committee.
Hypothesis 1
Sixty-nine patients (46 males, 23 females) were scanned at the end of
detoxification—a mean interval of 14 days after the last alcoholic drink.
These 69 patients had a minimum of 5 years of recent heavy drinking.
Their mean age was 44 years (range, 22-70; SE, 1.16). None had the
clinical features of Wernicke-Korsakoff syndrome, had a history of drug
abuse, were clinically malnourished, or had physical disorders other than
raised serum liver enzymes. They had all been drinking at least 130 g of
ethanol per day during drinking episodes. In Britain, a "standard drink,"
i.e., a half pint of beer, a glass of wine, or a single measure of spirits,
contains 8-9 g ethanol. They spanned the range of socioeconomic
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backgrounds, and though half were unemployed none were without a
. fixed address.
Hypotheses 2, 3, and 4
A subgroup of 48 of the above patients (32 males 16 females) was
invited to have cognitive testing and to attend for repeat MRI scans and
cognitive testing at 6 months, (though in the event only 26 patients kept
the following appointments for both scans and testing). These patients
were selected on the basis of their willingness and likely ability to attend
for further testing. Their mean age was 44 years (range, 22-70; se, 1.36).
They had mean red cell volumes ranging from 88 to 111 fl (mean, 98.9;
se, 0.98; n = 42) and serum •y-glutamyl transpeptidase (GGT) values
ranging from 5 to 1000 units (median, 100; mean, 217; se, 42; n = 43).
The consumption pattern of this group was studied in more detail. They
were asked to give anchor dates throughout their adult lives and com¬
mencing with the year in which they first drank alcohol, to reconstruct
their typical pattern of drinking month by month during each of the
succeeding years. The method is based on that of Skinner and Sheu.16
Thus an estimate was obtained of cumulative total lifetime alcohol
consumption. Inter-rater reliability of this method in 10 patients whose
responses were rated by two independent assessors showed an average
agreement between assessors of 87%. (Taking the past year's consump¬
tion enabled some of the relationships of interest to be analyzed using a
recent, rather than a lifetime consumption measure. However, to reduce
the total number of tests of significance made, it was decided to concen¬
trate on our cumulative lifetime measure of consumption).
Normal MRI values were available from a group (n = 26) recruited
from hospital staff and patients' relatives. Their usual alcohol consump¬
tion ranged from nil to 80 g ethanol per week. Their ages ranged from
23 to 74 years with a mean of 42 years, and a similar distribution to that
of the patients. The ratio of women to men in the normal sample was
14 males to 12 females, that is, a higher proportion of women than in
the patients. However a two-tailed t test of the differences in the females
and males of the control group found that there were no significant
differences in their whole brain 7j measurements (p = 0.88) so the
differences in the proportions of the sexes in the control and the alcoholic
samples are not considered to be of importance. They may have been of
slightly higher mean socioeconomic status than the patients but this was
not thought likely to bias the results, though no study of MRI and
socioeconomic status has to our knowledge been reported.
Our index of cognitive function was the microcomputer-administered
Maudsley Category Sorting Test.17 .'8 This provides a measure of abstract
reasoning ability and rigidity of thought processes and it is of interest
because rigidity of thinking in alcoholics is a major impediment in the
psychological treatment of the condition. The subject is required to
deduce the categorization system being used by the computer program
and to shift his or her set when the program changes. The program offers
six different methods and the number of times out of six in which the
subject correctly arrives at the solution is counted (CATEGORIES). The
number of trials needed to achieve that number of correct solutions is
counted (SORTS). The total number of errors made is summed (ER¬
RORS). The number of perseverative errors (errors repeated despite
feedback from the program) is totalled (PERSEVERATIONS). We have
concentrated on the Category Sorting Test because it has been shown
that deficits in this type of function correlate well with CT parameters of
atrophy," and are common to both older and younger alcoholics whereas
impairments on tests of memory and general intellect tend to be seen
only in older patients.3
Alcohol consumption in the follow-up period was estimated from the
clinic treatment records, and interviews with the patient conducted by a
research assistant at 3 months and 6 months. This information was
corroborated where possible by an additional interview with a relative
and by changes in the serum GGT in those patients who had an elevation
ofthis marker20 at intake to the study. For some patients onlya qualitative
report on consumption was available. Patients were categorized as follows
for each of the 3-month period: total abstinence;, "intermediate" drinking
(1-40 g per day); "heavy" drinking (over 40 g per day).
MRI measurements were performed using a 0.08 Tesla-resistive MRI
system.2' Three or four transverse sections were obtained through the
brain centered to the maximum diameter of the lateral ventricles. The
slice thickness was 12 mm and pixel size was 2x2 mm. An interleaved
saturation recovery and inversion recovery pulse sequence, with a repe¬
tition time of 1000 ms for both and a time from inversion of 200 ms for
the latter, was used to obtain a calculated 7j map of each section.
Measurements of the patient's brain 7j were made from a section
approximately 10 mm above the maximum diameter of the lateral
ventricles. The 7j in grey and white matter in the frontal and parietal
regions was measured from the T, map using small regions of interest
generated by the computer. Different size regions of interest were used
for grey matter (20 mm2) and for white matter (69 mm2) and the mean
of similar regions in the left and right hemisphere was noted. Larger
irregular regions of interest were also measured to attain mean T, values
of each cerebral hemisphere. To achieve this an electronic cursor was
used to delineate the border ofeach hemisphere directly on the computer-
reconstructed image of the bram as displayed on the monitor. Obvious
areas of CSF (which have a very high 7j and appear white on the
coloured image) were avoided. As a further precaution to exclude CSF,
the computer was programmed to display the mean 7j for each hemi¬
sphere only for values within the range 60-600 ms. An example of a 7j
map in a patient including the regions of interest used for analysis is
shown in Fig 1.
The precision of the T, measurements was estimated from four
repeated measurements on three normal volunteers over a period of a
month. The 7j precision of white matter was 2.8%, grey matter was
4.9%, and the whole brain 2.6%.22 The poorer precision of the measure¬
ments of grey matter are due to the fact that it is generally of small
volume and adjacent to CSF resulting in partial volume errors. In
addition smaller regions of interest are used resulting in a larger error.
The interoperator variation of our Ti measurements was assessed in two
independent operators in 20 sections from five different patients. The
percentage differences between rates were: whole brain 1.9%; frontal,
occipital, and parietal white matter 2.5%; temporal white matter 5.2%;
grey matter (all areas) 5.5%. All ratings were blind to the clinical state of
the patient, consumption measures, and cognitive test scores. However,
control scans were identified as such, and dates of all scans were also
known to the raters. T, maps were analyzed by three operators; results
from the same patient were always analyzed by the same operator.
Atrophy Measurements
Commonly used indices of cerebral atrophy23 were made by caliper
measurement on MRI scans: (a) Third ventricle, widest diameter, (b)
Fig. 1. An example of an MRI scan in a patient indicating region of interest
marker.
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The Ventricular Index, the distance between the choroid plexuses divided
by the maximum width between the frontal horns; (c) The Huckmann
Index, the sum of the maximum and minimum widths of the frontal
homs; and (d) The mean width offour cortical sulci was measured on a
slice 16 mm above the upper limit of the lateral ventricles, choosing the
two widest sulci on each side.
As an attempt at assessing, the- reliability- of these measures in our
hands, we checked the correlations between the indices of internal
atrophy. The Huckmann index correlated r — 0.33 (jp < 0.05) with the
ventricular index and r = 0.47 (p < 0.01) with "3rd ventricle" (n = 46).
Differences in T, values within groups of patients at different times
were compared using Student's t test. Changes in T, were assessed using
a paired Student's t test. The relationship between changes in T, values,
drinking and changes in cognitive function were assessed using, linear
regression analysis. Partial correlation analysis was used to investigate
the relationship between cognitive function and 7) value and cognitive
function and previous drinking history to control for the effect of age
and atrophy.
RESULTS
The T, values obtained from the patients at 2 weeks
and 6 months are given in Table 1 with the results from
normal controls for comparison. The most pronounced
differences between normals and alcoholic patients are
seen in the whole brain and in grey matter T\ values.
Relationship between T\, Age, and Alcohol Consumption
In the subgroup studied intensively the mean lifetime
drinking total was 775 x 103 g (se, .104 x 103; range, 71
x 103—3329 x 103). The Tx values at the time of the first
scan correlated positively with the patient's age, signifi¬
cantly so in frontal white matter (r = 0.49, p < 0.01) and
in posterior white matter (r= 0.41, p < 0.05). Eliminating
the effect of age using partial correlation, a significant
positive correlation was found between whole brain T, in
the detoxified patient and the patient's cumulative total
life's consumption r = 0.36, (p < 0.01). (The past year's
consumption, which not unexpectedly correlated signifi¬
cantly with lifetime consumption, correlated positively
with parietal white matter 7", but not significantly w
whole brain 7i). (n = 47).
Relationship between Tand Cognitive Impairment
In the alcoholics given cognitive testing, impairment
each of the scores on the Category Sorting Test was relat
to an increase in 7) in all regions of the brain. The findir
are shown in Table 2. The effect of age has been controll
for. Correlations of each of the test measures with whc
brain Tx and with frontal white 7) were significant
either the 99% or 95% levels. The relationships remaim
significant when the sexes were examined separately. Bo
lifetime consumption and past year's consumption con
lated significantly with each of the test measures with a;
controlled.
Role ofAtrophy
Table 3 shows that internal atrophy as measured by tl
Huckmann index appears to be associated with increase
Ti in white matter, and with impairment in the numb
of categories achieved in the sorting test. However, t
chance, in the 36 correlations shown in Table 3, tw
would be significant at the 5 % level.
There is little evidence of a relationship between oth<
measures of atrophy and either T\ values or cognitive te
impairment. However, the correlation of 0.26 betwee
sulcal width and 7) in frontal grey matter is probabl
meaningful in that when patients are divided about tb
median for sulcal width, the Tx (frontal grey) is 10 poin;
higher for those with sulcal width above the median tha
.for those below the median (t = 3.3, p < 0.01). Th:
supports the possibility that CSF in the subarachnoi
space, increased in cortical atrophy, might tend to increas
Ti measurements in grey matter.
Can atrophy account for the relationships shown i:
Table 2 between 7", increase and cognitive impairment
Table 1. Mean ± se (Range) of T-, in Whole Brain and Regions of Interest and in the Whole Sample of Alcoholics at a Mean of 15.0 Days after Admission
Timing
Whole brain Frontal white Parietal white Frontal grey Parietal grey (days after admission)
Control group (n = 26) 306 ± 1.69 268 ± 1.58 269 ± 1.97 341 ± 2.09 334 ±1.50
(290-324) (252-283) (248-296) (326-371) (310-351)
Patients—whole sample (n = 69) 321 ± 1.67* 265 ± 1.49 276 ± 1.45 367 ± 2.28* 360 ± 1.76* 15.0 ± 0.06
(283-383) (230-326) (230-326) (314-400) (321-392) (6-24)
Patients—subgroup with cognitive 325 ±1.01* 266 ± 1.93 277 ± 1.81* 373 ± 2.41* 361 ± 2.25 15.7'± 0.3
test (n = 48) (304-383) (230-326) (230-326) (315-400) (326-392) (6-24)
Patients—subgroup attending for
follow-up [n = 26)
First scan 322 ± 1.74* 265 ± 1.89 276 ±1.62 372 ± 2.99* 366 ± 2.90* 14.0 ±0.9
(304-383) (249-284) (256-288) (336-400) (335-392) (6-23)
Follow-up scan
< 40 g ethanol per day 324 ±1.31* 266 ± 1.88 280 ±2.71* 373 ± 4.17* 365 ± 296*
(312-333) (254-285) (262-301) (349—406) (348-390) f 192 ± 4.0
> 40 g ethanol per day 330 ± 5.55* 270 ± 3.84 277 ± 3.18 374 ±4.31* 363 ± 4.04 [ (147-253)
(311-378) (251-298) (258-293) (346-393) (342-392)
Patients greater than controls, p < 0.01; Tp < 0.05.
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Table 2. Age Controlled Correlation Coefficients of 7", Values and Estimated Lifetime Consumption with Scores on Components of the Category Sorting Test in
Alcoholics at a Mean of 15.7 Days after Admission (*p<0.01; rp<0,05). (Impairment Results in a Lower Score on Categories, and a Higher Score on Sorts, Errors, and
Perseverations).
Category Sorting Test scores [mean














































Table 3. Age-controlled Correlation Coefficients of Atrophy Indices,T, Values, and
Cognitive Test Scores (n = 46)
Huckmann Ventricular Third V Sulcal width
r,
Frontal white 0.33* 0.27 0.14 0.09
Frontal grey -0.13 0.04 -0.09 0.26
Parietal white 0.39' -0.10 0.26 0.23
Parietal grey 0.10 -0.15 0.06 0.12
Whole brain 0.03 -0.04 -0.01 0.06
Categories -0.30* 0.02 -0.21 -0.09
Sorts 0.16 I O o o o -ri. 0.03
Error total 0.15 -0.01 0.06 0.07
Perseverations 0.11 Oooo01 0.08
*p< 0.05;'p.< 0.01
Table 4. Correlation Coefficients of T, Values (White Matter and Whole Brain)
with Cognitive Test Scores, Controlling for Age and Huckmann Index (n = 46)
Whole brain Frontal white Parietal white
Categories -0.43* -0.55* -0.44
Sorts 0.32' 0.40* 0.30'
Errors 0.36' 0.47* 0.40*
Perseverations 0.38* 0.46* 0.40*
*p < 0.05; 'p < 0.01
Table 5. Correlation Coefficients of T, Values in Whole Brain and Grey Matter
with Cognitive Test Scores, Controlling for Sulcal Width and Age (a — 46)
Whole brain Frontal grey Parietal grey
Categories -0.43* -0.21 -0.20
Sorts 0.33' 0.20 0.17
Errors 0.37+ 0.21 0.23
Perseverations 0.40* 0.19 0.27
*p < 0.05;'p< 0.01.
Table 4 shows that internal atrophy did not account for
the relationship between raised 7j in white matter and
cognitive impairment. Table 2 showed, as already men¬
tioned, correlations in the expected direction though in
general not significant between 7) in grey matter and
cognitive impairment. Table 5 shows little alteration in
the size of these correlations when cortical atrophy as
measured by sulcal width is controlled for. I\ in whole
brain also remains significantly related to cognitive im¬
pairment despite the possible confounding effect of atro-
phy.
The relative lack of importance of atrophy in this study
may partly reflect our measurements. We used indices
previously used in CT scans, and by comparison MRI
scans lack definition. Our measurements were made by
caliper rather than by computer.
Changes in T\ and Cognitive Function in Relation to
Degree ofAbstinence
There were 26 patients who reattended for the repeat
scan and on whom we had data on consumption of alcohol
in the interval (Table 1).
Whether or not patients were deemed to have, resumed
drinking heavily, the trend was for whole brain Ti to rise
slightly over the 6-month period. Whole brain 7i meas¬
urements at 6 months in those 15 patients who had been
abstinent or who had drunk on average less than 40 g of
ethanol per day had risen by a mean of 2.33 ms (range,
— 11 to 29; se, 2.87) (see also Fig. 2). The mean serum
GGT of this group was within the normal range (21 IU/
liter, n — 14). In those 11 patients who had drunk more
than 40 g per day on average during, the 6-month period
the mean rise in whole brain 7", was 6.27 ms (range, —15
to 60; se, 5.94) (see also Fig. 2). This was not a significantly
greater mean rise (jp = 0.56) than in those drinking less
than 40 g/day. The mean serum GGT of this group was
elevated (178 lU/liter, n = 10). The two patients with the
highest 7) values at follow-up were in this group. They
were men who had severe long-standing dependence on
alcohol for many years and were once again, drinking in
excess of a bottle of spirits per day (280 g ethanol per day)
up to the time of the scan.
There were only nine patients in whom we could be
sure that abstinence or near abstinence had been achieved
for the whole of the 6-month period. The mean change in
whole brain 7) in these patients was —0.78 ms (range, —11
to 10; se 2.85). Figure 2 illustrates the pattern of whole
brain T, changes in individual subjects from the initial
scan to the 6-month scan showing abstainers, "interme¬
diate" and "heavy" drinkers separately. Analysis of vari¬
ance to compare the changes in T\ values in whole brain
and regions of interest over the 6-month period across
these three groups defined by increasing posttreatment
consumption did not reveal a significant trend for any of
the Ti measurements (frontal white, F = 1.65, p — 0.21;
frontal grey F = 1.06, p = 0.36; parietal white, F = 1.92,
p = 0.17; parietal grey, F = 0.26, p — 0.77; whole brain,
F = 0.67, p = 0.52; in each,test df= 2/23).
There were 25 patients who repeated the Category Sort¬
ing Test in a sober state at the time of the 6-month scan.
The mean changes in these individuals' scores were: CAT-

















Fig. 2. Whole brain 7", measurements, separately
for those patients who abstained, drank 40 g
ethanol per day or less, and who drank over 40
g ethanol per day, to illustrate change between
scan at 2 weeks after admission and at approxi¬
mately 6 months later.
EGORIES, +0.44 (range, -1 to +3; se, 0.17); SORTS,
-5.2 (range, -44 to +18; SE, 3.4); ERRORS, -5.2 (range,
-32 to +16; se, 2.5); PERSEVERATIONS, —0.8 (range,
— 15 to +7; SE,N-0). However despite this trend towards
amelioration, no significant correlations were found be¬
tween these changes and changes in 7j.
DISCUSSION
The findings of a raised whole brain T, in newly detox¬
ified patients and of a significant relationship between T\
measurements and both cognitive impairment and the
possible cause of that impairment, total lifetime consump¬
tion, suggest that 7) measurements have both potential
clinical utility and a neuropathological significance. Cog¬
nitive deficits were also linked to increased 7) in white
matter, but not grey matter. The finding that is not cor¬
roborative is the lack of difference between controls and
patients in frontal white matter 7), given that cognitive
deficits appeared to relate to that measure. Grey matter
7j measures, while they did distinguish alcoholics from
controls did not relate (significantly) to cognitive impair¬
ment. This raises the question that our 7j findings are
artefacts due to cerebral atrophy (which would be expected
to affect grey rather than white matter T, measurements).
However, the only T, measurement which we made which
was significantly related to atrophy was that in frontal grey
matter. Thus, while noting that frontal white matter 7)
measurements did not distinguish alcoholics from con¬
trols, we feel we have found a relationship between 7) in
whole brain and in white matter that relates to alcohol
consumption and to cognitive impairment, and that this
is independent of atrophy. We note that Harper et al.4
have stressed that it is loss of white matter, rather than
grey matter, which is most important in alcoholics.




time consumption1-16 but its reliability remains in some
doubt. Although we have little confidence in the absolute
accuracy of the estimates, the rank ordering that the
method yields is possibly more reliable. This is supported
by our finding a correlation of this estimate with Tt values,
and with cognitive test scores (Table 2). Measures of more
recent consumption might be thought to be more reliable.
However, while more reliable because the memory is
fresher, patients' recent consumption often poorly reflects
longer standing patterns of drinking: for example, the
patient coming to a clinic has often been trying recently
to abstain for periods; or, he has presented for treatment
because of one or two especially heavy recent binges. Thus
in the general working population, where patterns of
drinking are fairly stable over time, a marker such as the
serum GGT may correlate well with a measure of recent
drinking20; while in patients admitted to clinics no appar¬
ent relationship is found.24
In the "Subjects and Methods" section we explained
some of the reasons for our choice of the Category Sorting
Test. In addition, its microcomputer-assisted administra¬
tion makes it an inexpensive and convenient test to per¬
form and reduces tester-induced bias; it tests a psycholog¬
ical function of clinical relevance; previous (unpublished)
work in some 150 patients had led us to conclude that
among a range of tests it was sensitive to increasing severity
of alcoholism. It is not a widely used test in the literature,
but it is closely based on the better known Wisconsin Card
Sorting Test.22 Category Sorting Tests are believed to
reflect frontal lobe functioning.17,25 It is notable therefore
that the largest correlations between test scores and Ti in
the region of interest measurements were found in frontal
tissue. Unfortunately, over a period of 6 months, we
believe that a subject who had mastered the test could
later recall his method of doing it and so we hesitate to
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interpret changes in scores in this test during the follow-
up period.
The associations which have been found by other au¬
thors between CT changes and cognitive tests suggest that
it is central atrophy (i.e., loss of white matter), rather than
cortical atrophy (loss of grey matter) which best predicts
cognitive impairment, albeit only explaining less than 20%
of the variance in cognitive performance overall.3 Central
changes appear to regress less quickly with abstinence than
cortical changes.3 Thus, our failure to find significant
correlation between Tt in grey matter and cognitive im¬
pairment is consistent with Bergman3 and also Ron.1
Only slightly over half of the patients invited for a 6-
month scan attended, despite repeated arrangements being
made in some cases. Only very occasionally did the patient
give as a reason that he or she found the enclosed space
of the scanner unpleasant. Nonattenders were mostly pa¬
tients who had resumed drinking and wished to break off
contact with the clinic. It is difficult to obtain reliable
information on drinking in the follow-up phase without,
for example, incorporating at the outset specific monitor¬
ing by relatives, or urine, blood, or sweat testing at frequent
intervals. It would be premature to conclude that our lack
of 7*i reduction in our small number of supposedly absti¬
nent patients indicates that elevated values are permanent
in the established alcoholic. However, other follow-up
studies of abstinent alcoholics have failed to show im¬
provements in cognitive function26 and the classic alcohol-
related deficit, Korsakoff's syndrome, is marked by per¬
sisting permanent alterations in brain cells and persisting
cognitive impairment despite abstinence. On the other
hand, cortical shrinkage as identified by cerebral tomog¬
raphy sometimes resolves with abstinence.3 Also, cerebral
perfusion, diminished in the newly detoxified alcoholic by
comparison to controls, appears to improve with absti¬
nence.27
A number of neuropathological processes may occur
simultaneously in the alcoholic. An increase in the meas¬
ured I*, is a marker of overhydration or oedema of either
intra- or extracellular tissue. It remains speculative
whether an elevated 7j is a marker of damaged neurones.
Christie et al.28 have shown that frontal and parietal grey
and white matter 7*, values are not elevated in patients
with presenile Alzheimer-type dementia when compared
to age-matched controls whereas patients with Korsakoff
psychosis, abstinent for 1-14 years, (mean, 5 years), have
raised cortical T\ values when compared to age-matched
normal controls and to frontal grey and white matter in
patients with Alzheimer's disease. (Christie et al. were able
to distinguish increased 7) measurements from atrophy
in this study of dementia, supporting our conclusion in
the present study that our findings are independent of
atrophy). Measurements of 7), like cortical atrophy, in¬
crease with age as also found in a previous study29 as well
of the present study.
In conclusion we believe we have shown that MRI 7)
measurements, especially in white matter, are elevated in
alcoholics proportionate to their cumulative alcohol in¬
take and to the degree of impairment on a Category
Sorting Test of cognitive function. These findings are
analogous to those of ageing. The precise location of the
extra water which is presumed to underly this change, and
its cause, is unknown. Potentially, MRI Tt is of clinical
value as a marker of alcohol-related brain damage.
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Phospholipids are visible in 31P n.m.r. spectra of human breast tumours
MARTIN LOWRY,* DAVID A. PORTER,f
CHRISTOPHER J. TWELVES,* PHILIPPA E. HEASLEY,t
PAMELA B. GARLICK,t MICHAEL A. SMITH,f
ROBERT D. RUBENS,* MICHAEL N. MAISEYf and
MICHAEL A. RICHARDS*
*/. C.R.F. Clinical Oncology Unit and |Division of
Radiological Sciences, Guy's Hospital, London SE1 9RT,
U.K.
31P magnetic resonance spectroscopy provides a non-inva¬
sive method for studying human tumour biochemistry. In
vivo, spectral resolution is, however, inferior to that achiev¬
able in vitro. Furthermore, analysis in vitro may assist in
determining the chemical composition of the peaks observed
in vivo. In particular, the peaks commonly known as phos-
phomonoesters (PME) and phosphodiesters (PDE) may arise
from several different compounds. As a preliminary to
studies of breast cancer patients, we have characterized the
spectra obtained both in vivo and in vitro from this tumour
type.
Tumours (>6 cm) from 15 patients with breast cancer
were studied (4 by spectroscopy in vivo alone, 8 in vitro only
and 3 both in vivo and in vitro). Spectra were obtained in
vivo with a Philips Gyroscan 1.5 T system using a 5 cm sur¬
face coil for volume localization. In 11 patients a biopsy was
obtained and rapidly frozen in liquid nitrogen. The specimen
was divided and two extracts prepared by homogenization in
6% (v/v) perchloric acid (PCA) and chloroform/methanol
(CM), respectively. Spectra from these extracts were
obtained with a 9.4 T Bruker AM400 spectrometer.
The spectra collected from PCA extracts of breast tumour
specimens consisted of approximately 12 peaks each of
Abbreviations used: PCA, perchloric acid; PME, phosphomono-
ester; PDE, phosphodiester; CM, chloroform/methanol; GPE,
glycerophosphoethanolamine; GPC, glycerophosphocholine.
which was identified and quantified. These results are shown
in Table 1. Pj was present in high concentrations while phos-
phocreatine (PCr) was present in only 6 of the 11 tumours at
very low concentrations. Other compounds identified
include phosphoethanolamine, phosphocholine, glycero¬
phosphoethanolamine (GPE), glycerophosphocholine (GPC)
and nucleotide di- and tri-phosphates. Similar observations
have been made on several other tumour types [1,2, 3].
Comparison of spectra obtained in vivo with correspond¬
ing spectral regions in the PCA-extract spectra revealed the
following major differences. The PCA-extract spectra had
greater relative proportions of Pj and PME and smaller PDE
than the spectra in vivo. In contrast the CM extract showed a
large peak in the PDE position (5340 ± 1235 nmol/g wet wt.
of tissue), i.e. about 20-fold greater than the combined con¬
centrations of GPE and GPC. The differences in P, and PME
observed between in vivo and in the PCA-extract spectra can
be explained by saturation effects and n.m.r.-invisible pools.
The low PDE in PCA-extract spectra cannot be explained in
this way and suggests that some n.m.r.-visible phosphate-
containing material has been lost during the extraction
procedure. As PCA only extracts the water-soluble metabo¬
lites from tissue, one candidate for the missing PDE is
phospholipids in cell membranes. The results imply that the
PDE peak observed in vivo arises primarily from membrane
phospholipids. However, phospholipids are generally con¬
sidered to be n.m.r. invisible owing to their low mobility
giving rise to very broad signals. The solution to this appar¬
ent paradox lies in the fact that the line-width of the peak is
proportional to the magnetic field strength [4], At the low
field strengths used for human spectroscopy in vivo, the line-
width is small enough for the phospholipid peak to make a
significant contribution to the spectrum.
The results of these extract studies have major implica¬
tions with respect to the interpretation of spectra collected
from patients in vivo. The finding that the PDE peak is pri-
Table 1. Concentrations ofphosphorus-containing metabolites in human breast tumours
Individual metabolites were determined by 31P n.m.r. of PCA extracts by calibration of the
spectrometer against methylene diphosphonate and correction for saturation effects using
separately determined T, values. The relative concentrations for spectra in vivo were
determined from integrals of the appropriate spectral regions. Values shown are the














Phosphoethanolamine 1295 + 491
Phosphocholine 554 ±478
Inorganic phosphate 2543±1871
Glycerophosphoethanolamine 125 ± 80
Glycerophosphocholine 160 ±65
Phosphocreatine 47±57
[y-P]Nucleotide triphosphate 467 ±230
[/3-P]Nucleotide diphosphate 223 ±83
[a-P]Nucleotide diphosphate 188 ± 72
[a-P]Nucleotide triphosphate 430 ±212
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marily caused by mobile phospholipids requires that we
reconsider the implications of changes in this peak during
treatment. Previously it was reasoned that increases in this
peak represented the accumulation of GPE and GPC in the
tumour as a consequence of cell death [2, 5]. However, if in
fact the 'PDE' peak represents phospholipid it could mean
exactly the opposite, i.e. an increase in cell proliferation.
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Molecular graphic displays of antibody-antigen interactions
MALCOLM M. FRASER and
E. JAMES MILNER-WHITE
Department ofBiochemistry, University of Glasgow, Glasgow
G12 8QQ, U.K.
The three-dimensional structure of the complex between
chicken egg white lysozyme and the mouse antibody
HyHEL-5 has been determined by X-ray crystallography at
2.5 A resolution [1], In this communication, we present
photographs of models of the complex displayed on Gemini
Challenger graphics workstations. The displays make use of
new software based on the CHEMMOD molecular graphics
package (U-Microcomputers Ltd, Calver Rd., Warrington,
Cheshire WA2 8RF, U.K.) designed for investigating inter¬
faces between macromolecules.
The molecule to be displayed consists of the smoothed
a-carbon atoms of the two variable domains of the antibody
complexed to lysozyme (Fig. 1). Smoothing was described
previously [2] and involves averaging the x, y and z coordi¬
nates of five successive a-carbons. Atoms are divided into
interacting and non-interacting ones. The non-interacting
ones form the bulk of each molecule, being drawn, as large
grey spheres (diameter 0.4 nm). The less numerous inter¬
acting atoms are drawn as pale spheres (diameter 1.5-2.5
nm) to show the contact area.
The variable domains of both light and heavy chains have
three hypervariable regions, called LI, L2 and L3 and HI,
H2 and H3 [3], These correspond to the six regions of inter¬
acting atoms found, which are labelled as such in Fig. 2. Each
is a loop joining strands of /3-sheet and L2, L3, H2 and H3
Fig. 1. The interface between the antibody (two variable domains, VL and VH) and
antigen
Residues that lie within 13 A of any residue in the other interface are drawn as pale
spheres, shaded according to depth. The program originally selects a view along the
line joining their centres of gravity. To view the two interacting interfaces simultane¬
ously, the lysozyme molecule is rotated by 180° so that it is placed next to the anti¬
body. Geometricaly this is like opening a book. In the original view the interacting
interfaces correspond to middle pages of the book. A simultaneous view of both
interfaces is produced by opening the book.
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